en Chris mungall Erica Marcos Ningxian Fan Paul Fabry Randi Vita Ryan R. Brinkman Shunzhou Deng Alan Ruttenburg Alexander D. Diehl Amogh Madireddi Anna Maria Masci Anthony Huffman Barry Smith Bjoern Peters Edison Ong Hong Yu Jason Hu Jie Zheng Kallan Roan Khadeejah Khan Lindsay Cowell Melanie Courtot Ningxian Fan Omar Tibi Philip Huang Randi Vita Rebecca Racz Richard H. Scheuermann Rohit Goru Ronak Sutariya Samantha G. Sayers (SGS) Thomas Todd Yongqun "Oliver" He (YH) Yu Lin (YL) Yuanyi (Penny) Pan Zuoshuang "Allen" Xiang 2023-11-17 The Vaccine Ontology (VO) is a community-based biomedical ontology in the domain of vaccine and vaccination. VO aims to standardize vaccine types and annotations, integrate various vaccine data, and support computer-assisted reasoning. The VO supports basic vaccine R&D and clincal vaccine usage. VO is being developed as a community-based ontology with support and collaborations from the vaccine and bio-ontology communities. OWL-DL Vaccine Ontology 2023-11-17 Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. Really of interest to developers only BFO OWL specification label Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 Person:Alan Ruttenberg Really of interest to developers only BFO CLIF specification label editor preferred term The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> editor preferred term example of usage A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> example of usage in branch An annotation property indicating which module the terms belong to. This is currently experimental and not implemented yet. GROUP:OBI OBI_0000277 in branch has curation status PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot has curation status definition The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition editor note An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. PERSON:Daniel Schober GROUP:OBI:<http://purl.obofoundry.org/obo/obi> editor note term editor Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people 20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> term editor alternative label A label for a class or property that can be used to refer to the class or property instead of the preferred rdfs:label. Alternative labels should be used to indicate community- or context-specific labels, abbreviations, shorthand forms and the like. OBO Operations committee PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related). alternative label alternative term definition source Formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 PERSON:Daniel Schober Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition source has obsolescence reason Relates an annotation property to an obsolescence reason. The values of obsolescence reasons come from a list of predefined terms, instances of the class obsolescence reason specification. PERSON:Alan Ruttenberg PERSON:Melanie Courtot has obsolescence reason curator note An administrative note of use for a curator but of no use for a user PERSON:Alan Ruttenberg curator note term tracker item the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/ An IRI or similar locator for a request or discussion of an ontology term. Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg The 'tracker item' can associate a tracker with a specific ontology term. term tracker item ontology term requester The name of the person, project, or organization that motivated inclusion of an ontology term by requesting its addition. Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg The 'term requester' can credit the person, organization or project who request the ontology term. ontology term requester is denotator type Relates an class defined in an ontology, to the type of it's denotator In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type') Alan Ruttenberg is denotator type imported from For external terms/classes, the ontology from which the term was imported PERSON:Alan Ruttenberg PERSON:Melanie Courtot GROUP:OBI:<http://purl.obolibrary.org/obo/obi> imported from expand expression to ObjectProperty: RO_0002104 Label: has plasma membrane part Annotations: IAO_0000424 "http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.org/obo/owl/GO#GO_0005886 and http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" A macro expansion tag applied to an object property (or possibly a data property) which can be used by a macro-expansion engine to generate more complex expressions from simpler ones Chris Mungall expand expression to expand assertion to ObjectProperty: RO??? Label: spatially disjoint from Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary.org/obo/BFO_0000051 some ?X) (http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" A macro expansion tag applied to an annotation property which can be expanded into a more detailed axiom. Chris Mungall expand assertion to first order logic expression PERSON:Alan Ruttenberg first order logic expression antisymmetric property part_of antisymmetric property xsd:true Use boolean value xsd:true to indicate that the property is an antisymmetric property Alan Ruttenberg antisymmetric property OBO foundry unique label An alternative name for a class or property which is unique across the OBO Foundry. The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools . PERSON:Alan Ruttenberg PERSON:Bjoern Peters PERSON:Chris Mungall PERSON:Melanie Courtot GROUP:OBO Foundry <http://obofoundry.org/> OBO foundry unique label has ID digit count Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relates an ontology used to record id policy to the number of digits in the URI. The URI is: the 'has ID prefix" annotation property value concatenated with an integer in the id range (left padded with "0"s to make this many digits) Person:Alan Ruttenberg has ID digit count has ID range allocated Datatype: idrange:1 Annotations: 'has ID range allocated to': "Chris Mungall" EquivalentTo: xsd:integer[> 2151 , <= 2300] Relates a datatype that encodes a range of integers to the name of the person or organization who can use those ids constructed in that range to define new terms Person:Alan Ruttenberg has ID range allocated to has ID policy for Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relating an ontology used to record id policy to the ontology namespace whose policy it manages Person:Alan Ruttenberg has ID policy for has ID prefix Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO" Relates an ontology used to record id policy to a prefix concatenated with an integer in the id range (left padded with "0"s to make this many digits) to construct an ID for a term being created. Person:Alan Ruttenberg has ID prefix elucidation person:Alan Ruttenberg Person:Barry Smith Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms elucidation has associated axiom(nl) Person:Alan Ruttenberg Person:Alan Ruttenberg An axiom associated with a term expressed using natural language has associated axiom(nl) has associated axiom(fol) Person:Alan Ruttenberg Person:Alan Ruttenberg An axiom expressed in first order logic using CLIF syntax has associated axiom(fol) is allocated id range Relates an ontology IRI to an (inclusive) range of IRIs in an OBO name space. The range is give as, e.g. "IAO_0020000-IAO_0020999" PERSON:Alan Ruttenberg Add as annotation triples in the granting ontology is allocated id range has ontology root term Ontology annotation property. Relates an ontology to a term that is a designated root term of the ontology. Display tools like OLS can use terms annotated with this property as the starting point for rendering the ontology class hierarchy. There can be more than one root. Nicolas Matentzoglu has ontology root term may be identical to A annotation relationship between two terms in an ontology that may refer to the same (natural) type but where more evidence is required before terms are merged. David Osumi-Sutherland #40 VFB Edges asserting this should be annotated with to record evidence supporting the assertion and its provenance. may be identical to scheduled for obsoletion on or after Used when the class or object is scheduled for obsoletion/deprecation on or after a particular date. Chris Mungall, Jie Zheng https://github.com/geneontology/go-ontology/issues/15532 https://github.com/information-artifact-ontology/ontology-metadata/issues/32 GO ontology scheduled for obsoletion on or after has axiom id Person:Alan Ruttenberg Person:Alan Ruttenberg A URI that is intended to be unique label for an axiom used for tracking change to the ontology. For an axiom expressed in different languages, each expression is given the same URI has axiom label term replaced by Use on obsolete terms, relating the term to another term that can be used as a substitute Person:Alan Ruttenberg Person:Alan Ruttenberg Add as annotation triples in the granting ontology term replaced by ISA alternative term An alternative term used by the ISA tools project (http://isa-tools.org). Requested by Alejandra Gonzalez-Beltran https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178 Person: Alejandra Gonzalez-Beltran Person: Philippe Rocca-Serra ISA tools project (http://isa-tools.org) ISA alternative term IEDB alternative term An alternative term used by the IEDB. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB IEDB alternative term A GeneID in the NCBI Gene database Oliver He, Yue Liu NCBI GeneID the NCBI LocusTag name of a gene Oliver He, Yue Liu NCBI LocusTag a date of content modification Oliver He, Yue Liu modification date The NCBITaxon ontology ID of an organism. Oliver He, Yue Liu organism NCBITaxon ID A chromosome ID where a gene is located. Oliver He chromosome ID of gene an annotation property that specifies the type of a gene Oliver He type of gene an annotation property that specifies a nomenclature status Oliver He nomenclature status An annotation property that represents a gene's association with PubMed publication(s). Yongqun He has PubMed association This is an annotation used on an object property to indicate a logical characterstic beyond what is possible in OWL. OBO Operations call logical characteristic of object property 'part disjoint with' 'defined by construct' """ PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX : <http://example.org/ CONSTRUCT { [ a owl:Restriction ; owl:onProperty :part_of ; owl:someValuesFrom ?a ; owl:disjointWith [ a owl:Restriction ; owl:onProperty :part_of ; owl:someValuesFrom ?b ] ] } WHERE { ?a :part_disjoint_with ?b . } Links an annotation property to a SPARQL CONSTRUCT query which is meant to provide semantics for a shortcut relation. defined by construct CHEBI:26523 (reactive oxygen species) has an exact synonym (ROS), which is of type OMO:0003000 (abbreviation) A synonym type for describing abbreviations or initalisms 2023-03-03 abbreviation A synonym type for describing ambiguous synonyms 2023-03-03 ambiguous synonym A synonym type for describing dubious synonyms 2023-03-03 dubious synonym EFO:0006346 (severe cutaneous adverse reaction) has an exact synonym (scar), which is of the type OMO:0003003 (layperson synonym) A synonym type for describing layperson or colloquial synonyms 2023-03-03 layperson synonym CHEBI:23367 (molecular entity) has an exact synonym (molecular entities), which is of the type OMO:0003004 (plural form) A synonym type for describing pluralization synonyms 2023-03-03 plural form CHEBI:16189 (sulfate) has an exact synonym (sulphate), which is of the type OMO:0003005 (UK spelling synonym) A synonym type for describing UK spelling variants 2023-03-03 UK spelling synonym A synonym type for common misspellings 2023-03-03 misspelling A synonym type for misnomers, i.e., a synonym that is not technically correct but is commonly used anyway 2023-03-03 misnomer MAPT, the gene that encodes the Tau protein, has a previous name DDPAC. Note: in this case, the name type is more specifically the gene symbol. A synonym type for names that have been used as primary labels in the past. 2023-07-25 previous name The legal name for Harvard University (https://ror.org/03vek6s52) is President and Fellows of Harvard College A synonym type for the legal entity name 2023-07-27 legal name CHEBI:46195 has been assigned the english International Nonproproprietary Name (INN) "paracetamol". In some cases such as this one, the INN might be the same as the ontology's primary label The International Nonproprietary Name (INN) is a standardize name for a pharmaceutical drug or active ingredient issued by the World Health Organization (WHO) meant to address the issues with country- or language-specific brand names. These are issued in several languages, including English, Latin, French, Russian, Spanish, Arabic, and Chinese. 2023-09-30 INN International Nonproprietary Name nasopharynx (UBERON:0001728) has the latin name "pars nasalis pharyngis A synonym type for describing Latin term synonyms. 2023-10-12 latin term NASA is an word acronym for the US National Aeronautics and Space Administration because the acronym is pronounced. FBI is an initialism (also known as alphabetism) for the US Federal Bureau of Investigation since the letters are pronounced one at a time. JPEG is an acronym for Joint Photographic Experts Group but does not count as a word acronym nor an initialism since it is mixed how it is pronounced. A synonym type for describing abbreviations that are a part of the full name's words, such as initialisms or alphabetisms. 2023-11-01 acronym An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. temporal interpretation tooth SubClassOf 'never in taxon' value 'Aves' x never in taxon T if and only if T is a class, and x does not instantiate the class expression "in taxon some T". Note that this is a shortcut relation, and should be used as a hasValue restriction in OWL. Class: ?X DisjointWith: RO_0002162 some ?Y PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX never_in_taxon: <http://purl.obolibrary.org/obo/RO_0002161> CONSTRUCT { in_taxon: a owl:ObjectProperty . a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . ?x rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom [ a owl:Class ; owl:complementOf ?taxon ] ] . } WHERE { ?x never_in_taxon: ?taxon . } never in taxon A is mutually_spatially_disjoint_with B if both A and B are classes, and there exists no p such that p is part_of some A and p is part_of some B. non-overlapping with shares no parts with Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y) PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX part_of: <http://purl.obolibrary.org/obo/BFO_0000050> PREFIX mutually_spatially_disjoint_with: <http://purl.obolibrary.org/obo/RO_0002171> CONSTRUCT { part_of: a owl:ObjectProperty . [ a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?x ; a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?y ] ] } WHERE { ?x mutually_spatially_disjoint_with: ?y . } mutually spatially disjoint with https://github.com/obophenotype/uberon/wiki/Part-disjointness-Design-Pattern An assertion that holds between an ontology class and an organism taxon class, which is intepreted to yield some relationship between instances of the ontology class and the taxon. taxonomic class assertion S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX present_in_taxon: <http://purl.obolibrary.org/obo/RO_0002175> CONSTRUCT { in_taxon: a owl:ObjectProperty . ?witness rdfs:label ?label . ?witness rdfs:subClassOf ?x . ?witness rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . } WHERE { ?x present_in_taxon: ?taxon . BIND(IRI(CONCAT( "http://purl.obolibrary.org/obo/RO_0002175#", MD5(STR(?x)), "-", MD5(STR(?taxon)) )) as ?witness) BIND(CONCAT(STR(?x), " in taxon ", STR(?taxon)) AS ?label) } The SPARQL expansion for this relation introduces new named classes into the ontology. For this reason it is likely that the expansion should only be performed during a QC pipeline; the expanded output should usually not be included in a published version of the ontology. present in taxon An assertion that involves at least one OWL object that is intended to be expanded into one or more logical axioms. The logical expansion can yield axioms expressed using any formal logical system, including, but not limited to OWL2-DL. logical macro assertion http://purl.obolibrary.org/obo/ro/docs/shortcut-relations/ A logical macro assertion whose domain is an IRI for a class The domain for this class can be considered to be owl:Class, but we cannot assert this in OWL2-DL logical macro assertion on a class A logical macro assertion whose domain is an IRI for a property logical macro assertion on a property Used to annotate object properties to describe a logical meta-property or characteristic of the object property. logical macro assertion on an object property A shortcut relationship that holds between two entities based on their identity criteria logical macro assertion involving identity A shortcut relationship between two entities x and y1, such that the intent is that the relationship is functional and inverse function, but there is no guarantee that this property holds. in approximate one to one relationship with 'anterior end of organism' is-opposite-of 'posterior end of organism' 'increase in temperature' is-opposite-of 'decrease in temperature' x is the opposite of y if there exists some distance metric M, and there exists no z such as M(x,z) <= M(x,y) or M(y,z) <= M(y,x). is opposite of external_definition axiom_lost_from_external_ontology homology_notes has_relational_adjective taxon_notes development_notes external_ontology_notes fma_set_term Oliver He, Omar Tibi An annotation property that represents a matched vaccine identifier used in the VIOLIN database. VIOLIN vaccine ID VIOLIN vaccine ID An annotation property that represents the trade name of a product. YH trade name trade name An annotation property that represents the active ingredient of a vaccine. Oliver He has vaccine active ingredient has vaccine active ingredient An annotation property that represents the vaccine ingredient of a vaccine. Such an ingredient may not be active. Oliver He has vaccine ingredient has vaccine ingredient An annotation property that describes the dose information of a vaccine Oliver He vaccine dose annotation vaccine dose annotation The vaccine Prevnar (trade name) has a FDA-defined proper name: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein). Reference: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm An annotation property that represents the proper name of a vaccine, which is defined in an official way such as one defined by FDA. Oliver He, Kallan Roan vaccine proper name vaccine proper name The vaccine Prevnar has the manufacturer: Wyeth Pharmaceuticals Inc. Reference: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm An annotation property that represents the manufacturer of a product such as vaccine Oliver He, Kallan Roan manufacturer manufacturer The vaccine Prevnar has the indications: - Immunization of infants 2, 4, 6 and 12-15 months of age to prevent invasive pneumococcal disease. - Immunization of infants and toddlers against otitis media caused by vaccine serotypes. Reference: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm An annotation property that represents the indications of a vaccine defined by the USA FDA. Oliver He, Kallan Roan FDA vaccine indications FDA vaccine indications Prevnar has the package insert PDF URL: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM137038.pdf . Recorded on 11/26/2018. An annotation property that represents a URL of the package insert PDF document of a licensed vaccine Oliver He, Kallan Roan vaccine package insert PDF URL vaccine package insert PDF URL A number that is generated by FDA based on a request from an applicant of a product licensing. Oliver He, Kallan Roan vaccine submission’s tracking number https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ProceduresSOPPs/UCM461225.pdf BLA 101094 vaccine STN RxNORM ID RxNORM ID has Protegen id has Protegen id has Protegen annotation has Protegen annotation As seen: http://purl.bioontology.org/ontology/RXNORM/901644, the RxNORM vaccine term "Prevnar 13 vaccine 0.5 ML Prefilled Syringe" has Preferred Name of: 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Prefilled Syringe [Prevnar 13]". In this case, the whole preferred name is annotated under the annotation property "RxNORM Preferred Name". RxNORM Preferred Name RxNORM Preferred Name An identifier assigned by the Vaccine Adjuvant Compendium (VAC: https://vac.niaid.nih.gov/) https://vac.niaid.nih.gov/ VAC adjuvant ID An annotation property that represents the annotated information about the antigens used for a specific vaccine. Oliver He, Penny Pan https://en.wikipedia.org/wiki/Antigen vaccine antigen annotation vaccine preparation annotation vaccine response annotation This is annotation property that refers to a specific CVX ID. Penny Pan, Oliver He https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx CVX code An annotation property that shows the status of vaccine developmeint including: clinical trial, research, licensed, or Emergency Use Authorization (EUA). Oliver He, Jie Zheng, Anthony Huffman, Penny Pan status of vaccine development has_rank An alternative label for a class or property which has a more general meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/18 has broad synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/18 An alternative label for a class or property which has the exact same meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/20 has exact synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/20 An alternative label for a class or property which has a more specific meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/19 has narrow synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/19 An alternative label for a class or property that has been used synonymously with the primary term name, but the usage is not strictly correct. https://github.com/information-artifact-ontology/ontology-metadata/issues/21 has related synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/21 is part of my brain is part of my body (continuant parthood, two material entities) my stomach cavity is part of my stomach (continuant parthood, immaterial entity is part of material entity) this day is part of this year (occurrent parthood) a core relation that holds between a part and its whole Everything is part of itself. Any part of any part of a thing is itself part of that thing. Two distinct things cannot be part of each other. Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ Parthood requires the part and the whole to have compatible classes: only an occurrent can be part of an occurrent; only a process can be part of a process; only a continuant can be part of a continuant; only an independent continuant can be part of an independent continuant; only an immaterial entity can be part of an immaterial entity; only a specifically dependent continuant can be part of a specifically dependent continuant; only a generically dependent continuant can be part of a generically dependent continuant. (This list is not exhaustive.) A continuant cannot be part of an occurrent: use 'participates in'. An occurrent cannot be part of a continuant: use 'has participant'. A material entity cannot be part of an immaterial entity: use 'has location'. A specifically dependent continuant cannot be part of an independent continuant: use 'inheres in'. An independent continuant cannot be part of a specifically dependent continuant: use 'bearer of'. part_of part of http://www.obofoundry.org/ro/#OBO_REL:part_of has part my body has part my brain (continuant parthood, two material entities) my stomach has part my stomach cavity (continuant parthood, material entity has part immaterial entity) this year has part this day (occurrent parthood) a core relation that holds between a whole and its part Everything has itself as a part. Any part of any part of a thing is itself part of that thing. Two distinct things cannot have each other as a part. Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ Parthood requires the part and the whole to have compatible classes: only an occurrent have an occurrent as part; only a process can have a process as part; only a continuant can have a continuant as part; only an independent continuant can have an independent continuant as part; only a specifically dependent continuant can have a specifically dependent continuant as part; only a generically dependent continuant can have a generically dependent continuant as part. (This list is not exhaustive.) A continuant cannot have an occurrent as part: use 'participates in'. An occurrent cannot have a continuant as part: use 'has participant'. An immaterial entity cannot have a material entity as part: use 'location of'. An independent continuant cannot have a specifically dependent continuant as part: use 'bearer of'. A specifically dependent continuant cannot have an independent continuant as part: use 'inheres in'. has_part has part realized in this disease is realized in this disease course this fragility is realized in this shattering this investigator role is realized in this investigation is realized by realized_in [copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) Paraphrase of elucidation: a relation between a realizable entity and a process, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process realized in realizes this disease course realizes this disease this investigation realizes this investigator role this shattering realizes this fragility to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) Paraphrase of elucidation: a relation between a process and a realizable entity, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process realizes preceded by x is preceded by y if and only if the time point at which y ends is before or equivalent to the time point at which x starts. Formally: x preceded by y iff ω(y) <= α(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. An example is: translation preceded_by transcription; aging preceded_by development (not however death preceded_by aging). Where derives_from links classes of continuants, preceded_by links classes of processes. Clearly, however, these two relations are not independent of each other. Thus if cells of type C1 derive_from cells of type C, then any cell division involving an instance of C1 in a given lineage is preceded_by cellular processes involving an instance of C. The assertion P preceded_by P1 tells us something about Ps in general: that is, it tells us something about what happened earlier, given what we know about what happened later. Thus it does not provide information pointing in the opposite direction, concerning instances of P1 in general; that is, that each is such as to be succeeded by some instance of P. Note that an assertion to the effect that P preceded_by P1 is rather weak; it tells us little about the relations between the underlying instances in virtue of which the preceded_by relation obtains. Typically we will be interested in stronger relations, for example in the relation immediately_preceded_by, or in relations which combine preceded_by with a condition to the effect that the corresponding instances of P and P1 share participants, or that their participants are connected by relations of derivation, or (as a first step along the road to a treatment of causality) that the one process in some way affects (for example, initiates or regulates) the other. is preceded by preceded_by http://www.obofoundry.org/ro/#OBO_REL:preceded_by preceded by precedes x precedes y if and only if the time point at which x ends is before or equivalent to the time point at which y starts. Formally: x precedes y iff ω(x) <= α(y), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. precedes occurs in b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t occurs_in unfolds in unfolds_in Paraphrase of definition: a relation between a process and an independent continuant, in which the process takes place entirely within the independent continuant occurs in site of [copied from inverse property 'occurs in'] b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t Paraphrase of definition: a relation between an independent continuant and a process, in which the process takes place entirely within the independent continuant contains process This document is about information artifacts and their representations A (currently) primitive relation that relates an information artifact to an entity. 7/6/2009 Alan Ruttenberg. Following discussion with Jonathan Rees, and introduction of "mentions" relation. Weaken the is_about relationship to be primitive. We will try to build it back up by elaborating the various subproperties that are more precisely defined. Some currently missing phenomena that should be considered "about" are predications - "The only person who knows the answer is sitting beside me" , Allegory, Satire, and other literary forms that can be topical without explicitly mentioning the topic. person:Alan Ruttenberg Smith, Ceusters, Ruttenberg, 2000 years of philosophy is about An information artifact IA mentions an entity E exactly when it has a component/part that denotes E 7/6/2009 Alan Ruttenberg. P4 RC1 munges our GCI so remove it for now: mentions some entity equivalentTo has_part some ('generically denotes' some entity) 7/6/2009 Alan Ruttenberg: Add this relation following conversation with Jonathan Rees that N&S GCI for is_about was too strong. Really it was simply sufficient. To effect this change we introduce this relation, which is subproperty of is_about, and have previous GCI use this relation "mentions" in it's (logical) definition PERSON: Jonathan Rees Person: Alan Ruttenberg mentions has_specified_input has_specified_input see is_input_of example_of_usage The inverse property of is_specified_input_of 8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works. PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Coutot has_specified_input is_specified_input_of some Autologous EBV(Epstein-Barr virus)-transformed B-LCL (B lymphocyte cell line) is_input_for instance of Chromum Release Assay described at https://wiki.cbil.upenn.edu/obiwiki/index.php/Chromium_Release_assay A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of. Alan Ruttenberg PERSON:Bjoern Peters is_specified_input_of has_specified_output has_specified_output The inverse property of is_specified_output_of PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Courtot has_specified_output is_manufactured_by http://www.affymetrix.com/products/arrays/specific/hgu133.affx is_manufactered_by http://www.affymetrix.com/ (if we decide to use these URIs for the actual entities) c is_manufactured_by o means that there was a process p in which c was built in which a person, or set of people or machines did the work(bore the "Manufacturer Role", and those people/and or machines were members or of directed by the organization to do this. Alan Ruttenberg Liju Fan has_make has_manufacturer is_manufactured_by is_specified_output_of is_specified_output_of A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of. Alan Ruttenberg PERSON:Bjoern Peters is_specified_output_of achieves_planned_objective A cell sorting process achieves the objective specification 'material separation objective' This relation obtains between a planned process and a objective specification when the criteria specified in the objective specification are met at the end of the planned process. BP, AR, PPPB branch PPPB branch derived modified according to email thread from 1/23/09 in accordince with DT and PPPB branch achieves_planned_objective has grain the relation of the cells in the finger of the skin to the finger, in which an indeterminate number of grains are parts of the whole by virtue of being grains in a collective that is part of the whole, and in which removing one granular part does not nec- essarily damage or diminish the whole. Ontological Whether there is a fixed, or nearly fixed number of parts - e.g. fingers of the hand, chambers of the heart, or wheels of a car - such that there can be a notion of a single one being missing, or whether, by contrast, the number of parts is indeterminate - e.g., cells in the skin of the hand, red cells in blood, or rubber molecules in the tread of the tire of the wheel of the car. Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. Definition take from the definition of granular parthood in the cited paper. Needs work to put into standard form PERSON: Alan Ruttenberg PAPER: Granularity, scale and collectivity: When size does and does not matter, Alan Rector, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349 has grain objective_achieved_by This relation obtains between an objective specification and a planned process when the criteria specified in the objective specification are met at the end of the planned process. OBI OBI objective_achieved_by has value specification A relation between an information content entity and a value specification that specifies its value. PERSON: James A. Overton OBI has value specification A relation between an organism and an organism that has vector role. obsolete_has vector true A relation between an organism and an organism that has host role. obsolete_has host true inheres in this fragility is a characteristic of this vase this red color is a characteristic of this apple a relation between a specifically dependent continuant (the characteristic) and any other entity (the bearer), in which the characteristic depends on the bearer for its existence. inheres_in Note that this relation was previously called "inheres in", but was changed to be called "characteristic of" because BFO2 uses "inheres in" in a more restricted fashion. This relation differs from BFO2:inheres_in in two respects: (1) it does not impose a range constraint, and thus it allows qualities of processes, as well as of information entities, whereas BFO2 restricts inheres_in to only apply to independent continuants (2) it is declared functional, i.e. something can only be a characteristic of one thing. characteristic of bearer of this apple is bearer of this red color this vase is bearer of this fragility Inverse of characteristic_of A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. bearer_of is bearer of has characteristic participates in this blood clot participates in this blood coagulation this input material (or this output material) participates in this process this investigator participates in this investigation a relation between a continuant and a process, in which the continuant is somehow involved in the process participates_in participates in has participant this blood coagulation has participant this blood clot this investigation has participant this investigator this process has participant this input material (or this output material) a relation between a process and a continuant, in which the continuant is somehow involved in the process Has_participant is a primitive instance-level relation between a process, a continuant, and a time at which the continuant participates in some way in the process. The relation obtains, for example, when this particular process of oxygen exchange across this particular alveolar membrane has_participant this particular sample of hemoglobin at this particular time. has_participant http://www.obofoundry.org/ro/#OBO_REL:has_participant has participant A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The journal article (a generically dependent continuant) is concretized as the quality (a specifically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). A relationship between a generically dependent continuant and a specifically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. A generically dependent continuant may be concretized as multiple specifically dependent continuants. is concretized as A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The quality (a specifically dependent continuant) concretizes the journal article (a generically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). A relationship between a specifically dependent continuant and a generically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. Multiple specifically dependent continuants can concretize the same generically dependent continuant. concretizes this catalysis function is a function of this enzyme a relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence A function inheres in its bearer at all times for which the function exists, however the function need not be realized at all the times that the function exists. function_of is function of This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. function of this red color is a quality of this apple a relation between a quality and an independent continuant (the bearer), in which the quality specifically depends on the bearer for its existence A quality inheres in its bearer at all times for which the quality exists. is quality of quality_of This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. quality of this investigator role is a role of this person a relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence A role inheres in its bearer at all times for which the role exists, however the role need not be realized at all the times that the role exists. is role of role_of This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. role of this enzyme has function this catalysis function (more colloquially: this enzyme has this catalysis function) a relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence A bearer can have many functions, and its functions can exist for different periods of time, but none of its functions can exist when the bearer does not exist. A function need not be realized at all the times that the function exists. has_function has function this apple has quality this red color a relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence A bearer can have many qualities, and its qualities can exist for different periods of time, but none of its qualities can exist when the bearer does not exist. has_quality has quality this person has role this investigator role (more colloquially: this person has this role of investigator) a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. has_role has role a relation between an independent continuant (the bearer) and a disposition, in which the disposition specifically depends on the bearer for its existence has disposition inverse of has disposition This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020. disposition of this cell derives from this parent cell (cell division) this nucleus derives from this parent nucleus (nuclear division) a relation between two distinct material entities, the new entity and the old entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops from'. derives_from derives from this parent cell derives into this cell (cell division) this parent nucleus derives into this nucleus (nuclear division) a relation between two distinct material entities, the old entity and the new entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops into'. To avoid making statements about a future that may not come to pass, it is often better to use the backward-looking 'derives from' rather than the forward-looking 'derives into'. derives_into derives into is location of my head is the location of my brain this cage is the location of this rat a relation between two independent continuants, the location and the target, in which the target is entirely within the location Most location relations will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ location_of location of located in my brain is located in my head this rat is located in this cage a relation between two independent continuants, the target and the location, in which the target is entirely within the location Location as a relation between instances: The primitive instance-level relation c located_in r at t reflects the fact that each continuant is at any given time associated with exactly one spatial region, namely its exact location. Following we can use this relation to define a further instance-level location relation - not between a continuant and the region which it exactly occupies, but rather between one continuant and another. c is located in c1, in this sense, whenever the spatial region occupied by c is part_of the spatial region occupied by c1. Note that this relation comprehends both the relation of exact location between one continuant and another which obtains when r and r1 are identical (for example, when a portion of fluid exactly fills a cavity), as well as those sorts of inexact location relations which obtain, for example, between brain and head or between ovum and uterus Most location relations will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/ located_in http://www.obofoundry.org/ro/#OBO_REL:located_in located in This is redundant with the more specific 'independent and not spatial region' constraint. We leave in the redundant axiom for use with reasoners that do not use negation. This is redundant with the more specific 'independent and not spatial region' constraint. We leave in the redundant axiom for use with reasoners that do not use negation. the surface of my skin is a 2D boundary of my body a relation between a 2D immaterial entity (the boundary) and a material entity, in which the boundary delimits the material entity A 2D boundary may have holes and gaps, but it must be a single connected entity, not an aggregate of several disconnected parts. Although the boundary is two-dimensional, it exists in three-dimensional space and thus has a 3D shape. 2D_boundary_of boundary of is 2D boundary of is boundary of 2D boundary of my body has 2D boundary the surface of my skin a relation between a material entity and a 2D immaterial entity (the boundary), in which the boundary delimits the material entity A 2D boundary may have holes and gaps, but it must be a single connected entity, not an aggregate of several disconnected parts. Although the boundary is two-dimensional, it exists in three-dimensional space and thus has a 3D shape. has boundary has_2D_boundary has 2D boundary A relation that applies between a cell(c) and a gene(g) , where the process of 'transcription, DNA templated (GO_0006351)' is occuring in in cell c and that process has input gene g. x 'cell expresses' y iff: cell(x) AND gene(y) AND exists some 'transcription, DNA templated (GO_0006351)'(t) AND t occurs_in x AND t has_input y cell expresses David Osumi-Sutherland X ends_after Y iff: end(Y) before_or_simultaneous_with end(X) ends after David Osumi-Sutherland io X starts_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (start(X) before_or_simultaneous_with end(Y)) starts during David Osumi-Sutherland d during X happens_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (end(X) before_or_simultaneous_with end(Y)) happens during https://wiki.geneontology.org/Happens_during David Osumi-Sutherland o overlaps X ends_during Y iff: ((start(Y) before_or_simultaneous_with end(X)) AND end(X) before_or_simultaneous_with end(Y). ends during x is in taxon y if an only if y is an organism, and the relationship between x and y is one of: part of (reflexive), developmentally preceded by, derives from, secreted by, expressed. Connects a biological entity to its taxon of origin. in taxon w 'has component' p if w 'has part' p and w is such that it can be directly disassembled into into n parts p, p2, p3, ..., pn, where these parts are of similar type. The definition of 'has component' is still under discussion. The challenge is in providing a definition that does not imply transitivity. For use in recording has_part with a cardinality constraint, because OWL does not permit cardinality constraints to be used in combination with transitive object properties. In situations where you would want to say something like 'has part exactly 5 digit, you would instead use has_component exactly 5 digit. has component definition "x has gene product of y if and only if y is a gene (SO:0000704) that participates in some gene expression process (GO:0010467) where the output of that process is either y or something that is ribosomally translated from x" We would like to be able to express the rule: if t transcribed from g, and t is a noncoding RNA and has an evolved function, then t has gene product g. gene product of every HOTAIR lncRNA is the gene product of some HOXC gene every sonic hedgehog protein (PR:000014841) is the gene product of some sonic hedgehog gene x has gene product y if and only if x is a gene (SO:0000704) that participates in some gene expression process (GO:0010467) where the output of that process is either y or something that is ribosomally translated from y has gene product 'neural crest cell' SubClassOf expresses some 'Wnt1 gene' x expressed in y if and only if there is a gene expression process (GO:0010467) that occurs in y, and one of the following holds: (i) x is a gene, and x is transcribed into a transcript as part of the gene expression process (ii) x is a transcript, and the transcription of x is part of the gene expression process (iii) x is a mature gene product such as a protein, and x was translated or otherwise processes from a transcript that was transcribed as part of this gene expression process expressed in Do not use this relation directly. It is ended as a grouping for relations between occurrents involving the relative timing of their starts and ends. https://docs.google.com/document/d/1kBv1ep_9g3sTR-SD3jqzFqhuwo9TPNF-l-9fUDbO6rM/edit?pli=1 A relation that holds between two occurrents. This is a grouping relation that collects together all the Allen relations. temporally related to g is over-expressed in t iff g is expressed in t, and the expression level of g is increased relative to some background. over-expressed in g is under-expressed in t iff g is expressed in t, and the expression level of g is decreased relative to some background. under-expressed in c has-biological-role r iff c has-role r and r is a biological role (CHEBI:24432) has biological role c has-application-role r iff c has-role r and r is an application role (CHEBI:33232) has application role c has-chemical-role r iff c has-role r and r is a chemical role (CHEBI:51086) has chemical role x is ubiquitously expressed in y if and only if x is expressed in y, and the majority of cells in y express x Revisit this term after coordinating with SO/SOM. The domain of this relation should be a sequence, as an instance of a DNA molecule is only expressed in the cell of which it is a part. ubiquitously expressed in y expresses x if and only if there is a gene expression process (GO:0010467) that occurs in y, and one of the following holds: (i) x is a gene, and x is transcribed into a transcript as part of the gene expression process (ii) x is a transcript, and x was transcribed from a gene as part of the gene expression process (iii) x is a mature gene product (protein or RNA), and x was translated or otherwise processed from a transcript that was transcribed as part of the gene expression process. expresses inverse of ubiquiotously expressed in ubiquitously expresses q characteristic of part of w if and only if there exists some p such that q inheres in p and p part of w. Because part_of is transitive, inheres in is a sub-relation of characteristic of part of inheres in part of characteristic of part of A relationship that holds via some environmental process Do not use this relation directly. It is ended as a grouping for a diverse set of relations, all involving the process of evolution. evolutionarily related to A relationship that is mediated in some way by the environment or environmental feature (ENVO:00002297) ecologically related to holds between two entities when some genome-level process such as gene expression is involved. This includes transcriptional, spliceosomal events. These relations can be used between either macromolecule entities (such as regions of nucleic acid) or between their abstract informational counterparts. Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all involving the genome of an organism genomically related to An organism that is a member of a population of organisms is member of is a mereological relation between a item and a collection. is member of member part of SIO member of has member is a mereological relation between a collection and an item. SIO has member X 'has host' y if and only if: x is an organism, y is an organism, and x can live on the surface of or within the body of y has host has vector depends on q towards e2 if and only if q is a relational quality such that q inheres-in some e, and e != e2 and q is dependent on e2 This relation is provided in order to support the use of relational qualities such as 'concentration of'; for example, the concentration of C in V is a quality that inheres in V, but pertains to C. towards x is transcribed from y if and only if x is synthesized from template y http://www.ncbi.nlm.nih.gov/pubmed/20226267 transcribed from inverse of transcribed from http://www.ncbi.nlm.nih.gov/pubmed/20226267 transcribed to x is the ribosomal translation of y if and only if a ribosome reads x through a series of triplet codon-amino acid adaptor activities (GO:0030533) and produces y http://www.ncbi.nlm.nih.gov/pubmed/20226267 ribosomal translation of inverse of ribosomal translation of http://www.ncbi.nlm.nih.gov/pubmed/20226267 ribosomally translates to DEPRECATED This relation is similar to but different in important respects to the characteristic-of relation. See comments on that relation for more information. DEPRECATED inheres in true DEPRECATED bearer of true a type of 'has vaccine component' relation that specifies a vaccine conjugate protein for a specific vaccine has vaccine conjugate protein YH a type of 'has vaccine vector' relation that specifies a bacterial vaccine vector has bacterial vaccine vector has_vaccine_contraindication is a relation that specifies contraindication of a vaccine. This relation may be replaced by has_vaccine_allergen. We need to determine if any vaccine contraindicator is not a vaccine allergen. YH has vaccine contraindication a type of 'has vaccine vector' that is specifically for viral vaccine vector has viral vaccine vector a 'has vaccine component' relation that specifies the plasmid used for development of a particular DNA vaccine. YH has DNA vaccine plasmid infection_of is a relation between a disorder and an infectious pathogen. The relation 'infection_of' is introduced to represent an infection caused by an infectious pathogen. A pathogen infection is a disorder. Since the number of pathogens is large, there are numerous infections. To make the description of a specific infection simple, the shortcut term 'infection_of' is defined: infection_of X = infection and has_part some (organism X and has_disposition some infectious disposition) YH, XZ, MC, BP, AR infection_of an object property that specifies a process that is induced by vaccination of a vaccine YH induced by vaccination of a 'has vaccine component' relation that specifies a gene inserted to DNA vaccine plasmid for development of a particular DNA vaccine, and this gene encodes for a protein antigen. YH has DNA vaccine antigen gene an object property that defines a relation between a vaccine and its component YL, YH has vaccine component an object property that specifies a vaccine antigen YL, YH This relation only works for those vaccine antigen that is physically part of a vaccine preparation. It does not include those antigens that are not part of vaccine. For example, a protein antigen expressed in a DNA vaccine is not a part of vaccine pe ser. In this case, the vaccine expresses the protein, but the gene is part of the vaccine, not the protein. For the case, we can use the relation 'DNA vaccine expresses protein antigen' under the relation 'expresses'. has vaccine antigen a type of 'has vaccine antigen' relation that is specifically for vaccine protective protein antigen used in subunit vaccine development YL, YH has subunit vaccine antigen a type of 'has vaccine antigen' relation that is specifically for vaccine protective antigen component YL, YH has vaccine protective antigen a type of 'has vaccine component' relation that is specifically for vaccine adjuvant component YL, YH has vaccine adjuvant a type of 'has vaccine component' relation that is specifically for vaccine vector component YL, YH has vaccine vector a object property that specifies a relation between a vaccine and a vaccine allergen YH has vaccine allergen an object property that indicates a secretion of a material (e.g., protein) from a vaccine organism. YH vaccine organism secretes YL, YH a 'has vaccine component' relation that is specifically used for vaccine preservative has vaccine preservative an object property that specifies a relation between a vaccine and a vaccinate route vaccinated in route an object property that specifies a relation between a vaccine and its vaccinee has vaccinee YH an 'expresses' relation that specifies a relation between a DNA vaccine and a protein antigen to be expressed by the DNA vaccine. DNA vaccine expresses protein antigen "A vaccinates B" means that the vaccine A is used for vaccinating the host B (e.g., human). A relationship between a vaccine instance and an organism type such that if the vaccine instance is given to an instance of the organism by the process vaccination, then it changes the organism's disposition to have an immune response against a disease. YH, AR, ZX, MC vaccinates has_vaccine_allegen is a relation that specifies an allegen to a vaccine. YH has_vaccine_allergen an object property that represents a mutational relation between a vaccine organism and another material (e.g., gene or protein). the mutated material initially exists in the original wildtype organism. YH vaccine organism has mutation YH an object property that specifies a relation between a vaccine and a vaccine virmugen. This is a short cut relation. Domain: vaccine Range: a gene Shortcut: is_specified_output_of some ('preparation of gene mutant vaccine' and (has_specified_input some gene)) has vaccine virmugen YH a 'has subunit vaccine antigen' relation that indicates the antigen is protective. has subunit vaccine protective antigen is_distributed_by is a relation that specifies a company that distributes a product (e.g., vaccine). The company is very likely not the manufacturer of the product. YH, ZX is_distributed_by a shortcut relation that equals to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism' and has_disposition some disease)))))))). The domain of this relation is a vaccine. The range of this relation is a disease. Asiyah Yu Lin Oliver He immunization against disease vaccine immunization against disease immunizes against disease an object property that represents an organism has a mutation of a specific gene from the organism genome. Yongqun He has gene mutation a shortcut relation that equals to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism')))))))). The domain of this relation is a vaccine. The range of this relation is a organism. YL Yongqun He immunization for host vaccine immunization for host immunizes host An object property that represents a relation between a vaccine with a prime-boost schedule and a vaccine used for priming. Oliver He has prime vaccine An object property that represents a relation between a vaccine with a prime-boost schedule and a vaccine used for boost. Oliver He has boost vaccine a shortcut relation that equals to: processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'MICROBE')))))))) The domain of this relation is a vaccine. The range of this relation is a microbe (a bacterium, a virus, a fungus, and a parasite) Yongqun He immunization against microbe vaccine immunization against microbe immunizes against microbe a shortcut object property that represents a relation between a vaccine and a disease process where the vaccine immunizes a host against a disease process. Oliver He immunizes against disease process An object property that represents a relation between a material entity and biological process Anthony Huffman, Oliver He up-expressed as immune signature of An object property that represents a relation between a material entity (such as vaccine or vaccine adjuvant) and an immune profile where the material entity can induce the immune profile in a host. Oliver He, Amogh Madireddi induces immune profile A vaccine adjuvant T-vant has molecular receptor of TLR4. Reference: https://vac.niaid.nih.gov/view?id=61. An object property that represents a relation between a material entity and a molecular entitiy that serves as the molecular receptor to the material entity. Oliver He has molecular receptor A relationship between relationship between a material entity and a parasite where the material entity causes some processagainst some parasite such that transmitting to additional hosts or vectors. capable of blocking transmission (of life cycle) A relationship between relationship between a vaccine and a parasite where the vaccine immunizes against some parasite such that transmitting to additional hosts or vectors. Anthony Huffman, Anna Maria Masci, Oliver He, Jie Zheng blocks transmission of pathogen via vaccine A relationship between a vaccine X and organism Y where the vaccine X generates an immune response in a vaccinated organism and the immune product (e.g., antibody) can be transferred to the organism Y Anthony Huffman, Anna Maria Masci, Oliver He, Jie Zheng vaccine immunity response transferrable to organism entity Entity Julius Caesar Verdi’s Requiem the Second World War your body mass index BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) entity Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf per discussion with Barry Smith An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) continuant Continuant An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts. BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] continuant Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] occurrent Occurrent An entity that has temporal parts and that happens, unfolds or develops through time. BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] occurrent Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. per discussion with Barry Smith Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] ic IndependentContinuant a chair a heart a leg a molecule a spatial region an atom an orchestra. an organism the bottom right portion of a human torso the interior of your mouth b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] A continuant that is a bearer of quality and realizable entity entities, in which other entities inhere and which itself cannot inhere in anything. independent continuant b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] s-region SpatialRegion BFO 2 Reference: Spatial regions do not participate in processes. Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional. A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001]) All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001]) (forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] (forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] spatial region Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional. per discussion with Barry Smith A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001]) All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001]) (forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] (forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] t-region TemporalRegion Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001]) All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001]) Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002]) (forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] (forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] (forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] temporal region Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional per discussion with Barry Smith A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001]) All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001]) Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002]) (forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] (forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] (forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] 2d-s-region TwoDimensionalSpatialRegion an infinitely thin plane in space. the surface of a sphere-shaped part of space A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001]) (forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] two-dimensional spatial region A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001]) (forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] st-region SpatiotemporalRegion the spatiotemporal region occupied by a human life the spatiotemporal region occupied by a process of cellular meiosis. the spatiotemporal region occupied by the development of a cancer tumor A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001]) All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001]) Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001]) Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001]) Every spatiotemporal region occupies_spatiotemporal_region itself. Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002]) (forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] (forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] (forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] (forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] (forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] spatiotemporal region A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001]) All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001]) Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001]) Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001]) Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002]) (forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] (forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] (forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] (forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] (forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] process Process a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping the course of a disease the flight of a bird the life of an organism your process of aging. p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. process p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] disposition Disposition an atom of element X has the disposition to decay to an atom of element Y certain people have a predisposition to colon cancer children are innately disposed to categorize objects in certain ways. the cell wall is disposed to filter chemicals in endocytosis and exocytosis BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] disposition b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] realizable RealizableEntity the disposition of this piece of metal to conduct electricity. the disposition of your blood to coagulate the function of your reproductive organs the role of being a doctor the role of this boundary to delineate where Utah and Colorado meet A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances. To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] realizable entity To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] 0d-s-region ZeroDimensionalSpatialRegion A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001]) (forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] zero-dimensional spatial region A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001]) (forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] quality Quality the ambient temperature of this portion of air the color of a tomato the length of the circumference of your waist the mass of this piece of gold. the shape of your nose the shape of your nostril a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] quality a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] sdc SpecificallyDependentContinuant Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key of one-sided specifically dependent continuants: the mass of this tomato of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. the disposition of this fish to decay the function of this heart: to pump blood the mutual dependence of proton donors and acceptors in chemical reactions [79 the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction the pink color of a medium rare piece of grilled filet mignon at its center the role of being a doctor the shape of this hole. the smell of this portion of mozzarella b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] A continuant that inheres in or is borne by other entities. Every instance of A requires some specific instance of B which must always be the same. specifically dependent continuant b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. per discussion with Barry Smith (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] role Role John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. the priest role the role of a boundary to demarcate two neighboring administrative territories the role of a building in serving as a military target the role of a stone in marking a property boundary the role of subject in a clinical trial the student role A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts. BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] role b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] fiat-object-part FiatObjectPart or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29 the FMA:regional parts of an intact human body. the Western hemisphere of the Earth the division of the brain into regions the division of the planet into hemispheres the dorsal and ventral surfaces of the body the upper and lower lobes of the left lung BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004]) (forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] fiat object part b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004]) (forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] 1d-s-region OneDimensionalSpatialRegion an edge of a cube-shaped portion of space. A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001]) (forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] one-dimensional spatial region A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001]) (forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] object-aggregate ObjectAggregate a collection of cells in a blood biobank. a swarm of bees is an aggregate of members who are linked together through natural bonds a symphony orchestra an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team) defined by fiat: the aggregate of members of an organization defined through physical attachment: the aggregate of atoms in a lump of granite defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container defined via attributive delimitations such as: the patients in this hospital the aggregate of bearings in a constant velocity axle joint the aggregate of blood cells in your body the nitrogen atoms in the atmosphere the restaurants in Palo Alto your collection of Meissen ceramic plates. An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee). ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158. b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004]) (forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] object aggregate An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158. b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004]) (forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] 3d-s-region ThreeDimensionalSpatialRegion a cube-shaped region of space a sphere-shaped region of space, A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001]) (forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] three-dimensional spatial region A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001]) (forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] site Site Manhattan Canyon) a hole in the interior of a portion of cheese a rabbit hole an air traffic control region defined in the airspace above an airport the Grand Canyon the Piazza San Marco the cockpit of an aircraft the hold of a ship the interior of a kangaroo pouch the interior of the trunk of your car the interior of your bedroom the interior of your office the interior of your refrigerator the lumen of your gut your left nostril (a fiat part – the opening – of your left nasal cavity) b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]) (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] site b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]) (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] object Object atom cell cells and organisms engineered artifacts grain of sand molecule organelle organism planet solid portions of matter star BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting. BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below). BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47 BFO 2 Reference: an object is a maximal causally unified material entity BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74 b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) object b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) gdc GenericallyDependentContinuant The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. the pdf file on your laptop, the pdf file that is a copy thereof on my laptop the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time. generically dependent continuant b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] function Function the function of a hammer to drive in nails the function of a heart pacemaker to regulate the beating of a heart through electricity the function of amylase in saliva to break down starch into sugar BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc. A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] function A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] p-boundary ProcessBoundary the boundary between the 2nd and 3rd year of your life. p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001]) Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002]) (forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] (iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] process boundary p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001]) Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002]) (forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] (iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] 1d-t-region OneDimensionalTemporalRegion the temporal region during which a process occurs. BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks). A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001]) (forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] one-dimensional temporal region A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001]) (forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] material MaterialEntity a flame a forest fire a human being a hurricane a photon a puff of smoke a sea wave a tornado an aggregate of human beings. an energy wave an epidemic the undetached arm of a human being An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time. BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] material entity A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] cf-boundary ContinuantFiatBoundary b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001]) BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions. BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29 Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions. Every continuant fiat boundary is located at some spatial region at every time at which it exists (iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] continuant fiat boundary b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001]) Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions. (iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] immaterial ImmaterialEntity BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10 immaterial entity 1d-cf-boundary OneDimensionalContinuantFiatBoundary The Equator all geopolitical boundaries all lines of latitude and longitude the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin. the median sulcus of your tongue a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001]) (iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] one-dimensional continuant fiat boundary a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001]) (iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] process-profile ProcessProfile On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance. The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on. b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002]) b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005]) (forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] (iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] process profile b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002]) b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005]) (forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] (iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] r-quality RelationalQuality John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. a marriage bond, an instance of requited love, an obligation between one person and another. b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001]) (iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] relational quality b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001]) (iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] 2d-cf-boundary TwoDimensionalContinuantFiatBoundary a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001]) (iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] two-dimensional continuant fiat boundary a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001]) (iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] 0d-cf-boundary ZeroDimensionalContinuantFiatBoundary the geographic North Pole the point of origin of some spatial coordinate system. the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona. a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001]) (iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] zero-dimensional continuant fiat boundary zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona. requested by Melanie Courtot a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001]) (iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] 0d-t-region ZeroDimensionalTemporalRegion a temporal region that is occupied by a process boundary right now the moment at which a child is born the moment at which a finger is detached in an industrial accident the moment of death. temporal instant. A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001]) (forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] zero-dimensional temporal region A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001]) (forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] history History A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001]) history A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001]) Digestive gland of crustaceans with functions approximately analogous to liver and pancreas of vertebrates - enzyme secretion, food absorption and storage. hepatopancreas 1: The trunk of an elephant; also: any long flexible snout. 2: Any of various elongated or extensible tubular processes as the sucking organ of a butterfly of the oral region of an invertebrate. proboscis An organic hydroxy compound that consists of benzene bearing a single hydroxy substituent. The parent of the class of phenols. 0 C6H6O InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H ISWSIDIOOBJBQZ-UHFFFAOYSA-N 94.11120 94.04186 Oc1ccccc1 CHEBI:14777 CHEBI:25966 CHEBI:43543 CHEBI:8071 Beilstein:969616 CAS:108-95-2 DrugBank:DB03255 Drug_Central:4266 Gmelin:2794 HMDB:HMDB0000228 KEGG:C00146 KEGG:C15584 KEGG:D00033 KEGG:D06536 KNApSAcK:C00002664 PDBeChem:IPH PMID:12058733 PMID:16953321 PMID:17852157 PMID:19029204 PMID:20886261 PMID:21492257 PMID:21689881 PMID:21809019 PMID:21822930 Reaxys:969616 UM-BBD_compID:c0128 Wikipedia:Phenol PHENOL Phenol phenol chebi_ontology Benzenol Carbolsaeure Hydroxybenzene Karbolsaeure Oxybenzene PhOH Phenic acid Phenylic acid Phenylic alcohol acide carbolique acide phenique carbolic acid CHEBI:15882 phenol A carbonyl group with two C-bound amine groups. The commercially available fertilizer has an analysis of 46-0-0 (N-P2O5-K2O). 0 CH4N2O InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4) XSQUKJJJFZCRTK-UHFFFAOYSA-N 60.05534 60.03236 NC(N)=O CHEBI:15292 CHEBI:27218 CHEBI:46379 CHEBI:9888 Beilstein:635724 CAS:57-13-6 DrugBank:DB03904 Drug_Central:4264 ECMDB:ECMDB04172 Gmelin:1378 HMDB:HMDB0000294 KEGG:C00086 KEGG:D00023 KNApSAcK:C00007314 MetaCyc:UREA PDBeChem:URE PMID:18037357 PMID:22770225 PPDB:1728 Reaxys:635724 UM-BBD_compID:c0165 Wikipedia:Urea YMDB:YMDB00003 UREA Urea urea chebi_ontology 1728 Carbamide E927b H2NC(O)NH2 Harnstoff Karbamid carbamide carbonyldiamide ur uree CHEBI:16199 urea Liposaccharide natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria). CHEBI:14520 CHEBI:25062 CHEBI:6494 KEGG:C00338 PMID:15589368 PMID:24186868 PMID:24506665 PMID:24642373 PMID:24659348 Lipopolysaccharide chebi_ontology LPS lipopolysaccharides CHEBI:16412 lipopolysaccharide Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. 0 (C2H2NOR)nC2H3NOR CHEBI:14753 CHEBI:25906 CHEBI:7990 KEGG:C00012 Peptide peptides chebi_ontology Peptid peptido peptidos CHEBI:16670 peptide An aldehyde resulting from the formal oxidation of methanol. 0 CH2O InChI=1S/CH2O/c1-2/h1H2 WSFSSNUMVMOOMR-UHFFFAOYSA-N 30.02598 30.01056 [H]C([H])=O CHEBI:14274 CHEBI:24077 CHEBI:337763 CHEBI:5142 Beilstein:1209228 CAS:50-00-0 DrugBank:DB03843 Drug_Central:3244 Gmelin:445 HMDB:HMDB0001426 KEGG:C00067 KEGG:D00017 MetaCyc:FORMALDEHYDE PDBeChem:FOR PMID:110589 PMID:12686735 PMID:15091529 PMID:16423181 PMID:17618393 PMID:18837732 PMID:25042713 PMID:7381846 PMID:7548723 PMID:7689168 PMID:7896413 PMID:9686972 PPDB:359 Reaxys:1209228 UM-BBD_compID:c0122 Wikipedia:Formaldehyde FORMALDEHYDE Formaldehyde formaldehyde chebi_ontology FORMALIN Formaldehyd Formalin Methanal Methylene oxide Oxomethane Oxomethylene CHEBI:16842 formaldehyde A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class 0 C21H39N7O12 InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1 UCSJYZPVAKXKNQ-HZYVHMACSA-N 581.57434 581.26567 CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@@H](O[C@@H](C)[C@]1(O)C=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]1NC(N)=N CHEBI:15119 CHEBI:26784 CHEBI:45745 CHEBI:9284 Beilstein:74498 CAS:57-92-1 DrugBank:DB01082 Drug_Central:2481 HMDB:HMDB0015214 KEGG:C00413 KEGG:D08531 MetaCyc:STREPTOMYCIN PDBeChem:SRY PMID:11228320 PMID:11905029 PMID:12118520 PMID:13030054 PMID:13116094 PMID:13136149 PMID:13596285 PMID:13691614 PMID:13985260 PMID:13990247 PMID:14623118 PMID:14828344 PMID:14852338 PMID:14939639 PMID:15081082 PMID:15137533 PMID:15207172 PMID:15686853 PMID:15736038 PMID:16904706 PMID:17105735 PMID:17238915 PMID:17429930 PMID:18173084 PMID:18916143 PMID:19052412 PMID:19335957 PMID:21350946 PMID:21362244 PMID:21593257 PMID:21937264 PMID:22101040 Pesticides:streptomycin Reaxys:74498 Wikipedia:Streptomycin N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine STREPTOMYCIN chebi_ontology 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside Kantrex SM [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine} streomycin streptomycin CHEBI:17076 streptomycin A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form. 0 C12H22O11 InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11?,12+/m1/s1 GUBGYTABKSRVRQ-QKKXKWKRSA-N 342.297 342.11621 OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O CHEBI:10296 CHEBI:10380 CHEBI:14497 CHEBI:22460 CHEBI:22760 CHEBI:25005 CHEBI:27755 CHEBI:613009 Beilstein:1292745 CAS:63-42-3 GlyGen:G74621DY GlyTouCan:G74621DY Gmelin:882872 KEGG:C00243 KEGG:D00046 KEGG:G10504 KNApSAcK:C00001136 PMID:1292745 PMID:17329833 PMID:18300214 PMID:19053747 PMID:19846069 PMID:19913595 PMID:20094999 PMID:20503067 PMID:20699559 PMID:20873837 PMID:20961532 PMID:21403918 PMID:2432147 PMID:2456994 PMID:28690131 PMID:28807538 PMID:6194884 PMID:7574700 Reaxys:1292745 beta-D-galactopyranosyl-(1->4)-D-glucopyranose lactose chebi_ontology (+)-lactose (Gal)1 (Glc)1 1-beta-D-Galactopyranosyl-4-D-glucopyranose 4-(beta-D-galactosido)-D-glucose 4-O-beta-D-galactopyranosyl-D-glucose D-lactose Galbeta1-4Glc Lac Laktobiose Laktose Milchzucker Milk sugar WURCS=2.0/2,2,1/[a2122h-1x_1-5][a2112h-1b_1-5]/1-2/a4-b1 beta-D-Gal-(1->4)-D-Glc beta-D-Galp-(1->4)-D-Glcp beta-Gal1,4-Glc lactobiose milk sugar CHEBI:17716 lactose Any of a group of aminoglycoside antibiotics produced by fermentation of some Micromonospora spp. CHEBI:14293 CHEBI:24206 CHEBI:24212 CHEBI:5306 CAS:1403-66-3 DrugBank:DB00798 KEGG:C00505 4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)pentopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside chebi_ontology Gentamicin gentamycins CHEBI:17833 gentamycin A glycosyl glycoside formed by glucose and fructose units joined by an acetal oxygen bridge from hemiacetal of glucose to the hemiketal of the fructose. 0 C12H22O11 InChI=1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1 CZMRCDWAGMRECN-UGDNZRGBSA-N 342.29650 342.11621 OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O CHEBI:15128 CHEBI:26812 CHEBI:45795 CHEBI:9314 Beilstein:90825 CAS:57-50-1 DrugBank:DB02772 Drug_Central:4610 Gmelin:97695 HMDB:HMDB0000258 KEGG:C00089 KEGG:D00025 KEGG:D06533 KEGG:G00370 KNApSAcK:C00001151 MetaCyc:SUCROSE PDBeChem:SUC PMID:11021636 PMID:11093712 PMID:11111003 PMID:12065720 PMID:12706980 PMID:13508893 PMID:15291457 PMID:15660210 PMID:15792978 PMID:15845855 PMID:16228482 PMID:16304615 PMID:16313996 PMID:16525719 PMID:16660545 PMID:16663947 PMID:16665852 PMID:17233733 PMID:17439666 PMID:17597061 PMID:18625236 PMID:19199566 PMID:19726178 PMID:21703290 PMID:21972845 PMID:22085755 PMID:22311778 PMID:22404833 PMID:22751876 Reaxys:1435311 Reaxys:90825 Wikipedia:Sucrose SUCROSE Sucrose beta-D-fructofuranosyl alpha-D-glucopyranoside sucrose chebi_ontology 1-alpha-D-Glucopyranosyl-2-beta-D-fructofuranoside Cane sugar Saccharose Sacharose White sugar beta-D-Fruf-(2<->1)-alpha-D-Glcp sacarosa table sugar CHEBI:17992 sucrose Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. molecular entity chebi_ontology entidad molecular entidades moleculares entite moleculaire molecular entities molekulare Entitaet CHEBI:23367 molecular entity A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances. chemical entity chebi_ontology CHEBI:24431 chemical entity An inorganic chloride salt having sodium(1+) as the counterion. 0 ClNa InChI=1S/ClH.Na/h1H;/q;+1/p-1 FAPWRFPIFSIZLT-UHFFFAOYSA-M 58.44247 57.95862 [Na+].[Cl-] Beilstein:3534976 CAS:7647-14-5 Gmelin:13673 KEGG:C13563 KEGG:D02056 MetaCyc:NACL PPDB:595 Reaxys:3534976 Wikipedia:Sodium_Chloride sodium chloride chebi_ontology Kochsalz NaCl Natriumchlorid chlorure de sodium cloruro sodico common salt halite natrii chloridum rock salt salt table salt CHEBI:26710 sodium chloride A dipeptide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of methyl L-phenylalaninate. Commonly used as an artificial sweetener. 0 C14H18N2O5 InChI=1S/C14H18N2O5/c1-21-14(20)11(7-9-5-3-2-4-6-9)16-13(19)10(15)8-12(17)18/h2-6,10-11H,7-8,15H2,1H3,(H,16,19)(H,17,18)/t10-,11-/m0/s1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 294.304 294.12157 C(C[C@@H](C(N[C@@H](CC1=CC=CC=C1)C(=O)OC)=O)N)(=O)O CHEBI:45047 Beilstein:2223850 CAS:22839-47-0 DrugBank:DB00168 HMDB:HMDB0001894 KEGG:C11045 KEGG:D02381 PDBeChem:PME PMID:1771173 PMID:2013754 PMID:21150094 PMID:21372000 PMID:22354473 PMID:24355796 PMID:24925367 PMID:24944748 PMID:24965331 PMID:25431414 PMID:25543075 PMID:25786106 PMID:25951455 PMID:25991916 PMID:26015492 PMID:26099025 PMID:26159964 PMID:26247507 PMID:26308194 PMID:26321723 PMID:26377607 PMID:26582819 PMID:26593524 PMID:26912665 PMID:27015640 PMID:27038223 PMID:27088715 PMID:27127997 PMID:27216413 PMID:27298583 PMID:27492574 PMID:27565676 PMID:27614095 PMID:27640132 PMID:27699780 PMID:27728881 PMID:27840415 PMID:27845306 PMID:30000570 PMID:37291632 PMID:37297402 PMID:37454665 Patent:US3492131 Reaxys:2223850 Wikipedia:Aspartame Aspartame methyl L-alpha-aspartyl-L-phenylalaninate chebi_ontology 1-methyl N-L-alpha-aspartyl-L-phenylalanate 3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester 3-Amino-N-(alpha-methoxycarbonylphenethyl) succinamic acid AminoSweet Asp-phe-ome Aspartylphenylalanine methyl ester E 951 L-Aspartyl-L-phenylalanine methyl ester NutraSweet Sanecta aspartam aspartamo aspartamum CHEBI:2877 aspartame 0 C6H14O6 182.172 182.07904 CHEBI:15093 CHEBI:26724 CHEBI:26726 CHEBI:33795 CHEBI:33796 CHEBI:9201 Beilstein:1721909 Gmelin:83165 Wikipedia:Sorbitol glucitol chebi_ontology Sorbitol gulitol rel-(2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol CHEBI:30911 glucitol A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent. 0 C7H5NO3S InChI=1S/C7H5NO3S/c9-7-5-3-1-2-4-6(5)12(10,11)8-7/h1-4H,(H,8,9) CVHZOJJKTDOEJC-UHFFFAOYSA-N 183.18500 182.99901 O=C1NS(=O)(=O)c2ccccc12 CHEBI:49717 Beilstein:6888 CAS:81-07-2 Gmelin:4203 HMDB:HMDB0029723 KEGG:D01085 MetaCyc:CPD-5581 PDBeChem:LSA PMID:24456165 PMID:24549104 PMID:24739358 PMID:24780866 Reaxys:6888 Wikipedia:Saccharin 1,2-benzisothiazol-3(2H)-one 1,1-dioxide Saccharin chebi_ontology 1,1-Dioxo-1,2-benzisothiazol-3(2H)-one 1,1-Dioxo-1,2-dihydro-benzo[d]isothiazol-3-one 1,2-Benzisothiazol-3(2H)-one 1,1-dioxide 1,2-Benzisothiazolin-3-one 1,1-dioxide 1,2-Dihydro-2-ketobenzisosulfonazole 1,2-Dihydro-2-ketobenzisosulphonazole 2,3-Dihydro-3-oxobenzisosulfonazole 2,3-Dihydro-3-oxobenzisosulphonazole 3-Hydroxybenzisothiazole-S,S-dioxide Anhydro-o-sulfaminebenzoic acid Benzo-2-sulphimide Benzoic acid sulfimide Benzoic sulfimide Benzoic sulphimide Benzosulfimide Benzosulphimide Benzoylsulfonic Imide Saccharimide Saccharine o-Benzoic sulfimide o-Benzosulfimide o-Sulfobenzimide o-Sulfobenzoic acid imide CHEBI:32111 saccharin 0 AlH3O3 H3AlO3 InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3 WNROFYMDJYEPJX-UHFFFAOYSA-K 78.00356 77.98976 [H]O[Al](O[H])O[H] CHEBI:30193 CHEBI:31195 CAS:21645-51-2 Drug_Central:4250 Gmelin:22216 KEGG:C13391 KEGG:D02859 Wikipedia:Aluminum_Hydroxide aluminium(3+) hydroxide aluminium(III) hydroxide trihydroxidoaluminium chebi_ontology Al(OH)3 Aluminiumhydroxid Aluminum hydroxide CHEBI:33130 aluminium hydroxide CAS:7632-05-5 Wikipedia:Sodium_phosphates sodium phosphate chebi_ontology phosphoric acid, sodium salt sodium orthophosphate sodium phosphates sodium salt of phosphoric acid CHEBI:37586 sodium phosphate A (1->6)-alpha-D-glucan which has extra branching consisting of (1->2), (1->3) or (1->4) linkages. CAS:9004-54-0 KEGG:C00372 KEGG:D00060 KEGG:D06541 KEGG:G10502 PMID:8154046 chebi_ontology (1,6-alpha-D-Glucosyl)m (1,6-alpha-D-Glucosyl)m+1 (1,6-alpha-D-Glucosyl)n (1,6-alpha-D-Glucosyl)n+1 1,6-alpha-D-Glucan Dextran 40 Dextran 70 Dextran 75 dextran dextrane dextrano dextrans dextranum CHEBI:52071 dextran A polymer composed of PEG-ylated sorbitan, where the total number of poly(ethylene glycol) units is 20 (w + x + y + z = 20) and a single terminal is capped by a dodecanoyl group. 0 C58H114O26 1226.75977 1226.760 Beilstein:8973037 CAS:9005-64-5 KEGG:C11624 KEGG:D05565 Reaxys:8187252 Reaxys:8973037 Wikipedia:Polysorbate_20 chebi_ontology Polyoxyethylene (20) sorbitan monolaurate Polyoxyethylene sorbitan monolaurate Polysorbate Polysorbate 20 Tween 20 polisorbato polysorbate polysorbatum CHEBI:53424 polysorbate 20 A polymer composed of PEG-ylated sorbitan, where the total number of poly(ethylene glycol) units is 20 (w + x + y + z = 20) and a single terminal is capped by an oleoyl group. 0 C64H124O26 1308.83802 1308.838 CHEBI:9785 Beilstein:8187125 CAS:9005-65-6 KEGG:C11625 KEGG:D01067 Reaxys:8187125 Reaxys:8190601 Reaxys:8898414 Reaxys:9040798 Wikipedia:Polysorbate_80 chebi_ontology Glycol (polysorbate 80) Polyethylene oxide sorbitan mono-oleate Polyoxyethylene (20) sorbitan monooleate Polyoxyethylene sorbitan monooleate Polyoxyethylene sorbitan oleate Polysorbate 80 Tween 80 polisorbato polysorbate polysorbatum CHEBI:53426 polysorbate 80 An organic sodium salt that is the monosodium salt of glutamic acid. 0 C5H8NNaO4 InChI=1S/C5H9NO4.Na/c6-3(5(9)10)1-2-4(7)8;/h3H,1-2,6H2,(H,7,8)(H,9,10);/q;+1/p-1 LPUQAYUQRXPFSQ-UHFFFAOYSA-M 169.11110 169.03510 [Na+].[NH3+]C(CCC([O-])=O)C([O-])=O PMID:22293291 Reaxys:17003240 sodium 2-azaniumylpentanedioate chebi_ontology MSG sodium 2-ammoniopentanedioate sodium glutamate CHEBI:64220 monosodium glutamate A broad-spectrum highly toxic antibiotic or mixture of antibiotics produced by a streptomyces (Streptomyces fradiae) and used medically especially to treat local infections. CAS:1404-04-2 DrugBank:DB00994 KEGG:C00384 KEGG:D08260 Neomycin chebi_ontology CHEBI:7507 neomycin An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent. 0 C9H9HgNaO2S C9H9HgO2S.Na InChI=1S/C7H6O2S.C2H5.Hg.Na/c8-7(9)5-3-1-2-4-6(5)10;1-2;;/h1-4,10H,(H,8,9);1H2,2H3;;/q;;2*+1/p-2 RTKIYNMVFMVABJ-UHFFFAOYSA-L 404.81233 405.99274 [Na+].CC[Hg]Sc1ccccc1C([O-])=O Beilstein:8169555 CAS:54-64-8 Gmelin:1677155 KEGG:D00864 PMID:18837732 PMID:21616561 PMID:21785120 PMID:22015977 PMID:22366633 PMID:22658806 PMID:22811707 PMID:23145070 PMID:23223227 PMID:23282150 PMID:23401210 PMID:23554557 PMID:23843785 PMID:23949514 PMID:23965928 PMID:23992327 PMID:25042713 PPDB:3062 Reaxys:8169555 VSDB:3062 Thimerosal sodium [(2-carboxylatophenyl)sulfanyl](ethyl)mercurate(1-) sodium ethyl[2-(sulfanyl-kappaS)benzoato(2-)]mercurate(1-) chebi_ontology Merthiolate Thiomersal [(o-carboxyphenyl)thio]ethylmercury sodium salt ethyl(2-mercaptobenzoato-S)mercury sodium salt ethylmercurithiosalicylate sodium ethylmercurithiosalicylic acid sodium salt mercurothiolate o-(ethylmercurithio)benzoic acid sodium salt sodium ethylmercurithiosalicylate sodium merthiolate thiomersal thiomersalate thiomersalum tiomersal CHEBI:9546 thimerosal A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. cell The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated. hepatocyte A red blood cell. In mammals, mature erythrocytes are biconcave disks containing hemoglobin whose function is to transport oxygen. erythrocyte A mononuclear phagocyte present in variety of tissues, typically differentiated from monocytes, capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells. macrophage A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions. infectious disease DOID:10115 DOID:11078 DOID:1304 DOID:1321 DOID:2040 DOID:2288 DOID:3099 DOID:4120 DOID:4620 DOID:5256 DOID:945 DOID:95 DOID:9532 DOID:9696 ICD9CM:079.0 UMLS_CUI:C0001485 infectious disease disease_ontology DOID:0050117 DO:wk disease by infectious agent A bacterial infectious disease that results_in infection by bacteria as a result of their presence or activity within the normal, healthy host, and their intrinsic virulence is, in part, a necessary consequence of their need to reproduce and spread. disease_ontology DOID:0050338 primary bacterial infectious disease A cancer that is classified by the type of cell from which it is derived. snadendla 2011-06-13T03:28:50Z disease_ontology DOID:0050687 cell type cancer A disease by infectious agent that results_in infection, has_material_basis_in Bacteria. ICD10CM:A49.9 MESH:D001424 NCI:C2890 SNOMEDCT_US_2023_03_01:87628006 UMLS_CUI:C0004623 disease_ontology DOID:104 bacterial infectious disease A brucellosis that involves an infection caused by Brucella suis [NCBITaxon:29461] in swine and humans. The disease has_symptom fever, has_symptom chills, has_symptom malaise, has_symptom diaphoresis, has_symptom arthralgia, has_symptom myalgia, has_symptom headache, has_symptom anorexia, and has_symptom fatigue. disease_ontology DOID:11076 Brucella suis brucellosis A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has_symptom fever, has_symptom sweat, has_symptom headache, has_symptom back pain, has_symptom physical weakness, has_symptom joint pain and has_symptom fatigue. DOID:0050060 GARD:5966 ICD10CM:A23 ICD9CM:023 MESH:D002006 NCI:C84602 SNOMEDCT_US_2023_03_01:154296006 UMLS_CUI:C0006309 Maltese fever undulant fever disease_ontology Bang's disease Gibraltar fever Malta fever Mediterranean fever DOID:11077 brucellosis A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle. DOID:12552 EFO:0001068 GARD:6961 ICD10CM:B54 ICD9CM:084 MESH:D008288 NCI:C34797 SNOMEDCT_US_2023_03_01:154374002 UMLS_CUI:C0024530 induced malaria disease_ontology DOID:12365 Xref MGI. malaria A disease by infectious agent that is carried out by a parasite which by definition is a pathogen that simultaneously injures and derives sustenance from its host. DOID:11681 DOID:13509 DOID:1396 DOID:1494 DOID:2114 DOID:2293 DOID:2922 DOID:3564 DOID:4191 DOID:886 DOID:948 DOID:9639 DOID:9644 ICD10CM:H44.12 ICD9CM:360.13 NCI:C34587 SNOMEDCT_US_2023_03_01:57100005 UMLS_CUI:C0014238 Ectoparasitic disease parasitemia disease_ontology DOID:1398 parasitic infectious disease A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever. ICD10CM:B50 ICD9CM:084.0 MESH:D016778 NCI:C34798 SNOMEDCT_US_2023_03_01:62676009 UMLS_CUI:C0024535 Malaria fever, subtertian falciparum malaria malignant tertian fever disease_ontology DOID:14067 Plasmodium falciparum malaria A brucellosis that involves an infection caused by Brucella melitensis [NCBITaxon:29459] in cattle, goats, sheep and humans. The disease has_symptom fever, has_symptom malaise, has_symptom anorexia, has_symptom limb pain and has_symptom back pain. ICD10CM:A23.0 ICD9CM:023.0 SNOMEDCT_US_2023_03_01:186305007 UMLS_CUI:C0302362 disease_ontology DOID:14456 Brucella melitensis brucellosis A brucellosis that involves an infection caused by Brucella abortus [NCBITaxon:235] in cattle and humans. The disease has_symptom fever, has_symptom chills, has_symptom sweats, has_symptom weight loss, has_symptom malaise, has_symptom headaches, has_symptom myalgia, and has_symptom arthralgia. ICD10CM:A23.1 ICD9CM:023.1 MESH:D002007 SNOMEDCT_US_2023_03_01:427795000 UMLS_CUI:C0302363 disease_ontology DOID:14457 Brucella abortus brucellosis A disease that is characterized by abnormally rapid cell division. neoplasm DOID:0000818 cell process disease neoplasm disease_ontology DOID:14566 disease of cellular proliferation A disease of anatomical entity that located_in the respiratory system which extends from the nasal sinuses to the diaphragm. DOID:3226 ICD10CM:J98 ICD9CM:519 SNOMEDCT_US_2023_03_01:155603009 UMLS_CUI:C0029582 disease_ontology DOID:1579 respiratory system disease A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis. ICD10CM:C80.1 ICD9CM:199 ICDO:8000/3 MESH:D009369 NCI:C9305 SNOMEDCT_US_2023_03_01:269513004 UMLS_CUI:C0006826 malignant neoplasm malignant tumor primary cancer disease_ontology DOID:162 Updating out dated UMLS CUI. cancer A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye. EFO:0000756 ICDO:8720/3 KEGG:05218 MESH:D008545 NCI:C3224 SNOMEDCT_US_2023_03_01:2092003 UMLS_CUI:C0025202 Naevocarcinoma malignant melanoma disease_ontology DOID:1909 melanoma MESH:D008545 A parasitic infectious disease that is caused by parasitic protozoa which are microorganisms classified as unicellular eukaryotes. DOID:0060003 DOID:10553 DOID:3734 DOID:3804 DOID:947 ICD10CM:B64 MESH:D011528 NCI:C34953 SNOMEDCT_US_2023_03_01:95896000 UMLS_CUI:C0033740 mastigophora infectious disease sarcomastigophora infectious disease disease_ontology DOID:2789 parasitic protozoa infectious disease A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. MESH:D004194 NCI:C2991 SNOMEDCT_US_2023_03_01:64572001 UMLS_CUI:C0012634 disease_ontology DOID:4 disease A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands. ICD10CM:B20 ICD9CM:042-042.99 MESH:D015658 NCI:C3108 SNOMEDCT_US_2023_03_01:86406008 UMLS_CUI:C0019693 HIV infection disease_ontology DOID:526 human immunodeficiency virus infectious disease A disease that manifests in a defined anatomical structure. DOID:1 DOID:2 DOID:5 DOID:71 DOID:72 DOID:8 disease_ontology DOID:7 disease of anatomical entity A viral infectious disease that results in infection, located in respiratory tract, has_material_basis_in Influenzavirus A, has_material_basis_in Influenzavirus B, or has_material_basis_in Influenzavirus C, which are transmitted_by droplet spread of oronasal secretions during coughing, sneezing, or talking from an infected person. It is a highly contagious disease that affects birds and mammals and has_symptom chills, has_symptom fever, has_symptom sore throat, has_symptom runny nose, has_symptom muscle pains, has_symptom severe headache, has_symptom cough, and has_symptom weakness. DOID:8468 ICD10CM:J11.1 ICD9CM:487 MESH:D007251 NCI:C53482 SNOMEDCT_US_2023_03_01:155559006 UMLS_CUI:C0021400 Influenza with other manifestations flu influenza with non-respiratory manifestation disease_ontology DOID:8469 influenza A disease by infectious agent that results in infection, has_material_basis_in Viruses. DOID:1329 ICD10CM:A94 ICD10CM:B34.9 ICD9CM:060-066.99 MESH:D001102 MESH:D014777 NCI:C3439 NCI:C34396 SNOMEDCT_US_2023_03_01:34014006 SNOMEDCT_US_2023_03_01:40610006 UMLS_CUI:C0003723 UMLS_CUI:C0042769 Viral Infection Viral disease virus infection disease_ontology DOID:934 viral infectious disease fma FMA:12278 Hormone An immune response mediated by cells expressing specific receptors for antigens produced through a somatic diversification process, and allowing for an enhanced secondary response to subsequent exposures to the same antigen (immunological memory). Wikipedia:Adaptive_immune_system acquired immune response immune memory response biological_process GO:0002250 adaptive immune response An immune response taking place in mucosal tissues, including those of the intestinal tract, nasal and upper respiratory tract, and genital tract. GO:0002386 GO:0002422 immune response in MALT immune response in mucosal-associated lymphoid tissue immune response in urogenital tract biological_process GO:0002385 mucosal immune response Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. biological_process GO:0006955 immune response A biological process is the execution of a genetically-encoded biological module or program. It consists of all the steps required to achieve the specific biological objective of the module. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. https://github.com/geneontology/go-ontology/issues/24968 jl 2012-09-19T15:05:24Z GO:0000004 GO:0007582 GO:0044699 Wikipedia:Biological_process biological process physiological process biological_process single organism process single-organism process GO:0008150 Note that, in addition to forming the root of the biological process ontology, this term is recommended for use for the annotation of gene products whose biological process is unknown. When this term is used for annotation, it indicates that no information was available about the biological process of the gene product annotated as of the date the annotation was made; the evidence code 'no data' (ND), is used to indicate this. biological_process A protein complex that in its canonical form is composed of two identical immunoglobulin heavy chains and two identical immunoglobulin light chains, held together by disulfide bonds and sometimes complexed with additional proteins. An immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph. antibody cellular_component GO:0019814 Note that an immunoglobulin complex has the function of antigen binding if a suitable antigen is available. immunoglobulin complex A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. GO:0043234 macromolecular complex macromolecule complex protein containing complex protein complex protein-protein complex cellular_component GO:0032991 A protein complex in this context is meant as a stable set of interacting proteins which can be co-purified by an acceptable method, and where the complex has been shown to exist as an isolated, functional unit in vivo. Acceptable experimental methods include stringent protein purification followed by detection of protein interaction. The following methods should be considered non-acceptable: simple immunoprecipitation, pull-down experiments from cell extracts without further purification, colocalization and 2-hybrid screening. Interactions that should not be captured as protein complexes include: 1) enzyme/substrate, receptor/ligand or any similar transient interactions, unless these are a critical part of the complex assembly or are required e.g. for the receptor to be functional; 2) proteins associated in a pull-down/co-immunoprecipitation assay with no functional link or any evidence that this is a defined biological entity rather than a loose-affinity complex; 3) any complex where the only evidence is based on genetic interaction data; 4) partial complexes, where some subunits (e.g. transmembrane ones) cannot be expressed as recombinant proteins and are excluded from experiments (in this case, independent evidence is necessary to find out the composition of the full complex, if known). Interactions that may be captured as protein complexes include: 1) enzyme/substrate or receptor/ligand if the complex can only assemble and become functional in the presence of both classes of subunits; 2) complexes where one of the members has not been shown to be physically linked to the other(s), but is a homologue of, and has the same functionality as, a protein that has been experimentally demonstrated to form a complex with the other member(s); 3) complexes whose existence is accepted based on localization and pharmacological studies, but for which experimental evidence is not yet available for the complex as a whole. protein-containing complex Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism. GO:0051869 physiological response to stimulus biological_process GO:0050896 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. response to stimulus The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells. cell division A protein complex composed of two identical immunoglobulin heavy chains of an IgG isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgG immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph. mah 2010-03-24T01:44:53Z IgG1 IgG2 IgG2a IgG2b IgG2c IgG3 IgG4 cellular_component GO:0071735 Note that an IgG immunoglobulin complex has the function of antigen binding if a suitable antigen is available. Also, IgG isotypes vary by species. IgG immunoglobulin complex A protein complex composed of two identical immunoglobulin heavy chains of the IgD isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgD immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph. mah 2010-03-24T01:44:53Z cellular_component GO:0071738 Note that an IgD immunoglobulin complex has the function of antigen binding if a suitable antigen is available. IgD immunoglobulin complex A protein complex composed of two identical immunoglobulin heavy chains of the IgE isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgE immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph. mah 2010-03-24T01:44:53Z cellular_component GO:0071742 Note that an IgE immunoglobulin complex has the function of antigen binding if a suitable antigen is available. IgE immunoglobulin complex A protein complex composed of two identical immunoglobulin heavy chains of the IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and sometimes complexed with J chain or J chain and secretory component. An IgA immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph. mah 2010-03-24T01:44:53Z IgA1 antibody IgA2 antibody cellular_component GO:0071745 Note that an IgA immunoglobulin complex has the function of antigen binding if a suitable antigen is available. IgA immunoglobulin complex A protein complex composed of two identical immunoglobulin heavy chains of the IgM isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and in its circulating form complexed with J chain in polymeric forms. An IgM immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph. mah 2010-03-24T01:44:53Z cellular_component GO:0071753 Note that an IgM immunoglobulin complex has the function of antigen binding if a suitable antigen is available. IgM immunoglobulin complex conditional specification A directive information entity that specifies what should happen if the trigger condition is fulfilled. PlanAndPlannedProcess Branch OBI branch derived OBI_0000349 conditional specification measurement unit label Examples of measurement unit labels are liters, inches, weight per volume. A measurement unit label is as a label that is part of a scalar measurement datum and denotes a unit of measure. 2009-03-16: provenance: a term measurement unit was proposed for OBI (OBI_0000176) , edited by Chris Stoeckert and Cristian Cocos, and subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definition of this, different, term. 2009-03-16: review of this term done during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI. PERSON: Alan Ruttenberg PERSON: Melanie Courtot measurement unit label objective specification In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction. A directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved. 2009-03-16: original definition when imported from OBI read: "objective is an non realizable information entity which can serve as that proper part of a plan towards which the realization of the plan is directed." 2014-03-31: In the example of usage ("In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction") there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that. Answers the question, why did you do this experiment? PERSON: Alan Ruttenberg PERSON: Barry Smith PERSON: Bjoern Peters PERSON: Jennifer Fostel goal specification OBI Plan and Planned Process/Roles Branch OBI_0000217 objective specification Pour the contents of flask 1 into flask 2 A directive information entity that describes an action the bearer will take. Alan Ruttenberg OBI Plan and Planned Process branch action specification datum label A label is a symbol that is part of some other datum and is used to either partially define the denotation of that datum or to provide a means for identifying the datum as a member of the set of data with the same label http://www.golovchenko.org/cgi-bin/wnsearch?q=label#4n GROUP: IAO 9/22/11 BP: changed the rdfs:label for this class from 'label' to 'datum label' to convey that this class is not intended to cover all kinds of labels (stickers, radiolabels, etc.), and not even all kind of textual labels, but rather the kind of labels occuring in a datum. datum label journal article Examples are articles published in the journals, Nature and Science. The content can often be cited by reference to a paper based encoding, e.g. Authors, Title of article, Journal name, date or year of publication, volume and page number. A report that is published in a journal. PERSON: Alan Ruttenberg PERSON: Chris Stoeckert OBI_0000159 group:OBI journal article data item Data items include counts of things, analyte concentrations, and statistical summaries. An information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements. 2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers. 2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum. 2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym. 2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/ JAR: datum -- well, this will be very tricky to define, but maybe some information-like stuff that might be put into a computer and that is meant, by someone, to denote and/or to be interpreted by some process... I would include lists, tables, sentences... I think I might defer to Barry, or to Brian Cantwell Smith JAR: A data item is an approximately justified approximately true approximate belief PERSON: Alan Ruttenberg PERSON: Chris Stoeckert PERSON: Jonathan Rees data data item information content entity Examples of information content entites include journal articles, data, graphical layouts, and graphs. A generically dependent continuant that is about some thing. 2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ). information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907). Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity. PERSON: Chris Stoeckert OBI_0000142 information content entity 10 feet. 3 ml. A scalar measurement datum is a measurement datum that is composed of two parts, numerals and a unit label. 2009-03-16: we decided to keep datum singular in scalar measurement datum, as in this case we explicitly refer to the singular form Would write this as: has_part some 'measurement unit label' and has_part some numeral and has_part exactly 2, except for the fact that this won't let us take advantage of OWL reasoning over the numbers. Instead use has measurment value property to represent the same. Use has measurement unit label (subproperty of has_part) so we can easily say that there is only one of them. PERSON: Alan Ruttenberg PERSON: Melanie Courtot scalar measurement datum An information content entity whose concretizations indicate to their bearer how to realize them in a process. 2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was "is the specification of a process that can be concretized and realized by an actor" with alternative term "instruction".It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term. 2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it. 8/6/2009 Alan Ruttenberg: Changed label from "information entity about a realizable" after discussions at ICBO Werner pushed back on calling it realizable information entity as it isn't realizable. However this name isn't right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn't about the plan, it, once concretized, *is* the plan. -Alan PERSON: Alan Ruttenberg PERSON: Bjoern Peters directive information entity algorithm PMID: 18378114.Genomics. 2008 Mar 28. LINKGEN: A new algorithm to process data in genetic linkage studies. A plan specification which describes the inputs and output of mathematical functions as well as workflow of execution for achieving an predefined objective. Algorithms are realized usually by means of implementation as computer programs for execution by automata. Philippe Rocca-Serra PlanAndPlannedProcess Branch OBI_0000270 adapted from discussion on OBI list (Matthew Pocock, Christian Cocos, Alan Ruttenberg) algorithm curation status specification The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) PERSON:Bill Bug GROUP:OBI:<http://purl.obolibrary.org/obo/obi> OBI_0000266 curation status specification report Examples of reports are gene lists and investigation reports. These are not published (journal) articles but may be included in a journal article. A document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. Examples of reports are journal article, patent application, grant progress report, case report (not patient record). 2009-03-16: comment from Darren Natale: I am slightly uneasy with the sentence "Topic of the report is on something that has completed." Should it be restricted to those things that are completed? For example, a progress report is (usually) about something that definitely has *not* been completed, or may include (only) projections. I think the definition would not suffer if the whole sentence is deleted. 2009-03-16: this was report of results with definition: A report is a narrative object that is a formal statement of the results of an investigation, or of any matter on which definite information is required, made by some person or body instructed or required to do so. 2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI. 2009-08-10 Alan Ruttenberg: Larry Hunter suggests that this be obsoleted and replaced by 'document'. Alan restored as there are OBI dependencies and this merits further discussion disagreement about where reports go. alan: only some gene lists are reports. Is a report all the content of some document? The example of usage suggests that a report may be part of some article. Term needs clarification PERSON: Alan Ruttenberg PERSON: Chris Stoeckert PERSON: Melanie Courtot GROUP: OBI OBI_0000099 report data set Intensity values in a CEL file or from multiple CEL files comprise a data set (as opposed to the CEL files themselves). A data item that is an aggregate of other data items of the same type that have something in common. Averages and distributions can be determined for data sets. 2009/10/23 Alan Ruttenberg. The intention is that this term represent collections of like data. So this isn't for, e.g. the whole contents of a cel file, which includes parameters, metadata etc. This is more like java arrays of a certain rather specific type 2014-05-05: Data sets are aggregates and thus must include two or more data items. We have chosen not to add logical axioms to make this restriction. person:Allyson Lister person:Chris Stoeckert OBI_0000042 group:OBI data set data about an ontology part Data about an ontology part is a data item about a part of an ontology, for example a term Person:Alan Ruttenberg data about an ontology part plan specification PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice. A directive information entity with action specifications and objective specifications as parts, and that may be concretized as a realizable entity that, if realized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified. 2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was " a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan". It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term. 2014-03-31: A plan specification can have other parts, such as conditional specifications. 2022-01-16 Updated definition to that proposed by Clint Dowloand, IAO Issue 231. Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved Alan Ruttenberg Clint Dowland OBI Plan and Planned Process branch OBI_0000344 2/3/2009 Comment from OBI review. Action specification not well enough specified. Conditional specification not well enough specified. Question whether all plan specifications have objective specifications. Request that IAO either clarify these or change definitions not to use them plan specification https://github.com/information-artifact-ontology/IAO/issues/231#issuecomment-1010455131 measurement datum Examples of measurement data are the recoding of the weight of a mouse as {40,mass,"grams"}, the recording of an observation of the behavior of the mouse {,process,"agitated"}, the recording of the expression level of a gene as measured through the process of microarray experiment {3.4,luminosity,}. A measurement datum is an information content entity that is a recording of the output of a measurement such as produced by a device. 2/2/2009 is_specified_output of some assay? person:Chris Stoeckert OBI_0000305 group:OBI measurement datum obsolescence reason specification The reason for which a term has been deprecated. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. The creation of this class has been inspired in part by Werner Ceusters' paper, Applying evolutionary terminology auditing to the Gene Ontology. PERSON: Alan Ruttenberg PERSON: Melanie Courtot obsolescence reason specification document A journal article, patent application, laboratory notebook, or a book A collection of information content entities intended to be understood together as a whole PERSON: Lawrence Hunter document publication journal article, newspaper story, book, etc. A document that is the output of a publishing process. PERSON: Chris Stoeckert PERSON: Jie Zheng PERSON: Lawrence Hunter published document Revisit the term in Octorber 2020. Improve the defintion. publication denotator type The Basic Formal Ontology ontology makes a distinction between Universals and defined classes, where the formal are "natural kinds" and the latter arbitrary collections of entities. A denotator type indicates how a term should be interpreted from an ontological perspective. Alan Ruttenberg Barry Smith, Werner Ceusters denotator type ontology module I have placed this under 'data about an ontology part', but this can be discussed. I think this is OK if 'part' is interpreted reflexively, as an ontology module is the whole ontology rather than part of it. ontology file This class and it's subclasses are applied to OWL ontologies. Using an rdf:type triple will result in problems with OWL-DL. I propose that dcterms:type is instead used to connect an ontology URI with a class from this hierarchy. The class hierarchy is not disjoint, so multiple assertions can be made about a single ontology. ontology module base ontology module An ontology module that comprises only of asserted axioms local to the ontology, excludes import directives, and excludes axioms or declarations from external ontologies. base ontology module editors ontology module An ontology module that is intended to be directly edited, typically managed in source control, and typically not intended for direct consumption by end-users. source ontology module editors ontology module main release ontology module An ontology module that is intended to be the primary release product and the one consumed by the majority of tools. TODO: Add logical axioms that state that a main release ontology module is derived from (directly or indirectly) an editors module main release ontology module bridge ontology module An ontology module that consists entirely of axioms that connect or bridge two distinct ontology modules. For example, the Uberon-to-ZFA bridge module. bridge ontology module import ontology module A subset ontology module that is intended to be imported from another ontology. TODO: add axioms that indicate this is the output of a module extraction process. import file import ontology module subset ontology module An ontology module that is extracted from a main ontology module and includes only a subset of entities or axioms. ontology slim subset ontology subset ontology module curation subset ontology module A subset ontology that is intended as a whitelist for curators using the ontology. Such a subset will exclude classes that curators should not use for curation. curation subset ontology module analysis ontology module An ontology module that is intended for usage in analysis or discovery applications. analysis subset ontology module single layer ontology module A subset ontology that is largely comprised of a single layer or strata in an ontology class hierarchy. The purpose is typically for rolling up for visualization. The classes in the layer need not be disjoint. ribbon subset single layer subset ontology module exclusion subset ontology module A subset of an ontology that is intended to be excluded for some purpose. For example, a blacklist of classes. antislim exclusion subset ontology module external import ontology module An imported ontology module that is derived from an external ontology. Derivation methods include the OWLAPI SLME approach. external import external import ontology module species subset ontology module A subset ontology that is crafted to either include or exclude a taxonomic grouping of species. taxon subset species subset ontology module reasoned ontology module An ontology module that contains axioms generated by a reasoner. The generated axioms are typically direct SubClassOf axioms, but other possibilities are available. reasoned ontology module generated ontology module An ontology module that is automatically generated, for example via a SPARQL query or via template and a CSV. TODO: Add axioms (using PROV-O?) that indicate this is the output-of some reasoning process generated ontology module template generated ontology module An ontology module that is automatically generated from a template specification and fillers for slots in that template. template generated ontology module taxonomic bridge ontology module taxonomic bridge ontology module ontology module subsetted by expressivity ontology module subsetted by expressivity obo basic subset ontology module A subset ontology that is designed for basic applications to continue to make certain simplifying assumptions; many of these simplifying assumptions were based on the initial version of the Gene Ontology, and have become enshrined in many popular and useful tools such as term enrichment tools. Examples of such assumptions include: traversing the ontology graph ignoring relationship types using a naive algorithm will not lead to cycles (i.e. the ontology is a DAG); every referenced term is declared in the ontology (i.e. there are no dangling clauses). An ontology is OBO Basic if and only if it has the following characteristics: DAG Unidirectional No Dangling Clauses Fully Asserted Fully Labeled No equivalence axioms Singly labeled edges No qualifier lists No disjointness axioms No owl-axioms header No imports obo basic subset ontology module ontology module subsetted by OWL profile ontology module subsetted by OWL profile EL++ ontology module EL++ ontology module A symbiont role borne by an organism in virtue of the fact that it derives a growth, survival, or fitness advantage from symbiosis while the other symbiont's growth, survival, or fitness is reduced. Albert Goldfain Alexander Diehl Lindsay Cowell In the medical community, the term 'parasite' is used with the narrower meaning of eukaryotic pathogen. The role is realized in processes that result in the parasite's growth, survival, or fitness advantage or in the other organism's growth, survival, or fitness reduction. parasite role A role borne by an infectious agent when contained in a host in which its infectious disposition can be realized. infectious agent role A role borne by pathogen in virtue of the fact that it or one of its products is sufficiently close to an organism towards which it has the pathogenic disposition to allow realization of the pathogenic disposition. pathogen role A symbiont host role borne by an organism in virtue of the fact that its partner in symbiosis reaches developmental maturity or reproduces sexually in the host. Albert Goldfain Alexander Diehl Lindsay Cowell primary host role The role is realized in developmental and reproduction processes of the host's partner in symbiosis. definitive host role A symbiont host role borne by an organism in virtue of the fact that its partner in symbiosis utilizes the host to undergo a developmental stage transition, and the host is required for continuation of the partner's life cycle. intermediate host role A symbiont host role borne by an organism in virtue of the fact that its partner in symbiosis derives from the host a growth, survival, or fitness advantage while the host's growth, survival, or fitness is reduced. parasite host role An infectious agent transporter role that is borne by an organism active in the transfer of an infectious agent to an organism of another Species and in which the agent is infectious. Albert Goldfain Alexander Diehl Lindsay Cowell The role is realized in a transmission process. A bearer of a vector role is also a bearer of a host role. infectious agent vector role An infectious agent vector role borne by an organism in virtue of the fact that the infectious agent multiplies in the vector. Albert Goldfain Alexander Diehl Lindsay Cowell biological vector of infectious agent role A disposition to initiate processes that result in a disorder. Albert Goldfain Alexander Diehl Lindsay Cowell pathogenicity A pathogenic disposition is realized in processes that create a disorder. The use of 'initiates' is intended to convey that a pathogenic disposition is realized when processes resulting in a disorder begin because of some action on the part of the bearer of the disposition. By this interpretation of 'initiates', disorder-causing entities such as glass, UV light, and toxins do not have a pathogenic disposition. pathogenic disposition A material entity with a pathogenic disposition. Albert Goldfain Alexander Diehl Lindsay Cowell pathogen A biological macromolecule produced by a pathogen and that has a virulence factor disposition. Albert Goldfain Alexander Diehl Lindsay Cowell virulence factor house mouse mouse NCBITaxon:85055 GC_ID:1 house mouse mouse ncbi_taxonomy Mus musculus GC_ID:1 rat rats ncbi_taxonomy Rattus NCBITaxon:84274 GC_ID:1 domestic guinea pig guinea pig ncbi_taxonomy Cavia aperea porcellus Cavia cobaya Mus porcellus Cavia porcellus GC_ID:1 chinchillas chinchillas and viscachas ncbi_taxonomy Chinchillidae GC_ID:1 ncbi_taxonomy Vira Viridae viruses Viruses GC_ID:1 ncbi_taxonomy Poxviridae GC_ID:1 ncbi_taxonomy Chordopoxvirinae GC_ID:1 ncbi_taxonomy Orthopoxvirus NCBITaxon:130669 NCBITaxon:130670 GC_ID:1 monkey pox virus ncbi_taxonomy Monkeypox virus GC_ID:1 vaccinia virus VV ncbi_taxonomy Vaccinia virus NCBITaxon:12871 GC_ID:1 small pox virus smallpox smallpox virus variola virus VAR ncbi_taxonomy Variola virus GC_ID:1 Contagious pustular dermatitis virus ncbi_taxonomy Orf virus GC_ID:1 ncbi_taxonomy Avipoxvirus FWPV GC_ID:1 Avipoxvirus clade A1 Fowlpoxvirus fowl poxvirus fowlpox virus FP fowlpox virus FPV ncbi_taxonomy Fowlpox virus GC_ID:1 Pigeon pox virus Pigeon poxvirus pigeonpox virus PPV ncbi_taxonomy Pigeonpox virus GC_ID:1 H5N1 ncbi_taxonomy H5N1 subtype GC_ID:1 ncbi_taxonomy Herpesviridae GC_ID:1 Alphaherpesviruses ncbi_taxonomy Alphaherpesvirinae GC_ID:1 ncbi_taxonomy Simplexvirus HSV-1 HSV1 GC_ID:1 Herpes simplex virus type 1 Human herpesvirus type 1 herpes simplex virus 1 HSV-1 herpes simplex virus HSV-1 herpes simplex virus type 1 HSV-1 herpes simplex virus type 1 HSV1 herpes simplex virus type-1 HSV-1 ncbi_taxonomy Herpes simplex virus 1 Human herpesvirus 1 Human alphaherpesvirus 1 HSV2 GC_ID:1 Herpes simplex virus (type 2) Herpes simplex virus II Herpes simplex virus type 2 Herpes simplex virus type 2 (HSV-2) Human herpesvirus 2 ncbi_taxonomy Herpes simplex virus 2 herpes simplex virus type 2 HSV-2 Human alphaherpesvirus 2 GC_ID:1 ncbi_taxonomy Varicellovirus NCBITaxon:11265 NCBITaxon:12738 BoHV-1 GC_ID:1 Bovine herpesvirus 1 Bovine herpesvirus type 1 Bovine herpesvirus-1 Bovine rhinotracheitis virus bovine herpesvirus 1 BHV 1 bovine herpesvirus 1 BHV-1 bovine herpesvirus 1 BHV1 bovine herpesvirus BHV-1 bovine herpesvirus type 1 BHV-1 bovine herpesvirus type-1 BHV-1 infectious bovine rhinotracheitis virus BHV-1 ncbi_taxonomy Infectious bovine rhinotracheitis virus Bovine alphaherpesvirus 1 EHV-1 GC_ID:1 Equid herpesvirus 1 Equine herpesvirus 1 Equine herpesvirus type 1 Equine herpesvirus-1 equine abortion virus equine herpesvirus 1 EHV-1 equine herpesvirus type-1 ncbi_taxonomy equine herpesvirus type 1 EHV-1 Equid alphaherpesvirus 1 GC_ID:1 Felid herpesvirus 1 Feline alphaherpesvirus 1 Feline herpesvirus 1 Feline herpesvirus type 1 feline herpesvirus feline herpesvirus type 1 FHV-1 feline herpesvirus-1 feline herpesvirus-1 FHV-1 ncbi_taxonomy Felid alphaherpesvirus 1 HHV-3 VZV GC_ID:1 Human herpes virus 3 Human herpesvirus 3 Varicella Zoster Virus Varicella-zoster virus varicella zoster virus VZV varicella-zoster virus VZV ncbi_taxonomy Human alphaherpesvirus 3 NCBITaxon:44156 PRV GC_ID:1 Alphaherpesvirus pseudorabies virus PRV Aujeszky's disease virus Pseudorabies Virus PRV Pseudorabies virus Suid herpesvirus 1 Suid herpesvirus type 1 ncbi_taxonomy Suid alphaherpesvirus 1 GC_ID:1 Betaherpesviruses ncbi_taxonomy Betaherpesvirinae HHV-5 GC_ID:1 Human cytomegalovirus Human herpesvirus 5 human herpesvirus type 5 ncbi_taxonomy Human betaherpesvirus 5 GC_ID:1 Mouse cytomegalovirus 1 Murid herpesvirus 1 Murine cytomegalovirus murine cytomegalovirus (MCMV) murine cytomegalovirus MCMV murine herpesvirus 1 ncbi_taxonomy Murid betaherpesvirus 1 NCBITaxon:10342 NCBITaxon:12743 NCBITaxon:46620 GaHV-1 ILTV GC_ID:1 Avian infectious laryngotracheitis virus Gallid herpesvirus 1 Gallid herpesvirus type 1 Laryngotracheitis virus infectious laryngotracheitis virus ILTV ncbi_taxonomy Infectious laryngotracheitis virus Gallid alphaherpesvirus 1 NCBITaxon:38013 NCBITaxon:39111 NCBITaxon:43684 GaHV-2 MDV1 GC_ID:1 Gallid herpesvirus 2 Gallid herpesvirus type 2 Marek disease virus Marek disease virus type 1 Marek's disease herpesvirus Marek's disease herpesvirus 1 Marek's disease virus Marek's disease virus (MDV) Marek's disease virus MDV Marek's disease virus MDV1 Marek's disease virus serotype 1 MDV-1 Marek's disease virus type 1 MDV1 Mareks disease virus ncbi_taxonomy Marek's disease virus type 1 Gallid alphaherpesvirus 2 GC_ID:1 mammalian hepatitis B-type viruses ncbi_taxonomy Orthohepadnavirus HBV GC_ID:1 Human hepatitis B virus hepatitis B virus (HBV) hepatitis B virus HBV hepatitis B virus, HBV human hepatitis B virus HBV ncbi_taxonomy Hepatitis B virus NCBITaxon:72150 GC_ID:1 Anatid Herpes virus-1 Anatid herpesvirus 1 Duck enteritis virus Duck plague virus ncbi_taxonomy Anatid alphaherpesvirus 1 GC_ID:1 Baculovirus Baculovirus sp. ncbi_taxonomy unidentified baculovirus ASFV GC_ID:1 African swine fever virus ASF African swine fever virus ASFV African swine fever virus, ASFV ncbi_taxonomy African swine fever virus GC_ID:1 ncbi_taxonomy Adenoviridae GC_ID:1 ncbi_taxonomy Mastadenovirus NCBITaxon:12607 GC_ID:1 Canine adenovirus type 1 Canine adenovirus type 1 Cav-1 Mastadenovirus c1 Mastadenovirus can1 canine adenovirus type 1 Can1 dog adenovirus 1 ncbi_taxonomy Canine adenovirus 1 GC_ID:1 Canine adenovirus type 2 Canine adenovirus type 2 Cav-1 Mastadenovirus c2 Mastadenovirus can2 dog adenovirus 2 ncbi_taxonomy Canine adenovirus 2 GC_ID:1 Adenovirus ncbi_taxonomy unidentified adenovirus GC_ID:1 Canine adenovirus Canine adenovirus A ncbi_taxonomy Canine mastadenovirus A GC_ID:1 Human Papilloma Virus human papillomavirus HPV ncbi_taxonomy Human papillomavirus GC_ID:1 ncbi_taxonomy Bovine papillomavirus GC_ID:11 ncbi_taxonomy Clostridium perfringens (type D) Clostridium perfringens D FPLV GC_ID:1 Feline panleucopenia virus Feline panleukopaenia virus ncbi_taxonomy Feline panleukopenia virus GC_ID:1 ncbi_taxonomy Feline panleukopenia virus (strain 193) CPV GC_ID:1 ncbi_taxonomy Canine parvovirus MEV GC_ID:1 ncbi_taxonomy Mink enteritis virus PPV GC_ID:1 porcine parvovirus PPV ncbi_taxonomy Porcine parvovirus GC_ID:1 Orbiviridae Orbiviruses ncbi_taxonomy Orbivirus GC_ID:1 Rotaviruses ncbi_taxonomy Rotavirus GC_ID:1 ncbi_taxonomy Porcine rotavirus GC_ID:1 bovine rotavirus BRV ncbi_taxonomy Bovine rotavirus GC_ID:1 ncbi_taxonomy Equine rotavirus GC_ID:1 ncbi_taxonomy Birnaviridae NCBITaxon:12740 IBDV GC_ID:1 Avian infectious bursal disease virus Gumboro virus Infectious bursal disease virus of chickens infectious bursal disease virus IBDV ncbi_taxonomy Infectious bursal disease virus NCBITaxon:12744 IPNV GC_ID:1 infectious pancreatic necrosis virus IPNV ncbi_taxonomy Infectious pancreatic necrosis virus GC_ID:1 Alphaviridae arboviruses group A ncbi_taxonomy Alphavirus GC_ID:1 Eastern equine encephalomyelitis virus eastern equine encephalomyelitis EEE eastern equine encephalomyelitis virus EEEV ncbi_taxonomy Eastern equine encephalitis virus GC_ID:1 ncbi_taxonomy Sindbis virus VEE VEEV GC_ID:1 Venezuelan equine encephalitis VEE Venezuelan equine encephalitis virus VEE Venezuelan equine encephalomyelitis virus ncbi_taxonomy Venezuelan equine encephalitis virus GC_ID:1 ncbi_taxonomy Western equine encephalomyelitis virus Western equine encephalitis virus GC_ID:1 ncbi_taxonomy Rubivirus GC_ID:1 ncbi_taxonomy Rubella virus EAV GC_ID:1 ncbi_taxonomy Equine arteritis virus GC_ID:1 Flavivirus (arbovirus group B) ncbi_taxonomy Flaviviridae GC_ID:1 arboviruses group B ncbi_taxonomy Flavivirus GC_ID:1 Japanese encephalitis (JE) virus Japanese encephalitis virus JE Japanese encephalitis virus JEV ncbi_taxonomy Japanese encephalitis virus WNV GC_ID:1 ncbi_taxonomy West Nile virus TBEV GC_ID:1 FSME virus Tick born encephalitis virus tick-borne encephalitis virus TBE virus tick-borne encephalitis virus TBEV ncbi_taxonomy Tick-borne encephalitis virus YFV GC_ID:1 Flavivirus febricis yellow fever virus YFV ncbi_taxonomy Yellow fever virus GC_ID:1 PMID:12832207 PMID:7747470 ncbi_taxonomy Pestivirus NCBITaxon:12625 NCBITaxon:54314 GC_ID:1 PMID:7747470 Hog cholera virus Pestivirus type 2 classical swine fever virus CSFV swine fever virus ncbi_taxonomy Classical swine fever virus NCBITaxon:121864 BVDV BVDV-1 GC_ID:1 PMID:7747470 Bovine viral diarrhea virus Bovine viral diarrhea virus type 1 Bovine viral diarrhea virus-1 Mucosal disease virus Pestivirus type 1 bovine viral diarrhea virus BVDV bovine viral diarrhea virus type I ncbi_taxonomy Bovine viral diarrhea virus 1 GC_ID:11 PMID:11411686 PMID:28066339 ncbi_taxonomy Porphyromonas gulae GC_ID:1 ncbi_taxonomy Coronaviridae IBV GC_ID:1 Avian infectious bronchitis virus avian infectious bronchitis coronavirus IBV avian infectious bronchitis virus IBV avian infectious bronchitis virus, IBV infectious bronchitis virus IBV ncbi_taxonomy Infectious bronchitis virus BCV BECV GC_ID:1 Bovine enteritic coronavirus Bovine enteritic coronavirus BECV bovine coronavirus BCV bovine enteric coronavirus calf diarrheal coronavirus neonatal calf diarrhea virus ncbi_taxonomy Bovine coronavirus FIPV GC_ID:1 ncbi_taxonomy Feline infectious peritonitis virus NCBITaxon:12859 TGEV GC_ID:1 Porcine transmissable gastroenteritis coronavirus Porcine transmissible gastroenteritis coronavirus porcine transmissible gastroenteritis virus transmissible gastroenteritis coronavirus transmissible gastroenteritis virus TGEV ncbi_taxonomy Transmissible gastroenteritis virus GC_ID:1 Canine enteric coronavirus canine coronavirus CCV ncbi_taxonomy Canine coronavirus GC_ID:1 negative-sense genome single-stranded RNA viruses ncbi_taxonomy Mononegavirales GC_ID:1 ncbi_taxonomy Paramyxoviridae GC_ID:1 Morbilliviruses ncbi_taxonomy Morbillivirus NCBITaxon:11230 GC_ID:1 Cell-associated subacute sclerosing panencephalitis Measles virus Subacute sclerosing panencephalitis virus measles virus MV rougeole virus rubeola virus subacute sclerose panencephalitis virus subacute sclerosing panencephalitis virus, SSPEV ncbi_taxonomy Measles morbillivirus RDV GC_ID:1 Rinderpest virus rinderpest virus RPV rinderpest virus RV ncbi_taxonomy Rinderpest morbillivirus GC_ID:1 Pneumovirinae ncbi_taxonomy Pneumoviridae NCBITaxon:12604 BRS BRSV GC_ID:1 Bovine respiratory syncytial virus bovine RSV bovine respiratory syncytial virus BRSV ncbi_taxonomy Bovine orthopneumovirus HRSV GC_ID:1 Human respiratory syncytial virus human RSV ncbi_taxonomy Human orthopneumovirus NCBITaxon:11267 GC_ID:1 Filovirus ncbi_taxonomy Filoviridae GC_ID:1 PMID:16186241 ncbi_taxonomy Rhabdoviridae GC_ID:1 ncbi_taxonomy Lyssavirus NCBITaxon:12873 NCBITaxon:12874 VHSV GC_ID:1 Haemorrhagic septicemia virus Hemorrhagic septicemia virus Viral haemorrhagic septicaemia virus hemorragic septicemy virus of fish viral haemorrhagic scepticaemia virus VHS viral haemorrhagic septicaemia virus VHSV viral hemorrhagic septicemia virus VHSV ncbi_taxonomy Viral hemorrhagic septicemia virus IHNV GC_ID:1 ncbi_taxonomy Infectious hematopoietic necrosis virus GC_ID:1 Rabies lyssavirus Rabies virus ncbi_taxonomy Lyssavirus rabies GC_ID:1 ncbi_taxonomy Orthomyxoviridae GC_ID:1 Influenza virus Influenza virus sp. Influenzavirus avian influenza virus ncbi_taxonomy unidentified influenza virus GC_ID:1 Dhori thogotovirus Dhori virus Tick-borne virus ncbi_taxonomy Thogotovirus dhoriense FLUAV GC_ID:1 Human Influenza A Virus Influenza virus type A influenza A virus ncbi_taxonomy Influenza A virus GC_ID:1 H1N1 ncbi_taxonomy H1N1 subtype RVFV GC_ID:1 ncbi_taxonomy Rift Valley fever virus NCBITaxon:11835 NCBITaxon:11872 NCBITaxon:36380 GC_ID:1 Avian reticuloendotheliosis virus reticuloendotheliosis virus A REV-A reticuloendotheliosis virus REV-A ncbi_taxonomy Reticuloendotheliosis virus GC_ID:1 Lentivirinae ncbi_taxonomy Lentivirus FIV GC_ID:1 feline immunodeficiency virus FIV ncbi_taxonomy Feline immunodeficiency virus NCBITaxon:11677 NCBITaxon:11739 NCBITaxon:11740 CIV SIV GC_ID:1 Chimpanzee immunodeficiency virus Chimpanzee immunodeficiency virus (SIV(CPZ)) Simian immunodeficiency virus SIVcpz simian immunodeficiency virus SIV simian immunodeficiency virus, SIV simian immunodeficiency viruses SIV ncbi_taxonomy Simian immunodeficiency virus GC_ID:1 fish fishes ncbi_taxonomy Agnatha Hyperotreti Myxini NCBITaxon:40673 GC_ID:1 bony vertebrates ncbi_taxonomy Euteleostomi NCBITaxon:11920 GC_ID:1 Feline leukemia provirus feline leukemia virus FeLV ncbi_taxonomy Feline leukemia virus BLV GC_ID:1 bovine leukemia virus BLV bovine leukemia virus, BLV ncbi_taxonomy Bovine leukemia virus GC_ID:1 ncbi_taxonomy Enoplea GC_ID:1 ncbi_taxonomy Caliciviridae NCBITaxon:12806 NCBITaxon:31701 RHDV GC_ID:1 Rabbit haemorrhagic disease virus rabbit hemorrhagic disease virus RHDV ncbi_taxonomy Rabbit hemorrhagic disease virus FCV GC_ID:1 Feline vesivirus feline calicivirus FCV ncbi_taxonomy Feline calicivirus GC_ID:1 ncbi_taxonomy Picornavirus Picornaviridae NCBITaxon:12128 GC_ID:1 Enteroviruses ncbi_taxonomy Enterovirus GC_ID:1 ncbi_taxonomy Coxsackievirus GC_ID:1 ncbi_taxonomy Ecdysozoa HPV-1 PV1 GC_ID:1 Human poliovirus 1 Human poliovirus type 1 Polio virus 1 Poliovirus type 1 poliovirus type 1 PV1 ncbi_taxonomy Poliovirus 1 HPV-2 GC_ID:1 Human Poliovirus type 2 Human poliovirus 2 Poliovirus type 2 ncbi_taxonomy Poliovirus 2 HPV-3 GC_ID:1 Human poliovirus 3 Human poliovirus type 3 Polio virus 3 ncbi_taxonomy Poliovirus serotype 3 Poliovirus type 3 Poliovirus 3 GC_ID:1 ncbi_taxonomy Hepatovirus HAV GC_ID:1 Hepatitis A virus ncbi_taxonomy Hepatovirus A FMDV GC_ID:1 Foot and mouth disease virus foot and mouth disease virus FMDV foot-and-mouth disease virus FMDV ncbi_taxonomy Foot-and-mouth disease virus GC_ID:11 PMID:11321122 PMID:11837318 purple photosynthetic bacteria and relatives ncbi_taxonomy "Alphaproteobacteriota" Whitman et al. 2018 Alphaproteobacteriota Proteobacteria Proteobacteriota proteobacteria Pseudomonadota GC_ID:11 PMID:23334881 ncbi_taxonomy Proteobacteria gamma subdivision Pseudomonadia Purple bacteria, gamma subdivision g-proteobacteria gamma proteobacteria gamma subdivision gamma subgroup Gammaproteobacteria GC_ID:11 PMID:1371057 ncbi_taxonomy Piscirickettsia salmonis NCBITaxon:31968 GC_ID:11 PMID:10555317 PMID:11034484 PMID:11542017 PMID:15143038 PMID:25403554 PMID:37409558 Firmicutes low G+C Gram-positive bacteria low GC Gram+ ncbi_taxonomy "Firmicutes" corrig. Gibbons and Murray 1978 (Approved Lists 1980) Bacillaeota Bacillota corrig. Gibbons and Murray 2021 Bacillus/Clostridium group Clostridium group firmicutes Firmicuteota Low G+C firmicutes clostridial firmicutes firmicutes Bacillota BDV GC_ID:1 PMID:25449305 Borna disease virus BDV ncbi_taxonomy Borna disease virus NCBITaxon:12682 HDV GC_ID:1 Hepatitis D virus hepatitis delta virus HDV ncbi_taxonomy Hepatitis delta virus CAV GC_ID:1 Chicken infectious anemia virus chicken anaemia agent CAA chicken anemia virus CAV chicken anemia virus, CAV ncbi_taxonomy chicken anaemia agent virus CAA Chicken anemia virus GC_ID:1 ncbi_taxonomy Dengue virus HIV GC_ID:1 ncbi_taxonomy AIDS virus Human immunodeficiency virus GC_ID:11 PMID:10319469 PMID:10319495 PMID:10425778 PMID:10758876 PMID:12656157 PMID:17220435 PMID:9734063 ncbi_taxonomy Aurococcus Staphylococcus NCBITaxon:325213 NCBITaxon:46170 NCBITaxon:72759 GC_ID:11 PMID:31023808 PMID:8573498 ncbi_taxonomy Micrococcus aureus Micrococcus pyogenes Staphlococcus pyogenes citreus Staphylococcus aureus subsp. anaerobius Staphylococcus pyogenes aureus Staphylococcus aureus RSV GC_ID:1 respiratory syncytial virus RS respiratory syncytial virus RS virus respiratory syncytial virus RSV ncbi_taxonomy Respiratory syncytial virus GC_ID:1 ncbi_taxonomy Swine influenza virus GC_ID:11 PMID:10555340 PMID:14657115 PMID:1720654 PMID:19620365 PMID:19880633 PMID:7537076 PMID:8995803 ncbi_taxonomy Streptococcus GC_ID:11 PMID:23245487 PMID:5220563 PMID:9731300 PMID:9734065 ncbi_taxonomy Streptococcus suis NCBITaxon:76757 GC_ID:11 PMID:15774692 PMID:8995807 ncbi_taxonomy Streptoccocus de la mammite Streptococcus agalactiae contagiosae Streptococcus difficile Streptococcus difficilis Streptococcus mastitidis Streptococcus agalactiae GC_ID:11 ncbi_taxonomy Diplococcus pneumoniae Micrococcus pneumoniae Streptococcus pneumoniae GC_ID:11 ncbi_taxonomy Micrococcus scarlatinae Streptococcus erysipelatos Streptococcus hemolyticus Streptococcus scarlatinae Streptococcus pyogenes MERS MERS-CoV GC_ID:1 MERS coronavirus MERS virus Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Middle East respiratory syndrome coronavirus ncbi_taxonomy Middle East respiratory syndrome-related coronavirus GC_ID:11 ncbi_taxonomy Streptococcus equi GC_ID:1 ncbi_taxonomy Dicentrarchus GC_ID:1 European sea bass European seabass ncbi_taxonomy Labrax labrax Morone labrax Perca labrax Roccus labrax Sciaena labrax Dicentrarchus labrax GC_ID:11 PMID:11075904 PMID:11542017 PMID:16558735 PMID:1917844 PMID:23908650 ncbi_taxonomy spirochetes Spirochaetales NCBITaxon:2954866 GC_ID:11 ncbi_taxonomy Bacillus/Staphylococcus group Caryophanales Bacillales GC_ID:11 PMID:10843090 PMID:11491334 PMID:1742196 PMID:2223602 PMID:23475340 PMID:7727277 PMID:8138135 PMID:8863420 Bacillus Bacillus rRNA group 1 ncbi_taxonomy Bacillus <firmicutes> NCBITaxon:138953 GC_ID:1 Enterovirus EV-C Human enterovirus C Poliovirus ncbi_taxonomy Enterovirus C GC_ID:11 PMID:1380285 PMID:1503971 PMID:24744012 PMID:7699027 PMID:7981102 PMID:8995796 PMID:9336916 Lyme disease spirochete ncbi_taxonomy Borrelia burgdorferi Borreliella burgdorferi NCBITaxon:1494525 NCBITaxon:1494531 NCBITaxon:1494577 GC_ID:11 PMID:8123566 anthrax anthrax bacterium ncbi_taxonomy Bacillus cereus var. anthracis Bacteridium anthracis Bacillus anthracis GC_ID:1 PMID:11743200 PMID:11791233 ncbi_taxonomy Boreotheria Boreoeutheria NCBITaxon:69207 GC_ID:11 PMID:26643615 PMID:27488356 ncbi_taxonomy Anaerobacter Clostridium GC_ID:1 ncbi_taxonomy Euteleosteomorpha NCBITaxon:29368 GC_ID:11 PMID:10028279 PMID:15244052 ncbi_taxonomy Bacillus botulinus Bacillus putrificus Botulobacillus botulinus Clostridium putrificum Ermengemillus botulinus Pacinia putrifica Clostridium botulinum NCBITaxon:2588446 NCBITaxon:2588447 NCBITaxon:41533 NCBITaxon:592 GC_ID:11 PMID:10758910 Salmonella enterica serovar Enteritidis ncbi_taxonomy Bacillus enteritidis Salmonella enteritidis Salmonella enterica subsp. enterica serovar Enteritidis GC_ID:1 ncbi_taxonomy Canine parainfluenza virus GC_ID:11 PMID:11043982 ncbi_taxonomy Yersinia enterocolitica subsp. enterocolitica NCBITaxon:1683536 GC_ID:11 PMID:1374625 PMID:184898 ncbi_taxonomy 'Clostridium plagarum' Bacillus perfringens Bacterium welchii Clostridium plagarum Clostridium perfringens NCBITaxon:10781 GC_ID:1 Parvovirus Parvoviruses ncbi_taxonomy Protoparvovirus GC_ID:11 ncbi_taxonomy Bacillus tetani Clostridium tetani GC_ID:1 PMID:20206957 Papillomavirus ncbi_taxonomy Papillomaviridae GC_ID:1 ncbi_taxonomy Polyomaviridae NCBITaxon:11762 GC_ID:1 MLV-related viruses Mammalian type C retrovirus group Mammalian type C retroviruses mammalian type C oncoviruses type C oncoviruses ncbi_taxonomy Gammaretrovirus GC_ID:1 ncbi_taxonomy Galloanseri ducks, geese, chickens, fowl, quail, currasows and allies Galloanserae Bulinus GC_ID:11 ncbi_taxonomy Microspironema pallidum Spirillum pallidum Spirochaeta pallida Spironema pallidum Treponema pallidum HMPV GC_ID:1 ncbi_taxonomy Human metapneumovirus GC_ID:1 ncbi_taxonomy Metapneumovirus NCBITaxon:1634566 NCBITaxon:2293539 NCBITaxon:2293540 NCBITaxon:2293541 NCBITaxon:2293542 NCBITaxon:2293543 NCBITaxon:2293544 NCBITaxon:2293545 NCBITaxon:2293546 NCBITaxon:2293547 NCBITaxon:2364651 NCBITaxon:2364652 NCBITaxon:2364653 NCBITaxon:2364654 NCBITaxon:2364655 NCBITaxon:2364656 NCBITaxon:2364657 NCBITaxon:2364658 NCBITaxon:2364659 NCBITaxon:2364660 NCBITaxon:2482733 NCBITaxon:2482734 NCBITaxon:2482735 NCBITaxon:2482736 NCBITaxon:2482737 NCBITaxon:2482738 NCBITaxon:2482739 NCBITaxon:2482740 NCBITaxon:2482741 NCBITaxon:2482742 NCBITaxon:2482743 NCBITaxon:2482744 NCBITaxon:2482745 NCBITaxon:2482746 NCBITaxon:2482747 NCBITaxon:2482748 NCBITaxon:2482749 NCBITaxon:2484857 NCBITaxon:2484858 NCBITaxon:2485082 NCBITaxon:2485083 NCBITaxon:2485084 NCBITaxon:2485085 NCBITaxon:2485086 NCBITaxon:2485087 NCBITaxon:2485088 NCBITaxon:2485089 NCBITaxon:2485090 NCBITaxon:2485091 NCBITaxon:2485092 NCBITaxon:2485093 NCBITaxon:2485094 NCBITaxon:2485095 NCBITaxon:2485096 NCBITaxon:2486732 NCBITaxon:2486733 NCBITaxon:2486734 NCBITaxon:2486735 NCBITaxon:2486736 NCBITaxon:2486737 NCBITaxon:2486738 NCBITaxon:2486739 NCBITaxon:2486740 NCBITaxon:2486741 GC_ID:11 PMID:17773427 PMID:1906732 PMID:8782698 ncbi_taxonomy Bacterium monocytogenes Bacterium monocytogenes hominis Corynebacterium infantisepticum Corynebacterium parvulum Erysipelothrix monocytogenes Listerella hepatolytica Listeria monocytogenes GC_ID:11 PMID:1503975 PMID:8427802 ncbi_taxonomy Bacillus insidiosus Bacillus rhusiopathiae suis Bacterium rhusiopathiae Erysipelothrix erysipeloides Erysipelothrix insidiosa Erysipelothrix murisepticus Erysipelothrix porci Erysipelothrix rhusiopathiae GC_ID:11 ncbi_taxonomy Yersinia pseudotuberculosis complex GC_ID:1 ncbi_taxonomy Mammarenavirus NCBITaxon:12461 NCBITaxon:2953663 GC_ID:1 ncbi_taxonomy Orthohepevirus A Paslahepevirus balayani NCBITaxon:29512 NCBITaxon:29514 NCBITaxon:29516 GC_ID:11 PMID:10425768 PMID:1581182 PMID:19868121 PMID:9103653 ncbi_taxonomy Leptospira NCBITaxon:144193 GC_ID:11 PMID:10425754 PMID:19661509 PMID:29760685 PMID:30186281 PMID:7547284 PMID:7547291 PMID:7547293 PMID:8186090 ncbi_taxonomy Turicella Corynebacterium GC_ID:11 PMID:7729671 ncbi_taxonomy Bacillus diphtheriae Bacterium diphtheriae Microsporon diphthericum Microsporon diphtheriticum Mycobacterium diphtheriae Pacinia loeffleri Corynebacterium diphtheriae GC_ID:11 ncbi_taxonomy Bacillus pseudotuberculosis Bacillus pseudotuberculosis-ovis Corynebacterium ovis Corynebacterium preisz-nocardi Corynebacterium pseudotuberculosis-ovis Mycobacterium tuberculosis-ovis Corynebacterium pseudotuberculosis NCBITaxon:2843297 NCBITaxon:2843299 GC_ID:11 PMID:15545494 PMID:19867994 PMID:19868337 PMID:19972157 PMID:25288661 PMID:9542090 ncbi_taxonomy Leptospira icteroides Spirochaeta biflexa Spirochaeta icterogenes Spirochaeta icterohaemorrhagiae Spirochaeta interrogans Spirochaeta nodosa Leptospira interrogans GC_ID:1 ncbi_taxonomy Passeroidea GC_ID:11 ncbi_taxonomy Leptospira hardjo Leptospira interrogans serovar Hardjo GC_ID:11 PMID:1380284 PMID:1581193 PMID:16014496 PMID:1883713 PMID:2275850 PMID:31296783 PMID:31649146 PMID:31649147 PMID:34554081 PMID:7547284 PMID:7547304 PMID:7907223 PMID:8863452 ncbi_taxonomy Mycobacterium Lehmann and Neumann 1896 (Approved Lists 1980) Mycobacterium GC_ID:11 PMID:2397193 PMID:8347508 ncbi_taxonomy Bacillus tuberculosis gallinarum Mycobacterium tuberculosis avium Mycobacterium tuberculosis typus gallinaceus Tuberculose des oiseaux Mycobacterium avium NCBITaxon:115863 GC_ID:11 PMID:10618079 PMID:11931153 PMID:14657105 PMID:29205127 ncbi_taxonomy Mycobacterium bovis Mycobacterium tuberculosis typus bovinus Mycobacterium tuberculosis var. bovis Mycobacterium tuberculosis variant bovis GC_ID:11 ncbi_taxonomy Bacillus leprae Mycobacterium leprae NCBITaxon:2528440 GC_ID:11 PMID:29205127 ncbi_taxonomy Bacillus tuberculosis Bacterium tuberculosis Mycobacterium tuberculosis typus humanus Mycobacterium tuberculosis var. hominis Mycobacterium tuberculosis variant tuberculosis Mycobacterium tuberculosis GC_ID:11 PMID:12089250 PMID:20668542 ncbi_taxonomy Mycobacterium balnei Mycobacterium platypoecilus Mycobacterium marinum GC_ID:11 PMID:18988685 PMID:23851394 ncbi_taxonomy Terrabacteria group GC_ID:1 Marek's disease-like viruses ncbi_taxonomy Mardivirus GC_ID:1 Infectious laryngo-tracheitis-like viruses Infectious laryngotracheitis-like viruses ncbi_taxonomy Iltovirus GC_ID:1 Marburg-like viruses ncbi_taxonomy Marburgvirus GC_ID:1 ncbi_taxonomy Clupeocephala GC_ID:1 ncbi_taxonomy Novirhabdovirus GC_ID:1 ncbi_taxonomy Orthopneumovirus NCBITaxon:10625 BFPyV GC_ID:1 Aves polyomavirus 1 BFDV Budgerigar fledgling disease polyomavirus Budgerigar fledgling disease virus Budgerigar fledgling polyomavirus ncbi_taxonomy Gammapolyomavirus avis GC_ID:11 PMID:27620848 ncbi_taxonomy Yersiniaceae GC_ID:11 PMID:11542086 PMID:12361288 PMID:16627635 PMID:1704793 PMID:19801389 PMID:29034857 ncbi_taxonomy Campylobacter GC_ID:11 PMID:11321120 PMID:1354478 ncbi_taxonomy Spirillum fetus Vibrio fetus Campylobacter fetus NCBITaxon:2172531 NCBITaxon:2182326 NCBITaxon:2201165 NCBITaxon:2211407 NCBITaxon:2211408 NCBITaxon:2211409 NCBITaxon:2293848 NCBITaxon:2293849 NCBITaxon:2293850 NCBITaxon:2303571 NCBITaxon:2305452 NCBITaxon:2305453 NCBITaxon:2305454 NCBITaxon:2305455 NCBITaxon:2305456 NCBITaxon:2305457 NCBITaxon:2305458 NCBITaxon:2305459 NCBITaxon:2340789 NCBITaxon:2478524 NCBITaxon:2572055 NCBITaxon:2572062 NCBITaxon:2572070 NCBITaxon:2572072 NCBITaxon:2572075 NCBITaxon:2572080 NCBITaxon:2572086 NCBITaxon:3042472 NCBITaxon:3042475 NCBITaxon:3042476 NCBITaxon:3042477 NCBITaxon:3042478 NCBITaxon:3042479 NCBITaxon:3042480 NCBITaxon:3042481 NCBITaxon:3042482 NCBITaxon:3042483 NCBITaxon:3042484 NCBITaxon:3042485 NCBITaxon:3042486 NCBITaxon:3042488 GC_ID:11 PMID:11321120 ncbi_taxonomy Campylobacter fetus subsp. jejuni Vibrio hepaticus Vibrio jejuni Campylobacter jejuni GC_ID:1 Influenzavirus A ncbi_taxonomy Alphainfluenzavirus GC_ID:1 Influenzavirus B ncbi_taxonomy Betainfluenzavirus GC_ID:1 Influenzavirus C ncbi_taxonomy Gammainfluenzavirus GC_ID:1 ncbi_taxonomy Bunyavirales NCBITaxon:11598 GC_ID:1 ncbi_taxonomy Hantavirus Orthohantavirus NCBITaxon:38142 HIRRV GC_ID:1 Hirame novirhabdovirus Hirame rhabdovirus ncbi_taxonomy Novirhabdovirus hirame GC_ID:11 PMID:10425795 PMID:10425796 PMID:10425797 PMID:10490293 PMID:10843050 PMID:10939651 PMID:10939673 PMID:10939677 PMID:11211268 PMID:11321083 PMID:11321113 PMID:11411719 PMID:11540071 PMID:11542017 PMID:11542087 PMID:11760965 PMID:12054223 PMID:2112744 PMID:270744 PMID:32628106 PMID:36748408 PMID:7520741 PMID:8123559 PMID:8186100 PMID:8590690 PMID:9103655 PMID:9336922 eubacteria ncbi_taxonomy Monera Procaryotae Prokaryota Prokaryotae bacteria prokaryote prokaryotes Bacteria GC_ID:11 ncbi_taxonomy Flavobacteriales GC_ID:11 PMID:11837318 PMID:25288668 PMID:26654112 ncbi_taxonomy "Leptospiria" Cavalier-Smith 2020 Spirochaetes Spirochaetia GC_ID:11 PMID:12271122 Brucella suis str. 1330 ncbi_taxonomy Brucella melitensis biovar Suis str. 1330 Brucella suis ATCC 23444 Brucella suis NCTC 10316 Brucella suis 1330 NCBITaxon:11268 GC_ID:1 Ebola virus EBO unidentified Ebola virus ncbi_taxonomy Ebola virus sp. GC_ID:11 PMID:23575986 ncbi_taxonomy Neisseriales GC_ID:4 PMID:13403276 PMID:16350067 ncbi_taxonomy Borrelomycetaceae Parasitaceae Pleuropneumoniaceae Mycoplasmataceae NCBITaxon:29500 NCBITaxon:57371 GC_ID:4 PMID:10826816 PMID:11321109 PMID:11411711 PMID:11931184 PMID:13403276 PMID:15176735 PMID:16350067 PMID:16403858 PMID:25288662 PMID:8863441 PMID:8995799 ncbi_taxonomy Asterococcus Asteromyces Borrelomyces Bovimyces Eperythrozoon Haemobartonella Pleuropneumonia Mycoplasma GC_ID:4 ncbi_taxonomy Mycoplasma gallisepticum Mycoplasmoides gallisepticum GC_ID:4 PMID:11491338 PMID:1316139 PMID:1374621 PMID:8573513 ncbi_taxonomy Mycoplasma suipneumoniae Mesomycoplasma hyopneumoniae NCBITaxon:219 GC_ID:11 PMID:11931154 PMID:1995031 PMID:8186097 PMID:8494747 ncbi_taxonomy Campylobacter pylori Campylobacter pylori subsp. pylori Campylobacter pyloridis Helicobacter nemestrinae Helicobacter pylori GC_ID:4 ncbi_taxonomy Mycoplasma synoviae Mycoplasmopsis synoviae GC_ID:11 ncbi_taxonomy Leptospira canicola Leptospira interrogans serovar Canicola GC_ID:11 PMID:16403855 ncbi_taxonomy Campylobacterales GC_ID:11 PMID:10425795 PMID:10425796 PMID:10425797 PMID:10490293 PMID:10843050 PMID:10939651 PMID:10939673 PMID:10939677 PMID:11211268 PMID:11321083 PMID:11321113 PMID:11411719 PMID:11540071 PMID:11541975 PMID:11542064 PMID:11542149 PMID:11760965 PMID:12054223 PMID:2112744 PMID:25527841 PMID:270744 PMID:32628106 PMID:36748408 PMID:8123559 PMID:8590690 PMID:9103655 PMID:9336922 ncbi_taxonomy Archaebacteria Mendosicutes Metabacteria Monera Procaryotae Prokaryota Prokaryotae archaea prokaryote prokaryotes Archaea NCBITaxon:11619 GC_ID:1 Argentinian mammarenavirus Junin arenavirus Junin mammarenavirus Junin virus Junn mammarenavirus ncbi_taxonomy Mammarenavirus juninense GC_ID:11 PMID:11756688 ncbi_taxonomy Brucella melitensis ATCC 23456 Brucella melitensis bv. 1 str. 16M GC_ID:11 PMID:28066370 PMID:32373076 PMID:35335701 PMID:37395662 PMID:8573514 ncbi_taxonomy Brucella GC_ID:11 Brucella melitensis bv. Abortus ncbi_taxonomy "Bacillus of abortion" Bang 1897 Bacterium abortus Brucella melitensis biovar Abortus Brucella abortus GC_ID:11 Brucella melitensis bv. Ovis ncbi_taxonomy Brucella melitensis biovar Ovis Brucella ovis GC_ID:1 Negative-strand RNA viruses ncbi_taxonomy Negarnaviricota GC_ID:1 ncbi_taxonomy Polyploviricotina GC_ID:1 ncbi_taxonomy Orthocoronavirinae GC_ID:1 RNA viruses RNA viruses and viroids ncbi_taxonomy Riboviria GC_ID:1 ncbi_taxonomy Avulavirinae GC_ID:1 ncbi_taxonomy Orthoparamyxovirinae GC_ID:1 ncbi_taxonomy Rubulavirinae NCBITaxon:11176 NDV GC_ID:1 Avian Paramyxovirus Serotype I Avian paramyxovirus type 1 Avian paramyxovirus type-1 Newcastle disease virus Newcastle disease virus NDV avian paramyxovirus 1 ncbi_taxonomy Avian avulavirus 1 Avian orthoavulavirus 1 NCBITaxon:11161 NCBITaxon:1979165 GC_ID:1 Mumps virus ncbi_taxonomy Mumps rubulavirus Mumps orthorubulavirus GC_ID:1 ncbi_taxonomy Avulavirus GC_ID:1 ncbi_taxonomy Henipavirus GC_ID:1 PMID:30257078 ncbi_taxonomy Metamonada GC_ID:1 ncbi_taxonomy Discoba GC_ID:11 PMID:15805518 Brucella abortus biovar 1 str. 9-941 Brucella abortus bv. 1 strain 9-941 ncbi_taxonomy Brucella abortus bv. 1 str. 9-941 GC_ID:11 ncbi_taxonomy Bacterium tularense Brucella tularensis Francisella tularense Pasteurella tularensis Francisella tularensis SARS-CoV-2 GC_ID:1 2019-nCoV COVID-19 virus HCoV-19 Human coronavirus 2019 SARS-2 SARS-CoV2 SARS2 ncbi_taxonomy Severe acute respiratory syndrome coronavirus 2 GC_ID:1 ncbi_taxonomy Bamfordvirae GC_ID:1 ncbi_taxonomy Shotokuvirae GC_ID:1 ncbi_taxonomy Orthornavirae GC_ID:1 ncbi_taxonomy Kitrinoviricota GC_ID:1 ncbi_taxonomy Cossaviricota GC_ID:1 ncbi_taxonomy Papovaviricetes GC_ID:1 ncbi_taxonomy Alsuviricetes GC_ID:1 ncbi_taxonomy Pisoniviricetes GC_ID:1 ncbi_taxonomy Revtraviricetes GC_ID:1 ncbi_taxonomy Pokkesviricetes NCBITaxon:10880 GC_ID:1 ncbi_taxonomy Reoviridae Reovirales GC_ID:1 ncbi_taxonomy Hepelivirales GC_ID:1 PMID:23020233 PMID:30257078 eucaryotes eukaryotes ncbi_taxonomy Eucarya Eucaryotae Eukarya Eukaryotae eukaryotes Eukaryota GC_ID:1 ncbi_taxonomy Bovinae NCBITaxon:29525 GC_ID:11 PMID:1503973 ncbi_taxonomy Bacteroides macacae Bacteroides melaninogenicus subsp. macacae Bacteroides salivosus Porphyromonas salivosa Porphyromonas macacae NCBITaxon:707 GC_ID:11 ncbi_taxonomy Listonella ordalii Vibrio ordalii GC_ID:11 PMID:11541974 PMID:11837318 PMID:16166687 PMID:16403855 PMID:19060069 ncbi_taxonomy Alphabacteria Proteobacteria alpha subdivision Purple bacteria, alpha subdivision a-proteobacteria alpha proteobacteria alpha subdivision alpha subgroup Alphaproteobacteria GC_ID:11 PMID:16403855 PMID:28581923 ncbi_taxonomy Proteobacteria beta subdivision Purple bacteria, beta subdivision b-proteobacteria beta proteobacteria beta subdivision beta subgroup Betaproteobacteria NCBITaxon:12796 NCBITaxon:70172 PRRSV GC_ID:1 Porcine reproductive and respiratory syndrome virus (PRRSV) Porcine respiratory and reproductive syndrome virus porcine reproductive and respiratory syndrome virus PRRSV porcine reproductive and respiratory syndrome virus, PRRSV ncbi_taxonomy Porcine reproductive and respiratory syndrome virus NCBITaxon:1435366 NCBITaxon:1435368 NCBITaxon:1435988 NCBITaxon:1439853 NCBITaxon:1487954 NCBITaxon:1487955 GC_ID:11 PMID:12734250 PMID:1283774 ncbi_taxonomy Bacillus pseudomallei Bacterium whitmori Loefflerella pseudomallei Malleomyces pseudomallei Pseudomonas pseudomallei Burkholderia pseudomallei NCBITaxon:212745 GC_ID:11 PMID:10758879 PMID:10939664 PMID:15950132 PMID:18048745 PMID:23918787 PMID:7727274 PMID:9103607 ncbi_taxonomy "Chlorobacterium" Guillebeau 1890, nom. rejic. Opin. 6 (not "Chlorobacterium" Lauterborn 1916) Liquidomonas Loefflerella RNA similarity group I Pseudomonas NCBITaxon:1224290 NCBITaxon:1437768 NCBITaxon:1437769 NCBITaxon:1437770 NCBITaxon:1508364 NCBITaxon:1607811 NCBITaxon:1607813 NCBITaxon:1683559 NCBITaxon:1683561 NCBITaxon:1851858 NCBITaxon:1851865 NCBITaxon:1860124 NCBITaxon:665948 NCBITaxon:912077 NCBITaxon:931955 NCBITaxon:931956 NCBITaxon:931957 NCBITaxon:931958 NCBITaxon:932477 GC_ID:11 ncbi_taxonomy Bacillus aeruginosus Bacillus pyocyaneus Bacterium aeruginosum Bacterium pyocyaneum Micrococcus pyocyaneus Pseudomonas polycolor Pseudomonas pyocyanea probable synonym or variety: "Pseudomonas polycolor" Clara 1930 Pseudomonas aeruginosa GC_ID:1 ncbi_taxonomy Neospora caninum GC_ID:11 PMID:8573514 ncbi_taxonomy Micrococcus melitensis Streptococcus Miletensis Brucella melitensis GC_ID:11 Brucella melitensis bv. Suis ncbi_taxonomy Brucella melitensis biovar Suis Brucella suis NCBITaxon:689832 GC_ID:1 ncbi_taxonomy Sedoreovirinae Sedoreoviridae GC_ID:1 ncbi_taxonomy Heptrevirinae GC_ID:11 ncbi_taxonomy Yersinia ruckeri GC_ID:11 PMID:7547305 PMID:7857801 PMID:7981108 PMID:8123559 PMID:8347512 PMID:9226893 ncbi_taxonomy Candidatus intracellularis Ileal symbiont intracellularis Lawsonia intracellularis GC_ID:1 ncbi_taxonomy Orthoherpesviridae GC_ID:1 ncbi_taxonomy Orthoflavivirus NCBITaxon:45337 NCBITaxon:63330 GC_ID:1 PMID:7701348 Equine morbillivirus Hendra henipavirus Hendra virus ncbi_taxonomy Henipavirus hendraense NCBITaxon:121791 GC_ID:1 Nipah henipavirus Nipah virus Nipah-virus ncbi_taxonomy Henipavirus nipahense NCBITaxon:11103 HCV GC_ID:1 Hepacivirus C Hepatitis C virus hepatitis C virus HCV human hepatitis C virus human hepatitis C virus HCV human hepatitis virus C HCV post-transfusion hepatitis non A non B virus ncbi_taxonomy Hepacivirus hominis NCBITaxon:11623 NCBITaxon:12748 LCMV GC_ID:1 Lymphocytic choriomeningitis mammarenavirus Lymphocytic choriomeningitis virus lymphocytic choriomeningitis virus LCMV ncbi_taxonomy Mammarenavirus choriomeningitidis NCBITaxon:11620 GC_ID:1 Lassa mammarenavirus Lassa virus ncbi_taxonomy Mammarenavirus lassaense NCBITaxon:11232 CDV GC_ID:1 Canine distemper virus Canine morbillivirus canine distemper virus CDV ncbi_taxonomy Morbillivirus canis NCBITaxon:11593 NCBITaxon:1980519 CCHFV GC_ID:1 Crimean-Congo haemorrhagic fever virus Crimean-Congo hemorrhagic fever nairovirus Crimean-Congo hemorrhagic fever orthonairovirus Crimean-Congo hemorrhagic virus ncbi_taxonomy Crimean-Congo hemorrhagic fever virus Orthonairovirus haemorrhagiae NCBITaxon:1511906 GC_ID:1 Carnivore protoparvovirus 1 ncbi_taxonomy Protoparvovirus carnivoran1 NCBITaxon:11215 GC_ID:1 Bovine parainfluenza 3 virus Bovine parainfluenza virus 3 Bovine parainfluenza virus type 3 Bovine respirovirus 3 ncbi_taxonomy Respirovirus bovis GC_ID:1 ncbi_taxonomy Musteloidea GC_ID:1 PMID:11214318 PMID:11214319 PMID:12878460 ncbi_taxonomy Laurasiatheria GC_ID:1 PMID:11214319 PMID:12082125 PMID:12878460 PMID:15522813 ncbi_taxonomy Euarchontoglires GC_ID:1 PMID:11214319 PMID:12082125 PMID:15522813 Rodents and rabbits ncbi_taxonomy Glires GC_ID:1 ncbi_taxonomy Anthropoidea Simiiformes GC_ID:1 amniotes ncbi_taxonomy Amniota GC_ID:1 diapsids ncbi_taxonomy Diapsida Sauria GC_ID:1 ncbi_taxonomy Orthoretrovirinae NCBITaxon:186155 GC_ID:1 Canine parvovirus-1 Minute virus of canines ncbi_taxonomy Canine minute virus GC_ID:1 ncbi_taxonomy Fungi/Metazoa group opisthokonts Opisthokonta GC_ID:1 ncbi_taxonomy Bilateria GC_ID:1 ncbi_taxonomy Protostomia GC_ID:1 ncbi_taxonomy unclassified Papillomaviridae GC_ID:1 guinea pigs and others ncbi_taxonomy Hystricognathi Hystricomorpha GC_ID:1 carnivores ncbi_taxonomy carnivores Carnivora GC_ID:11 PMID:13200095 PMID:22427448 PMID:8240957 PMID:9103649 ncbi_taxonomy Moraxella anatipestifer Pasteurella anapestifer Pasteurella anatipestifer Pfeifferella anatipestifer Riemerella anatipestifer GC_ID:1 ncbi_taxonomy Replication competent viruses GC_ID:1 ncbi_taxonomy unclassified Orthomyxoviridae GC_ID:1 ncbi_taxonomy Pecora GC_ID:11 PMID:16299333 PMID:20462421 ncbi_taxonomy Brucella melitensis biovar Abortus 2308 Brucella abortus 2308 NCBITaxon:10624 GC_ID:1 Polyomavirus Polyomaviruses ncbi_taxonomy Polyomavirus sp. GC_ID:1 ncbi_taxonomy H1N1 swine influenza virus GC_ID:11 ncbi_taxonomy Streptococcus sp. (group A) group A streptococci group A streptococcus Streptococcus sp. 'group A' GC_ID:11 Brucella melitensis bv. Canis ncbi_taxonomy Brucella melitensis biovar Canis Brucella canis GC_ID:1 ncbi_taxonomy Chikungunya virus GC_ID:1 ncbi_taxonomy Caniformia GC_ID:1 Avian reovirus ncbi_taxonomy Avian orthoreovirus GC_ID:11 PMID:1581182 ncbi_taxonomy Leptospira grippotyphosa Leptospira kirschneri serovar Grippotyphosa GC_ID:1 Avian pneumovirus ncbi_taxonomy Avian metapneumovirus GC_ID:1 Leishmania ncbi_taxonomy Leishmania <subgenus> GC_ID:1 ncbi_taxonomy Leishmania donovani species complex NCBITaxon:109679 GC_ID:1 ncbi_taxonomy Murinae GC_ID:1 ncbi_taxonomy Bos bubalis bubalis Bubalus bubalis bubalis GC_ID:11 Yersinia enterocolitica subsp. enterocolitica str. 8081 Yersinia enterocolitica subsp. enterocolitica strain 8081 ncbi_taxonomy Yersinia enterocolitica subsp. enterocolitica 8081 GC_ID:1 ncbi_taxonomy Rubulavirus CpHV-1 GC_ID:1 Caprine herpesvirus 1 Caprine herpesvirus type 1 goat herpesvirus ncbi_taxonomy Caprine alphaherpesvirus 1 NCBITaxon:10896 AHSV GC_ID:1 African horse sickness group African horse sickness virus (AHSV) African horsesickness virus ncbi_taxonomy African horse sickness virus AHSV African horse sickness virus NCBITaxon:12591 GC_ID:1 Bluetongue virus group bluetongue virus BTV ncbi_taxonomy Bluetongue virus GC_ID:1 ncbi_taxonomy Quailpox virus GC_ID:1 ncbi_taxonomy Parvovirinae GC_ID:11 PMID:18048732 ncbi_taxonomy Vibrio salmonicida Aliivibrio salmonicida mammals GC_ID:1 mammals ncbi_taxonomy mammals Mammalia TAdV-3 GC_ID:1 Marble spleen disease virus Turkey adenovirus serotype 3 Turkey haemorrhagic enteritis virus Turkey hemorrhagic enteritis virus hemorrhagic enteritis virus ncbi_taxonomy Turkey adenovirus 3 GC_ID:1 ncbi_taxonomy Vinckeia Plasmodium (Vinckeia) GC_ID:1 ncbi_taxonomy Hematozoa Vivier 1982 Aconoidasida GC_ID:1 ncbi_taxonomy Eimeriorina GC_ID:1 ncbi_taxonomy Sarcocystis neurona GC_ID:11 Brucella abortus str. S19 Brucella abortus strain S19 ncbi_taxonomy Brucella abortus S19 CNPV GC_ID:1 Avipoxvirus clade B1 Canary poxvirus ncbi_taxonomy Canarypox virus NCBITaxon:399128 GC_ID:11 PMID:18218934 ncbi_taxonomy Brucella microti GC_ID:11 Brucella ovis str. ATCC 25840 Brucella ovis strain ATCC 25840 ncbi_taxonomy Brucella ovis ATCC 25840 GC_ID:1 ncbi_taxonomy Picornavirales GC_ID:11 PMID:19346311 Brucella suis str. ATCC 23445 Brucella suis strain ATCC 23445 ncbi_taxonomy Brucella suis ATCC 23445 GC_ID:1 PMID:11062127 PMID:12684019 ncbi_taxonomy Mycota fungi Fungi GC_ID:11 PMID:19346311 Brucella canis str. ATCC 23365 Brucella canis strain ATCC 23365 ncbi_taxonomy Brucella canis ATCC 23365 GC_ID:11 ncbi_taxonomy Diplokokkus intracellularis meningitidis Micrococcus intracellularis Micrococcus meningitidis Micrococcus meningitidis cerebrospinalis Neisseria weichselbaumii Neisseria meningitidis PsHV-1 GC_ID:1 Pacheco's disease virus Psittacid herpesvirus 1 ncbi_taxonomy Psittacid alphaherpesvirus 1 GC_ID:1 trouts, salmons & chars ncbi_taxonomy Salmoninae true insects Insecta GC_ID:11 PMID:11491321 ncbi_taxonomy Bordetella NCBITaxon:514 GC_ID:11 PMID:8240949 PMID:8782670 PMID:9226899 ncbi_taxonomy Alcaligenes bronchicanis Alcaligenes bronchisepticus Bacillus bronchicanis Bacillus bronchisepticus Bacterium bronchisepticus Brucella bronchiseptica Haemophilus bronchisepticus Bordetella bronchiseptica GC_ID:11 PMID:8240949 ncbi_taxonomy Bacterium tussis-convulsivae Haemophilus pertussis Hemophilus pertussis Microbe de la coqueluche Bordetella pertussis GC_ID:11 PMID:4074238 ncbi_taxonomy Bordetella avium GC_ID:11 PMID:10555323 PMID:10555334 PMID:16166704 PMID:27620848 ncbi_taxonomy Enterobacteraceae enterobacteria gamma-3 proteobacteria Enterobacteriaceae NCBITaxon:136447 NCBITaxon:64986 NCBITaxon:96055 BVDV type II BVDV-2 GC_ID:1 PMID:7747470 Bovine viral diarrhea virus genotype 2 Bovine viral diarrhea virus type 2 Bovine viral diarrhea virus-2 bovine viral diarrhea virus type II pestivirus type 4 ncbi_taxonomy Bovine viral diarrhea virus 2 GC_ID:11 Tenericutes ncbi_taxonomy "Mollicutaeota" Oren et al. 2015 "Tenericutes" Murray 1984 Mollicutota Mycoplasmatota GC_ID:11 PMID:19346311 Brucella melitensis str. ATCC 23457 Brucella melitensis strain ATCC 23457 ncbi_taxonomy Brucella melitensis ATCC 23457 GC_ID:1 ncbi_taxonomy Herpesvirales GC_ID:1 ncbi_taxonomy Coccidioides NCBITaxon:28167 NCBITaxon:665 GC_ID:11 PMID:21296930 ncbi_taxonomy Achromobacter ichthyodermis Listonella anguillara Listonella anguillarum Pseudomonas ichthyodermis Vibrio ichthyodermis Vibrio piscium Vibrio piscium var. japonicus Vibrio anguillarum NCBITaxon:155284 NCBITaxon:86501 GC_ID:1 Salmon isavirus ncbi_taxonomy Isavirus salaris GC_ID:1 ncbi_taxonomy Dintheria Oncomelania NCBITaxon:1637691 NCBITaxon:1806490 NCBITaxon:469598 NCBITaxon:662101 NCBITaxon:662104 GC_ID:11 PMID:10319482 E. coli Escherichia/Shigella coli ncbi_taxonomy Bacillus coli Bacterium coli Bacterium coli commune Enterococcus coli Escherichia coli GC_ID:1 ncbi_taxonomy Trypanosomatidae Leishmania GC_ID:1 Leishmania ncbi_taxonomy Leishmania <genus> NCBITaxon:31284 GC_ID:1 ncbi_taxonomy Leishmania (Leishmania) amazonensis Leishmania mexicana amazonensis Leishmania amazonensis GC_ID:1 ncbi_taxonomy Leishmania (Leishmania) donovani Leishmania donovani GC_ID:1 ncbi_taxonomy Leishmania (Leishmania) major Leishmania tropica major Leishmania major NCBITaxon:33701 NCBITaxon:5724 GC_ID:1 PMID:12046599 PMID:15734659 PMID:22000167 ncbi_taxonomy Tritrichomonas suis NCBITaxon:5662 GC_ID:1 ncbi_taxonomy Leishmania (Leishmania) infantum Leishmania donovani infantum Leishmania infantum NCBITaxon:399127 GC_ID:11 PMID:19653890 Brucella microti str. CCM 4915 Brucella microti strain CCM 4915 ncbi_taxonomy Brucella sp. CCM 4915 Brucella microti CCM 4915 GC_ID:1 ncbi_taxonomy Trypanosoma GC_ID:1 ncbi_taxonomy Trypanosoma (Trypanozoon) brucei Trypanosoma brucei subgroup Trypanosoma brucei GC_ID:1 ncbi_taxonomy Trypanosoma cruzi GC_ID:1 PMID:11432808 PMID:19135417 ncbi_taxonomy Giardia duodenalis Giardia lamblia Lamblia intestinalis Giardia intestinalis GC_ID:1 ncbi_taxonomy Entamoeba histolytica GC_ID:1 ncbi_taxonomy Naegleria GC_ID:1 ncbi_taxonomy Naegleria gruberi GC_ID:1 brain-eating amoeba ncbi_taxonomy Naegleria fowleri GC_ID:1 apicomplexans ncbi_taxonomy apicomplexans Apicomplexa GC_ID:1 ncbi_taxonomy Eimeria Eimeria acervulina GC_ID:1 ncbi_taxonomy Eimeria tenella GC_ID:1 ncbi_taxonomy Eimeria maxima Cryptosporidium NCBITaxon:2200815 NCBITaxon:2200816 NCBITaxon:2200817 NCBITaxon:2200818 NCBITaxon:2200819 NCBITaxon:2200820 NCBITaxon:2200821 NCBITaxon:2200822 NCBITaxon:2200823 NCBITaxon:2200824 NCBITaxon:2200825 NCBITaxon:2200826 GC_ID:1 ncbi_taxonomy Cryptosporidium parvum GC_ID:1 ncbi_taxonomy Sarcocystids Sarcocystidae GC_ID:1 ncbi_taxonomy Toxoplasma gondii GC_ID:1 ncbi_taxonomy Plasmodium GC_ID:1 ncbi_taxonomy Plasmodium berghei Plasmodium chabaudi malaria parasite P. falciparum GC_ID:1 malaria parasite P. falciparum ncbi_taxonomy Plasmodium (Laverania) falciparum Plasmodium falciparum Plasmodium knowlesi malaria parasite P. vivax GC_ID:1 malaria parasite P. vivax ncbi_taxonomy Haemamoeba vivax Haemamoeba vivax Grassi and Feletti, 1890 Plasmodium vivax GC_ID:1 ncbi_taxonomy Plasmodium yoelli Plasmodium yoelii GC_ID:1 Piroplasmids ncbi_taxonomy Piroplasmida GC_ID:1 ncbi_taxonomy Babesia GC_ID:1 ncbi_taxonomy Babesia bovis GC_ID:1 ncbi_taxonomy Babesia bigemina GC_ID:1 ncbi_taxonomy Babesia canis GC_ID:1 ncbi_taxonomy Theileria GC_ID:1 ncbi_taxonomy Theileria annulata GC_ID:1 ncbi_taxonomy Theileria parva GC_ID:11 PMID:10319519 PMID:10939679 PMID:12072558 PMID:15653929 PMID:15653930 PMID:3231714 PMID:37486130 PMID:9731304 ncbi_taxonomy Salmonella NCBITaxon:149049 GC_ID:11 PMID:15653929 PMID:15653930 PMID:7149525 ncbi_taxonomy Salmonella cholerae-suis subsp. cholerae-suis Salmonella choleraesuis subsp. choleraesuis Salmonella enterica I Salmonella enterica subsp. I Salmonella enterica subsp. Subsp. I Salmonella enterica subsp. Subsp. Ixxx Salmonella enterica subsp. enterica NCBITaxon:41510 GC_ID:11 ncbi_taxonomy Salmonella enterica serovar Gallinarum Salmonella gallinarum Salmonella enterica subsp. enterica serovar Gallinarum GC_ID:1 ncbi_taxonomy Schistosoma GC_ID:1 ncbi_taxonomy Schistosoma japonicum GC_ID:1 ncbi_taxonomy Schistosoma mansoni Schistosoma haematobium GC_ID:1 ncbi_taxonomy Monkeypox virus Zaire-96-I-16 GC_ID:11 PMID:26834722 ncbi_taxonomy Shigella GC_ID:11 PMID:12054222 Escherichia/Shigella dysenteriae ncbi_taxonomy Bacillus dysenteriae Bacillus dysentericus Bacillus shigae Eberthella dysenteriae Shigella shigae Shigella dysenteriae GC_ID:11 Escherichia flexneri Escherichia/Shigella flexneri ncbi_taxonomy Shigella paradysenteriae Shigella flexneri GC_ID:11 ncbi_taxonomy Bacterium sonnei Shigella sonnei GC_ID:11 Yersinia ncbi_taxonomy Yersinia <enterobacteria> GC_ID:11 PMID:15084509 ncbi_taxonomy Bacillus pestis Bacterium pestis Pasteurella pestis Pestisella pestis Yersinia pseudotuberculosis subsp. pestis Yersinia pestis NCBITaxon:1161941 GC_ID:11 PMID:2223608 PMID:23919959 ncbi_taxonomy Bacillus pseudotuberkulosis Bacterium pseudotuberculosis Pasteurella lymphangitidis Pasteurella pseudotuberculosis Shigella pseudotuberculosis Yersinia pseudotuberculosis GC_ID:1 ncbi_taxonomy Trichinella spiralis GC_ID:11 Edwardsiella ncbi_taxonomy Asakusa group Bartholomew group Edwardsiella <enterobacteria> NCBITaxon:1471792 NCBITaxon:1471793 GC_ID:11 PMID:27539016 ncbi_taxonomy Edwardsiella anguillimortifera Paracolobactrum anguillimortiferum Edwardsiella tarda GC_ID:11 PMID:15143042 PMID:4954820 PMID:8427811 ncbi_taxonomy gamma-3 proteobacteria Vibrionaceae GC_ID:11 PMID:11155981 PMID:12067377 PMID:12807216 PMID:1380286 PMID:1380289 PMID:15388703 PMID:16560691 PMID:17012583 PMID:17158971 PMID:19567585 PMID:7520733 PMID:8347521 PMID:8934910 ncbi_taxonomy Aeromonas NCBITaxon:1471787 NCBITaxon:1471788 NCBITaxon:329135 NCBITaxon:329140 NCBITaxon:346633 NCBITaxon:346634 NCBITaxon:582196 NCBITaxon:582198 NCBITaxon:582214 NCBITaxon:582215 NCBITaxon:582216 NCBITaxon:582217 NCBITaxon:582218 NCBITaxon:582219 NCBITaxon:582220 NCBITaxon:582221 NCBITaxon:582222 NCBITaxon:582223 NCBITaxon:582224 NCBITaxon:582225 NCBITaxon:582226 NCBITaxon:582228 NCBITaxon:582229 NCBITaxon:582231 NCBITaxon:582236 NCBITaxon:582237 NCBITaxon:582240 NCBITaxon:582250 NCBITaxon:582251 NCBITaxon:582253 NCBITaxon:582254 NCBITaxon:582265 NCBITaxon:582266 NCBITaxon:582267 NCBITaxon:582279 NCBITaxon:582282 NCBITaxon:582284 NCBITaxon:582286 NCBITaxon:582287 NCBITaxon:582289 NCBITaxon:582290 NCBITaxon:582291 NCBITaxon:582292 NCBITaxon:582295 NCBITaxon:582297 NCBITaxon:582299 NCBITaxon:582300 NCBITaxon:582302 NCBITaxon:582303 NCBITaxon:582304 NCBITaxon:582305 NCBITaxon:582306 NCBITaxon:582307 NCBITaxon:582308 NCBITaxon:582309 NCBITaxon:582310 NCBITaxon:582311 NCBITaxon:582312 NCBITaxon:582313 NCBITaxon:582314 NCBITaxon:582315 NCBITaxon:582316 NCBITaxon:582317 NCBITaxon:582318 NCBITaxon:582319 NCBITaxon:582320 NCBITaxon:582321 NCBITaxon:582322 NCBITaxon:582323 NCBITaxon:582324 NCBITaxon:98358 GC_ID:11 PMID:16560691 PMID:19965992 PMID:23485124 PMID:932684 ncbi_taxonomy Aeromonas dourgesi Aeromonas hydrophila (Chester 1901) Stanier 1943 (Approved Lists 1980) Aeromonas liquefaciens Bacillus hydrophilus fuscus Bacterium hydrophilum Proteus hydrophilus Proteus ichthyosmius Pseudomonas hydrophila Aeromonas hydrophila molluscs mollusks Mollusca NCBITaxon:1055664 NCBITaxon:697046 GC_ID:11 PMID:19965992 ncbi_taxonomy Bacillus salmonicida Bacterium salmonicida Proteus salmonicida Aeromonas salmonicida NCBITaxon:1618316 GC_ID:11 PMID:10515907 PMID:10758897 PMID:16585709 PMID:24744012 PMID:27930271 PMID:28141502 PMID:30154058 PMID:30586413 PMID:31454394 PMID:31722850 PMID:31836459 PMID:32320380 PMID:35816828 PMID:36748499 PMID:7981102 PMID:8573491 PMID:8934900 PMID:8995795 PMID:9336916 Lyme Disease Borrelia ncbi_taxonomy Borrelia burgdorferi group Borrelia burgdorferi sensu lato Borreliella Biomphalaria NCBITaxon:705 GC_ID:11 PMID:1371064 PMID:17978204 PMID:21057054 PMID:21296930 PMID:24409173 PMID:4935323 PMID:7520733 PMID:8590667 ncbi_taxonomy Beneckea Listonella Microspira Pacinia Vibrio NCBITaxon:140100 NCBITaxon:376726 GC_ID:11 PMID:1015934 PMID:9272984 ncbi_taxonomy Bacillo virgola del Koch Bacillus cholerae Bacillus cholerae-asiaticae Kommabacillus Liquidivibrio cholerae Microspira comma Pacinia cholerae-asiaticae Spirillum cholerae Spirillum cholerae-asiaticae Vibrio albensis Vibrio cholera Vibrio cholerae biovar albensis Vibrio cholerae bv. albensis Vibrio cholerae-asiaticae Vibrio comma Vibrio cholerae GC_ID:11 ncbi_taxonomy Edwardsiella ictaluri NCBITaxon:352473 DHV-1 GC_ID:1 Duck hepatitis A virus Duck hepatitis virus 1 Duck hepatitis virus type 1 ncbi_taxonomy Avihepatovirus A GC_ID:1 ncbi_taxonomy Coronavirinae GC_ID:1 Alphacoronavirus-1 ncbi_taxonomy Alphacoronavirus 1 NCBITaxon:156439 GC_ID:1 Coronavirus group 2 Group 2 species ncbi_taxonomy Coronavirus Betacoronavirus NCBITaxon:227859 NCBITaxon:311178 HCoV-SARS SARS SARSr-CoV SARSrCoV GC_ID:1 Human coronavirus (strain SARS) SARS-like coronavirus SARS-related coronavirus ncbi_taxonomy Severe acute respiratory syndrome-related coronavirus GC_ID:1 ncbi_taxonomy Tremovirus A kissing bugs Triatominae GC_ID:11 PMID:10843050 PMID:15280320 PMID:15388716 PMID:17220461 PMID:2223605 PMID:29923825 ncbi_taxonomy Pasteurellaceae GC_ID:11 PMID:1847295 ncbi_taxonomy Haemophilus pleuropneumoniae Actinobacillus pleuropneumoniae Anopheles GC_ID:1 Anopheles ncbi_taxonomy Anopheles <genus> sand flies sandflies Phlebotominae GC_ID:11 ncbi_taxonomy Thiomicrospira group Thiothrix/Francisella group Thiotrichales GC_ID:11 PMID:1736960 ncbi_taxonomy Haemophilus GC_ID:11 ncbi_taxonomy Bacterium influenzae Coccobacillus pfeifferi Haemophilus meningitidis Influenza-bacillus Mycobacterium influenzae Haemophilus influenzae NCBITaxon:163489 NCBITaxon:214923 GC_ID:11 PMID:13130032 PMID:4333932 ncbi_taxonomy Haemophilus agni Haemophilus ovis Haemophilus somnifer Haemophilus somnus Hemophilus agni Histophilus ovis Histophilus somni GC_ID:11 PMID:5821848 ncbi_taxonomy Haemophilus parasuis Glaesserella parasuis Glossina tsetse flies tsetse fly Glossina <genus> GC_ID:11 PMID:15184562 ncbi_taxonomy Bacterium multocidum Micrococcus gallicidus Pasteurella cholerae-gallinarum Pasteurella gallicida Pasteurella multocida NCBITaxon:746 GC_ID:11 PMID:10028248 PMID:8782683 ncbi_taxonomy Pasteurella haemolytica Newsom and Cross 1932 (Approved Lists 1980) Mannheimia haemolytica GC_ID:11 PMID:11760958 PMID:8240958 rickettsias ncbi_taxonomy alpha-1 proteobacteria Rickettsiales GC_ID:1 ncbi_taxonomy Arteriviridae GC_ID:1 ncbi_taxonomy Nidovirales NCBITaxon:61430 GC_ID:1 ncbi_taxonomy Theileria hirci Theileria lestoquardi Vertebrata vertebrates GC_ID:1 Vertebrata vertebrates ncbi_taxonomy vertebrates Vertebrata <vertebrates> GC_ID:11 PMID:9226923 ncbi_taxonomy Rickettsia burneti Rickettsia diaporica Coxiella burnetii GC_ID:11 PMID:10939649 PMID:11491333 PMID:14662925 PMID:9103608 ncbi_taxonomy Rickettsia GC_ID:1 fish fishes ray-finned fishes ncbi_taxonomy Actinopterygi Osteichthyes bony fishes Actinopterygii GC_ID:11 ncbi_taxonomy Clostridium perfringens C GC_ID:1 catfishes ncbi_taxonomy Siluriformes GC_ID:1 PMID:15062801 salmonids ncbi_taxonomy Salmonidae NCBITaxon:1311475 GC_ID:1 rainbow trout ncbi_taxonomy Oncorhynchus nerka mykiss Parasalmo mykiss Salmo mykiss Oncorhynchus mykiss GC_ID:11 PMID:16403855 ncbi_taxonomy Burkholderia/Oxalobacter/Ralstonia group Burkholderiales NCBITaxon:83553 GC_ID:11 PMID:10319462 PMID:11211265 PMID:21048221 PMID:21048222 PMID:23620152 PMID:25618261 PMID:9103632 PMID:9103637 ncbi_taxonomy "Prowazekia" Coles 1953 Bedsonia Chlamydophila Miyagawanella Rakeia Rickettsiaformis Chlamydia GC_ID:11 PMID:10192388 PMID:10319462 PMID:8102247 PMID:8347519 ncbi_taxonomy Chlamydozoon trachomatis Rickettsia trachomae Rickettsia trachomatis Chlamydia trachomatis GC_ID:11 ncbi_taxonomy Escherichia coli O157:H7 NCBITaxon:812 GC_ID:11 PMID:10319462 PMID:12807198 PMID:8102247 PMID:8347519 ncbi_taxonomy Chlamydophila psittaci Chlamydozoon psittaci Ehrlichia psittaci Rickettsia psittaci Rickettsiaformis psittacosis Chlamydia psittaci GC_ID:11 PMID:10319462 PMID:12807198 PMID:25618261 ncbi_taxonomy Chlamydia psittaci (Lillie 1930) Page 1968 Chlamydia psittaci serotype 1 Chlamydophila abortus Chlamydia abortus NCBITaxon:811 GC_ID:11 PMID:10319462 PMID:8102247 PMID:8347519 ncbi_taxonomy Chlamydophila pneumoniae Chlamydia pneumoniae GC_ID:11 PMID:10319462 agent of mouse pneumonitis ncbi_taxonomy Chlamydia trachomatis MoPn Chlamydia muridarum GC_ID:11 PMID:15774632 PMID:24158948 PMID:25481042 PMID:8186083 PMID:8590687 ncbi_taxonomy Porphyromonas NCBITaxon:1761 GC_ID:11 PMID:11837321 PMID:1736962 PMID:19244447 PMID:31157615 ncbi_taxonomy Corynebacteriales Corynebacteriales Goodfellow and Jones 2015 Corynebacterineae Mycobacteriales Janke 1924 (Approved Lists 1980) Mycobacteriales PCV2 GC_ID:1 Porcine circovirus Type II Porcine circovirus type 2 Porcine circovirus-2 ncbi_taxonomy Porcine circovirus 2 GC_ID:1 birds ncbi_taxonomy avian birds Aves GC_ID:1 ncbi_taxonomy Neognathae GC_ID:1 ducks ncbi_taxonomy Anas NCBITaxon:9099 GC_ID:1 turkeys ncbi_taxonomy Phasianidae GC_ID:11 ncbi_taxonomy Leptospira interrogans serovar Icterohaemorrhagiae Gallus domesticus bantam chicken chickens GC_ID:1 Gallus domesticus bantam chicken chickens ncbi_taxonomy Gallus gallus domesticus Phasianus gallus Gallus gallus NCBITaxon:41530 NCBITaxon:601 NCBITaxon:72667 GC_ID:11 PMID:10319519 PMID:10758910 PMID:15653930 PMID:16558776 PMID:9336938 ncbi_taxonomy Bacillus typhi Bacterium (subgen. Eberthella) typhi Salmonella choleraesuis serovar Typhi Salmonella choleraesuis typhi Salmonella enterica ser. typhi Salmonella enterica serotype Typhi Salmonella enterica serovar Typhi Salmonella typhi Salmonella enterica subsp. enterica serovar Typhi NCBITaxon:41532 NCBITaxon:59210 NCBITaxon:602 GC_ID:11 PMID:10758910 PMID:15653930 PMID:9336938 ncbi_taxonomy Bacillus typhimurium Salmonella choleraesuis serotype typhimurium Salmonella enterica 1,4,[5],12,:i:1,2 Salmonella enterica ser. typhimurium Salmonella enterica serotype Typhimurium Salmonella enterica serovar Typhimurium Salmonella enterica subsp. enterica serovar 1,4,[5],12:i:1,2 Salmonella typhi-murium Salmonella typhimurium Salmonella enterica subsp. enterica serovar Typhimurium GC_ID:1 common turkey turkey wild turkey ncbi_taxonomy Meleagris gallopavo GC_ID:11 ncbi_taxonomy Bacillus/Lactobacillus/Streptococcus group Firmibacteria Bacilli GC_ID:11 PMID:27620848 ncbi_taxonomy Enterobacteriaceae and related endosymbionts Enterobacteriaceae group Enterobacteriales gamma-3 proteobacteria Enterobacterales GC_ID:1 whales, hippos, ruminants, pigs, camels etc. ncbi_taxonomy Cetartiodactyla even-toed ungulates Artiodactyla GC_ID:1 parrot parrots ncbi_taxonomy Psittacidae GC_ID:11 ncbi_taxonomy Leptospira sp. Pomona primate Primates GC_ID:1 New World monkeys monkey monkeys ncbi_taxonomy Platyrrhini GC_ID:11 PMID:11760958 PMID:1736961 PMID:7537065 Potomac horse fever agent equine monocytic ehrlichiosis agent ncbi_taxonomy Ehrlichia risticii Neorickettsia risticii GC_ID:1 ncbi_taxonomy Catarrhini GC_ID:1 African green monkey African green monkeys grivet savanah monkey ncbi_taxonomy Cercopithecus aethiops Ceropithecus aethiops Simia aethiops Chlorocebus aethiops human GC_ID:1 human ncbi_taxonomy Homo sapiens GC_ID:1 dog, coyote, wolf, fox ncbi_taxonomy Canidae GC_ID:1 ncbi_taxonomy Canis GC_ID:1 gray wolf grey wolf ncbi_taxonomy Canis lupus dog dogs GC_ID:1 dog dogs ncbi_taxonomy Canis canis Canis domesticus Canis familiaris Canis lupus familiaris NCBITaxon:68731 NCBITaxon:9609 GC_ID:1 ncbi_taxonomy Fennecus Vulpes GC_ID:1 northern raccoon raccoon ncbi_taxonomy Ursus lotor Procyon lotor NCBITaxon:77150 GC_ID:1 black ferret domestic ferret ferret ncbi_taxonomy Mustela furo Mustela putorius furo GC_ID:1 ncbi_taxonomy Felis NCBITaxon:36475 GC_ID:1 PMID:17600185 PMID:8581300 PMID:8603894 cat cats domestic cat ncbi_taxonomy Felis domesticus Felis silvestris catus Felis catus NCBITaxon:171554 GC_ID:11 PMID:11541229 PMID:11542017 PMID:28066339 BCF group Bacteroides-Cytophaga-Flexibacter group CFB group Cytophaga-Flexibacter-Bacteroides phylum ncbi_taxonomy "Bacteroidota" Whitman et al. 2018 Bacteroidetes CFB group bacteria Sphingobacteria Bacteroidota GC_ID:1 sei whale ncbi_taxonomy Balaenoptera borealis GC_ID:1 horses ncbi_taxonomy Equidae GC_ID:1 domestic horse equine horse ncbi_taxonomy Equus przewalskii f. caballus Equus przewalskii forma caballus Equus caballus GC_ID:1 pig pigs swine wild boar ncbi_taxonomy Sus scrofa GC_ID:1 deer ncbi_taxonomy Cervidae white-tailed deer Odocoileus virginianus GC_ID:1 ncbi_taxonomy Bovidae GC_ID:1 ncbi_taxonomy Bison GC_ID:1 American bison Bison ncbi_taxonomy Bos (Bison) bison Bos bison Bison bison bovine cattle cow dairy cow domestic cattle domestic cow ox oxen NCBITaxon:272461 GC_ID:1 bovine cattle cow dairy cow domestic cattle domestic cow ox oxen ncbi_taxonomy Bos bovis Bos primigenius taurus Bos taurus NCBITaxon:57076 GC_ID:1 domestic goat goat goats ncbi_taxonomy Capra aegagrus hircus Capra hircus GC_ID:1 ncbi_taxonomy Ovis NCBITaxon:9936 GC_ID:1 domestic sheep lambs sheep wild sheep ncbi_taxonomy Ovis ammon aries Ovis orientalis aries Ovis ovis Ovis aries NCBITaxon:29531 GC_ID:11 PMID:11594628 PMID:16560903 PMID:29593693 ncbi_taxonomy Chondrococcus columnaris Cytophaga columnaris Flavobacterium columnare (Bernardet and Grimont 1989) Bernardet et al. 1996 Flexibacter columnaris Flexibacter columnaris (ex Davis 1922) Bernardet and Grimont 1989 Flavobacterium columnare GC_ID:1 ncbi_taxonomy Caprinae NCBITaxon:34833 NCBITaxon:9985 GC_ID:1 European rabbit Japanese white rabbit domestic rabbit rabbit rabbits ncbi_taxonomy Lepus cuniculus Oryctolagus cuniculus GC_ID:1 rodent ncbi_taxonomy rodents Rodentia a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event. Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'. YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device. YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention. YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action). Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623. YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process. The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740. YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events. YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'. Yongqun He AE adverse reaction WEB: http://en.wikipedia.org/wiki/Adverse_event WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068 The OAE official website is: http://www.oae-ontology.org/. adverse event an adverse event that occurs after a vaccination. YH vaccine adverse event A contraindication is a disposition that increases the risk of harm involved in using a particular drug, carrying out a medical procedure, or engaging in a particular activity such that the risk of harm exceeds a threshold. An contraindication serves as a reason to withhold a certain medical treatment. Yongqun He, Sirarat Sarntivijai, Mathias Brochhausen, William Hogan, ‎Philip E. Empey http://en.wikipedia.org/wiki/Contraindication contraindication an adverse event that is induced by a vaccination. YH vaccine-induced adverse event planned process planned process Injecting mice with a vaccine in order to test its efficacy A process that realizes a plan which is the concretization of a plan specification. 'Plan' includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn't have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.) We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some objectives is a planned process. Bjoern Peters branch derived 6/11/9: Edited at workshop. Used to include: is initiated by an agent This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call) planned process regulator role Fact sheet - Regulating the companies The role of the regulator. Ofwat is the economic regulator of the water and sewerage industry in England and Wales. http://www.ofwat.gov.uk/aptrix/ofwat/publish.nsf/Content/roleofregulator_factsheet170805 a regulatory role involved with making and/or enforcing relevant legislation and governmental orders Person:Jennifer Fostel regulator OBI regulator role regulation-assigned role Approval letter Regulation-assigned role is a regulatory role defined by legislation or governmental orders Person: Jennifer Fostel regulation-assigned role regulatory role Regulatory agency, Ethics committee, Approval letter; example: Browse these EPA Regulatory Role subtopics http://www.epa.gov/ebtpages/enviregulatoryrole.html Feb 29, 2008 a role which inheres in material entities and is realized in the processes of making, enforcing or being defined by legislation or orders issued by a governmental body. GROUP: Role branch OBI, CDISC govt agents responsible for creating regulations; proxies for enforcing regulations. CDISC definition: regulatory authorities. Bodies having the power to regulate. NOTE: In the ICH GCP guideline the term includes the authorities that review submitted clinical data and those that conduct inspections. These bodies are sometimes referred to as competent regulatory role processed material Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples Is a material entity that is created or changed during material processing. PERSON: Alan Ruttenberg processed material evaluant role When a specimen of blood is assayed for glucose concentration, the blood has the evaluant role. When measuring the mass of a mouse, the evaluant is the mouse. When measuring the time of DNA replication, the evaluant is the DNA. When measuring the intensity of light on a surface, the evaluant is the light source. a role that inheres in a material entity that is realized in an assay in which data is generated about the bearer of the evaluant role Role call - 17nov-08: JF and MC think an evaluant role is always specified input of a process. Even in the case where we have an assay taking blood as evaluant and outputting blood, the blood is not the specified output at the end of the assay (the concentration of glucose in the blood is) examples of features that could be described in an evaluant: quality.... e.g. "contains 10 pg/ml IL2", or "no glucose detected") GROUP: Role Branch OBI Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term. evaluant role assay Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house. A planned process that has the objective to produce information about a material entity (the evaluant) by examining it. 12/3/12: BP: the reference to the 'physical examination' is included to point out that a prediction is not an assay, as that does not require physical examiniation. Discussion on OBI call 2023-05-01 resulted in an agreement to revise the textual definition of 'assay'. https://github.com/obi-ontology/obi/issues/1683. PlanAndPlannedProcess Branch measuring scientific observation OBI branch derived study assay any method assay reagent role Buffer, dye, a catalyst, a solvating agent. A role inhering in a biological or chemical entity that is intended to be applied in a scientific technique to participate (or have molecular components that participate) in a chemical reaction that facilitates the generation of data about some entity distinct from the bearer, or the generation of some specified material output distinct from the bearer. PERSON:Matthew Brush reagent PERSON:Matthew Brush Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term. May 28 2013. Updated definition taken from ReO based on discussions initiated in Philly 2011 workshop. Former defnition described a narrower view of reagents in chemistry that restricts bearers of the role to be chemical entities ("a role played by a molecular entity used to produce a chemical reaction to detect, measure, or produce other substances"). Updated definition allows for broader view of reagents in the domain of biomedical research to include larger materials that have parts that participate chemically in a molecular reaction or interaction. (copied from ReO) Reagents are distinguished from instruments or devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in or have parts that participate in some chemical interaction or reaction during their intended participation in some technique. By contrast, instruments do not participate in a chemical reaction/interaction during the technique. Reagents are distinguished from study subjects/evaluants in that study subjects and evaluants are that about which conclusions are drawn and knowledge is sought in an investigation - while reagents, by definition, are not. It should be noted, however, that reagent and study subject/evaluant roles can be borne by instances of the same type of material entity - but a given instance will realize only one of these roles in the execution of a given assay or technique. For example, taq polymerase can bear a reagent role or an evaluant role. In a DNA sequencing assay aimed at generating sequence data about some plasmid, the reagent role of the taq polymerase is realized. In an assay to evaluate the quality of the taq polymerase itself, the evaluant/study subject role of the taq is realized, but not the reagent role since the taq is the subject about which data is generated. In regard to the statement that reagents are 'distinct' from the specified outputs of a technique, note that a reagent may be incorporated into a material output of a technique, as long as the IDENTITY of this output is distinct from that of the bearer of the reagent role. For example, dNTPs input into a PCR are reagents that become part of the material output of this technique, but this output has a new identity (ie that of a 'nucleic acid molecule') that is distinct from the identity of the dNTPs that comprise it. Similarly, a biotin molecule input into a cell labeling technique are reagents that become part of the specified output, but the identity of the output is that of some modified cell specimen which shares identity with the input unmodified cell specimen, and not with the biotin label. Thus, we see that an important criteria of 'reagent-ness' is that it is a facilitator, and not the primary focus of an investigation or material processing technique (ie not the specified subject/evaluant about which knowledge is sought, or the specified output material of the technique). reagent role material processing A cell lysis, production of a cloning vector, creating a buffer. A planned process which results in physical changes in a specified input material PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca Serra material transformation OBI branch derived material processing population PMID12564891. Environ Sci Technol. 2003 Jan 15;37(2):223-8. Effects of historic PCB exposures on the reproductive success of the Hudson River striped bass population. a population is a collection of individuals from the same taxonomic class living, counted or sampled at a particular site or in a particular area 1/28/2013, BP, on the call it was raised that we may want to switch to an external ontology for all populatin terms: http://code.google.com/p/popcomm-ontology/ PERSON: Philippe Rocca-Serra adapted from Oxford English Dictionnary rem1: collection somehow always involve a selection process population antigen role A role of a material entity that is being recognized in whole or in part by receptors of the immune system such as antibodies or T cell receptors. An antigen is a substance that prompts the generation of antibodies and can cause an immune response. Wikipedia http://en.wikipedia.org/wiki/Antigen. In the strict sense, immunogens are those substances that elicit a response from the immune system, whereas antigens are defined as substances that bind to specific antibodies. Not all antigens produce an immunogenic response, but all immunogens are antigens Role Branch OBI 9Mar09 waiting for discussion with immunology terms antigen role organization PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods. An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members. BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that. The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based: 1) there are organization_member_roles (president, treasurer, branch editor), with individual persons as bearers 2) there are organization_roles (employer, owner, vendor, patent holder) 3) an organization has a charter / rules / bylaws, which specify what roles there are, how they should be realized, and how to modify the charter/rules/bylaws themselves. It is debatable what the organization itself is (some kind of dependent continuant or an aggregate of people). This also determines who/what the bearer of organization_roles' are. My personal favorite is still to define organization as a kind of 'legal entity', but thinking it through leads to all kinds of questions that are clearly outside the scope of OBI. Interestingly enough, it does not seem to matter much where we place organization itself, as long as we can subclass it (University, Corporation, Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO, W3C, University of Oklahoma), and have it play roles. This leads to my proposal: We define organization through the statements 1 - 3 above, but without an 'is a' statement for now. We can leave it in its current place in the is_a hierarchy (material entity) or move it up to 'continuant'. We leave further clarifications to BFO, and close this issue for now. PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Philippe Rocca-Serra PERSON: Susanna Sansone GROUP: OBI organization protocol PCR protocol, has objective specification, amplify DNA fragment of interest, and has action specification describes the amounts of experimental reagents used (e..g. buffers, dNTPS, enzyme), and the temperature and cycle time settings for running the PCR. A plan specification which has sufficient level of detail and quantitative information to communicate it between investigation agents, so that different investigation agents will reliably be able to independently reproduce the process. PlanAndPlannedProcess Branch OBI branch derived + wikipedia (http://en.wikipedia.org/wiki/Protocol_%28natural_sciences%29) study protocol protocol adding a material entity into a target Injecting a drug into a mouse. Adding IL-2 to a cell culture. Adding NaCl into water. is a process with the objective to place a material entity bearing the 'material to be added role' into a material bearing the 'target of material addition role'. Class was renamed from 'administering substance', as this is commonly used only for additions into organisms. BP branch derived adding a material entity into a target intraperitoneal injection is the injection of a material entity (bearing the administered substance role) into the peritoneum (bearing the target role) of an organism using a syringe BP intraperitoneal injection material to be added role drug added to a buffer contained in a tube; substance injected into an animal; A role of a material entity that is realized in an "adding a material entity into a target" process where the bearer of the role is added into another material entity (the target). Role Branch OBI 9 March 09 from discussion with PA branch material to be added role transfer function A transfer function is a function to displace a material from one location to another. Bill Bug Daniel Schober Frank Gibson Melanie Courtot transfer function syringe Accuracy of oral liquid measuring devices: comparison of dosing cup and oral dosing syringe.Ann Pharmacother. 2008 Jan;42(1):46-52. Epub 2007 Dec 4. PMID: 18056832 A processed material which is used to introduce or draw fluids from a material entity. A syringe is made of a piston and body. the movement of the piston in the body determines the amount/volume of fluid to inject or draw Philippe Rocca-Serra OBI Instrument adapted from Wikipedia syringe injection Multiple Small-Dose Injections Can Reduce the Passage of Sclerosant Foam into Deep Veins During Foam Sclerotherapy for Varicose Veins. Eur J Vasc Endovasc Surg. 2008 Oct 13. PMID: 18922712 injection is process which aims at introducing a compound or a mixture into a material entity (either biological entity or instrument) by relying on devices such as syringe or injector connection, attached or forced into a vascular system (veins of an organism or tubes of a machine) or in a tissue. Philippe Rocca-Serra OBI Biomaterial injection intraperitoneal administration Rats were injected intraperitoneally with either rrIL-6 (250 ng/0.5 ml) or equal-volume sterile saline twice within an interval of 24 h The administration of a substance into the peritoneum of an organism Person:Bjoern Peters intraperitoneal administration adding material objective creating a mouse infected with LCM virus is the specification of an objective to add a material into a target material. The adding is asymmetric in the sense that the target material largely retains its identity BP adding material objective assay objective the objective to determine the weight of a mouse. an objective specification to determine a specified type of information about an evaluated entity (the material entity bearing evaluant role) PPPB branch PPPB branch assay objective target of material addition role peritoneum of an animal receiving an interperitoneal injection; solution in a tube receiving additional material; location of absorbed material following a dermal application. A role of a material entity that is realized in an "adding a material entity into a target" process where the bearer of the role (the target) receives the addition of another material entity. From Branch discussion with BP, AR, MC -- there is a need for the recipient to interact with the administered material. for example, a tooth receiving a filling was not considered to be a target role. GROUP: Role Branch OBI target of material addition role regulatory agency The US Environmental Protection Agency A regulatory agency is a organization that has responsibility over or for the legislation (acts and regulations) for a given sector of the government. GROUP: OBI Biomaterial Branch WEB: en.wikipedia.org/wiki/Regulator regulatory agency material transformation objective The objective to create a mouse infected with LCM virus. The objective to create a defined solution of PBS. an objective specifiction that creates an specific output object from input materials. PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra artifact creation objective GROUP: OBI PlanAndPlannedProcess Branch material transformation objective manufacturing A planned process with the objective to produce a processed material which will have a function for future use. A person or organization (having manufacturer role) is a participant in this process Manufacturing implies reproducibility and responsibility AR This includes a single scientist making a processed material for personal use. PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra GROUP: OBI PlanAndPlannedProcess Branch manufacturing manufacturing objective is the objective to manufacture a material of a certain function (device) PERSON: Bjoern Peters PERSON: Frank Gibson PERSON: Jennifer Fostel PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra GROUP: OBI PlanAndPlannedProcess Branch manufacturing objective manufacturer role With respect to The Accuri C6 Flow Cytometer System, the organization Accuri bears the role manufacturer role. With respect to a transformed line of tissue culture cells derived by a specific lab, the lab whose personnel isolated the cll line bears the role manufacturer role. With respect to a specific antibody produced by an individual scientist, the scientist who purifies, characterizes and distributes the anitbody bears the role manufacturer role. Manufacturer role is a role which inheres in a person or organization and which is realized by a manufacturing process. GROUP: Role Branch OBI manufacturer role scattered molecular aggregate the sodium and chloride ions in a glass of salt water a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates PERSON: Alan Ruttenberg Collective Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. With inspiration from the paper Granularity, scale and collectivity: When size does and does not matter, Alan Recto, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349 scattered molecular aggregate material combination Mixing two fluids. Adding salt into water. Injecting a mouse with PBS. is a material processing with the objective to combine two or more material entities as input into a single material entity as output. created at workshop as parent class for 'adding material into target', which is asymmetric, while combination encompasses all addition processes. bp bp material combination statistical hypothesis test A statistical hypothesis test data transformation is a data transformation that has objective statistical hypothesis test. James Malone PERSON: James Malone statistical hypothesis test statistical hypothesis test objective is a data transformation objective where the aim is to estimate statistical significance with the aim of proving or disproving a hypothesis by means of some data transformation. James Malone Person:Helen Parkinson hypothesis test objective WEB: http://en.wikipedia.org/wiki/Statistical_hypothesis_testing statistical hypothesis test objective creating a mixture of molecules in solution The production of PBS is a process with the objective to prepare a liquid solution of one or more chemicals at desired concentrations. Bjoern Peters PERSON: Helen Parkinson creating a mixture of molecules in solution material combination objective is an objective to obtain an output material that contains several input materials. PPPB branch bp material combination objective pathogen challenge The administration of a live pathogenic organism to a host. pathogen challenge pathogen role Pathogen: An agent of disease. A disease producer. The term pathogen most commonly is used to refer to infectious organisms. These include bacteria (such as staph), viruses (such as HIV), and fungi (such as yeast). Less commonly, pathogen refers to a noninfectious agent of disease such as a chemical. http://www.medterms.com/script/main/art.asp?articlekey=6383 pathogen role is a role which inheres in an organism and realized in the process of disease course in the organism bearing host role caused by the organism bearing pathogen role GROUP: Role Branch OBI 6 April 2009: from the Vaccine Community pathogen role host role In biology, a host is an organism that harbors a virus or parasite, or a mutual or commensal symbiont, typically providing nourishment and shelter. http://en.wikipedia.org/wiki/Host_(biology) 30 March 09 host role is a role played by an organism and realized by providing nourishment, shelter or a means of reproduction to another organism within the organism playing the host role 30Mar09 virus reproducing inside a cell; bacteria causing a disease, host can be harmed or not. we want to avoid a cat sitting on my lap and an animal care technician; these are not examples or hosts; dental cares = on tooth, but part of outer layer of tooth, so covered by "within" in the definition GROUP: Role Branch 30 Mar09 submitted by vaccine community OBI http://en.wikipedia.org/wiki/Host_(biology) host role independent variable specification In a study in which gene expression is measured in patients between 8 month to 4 years old that have mild or severe malaria and in which the hypothesis is that gene expression in that age group is a function of disease status, disease status is the independent variable. a directive information entity that is part of a study design. Independent variables are entities whose values are selected to determine its relationship to an observed phenomenon (the dependent variable). In such an experiment, an attempt is made to find evidence that the values of the independent variable determine the values of the dependent variable (that which is being measured). The independent variable can be changed as required, and its values do not represent a problem requiring explanation in an analysis, but are taken simply as given. The dependent variable on the other hand, usually cannot be directly controlled 2/2/2009 Original definition - In the design of experiments, independent variables are those whose values are controlled or selected by the person experimenting (experimenter) to determine its relationship to an observed phenomenon (the dependent variable). In such an experiment, an attempt is made to find evidence that the values of the independent variable determine the values of the dependent variable (that which is being measured). The independent variable can be changed as required, and its values do not represent a problem requiring explanation in an analysis, but are taken simply as given. The dependent variable on the other hand, usually cannot be directly controlled. In the Philly 2013 workshop the label was chosen to distinguish it from "dependent variable" as used in statistical modelling. See: http://en.wikipedia.org/wiki/Statistical_modeling PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Chris Stoeckert experimental factor independent variable Web: http://en.wikipedia.org/wiki/Dependent_and_independent_variables 2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify thisdefinition please notify OBI. study factor study design independent variable dependent variable specification In a study in which gene expression is measured in patients between 8 month to 4 years old that have mild or severe malaria and in which the hypothesis is that gene expression in that age group is a function of disease status, the gene expression is the dependent variable. dependent variable specification is part of a study design. The dependent variable is the event studied and expected to change when the independent variable varies. 2/2/2009 In the design of experiments, independent variables are those whose values are controlled or selected by the person experimenting (experimenter) to determine its relationship to an observed phenomenon (the dependent variable). In such an experiment, an attempt is made to find evidence that the values of the independent variable determine the values of the dependent variable (that which is being measured). The independent variable can be changed as required, and its values do not represent a problem requiring explanation in an analysis, but are taken simply as given. The dependent variable on the other hand, usually cannot be directly controlled. In the Philly 2013 workshop the label was chosen to distinguish it from "dependent variable" as used in statistical modelling. See: http://en.wikipedia.org/wiki/Statistical_modeling PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Chris Stoeckert dependent variable WEB: http://en.wikipedia.org/wiki/Dependent_and_independent_variables 2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify thisdefinition please notify OBI. study design dependent variable material maintenance objective An objective specification maintains some or all of the qualities of a material over time. PERSON: Bjoern Peters PERSON: Bjoern Peters material maintenance objective manufacturer A person or organization that has a manufacturer role. manufacturer material maintenance A planned process with the objective to maintain some or all of the characteristics of an input material over time. material maintenance categorical measurement datum A measurement datum that is reported on a categorical scale. Bjoern Peters nominal mesurement datum Bjoern Peters categorical measurement datum device A voltmeter is a measurement device which is intended to perform some measure function. An autoclave is a device that sterlizes instruments or contaminated waste by applying high temperature and pressure. A material entity that is designed to perform a function in a scientific investigation, but is not a reagent. 2012-12-17 JAO: In common lab usage, there is a distinction made between devices and reagents that is difficult to model. Therefore we have chosen to specifically exclude reagents from the definition of "device", and are enumerating the types of roles that a reagent can perform. 2013-6-5 MHB: The following clarifications are outcomes of the May 2013 Philly Workshop. Reagents are distinguished from devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in some chemical interaction or reaction during the realization of their experimental role. By contrast, devices do not participate in such chemical reactions/interactions. Note that there are cases where devices use reagent components during their operation, where the reagent-device distinction is less clear. For example: (1) An HPLC machine is considered a device, but has a column that holds a stationary phase resin as an operational component. This resin qualifies as a device if it participates purely in size exclusion, but bears a reagent role that is realized in the running of a column if it interacts electrostatically or chemically with the evaluant. The container the resin is in (“the column”) considered alone is a device. So the entire column as well as the entire HPLC machine are devices that have a reagent as an operating part. (2) A pH meter is a device, but its electrode component bears a reagent role in virtue of its interacting directly with the evaluant in execution of an assay. (3) A gel running box is a device that has a metallic lead as a component that participates in a chemical reaction with the running buffer when a charge is passed through it. This metallic lead is considered to have a reagent role as a component of this device realized in the running of a gel. In the examples above, a reagent is an operational component of a device, but the device itself does not realize a reagent role (as bearing a reagent role is not transitive across the part_of relation). In this way, the asserted disjointness between a reagent and device holds, as both roles are never realized in the same bearer during execution of an assay. PERSON: Helen Parkinson instrument OBI development call 2012-12-17. device dose specification a protocol specifying to administer 1 ml of vaccine to a mouse a directive information entity that describes the dose that will be administered to a target dose specification dose An organism has been injected 1ml of vaccine A measurement datum that measures the quantity of something that may be administered to an organism or that an organism may be exposed to. Quantities of nutrients, drugs, vaccines and toxins are referred to as doses. dose categorical value specification A value specification that is specifies one category out of a fixed number of nominal categories PERSON:Bjoern Peters categorical value specification value specification The value of 'positive' in a classification scheme of "positive or negative"; the value of '20g' on the quantitative scale of mass. An information content entity that specifies a value within a classification scheme or on a quantitative scale. This term is currently a descendant of 'information content entity', which requires that it 'is about' something. A value specification of '20g' for a measurement data item of the mass of a particular mouse 'is about' the mass of that mouse. However there are cases where a value specification is not clearly about any particular. In the future we may change 'value specification' to remove the 'is about' requirement. PERSON:Bjoern Peters value specification in vivo challenge The administration of a challenge to a live host. Hector Guzman-Orozco IEDB in vivo challenge organism animal fungus plant virus A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') 13-02-2009: OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. This issue is outside the scope of OBI. GROUP: OBI Biomaterial Branch WEB: http://en.wikipedia.org/wiki/Organism organism phosphate buffered saline solution PMID: 16279733.Dent Mater J. 2005 Sep;24(3):414-21.PBS buffer solutions with different pH values can change porosity of DNA-chitosan complexes. Phosphate buffered saline (abbreviated PBS) is a buffer solution commonly used in biochemistry. It is a salty solution containing sodium chloride, sodium phosphate and in some preparations potassium chloride and potassium phosphate. The buffer helps to maintain a constant pH. The concentration usually matches the human body (isotonic). PERSON: Melanie Courtot PERSON: Philippe Rocca-Serra PERSON: Tina Boussard PBS buffer WEB: http://en.wikipedia.org/wiki/Phosphate_buffered_saline phosphate buffered saline solution data transformation The application of a clustering protocol to microarray data or the application of a statistical testing method on a primary data set to determine a p-value. A planned process that produces output data from input data. Elisabetta Manduchi Helen Parkinson James Malone Melanie Courtot Philippe Rocca-Serra Richard Scheuermann Ryan Brinkman Tina Hernandez-Boussard data analysis data processing Branch editors data transformation data transformation objective normalize objective An objective specification to transformation input data into output data Modified definition in 2013 Philly OBI workshop James Malone PERSON: James Malone data transformation objective ANOVA A statistical hypothesis test in which the means of several groups are all equal. James Malone ANOVA chemical solution PMID: 18289311.Anesth Analg. 2008 Apr;106(4):1078-86.Less impairment of hemostasis and reduced blood loss in pigs after resuscitation from hemorrhagic shock using the small-volume concept with hypertonic saline/hydroxyethyl starch as compared to administration of 4% gelatin or 6% hydroxyethyl starch solution. A material entity that is made up of at least 2 scattered molecular aggregates, one playing the role of solvent and the other one playing the role of solute. PERSON: Bjoern Peters PERSON: Philippe Rocca-Serra liquid chemical solution GROUP: OBI Biomaterial Branch chemical solution buffer role A buffer of carbonic acid (H2CO3) and bicarbonate (HCO3-) is present in blood plasma, to maintain a pH between 7.35 and 7.45. http://en.wikipedia.org/wiki/Buffer_solution a role which inheres in some molecular entity realized during the process of buffering Person:Helen Parkinson Person:Philippe Rocca-Serra buffer OBI buffer role solvent role PMID: 18373502.Transfusion. 2008 Mar 25. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. solvent role is a role which inheres in a molecular entity capable of ensuring the dissolution of another chemical entity and realized by the process of solvation Philippe Rocca-Serra adpated from wikipedia (http://en.wikipedia.org/wiki/Solvatation) solvent role solute role PMID: 18380397.Pharmazie. 2008 Feb;63(2):113-21.Deviations of drug solubility in water-cosolvent mixtures from the Jouyban-Acree model--effect of solute structure. solute role is a role played by a chemical entity which is dissolved by another chemical entity (the solvent) when creating a solution Philippe Rocca-Serra adapted from wikipedia (http://en.wikipedia.org/wiki/Solute) solute role storage PMID: 18550121.Total Prostate Specific Antigen Stability Confirmed After Long-Term Storage of Serum at -80C. J Urol. 2008 Jun 10. A planned process with the objective to preserve and protect material entities by placing them in an identified location which may have a controlled environment. Philippe Rocca-Serra OBI-Branch storage study design a matched pairs study design describes criteria by which subjects are identified as pairs which then undergo the same protocols, and the data generated is analyzed by comparing the differences between the paired subjects, which constitute the results of the executed study design. A plan specification comprised of protocols (which may specify how and what kinds of data will be gathered) that are executed as part of an investigation and is realized during a study design execution. Editor note: there is at least an implicit restriction on the kind of data transformations that can be done based on the measured data available. PERSON: Chris Stoeckert experimental design rediscussed at length (MC/JF/BP). 12/9/08). The definition was clarified to differentiate it from protocol. study design administering substance in vivo Balb/c mice received an intracameral or subconjunctival injection of trinitrophenylated spleen cells injecting mice with 10 ug morphine intranasally, a patient taking two pills of 1 mg aspirin orally A process by which a substance is intentionally given to an organism resulting in exposure of the organism to that substance. 2009-11-10. Tracker: https://sourceforge.net/tracker/?func=detail&aid=2893050&group_id=177891&atid=886178 Different routes and means of administration should go as children underneath this Update the definition based on the discussion. Details see the tracker: https://sourceforge.net/p/obi/obi-terms/738/ needs roles such as perturber and perturbee (children of input role). Perturb is too strong. Host might be the name for one role. Others considered: Doner, Donated, Acceptor. Bjoern Peters Person:Bjoern Peters IEDB administering substance in vivo antigen A material entity that has the antigen role. IEDB IEDB antigen A gene is a material entity that represents the entire DNA sequence required for synthesis of a functional protein or RNA molecule. Oliver He WEB: http://www.ncbi.nlm.nih.gov/books/NBK21640/ gene A gene of an organism of Bacteria Yue Liu, Bin Zhao, Oliver He 2 gene of Bacteria A gene of an organism of Proteobacteria Yue Liu, Bin Zhao, Oliver He 1224 gene of Proteobacteria A gene of an organism of Mycobacterium tuberculosis H37Rv Yue Liu, Bin Zhao, Oliver He 83332 gene of Mycobacterium tuberculosis H37Rv A gene of an organism of Brucella melitensis bv. 1 str. 16M Yue Liu, Bin Zhao, Oliver He 224914 gene of Brucella melitensis bv. 1 str. 16M A gene of Mycobacterium tuberculosis H37Rv that has a protein-coding gene disposition Bin Zhao, Oliver He 83332 protein-coding gene of Mycobacterium tuberculosis H37Rv A gene of Brucella melitensis bv. 1 str. 16M that has a protein-coding gene disposition Bin Zhao, Oliver He 224914 protein-coding gene of Brucella melitensis bv. 1 str. 16M Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 885459 Rv3602c 20140405 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 20980199 Pantoate--beta-alanine ligase PanC (pantothenate synthetase) (pantoate activating enzyme) panC Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 885594 Rv1821 20140329 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 17030572; 18487341; 19240020; 20980199; 24297168 Possible preprotein translocase ATPase SecA2 secA2 Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 885596 Rv3601c 20140405 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 20980199 Probable aspartate 1-decarboxylase precursor PanD (aspartate alpha-decarboxylase) panD Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 886960 Rv1293 20140405 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 16511157; 19543810; 20980199 Diaminopimelate decarboxylase LysA (DAP decarboxylase) lysA Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 887603 Rv2930 20140322 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 15749014; 20553505; 20980199 Fatty-acid-AMP ligase FadD26 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase) fadD26 Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 887681 Rv2192c 20140405 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 16337227; 20980199; 23363292 Probable anthranilate phosphoribosyltransferase TrpD trpD Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 888225 Rv2987c 20140405 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 19194004; 20980199 Probable 3-isopropylmalate dehydratase (small subunit) LeuD (isopropylmalate isomerase) (alpha-IPM isomerase) (IPMI) leuD Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 888491 Rv2938 20140322 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 20980199 Probable daunorubicin-dim-transport integral membrane protein ABC transporter DrrC drrC Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 888751 Rv1221 20140406 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 16513743; 18192397; 18606740; 18657035; 20980199 Alternative RNA polymerase sigma factor SigE sigE Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 888772 Rv0757 20140322 83332 protein-coding NCBI-supplied PMID: 9634230; 12368430; 16573683; 18052041; 18065542; 18065544; 18282096; 18757548; 18946503; 19820095; 20363229; 20814030; 20980199; 21634789; 22072719; 22880126 Possible two component system response transcriptional positive regulator PhoP phoP Bin Zhao, Yue Liu, Oliver He WEB: http://www.ncbi.nlm.nih.gov/gene 1197075 BMEI1364 20140222 224914 I protein-coding NCBI-supplied PMID: 11756688; 12271122; 23161025 transcriptional regulatory protein MUCR BMEI1364 Albert Goldfain creation date: 2009-06-23T11:53:49Z bodily process A bodily process that is clinically abnormal. Albert Goldfain http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf creation date: 2009-06-23T11:54:29Z pathological bodily process The totality of all processes through which a given disease instance is realized. Albert Goldfain http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf creation date: 2009-06-23T11:55:44Z disease course A Leishmania major promastigote that undergoes a second developmental transition yielding the metacyclic promastigote. This form of parasite is infective to its mammalian host. Chris Stoeckert Jie Zheng Priti Parikh L. major metacyclic promastigote PMID:11748963 Leishmania major metacyclic promastigote A hindgut that is a part of or originated from a Triatominae bug. Priti Parikh Triatominae hindgut A liver that is a part of or originated from a human (Homo sapiens). Priti Parikh human liver FMA:7197 Homo sapiens liver A promastigote stage of some kinetoplastids. Chris Stoeckert Jie Zheng Priti Parikh PMID:13129524 metacyclic promastigote stage An exflagellated microgametocyte stage in the lifecycle of Plasmodium falciparum that occurs in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum exflagellated microgametocyte stage Plasmodium falciparum exflagellated microgametocyte stage A sporocyst stage in the Schistosoma haematobium lifecycle that occurs within the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium sporocyst stage Schistosoma haematobium sporocyst stage A cercaria stage in the lifecycle of Schistosoma japonicum that occurs in a freshwater snail and in fresh water. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum cercaria stage Schistosoma japonicum cercaria stage A microgametocyte stage in the Plasmodium falciparum lifecycle that occurs either in the bloodstream of a human host or the midgut of a mosquito vector. C. Janse Chris Stoeckert Jie Zheng P. Parkh S. Khan. P. falciparum microgametocyte stage Plasmodium falciparum microgametocyte stage A Schistosoma haematobium schistosomulum in a migratory larval form that is found within blood vessels of mammal, as definitive host, 3 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 3 hour schistosomulum Schistosoma haematobium 3 hour schistosomulum A Schistosoma haematobium in a free-living motile form that is covered with cilia and develops in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium miracidium Schistosoma haematobium miracidium A 3 days schistosomulum stage of Schistosoma mansoni that occurs in the definitive host 3 days post-infection. Chris Stoeckert Jie Zheng Priti Parikh S. mansoni 3 day schistosomulum stage Schistosoma mansoni 3 day schistosomulum stage A proboscis that is a part of or originated from a sand fly of genus Phlebotominae. Priti Parikh Phlebotominae proboscis A Leishmania major that is extracellular and motile form with an anterior flagellum. It grows and divides by longitudinal binary fission in the insect vector; i.e., sandfly. Chris Stoeckert Jie Zheng Priti Parikh L. major promastigote http://dna.kdna.ucla.edu/parasite_course-old/leish_files/introduction1.htm Leishmania major promastigote A schistosomulum stage that occurs in 3 hours after infection of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng PMID:19885392 3 hour schistosomulum stage A parasite lifecycle stage of Trematodes where the parasite is in free-living motile form, covered with cilia and settles in the mollusc to become a sporocyst. Chris Stoeckert Jie Zheng Priti Parikh Wikipedia: Trematode lifecycle stages miracidium stage Cerebrospinal fluid that is a part of or originated from a human (Homo sapiens). Priti Parikh human CSF human cerebral spinal fluid human cerebrospinal fluid FMA:20935 Homo sapiens cerebrospinal fluid A Schistosoma japonicum schistosomulum in a migratory larval form that is found within blood vessels of the mammal, as definitive host, 3 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum 3 day schistosomulum Schistosoma japonicum 3 day schistosomulum A Schistosoma japonicum schistosomulum in a migratory larval form that is found within blood vessels of the mammal, as definitive host, 3 weeks post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum 3 hour schistosomulum Schistosoma japonicum 3 hour schistosomulum A trypomastigote stage where trypmastigote form of parasites are found in mammalian host blood stream. Chris Stoeckert Jie Zheng Priti Parikh bloodstream trypomastigote stage A miracidium stage in the Schistosoma japonicum lifecycle that occurs in the intermediate snail host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum miracidium stage Schistosoma japonicum miracidium stage A daughter sporocyst stage of Schistosoma japonicum that occurs in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum daughter sporocyst stage Schistosoma japonicum daughter sporocyst stage A Schistosoma mansoni schistosomulum in a migratory larval formi that is found within blood vessels of the definitive host, mammal, 24 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 24hour schistosomulum Schistosoma mansoni 24 hour schistosomulum A gamete stage in apicomplexan parasites when exflagellated microgametocyte divides into microgamete. Chris Stoeckert Jie Zheng Matt Berriman microgamete stage A skin that is a part of or originated from a human (Homo sapiens) body. Priti Parikh human skin FMA:7163 Homo sapiens skin A gametocyte stage where a cell differentiates into a female sexual form called macrogametocyte. Chris Stoeckert Jie Zheng Priti Parikh macrogametocyte stage A Schistosoma haematobium schistosomulum in a migratory larval form that is found within blood vessels of mammal, as definitive host, 24 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 24 hour schistosomulum Schistosoma haematobium 24 hour schistosomulum A Schistosoma japonicum sporocyst that develops into cercariae. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum daughter sporocyst Schistosoma japonicum daughter sporocyst A Trypanosoma brucei trypomastigote that is a dividing form of Trypanosoma brucei found in the midgut of an insect vector. Chris Stoeckert Jie Zheng Priti Parikh T. brucei procyclic trypomastigote Trypanosoma brucei procyclic trypomastigote A midgut that is a part of or originated from an Anopheles mosquito. Jie Zheng Anopheles midgut A parasite lifecycle stage of trypanosomes. In trypomastigote stage, the kinetoplast is near the posterior end of the body, and the flagellum lies attached to the cell body for most of its length by an undulating membrane. Chris Stoeckert Jie Zheng Priti Parikh Wikipedia: Trypanosomatid trypomastigote stage A Trypanosoma brucei trypomastigote that is a non-dividing form infectious for the mammal host. It is found in the salivary gland of an insect vector or blood of a mammal host. Chris Stoeckert Jie Zheng Priti Parikh T. brucei metacyclic trypomastigote http://dna.kdna.ucla.edu/parasite_course-old/african%20tryps%20new_files/subchapters/Life%20cycle.htm Trypanosoma brucei metacyclic trypomastigote An erythrocytic schizont stage in the Plasmodium falciparum lifecycle that occurs in the infected erythrocytes of a human host. updated according to OPL terms Plasmodium final excel file from C. Janse, S. Khan C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum erythorcytic schizont stage Plasmodium falciparum erythrocytic schizont stage A parasite lifecycle stage of apicomplexan species where a daughter cell, called merozoite is produced from schizont through schizogony. adjusted to be more general Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarM.htm merozoite stage A Schistosoma haematobium is a mature form of Schistosoma haematobium and capable of sexual reproduction, which lives in the pelvic blood vessels of the vesicle plexis of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium worm Schistosoma haematobium worm A Schistosoma mansoni in a migratory larval form that is found within blood vessels of the definitive host, mammal, and develops into the worm. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni schistosomulum Schistosoma mansoni schistosomulum A Schistosoma japonicum schistosomulum in a migratory larval form that is found within blood vessels of the mammal, as definitive host, 6 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum 6 day schistosomulum Schistosoma japonicum 6 day schistosomulum A hepatocyte that is a part of or originated from a human (Homo sapiens). Priti Parikh human hepatocyte FMA:14515 Homo sapiens hepatocyte A sporocyst stage in the Schistosoma mansoni lifecycle that occurs in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni sporocyst stage Schistosoma mansoni sporocyst stage An erythrocytic ring trophozoite stage in the Plasmodium falciparum life cycle that occurs in erythrocytes of a human host. During this stage some Plasmodium falciparum merozoites undergo asexual reproduction cycle in erythrocytes and form young trophozoites that are referred to as "ring form" due to their morphology. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum erythrocytic ring trophozoite stage Wikipedia: Plasmodium falciparum biology Plasmodium falciparum erythrocytic ring trophozoite stage A Schistosoma japonicum in a parasitic larval form that develops in a freshwater snail and is released into the water. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum cercaria Schistosoma japonicum cercaria A promastigote stage where the form of parasite is short, ovoid, and slightly motile. Chris Stoeckert Jie Zheng Priti Parikh PMID:13129524 procyclic promastigote stage A 6 day schistosomulum stage of Schistosoma mansoni that occurs in the definitive host 6 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 6 day schistosomulum stage Schistosoma mansoni 6 day schistosomulum stage A schistosoma japonicum schistosomulum stage that occurs in the definitive host 6 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum 6 day schistosomulum stage Schistosoma japonicum 6 day schistosomulum stage A mesenteric vein that is a part of or originated from a human (Homo sapiens). Priti Parikh human mesenteric vein Homo sapiens mesenteric vein A lifecycle stage of Trypanosoma brucei. Chris Stoeckert Jie Zheng Priti Parikh T. brucei lifecycle stage Trypanosoma brucei lifecycle stage A Trypanosoma cruzi that is found in the intestinal tract of the insect vector. In this form, the kinetoplast is found anterior and adjacent to the nucleus. The flagellum emerges in the middle of the cell. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi epimastigote http://dna.kdna.ucla.edu/parasite_course-old/cruzi_files/intro.htm Trypanosoma cruzi epimastigote A Plasmodium falciparum gametocyte that is a male gametocyte and found in either bloodstream of a human host or midgut of a mosquito vector. The microgametocyte is a precursor cell of the microgamete. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum microgametocyte Plasmodium falciparum microgametocyte A Schistosoma japonicum worm is the mature form of Schistosoma japonicum and capable of sexual reproduction, which is found in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the human host 7 weeks after infection of the mammal host. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum 7 week worm Schistosoma japonicum 7 week worm A Schistosoma japonicum in an egg form that is laid by the female adult worm and released into the host gut where they leave the host in the faeces. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum egg Schistosoma japonicum egg A Schistosoma japonicum worm is capable of sexual reproduction, which is found in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammal host 3 weeks after infection of the human host. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum 3 week worm Schistosoma japonicum 3 week worm A metacyclic trypomastigote stage in the lifecycle of Trypanosoma brucei that occurs either in vertebrate host bloodstream or in salivary glands of an insect vector. Chris Stoeckert Jie Zheng Priti Parikh T. brucei metacyclic trypomastigote stage Trypanosoma brucei metacyclic trypomastigote stage A parasite lifecycle stage of some protozoan parasites that is a non-reproductive, feeding and growing stage. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarT.htm trophozoite stage A procyclic promastigote stage in the Leishmania major lifecycle. Chris Stoeckert Jie Zheng Priti Parikh L. major procyclic promastigote stage Leishmania major procyclic promastigote stage A schizont stage that occurs in hepatocyte where sporozoites mature into a schizont. Chris Stoeckert Jie Zheng Matt Berriman Priti Parikh PMID:11006474 hepatic schizont stage A Plasmodium falciparum divides through schizogony. Depending on its location, it is either called hepatic or erythrocytic schizont. The schizont is a dividing stage with 2 or more nuclei. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum schizont Plasmodium falciparum schizont A Trypanosoma cruzi that is the intracellular dividing form in the cytoplasm of mammalian cells. It is a round/oval-shaped cell with no protruding flagellum. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi amastigote http://dna.kdna.ucla.edu/parasite_course-old/cruzi_files/intro.htm Trypanosoma cruzi amastigote A 3 days schistosomulum stage of Schistosoma haematobium occurs in the definitive host 3 days post-infection. Chris Stoeckert Jie Zheng Priti Parikh S. haematobium 3 day schistosomulum stage Schistosoma haematobium 3 day schistosomulum stage A 24 hours schistosomulum stage of Schistosoma mansoni that occurs in the definitive host 24 hours post-infection. Chris Stoeckert Jie Zheng Priti Parikh S. mansoni 24 hour schistosomulum stage Schistosoma mansoni 24 hour schistosomulum stage An amastigote stage in the lifecycle of Trypanosoma cruzi that occurs in mammalian hosts. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi amastigote stage Trypanosoma cruzi amastigote stage A schistosomulum stage that occurs in 6 days after infection of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh PMID:19885392 6 day schistosomulum stage A Schistosoma mansoni schistosomulum in a migratory larval formi that is found within blood vessels of the definitive host, mammal, 3 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 3hour schistosomulum Schistosoma mansoni 3 hour schistosomulum A macrogametocyte stage in the Plasmodium falciparum lifecycle that occurs either in the bloodstream of a human host or the midgut of a mosquito vector. gametocytes are mainly found in the blood C. Janse Chris Stoeckert Jie Zheng Priti Parikh S. Khan P. falciparum macrogametocyte stage Plasmodium falciparum macrogametocyte stage A miracidium stage in the Schistosoma haematobium lifecycle that occurs in the intermediate snail host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium miracidium stage Schistosoma haematobium miracidium stage A parasite lifecycle stage that is a free-living larval stage of Digenea, developed within the germinal cells of the sporocyst or redia. A cercaria has a tapering head with large penetration glands. It may or may not have a long swimming "tail", depending on the species. The motile cercaria finds and settles in a host where it will become either an adult, or a mesocercaria, or a metacercaria, according to species. Chris Stoeckert Jie Zheng Priti Parikh Wikipedia: Trematode lifecycle stages cercaria stage A worm stage of Schistosoma japonicum that is fully developed mature form and found in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum worm stage Schistosoma japonicum worm stage An egg stage in the lifecycle of Schistosoma japonicum that occurs in the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum egg stage Schistosoma japonicum egg stage A parasite lifecycle stage of sporozoa consisting of a zygote enclosed by cyst wall. Chris Stoeckert Jie Zheng Priti Parikh Mosby's Medical Dictionary, 8th edition. � 2009, Elsevier. (http://medical-dictionary.thefreedictionary.com/oocyst) oocyst stage A 3 hours schistosomulum stage of Schistosoma haematobium that occurs in the definitive host 3 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 3 hour schistosomulum stage Schistosoma haematobium 3 hour schistosomulum stage A macrogamete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum macrogamete stage Plasmodium falciparum macrogamete stage A trypomastigote stage where trypomastigote form of parasites are in dividing form. This stage occurs in fly vector. Chris Stoeckert Jie Zheng Priti Parikh procyclic trypomastigote stage A Schistosoma japonicum in a migratory larval form that is found within blood vessels of the definitive host and develops into the worm. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum schistosomulum Schistosoma japonicum schistosomulum A schizont stage that occurs in erythrocytes where trophozoites mature into a schizont and schizont produces daughter trophozoites or merozoites. Chris Stoeckert Jie Zheng Matt Berriman Priti Parikh PMID: 11006474 erythrocytic schizont stage A Schistosoma haematobium is the parasitic larval form of the Schistosoma haematobium that develops in a freshwater snail and is released into the water. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium cercaria Schistosoma haematobium cercaria A parasite lifecycle stage that occurs in the liver of the host organism. For Plasmodium species these stages can include sporozoites, trophozoites, schizonts, and merozoites. Chris Stoeckert liver stage EuPathDB parasite lifecycle in host liver stage A procyclic promastigote stage in the Trypanosoma brucei lifecycle. Chris Stoeckert Jie Zheng Priti Parikh Trypanosoma brucei procyclic trypomastigote stage A parasite lifecycle stage of some parasites in which the parasite develops into a worm form, and undergoes maturation. Chris Stoeckert Jie Zheng Priti Parikh http://www.path.cam.ac.uk/~schisto/schistosoma/schisto_lifecycle_egg.html parasitic worm stage Hepatopancreas that is a part of or originated from a Bulinus snail. Priti Parikh Bulinus hepatopancreas A parasite lifecycle stage that is the multinucleate stage in the development of some members of the Sarcodina and some sporozoans during schizogony. Chris Stoeckert Jie Zheng Priti Parikh http://medical-dictionary.thefreedictionary.com/schizont schizont stage A gamete stage in parasites when macrogametocytes produce macrogametes through the process known as gametogenesis. Chris Stoeckert Jie Zheng Priti Parikh http://www.tulane.edu/~wiser/malaria/mal_lc.PDF macrogamete stage A sporocyst stage of Trematodes produced by a mother sporocyst; it lacks a gut and is capable of asexual production of either rediae or cercariae. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarD.htm daughter sporocyst stage A Schistosoma haematobium worm is the mature form of Schistosoma haematobium and capable of sexual reproduction, which is found in the pelvic blood vessels of the vesicle plexis of the mammal host 7 weeks after infection of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 7 week worm Schistosoma haematobium 7 week worm A midgut that is a part of or originated from a Triatominae bug. Priti Parikh Triatominae midgut A Plasmodium falciparum that is a 'banana-shaped' form and originates from the round zygote. The ookinete is found in the midgut of a mosquito vector and traverses the midgut wall of a mosquito vector. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum ookinete Wikipedia: Plasmodium falciparum biology Plasmodium falciparum ookinete A Schistosoma mansoni worm that is capable of sexual reproduction, which is found in the small inferior mesenteric blood vessels surrounding the large intestine of the mammal host 3 weeks after infection of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 3 week worm Schistosoma mansoni 3 week worm A worm stage of Schistosoma haematobium that is fully developed mature form and found in the pelvic blood vessels of the vesicle plexis of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium worm stage Schistosoma haematobium worm stage A Trypanosoma brucei that is found in the salivary glands of tse-tse fly. In this form the kinetoplast is anterior to the nucleus with a short undulating membrane running about half the length of the body. Chris Stoeckert Jie Zheng Priti Parikh T. brucei epimastigote http://dna.kdna.ucla.edu/parasite_course-old/african%20tryps%20new_files/contents1.htm Trypanosoma brucei epimastigote A hepatic schizont stage in the lifecycle of Plasmodium falciparum that occurs in the infected hepatocytes of a human host. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum hepatic schizont stage Plasmodium falciparum hepatic schizont stage A Schistosoma japonicum is an elongated sac that develops from the miracidium within the snail indermediate host, and that either produces more sporocysts or develops into cercariae. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum sporocyst Schistosoma japonicum sporocyst A parasite lifecycle stage that is the migratory stage between cercaria and adult of the schistosomes; equivalent to the metacercarial stage in other digeneans. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarS.htm schistomulum stage An erythrocyte that is a part of or originated from a human (Homo sapiens). Priti Parikh human RBC human erythrocyte human red blood cell FMA:62845 Homo sapiens erythrocyte Vesical venus plexus that is a part of or originated from a human (Homo sapiens). Priti Parikh human vesical venus plexus FMA:18934 Homo sapiens vesical venus plexus A parasite lifecycle stage that is the early developmental stage capable of asexual reproduction: in sporozoans it is usually enclosed within an oocyst; in digeneans it is an intramolluscan stage lacking a gut. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarD.htm sporocyst stage A Schistosoma haematobium worm is the mature form of Schistosoma haematobium and capable of sexual reproduction, which is found in the pelvic blood vessels of the vesicle plexis of the human host 3 weeks after infection of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 3 week worm Schistosoma haematobium 3 week worm A schistosomulum stage of Schistosoma mansoni that occurs in the definitive host and is followed by the parasitic worm stage. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni schistosomulum stage Schistosoma mansoni schistosomulum stage A cercaria stage in the lifecycle of Schistosoma haematobium that occurs in a freshwater snail and in fresh water. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium cercaria stage Schistosoma haematobium cercaria stage A metacyclic promastigote stage in the lifecycle of Leishmania major. Chris Stoeckert Jie Zheng Priti Parikh L. major metacyclic promastigote stage Leishmania major metacyclic promastigote stage A merozoite stage in the Plasmodium falciparum lifecycle that occurs in the bloodstream or hepatocytes of a human host. Chris Stoeckert Priti Parikh P. falciparum merozoite stage Plasmodium falciparum merozoite stage Hepatopancreas that is a part of or originated from a Biomphalaria snail. Priti Parikh Biomphalaria hepatopancreas A Schistosoma mansoni in an egg form that is laid by the female adult worm and released into the host gut where they leave the host in the faeces. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni egg Schistosoma mansoni egg A worm stage of Schistosoma japonicum that is found in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the definitive host 3 weeks after infection. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum 3 week worm stage Schistosoma japonicum 3 week worm stage A worm stage of Schistosoma mansoni that is found in the small inferior mesenteric blood vessels surrounding the large intestine of the definitive host 3 weeks after infection. Chris Stoeckert Jie Zheng Priti Parikh S. mansoni 3 week worm stage Schistosoma mansoni 3 week worm stage A parasite lifecycle stage of Trypanosomatids. During this stage, the undulating membrane is shortened and the flagellar pocket and the kinetoplast are anterior to the nucleus. This stage occurs in the insect host. Chris Stoeckert Jie Zheng Priti Parikh epimastigote stage A Schistosoma haematobium sporocyst that develops into cercariae. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium daughter sporocyst Schistosoma haematobium daughter sporocyst A Plasmodium falciparum schizont that is found in infected erythrocytes of a human host. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum erythrocytic schizont Plasmodium falciparum erythrocytic schizont A 7 week worm stage of Schistosoma haematobium that is the mature stage of Schistosoma haematobium and found in the pelvic blood vessels of the vesicle plexis of the definitive host 7 weeks after weeks after infection . Chris Stoeckert Jie Zheng Priti Parikh S. haematobium 7 week worm stage Schistosoma haematobium 7 week worm stage A miracidium stage in the Schistosoma mansoni lifecycle that occurs in the intermediate snail host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni miracidium stage Schistosoma mansoni miracidium stage An oocyst stage in the Plasmodium falciparum lifecycle that occurs on the hemocoel side of the midgut of a mosquito vector. During this stage Plasmodium falciparum ookinete invades and escapes midgut wall of mosquito and embed itself onto the exterior of the gut membrane and develop encysted zygote, called oocyst. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum oocyst stage Plasmodium falciparum oocyst stage A parasite lifecycle stage is a nonflagellate intracellular developmental stage in the trypanosomatid parasites lifecycle that occurs in mammalian host. Chris Stoeckert Jie Zheng Priti Parikh amastigote stage A sporozoite stage in the Plasmodium falciparum lifecycle that occurs in the salivary glands of the mosquito and invades hepatocytes in the human host. C. Janse Chris Stoeckert Jie Zheng Matt Berrimen Priti Parikh S. Khan P. falciparum sporozoite stage Plasmodium falciparum sporozoite stage A Trypanosoma cruzi trypomastigote that is found in blood or cells of mammal hosts at the infectious stage for mammals. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi metacyclic trypomastigote http://dna.kdna.ucla.edu/parasite_course-old/cruzi_files/intro.htm Trypanosoma cruzi metacyclic trypomastigote Blood that is part of or originated from a human (Homo sapiens). previous def was: blood of human Chris Stoeckert human blood OPL Homo sapiens blood A schistosomulum stage of Schistosoma japonicum that occurs in the definitive host and is followed by the parasitic worm stage. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum schistosomulum stage Schistosoma japonicum schistosomulum stage A microgametocyte stage in some apicomplexan parasites where microgametocyte gets matured and form microgamete through the process known as exflagellation. Chris Stoeckert Jie Zheng Priti Parikh exflagellated microgametocyte stage A 3 hours schistosomulum stage of Schistosoma mansoni that occurs in the definitive host 3 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 3 hour schistosomulum stage Schistosoma mansoni 3 hour schistosomulum stage A salivary gland that is a part of or originated from an Anopheles mosquito. Priti Parikh Anopheles salivary gland A macrophage that is a part of or originated from a human (Homo sapiens). Jie Zheng human macrophage FMA:63261 Homo sapiens macrophage A Schistosoma mansoni schistosomulum in a migratory larval formi that is found within blood vessels of the definitive host, mammal, 3 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 3day schistosomulum Schistosoma mansoni 3 day schistosomulum A 6 day schistosomulum stage of Schistosoma haematobium that occurs in the definitive host 6 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 6 day schistosomulum stage Schistosoma haematobium 6 day schistosomulum stage An egg stage in the lifecycle of Schistosoma haematobium that occurs in the mammalian host.. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium egg stage Schistosoma haematobium egg stage A Schistosoma japonicum is the mature form of Schistosoma japonicum and capable of sexual reproduction, which lives in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum worm Schistosoma japonicum worm An adult worm stage of a female parasitic worm. Chris Stoeckert Jie Zheng Priti Parikh http://www.path.cam.ac.uk/~schisto/schistosoma/schisto_lifecycle_egg.html adult female parasitic worm stage A Schistosoma mansoni in the mature form that is capable of sexual reproduction, which lives in the small inferior mesenteric blood vessels surrounding the large intestine of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni worm Schistosoma mansoni worm A 24 hours schistosomulum stage of Schistosoma haematobium that occurs in the definitive host 24 hours post-infection. Chris Stoeckert Jie Zheng Priti Parikh S. haematobium 24 hour schistosomulum stage Schistosoma haematobium 24 hour schistosomulum stage A Plasmodium falciparum that is produced in a schizont, found in the bloodstream of a human host and invades erythrocytes. Chris Stoeckert Jie Zheng Priti Parkh P. falciparum merozoite Plasmodium falciparum merozoite A metacyclic trypomastigote stage in the lifecycle of Trypanosoma cruzi that occurs in a vertebrate host. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi metacyclic trypomastigote stage Trypanosoma cruzi metacyclic trypomastigote stage A Schistosoma japonicum schistosomulum in a migratory larval form that is found within blood vessels of the mammal, as definitive host, 24 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum 24 hour schistosomulum Schistosoma japonicum 24 hour schistosomulum A lung that is a part of or originated from a human (Homo sapiens). Priti Parikh human lung FMA:7195 Homo sapiens lung Hepatopancreas that is a part of or originated from a Oncomelania snail. Priti Parikh Oncomelania hepatopancreas An egg stage in the lifecycle of Schistosoma mansoni that occurs in the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni egg stage Schistosoma mansoni egg stage A Schistosoma mansoni worm is the mature form of Schistosoma mansoni and capable of sexual reproduction, which is found in the small inferior mesenteric blood vessels surrounding the large intestine of the mammal host 7 weeks after infection of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 7 week worm Schistosoma mansoni 7 week worm A Plasmodium falciparum is formed in the oocyst. It migrates to and resides in the salivary glands of the mosquito vector. A distinction is made between oocyst-derived and salivary gland-derived sporozoites. Sporozoites invade hepatocytes in the vertebrate host. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum sporozoite Wikipedia: Plasmodium falciparum biology Plasmodium falciparum sporozoite A Plasmodium falciparum that oocyst is formed, after traversal of the midgut wall by the ookinete stage, on the hemocoel side of the midgut wall of the mosquito vector. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum oocyst Plasmodium falciparum oocyst A 7 week worm stage of Schistosoma japonicum that is the mature stage of Schistosoma japonicum and found in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the definitive host 7 weeks after weeks after infection. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum 7 week worm stage Schistosoma japonicum 7 week worm stage An early trophozoite stage of Plasmodium sp. where a large central vacuole and peripheral nucleus give an appearance of a signet ring. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarR.htm erythrocytic ring trophozoite stage An intestine that is a part of or originated from a human (Homo sapiens). Priti Parikh human intestine FMA:7199 Homo sapiens intestine A mother sporocyst stage in the Schistosoma mansoni lifecycle that occurs in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni mother sporocyst stage Schistosoma mansoni mother sporocyst stage A gametocyte stage where a cell differentiates into a male sexual form called microgametocyte. Chris Stoeckert Jie Zheng Priti Parikh microgametocyte stage A Schistosoma haematobium sporocyst that produces more sporocysts. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium mother sporocyst Schistosoma haematobium mother sporocyst A Schistosoma japonicum sporocyst that produces more sporocysts. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum mother sporocyst Schistosoma japonicum mother sporocyst A Plasmodium falciparum is a feeding form. The trophozoite stage has only 1 nucleus. Depending on its location, it is either called hepatic or erythrocytic trophozoite. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum trophozoite Plasmodium falciparum trophozoite A Schistosoma mansoni is an elongated sac that develops from the miracidium within the snail indermediate host, and that either produces more sporocysts or develops into cercariae. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni sporocyst Schistosoma mansoni sporocyst A parasitic worm stage of development 7 weeks post differentiation into a worm form. Chris Stoeckert Jie Zheng Priti Parikh PMID:19885392 7 week parasitic worm stage A trypomastigote stage of Trypanosoma species which are nondividing forms resistant to mammalian complement that have the capacity to infect mammalian cells. Chris Stoeckert Jie Zheng Priti Parikh metacyclic trypomastigote stage A life cycle stage where a cell differentiates into male or female sexual forms. Chris Stoeckert Jie Zheng Priti Parikh gametocyte stage A parasite lifecycle stage of Trypanosomatids. In this stage, the flagellum is found anterior of nucleus and flagellum not attached to the cell body. The kinetoplast is located in front of the nucleus, near the anterior end of the body. (Wikipedia: Trypanosomatid) Chris Stoeckert Jie Zheng Priti Parikh promastigote stage A parasite lifecycle stage of some sporozoans where cells divide through sporogony producing daughter cells called sporozoites that infect new hosts. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarS.htm sporozoite stage A parasite lifecycle stage of some sporozoans where motile and elongated zygote is formed by the fertilization of the macrogamete during the sexual reproductive phase of the sporozoan life cycle, specifically the malarial parasite Plasmodium. Chris Stoeckert Jie Zheng Priti Parikh Mosby's Medical Dictionary, 8th edition. � 2009, Elsevier. (http://medical-dictionary.thefreedictionary.com/ookinete) ookinete stage A salivary gland that is a part of or originated from a tsetse fly of genus Glossina. Priti Parikh Glossina salivary gland Plasmodium falciparum is a protozoan parasite, one of the species of Plasmodium that cause malignant malaria in humans. It is transmitted by the female Anopheles mosquito. Replaced by NCBITaxon term. Definition and axioms were added by OPL developers. P. falciparum Wikipedia: Plasmodium falciparum obsolete_Plasmodium falciparum true A lifecycle stage of Schistosoma japonicum. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum lifecycle stage Schistosoma japonicum lifecycle stage An amastigote stage in the lifecycle of Leishmania major that occurs in mammalian hosts. Chris Stoeckert Jie Zheng Priti Parikh L. major amastigote stage Leishmania major amastigote stage A schizont stage in the Plasmodium falciparum lifecycle that occurs in erythrocytes or in hepatocytes. updated according to OPL terms Plasmodium final excel file from C. Janse, S. Khan C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum schizont stage Plasmodium falciparum schizont stage A 3 days schistosomulum stage of Schistosoma japonicum that occurs in the definitive host 3 days post-infection. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum 3 day schistosomulum stage Schistosoma japonicum 3 day schistosomulum stage A Leishmania major promastigote that is found in the alimentary tract of an insect vector. It is non-infective to its mammalian host. Chris Stoeckert Jie Zheng Priti Parikh L. major procyclic promastigote PMID:11748963 Leishmania major procyclic promastigote A Plasmodium falciparum zygote is formed after fertilisation of the macrogamete by a microgamete in the midgut of the mosquito vector. This round form is the only diploid stage in the Plasmodium falciparum life cycle. C. Janse Chris Stoeckert Jie Zheng P. Parkh S. Khan P. falciparum zygote Wikipedia: Plasmodium falciparum biology Plasmodium falciparum zygote A Plasmodium falciparum microgametocyte that is matured with flagellated motile microgametes still attached to its central body. Exflagellated microgametocyte of Plasmodium falciparum is found in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Matt Berriman Priti Parikh P. falciparum exflagellated microgametocyte Plasmodium falciparum exflagellated microgametocyte A daughter sporocyst stage in the lifecycle of Schistosoma haematobium that occurs within the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium daughter sporocyst stage Schistosoma haematobium daughter sporocyst stage A Trypanosoma cruzi that is found in the bloodstream of infected mammals. It is a non-dividing form that is infectious for its insect vector. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi trypomastigote http://dna.kdna.ucla.edu/parasite_course-old/cruzi_files/intro.htm Trypanosoma cruzi trypomastigote A lifecycle stage of Plasmodium falciparum. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum lifecycle stage Plasmodium falciparum lifecycle stage A Schistosoma haematobium that is an elongated sac and develops from the miracidium within the snail indermediate host, and that either produces more sporocysts or develops into cercariae. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium sporocyst Schistosoma haematobium sporocyst A Plasmodium falciparum gamete that is a matured form of the macrogametocyte and is found in the midgut of a mosquito vector. The macrogamete is fertilized by the microgamete, forming the zygote Chris Stoeckert Jie Zheng P. falciparum macrogamete Plasmodium falciparum macrogamete A Schistosoma mansoni in a parasitic larval form that develops in a freshwater snail and is released into the water. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni cercaria Schistosoma mansoni cercaria A trypomastigote stage in the Trypanosoma cruzi lifecycle that occurs either in the vertebrate host or an insect vector. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi trypomastigote stage Trypanosoma cruzi trypomastigote stage A microgamete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum microgamete stage Plasmodium falciparum microgamete stage A parasite role which is realized only during parasitic infection of a human. previous def was not about a role. Chris Stoeckert Priti Parikh human parasite role A schistosomulum stage that occurs in 24 hours after infection of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh PMID:19885392 24 hour schistosomulum stage A parasite lifecycle stage of some Plasmodium sp., such as Plasmodium vivax and Plasmodium ovale, the parasite in the liver cells do not achieve matuaration to a schizont immediately, but remain in a dormant form. This dormant form stage is called hypnozoite stage. Chris Stoeckert Jie Zheng Priti Parikh Wikipedia: Plasmodium hypnozoite stage A Plasmodium falciparum gamete that is a matured form of exflagellated microgametocyte and found in the midgut of a mosquito vector. The microgamete fertilizes the macrogamete, forming the zygote. Chris Stoeckert Jie Zheng P. falciparum microgamete Plasmodium falciparum microgamete A trypomastigote stage in the Trypanosoma brucei lifecycle that occurs in the vertebrate host. Chris Stoeckert Jie Zheng Priti Parikh T. brucei trypomastigote stage Trypanosoma brucei trypomastigote stage A ureter that is a part of or originated from a human (Homo sapiens). Priti Parikh human ureter FMA:9704 Homo sapiens ureter A lifecycle stage of Schistosoma haematobium. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium lifecycle stage Schistosoma haematobium lifecycle stage A Schistosoma haematobium in a migratory larval form that is found within blood vessels of the definitive host, mammal, and develops into the flatworm. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium schistosomulum Schistosoma haematobium schistosomulum A Schistosoma japonicum in a free-living motile form that is covered with cilia, and develops in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum miracidium Schistosoma japonicum miracidium A life cycle stage of some parasites in which a non-operculate egg emerges from the adult female worm. Chris Stoeckert Jie Zheng Priti Parikh http://www.path.cam.ac.uk/~schisto/schistosoma/schisto_lifecycle_egg.html egg stage A life cycle stage of a parasite. Chris Stoeckert Jie Zheng Priti Parikh parasite lifecycle stage A Trypanosoma brucei that is a Trypomastigote form of Trypanosoma brucei. In this form the large kinetoplast is postnuclear and is at the most posterior part of the body and the flagellum emerges from the flagellar pocket, and runs along the entire length of the body as an undulating membrane. Chris Stoeckert Jie Zheng Priti Parikh T. brucei trypomastigote http://dna.kdna.ucla.edu/parasite_course-old/african%20tryps%20new_files/contents1.htm Trypanosoma brucei trypomastigote A parasitic worm stage of development 3 weeks post differentiation into a worm form. Chris Stoeckert Jie Zheng Priti Parikh PMID:19885392 3 week parasitic worm stage A mother sporocyst stage in the Schistosoma japonicum lifecycle that occurs in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum mother sporocyst stage Schistosoma japonicum mother sporocyst stage A lifecycle stage of Trypanosoma cruzi. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi lifecycle stage Trypanosoma cruzi lifecycle stage A sporocyst stage in the Schistosoma japonicum lifecycle that is found within the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum sporocyst stage Schistosoma japonicum sporocyst stage An ookinete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector and on the outside of the midgut. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum ookinete stage Plasmodium falciparum ookinete stage Bloodstream trypomastigote stage in the lifecycle of Trypanosoma brucei. Priti Parikh T. brucei bloodstream trypomastigote stage obsolete_Trypanosoma brucei bloodstream trypomastigote stage true A promastigote stage in the Leishmania major lifecycle. Chris Stoeckert Jie Zheng Priti Parikh L. major promastigote stage Leishmania major promastigote stage A Plasmodium falciparum schizont that is found in infected hepatocytes (i.e., liver cells) of a human host. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum hepatic schizont Plasmodium falciparum hepatic schizont A Schistosoma mansoni sporocyst that develops into cercariae. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni daughter sporocyst Schistosoma mansoni daughter sporocyst A gametocyte stage in the lifecycle of Plasmodium falciparum. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum gametocyte stage Plasmodium falciparum gametocyte stage A 3 hours schistosomulum stage of Schistosoma japonicum that occurs in the definitive host 3 hours post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. japonicum 3 hour schistosomulum stage Schistosoma japonicum 3 hour schistosomulum stage A midgut that is a part of or originated from a sand fly of genus Phlebotominae. Priti Parikh Phlebotominae midgut A 24 hours schistosomulum stage of Schistosoma japonicum that occurs in the definitive host 24 hours post-infection. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum 24 hour schistosomulum stage Schistosoma japonicum 24 hour schistosomulum stage A Schistosoma mansoni sporocyst that produces more sporocysts. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni mother sporocyst Schistosoma mansoni mother sporocyst A schistosomulum stage of Schistosoma haematobium that occurs in the definitive host and is followed by the parasitic worm stage. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium schistosomulum stage Schistosoma haematobium schistosomulum stage A Schistosoma haematobium adult worm is a fully developed mature male form of Schistosoma haematobium and capable of sexual reproduction, which lives in the pelvic blood vessels of the vesicle plexis of the mammal host and has 4-5 testes. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium adult male worm http://www.path.cam.ac.uk/~schisto/schistosoma/schisto_lifecycle_egg.html Schistosoma haematobium adult male worm A zygote stage in the Plasmodium falciparum lifecycle that occurs in the midgut of the mosquito vector where a microgamete and a macrogamete fertilizes each other to produce a diploid cell. Chris Stoeckert Jie Zheng Priti Parikh P. falciparum zygote stage Wikipedia: Plasmodium falciparum biology Plasmodium falciparum zygote stage A Schistosoma haematobium in an egg form that is laid by the female adult worm and released into the host gut where they leave the host in the faeces. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium egg Schistosoma haematobium egg A Schistosoma haematobium schistosomulum in a migratory larval form that is found within blood vessels of mammal, as definitive host, 6 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 6 day schistosomulum Schistosoma haematobium 6 day schistosomulum A worm stage of Schistosoma haematobium that is found in the pelvic blood vessels of the vesicle plexis of the definitive host 3 weeks after infection. Chris Stoeckert Jie Zheng Priti Parikh S. haematobium 3 week worm stage Schistosoma haematobium 3 week worm stage A lifecycle stage of Schistosoma mansoni. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni lifecycle stage Schistosoma mansoni lifecycle stage A Leishmania major that is the intracellular, non-motile form of the parasite found in the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh L. major amastigote http://dna.kdna.ucla.edu/parasite_course-old/leish_files/introduction1.htm Leishmania major amastigote A Schistosoma haematobium schistosomulum in a migratory larval form that is found within blood vessels of mammal, as definitive host, 3 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium 3 day schistosomulum Schistosoma haematobium 3 day schistosomulum A Plasmodium falciparum gametocyte that is a female gametocyte and found either in bloodstream of a human host or midgut of mosquito vector. The macrogametocyte is a precursor of the macrogamete. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum macrogametocyte Plasmodium falciparum macrogametocyte An erythrocytic trophozoite stage in the Plasmodium falciparum life cycle that occurs in erythrocytes of a human host. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum erythrocytic trophozoite stage Plasmodium falciparum erythrocytic trophozoite stage A Schistosoma mansoni in a free-living motile form that is covered with cilia and develops in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni miracidium Schistosoma mansoni miracidium A parasite lifecycle stage of Leishmania major. Chris Stoeckert Jie Zheng Priti Parikh L. major lifecycle stage Leishmania major lifecycle stage A cercaria stage in the lifecycle of Schistosoma mansoni that occurs in a freshwater snail and in fresh water. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni cercaria stage Schistosoma mansoni cercaria stage A worm stage of Schistosoma mansoni that is fully developed mature form and found in the small inferior mesenteric blood vessels surrounding the large intestine of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni worm stage Schistosoma mansoni worm stage A mother sporocyst stage in the Schistosoma haematobium lifecycle that occurs in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium mother sporocyst stage Schistosoma haematobium mother sporocyst stage The vesical plexus envelops the lower part of the bladder and the base of the prostate and communicates with the pudendal and prostatic plexuses. Priti Parikh Wikipedia - Vesical venus plexus vesical venus plexus A sporocyst stage of Digenea formed after penetration of the miracidium into a mollusc; it lacks a gut and gives rise asexually to daughter sporocysts or rediae. Chris Stoeckert Jie Zheng Priti Parikh http://www.biology.ualberta.ca/parasites/parpub/text/text/glossarM.htm mother sporocyst stage A midgut that is a part of or originated from a tsetse fly of genus Glossina. Priti Parikh Glossina midgut An epimastigote stage in the lifecycle of Trypanosoma brucei. Chris Stoeckert Jie Zheng Priti Parikh T. brucei epimastigote stage Trypanosoma brucei epimastigote stage A 7 week worm stage of Schistosoma mansoni that is the mature stage of Schistosoma mansoni and found in the small inferior mesenteric blood vessels surrounding the large intestine of the definitive host 7 weeks after weeks after infection. Chris Stoeckert Jie Zheng Priti Parikh S. mansoni 7 week worm stage Schistosoma mansoni 7 week worm stage A Schistosoma mansoni schistosomulum in a migratory larval formi that is found within blood vessels of the definitive host, mammal, 6 days post-infection. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni 6day schistosomulum Schistosoma mansoni 6 day schistosomulum A urinary bladder that is a part of or originated from a human (Homo sapiens). Priti Parikh human bladder human urinary bladder FMA:15900 Homo sapiens urinary bladder A daughter sporocyst stage of Schistosoma mansoni that occurs in the snail intermediate host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni daughter sporocyst stage Schistosoma mansoni daughter sporocyst stage A schistosomulum stage that occurs in 3 days after infection of the mammalian host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng PMID:19885392 3 day schistosomulum stage A Plasmodium falciparum erythrocytic trophozoite that is found in erythrocytes. It is a young trophozoite stage that has a typical 'ring-like' appearance. Ring-form trophozoites of Plasmodium falciparum are often thin and delicate, measuring on average 1/5 the diameter of the red blood cell. C. Janse Chris Stoeckert Jie Zheng Priti Parkh S. Khan P. falciparum erythrocytic ring trophozoite http://www.dpd.cdc.gov/dpdx/html/frames/m-r/malaria/falciparum/body_malariadffalcring.htm Plasmodium falciparum erythrocytic ring trophozoite An epimastigote stage in the lifecycle of Trypanosoma cruzi. Chris Stoeckert Jie Zheng Priti Parikh T. cruzi epimastigote stage Trypanosoma cruzi epimastigote stage An adult female worm stage of Schistosoma japonicum that is fully developed mature female stage of Schistosoma japonicum and occurs in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum adult female worm stage Schistosoma japonicum adult female worm stage An adult male worm stage of Schistosoma japonicum that is fully developed mature male stage of Schistosoma japonicum and occurs in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum adult male worm stage Schistosoma japonicum adult male worm stage A Schistosoma japonicum worm is a fully developed mature form of Schistosoma japonicum and capable of sexual reproduction, which lives in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammal host. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum adult worm Schistosoma japonicum adult worm A Schistosoma mansoni worm is the fully developed mature form of Schistosoma mansoni and capable of sexual reproduction, which lives in the small inferior mesenteric blood vessels surrounding the large intestine of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni adult worm Schistosoma mansoni adult worm An adult male worm stage of Schistosoma haematobium that is fully developed mature male stage of Schistosoma haematobium and found in the pelvic blood vessels of the vesicle plexis of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh S. haematobium adult male worm stage Schistosoma haematobium adult male worm stage A Schistosoma japonicum adult worm is a fully developed mature male form of Schistosoma japonicum and capable of sexual reproduction, which lives in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammal host and has 4-5 testes. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum adult male worm Schistosoma japonicum adult male worm An adult male worm stage of Schistosoma mansoni that is fully developed mature male stage of Schistosoma mansoni and found in the small inferior mesenteric blood vessels surrounding the large intestine of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh S. mansoni adult male worm stage Schistosoma mansoni adult male worm stage A Schistosoma mansoni adult worm is the fully developed mature female form of Schistosoma mansoni and capable of sexual reproduction, which lives within the gynacophoric canal of the adult male worm in the small inferior mesenteric blood vessels surrounding the large intestine of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni adult female worm Schistosoma mansoni adult female worm An organism living in, with, or on another organism in parasitism. Individual members of parasite species, such as Leishmania, Plasmodium, Trypanosoma, etc. are members of this class. Jie Zheng Priti Parikh http://www.merriam-webster.com/dictionary/parasite?show=0&t=1310398415 parasite organism A Schistosoma haematobium worm is a fully developed mature form of Schistosoma haematobium and capable of sexual reproduction, which lives in the pelvic blood vessels of the vesicle plexis of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium adult worm Schistosoma haematobium adult worm An adult female worm stage of Schistosoma haematobium that is fully developed mature female stage of Schistosoma haematobium and found in the pelvic blood vessels of the vesicle plexis of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh S. haematobium adult female worm stage Schistosoma haematobium adult female worm stage A Schistosoma haematobium adult worm is a fully developed mature female form of Schistosoma haematobium and capable of sexual reproduction, which lives within the gynacophoric canal of the adult male worm in the pelvic blood vessels of the vesicle plexis of the mammal host. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. haematobium adult female worm Schistosoma haematobium adult female worm An adult female worm stage of Schistosoma mansoni that is fully developed mature female stage of Schistosoma mansoni and found in the small inferior mesenteric blood vessels surrounding the large intestine of the mammalian host. Chris Stoeckert Jie Zheng Priti Parikh S. mansoni adult female worm stage Schistosoma mansoni adult female worm stage A parasitic worm stage where the worm is matured and ready to pair up with another adult worm of the opposite gender, and reproduce. Chris Stoeckert Jie Zheng Priti Parikh http://www.path.cam.ac.uk/~schisto/schistosoma/schisto_lifecycle_egg.html adult parasitic worm stage A Schistosoma japonicum adult worm is a fully developed mature female form of Schistosoma japonicum and capable of sexual reproduction, which lives within the gynacophoric canal of the adult male worm in the small superior mesenteric blood vessels associated with the ileo-caecal area of the intestine of the mammal host. Chris Stoeckert Jie Zheng Priti Parikh S. japonicum adult female worm Schistosoma japonicum adult female worm An adult worm stage of a male parasitic worm. Chris Stoeckert Jie Zheng Priti Parikh http://www.path.cam.ac.uk/~schisto/schistosoma/schisto_lifecycle_egg.html adult male parasitic worm stage A Schistosoma mansoni adult worm is the fully developed mature male form of Schistosoma mansoni and capable of sexual reproduction, which lives in the small inferior mesenteric blood vessels surrounding the large intestine of the mammal host and has 4-5 testes. Anna Protasio Chris Stoeckert Flora Logan Jie Zheng S. mansoni adult male worm Schistosoma mansoni adult male worm A Plasmodium falciparum merozoite that is produced in a hepatic schizont and released into the bloodstream of a human host. These forms invade erythrocytes. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum hepatic merozoite Plasmodium falciparum hepatic merozoite A Plasmodium falciparum merozoite that is produced in an erythrocytic schizont and released into the bloodstream of a human host. These forms invade erythrocytes. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum erythrocytic merozoite Plasmodium falciparum erythrocytic merozoite A trophozoite stage in some protozoan parasite life cycle that occurs in erythrocytes. definition adapted from that for P. falciparum erythrocytic trophozoite stage and parent trophozoite stage Chris Stoeckert erythrocytic trophozoite stage A Plasmodium falciparum trophozoite that is found in erythrocytes. It is a feeding stage with a single nucleus. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum erythrocytic trophozoite Plasmodium falciparum erythrocytic trophozoite An erythrocytic merozoite stage in the Plasmodium falciparum lifecycle that occurs in the bloodstream of a human host. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum erythrocytic merozoite stage Plasmodium falciparum erythrocytic merozoite stage A hepatic merozoite stage in the Plasmodium falciparum lifecycle that occurs in the hepatocyte of a human host. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum hepatic merozoite stage Plasmodium falciparum hepatic merozoite stage A merozoite stage in the Plasmodium lifecycle that occurs in the hepatocyte of a vertebrate host. definition adapted from that for P. falciparum hepatic merozoite stage Chris Stoeckert Jie Zheng hepatic merozoite stage A merozoite stage in the apicomplexan lifecycle that occurrs in the bloodstream of a vertebrate host. definition adapted from that for P. falciparum salivary erythrocytic merozoite stage and from the general merozoite definition Chris Stoeckert Jie Zheng erythrocytic merozoite stage A Plasmodium falciparum that is located either in the bloodstream of the human host or midgut of mosquito vector. Gametocytes are the precursor cells of the macro- or micro-gametes. C. Janse Chris Stoeckert Jie Zheng K. Louis S Khan Plasmodium falciparum gametocyte A hepatic trophozoite stage in the Plasmodium falciparum life cycle that occurs in hepatocytes of a human host. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum hepatic trophozoite stage Plasmodium falciparum hepatic trophozoite stage A trophozoite stage in the Plasmodium falciparum lifecycle that occurs in a human host. Chris Stoeckert Jie Zheng P. falciparum trophozoite stage Plasmodium falciparum trophozoite stage A sporozoite stage in the Plasmodium falciparum lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the human host. C. Janse Chris Stoeckert Jie Zheng S. Khan Plasmodium falciparum oocyst-derived sporozoite stage A sporozoite stage in the Plasmodium lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the vertebrate host. definition adapted from that for P. falciparum salivary gland derived sporozoite stage Chris Stoeckert salivary gland-derived sporozoite stage A salivary gland-derived sporozoite stage in the Plasmodium falciparum lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the human host. C. Janse Chris Stoeckert Jie Zheng S. Khan Plasmodium falciparum salivary gland-derived sporozoite stage A Plasmodium falciparum sporozoite that is formed in the oocyst. It migrates to and resides in the salivary glands of the mosquito vector. Sporozoites invade hepatocytes in a human host. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum salivary gland-derived sporozoite Plasmodium falciparum salivary gland-derived sporozoite A sporozoite stage in some parasite lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the vertebrate host. definition adapted from that for P. falciparum oocyte derived sporozoite stage Chris Stoeckert oocyst-derived sporozoite stage A Plasmodium falciparum trophozoite that is found in hepatocytes of a human host. It is a feeding stage with a single nucleus C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum hepatic trophozoite Plasmodium falciparum hepatic trophozoite A Plasmodium falciparum that is found in midgut of mosquito vector. There are two forms of gametes: micro- and macrogametocytes. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum gamete Plasmodium falciparum gamete A Plasmodium falciparum sporozoite that is found in the infected hepatocytes of a human host. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum oocyst-derived sporozoite Plasmodium falciparum oocyst-derived sporozoite A life cycle stage of some parasites that develop into mature sexual cells. Jie Zheng gamete stage A trophozoite stage in some protozoan parasite life cycle that occurs in hepatocytes. definition adapted from that for P. falciparum hepatic trophozoite stage and from parent trophozoite stage Chris Stoeckert hepatic trophozoite stage A gamete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector. C. Janse Chris Stoeckert Jie Zheng S. Khan P. falciparum gamete stage Plasmodium falciparum gamete stage A parasite lifecycle stage that occurs as a result of asexual replication in the red blood cells of the host organism. For Plasmodium species these stages can include merozoites, trophozoites, and schizonts. Chris Stoeckert asexual blood stage VEuPathDB asexual lifecycle in host red blood cell stage A Plasmodium that is found in the midgut of a mosquito vector during gamete lifecycle stage. There are two forms of gametes: micro- and macrogametocytes. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium gamete A Plasmodium gamete that is in a matured form of the macrogametocyte and found in the midgut of a mosquito vector. The macrogamete is fertilized by the microgamete, forming the zygote. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium macrogamete A Plasmodium gamete that is in a matured form of exflagellated microgametocyte and found in the midgut of a mosquito vector. The microgamete fertilises the macrogamete, forming the zygote. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium microgamete A Plasmodium that is located either in the bloodstream of the vertebrate host or midgut of mosquito vector during gametocyte stage. Gametocytes are the precursor cells of the macro- or microgametes Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium gametocyte A Plasmodium gametocyte that is a female gametocyte of Plasmodium and found either in the bloodstream of the vertebrate host or midgut of mosquito vector. The macrogametocyte is a precursor of the macrogamete. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium macrogametocyte A Plasmodium gametocyte that is a male gametocyte of Plasmodium and found either in the bloodstream of a vertebrate host or midgut of a mosquito vector. The microgametocyte is a precursor cell of the microgamete Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium microgametocyte A Plasmodium that is during merozoite lifecycle stage, occurs in the bloodstream of a vertebrate host. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium merozoite A Plasmodium merozoite that is produced in an erythrocytic schizont and released into the bloodstream of a vertebrate host. These forms invade erythrocytes. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium erythrocytic merozoite A Plasmodium merozoite that is produced in a hepatic schizont and released into the bloodstream of a vertebrate host. These forms invade erythrocytes. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium hepatic merozoite A Plasmodium that is formed after traversal of the midgut wall by the ookinete stage, on the hemocoel side of the midgut wall of the mosquito vector. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium oocyst A Plasmodium that is a 'banana-shaped' form originates from the round zygote. The ookinete is found in the midgut of a mosquito vector and traverses the midgut wall of a mosquito vector. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium ookinete A Plasmodium that is a form divides through schizogony. Depending on its location, it is either called hepatic or erythrocytic schizont. The schizont is a dividing stage with 2 or more nuclei. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium schizont A Plasmodium schizont that is found in infected erythrocytes of a vertebrate host. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium erythrocytic schizont A Plasmodium schizont that is found in infected hepatocytes (i.e. liver cells) of a vertebrate host. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium hepatic schizont A Plasmodium that is formed in the oocyst and migrates to and reside in the salivary glands of the mosquito vector. A distinction is made between oocyst-derived and salivary gland-derived sporozoites. Sporozoites invade hepatocytes in the vertebrate host. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium sporozoite A Plasmodium sporozoite that is found in the infected hepatocytes of a vertebrate host. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium oocyst-derived sporozoite A Plasmodium sporozoite that is found in the salivary glands of the mosquito vector. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium salivary gland-derived sporozoite A Plasmodium that is a feeding form which has a single nucleus during the trophozoite stage. Depending on its location, it is either called hepatic or erythrocytic trophozoite. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium trophozoite A Plasmodium trophozoite that is found in erythrocytes of a vertebrate host. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium erythrocytic trophozoite A Plasmodium erythrocytic trophozoite that has a typical 'ring-like' appearance. Ring-form trophozoites of Plasmodium are often thin and delicate, measuring on average 1/5 the diameter of the red blood cell. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium erythrocytic ring trophozoite A Plasmodium trophozoite that is found in hepatocytes. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium hepatic trophozoite A Plasmodium that is formed after fertilization of the macrogamete by a microgamete in the midgut of the mosquito vector. This round form is the only diploid stage in the Plasmodium life cycle. Chris Stoeckert Jie Zheng Ulrike Boehme https://github.com/OPL-ontology/OPL/issues/2 GeneDB Plasmodium zygote A gamete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Plasmodium gamete stage A macrogamete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Plasmodium macrogamete stage A microgamete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Plasmodium microgamete stage A gametocyte stage in the lifecycle of Plasmodium. Chris Stoeckert Jie Zheng Plasmodium gametocyte stage A macrogametocyte stage in the Plasmodium lifecycle that occurs either in the bloodstream of a vertebrate host or the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Plasmodium macrogametocyte stage A microgametocyte stage in the Plasmodium lifecycle that occurs either in the bloodstream of a vertebrate host or the midgut of a mosquito vector. Chris Stoeckert Jie Zheng Plasmodium microgametocyte stage A merozoite stage in the Plasmodium lifecycle that occurs in the bloodstream or hepatocytes of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium merozoite stage An erythrocytic merozoite stage in the Plasmodium lifecycle that occurs in the bloodstream of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium erythrocytic merozoite stage A hepatic merozoite stage in the Plasmodium lifecycle that occurs in the hepatocyte of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium hepatic merozoite stage An oocyst stage in the Plasmodium lifecycle that occurs on the hemocoel side of the midgut of a mosquito vector. During this stage Plasmodium ookinete invades and escapes midgut wall of mosquito and embed itself onto the exterior of the gut membrane and develop encysted zygote, called oocyst. Chris Stoeckert Jie Zheng Plasmodium oocyst stage An ookinete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector and on the outside of the midgut. Chris Stoeckert Jie Zheng Plasmodium ookinete stage A schizont stage in the Plasmodium lifecycle that occurs in erythrocytes or in hepatocytes. Chris Stoeckert Jie Zheng Plasmodium schizont stage An erythrocytic schizont stage in the Plasmodium lifecycle that occurs in the infected erythrocytes of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium erythrocytic schizont stage A hepatic schizont stage in the Plasmodium lifecycle that occurs in the infected hepatocytes of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium hepatic schizont stage A sporozoite stage in the Plasmodium lifecycle that occurs in the salivary glands of the mosquito and invades hepatocytes in the vertebrate host. Chris Stoeckert Jie Zheng Plasmodium sporozoite stage A sporozoite stage in the Plasmodium lifecycle that develops in oocyst of the mosquito midgut. Chris Stoeckert Jie Zheng Omar harb Plasmodium oocyst-derived sporozoite stage A salivary gland-derived sporozoite stage in the Plasmodium lifecycle that occurs in the salivary glands of the mosquito and invades hepatocytes in the vertebrate host. Chris Stoeckert Jie Zheng Omar harb Plasmodium salivary gland-derived sporozoite stage A trophozoite stage in the Plasmodium lifecycle that occurs in a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium trophozoite stage An erythrocytic trophozoite stage in the Plasmodium life cycle that occurs in erythrocytes of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium erythrocytic trophozoite stage An erythrocytic ring trophozoite stage in the Plasmodium life cycle that occurs in erythrocytes of a vertebrate host. During this stage some Plasmodium merozoites undergo asexual reproduction cycle in erythrocytes and form young trophozoites that are referred to as "ring form" due to their morphology. Chris Stoeckert Jie Zheng Plasmodium erythrocytic ring trophozoite stage A hepatic trophozoite stage in the Plasmodium life cycle that occurs in hepatocytes of a vertebrate host. Chris Stoeckert Jie Zheng Plasmodium hepatic trophozoite stage A zygote stage in the Plasmodium lifecycle that occurs in the midgut of the mosquito vector where a microgamete and a macrogamete fertilizes each other to produce a diploid cell. Chris Stoeckert Jie Zheng Plasmodium zygote stage An adult worm stage in the Schistosoma haematobium lifecycle. Chris Stoeckert Jie Zheng Schistosoma haematobium adult worm stage An adult worm stage in the Schistosoma japonicum lifecycle. Chris Stoeckert Jie Zheng Schistosoma japonicum adult worm stage Blood that is part of or originated from a vertebrate. Jie Zheng OPL Vertebrate blood An erythrocyte that is a part of or originated from a vertebrate. Jie Zheng OPL Vertebrate erythrocyte A hepatocyte that is a part of or originated from a vertebrate. Jie Zheng OPL Vertebrate hepatocyte Cerebrospinal fluid that is a part of or originated from a mammal. Jie Zheng Mammalia cerebrospinal fluid A skin that is a part of or originated from a mammalian body. Jie Zheng Mammalia skin A liver that is a part of or originated from a mammal (Mammalia). Jie Zheng Mammalia liver A lung that is a part of or originated from a mammal (Mammalia). Jie Zheng Mammalia lung A mesenteric vein that is a part of or originated from a mammal (Mammalia). Jie Zheng Mammalia mesenteric vein An intestine that is a part of or originated from a mammal (Mammalia). Jie Zheng Mammalia intestine An adult worm stage in the Schistosoma mansoni lifecycle. Chris Stoeckert Jie Zheng Schistosoma mansoni adult worm stage Blood that is part of or originated from a mammalia. Jie Zheng Mammalia blood A macrophage that is a part of or originated from a mammalia. Jie Zheng Mammalia macrophage A parasite lifecycle stage of trypanosomatidae in which the organism is infectious and does not multiply. Chris Stoeckert Jie Zheng metacyclic stage https://microbewiki.kenyon.edu/index.php/Trypanosome_Life_Cycle https://web.stanford.edu/group/parasites/ParaSites2003/Leishmania/Leish%20Biology.html https://github.com/OPL-ontology/OPL/issues/9 Trypanosomatida metacyclic stage A parasite lifecycle stage of trypanosomatidae in which the organism is in dividing form and it occurs in fly vector. Achchuthan Shanmugasundram Chris Stoeckert Jie Zheng procyclic stage VEuPathDB https://github.com/OPL-ontology/OPL/issues/10 Trypanosomatida procyclic stage A parasite life cycle stage found in the tissue cyst which replicates slowly within a parasitophorous vacuole within the host cell. Jie Zheng https://orcid.org/0000-0002-2825-0621 Paola Roncaglia bradyzoite cystozoite https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/tachyzoite https://github.com/OPL-ontology/OPL/issues/19 https://github.com/obophenotype/cell-ontology/issues/270 Cell Ontology bradyzoite stage A parasite lifecycle stage that parasite replicates rapidly within the host cell. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744739/ tachyzoite stage A Plasmodium vivax that is found in the midgut of a mosquito vector. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax ookinete A Plasmodium vivax is formed in the oocyst. It migrates to and resides in the gut of the mosquito vector. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax sporozoite A Plasmodium vivax that is found in the bloodstream of the human host and invades erythrocytes. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax merozoite A Plasmodium vivax that is located in the bloodstream of the human host. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax gametocyte A Plasmodium berghei is formed in the oocyst. It migrates to and resides in the gut of the mosquito vector. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium berghei sporazoite A Plasmodium berghei that is found in the bloodstream of the human host and invades erythrocytes. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium berghei merozoite A Neospora caninum that is found intracellular in the intermediate hosts in which asexual replication takes place. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890850/ https://github.com/OPL-ontology/OPL/issues/21 He Group Neospora caninum tachyzoite An Eimeria maxima that is located in the bloodstream of the human host. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/21 He Group Eimeria maxima gametocyte An Eimeria tenella is formed in the oocyst. It migrates to and resides in the gut of the mosquito vector. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/21 He Group Eimeria tenella sprozoite An Eimeria tenella that oocyst is formed, found in the gut of the mosquito vector. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/21 He Group Eimeria tenella oocyst A Sarcocystis neurona that is found in the bloodstream of the human host and invades erythrocytes. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/books/NBK574577/ https://github.com/OPL-ontology/OPL/issues/21 He Group Sarcocystis neurona merozoite A Sarcocystis neurona is formed in the oocyst. It migrates to and resides in the gut of the mosquito vector. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/books/NBK574577/ https://github.com/OPL-ontology/OPL/issues/21 He Group Sarcocystis neurona sporozoite A Toxoplasma gondii that is formed in tissue in a host and replicates quickly. This replaces the previous term as . Anthony Huffman Jie Zheng Toxoplasma gondii trophozoite https://www.ncbi.nlm.nih.gov/pmc/articles/PMC106833/ https://github.com/OPL-ontology/OPL/issues/21 He Group Toxoplasma gondii tachyzoite A Toxoplasma gondii that is formed in a tissue cyst of host, replicating slowly. Anthony Huffman Jie Zheng Toxoplasma gondii cystozoites https://www.ncbi.nlm.nih.gov/pmc/articles/PMC106833/ https://github.com/OPL-ontology/OPL/issues/21 He Group Toxoplasma gondii bradyzoite A Toxoplasma gondii that oocyst is formed, found in the gut of the bug vector. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC106833/ https://github.com/OPL-ontology/OPL/issues/21 He Group Toxoplasma gondii oocyst A Leishmania amazonensis that occurs in the gut of a sandfly. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania amazonensis promastigote A Leishmania amazonensis that occurs in a mammal tissue. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania amazonensis amastigote A Leishmania donovani that is that occurs in the gut of a sandfly. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania donovani promastigote A Leishmania donovani that is that occurs in a mammal tissue. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania donovani amastigote A Leishmania infantum that is that occurs in the gut of a sandfly. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania infantum promastigote A Leishmania infantum that is that occurs in a mammal tissue. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania infantum amastigote An ookinete stage in Plasmodium vivax life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax ookinete stage A sporozoite stage in Plasmodium vivax life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax sporozoite stage A merozoite stage in the Plasmodium vivax life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax merozoite stage A gametocyte stage in the Plasmodium vivax life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium vivax gametocyte stage A sporozoite stage in the Plasmodium berghei life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium berghei sporazoite stage A merozoite stage in the Plasmodium berghei life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/21 He Group Plasmodium berghei merozoite stage A tachyzoite stage in the Neospora caninum life cycle. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890850/ https://github.com/OPL-ontology/OPL/issues/21 He Group Neospora caninum tachyzoite stage A gametocyte stage in the Eimeria maxima life cycle. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/21 He Group Eimeria maxima gametocyte stage A sporozoite stage in the Eimeria tenella life cycle. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2238154/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/21 He Group Eimeria tenella sporozoite stage An oocyst stage in the Eimeria tenella life cycle. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/21 He Group Eimeria tenella oocyst stage A merozoite stage in the Sarcocystis neurona life cycle. Anthony Huffman Jie Zheng https://wcvm.usask.ca/learnaboutparasites/parasites/sarcocystis-neurona.php https://github.com/OPL-ontology/OPL/issues/21 He Group Sarcocystis neurona merozoite stage A sporozoite stage in the Sarcocystis neurona life cycle. Anthony Huffman Jie Zheng https://pubmed.ncbi.nlm.nih.gov/15272465/ https://wcvm.usask.ca/learnaboutparasites/parasites/sarcocystis-neurona.php https://github.com/OPL-ontology/OPL/issues/21 He Group Sarcocystis neurona sporozoite stage A tachyzoite stage in the Toxoplasma gondii life cycle. Tachyzoites can be found in various organs and tissues during the acute phase of Toxoplasma gondii infection, including lymph nodes, spleen, liver, lungs, and the central nervous system. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC106833/ https://github.com/OPL-ontology/OPL/issues/21 He Group Toxoplasma gondii tachyzoite stage A bradyzoite stage in the Toxoplasma gondii life cycle. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC106833/ https://github.com/OPL-ontology/OPL/issues/21 He Group Toxoplasma gondii bradyzoite stage An oocyst stage in the Toxoplasma gondii life cycle. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC106833/ https://github.com/OPL-ontology/OPL/issues/21 He Group Toxoplasma gondii oocyst stage A promastigote stage in the Leishmania amazonensis life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania amazonensis promastigote stage An amastigote stage in the Leishmania amazonensis life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania amazonensis amastigote stage A promastigote stage in the Leishmania donovani life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania donovani promastigote stage An amastigote stage in the Leishmania donovani life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania donovani amastigote stage A promastigote stage in the Leishmania infantum life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania infantum promastigote stage An amastigote stage in the Leishmania infantum life cycle. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/leishmaniasis/biology.html https://github.com/OPL-ontology/OPL/issues/21 He Group Leishmania infantum amastigote stage An erythrocyte that is a part of or originated from a Gallus gallus. Jie Zheng He Group Gallus gallus erythrocyte An erythrocyte that is a part of or originated from a Canis lupus familiaris. Jie Zheng He Group Canis lupus familiaris erythrocyte A midgut that is a part of or originated from a Gallus gallus. Jie Zheng He Group Gallus gallus midgut An intestine that is a part of or originated from a Gallus gallus. Jie Zheng He Group Gallus gallus intestine A muscle tissue that is a part of or originated from a Mammalia. Jie Zheng He Group Mammalia muscle tissue An intestine that is a part of or originated from a Triatominae. Jie Zheng He Group Triatominae intestine A lifecycle stage of Plasmodium vivax. Jie Zheng He Group Plasmodium vivax lifecycle stage A lifecycle stage of Plasmodium berghei. Jie Zheng He Group Plasmodium berghei lifecycle stage A lifecycle stage of Neospora caninum. Jie Zheng He Group Neospora caninum lifecycle stage A lifecycle stage of Eimeria maxima. Jie Zheng He Group Eimeria maxima lifecycle stage A lifecycle stage of Eimeria tenella. Jie Zheng He Group Eimeria tenella lifecycle stage A lifecycle stage of Sarcocystis neurona. Jie Zheng He Group Sarcocystis neurona lifecycle stage A lifecycle stage of Toxoplasma gondii. Jie Zheng He Group Toxoplasma gondii lifecycle stage A lifecycle stage of Leishmania amazonensis. Jie Zheng He Group Leishmania amazonensis lifecycle stage A lifecycle stage of Leishmania donovani. Jie Zheng He Group Leishmania donovani lifecycle stage A lifecycle stage of Leishmania infantum. Jie Zheng He Group Leishmania infantum lifecycle stage A Plasmodium yoelii in ookinete stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii ookinete A Plasmodium yoelii in sporozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii sporozoite A Plasmodium yoelii in merozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii merozoite A Plasmodium yoelii in gametocyte stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii gametocyte A Plasmodium chabaudi in ookinete stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi ookinete A Plasmodium chabaudi in sporozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi sporozoite A Plasmodium chabaudi in merozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi merozoite A Plasmodium chabaudi in gametocyte stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi gametocyte A Plasmodium knowlesi in ookinete stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi ookinete A Plasmodium knowlesi in sporozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi sporozoite A Plasmodium knowlesi in merozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi merozoite A Plasmodium knowlesi in gametocyte stage. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi gametocyte A Eimeria acervulina in merozoite stage. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/24 He Group Eimeria acervulina merozoite A Cryptosporidium parvum in oocyst stage. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/crypto/pathogen.html https://github.com/OPL-ontology/OPL/issues/24 He Group Cryptosporidium parvum oocyst A Cryptosporidium parvum in sporozoite stage. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/crypto/pathogen.html https://github.com/OPL-ontology/OPL/issues/24 He Group Cryptosporidium parvum sporozoite An ookinete stage in the Plasmodium yoelii. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii ookinete stage A sporozoite stage in the Plasmodium yoelii. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii sporozoite stage A merozoite stage in the Plasmodium yoelii. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii merozoite stage A gametocyte stage in the Plasmodium yoelii. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium yoelii gametocyte stage An ookinete stage in the Plasmodium chabaudi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi ookinete stage A sporozoite stage in the Plasmodium chabaudi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi sporozoite stage A merozoite stage in the Plasmodium chabaudi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi merozoite stage A gametocyte stage in the Plasmodium chabaudi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium chabaudi gametocyte stage An ookinete stage in the Plasmodium knowlesi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi ookinete stage A sporozoite stage in the Plasmodium knowlesi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi sporozoite stage A merozoite stage in the Plasmodium knowlesi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi merozoite stage A gametocyte stage in the Plasmodium knowlesi. Anthony Huffman Jie Zheng https://www.cdc.gov/dpdx/malaria/index.html https://github.com/OPL-ontology/OPL/issues/24 He Group Plasmodium knowlesi gametocyte stage A merozoite stage in the Eimeria acervulina. Anthony Huffman Jie Zheng https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351014/ https://github.com/OPL-ontology/OPL/issues/24 He Group Eimeria acervulina merozoite stage An oocyst stage in the Cryptosporidium parvum. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/crypto/pathogen.html https://github.com/OPL-ontology/OPL/issues/24 He Group Cryptosporidium parvum oocyst stage A sporozoite stage in the Cryptosporidium parvum. Anthony Huffman Jie Zheng https://www.cdc.gov/parasites/crypto/pathogen.html https://github.com/OPL-ontology/OPL/issues/24 He Group Cryptosporidium parvum sporozoite stage An erythrocyte that is a part of or originated from a primate. Jie Zheng primate erythrocyte He Group He Group Primates erythrocyte A lifecycle stage of Plasmodium yoelii. Jie Zheng He Group He Group Plasmodium yoelii lifecycle stage A lifecycle stage of Plasmodium chabaudi. Jie Zheng He Group He Group Plasmodium chabaudi lifecycle stage A lifecycle stage of Plasmodium knowlesi. Jie Zheng He Group He Group Plasmodium knowlesi lifecycle stage A lifecycle stage of Eimeria acervulina. Jie Zheng He Group He Group Eimeria acervulina lifecycle stage A lifecycle stage of Cryptosporidium parvum. Jie Zheng He Group He Group Cryptosporidium parvum lifecycle stage A Neospora caninum in bradyzoite stage. Anthony Huffman Jie Zheng https://www.mdpi.com/2306-7381/9/2/87 https://github.com/OPL-ontology/OPL/issues/24 He Group Neospora caninum bradyzoite A bradyzoite stage in the Neospora caninum. Anthony Huffman Jie Zheng https://www.mdpi.com/2306-7381/9/2/87 https://github.com/OPL-ontology/OPL/issues/24 He Group Neospora caninum bradyzoite stage A dependent entity that inheres in a bearer by virtue of how the bearer is related to other entities PATO:0000072 quality PATO:0000001 quality A time quality inhering in a bearer by virtue of how long the bearer has existed. quality PATO:0000011 age A physical quality which inheres in a bearer by virtue of the number of the bearer's repetitive actions in a particular time. quality PATO:0000044 frequency An organismal quality inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved. quality PATO:0000047 biological sex A quality in which events occur in sequence. quality PATO:0000165 time An organismal quality inhering in a bearer or a population by virtue of the bearer's disposition to survive and develop normally or the number of surviving individuals in a given population. quality PATO:0000169 viability A viability quality inhering in a bearer or a population by virtue of the bearer's ability to survive or the long term survival ability of a given population. quality PATO:0000719 viable A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies. quality PATO:0000918 volume A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities. PATO:0002079 Wikipedia:Physical_property relational physical quality quality PATO:0001018 physical quality A physical quality inhering in a bearer by virtue of ratio of the bearer's output to the bearer's input. quality PATO:0001029 efficiency A quality which inheres in a continuant. PATO:0001237 PATO:0001238 snap:Quality monadic quality of a continuant multiply inhering quality of a physical entity quality of a continuant quality of a single physical entity quality of an object quality of continuant monadic quality of an object monadic quality of continuant quality PATO:0001241 Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles. physical object quality A viability quality inhering in a bearer by virtue of the cessation of the bearer's life. quality PATO:0001422 dead An efficiency quality inhering in a bearer by virtue of the bearer's lacking efficiency. quality PATO:0001677 inefficient An efficiency quality inhering in a bearer by virtue of the bearer's having efficiency. quality PATO:0001678 efficient A quality that inheres in an entire organism or part of an organism. quality PATO:0001995 organismal quality A quality inhering in a bearer by virtue of the severity of infectious disease caused by the bearer in a target organism. 2009-10-30T05:04:06Z quality PATO:0002146 virulence A virulence that is relatively low. 2009-10-30T05:05:02Z attenuated quality PATO:0002147 reduced virulence A quality of an object that has a value that is decreased compared to normal or average. 2011-06-16T06:51:54Z quality PATO:0002303 decreased object quality An amino acid chain that is produced de novo by ribosome-mediated translation of a genetically-encoded mRNA, and any derivatives thereof. natural protein native protein protein PR:000000001 The definition above excludes protein complexes, which some also consider a protein. Those who wish to refer to a class representing both senses of the word are directed to CHEBI:36080. Note that the definition allows for experimentally-manipulated genes, and allows for artifically-produced derivatives that mimic those found naturally. Proteins (in the sense defined here) that descended from a common ancestor can be classified into families and superfamilies composed of products of evolutionarily-related genes. The domain architecture of a protein is described by the order of its constituent domains. Proteins with the same domains in the same order are defined as homeomorphic [PRO:WCB]. protein A protein that has a core domain composition consisting of a signal peptide, an extracellular domain with multiple Leucine rich repeat (Pfam:PF13855) domain (LRR), a cysteine-rich region, a single-pass transmembrane domain and a C-terminal cytoplasmic tail containing a TIR domain (Pfam:PF01582). PIRSF:PIRSF800008 fam:TLR protein PR:000001096 Category=family. Toll-like receptor A Toll-like receptor that is a translation product of the human TLR2 gene or a 1:1 ortholog thereof. IUPHARobj:1752 CD282 TLR2 Toll/interleukin-1 receptor-like protein 4 protein TIL4 PR:000001153 Category=gene. Toll-like receptor 2 A Toll-like receptor that is a translation product of the human TLR3 gene or a 1:1 ortholog thereof. IUPHARobj:1753 CD283 TLR3 protein PR:000001154 Category=gene. Toll-like receptor 3 A Toll-like receptor that is a translation product of the human TLR4 gene or a 1:1 ortholog thereof. Toll IUPHARobj:1754 CD284 TLR4 protein Lps PR:000001155 Category=gene. Toll-like receptor 4 A Toll-like receptor that is a translation product of the human TLR7 gene or a 1:1 ortholog thereof. IUPHARobj:1757 TLR7 protein UNQ248/PRO285 PR:000001158 Category=gene. Toll-like receptor 7 A Toll-like receptor that is a translation product of the human TLR8 gene or a 1:1 ortholog thereof. IUPHARobj:1758 CD288 TLR8 protein UNQ249/PRO286 PR:000001159 Category=gene. Toll-like receptor 8 A protein that is a translation product of the human NLRP3 gene or a 1:1 ortholog thereof. IUPHARobj:1770 CLR1.1 NLRP3 PYRIN-containing APAF1-like protein 1 angiotensin/vasopressin receptor AII/AVP-like caterpiller protein 1.1 cold autoinflammatory syndrome 1 protein cold autoinflammatory syndrome 1 protein homolog cryopyrin mast cell maturation-associated-inducible protein 1 protein C1orf7 CIAS1 Mmig1 NALP3 PYPAF1 PR:000011271 Category=gene. NACHT, LRR and PYD domains-containing protein 3 A SODC domain protein that is a translation product of the human SOD1 gene or a 1:1 ortholog thereof. SOD1 protein PR:000015399 Category=gene. superoxide dismutase [Cu-Zn] A material entity that minimally consists of a protein. protein protein aggregate protein complex protein-containing complex protein PR:000050567 Note: This includes single proteins and derivatives thereof (PR:000000001), protein-containing complexes (GO:0032991), and protein aggregates (PR:000050566). protein-containing material entity A protein that is a translation product of the S gene in SARS-CoV-2. GenPept:YP_009724390 UniProtKB:P0DTC2 E2 (SARS-CoV-2) S (SARS2) S glycoprotein (SARS-CoV-2) peplomer protein (SARS-CoV-2) surface glycoprotein (SARS-CoV-2) protein 2 GU280_gp02 S PR:P0DTC2 Category=organism-gene. Note: 1273 aa protein. Undergoes additional processing by proteolytic cleavage. spike glycoprotein (SARS-CoV-2) Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs. ureter A spatiotemporal region encompassing some part of the life cycle of an organism. this class represents a proper part of the life cycle of an organism. The class 'life cycle' should not be placed here the WBls class 'all stages' belongs here as it is the superclass of other WBls stages we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage BILS:0000105 EFO:0000399 FBdv:00007012 FMA:24120 HsapDv:0000000 MESH:D008018 MmusDv:0000000 OlatDv:0000010 PdumDv:0000090 WBls:0000002 XAO:1000000 ZFS:0000000 ZFS:0100000 ncithesaurus:Developmental_Stage developmental stage stage uberon UBERON:0000105 life cycle stage A stage at which the organism is a single cell produced by means of sexual reproduction. As in all metazoans, eumetazoan development begins with a fertilized egg, or zygote.[well established][VHOG] BILS:0000106 BilaDO:0000005 EFO:0001322 EHDAA:27 FBdv:00005288 NCIT:C12601 PdumDv:0000100 VHOG:0000745 Wikipedia:Zygote XAO:1000001 ZFS:0000001 1-cell stage fertilized egg stage one cell stage uberon fertilized egg stage one-cell stage zygote zygotum UBERON:0000106 zygote stage Segment of the alimentary canal extending from the stomach to the anus and, in humans and other mammals, consists of two segments, the small intestine and the large intestine. intestine A fluid that is composed of blood plasma and erythrocytes. blood Anatomical entity that has mass. material anatomical entity Saliva-secreting exocrine glands of the oral cavity[GO]. saliva-secreting gland Middle subdivision of a digestive tract[CJM]. In vertebrates: The middle part of the alimentary canal from the stomach, or entrance of the bile duct, to, or including, the large intestine[GO]. midgut The caudalmost subdivision of a digestive tract. hindgut Distensible musculomembranous organ situated in the anterior part of the pelvic cavity in which urine collects before excretion[MP]. urinary bladder A clear, colorless, bodily fluid, that occupies the subarachnoid space and the ventricular system around and inside the brain and spinal cord. cerebrospinal fluid Respiration organ that develops as an outpocketing of the esophagus. lung The organ covering the body that consists of the dermis and epidermis. skin of body An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes[GO]. liver Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO]. muscle tissue A vein that returns blood from the intestines. mesenteric vein 'part of organism in vaccine' is a pathogen component in vaccine that contains only a part of the pathogen organism instead of the whole organism. YH part of pathogen organism in vaccine A vaccine is a processed material with the function that when administered, it prevents or ameliorates a disorder in a target organism by inducing or modifying adaptive immune responses specific to the antigens in the vaccine. Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases. YH, BP, BS, MC, LC, XZ, RS a role that inheres in a prepared material entity that is designed to induce protection or treament for a diease or infection in vivo. vaccine MeSH: D014612 a process of administering substance in vivo that involves in adding a vaccine into a host (e.g., human) in vivo with the intent to invoke a protective or therapeutic adaptive immune response. YH, BP vaccine administration vaccination Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/833083 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180810.htm ACAM2000 Smallpox (Vaccinia) Vaccine, Live Emergent Product Development Gaithersburg, Inc. Active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142572.pdf BL 125158 833083 ACAM2000 CVX: 75 Preparation: The vaccine consists of the Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high molecular weight polymer prepared from the Haemophilus influenzae type b (HiB) strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid. The tetanus toxoid is prepared by extraction, ammonium sulfate purification, and formalin inactivation of the toxin from cultures of Clostridium tetani (Harvard strain) grown in a modified Mueller and Miller medium. The toxoid is filter sterilized prior to the conjugation process. When ActHIB vaccine is reconstituted with saline diluent, each single dose of 0.5 mL is formulated to contain 10 mu g of purified capsular polysaccharide conjugated to 24 mu g of inactivated tetanus toxoid, and 8.5% of sucrose (ActHIB 2005). Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157&keywords= Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174743.htm ActHIB Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) Sanofi Pasteur, SA ActHIB vaccine is indicated for the active immunization of infants and children 2 months through 5 years of age for the prevention of invasive disease caused by H influenzae type b. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM109841.pdf 103935 ActHIB CVX: 48 PMID: PMID: 1517908 PMID: 1735812 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/605718 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm Adacel Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed Sanofi Pasteur, Ltd Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 through 64 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142764.pdf BL 125111 605718 Adacel CVX: 115 CVX: 20 Kallan Roan, Oliver He WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094043.htm AFLURIA Influenza Virus Vaccine Seqirus Pty. Ltd For active immunization of persons ages 6 months of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM263239.pdf BL 125254 Afluria CVX: 140 CVX: 141 YH Product Name: Measles Virus Vaccine, Live Trade Name: Attenuvax Attenuvax YH vaccine-induced lymphocyte activation YH vaccine-induced B cell antigen processing and presentation YH vaccine-induced B cell cytokine production YH B cell epitope in vaccine vaccine B cell epitope YH vaccine-induced B cell mediated immunity A vaccine that protects against Bacillus anthrax that causes anthrax. YH anthrax vaccine Bacillus anthracis vaccine MeSH: D022122 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/404894 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133822.htm Biothrax Anthrax Vaccine Adsorbed Emergent BioDefense Operations Lansing LLC For the active immunization for the prevention of disease caused by Bacillus anthracis in persons between 18 and 65 years of age at high risk of exposure. https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/UCM074923.pdf BL 103821 404894 Biothrax CVX: 24 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/583411 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm Boostrix Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed GlaxoSmithKline Biologicals Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 years of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/UCM152842.pdf BL 125106 583411 Boostrix CVX: 115 CVX: 20 whole organism vaccine that uses killed pathogen organism as its component. YL killed vaccine A Brucella abortus vaccine that expresses Cu/Zn SOD with DNA plasmid pcDNA. PMID: 15039330. YH Brucella abortus DNA vaccine pcDNA-SOD PMID: 15039330 YH, ZX pVAX DNA vaccine plasmid a bacterial vaccine vector that uses B. abortus vaccine strain RB51 as the vector. YH Brucella abortus strain RB51 vaccine vector Brucella abortus vaccine RB51 is a Brucella abortus vaccine that is licensed in the USA since 1992. Brucella abortus vaccine RB51 is a live attenuated cattle vaccine against brucellosis that is currently used in the USA and many other coutries. YH B. abortus RB51 Brucella RB-51 Brucella RB51 SRB51 Brucella abortus vaccine RB51 PMID: 10534009 PMID: 11193615 PMID: 11500423 PMID: 11504226 PMID: 11504238 PMID: 11553603 PMID: 11768128 PMID: 12119140 PMID: 12438380 PMID: 12704101 PMID: 1439207 PMID: 16713034 PMID: 17653832 PMID: 17894637 PMID: 18836016 PMID: 1908158 PMID: 19362381 PMID: 19439382 PMID: 7622248 PMID: 7806364 PMID: 7927779 PMID: 8039890 PMID: 8740701 PMID: 8890203 WEB: http://rb51.com A live attenuated Brucella abortus vaccine that is licensed and used in many countries. YH Brucella S19 Brucella strain-19 Brucella abortus vaccine strain 19 PMID: 11058778 PMID: 8039890 YH, ZX pVAX1 DNA vaccine plasmid A vaccine that protects against Brucella that causes brucellosis in animals and humans. YH brucellosis vaccine Brucella vaccine MeSH: D002004 YH, ZX pCMV4 DNA vaccine plasmid YH, ZX pAp031 DNA vaccine plasmid YH http://purl.bioontology.org/ontology/RXNORM/139056 139056 Product Name: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) & Hepatitis B Vaccine (Recombinant) Trade Name: Comvax Comvax CVX: 51 PMID: Vaccine components see http://www.vaccinesafety.edu/components-DTaP.htm Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/352572 https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241874.pdf DAPTACEL Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Sanofi Pasteur, Ltd. Indicated for active immunization against diphtheria, tetanus and pertussis as a five dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday). https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM103037.pdf 103666 352572 Daptacel CVX: 106 CVX: 20 YH Product Name: Tetanus & Diphtheria Toxoids Adsorbed for Adult Use Trade Name: DECAVAC DECAVAC CVX: 113 a vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age. Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437912 https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm308566.htm MenHibrix Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine GlaxoSmithKline Biologicals Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b for children 6 weeks of age through 18 months of age. BL 125363/0 1437912 MenHibrix DNA vaccine is a vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing genes encoding one or more proteins of a pathogen. synonym: naked DNA vaccine YH genetic vaccine naked DNA vaccine nucleic acid vaccine DNA vaccine YH Product Name: Diphtheria & Tetanus Toxoids Adsorbed Diphtheria and Tetanus Toxoids Adsorbed USP by Sanofi Pasteur Inc CVX: 28 YH Product Name: Diphtheria & Tetanus Toxoids Adsorbed This term is obsolete since there is another term with the same meaning. obsolete Diphtheria and Tetanus Toxoids Adsorbed by Sanofi Pasteur Ltd true a vaccinia virus vaccine that is a freeze-dried calf lymph smallpox vaccine, specifically, Dryvax is a live-virus preparation of vaccinia prepared from calf lymph. Dryvax is a freeze-dried calf lymph smallpox vaccine. It is the world's oldest smallpox vaccine, created in the late 19th century by American Home Products, a predecessor of Wyeth. By the 1940s, Wyeth was the leading US manufacturer of the vaccine and the only manufacturer by the 1960s. After world health authorities declared smallpox had been eradicated from nature in 1980, Wyeth stopped making the vaccine. YH http://en.wikipedia.org/wiki/Dryvax Product Name: Smallpox Vaccine, Dried, Calf Lymph Type Trade Name: Dryvax Dryvax CVX: 75 ACAM2007 is a vaccine candidate expressing CFA/II. YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095642/ ETEC vaccine ACAM2010 PMID: 17566016 A viral vaccine that protects against infection of an adenovirus. YH, SGS adenovirus vaccine An assay that measures the persistent survival of live vaccine in a host in vivo. YH vaccine persistence assay YH, ZX pBacPAK9 DNA vaccine plasmid YH, ZX pBC12/CMV DNA vaccine plasmid A bacterial vaccine that prevents against Escherichia coli infection. YH E. coli vaccine Escherichia coli vaccine MeSH: D022361 YH, ZX pBHT DNA vaccine plasmid Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112845.htm FluLaval Influenza Virus Vaccine ID Biomedical Corporation of Quebec Active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. FLULAVAL is approved for use in persons 6 months of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM112904.pdf BL 125163 Product Name: Influenza Virus Vaccine, Trivalent, Types A and B FluLaval CVX: 141 Kallan Roan, Oliver He WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094047.htm FluMist Influenza Vaccine Live, Intranasal MedImmune, LLC For the active immunization of individuals 2-49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. BL 125020 FluMist CVX: 111 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112850.htm Fluarix Influenza Virus Vaccine GlaxoSmithKline Biologicals For active immunization of persons 3 years of age and older for the prevention of disease caused by influenza virus subtypes A and type B contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM335392.pdf BL 125127 Fluarix CVX: 140 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112852.htm Fluvirin Influenza Virus Vaccine Seqirus Vaccines Limited For active immunization of persons 4 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123694.pdf BL 103837 Product Name: Influenza Virus Vaccine, Trivalent, Types A and B Fluvirin CVX: 140 CVX: 141 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm Fluzone Influenza Virus Vaccine Fluzone is indicated for active immunization of persons 6 months of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM619664.pdf BL 103914 Product Name: Influenza Virus Vaccine, Trivalent, Types A and B Fluzone CVX: 140 CVX: 141 CVX: 144 a gene that once deleted, would make an attenuated microbe that can be used as a live attenuated vaccine against virulent pathogen. YH, YL, ZX virmugen Gardasil is a quadrivalent vaccine meaning it protects against 4 strains of virus (types 6, 11, 16, and 18). The vaccine was made using genetic engineering techniques. The genes that encode a specific protein from each of these strains are expressed in yeast in large-scale fermentation cultures. Protein purification methods are then used to isolate the proteins and make the vaccine. Cited from: http://biotech.about.com/b/2008/09/03/gardasil-safety-of-genetically-engineered-hpv-vaccine-still-in-question.htm Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/659877 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm Gardasil Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant Merck & Co., Inc - Prevention of vulvar and vaginal cancer - Vaccination in females 9 through 26 years of age for prevention of the following diseases caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18: - Cervical Cancer - Genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions: - Cervical adenocarcinoma in situ (AIS)cancer - Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3 - Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 - Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 - Cervical intraepithelial neoplasia (CIN) grade 1 - Vaccination in boys and men 9 through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11 - Vaccination in people ages 9 through 26 years for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf 125126 659877 Gardasil CVX: 62 a lentivirus vaccine vector that uses a HIV strain as the vector YH HIV based lentivirus vaccine vector YH Balb/c mouse Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/203439 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110016.htm HAVRIX Hepatitis A Vaccine, Inactivated GlaxoSmithKline Biologicals For active immunization against disease caused by hepatitis A virus (HAV) for persons 12 months of age and older. BL 103475 https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224555.pdf 203439 Havrix CVX: 52 CVX: 83 A bacterial vaccine that prevents Neisseria meningitidis infection. YH Meningococcal vaccine Neisseria meningitidis vaccine MeSH: D022401 IPOL, Poliovirus Vaccine Inactivated is a sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). IPOL vaccine is a highly purified, inactivated poliovirus vaccine with enhanced potency. Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/287617 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180053.htm IPOL Poliovirus Vaccine Inactivated (Monkey Kidney Cell) Sanofi Pasteur, SA IPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM133479.pdf 103930 287617 IPOL CVX: 10 PMID: The jourmal article that mentions a vaccine, which was retrieved from PubMed and annotated using VO-SciMinner.(Hur J, Xiang Z, Feldman EL, He Y. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunology. 12(1):49 2011 Aug 26. PMID: 21871085.) YL vaccine related journal article The Imovax® 9 Rabies Vaccine is a sterile, stable, freeze-dried 10 suspension of rabies virus prepared from strain PM-1503-3M. YH http://purl.bioontology.org/ontology/RXNORM/1659730 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180097.htm IMOVAX Rabies Vaccine Sanofi Pasteur, SA Vaccine for use in all age groups for pre-exposure and post-exposure prophylaxis against rabies. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM133484.pdf 103931 1659730 Imovax Rabies (USA) CVX: 18 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/224903 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm INFANRIX Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed GlaxoSmithKline Biologicals For active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks to 7 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM124514.pdf BL 103647 224903 Infanrix CVX: 20 YH WEB: http://atomicnewsreview.org/2009/10/22/approval-for-the-arepanrix%E2%84%A2-gsk-vaccine-in-canada/ Product Name: Influenza Virus Vaccine, H5N1 (for National Stockpile) Influenza Virus Vaccine H5N1 (Sanofi Pasteur Inc) JE-VAX is a sterile, lyophilized vaccine for subcutaneous use, prepared by inoculating mice intracerebrally with Japanese encephalitis (JE) virus, “Nakayama-NIH” strain. Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179149.htm JE-Vax Japanese Encephalitis Virus Vaccine Inactivated Research Foundation for Microbial Diseases of Osaka University Indicated for Active Immunization against JE for persons one year age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123761.pdf JE-Vax CVX: 39 YH http://purl.bioontology.org/ontology/RXNORM/801721 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172495.htm KINRIX Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine GlaxoSmithKline Biologicals Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX® and/or PEDIARIX® for the first three doses and INFANRIX® for the fourth dose. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241453.pdf BL 125260 801721 Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine Trade Name: KINRIX Kinrix CVX: 130 a bacterial vaccine vector that uses L. moncytogenes as the vector. YH Listeria monocytogenes vaccine vector NCBI Taxonomy ID: 1639 A Measles-Mumps-Rubella vaccine that is live attenuated and manufactured by Merck & Co, Inc. Kallan Roan, Oliver He MMR II https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm094050.htm M-M-R II Measles, Mumps, and Rubella Virus Vaccine, Live Merck & Co., Inc M-M-R II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123789.pdf BL 101069 M-M-R II CVX: 03 A Measles-Mumps vaccine that is manufactured by Merck and used for human. YH MEASLES + MUMPS (MM-VAX) MM-VAX http://novaccine.com/wp-content/uploads/2014/02/mmvax_package_insert.pdf Product Name: Measles and Mumps Virus Vaccine, Live Trade Name: M-M-Vax M-M-Vax Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Kallan Roan, Oliver He Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine WEB: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm Menactra Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Sanofi Pasteur Inc Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf 125089 Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine Trade Name: Menactra Menactra CVX: 114 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179991.htm Menomune-A/C/Y/W-135 Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W-135 Combined Sanofi Pasteur Inc For active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135. Menomune – A/C/Y/W-135 vaccine is approved for use in persons 2 years of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308370.pdf BL 103926 Menomune A C Y W135 CVX: 32 YH Product Name: Rubella Virus Vaccine Live Trade Name: Meruvax II Meruvax II CVX: 06 YH Product Name: Mumps Virus Vaccine Live Trade Name: Mumpsvax Mumpsvax CVX: 07 YH, ZX pBI/tTA DNA vaccine plasmid YH, ZX pBISIA DNA vaccine plasmid A Mycobacterium vaccine that protects against Mycobacterium tuberculosis. YH tuberculosis vaccine Mycobacterium tuberculosis vaccine MeSH: D032581 Mycobax is a BCG vaccine that is made by Sanofi Pasteur, Ltd. Ref: http://www.biopharma.com/cgi/full6.lasso?Key=412.65916 YH Product Name: BCG Vaccine Trade Name: Mycobax Mycobax CVX: 19 an influenza vaccine that is similar to Fluzone but has high dose. Kallan Roan Oliver He WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM305079.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm Fluzone High-Dose Influenza Virus Vaccine Sanofi Pasteur, Inc Fluzone High-Dose is indicated for active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM619541.pdf BL 103914 Product Name: Influenza Virus Vaccine, Trivalent, Types A and B Fluzone High-dose CVX: 140 CVX: 141 CVX: 144 YH, ZX pBK-SFV DNA vaccine plasmid Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181973.htm Influenza A (H1N1) 2009 Monovalent Vaccine Novartis Vaccines and Diagnostics Limited Active immunization of persons 4 years of age and older against influenza disease caused by pandemic (H1N1) 2009 virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182242.pdf Influenza A (H1N1) 2009 Monovalent Vaccine (Novartis) Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/352877 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm Pediarix Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined GlaxoSmithKline Biologicals For active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday). https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241874.pdf BL 103907 352877 Pediarix CVX: 110 PedvaxHIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B. Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm253644.htm Liquid PedvaxHIB Haemophilus B Conjugate Vaccine (Meningococcal Protein Conjugate) Merck Sharp & Dohme Corp. Liquid PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM253652.pdf BL 103237/5285 PedvaxHIB CVX: 49 PMID: PMID: 2791073 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/674453 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm Pentacel Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Sanofi Pasteur Limited For active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease caused by Haemophilus influenzae type b when administered to infants and children 6 weeks through 4 years of age (prior to fifth birthday). https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM109810.pdf 125145 674453 Pentacel CVX: 120 YH Product Name: Plague Vaccine Plague Vaccine by Greer Laboratories Inc CVX: 23 YH, ZX pBudCE4.1 DNA vaccine plasmid a malaria vaccine that protects against malaria caused by Plasmodium falciparum. YH Plasmodium falciparum vaccine Oliver He, Kallan Roan https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm179996.htm Pneumovax 23 Pneumococcal Vaccine, Polyvalent Merck & Co., Inc PNEUMOVAX 23 is indicated for active immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine in persons 50 years of age or older and persons greater than or equal to 2 years of age who are at increased risk for pneumococcal disease. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM257088.pdf BLA 101094 Product Name: Pneumococcal Vaccine, Polyvalent Pneumovax 23 CVX: 33 YH Product Name: Poliovirus Vaccine Inactivated (Human Diploid Cell) Trade Name: Poliovax Poliovax YH https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm https://www.prevnar13.com/ Prevnar Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Wyeth Pharmaceuticals Inc - Immunization of infants 2, 4, 6 and 12-15 months of age to prevent invasive pneumococcal disease. - Immunization of infants and toddlers against otitis media caused by vaccine serotypes. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM137038.pdf Product Name: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) STN: BLA 101094 Prevnar CVX: 100 VIOLIN Vaccine ID: 1114 A Measles-Mumps-Rubella-Vericella vaccine that is live and manufactured by Merck & Co, Inc. Kallan Roan, Oliver He WEB: http://www.merck.com/product/usa/pi_circulars/p/proquad/proquad_pi.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm188806.htm PROQUAD Measles, Mumps, Rubella and Varicella Virus Vaccine Live Merck & Co, Inc For vaccination against measles, mumps, rubella, and varicella in children 12 months to 12 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123793.pdf 125108 ProQuad CVX: 94 Kallan Roan, Oliver He WEB: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm Fluzone Intradermal Influenza Virus Vaccine Sanofi Pasteur, Inc Fluzone Intradermal Quadrivalent indicated for active immunization for use in adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM566500.pdf BL 103914 Fluzone Intradermal Quadrivalent A vaccine adjuvant that is formed as a mineral salt. Oliver He Samantha G. Sayers mineral salt vaccine adjuvant RabAvert Rabies Vaccine is a sterile, freeze-dried vaccine obtained by growing the fixed-virus strain Flury Low Egg Passage (LEP) in primary cultures of chicken fibroblasts. Kallan Roan, Oliver He WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf http://purl.bioontology.org/ontology/RXNORM/219579 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133517.htm RabAvert Rabies Vaccine Novartis Vaccines and Diagnostics Pre-exposure and post-exposure immunization of children and adults https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM312931.pdf BL 103334 219579 RabAvert CVX: 18 YH Product Name: Rabies Vaccine Adsorbed Rabies Vaccine Adsorbed by BioPort Corp Kallan Roan, Oliver He, SGS https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm247508.htm Adenovirus Type 4 and Type 7 Vaccine, Live, Oral Barr Labs, Inc. Indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdf BL 125296/0 Adenovirus Type 4 and Type 7 Vaccine, Live, Oral CVX: 143; UMLS_CUI: C0695130; SNOMEDCT: 442561000 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/496892 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm RotaTeq Rotavirus Vaccine, Live, Oral, Pentavalent Merck & Co, Inc For prevention of rotavirus gastroenteritis in infants 6 weeks to 32 weeks of age caused by types G1, G2, G3, G4, and G9. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142288.pdf BL 125122 496892 RotaTeq CVX: 116 a lentivirus vaccine vector that uses a SIV strain as the vector YH SIV based lentivirus vaccine vector NCBI Taxonomy ID: 11723 YH, ZX Pcaggs DNA vaccine plasmid YH https://academic.oup.com/cid/article/32/1/76/311106 T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-γ, and lymphotoxin-α and stimulate type 1 immunity, which is characterized by intense phagocytic activity. https://academic.oup.com/cid/article/32/1/76/311106 vaccine-induced T-helper 1 type immune response YH https://academic.oup.com/cid/article/32/1/76/311106 Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. https://academic.oup.com/cid/article/32/1/76/311106 vaccine-induced T-helper 2 type immune response Kallan Roan, Oliver He Tenivac https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm152800.htm TENIVAC Tetanus and Diphtheria Toxoids Adsorbed For Adult Use Sanofi Pasteur, Ltd, License #1726 Indicated for active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM152826.pdf 103171 TENIVAC TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. Kallan Roan Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=351 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134033.htm 351 Clinical trial CVX:19 TICE BCG Typhim Vi, Typhoid Vi Polysaccharide Vaccine, for intramuscular use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/114883 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094072.htm Typhim Vi Typhoid Vi Polysaccharide Vaccine Sanofi Pasteur SA For active immunization against typhoid fever for persons two years of age or older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142811.pdf 103936 114883 TYPHIM VI CVX: 101 YH T cell epitope in vaccine vaccine T cell epitope YH vaccine-induced T cell mediated immunity YH T cell vaccine antigen processing and presentation YH Brucella abortus vaccine YH Product Name: Tetanus Toxoid Adsorbed Tetanus Toxoid Adsorbed by Aventis Pasteur Inc CVX: 35 E. coli Int280a has been found to be a protective antigen. This subunit vaccine uses E. coli Int280a combined with adjuvant. This antigen can be used for development of type-specific EPEC or EHEC vaccine. YH E. coli O157:H7 intimin vaccine PMID: 11500434 YH Product Name: Tetanus & Diphtheria Toxoids Adsorbed for Adult Use Tetanus and Diphtheria Toxoids Adsorbed by MA Biologic Lab YH Product Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed Trade Name: Tripedia Tripedia CVX: 20 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094035.htm Twinrix Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine GlaxoSmithKline Biologicals Active immunization of persons 18 years of age or older against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110079.pdf BL 103850 Twinrix CVX: 104 YH, ZX pCAGGST7 DNA vaccine plasmid vaccine-induced T cell activation YH, ZX pCBINT DNA vaccine plasmid YH, ZX pCdm7 DNA vaccine plasmid A vaccine adjuvant that contains microbial derived material. Oliver He Samantha G. Sayers microbial derivative vaccine adjuvant Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094073.htm Varicella Virus Vaccine Live Varivax Merck & Co, Inc Indicated for active immunization for the prevention of varicella in individuals 12 months of age and older https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142812.pdf https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142813.pdf BL 103552 Varivax CVX: 21 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094070.htm Vivotif Typhoid Vaccine Live Oral Ty21a Berna Biotech, Ltd. For immunization of adults and children greater than 6 years of age against disease caused by Salmonella typhi. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807.pdf 103123 Vivotif (USA) CVX: 25 Kallan Roan, Oliver He http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180913.htm YF-Vax Yellow Fever Vaccine Sanofi Pasteur, Inc For active immunization of persons 9 months of age and older who: - Are living in or traveling to endemic areas; - Travelling internationally to countries that require evidence of vaccination from entering travelers or; - Laboratory Personnel who might be expose to virulent yellow fever virus or to concentrated preparations of the yellow fever vaccine strain by direct or indirect contact or by aerosols should by vaccinated. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142831.pdf BL 103915 YF-Vax CVX: 37 a viral vaccine vector that uses Yellow fever vaccine strain 17D as the vector. YH PMID: 16755933 Yellow fever 17D vaccine vector NCBI Taxonomy ID: 11090 A viral vaccine that protects against infection with Yellow fever virus. YH Yellow fever virus vaccine MeSH: D022341 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136941.htm Zostavax Zoster Vaccine, Live Merck & Co., Inc For prevention of herpes zoster (shingles) in individuals 50 years of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM132831.pdf https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM285015.pdf 125123 Zostavax CVX: 121 YH licensed turkey vaccine a vaccine organism that is live and attenuated YH live attenuated vaccine organism An aluminum vaccine adjuvant that contains aluminum hydroxide. Oliver He alum aluminum hydroxide vaccine adjuvant An aluminum vaccine adjuvant that is aluminum phosphate. Oliver He Samantha G. Sayers Adju-Phos® Al(PO)4 aluminum phosphate vaccine adjuvant Vaccination frequency is a qualitative term that represents how many times vaccination has occurred. YH vaccination frequency YH, ZX pcDNA I/Amp DNA vaccine plasmid A mineral salt vaccine adjuvant composed of calcium phosphate. Oliver He Samantha G. Sayers CaHPO4 calcium phosphate vaccine adjuvant YH, ZX pcDNA3 DNA vaccine plasmid An emulsion vaccine adjuvant that consists of a water-in-oil emulsion of aqueous antigen in paraffin (mineral) oil of low specific gravity and low viscosity. It is named after Jules T. Freund (1890-1960), Hungarian-born American immunologist. It is a water in oil emulsion. Oliver He Samantha G. Sayers Freund's emulsified oil adjuvant vaccine-induced T cell proliferation YH vaccine-induced adaptive immune response a viral vaccine vector that uses an adenovirus as the vector. YH adenovirus vaccine vector NCBI Taxonomy ID: 10508 a vaccine role that indicates the vaccine being a combination vaccine. YH combination vaccine role A Freund's emulsified oil adjuvant that contains inactivated and dried mycobacteria, usually Mycobacterium tuberculosis (the pathogenic agent of tuberculosis). Oliver He complete Freund's adjuvant YH agglutinating antibody role YH obsolete virulence factor true A Freund's emulsified oil adjuvant that does not contain the mycobacterial components. Oliver He incomplete Freund's adjuvant A microbial derivative vaccine adjuvant consisting of cholera toxin (CT) from Vibrio cholerae. Oliver He Samantha G. Sayers CT cholera toxin cholera toxin vaccine adjuvant a viral vaccine vector that uses an alphavirus as the vector. YH alphavirus vaccine vector NCBI Taxonomy ID: 11019 a vaccine component role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine. YH,YL recombinant vaccine vector role A microbial derivative vaccine adjuvant that is the P40 particulate fraction isolated from Corynebacterium. Oliver He Samantha G. Sayers PMID:8447157 Corynebacterium-derived P40 vaccine adjuvant an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen. YH The Latin "adjuvans" means to help, particularly to reach a goal. Adjuvant therapy for cancer is surgery followed by chemotherapy or radiation to help decrease the risk of the cancer recurring (coming back). An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system. vaccine adjuvant role YH antibody role Antibody titer is a titer of antibody that shows how much antibody an organism has produced that recognizes a particular epitope, expressed as the greatest dilution ratio (or its reciprocal) that still gives a positive result. ELISA is a common means of determining antibody titers. YH WEB: http://en.wikipedia.org/wiki/Antibody_titer antibody titer an organismal quality that indicates an organism (e.g., human) is immunized against a disease. To assign the state of ‘immunized’, we will need to do some assay to measure indicators of immunity, e.g., antibody titers in serum samples. YH, YL immunized a bacterial vaccine against an infection with F. tularensis. YH Francisella tularensis vaccine A vaccine preparation that results in the generation of a toxoid vaccine YH preparation of toxoid vaccine A Brucella abortus gene that has the name sodC and comes from strain 2308. YH IMMUNOGENICITY: The SodC protein induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-alpha but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. This gene has been used for vaccine development [PubMed: 10816475][PubMed: 11953393][PubMed: 12933826]. MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages [PubMed: 15845493]. sodC from B. abortus strain 2308 NCBI Gene GI: 3827840; NCBITaxon: 234 YH obsolete bacterial gene true YH viral gene YH HIV gene YH, ZX pcDNA3.1 DNA vaccine plasmid Brucella abortus cattle vaccine RB51 was developed by serial passages of virulent B. abortus strain 2308 in vitro in rifampin agar plates (Reference: PMID: 1908158). A live attenuated vaccine prepraration process that is performed by serial passages in vitro for pathogen attenuation. YH preparation of live attenuated vaccine by serial passages in vitro Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181971.htm Influenza A (H1N1) 2009 Monovalent Vaccine Sanofi Pasteur, Inc. Active immunization of persons 6 months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182404.pdf Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur) YH E. coli gene Escherichia coli gene a virulence of vaccine organism that shows an avirulent pheontype of the organism as the major component of a vaccine. The avirulence means that an vaccine organism is not virulent and does not cause pathogenic phenotype in a host organism. YH vaccine organism avirulent vaccine-induced gene up-regulation controlling intracellular bacterial replication YH Mycobacterium tuberculosis gene A vaccine that targets against a bacterial disease. YH bacterial vaccine MeSH: D001428 a vaccine vector that uses a live bacterium as the vector YH bacterial vaccine vector NCBI Taxonomy ID: 2 YH, ZX pcDNA3.1V5HisTOPO/TA DNA vaccine plasmid YH Salmonella gene YH Shigella gene YH protozoan gene YH Plasmodium gene YH Plasmodium falciparum gene a virulence of vaccine organism that shows an attenuated pheontype of the organism as the major component of a vaccine. YH vaccine organism live attenuated YH Leishmania gene YH, ZX pCEP4 DNA vaccine plasmid vaccine-induced T cell differentiation A vaccine that prevents or treats cancer. It is produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. Oliver He neoplasm vaccine tumor vaccine MeSH:D019496 cancer vaccine A vaccine preparation that results in the generation of a inactivated vaccine YH inactivated vaccine preparation a processed material that is output of the vaccine preparation and part of a vaccine. YH cardinal part of vaccine vaccine ingredient vaccine component YH vaccine-induced cell activation A microbial derivative vaccine adjuvant made from bacterial lipopolysaccharide (LPS) of gram-negative bacteria. Oliver He Samantha G. Sayers LPS vaccine adjuvant lipopolysaccharide vaccine adjuvant YH vaccine-induced antibacterial agglutination antibody response YH Japanese encephalitis virus gene YH Ebola virus gene YH Influenza virus gene A vaccine that uses RNA(s) derived from a pathogen organism. Using RNA may eliminate the problem of having to tailor a vaccine for each individual patient with their specific immunity. The advantage of RNA is that it can be used for all immunity types and can be taken from a single cell. DNA vaccines need to produce RNA which then prompts the manufacture of proteins. However, RNA vaccine eliminates the step from DNA to RNA. Oliver He mRNA vaccine https://en.wikipedia.org/wiki/RNA_vaccine RNA vaccine A synthetic vaccine adjuvant formulated to correspond to a component found in a water-soluble extract of cell walls of mycobacteria used in complete Freund's adjuvant (CFA). Oliver He Samantha G. Sayers MDP muramyl dipeptide PMID:344799 muramyl dipeptide vaccine adjuvant YH Dengue virus gene Colony-forming unit (CFU) is a titer measurement of viable bacterial or fungal numbers. Unlike in direct microscopic counts where all cells, dead and living, are counted, CFU measures viable cells. By convenience the results are given as CFU/mL (colony-forming units per milliliter) for water, and CFU/g (colony-forming units per gram) for soil or other porous material. YH CFU WEB: http://en.wikipedia.org/wiki/Colony-forming_unit colony forming unit An emulsion vaccine adjuvant that contains an organic polymer with some antigenic epitopes which might be shared with other organic polymers acting as immunostimulators. Oliver He Samantha G. Sayers squalene squalene vacccine adjuvant A synthetic vaccine adjuvant that is an emulsifier called Arlacel A. Oliver He Samantha G. Sayers arlacel A PMID:2042393 arlacel A vaccine adjuvant A Montanide vaccine adjuvant that is Montanide 103. Oliver He Montanide 103 Montanide 103 vaccine adjuvant A microbial derivitive vaccine adjuvant that contains components from killed Bordetella pertussis. The killed B. pertussis has a strong adjuvant effect on the diphtheria and tetanus toxoids in the DPT vaccines. Oliver He Bordetella pertussis component vaccine adjuvant a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA. YH USA licensed human vaccine role Conjugate vaccine is vaccine that conjugates/links antigens to the molecules that form the outer coat of disease-causing bacteria to promote an immune response. YH A conjugate vaccine is created by covalently attaching a poor (polysaccharide organism) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes of the carrier on the attached antigen. --from wikipedia. conjugate vaccine A vaccine preparation that results in the generation of a recombinant vector vaccine YH preparation of recombinant vector vaccine YH West Nile virus gene YH chickenpox virus gene YH Rubella virus gene Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657331 1657331 influenza A virus A/California/7/2009 (H1N1) antigen Characteristics: Inactivated baculovirus expressed PCV2 ORF2 protein; adjuvanted YH Porcilis-PCV2 YH Hepatitis A virus gene Characteristics: Inactivated PCD1-2 chimera; adjuvanted YH Suvaxyn PCV2 YH licensed pig vaccine A vaccine contraindication is a contraindication that increases the risks of a vaccination. YH contraindication for vaccination vaccine contraindication a vaccine role that is not licensed or in clinical trial; instead, it has been experimently approved to induce protection or treatment effect in vivo in at least an experimental animal model. YH vaccine in research role YH, ZX pHIS64 DNA vaccine plasmid an immune response detection assay that detects specific antiviral antibodies in a test serum. The serum, usually a twofold dilution series, is mixed with a standard number, usually 4 to 8 HA units, of virus and incubated prior to the addition of a standard suspension of erythrocytes. The highest dilution of serum that inhibits hemagglutination is the HI titer of the serum. For example, influenza (AI) viruses agglutinate erythrocytes through the interaction of the virus surface glycoprotein, the hemagglutinin (HA), with receptors on the surface of the erythrocyte. Inhibition of the agglutination reaction by HA subtype-specific antisera is the basis of the hemagglutination-inhibition (HI) assay. YH HI assay hemagglutination-inhibition assay an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication. YH vaccine organism killed vaccine organism inactivated a DNA vaccine plasmid that uses the plasmid labeled pCI. YH, ZX WEB: http://www.ncbi.nlm.nih.gov/nuccore/5870896 pCI DNA vaccine plasmid YH hypersensitivity to chicken product YH, ZX pCI-neo DNA vaccine plasmid YH, ZX pCMV DNA vaccine plasmid YH, ZX pCMV-1 DNA vaccine plasmid YH, ZX pCMV4 DNA vaccine plasmid YH hypersensitivity to chicken egg a vaccine component that is used to dissolve vaccine powder into liquid. The vaccine in a powder form has to be reconstituted by mixing vaccine powder with vaccine solvent before administered. YH vaccine diluent vaccine liquid diluent vaccine solvent YH, ZX pCMVI.UBF3/2 DNA vaccine plasmid YH, ZX pCMV-3FUB DNA vaccine plasmid YH, ZX pCMV-int DNA vaccine plasmid YH, ZX pCMV-LacZ DNA vaccine plasmid YH hypersensitivity to antibiotic YH hypersensitivity to neomycin YH hypersensitivity to polymyxin YH reaction to previous vaccination a vaccine component that contains the solid form of all vaccine components. A vaccine can be reconstituted by mixing vaccine powder with vaccine solvent. YH vaccine powder A vaccine preparation that results in the generation of a bacterial vaccine YH, ZX bacterial vaccine preparation YH, ZX pCMV-LIC DNA vaccine plasmid YH, ZX pCMVLuc DNA vaccine plasmid YH, ZX pCR3 DNA vaccine plasmid YH life-threatening reaction to previous vaccination YH, ZX pCR3.1 DNA vaccine plasmid YH life-threatening reaction to previous influenza vaccination YH, ZX pCR4-TOPO DNA vaccine plasmid YH hypersensitivity to gentamicin YH dominant epitope in vaccine vaccine dominant epitope YH vaccine-induced down-regulated gene expression YH hypersensitity to gelatin A vaccine prepraration process that is performed by heat inactivation of virulent pathogen. YH preparation of vaccine using heat inactivation CFU reduction assay is an assay that measures the reduction of the colony forming units of infected pathogens in vaccine-vaccinated animals compared to nonvaccinated animals. YH CFU reduction assay assay of CFU reduction in spleen is a CFU reduction assay that is measured using the extracted spleen as the tissue for isolation of infected pathogens. YH assay of CFU reduction in spleen Arginine is a conditionally essential amino acid, meaning most of the time it can be manufactured by the human body, and does not need to be obtained directly through the diet. The biosynthetic pathway however does not produce sufficient arginine, and some must still be consumed through diet. Individuals who have poor nutrition or certain physical conditions may be advised to increase their intake of foods containing arginine. Infants are unable to meet their requirements and thus arginine is nutritionally essential for infants. YH hypersensitity to arginine A physical quality inhering in a bearer by virtue of the bearer being fit to be eaten. Melanie has submitted this term and its two subclasses to obo: http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&atid=595654 YH, MC edibility A quality of edibility that inheres in a bearer by virtue of the bearer being suitable for oral ingestion as food, drug, or vaccine. This term may be submitted to PATO. YH edible Vaccine efficacy is an efficacy of a vaccine in induction of protective immune response in vivo or protection against infection of a virulent pathogen. Specifically, vaccine efficacy (VE) is the percentage reduction in disease incidence attributable to vaccination, calculated by means of the following equation: VE(%) = (U - V)/U x 100 where U = the incidence in unvaccinated people and V = the incidence in vaccinated people. Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71. YH vaccine efficacy YH history of asthma YH vaccine-induced antiviral neutralizing antibody response YH, ZX pcREV DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pgp.LAMP-1. This plasmid has a CMV promoter and contains the human lysosomal-associated membrane protein-1 signal sequence. Rebecca Racz, Yongqun He pgp.LAMP-1 DNA vaccine plasmid PMID: 19356616 YH, ZX pDRVISV1.0 DNA vaccine plasmid YH, ZX pECK DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pES. This plasmid has a CMV promoter and contains a kanamycin resistance gene. Rebecca Racz, Yongqun He pES DNA vaccine plasmid PMID: 19406186 YH usage of bronchodilator YH, ZX pET21a DNA vaccine plasmid YH, ZX pET-28a DNA vaccine plasmid YH, ZX pGA DNA vaccine plasmid YH, ZX pGEX-3X DNA vaccine plasmid YH vaccine-induced follicular dendritic cell activation YH usage of steroid YH, ZX pIRES DNA vaccine plasmid sodBFt is a live vaccine strain mutant of Francisella tularensis with reduced Fe-superoxide dismutase gene expression. Ref: PMID: 18692537. YH C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. SodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice sodB(Ft) PMID: 16923916 PMID: 18692537 YH fungal disease A vaccine that targets against a fungus infection. YH fungal vaccine MeSH: D005657 A live attenuated Francisella tularensis vaccine. It is available in American Type Culture Collection with ATCC ID: 29684. YH F. tularensis vaccine LVS PMID: 16912944 PMID: 8757866 YH, ZX pIRES2 DsRed2 DNA vaccine plasmid vaccine-induced T cell interferon-gamma production YH, ZX pING DNA vaccine plasmid YH, ZX pJW24 DNA vaccine plasmid YH, ZX pJW4303 DNA vaccine plasmid YH, ZX pK0 DNA vaccine plasmid vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. YH, MC, XZ, and AR vaccine function YH, ZX pK3 DNA vaccine plasmid YH, ZX pMV60 DNA vaccine plasmid YH, ZX pMAMneoBlue DNA vaccine plasmid a viral vaccine vector that uses a herpesvirus as the vector. YH herpesvirus vaccine vector NCBI Taxonomy ID: 10292 YH, ZX pMASIA DNA vaccine plasmid YH, ZX pND DNA vaccine plasmid YH vaccine-induced host gene response Any immune system process that functions in the calibrated response of the host to a vaccine. The definition of this term is based on the definition of 'immune response (GO:0006955)' . It is a child term of this GO term. Y.L. Y.H. vaccine-induced host immune response a processual entity that specifies host response to a vaccine. YH vaccine-induced host response a process that specifies host response to a vaccine adjuvant. YH host response to vaccine adjuvant a processual entity that specifies host response to a vaccine component. YH host response to vaccine component a process that specifies host response to a vaccine antigen. YH host response to vaccine antigen a process that specifies host response to a vaccine vector. YH host response to vaccine vaccine vector YH, ZX pND2 DNA vaccine plasmid YH, ZX pNGVL DNA vaccine plasmid A viral vaccine that protects against infection with human immunodeficiency virus that causes AIDS. YH AIDS vaccine HIV vaccine human immunodeficiency virus vaccine MeSH: D016915 YH, ZX pNL3-gal DNA vaccine plasmid YH, ZX pN4a-gal DNA vaccine plasmid YH https://en.wikipedia.org/wiki/Company A legal organization that represents an association of people with a specific objective. company YH B. melitensis strain VTRM1 YH, ZX pRc/CMV DNA vaccine plasmid YH, ZX pRc/CMV2 DNA vaccine plasmid YH B. suis VTRS1 Brucella suis strain VTRS1 PMID: 17428946 YH, ZX pRK DNA vaccine plasmid YH, ZX pRSV DNA vaccine plasmid YH, ZX pRSV0 DNA vaccine plasmid KKF24 is a recombinant strain of Francisella novicida U112 with iglC mutation (F. novicida delta-iglC::ermC). PMID: 14680699. YH KKF24 PMID: 16552035 YH F. tularensis vaccine LVS lipopolysaccharide F. tularensis vaccine LVS LPS PMID: 10722593 YH immunoglobulin mediated immune response to vaccine vaccine-induced antibody mediated immune response a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier. YH, YL WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664 Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm vaccine emulsifier YH B. melitensis lipopolysaccharide vaccine YH B. melitensis LPS-GBOMP subunit vaccine B. melitensis LPS-GBOMP noncovalent complex vaccine PMID: 8723881 YH, ZX pSC65 DNA vaccine plasmid YH, ZX pSG2 DNA vaccine plasmid A whole organism vaccine that uses an inativated pathogen organism as its component. YH inactivated organism vaccine killed vaccine inactivated vaccine YH, ZX pSG5 DNA vaccine plasmid YH, ZX Psin DNA vaccine plasmid YH, ZX pTARGET DNA vaccine plasmid YH, ZX pTH DNA vaccine plasmid YH, ZX pTHamp DNA vaccine plasmid YH B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12 Brucella abortus DNA vaccine encoding BCSP31, SOD and L7/L12 PMID: 17570767 YH, ZX pTR600 DNA vaccine plasmid YH recombinant B. abortus L7/L12 vaccine PMID: 8873388 Brucella abortus conjugate vaccine using L7/L12 YH, ZX pTVG4 DNA vaccine plasmid YH B. melitensis DNA vaccine encoding Omp31 PMID: 17428946 YH, ZX pUC18 DNA vaccine plasmid YH, ZX pUC19 DNA vaccine plasmid YH, ZX pV1J DNA vaccine plasmid bacterial vaccine that protect against Mycoplasma hyopneumoniae infection YL Mycoplasma hyopneumoniae vaccine A quality of edibility that inheres in a bearer by virtue of the bearer being not suitable for oral ingestion. YH, MC inedible YH, ZX pVCL(pCXN2-mVIN) DNA vaccine plasmid tertiary vaccination is a vaccination that is performed at the third time in a row. YH, Thom Todd tertiary vaccination Protozoa are a diverse group of unicellular eukaryotic organisms,[1] many of which are motile. Originally, protozoa had been defined as unicellular protists with animal-like behavior, e.g., movement. Protozoa were regarded as the partner group of protists to protophyta, which have plant-like behaviour, e.g., photosynthesis.(http://en.wikipedia.org/wiki/Protozoa) YL Protozoa YH, ZX pVR1012 DNA vaccine plasmid a vaccination site that is used for injection of a vaccine. YH, YL vaccine injection site YH, ZX pVR1012x/s DNA vaccine plasmid YH, ZX pWRG1644 DNA vaccine plasmid A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the bp26 deletion. It has similar vaccine efficacy to Rev. 1. Its advantage compared to Rev. 1 is that this feature of bp26 deletion promotes diagnosis. PMID: 17070627. YH Brucella CGV26 CGV26 B. melitensis bp26 deletion vaccine PMID: 16519974 A spontaneous mutant of the SCHU S4 strain that protects against virulent F. tularensis infection. PMID: 16299332. YH F. tularensis vaccine FSC043 PMID: 16299332 a route of administration that inject the material(such as vaccines, allergens) directly into a muscle. YH,YL intramuscular injection route I.M. intramuscular route rounte of administration that located in nose. YH I.N. intranasal route YH intranasal route by drop YH intranasal route by spray a route of administration that located in the peritoneum. YL YH intraperitoneal route YH B. melitensis WR201 YH, ZX pWRG7077 DNA vaccine plasmid YH B. abortus bacA mutant Brucella abortus bacA mutant PMID: 17196866 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181975.htm Influenza A (H1N1) 2009 Monovalent Vaccine CSL Limited Active immunization of persons ages 6 months and older against influenza disease caused by pandemic (H1N1) 2009 virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182401.pdf Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited) Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181970.htm Influenza A (H1N1) 2009 Monovalent Vaccine MedImmune LLC Active immunization of individuals 2-49 years of age against influenza disease caused by pandemic (H1N1) 2009 virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182406.pdf Influenza A (H1N1) 2009 Monovalent Vaccine ( MedImmune LLC) MC, YH Arepanrix A synthetic vaccine adjuvant that is PCPP salt. Samantha G. Sayers Adjumer PCPP salt polyidi (carboxylatophenoxy) lphosphazene polyphosphazene PMID:75551218 Adjumer vaccine adjuvant YH Megan Egg is a Salmonella vaccine that that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is formulated fro immunization of pullets. Megan Egg contains the same Megan Vac1 organism but Megan Vac1 is used for younger birds (broilers). WEB: http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf Megan Egg YH, ZX pWRM DNA vaccine plasmid YH PMID: 16481077 B. ovis microparticle subunit vaccine YH, ZX pzz DNA vaccine plasmid YH, ZX pME18100 DNA vaccine plasmid YH, ZX pVIVO2 DNA vaccine plasmid YH Brucella rSurA protein vaccine Brucella recombinant SurA protein Brucella recombinant SurA protein vaccine PMID: 17686554 a viral vaccine vector that uses a lentivirus as the vector. YH lentivirus vaccine vector NCBI Taxonomy ID: 11646 YH, ZX pcDNA1.1/Amp DNA vaccine plasmid YH vaccine-induced leukocyte activation a licensed human vaccine that is licensed in the USA. YH https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm USA licensed human vaccine A vaccine that is licensed for commercial use. YH licensed vaccine YH, ZX pRK7 DNA vaccine plasmid YH lipopolysaccharide of pathogen organism as vaccine component A particulate antigen delivery system that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi. Oliver He http://www.vaccination.inoz.com/adjuvants.html liposome-based vaccine adjuvant A live vaccine that is made from microbes that have been attenuated (weakened) in the laboratory so that they can't cause disease. YH attenuated vaccine live attenuated vaccine a vaccine organism that is live YH live vaccine organism YH live virulent vaccine quaternary vaccination is a vaccination that is performed at the fourth time in a row. YH, Thom Todd quaternary vaccination A vaccine that is used to improve conception. YH profertility vaccine YH Brucella recombinant DnaK protein vaccine PMID: 17686554 YH divalent DNA B. abortus vaccine using L7/L12 and Omp16 PMID: 16622210 'Mycobacterium avium relA mutant vaccine' includes a gene mutation of relA from virulent Mycobacterium avium. A live attenuated vaccine prepraration process that is performed by mutation of a gene(s) from a virulent pathogen. YH, YL, ZX preparation of gene mutant vaccine a route of administration that is through the membrane covering the muscles and nerves at the back of the eyeball Y.L. subtenon route http://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI%20MetaThesaurus&code=CL426248 an oral route of administration that is underneath the tongue. sublingual route http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38300 Y.L. intravaginal route intravaginal vaccination YH subtenon vaccination sublingual vaccination pharyngeal mucosal vaccination a vaccine-induced T cell interferon-gramm production that results from the addition of a vaccine adjuvant YH vaccine-induced, adjuvant boosted T cell interferon-gramm production Oliver He PMID:18472194 IL-15 plasmid vaccine adjuvant YH B. abortus DNA vaccine encoding L7/L12 and P39 Brucella abortus DNA vaccine encoding L7/L12 and P39 PMID: 16537031 YH attenuated Brucella abortus with deletion of znuA PMID: 16790759 YH mucosal immune response to vaccine A microbial derivative vaccine adjuvant that is derived from E. coli heat labile toxin LT. Oliver He Samantha G. Sayers E. coli LT toxin derived vaccine adjuvant viral vaccine that is used to protect against Feline panleukopenia virus infection generated using OntoRat YL Feline panleukopenia virus vaccine Vaccine that used for immunizing birds. YL birds vaccine bacterial vaccine that is used to protect against Leptospira spp. infection YL Leptospira spp. vaccine a Campylobacter bacterial vaccine that is used to protect against Campylobacter fetus infection generated using OntoRat YL Campylobacter fetus vaccine bacterial vaccine that is used to protect against Pseudomonas aeruginosa infection generated using OntoRat YL Pseudomonas aeruginosa vaccine a Bordetella bacterial vaccine that is used to protect against Bordetella bronchiseptica infection generated using OntoRat YL Bordetella bronchiseptica vaccine YH, YL, ZX a vaccine organism that is inactived/killed killed vaccine organism inactivated vaccine organism licensed rabbit vaccine YH neutralizing antibody role A B. melitensis vaccine that is composed of live Brucella melitensis attenuated mutant vjbR::Tn5 (BMEII1116) delivered using alginate microspheres that is coated with a protein of the parasite Fasciola hepatica (vitelline protein B [VpB]). PMID: 18362129. A B. melitensis vaccine that is composed of live Brucella melitensis attenuated mutant delivered using a microsphere delivery system. YH The deletion of vjbR gene in Brucella melitensis strain 16M made a live attenuated vaccine and provided significance protection against mice microencapsulated B. melitensis mutant vaccine PMID: 18362129 a vaccine-induced adjuvant boosted T cell interferon-gramm production that results from the addition of a IL-15 vaccine adjuvant YH PMID: 18472194 vaccine-induced T cell interferon-gramm production boosted by IL-15 vaccine adjuvant a vaccine that contains one vaccine for priming and at least one other vaccine for boosting. YH, RR prime-boost vaccine a vaccine that contains one DNA vaccine for priming and at least one other vaccine for boosting. YH, RR prime-boost vaccine with DNA vaccine priming PMID: 12848591 a prophylactic vaccine developed by VaxGen company to against HIV-1 consisting of two recombinant gp120 surface protein from different HIV-1 strains. AIDSVAX http://en.wikipedia.org/wiki/AIDSVAX YH complex of porin and S-LPS from B. abortus strain 2308 porin-S-LPS from B. abortus strain 2308 PMID: 2844673 YH B. abortus RB51WboA Brucella abortus RB51WboA PMID: 15327798 link to another well-known study: VAX004 linkto the clinical trail database by : ClinicalTrials.gov Identifier: NCT00002441 The AIDSVAX that is bicovalent vaccine including two kinds of gp120 protein: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (MN and GNE8 are strain names). Resource: ClinicalTrials.gov AIDSVAX B/B AIDSVAX B/E YH recombinant O. anthropi 49237SOD PMID: 11953393 YH organ or tissue specific immune response to vaccine YH licensed horse vaccine Pandemrix is an influenza vaccine for influenza pandemics, such as the H1N1 2009 flu pandemic colloquially called the swine flu. The vaccine was developed by GlaxoSmithKline and patented in September 2006. Pandemrix H1N1 http://en.wikipedia.org/wiki/Pandemrix TODO: the component 'egg protein' and 'sodium deoxycholate' is not added yet. YL ATC code J07BB02 As well as the active antigen derived from A/California/7/2009 (H1N1), the vaccine contains an immunologic adjuvant AS03 which consists of DL-α-tocopherol (vitamin E), squalene and polysorbate 80. Thiomersal (thimerosal) is added as a preservative. Being manufactured in chicken eggs, it contains trace amounts of egg proteins. Additional important non-medicinal ingredients are formaldehyde, sodium deoxycholate, and sucrose. (http://en.wikipedia.org/wiki/Pandemrix) Pandemrix YH B. melitensis Bp26 and trigger factor B. melitensis Bp26 and Tf protein vaccine PMID: 17239499 A Brucella subunit vaccine that uses recombinant Brucella melitensis 16M P39, a putative periplasmic binding protein. PMID: 11447155. YH B. melitensis P39 recombinant protein vaccine PMID: 11447155 YH rBLSOmp31 recombinant chimera BLSOmp31 PMID: 17442465 Panvax is an H1N1 unadjuvanted monovalent vaccine. MC, YH WEB: http://www.infowars.com/h1n1-panvax-training-powerpoint-received-by-health-care-workers-in-australia/ Panvax YL,YH Page 73, Chapter 6, Vaccine, 5th Edition. EXPERT CONSULT by Plotkin SA., et. al. 2008 a role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity. vaccine additive role route of administration that is located in the vein YH, Thom Todd i.v. intravenous route A vaccine that protects against some protozoan disease. YH parasite vaccine parasitic vaccine protozoan vaccine MeSH: D016052 YH Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine injection 0.5mL vial WEB: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine injection 0.5mL vial Trade Name: Menactra Menactra injection 0.5mL vial SNOMEDCT: 416532007; UMLS_CUI:C1563043 a Varicella-zoster virus vaccine that is live attenuated. YH Varicella-zoster virus live vaccine SNOMEDCT: 412530002; ULMS_CUI: C0770687 a vaccine component that originates from an organism such as a pathogen or a modified organism. YH pathogen organism component in vaccine YH B. abortus pcDNA-BLS Brucella abortus pcDNA-BLS A cancer vaccine that is used against melanoma, a malignant tumor of melanocytes. Oliver He WEB: http://en.wikipedia.org/wiki/Melanoma SNOMEDCT:373869007 UMLS_CUI:C0796561 melanoma vaccine YH escheriosome-encapsulated B. abortus L7/L12 escheriosome-mediated delivery of B. abortus L7/L12 PMID: 17931756 a pneumococcal vaccine that is formed using polyvalent polysaccharides YH WEB: http://www.who.int/vaccines/en/pneumococcus.shtml The most common form of the polyvalent pneumococcal vaccine is called the protein-polysaccharide combinations which is known as conjugate vaccines and contain 7–11 selected polysaccharides bound to a protein carrier. The protein-polysaccharide combinations are able to induce a T-cell dependent immune response. These vaccines are likely to be protective even in children under two years of age, and may reduce pneumococcal transmission through a herd effect. polyvalent pneumococcal vaccine Yongqun He WEB: http://www.ncbi.nlm.nih.gov/pubmed/10700309 a Staphyloccoccus vaccine that is made using engineered toxoid. Staphylococcus toxoid vaccine period of persistence of vaccine induced immune response is a temporal interval during which a vaccine-induced immune response continuously exists. This term is related to the process 'persistence of vaccine induced immune response'. YH, MC period of persistence of vaccine induced immune response A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers. YH phase 1 vaccine trial A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose. YH phase 2 vaccine trial A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000. YH phase 3 vaccine trial The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed. YH phase 4 vaccine trial Seven F. tularensis proteins including IglC (rLm/iglC) were expressed in recombinant L. monocytogenes (rLm) vaccines. These 7 F. tularensis proteins are: AcpA, Bfr, DnaK, GroEL, IglC, Pld and KatG from SchuS4 strain. YH rLm/iglC A subunit nontypeable H. influenzae vaccine that uses Hap protein. YH nontypeable H. influenzae Hap Protein Vaccine PMID: 15557618 a Smallpox virus vaccine that uses vaccinia virus YH WEB: http://en.wikipedia.org/wiki/Vaccinia Vaccinia virus is well known for its role as a vaccine that helped eradicate the smallpox disease, making it the first human disease to be successfully eradicated by science. vaccinia virus vaccine Mixed Bacterial Vaccine (MBV, Coley's Toxins) is a historical, vaguely defined preparation of heat-inactivated Streptococcus pyogenes and Serratia marcescens used as non-specific immunotherapy in the treatment of cancer. Oliver He PubMed:22847809 Mixed Bacterial Vaccine a vaccine component that is composed of a plasmid and used in the generation of a DNA vaccine. YH DNA vaccine plasmid vector YH pCIBLSOmp31 B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 a bacterial vaccine against Moraxella bovis infection. Moraxella bovis is a Gram-negative, aerobic, oxidase-positive diplococcus that is implicated in infectious bovine keratoconjunctivitis, an eye disease of cattle, also colloquially known as Pink Eye. YH WEB: http://en.wikipedia.org/wiki/Moraxella_bovis Moraxella bovis vaccine YH a Moraxella bovis vaccine that is prepared using a bacterial bacterin. Moraxella bovis bacterin vaccine UMLS_CUI: C0310839; SNOMEDCT: 39730006 a USA licensed vaccine role that indicates the vaccine is for veterinary uses. YH USDA licensed veterinary vaccine role WEB: http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-15-2009/0005094621&EDATE @2009/10/06 WEB: http://www.examiner.com/x-7707-Infectious-Disease-Examiner~y2009m9d15-News-Release-H1N1-vaccines-get-FDA-approval-expected-to-be-available-in-4-weeks @2009/10/06. H1N1 vaccines get FDA approval. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. Obtaining FDA licensure of this vaccine for A (H1N1) pandemic response is a key milestone that will enable Sanofi Pasteur to provide a licensed vaccine to the U.S. government to support pandemic immunization efforts vaccine approval process is a processual entity that involves approval of a vaccine. YH, ZX, AR, and MC vaccine product approval process WEB: http://energycommerce.house.gov/images/stories/Documents/PDF/publications/109_health.pdf @2009/10/06. This is the US Health Law which includes a section about vaccine. WEB: http://www.hhs.gov/nvpo/factsheets/fs_tableII_doc2.htm @2009/10/06 #Following the FDA's review of a license application, the sponsor and the FDA may present their findings to the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC). This non-FDA expert committee (scientists, physicians, biostatisticians, and a consumer representative) provides advice to the Agency regarding the safety and efficacy of the vaccine for the proposed indication. vaccine approval process vaccine candidate role is the role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a host organism. BP, YH This role should be a subclass of 'test substance role', which will be mireoted from OBI by OntoFox. vaccine candidate role CFU measurement assay is an assay that measures the colony forming unit (CFU) of a bacterium in a specific location (e.g., spleen of a mouse). YH, MC CFU measurement assay vaccine effectiveness rate is a measurement datum that measues the vaccine effectiveness. It is assessed with respect to prevention of the disease against which the vaccine is given. One simple method to estimate vaccine effectiveness is to use routine data on notifications of disease cases in vaccinated and unvaccinatted children and to compare the porportion of cases vaccinated with the vaccine covervage among the same age group in the general population. If p is the proportion vaccinated in the population and c is the proportion of cases reported to be vaccinated, then VE = (p-c)/p(1-c) x 100%. YH, MC Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71. WEB: http://en.wikipedia.org/wiki/Influenza_vaccine vaccine effectiveness rate YH, ZX vaccine licensing is a vaccine approval process that involves in licensing a vaccine. vaccine licensing YH, XZ licensed chicken vaccine a viral vaccine vector that uses an poxvirus as the vector. YH poxvirus vaccine vector NCBI Taxonomy ID: 10240 a Salmonella vaccine against infection with S. paratyphi, which causes paratyphoid fevers. Paratyphoid fevers are a group of enteric illnesses caused by serotypic strains of the Salmonella genus of bacteria, S. Paratyphi. paratyphoid vaccine WED: http://en.wikipedia.org/wiki/Paratyphoid_fever Salmonella paratyphi vaccine YH WEB: http://www.jefferspet.com/%252332moraxella-bovis-bacterin-piliguard-pinkeye-1-trivalent/camid/liv/cp/16435/ Moraxella Bovis Bacterin Piliguard Pinkeye-1 Trivalent YH Brucella vaccine using nonpathogenic alphaproteobacteria NPAP Brucella vaccine PMID: 17715332 A viral vaccine that protects against infection with Parainfluenza 3 virus. YH Parainfluenza 3 virus vaccine UMLS_CUI: C0310756; SNOMEDCT: 82867008 preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder. YH prophylactic vaccine function preventive vaccine function YH prime boost regimen Colibacillosis, caused by avian pathogenic Escherichia coli (APEC), is a major problem for the poultry industry in the world. YH PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16863080 WEB: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=134 APEC vaccine using GST-Iss fusion protein a vaccine that is used for prevention against a disease. YH prophylactic vaccine Protection efficacy is an efficiency that is associated with protection by a biological product (e.g., vaccine) against a disease. YH protection efficacy Protective antigen is an antigen that stimulates protective immunity when used in vivo. YH protective antigen role YH E. coli heat-labile enterotoxin B-subunit (LB-T) vaccine E. coli LB-T vaccine PMID: 11500434 YH E. coli O157:H7 subunit vaccine expressing Esps and Tir PMID: 14670317 an influenza virus vaccine against equine influenza viral infection YH equine influenza vaccine UMLS_CUI: C0310723; SNOMEDCT: 51393000 YH avian influenza vaccine an influenza vaccine for avian use a bacterial vaccine against infection with Coxiella burnetii which causes Q fever YH Q fever vaccine WEB: http://en.wikipedia.org/wiki/Q_fever Coxiella burnetii vaccine YH protein of pathogen organism as vaccine component a S. aureus vaccine that uses bacterin as the protective antigen. Yongqun He Staphylococcus aureus bacterin vaccine UMLS_CUI: C0310856; SNOMEDCT: 52974007 YH soybean-expressed E. coli LTB vaccine PMID: 17188785 a S. aureus vaccine that uses the bacterial phage lysate as the protective antigen. Yongqun He Staphylococcus aureus phage lysate vaccine UMLS_CUI: C0311044; SNOMEDCT: 34679007 a Mycoplasma gallisepticum vaccine that uses bacterin as the protective antigen YH Mycoplasma gallisepticum bacterin vaccine UMLS_CUI: C0310841; SNOMEDCT: 38267006 a bacterial vaccine that uses bacterin from a bacterial strain isolated from a herd with a purpose to generate hard-specific vaccine. YH WEB: http://addisonlabs.com/products/autogenous-bacterins.php autogenous bacterin vaccine an autogenous bacterin vaccine that is prepared for poultry use. WEB: http://www.hygieialabs.com/autopoultry.html autogenous poulty bacterin vaccine YH nontypeable H. influenzae vaccine Nontypeable Haemophilus influenzae (NTHi) is a nonencapsulated Haemophilus influenzae (a gram-negative bacterium). It is the cause of a number of human respiratory tract diseases, such as otitis media, sinusitis, bronchitis, and pneumonia. YH NTHi nontypeable Haemophilus influenzae YH rLP4/rLP6/UspA2 non-typeable H. influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine PMID: 15308371 YH killed nontypeable H. influenzae whole-cell vaccine PMID: 1859055 PMID: 1953532 PMID: 2184330 PMID: 2867396 a Rabies virus vaccine against Rabies in animal YH animal Rabies vaccine UMLS_CUI: C0310767; SNOMEDCT: 10495001 a Rabies virus vaccine against Rabies in human YH human Rabies vaccine UMLS_CUI: C0305066; SNOMEDCT: 3526007 YH E. coli vaccine using intimin polypeptide PMID: 14688094 PMID: 17258324 YH nontypeable H. influenzae cell membrane vaccine (CM-Hi) PMID: 10353870 YH Nontypeable H. influenzae lipooligosaccharide-tetanus toxoid conjugate vaccine nontypeable H. influenzae LOS-TT conjugate vaccine PMID: 12706701 PMID: 9353024 YH E. coli subunit vaccine using IroN PMID: 17145948 A vaccine preparation process that uses recombinant molecular technology to prepare recombinant protein. YH preparation of recombinant protein vaccine A subunit vaccine that is made using a part of whole organism as subunit for vaccine development. YH protein subunit vaccine A vaccine that uses a modified virus or bacterium to deliver genes that code for microbial antigens to cells of the body. YH recombinant vector vaccine YH E. coli subunit vaccine using CO393 PMID: 17145948 YH a chicken egg protein allergen where the protein allergen is ovalbumin, the main protein found in egg write, making up 60-65% of the total protein. WEB: http://en.wikipedia.org/wiki/Ovalbumin chicken ovalbumin egg protein allergen YH a S. typhi vaccine that is live and orally administerred typhoid live oral vaccine UMLS_CUI: C0359940; SNOMEDCT: 346696005 YH E. coli subunit vaccine using FyuA PMID: 14688094 PMID: 17258324 a licensed vaccine role that is bears in a licensed human vaccine. YH licensed human vaccine role immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. YH, XZ, BP WEB: http://en.wikipedia.org/wiki/Immunization immunization Active immunization is an immunization process that entails the introduction of a foreign molecule into the body, which causes the body itself to generate adaptive immunity against the target. YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization Active immunization entails the introduction of a foreign molecule into the body, which causes the body itself to generate immunity against the target. This immunity comes from the T cells and the B cells with their antibodies. Active immunization can occur naturally when a person comes in contact with, for example, a microbe. If the person has not yet come into contact with the microbe and has no pre-made antibodies for defense (like in passive immunization), the person becomes immunized. The immune system will eventually create antibodies and other defenses against the microbe. The next time, the immune response against this microbe can be very efficient; this is the case in many of the childhood infections that a person only contracts once, but then is immune. Artificial active immunization is where the microbe, or parts of it, are injected into the person before they are able to take it in naturally. If whole microbes are used, they are pre-treated, Attenuated vaccine. (Wikipedia) active immunization Passive immunization is an immunization process where pre-synthesized elements of the immune system are transferred to an organism so that the body does not need to produce these elements itself. Currently, antibodies can be used for passive immunization. This method of immunization works very quickly. However, it is short lasting. The antibodies are naturally broken down. If there are no B cells to produce more antibodies, they will disappear. YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization passive immunization natural active immunization is an active immunization that occur naturally when a person or animal comes in contact with antigens includeing microbes. YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization natural active immunization artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. YH, XZ artificial active immunization WEB: http://en.wikipedia.org/wiki/Immunization vaccine immunization induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine. YH, XZ induction of adaptive immune response to antigen disorder prevention is a processual entity that prevents a disorder that is the physical basis of a disease. YH, XZ disorder prevention disorder treatment is a processual entity that leads to treat a disorder that is the physical basis of a disease. YH, XZ disorder treatment modification of adaptive immune response to antigen is an active immunization process that results in modification of an adaptive immune response to some antigens, for example, in a therapeutic vaccine. YH, XZ modification of adaptive immune response to antigen YH, XZ preventive infectious disease vaccine function infection disorder prevention is a process that prevents a disorder that is the physical basis of an infectious disease. YH, XZ infection disorder prevention YH E. coli vaccine using verocytotoxin toxoid PMID: 17145948 YH Inactivated ETEC expressing expressing CFA/I and CFA/II PMID: 1612730 YH licensed sheep vaccine a vaccine role that indicates the vaccine being a combination vaccine. YH whole organism vaccine role YH EHEC O157 subunit vaccine using his-tagged N-terminal intimin PMID: 1612730 an organism that is used as part of a vaccine Yongqun He vaccine organism a Canada licensed vaccine role that indicates the vaccine is for veterinary uses. YH Canada licensed veterinary vaccine role a diphtheria vaccine that uses diphtheria toxoid YH Diphtheria toxoid vaccine YH nontypeable H. influenzae P5 peptide MVF/H3 vaccine PMID: 10603411 YH nontypeable H. influenzae rTbpB vaccine PMID: 10225866 ACAM2007 is a vaccine candidate expressing CFA/II. YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095642/ ETEC vaccine ACAM2007 a viral vaccine against a disease caused by a virus belong to Poxviridae. Pox vaccine a Pox vaccine for Quail pox YH Quail pox vaccine UMLS_CUI: C0310765; SNOMEDCT: 10772009 a Salmonella vaccine against both typhoid caused by S. typhi and paratyphoid caused by S. paratyphi. YH typhoid-paratyphoid vaccine NDF-RT: N0000011275; UMLS_CUI: C0041470; SNOMEDCT: 52628005 YH rough phenotype a protein from human YH human protein ACAM2017 was derived from ACAM2007. Genes aroC, ompC, and ompF were deleted, while CS1 and pStrep were added. PMID: 17566016 YH WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095642/ ETEC vaccine ACAM2017 This DNA vaccine contains the gene fragment encoding AAs 173-764 of PA. YH B. anthracis DNA vaccine encoding PA63 PMID: 9987172 YH human ACPP GenBank: AC020633; Protein RefSeq: NP_001090 YH B. anthracis DNA vaccine encoding PA83 and LF PMID: 15342913 YH DAAV using PA and PGA PMID: 12960361 YH smooth phenotype YH rPA with adjuvant Nanoemulsion PMID: 17502384 Xref: VIOLIN vaccine ID: 223. YH M. tuberculosis arabinomannan-protein conjugate PMID: 12922145 a route of administration that is loacted in the hypodermis (subcutaneous tissue) region. YL YH S.C. subcutaneous route YH subdominant epitope in vaccine vaccine subdominant epitope A vaccine that is composed of a purified protein(s) or other antigenic determinant(s) from a disease-causing organism. A subunit vaccine does not include pathogen nucleic acids. The subunits have less risk of causing adverse reactions. YH subunit vaccine Xref: VIOLIN vaccineID: 176. YH recombinant S. typhimurium secreting M. tuberculosis ESAT-6 PMID: 11427279 YH Ag85B and ESAT-6 fusion protein PMID: YL, YH equine EEV, VEV and WEV encephalomyelitis-influenza vaccine-tetanus toxoid time of survival of live vaccine inside host is a temporal interval during which a live vaccine survives inside a host organism. This entity is related to the process survival of live vaccine inside host. YH, MC time of survival of live vaccine inside host YL, YH 'equine EEV, VEE & WEV encephalomyelitis-tetanus toxoid' YL equine EEV, VEV and WEV encephalomyelitis-rhinopneumonitis-influenza vaccine-tetanus toxoid YH attenuated M. bovis strain WAg539 PMID: 15784584 a vaccinee that is a human being human vaccinee a population of human beings who are vaccinated. human vaccinee population a population group that are vaccinated with a specific vaccine YH vaccinee group vaccinee population human vaccinee population at age 2-17 years old YH bacterial phenotype A vaccine that is used for treatment for a disease. YH therapeutic vaccine a licensed vaccine role that is bears in a licensed human vaccine. YH licensed veterinary vaccine role YH attenuated M. bovis strain WAg520 PMID: 10225931 human vaccinee at age 2-17 years old A titer (or titre) is a measure of concentration. Titer testing employs serial dilution to obtain approximate quantitative information from an analytical procedure that inherently only evaluates as positive or negative. The titer corresponds to the highest dilution factor that still yields a positive reading; for example, positive readings in the first 8 serial twofold dilutions translate into a titer of 1:256. YH WEB:http://en.wikipedia.org/wiki/Titer titer a vaccine that is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms. NF, YH WEB: http://coastalcarolinaresearch.com/?p=679 multivalent vaccine YH attenuated M. bovis strain WAg522 PMID: 10225931 YH recombinant nontypeable H. influenzae protein P6 with AdDP PMID: 15031801 A synthetic vaccine adjuvant, adamantylamide dipeptide (AdDP) is the desmuramyl analog of MDP. Oliver He Samantha G. Sayers AdDP PMID:8375945 adamantylamide dipeptide vaccine adjuvant A toxin (from Ancient Greek: τοξικόν toxikon) is a poisonous substance produced within living cells or organisms; man-made substances created by artificial processes are thus excluded. YH The term was first used by organic chemist Ludwig Brieger (1849–1919).[3] For a toxic substance not produced within living organisms, "toxicant" and "toxics" are also sometimes used.[citation needed]. Toxins can be small molecules, peptides, or proteins that are capable of causing disease on contact with or absorption by body tissues interacting with biological macromolecules such as enzymes or cellular receptors. Toxins vary greatly in their severity, ranging from usually minor and acute (as in a bee sting) to almost immediately deadly (as in botulinum toxin).-- from Wikipedia. toxin A vaccine containing a toxoid, used to protect against toxins produced by certain bacteria. A toxoid (also called inactivated toxin) is a processed toxin that has been treated by chemical means, heat, or irradiation and is no longer capable of causing disease. YH toxoid vaccine The therapeutic vaccine function is a function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which ameliorates a specific disorder. YH therapeutic vaccine function a combination vaccine that is used against both bacterial and viral infections. YH bacterial and viral combination vaccine YH M. tuberculosis secA2 mutant PMID: 17671656 YH rBCG-Ag85A[Tokyo] PMID: 17720625 a bacterial vaccine against Vibrio infection YH https://en.wikipedia.org/wiki/Vibrio Vibrio vaccine YH DNA vaccine Rv1806-1807 PMID: 16520093 A vaccine that protects against Campylobacter bacterial infectioni. YH, ZX Campylobacter vaccine YH vaccine-induced up-regulated gene expression a viral vaccine vector that uses an AAV virus as the vector. Yongqun He, Shunzhou Deng Adeno-associated virus vector PMID: 24702846; PMID: 24568220; PMID: 24660751; PMID: 24849042; PMID: 24742767; PMID: 24827459 AAV vaccine vector NCBI Taxonomy ID: 272636 vaccination protocol is the protocol of a vaccination procedure. YH vaccination schedule vaccination protocol A vaccine that protects against Chlamydia bacterial infection. YH, ZX Chlamydia vaccine a path that is located in gross anatomical part of an organism (e.g., human) and is used for administering a vaccine, a drug, fluid, poison, or other substance into the body. CDISC has a codelist: Rout of Administration. Desription from CDISC: The course by which a substance was administered in order to reach the site of action in the body. CDISC_SDTM_Route_of_Administration_Terminology YH,YL http://en.wikipedia.org/wiki/Route_of_administration route of administration http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38114 http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66729 vaccine candidate is a processed material that is designed to prevent or ameliorate a disorder in a target organism by modulating adaptive immune responses in that organism by administrating the vaccine. During our call, we decided not to say vaccine candidate is an output of vaccine preparation, which may be reserved for vaccine alone. -- Aug 4, 2009. YH, AR, BP, LC, MC, and ZX vaccine candidate vaccine preservative that has thimerosal as part. YH thimerosal vaccine preservative Peptide vaccine is a subunit vaccine that uses small peptide(s) as immunoepitopes. YH peptide vaccine H1N1 Influenza vaccine is an Influenza virus vaccine that is used to vaccinate against H1N1 Influenza subtype vaccine. YH H1N1 Influenza vaccine bacterial vaccine that is used to protect against Haemophilus somnus infection generated using OntoRat YL Haemophilus somnus vaccine A vaccine component that is chemical substance added to vaccine and enhance and direct immune response to protective antigen. Many of vaccine adjuvants cause a range of serious side-effects. Oliver He vaccine adjuvant YH H. influenzae gene A vaccine regulatory process that is for vaccine producer to apply for vaccine license. YH vaccine license application Encodes for protein P4 YH nontypeable H. influenzae gene hel (encoding P4) An assay that is used to detect the immune response of a host to vaccination of a vaccine. YH immune response detection assay immunization objective is the specification of an objective to achieve immunization. YH, XZ WEB: http://en.wikipedia.org/wiki/Immunization immunization objective a multivalent vaccine that is designed to immunize against at least one bacterial disease and one viral disease. NF, YH multivalent vaccine against bacterial and viral diseases a bacterial vaccine against infection of Bordetella bacterial infection YH https://en.wikipedia.org/wiki/Bordetella Bordetella vaccine YH M. tuberculosis phoP mutant SO2 PMID: 16564606 PMID: 17084814 A bacterial vaccine that is used to protect against Aeromonas bacterial infection YH Aeromonas vaccine vaccine preparation is a manufacturing process to produce a vaccine. YH, BP vaccine generation vaccine production vaccine preparation An assay that is used to detect if a vaccine protects a host against infection of virulent pathogen after vaccine immunization. YH vaccine challenge experiment vaccine protection assay A bacterial vaccine that protects against Mycobacterium bacterial infection. YH, RR https://en.wikipedia.org/wiki/Mycobacterium Mycobacterium vaccine YH vaccine specific T cell cytokine production YH vaccine specific T cell mediated cytotoxicity vaccine dose is a dose of vaccine specified by the vaccine manufacturer, distributor, or a regulatory agent. YH, MC vaccine dose A processual entity by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation. Most vaccines against a pathogen (e.g., HIV) are not tested by vaccinating people and then deliberately exposing them to virulent pathogen (e.g., HIV). This strategy is never for a vaccine against a disease as serious as HIV. The best way to determine if a vaccine is effective is to test it in a randomized, controlled, double-blind clinical trial. This type of trial is often referred to as the gold standard in medical research and provides the strongest evidence for the efficacy of a vaccine. YH vaccine clinical trial obsolete class true A vaccine that uses whole organism as its component YH WEB: http://onlinelibrary.wiley.com/doi/10.1038/npg.els.0000491/full whole organism vaccine a vaccine component that uses a microbe (e.g., bacterium, virus, and parasitic organism) as a vector that is inserted with the DNA(s) of a heterologous protective antigen(s) to generate a "recombinant vector vaccine". The microorganism used as a vector generally has a stable non or low pathogenic phenotype for the species the vaccine is intended for. YH recombinant vector WEB: http://en.wikipedia.org/wiki/Vaccine WEB: http://www.biosafety.be/GT/Regulatory/Veterinary_vaccines/EMEA_000404en.pdf WEB: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003856.pdf recombinant vaccine vector an orthopoxvirus vaccine vector that uses vaccinia virus as the vector YH vaccinia virus vector NCBI Taxonomy ID: 10245 A bacterial vaccine that protects against Yersinia bacterial infection. YH, ZX Yersinia vaccine A bacterial vaccine that is used to protect against Edwardsiella bacterial infection generated using OntoRat YL Edwardsiella vaccine YH BCG mutant secreting listeriolysin a bacterial vaccine against Mycoplasma bacterial infection YH Mycoplasma vaccine a Canada licensed vaccine role that indicates the vaccine is used for human YH Canada licensed human vaccine role YH delta ureC hly+ rBCG PMID: 16110326 A vaccine that targets against a viral disease. YH viral vaccine MeSH: D014765 a vaccine vector that uses a virus as the vector. YH viral vaccine vector NCBI Taxonomy ID: 10239 bacterial vaccine that is used to protect against Haemophilus parasuis infection generated using OntoRat YL Haemophilus parasuis vaccine a virulence of vaccine that shows a virulent pheontype of the organism as the major component of a vaccine. The virulent phenotype means that an vaccine organism is virulent and is able to cause a pathogenic phenotype in a host organism. YH vaccine organism virulent ‘M’ (intended to refer to a male biological sex), ‘Male’, ‘Man’, ‘1’ (intended to refer to a male biological sex) A biological sex datum that represents the biological sex of an animal (including human) as being male. Paul Fabry, Oliver He male biological sex datum YH Nontypeable H. influenzae protein P6 with cholera toxin PMID: 15297063 YH a role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection. vaccine role Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research. YH animal model of vaccine research YH a role that inheres in a material entity that becomes an ingredient of a vaccine. vaccine component role YH vaccine antigen role E. coli live attenuated vaccine bacterial vaccine that is used to protect against Pasteurella multocida infection generated using OntoRat YL Pasteurella multocida vaccine Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research in the laboratory. YH laboratory animal model of vaccine research a vaccine antigen role that inheres in a vaccine antigen which is capable of inducing protective immunity. YH vaccine protective antigen role a vaccine role that indicates the vaccine being a DNA vaccine. YH DNA vaccine role a vaccine role that indicates the vaccine being a subunit vaccine. YH subunit vaccine role a vaccine role that indicates the vaccine being a conjugate vaccine. YH conjugate vaccine role Survival assessment is an assay that measures the occurence of death events in one or more organisms that are monitored over time. Need to point out more specifically that survival / death is measured. YH survival assessment A vaccine used to prevent infection by Haemophilus influenzae type b (Hib) bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease. YH Hib polysaccharide vaccine https://www.mayoclinic.org/drugs-supplements/haemophilus-b-polysaccharide-vaccine-intramuscular-route-injection-route/description/drg-20064142 H. influenzae Type b capsular polysaccharide vaccine PMID: 335348 PMID: 6387614 An E. coli vaccine that uses subunit antigen type. E. coli subunit vaccine YH B. anthracis recombinant vaccine using PA domain 4 PMID: 11854261 PMID: 15935874 licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market. YH licensed vaccine role vaccine in clinical trial role is a regulation-assigned role that inheres in a vaccine that is currently in clinical trial. In medical research, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices. YH vaccine in clinical trial role Vaccine induced immue response mediated hrough a body fluid YL vaccine-induced humoral immune response A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the p39 gene deletion. YH B. melitensis Rev. 1 P39 deletion mutant PMID: 9784574 B. melitensis Rev. 1 with P39 deletion YL intravenous vaccination a licensed vaccine with license for human use. YH licensed human vaccine a vaccine role that indicates the vaccine being a recombinant vector vaccine. YH recombinant vector vaccine role bacterial vaccine that is used to protect against Flavobacterium columnare infection generated using OntoRat YL Flavobacterium columnare vaccine A bacterial vaccine that protects against infection with Clostridium spp. YH https://en.wikipedia.org/wiki/Clostridium Clostridium vaccine a Clostridium vaccine that protects against infection with Clostridium tetani that causes tenanus. Oliver He, Kallan Roan Tetanus toxoid vaccine tetanus vaccine https://vaccine-safety-training.org/tetanus-vaccine-example.html Clostridium tetani vaccine 2 Combination vaccine is a vaccine that induces protection against multiple infectious diseases or several different serotypes of the same organism. The anitgens contained in combination vaccines are either formulated together by the manufacturer or physically mixed by a health care provider just prior to administration. Both approaches require licensure. Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1624. YH combo vaccine combination vaccine MeSH: D017778 A viral vaccine that protects against infection with influenza virus. YH Influenza vaccine There is no single 'influenza virus' in NCBI_Taxon. We usually use: ('unidentified influenza virus' or 'Influenzavirus A' or 'Influenzavirus B' or 'Influenzavirus C') However, even this may not be comprehensive. Influenza virus vaccine MeSH: D007252; UMLS_CUI: C0021403; SNOMEDCT: 46233009 a vaccine with license that is used for cattle. YH licensed cattle vaccine A viral vaccine that protects against infection with Hepatitis B virus. YH https://en.wikipedia.org/wiki/Hepatitis_B_vaccine Hepatitis B virus vaccine MeSH: D017325 YH licensed fish vaccine A viral vaccine that protects against infection with Hepatitis A virus. YH Hepatitis A virus vaccine MeSH: D022362 YH licensed goat vaccine A bacteria vaccine that prevents against Yersinia pestis infection that causes plague. YH Plague vaccine Yersinia pestis vaccine MeSH: D010931; SNOMEDCT: 11866009; UMLS_CUI:C0032066 YH licensed dog vaccine A viral vaccine that protects against infection with Rabies virus. YH Rabies virus vaccine MeSH: D011819; SNOMEDCT: 333606008; UMLS_CUI:C0034496 A viral vaccine that protects against infection with Smallpox virus. YH Smallpox virus vaccine MeSH: D012900 YH licensed cat vaccine YH licensed ferret vaccine A viral vaccine that protects against infection with Measles virus. YH Measles vaccine Measles virus vaccine MeSH: D008458 YH licensed deer vaccine A viral vaccine that protects against infection with Mumps virus. YH Mumps virus vaccine MeSH: D009108 YH licensed bird vaccine A viral vaccine that protects against infection with Rotavirus. YH Rotavirus vaccine MeSH: D022243; UMLS_CUI: C0597418; SNOMEDCT: 116077000 In most cases HibTITER was administered concomitantly with other vaccines including DTP, DTaP, hepatitis B vaccine, IPV, OPV, pneumococcal 7-valent conjugate vaccine, MMR, and/or meningococcal group C conjugate vaccine (not licensed in the US). YH HIBTITER PMID: PMID: 2057256 PMID: 9353019 Ref: http://www.rxlist.com/prohibit-drug.htm YH ProHIBiT PMID: 2057256 A bacterial vaccine that protects against infection with Haemophilus. YH https://en.wikipedia.org/wiki/Haemophilus Haemophilus vaccine MeSH: D018073 A vaccine that protects against Haemophilus influenzae type b infection. Oliver He, Hector Guzman-Orozco Haemophilus b vaccine Haemophilus influenzae serotype b vaccine A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin). PMID: 10377124. YH SC602 PMID: 10377124 A viral vaccine that protects against infection with Poliovirus. YH Poliovirus vaccine MeSH: D023321 A viral vaccine that protects against infection with Japanese encephalitis virus. YH Japanese encephalitis vaccine Japanese encephalitis virus vaccine MeSH: D022321 CVD 1208 is derived from wild type Shigella flexneri 2a strain 2457T and has defined deletions in four genes: (1) the guaBA chromosomal operon that encodes two enzymes (inositol 5'-monophosphate dehydrogenase and guanosine 5'synthase) essential for de novo purine biosynthesis; (2) set, a locus in a chromosomal pathogenicity island that encodes Shigella enterotoxin (ShET); (3) Pic, an autotransporter mucinase encoded on the opposite strand from set; and (4) sen, an invasiveness plasmid gene encoding ShET. PMID: 15499528 YH CVD 1208 a vaccine against human papillomavirus infection YH human papillomavirus vaccine UMLS_CUI: C1512511; SNOMEDCT: 424519000 CVD 1208S is the same thing as CVD 1208, but CVD 1208S was prepared using animal-free media. PMID: 17938573. YH CVD 1208S PMID: 17938573 a Herpesvirus vaccine that is used against Varicella-zoster virus infection. Oliver He, Kallan Roan Varicella vaccine chickenpox and shingles virus vaccine Varicella-zoster virus vaccine UMLS_CUI: C0078048; SNOMEDCT: 108729007 This vaccine is an aro-D mutant derivative of EcSf2a-1. PMID: 1587589. YH EcSf2a-2 PMID: 1587589 a Salmonella vaccine against typhoid fever (or called typoid), caused by Salmonella enterica enterica, serovar Typhi. YH typhoid vaccine Salmonella typhi vaccine YH heat-killed virulent Shigella flexneri 2a PMID: 10102148 YH Shigella Sfl 124 vaccine PMID: 1937767 YH Recombinant SFL124-27 expressing S. dysenteriae type 1 O antigen PMID: 9169740 a Streptococcal vaccine that is used against S. pneumoniae infection, which causes pneumococcal diseases. YH pneumococcal vaccine WEB: http://www.who.int/vaccines/en/pneumococcus.shtml Streptococcus pneumoniae vaccine YH S. dysenteriae 1 strain WRSd1 PMID: 12010984 A live attenuated Shigella flexneri 2a vaccine with specific deletion mutations in virG, sen, set, and guaBA. YH S. flexneri 2a strain CVD 1207 PMID: 10678904 A stable attenuated Shigella sonnei strain with virG mutation. PMID: 9712824. YH S. sonnei strain WRSS1 PMID: 11895966 PMID: 9712824 YH Shigella sonnei vaccine YH Shigella flexneri vaccine YH Shigella dysenteriae vaccine YH S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes PMID: 8500877 A processual entity that regulates vaccine-related processes, such as vaccine trial, vaccine license application. YH vaccine regulation A processual entity of transporting vaccine from one place to another place. YH vaccine transportation a recombinant vector vaccine role that inheres in a bacterium that carries a vaccine antigen for development of a particular vaccine YH recombinant bacterial vector vaccine role a recombinant vector vaccine role that inheres in a virus that carries a vaccine antigen for development of a particular vaccine YH recombinant viral vector vaccine role a vaccine residual that is from antibiotics used during the manufacture process. YL, YH antibiotics vaccine residual YH vaccine specific antibody test A vaccine regulation process for vaccine clinical trials. YH vaccine trial regulation A vaccination process that occurs at the first time to a host organization in a specified period. YH prime vaccination primary vaccination A vaccination process that occurs after the primer vaccination with a purpose to boost host immune response to vaccine antigen. YH boost vaccination YH Brucella melitensis vaccine YH Brucella melitensis Rev 1 Brucella melitensis Rev. 1 B. melitensis strain Rev. 1 PMID: 13416171 a viral vaccine that is inactivated killed viral vaccine inactivated viral vaccine YH vaccine allergen disposition a licensed human vaccine that is licensed in Canada YH Canada licensed human vaccine A vaccine preparation that results in the generation of a DNA vaccine YH preparation of DNA vaccine A vaccine preparation that results in the generation of a conjugate vaccine YH preparation of conjugate vaccine A vaccine preparation that results in the generation of a subunit vaccine YH subunit vaccine preparation A vaccine preparation that results in the generation of a live attenuated vaccine YH live attenuated vaccine preparation A vaccine preparation that results in the generation of a RNA vaccine YH preparation of RNA vaccine YH B. abortus strain RB51SOD Brucella abortus strain RB51SOD PMID: 10816475 a Brucella vaccine against infection wtih B. suis YH Brucella suis vaccine An orally administrable brucellosis vaccine that was was developed in China. It is effective for oral vaccination of sheep, goats, cattle and pigsPMID: 3541425. YH Brucella suis S2 Brucella suis strain 2 YH B. abortus strain 45/20 Brucella abortus strain 45/20 PMID: 8236802 YH cytomegalovirus vaccine A viral vaccine that protects against infection with Dengue virus. YH Dengue vaccine Dengue virus vaccine MeSH: D053059 A viral vaccine that protects against infection with Ebola virus. YH Ebola vaccine Ebola virus vaccine MeSH: D046129 A viral vaccine that protects against infection with Herpesvirus. YH Herpesvirus vaccine MeSH: D022283 a vaccine role that indicates the vaccine being a RNA vaccine. YH RNA vaccine role YH Herpes simplex virus vaccine YH Marek disease vaccine A Measles-Mumps vaccine that also protects against infection with Rubella virus. YH MMR MMR is usually live attenuated. Measles-Mumps-Rubella vaccine A Corynebacterium diphtheriae vaccine that also protect against infection with Clostridium tetani. YH Diphtheria-Tetanus vaccine YH CVD 1204(pGA1-CS2) PMID: 11292735 YH CVD 1204(pGA1-CS3) PMID: 11292735 A bacterial vaccine that protects against infection with Corynebacterium diphtheriae that causes Diphtheria. YH diphtheria vaccine Corynebacterium diphtheriae vaccine A Measles virus vaccine that also protects against infection with Mumps virus. YH Measles-Mumps vaccine A Measles-Mumps-Rubella vaccine that also protects against Varicella. Oliver He, Kallan Roan https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmrv.html Measles-Mumps-Rubella-Varicella vaccine YH DTP vaccine DTaP vaccine Diphtheria-Tetanus-Pertussis vaccine UMLS_CUI: C0012559; SNOMEDCT: 421245007 YH Shigella ribosome-based Vaccine (SRB) PMID: 17507120 A malaria vaccine that comprises recombinant Plasmodium falciparum (P. falciparum) blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720. PMID: 14604568. YH P. falciparum vaccine Combination B PMID: 14604568 YH Haemophilus influenzae serotype b A vaccine that protects against diphtheria, tetanus, pertussis, and poliovirus. Kallan Roan, Oliver He DTaP/IPV vaccine diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine. https://www.nhsinform.scot/healthy-living/immunisation/vaccines/the-4-in-1-vaccine Diphtheria-Tetanus-Pertussis-Poliovirus vaccine A vaccine used to prevent infections of diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B, and poliovirus. Kallan Roan, Oliver He DTaP/IPV/HepB vaccine https://www.hendricks.org/HealthLibrary/default.aspx?sid=1&pTitle=%2CDrug&ContentTypeID=26&ContentID=2783&alpha=D&AdditionalTitle=Diphtheria+Toxoid%2C+Tetanus+Toxoid%2C+Acellular+Pertussis+Vaccine%2C+DTaP%3B+Hepatitis+B+Vaccine%2C+Recombinant%3B+Inactivated+Poliovirus+Vaccine%2C+IPV Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b. Kallan Roan, Oliver He DTaP/IPV/Hib vaccine https://www.healthlinkbc.ca/healthlinkbc-files/dtap-ipv-hib-vaccine Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine YH Hepatitis A&B vaccine a viral vaccine against Hepatitis B virus and at the same time against bacterial H. influenzae serotype b. YH Haemophilus b and Hepatitis B vaccine A vaccine that contains DNA and modified vaccinia virus Ankara (MVA) encoding thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP). This vaccine is used with a prime-boost regime by DNA priming and MVA boosting. PMID: 16988273. YH DNA and MVA encoding ME-TRAP PMID: 16988273 A viral vaccine that protects against infection with Papillomavirus. YH Papillomavirus vaccine MeSH: D053918 A viral vaccine that protects against infection with Parainfluenza virus. YH parainfluenza vaccine Parainfluenza virus vaccine MeSH: D022241 A viral vaccine that protects against infection with Pseudorabies virus. YH pseudorabies vaccine Pseudorabies virus vaccine MeSH: D022421 A viral vaccine that prevents against infection with Simian immunodeficiency virus. YH SAIDS vaccine Simian immunodeficiency virus vaccine MeSH: D018449 A viral vaccine that protects against West Nile virus infection. YH West Nile virus vaccine MeSH: D053060 A viral vaccine that prevents infection with Respiratory syncytial virus. YH Respiratory syncytial virus vaccine MeSH: D022261 A vaccine that is used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. It can be a subunit or a gene-deleted vaccine. YH marker vaccine MeSH: D022581 A vaccine that is edible and derived from an edible plant. The transgenic plant is used as recombinant protein production system. The edible plant tissue functions as an oral vaccine. YH edible vaccine MeSH: D022462 acellular vaccine is a subunit vaccine that is produced by using only the antigenic part of the disease causing organism. It often requires a "booster" every few years to maintain their effectiveness. MeSH term: D20.215.894.860.900. YH acellular vaccine A particulate antigen delivery system that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449. Oliver He ISCOM The immunostimulating complex ISCOM vaccine adjuvant YH Plasmodium vivax vaccine A vaccine that is used to prevent conception. YH antifertility vaccine contraceptive vaccine MeSH: D022642 A vaccine that prevents or treats Alzheimer disease. YH Alzheimer vaccine MeSH: D023582 Plasmodium vaccine is a vaccine that prevents against Plasmodium species causing malaria. It is made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents. YH Plasmodium vaccine malarial Vaccine malaria vaccine MeSH: D017780 a protozoan vaccine that prevents against infection with Leishmania. YH Leishmaniasis vaccine Leishmania vaccine MeSH: D054332 A bacterial vaccine that prevents infection with Vibrio cholera. YH cholera vaccine Vibrio cholerae vaccine MeSH: D022121 A vaccine that prevents Lyme disease caused by Borrelia burgdorferi. YH Borrelia burgdorferi vaccine Lyme disease vaccine MeSH: D022123 A bacterial vaccine that prevents against Bordetella pertussis infection that causes pertussis or whooping cough. YH Pertussis vaccine Bordetella pertussis vaccine MeSH: D010567 A bacterial vaccine that protects against infection with Pseudomonas. YH Pseudomonas vaccine MeSH: D054406 A bacterial vaccine that protects against diseases caused by various species of Rickettsia. Typhus is any of several similar diseases caused by Rickettsia bacteria. So Rickettsial vaccine is also called typhus vaccine. YH typhus vaccine WEB: http://en.wikipedia.org/wiki/Typhus_vaccine WEB: http://www.violinet.org/vaxquery/query_detail.php?c_pathogen_id=108 Rickettsial vaccine MeSH: D012290 A bacterial vaccine that protects against infections by various Salmonella species. YH https://en.wikipedia.org/wiki/Salmonella Salmonella vaccine MeSH: D022562 A bacterial vaccine that protects against infections with Shigella species. YH Shigella vaccine MeSH: D022281 A bacterial vaccine that protects against infection with Staphylococcus. YH Staph vaccine Staphylococcus vaccine Staphylococcal vaccine MeSH: D013209 BCG Vaccine is a Mycobacterium tuberculosis vaccine that is a live attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin; BCG). YH Bacillus Calmette Guerin BCG vaccine CVX: 19 A bacterial vaccine that prevents streptococcal infections. YH Streptococcus vaccine https://en.wikipedia.org/wiki/Streptococcus Streptococcal vaccine MeSH: D022541 YH MSP3-LSP with aluminium hydroxide PMID: 17280744 RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. PMID: 15488216. YH https://www.ncbi.nlm.nih.gov/pubmed/?term=15488216 P. falciparum RTS,S/AS02A YH P. falciparum MSP1 from transgenic mice with Freund's adjuvant PMID: 11752405 YH P. vivax PVS25 with Montanide ISA-720 PMID: 16291764 A recombinant E. coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant. PMID: 17442466. YH 'P. falciparum FMP1/AS02A PMID: 17442466 YH P. falciparum ABRA protein vaccine PMID: 11489167 PMID: 9400530 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus NP protein. YH NP-VRP An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus GP protein. YH GP-VRP An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP24 protein. YH alphavirus replicon expressing VP24 VRP expressing VP24 PMID: 11485406 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP30 protein. YH alphavirus replicon expressing VP30 VRP expressing VP30 PMID: 11485406 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP35 protein. YH alphavirus replicon expressing VP35 VRP expressing VP35 PMID: 11485406 An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP40 protein. YH alphavirus replicon expressing VP40 VRP expressing VP40 PMID: 11485406 A DNA vaccine that encodes for a secreted form of Ebola virus GP protein. YH DNA vaccine expressing sGP PMID: 9427604 A vaccine combination that includes a DNA vaccine and a recombinant adenovirus Ad5 expressing the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5 vaccine is used for boosting. PMID: 11797011. YH DNA and adenoviral vector Ad5 expressing SIV gag protein PMID: 11797011 A gene that is a pathogen gene used for vaccine preparation or a host gene encoding for an immune factor important in induction of protective immunity. a vaccine-associated gene that exists in a pathogen and has been engineered for vaccine develoment. This gene can encode for protective antigen that is overexpressed for vaccine development. This gene can also be a virulence factor that is mutated to attenuate a virulent pathogen with the purpose of making attenuated vaccine. The term 'gene' has appears in several ontologies, such as Sequence Ontology (SO) and Protein Ontology (PRO). We may choose to use a 'gene' term from other ontologies. The 'gene' term in SO has ID: SO:0000704. YH obsolete gene true A recombinant adenovirus (Ad5) expressing the codon-optimized SIV gag gene. PMID: 11797011. YH adenoviral vector Ad5 expressing SIV gag protein PMID: 11797011 A vaccine combination that includes a DNA vaccine and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) that express the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5/35 vaccine is used for boosting. PMID: 16079886. YH DNA and Ad5/35 vector expressing HIV gp160 protein PMID: 16079886 YH Brucella gene YH human gene YH mouse gene A Brucella gene that is from B. abortus. YH Brucella abortus gene A Brucella abortus gene that has the name wboA and comes from strain 2308. Brucella abortus gene wboA is interrupted in Brucella abortus cattle vaccine RB51. YH wboA from B. abortus strain 2308 Interferon-gamma (IFN-g) is an indicative of Th1 immune response. It is produced in host immunized by vaccines such as Brucella abortus cattle vaccine RB51. YH mouse Ifng Interferon-gamma (IFN-g) is an indicative of Th1 immune response. YH human ifng YH cattle gene Interferon-gamma (IFN-g) is an indicative of Th1 immune response. It is produced in host immunized by vaccines such as Brucella abortus cattle vaccine RB51. YH cattle Ifng a storage process that is specifically for vaccine. YH vaccine storage a vaccine storage that is execuated at room temperature. Room temperature is also referred to as ambient temperature. Room temperature denotes a certain temperature within enclosed space at which humans are accustomed. Room temperature is usually indicated by general human comfort, with the common range of 10 degree C (50 degree F) to 28 degree C (82.4 degree F). YH vaccine storage at room temperature vaccine storage that is executed in refrigerator, usually 0-10^C. YH vaccine storage in refrigerator vaccine storage that is executed in freezer under 0^C. YH vaccine storage in freezer Effectiveness is physical quality that represents the capability of a single physical entity (e.g., vaccine) producing an effect (e.g, protection against a disease). YH effectiveness YH effective YH ineffective a vaccine role that indicates the vaccine being a toxoid vaccine. YH toxoid vaccine role A vaccination process that is implemented fast. YH vaccine rapid implementation rapid vaccination A measure datum that measures the coverage of vaccination in a specific area during a specific time period. YH, MC immunization coverage WEB: http://www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCode=SP_CORP&codeRubrique=19 WEB: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/ vaccination coverage A DNA vaccine plasmid vector that has the plasmid label pSCAR . CMV promotor is used. Rebecca Racz, Yongqun He pSCAR DNA vaccine plasmid PMID: 18022294; PMID: 19712769. YH vaccine epitope a licensed vaccine role that indicates the vaccine occurs in USA. YH USA licensed vaccine role a cattle vaccine with license that is used in USA. YH USA licensed cattle vaccine vaccination dose is a dose of vaccine that is used in a vaccination. Vaccination dose may be and may be not the same as the vaccine dose. YH vaccination dose YH monthly YH biweekly A HIV vaccine that is composed of a DNA vaccine expressing conserved, multiple HIV epitopes. PMID: 16359234. YH DNA vaccine expressing multiple HIV epitopes PMID: 16359234 A HIV vaccine that is made of recombinant HIV gp120 protein adjuvanted with the adjuvant NanoEmulsion. PMID: 18260780. YH recombinant HIV gp120 with adjuvant NanoEmulsion PMID: 18260780 An Aeromonas bacterial vaccine that is used to protect against Aeromonas salmonicida infection YH Aeromonas salmonicida vaccine Gag-VRPs is a cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). PMID: 12120997. YH Gag-VRPs PMID: 10462249 PMID: 12120997 a bacterial vaccine against V. anguillarum infection YH Vibrio anguillarum vaccine A recombinant modified vaccinia Ankara (MVA) expressing HIV Gag, Pol, and Env proteins. PMID: 16472543. YH MVA expressing HIV Gag, Pol and Env proteins PMID: 16472543 A SIV vaccine that is composed of a DNA vaccine and a poxvirus vector expressing the same SIV antigens. PMID: 15258286. YH DNA and poxvirus priming-boosting SIV vaccine PMID: 15258286 A B. abortus vaccine that is recombinant B. abortus strain 19 vaccine with the p39 gene deletion. YH B. abortus S19 P39 deletion mutant PMID: 9784574 Brucella abortus S19 with P39 deletion A Yersinia pestis vaccine that uses a recombinant Ad5-based vector (E1a, partial E1b, and partial E3 deletion) to express Y. pestis V antigen. YH AdsecV PMID: 17041851 A Yersinia pestis vaccine that is a pigmentation negative mutant of Y. pestis derived from a fully virulent strain. YH Yersinia EV-76 Yersinia EV76 PMID: 4988692 PMID: 8578841 A Yersinia pestis subunit vaccine that uses Y. pestis F1 protein as antigen. YH Y. pestis F1 protein vaccine PMID: 312163 PMID: 8675324 A Y. pestis subunit vaccine that uses recombinant F1 and V antigens. PMID: 312163. YH rF1 + rV vaccine PMID: 10930691 PMID: 12922126 PMID: 15908389 A Y. pestis subunit vaccine that uses recombinant Y. pestis V antigen. PMID: 7622205. YH Recombinant Y. pestis V antigen vaccine PMID: 7622205 YH modified Y. pestis with TLR4-stimulating LPS PMID: 16980981 A Yersinia pestis subunit vaccine that contains staphylococcal protein A-V antigen fusion peptide (PAV). PMID: 7622225. YH Yersinia PAV PMID: 7622225 YH recombinant Y. pestis YopD protein vaccine PMID: 10024607 PMID: 8890210 In vitro-cultured merozoites, chemically inactivated YH Epm vaccine A Y. pestis subunit vaccine that uses Y. pestis YscF protein as antigen. PMID: 15978133. YH Y. pestis YscF subunit vaccine PMID: 15978133 YH microencapsulated Caf1 and LcrV vaccine PMID: 16546306 Live temperature-sensitive mutant strain for subcutaneous or intramuscular injection YH Ovilis Enzovax Fowlpox virus-vectored H5 YH Trovac AI H5 A Y. pestis vaccine that uses the recombinant V10 (rV10), a variant (lacking residues 271 to 300) of Yersinia pestis LcrV. PMID: 16861680. YH recombinant Yersinia rV10 vaccine PMID: 16861680 Killed oral vaccine YH AquaVac ERM YH Feline leukemia virus vaccine Live temperature-sensitive mutant strain; spray inhalation or drinking water YH Art Vax YH VSV vector expressing Y. pestis lcrV PMID: 16959385 A formalin-inactivated preparation that was manufactured by Cutter Biologicals (a division of Miles Laboratories, Inc.). It is now available only from Greer Laboratories, Inc. The killed or inactivated plague vaccine is prepared from Y. pestis organisms grown in artificial media and then inactivated in formaldehyde. URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/00044836.htm YH Plague vaccine USP PMID: 8578841 IMPROVAC is a vaccine that stimulates the pig’s own immune system to produce specific antibodies against GnRF. This temporarily inhibits testes function and thus stops the production and accumulation of boar taint-causing compounds. Peptide-protein conjugate and water-miscible adjuvant; control of boar taint YH WEB: http://www.improvac.co.nz/sites/improvac/en-nz/Pages/productoverview.aspx Improvac a vaccine component that is added to the immunogen by the vaccine manufacturer for a specific purpose. Additives include adjuvants, preservatives and stablizers, as well as materials that are added to affect pH and isotonicity. YH Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. vaccine additive vaccine preservative is an vaccine additive that is added to a vaccine formulation to prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during use. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. YH antimicrobial agent in vaccine vaccine preservative Killed vaccine against periodontitis YH Periovac a vaccine additive that helps to protect the vaccine from adverse conditions such as the freeze-drying process (for those vaccines that are freeze-dried) or heat. YH Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 75. vaccine stabilizer a vaccine component that remains from the vaccine manufacturing process. Although no all manufacturing residuals may be identified and quantified, their presence and quantity is assumed to be constant because of the constancy of the manufacturing process. YH Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73. vaccine residual a vaccine residual that is used to inactivate bacteria and viruses or to detoxify bacterial toxins. For example, formaldehyde is a frequently used inactivation agent in vaccine preparation. YH Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 78. inactivation residual in vaccine a vaccine residual that is generatead from cell culture for vaccine preparation. Examples include: antibiotics, sensitizing substances, bacterial and cellular residuals, and adventitious agents. YH Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 78-81. cell culture residual in vaccine Immune correlate of protection is a host immune response to vaccine that correlates with protective induced by the vaccine. YH vaccine-induced immune correlate of protection Serological correlate of protection is an immune correlate of protection that is reflected by serologic antibody levels. YH serologic correlate of protection A cell mediated immune correlate of protection is an immune correlate of protection that is reflected by a cell mediated immune response. YH cell mediated immune correlate of protection Vaccine effectiveness is an effectiveness associated with a vaccine. YH Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71. vaccine effectiveness Canada is a country that exists in north America. YH Canada In vitro-cultured supernatant antigens, reduce clinical disease YH Pirodog a licensed status that occurs in Canada. YH Canada licensed vaccine role a bacterial vaccine against Porphyromonas gulae infection YH Porphyromonas gulae vaccine YH Fluviral S/F Influvac is an Influenza virus vaccine that is manufactured by Solvay Pharma. YH Influvac Vaxigrip is an Influenza virus vaccine that is manufactured by 'Sanofi Pasteur Limited. YH, Melanie Vaxigrip YH Babesia bigemina vaccine by local veterinary institutes Canarypox virus-vectored vaccine YH Purevax Feline Rabies YH Babesia bovis vaccine by local veterinary institutes YH pGPA-incorporated microemulsion PGA/ME PMID: 16730934 Anthrax Spore Vaccine is a B. anthracis vaccine that is prepared with a relatively nonpathogenic, noncapsulated variant strain of B. anthracis, originally developed at the Onderstepoort Laboratory, Pretoria, South Africa. Further work was conducted in England, India and in many other countries. Vaccine Strain is Sterne 34F2. The vaccine is a suspension of viable Bacillus anthracis spores in saponin. YH B. anthracis Sterne strain spore vaccine Anthrax Spore Vaccine PMID: 3084385 YH pSecTag-PA83 PMID: 15293452 YH pCMV/ER-PA83 PMID: 15293452 Canarypox virus-vectored vaccine YH RECOMBITEKEquine WNV YH Porphyromonas denticanis pCLF4 is a Bacillus anthracis vaccine that contains the N-terminal region (amino acids [aa] 10-254) of Bacillus anthracis LF cloned into the pCI expression plasmid. YH pCLF4 PMID: 11401993 PMID: 15068841 Equity Oestrus Control Vaccine for Horses is prepared from an analogue of gonadotropin releasing factor (GnRF) linked to a carrier protein. It has an adjuvant that enhances the level and duration of the immune response to GnRF with minimal injection site reactivity. It is used as an aid in the control of oestrus and oestrus-related behaviour in fillies and mares not intended for breeding. Peptide-protein conjugate and proprietary adjuvant (immunostimulating complex); control of estrus and estrus-related behavior YH Equity Oestrus Control Vaccine for Horses WEB: https://www.pfizeranimalhealth.com.au/products/352/equityreg-oestrus-control-vaccine.aspx Equity single-dose Vaxigrip The difference between single-dose and multi-dose Vaxigrip is that multi-dose Vaxigrip contains preservative thimoseral. We still have not made it defined class since we still need to figure out how to represent multi-dose vs. single dose. The previous method discussed brief needs vetting. --YH YH, Melanie, and Allen multi-dose Vaxigrip A mineral salt vaccine adjuvant that is composed of some aluminum compound. Oliver He aluminum vaccine adjuvant a role inhers in a vaccine component that when added into a vccine formmulation, it can prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during administrating process or the manufacturing process. YH,YL P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al. The CFR requires that, with certain defined exceptions, preservatives must be added to mulitdose vials of vaccine. (P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.) vaccine preservative role YH a route of administration that located in the mouth oral route a route of administration that inject the material(such as vaccines, allergens) into the skin itself. YH,YL intradermal injection route I.D. intradermal route YH phenol vaccine preservative Recombinant ApxII, TbpB, CysL, OmlA(1), and OmlA(2) proteins YH PleuroStar APP YH phenoxy ethanol vaccine preservative Age at vaccination is the age of an experiment animal at the time of vaccination. YH age at vaccination Culture-derived schizonts YH Theileria annulata vaccine by local veterinary institutes dose is a measurement data that measures the quantity of something that may be eaten by or administered to an organism, or that an organism may be exposed to. Quantities of nutrients, drugs, vaccines and toxins are referred to as doses. YH, MC WEB: http://en.wikipedia.org/wiki/Dose_%28biochemistry%29 obsolete on 2/1/2020, using the OBI dose term (OBI_0000984) instead. obsolete dose true challenge dose is a dose of a virulent pathogen used for a vaccine challenge process. YH challenge dose Canarypox virus-vectored vaccine YH PROTEQ-FLU (European Union) Recombitek (United States) Secondary vaccination is a vaccination that is performed immediately after the primary or the first vaccination. YH, Thom Todd secondary vaccination YH Eimeria vaccine YH surface antigens from the zona pellucida YH Theileria annulata vaccine vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine. YH, ZX WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf vaccine allergen passive immunization that Immunity is transferred from mother to fetus through placental transfer of IgG or colostral transfer of IgA. http://pathmicro.med.sc.edu/ghaffar/immunization-ver2.htm YL passive immunization using natural maternal antibody Egg protein may come from NCIS thesaurus egg - poultry, combination of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicken egg protein allergen may become a cross product of sevreal ontology terms. YH, ZX, MC chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein. chicken egg protein allergen YH, ZX latex vaccine allergen YH, ZX gelatin vaccine allergen YH, ZX protamine sulfate vaccine allergen YH, ZX polymyxin B vaccine allergen Canarypox virus-vectored vaccine YH EURIFEL FeLV the vaccine component that is used as antigen to produce an immune responce protect against the specific pathogen or disease. This is a modified or partial form of the virus, bacteria or the toxin that causes the disease against which the vaccine protects. The vaccine antigen is altered from its original form so it no longer causes disease but it can produce an immune response.(Vaccine components FactSheet of NCIRS) YL, YH vaccine antigenic component To create this term for cover some other vaccines such as cancer vaccine and so on. vaccine antigen a cell culture residual in vaccine that is bovine albumin. YH, ZX bovine albumin cell culture residual in vaccine a cell culture residual in vaccine that is bovine serum. YH bovine serum cell culture residual in vaccine a vaccine stablizer that is based on monosodium glutamate. YL,YH C5H8NNaO4 http://www.novaccine.com/vaccine-ingredients/results.asp?sc=13 monosodium glutamate stabliizer Modified live virus YH RECOMBITEK Corona MLV glutaraldehyde vaccine additive Infected blood from splenectomized calves YH Babesia bovis vaccine a cell culture residual in vaccine that is human albumin. YH human albumin cell culture residual in vaccine a cell culture residual in vaccine that is human serum. YH human serum cell culture residual in vaccine Reference: http://www.raboral.com/ Vaccinia virus recombinant YH Raboral a vaccine stabilizer that is a polysorbate 20. It encourages the suspension of one liquid in another and has mild toxicity. YH, YL Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Reference: http://www.sciencelab.com/msds.php?msdsId=9926640 http://www.novaccine.com/vaccine-ingredients/results.asp?sc=95 polysorbate 20 vaccine stabilizer a vaccine emulsifier that uses polysorbate 80, also known as polyoxyethylene sorbitan monooleate or Tween™ 80. YH,YL Tween 80 vaccine emulsifier WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid. polysorbate 80 vaccine emulsifier a cell culture residual in vaccine that is residual protein from cell culture. YH vaccine residual protein from cell culture YH canine coronavirus vaccine YH E. coli CS3 in PLGA microspheres VIOLIN Vaccine ID: 3095 a vaccine stabilizer that is specifically made by sorbitol. YH, YL glucitol Sorbitol, also known as glucitol, is a sugar alcohol that the human body metabolizes slowly. It can be obtained by reduction of glucose, changing the aldehyde group to a hydroxyl group. Sorbitol is found in apples, pears, peaches, and prunes. It is synthesized by sorbitol-6-phosphate dehydrogenase, and converted to fructose by succinate dehydrogenase and sorbitol dehydrogenase. Succinate dehydrogenase is an enzyme complex that participates in the citric acid cycle. (wikipedia) sorbitol vaccine stabilizer YH Sarcocystis neurona vaccine A vaccine that is made of a TK-negative (TK -) and gI/gE-negative (gI/gE -) pseudorabies virus (PRV) mutant to protect pigs against Aujeszky's disease. Aujeszky's disease is also known as pseudorabies. It is a disease primarily of pigs and is caused by porcine herpesvirus 1. This disease is characterized by respiratory, reproductive and nervous signs. gE- and thymidine kinase-deleted marker vaccine YH Suvaxyn Aujeszky a cell culture residual in vaccine that is sucrose albumin. YH sucrose albumin cell culture residual in vaccine A synthetic vaccine adjuvant that is derived from Xanthomonas campestris, has a pentasaccharide repeating unit structure, and its terminus contains a mannose moiety which acts as a toll-like receptor 2 agonist. Asiyah Yu Lin PMID:19608270 http://www.sciencedirect.com/science/article/pii/S0142961209006371 xanthan gum vaccine ajuvant a cell culture residual in vaccine that is from yeast extract. YH yeast extract cell culture residual in vaccine a cell culture residual in vaccine that is yeast protein. YH yeast protein cell culture residual in vaccine DNA vaccine YH Apex-IHN DTP-Hib vaccine Diphtheria-Tetanus-Pertussis-Haemophilus b vaccine Diphtheria-Tetanus-Poliovirus vaccine V. cholerae and E. coli vaccine A Measles virus vaccine that is also used against Rubella virus infection. YH Measles-Rubella vaccine https://www.nhsinform.scot/healthy-living/immunisation/vaccines/the-6-in-1-vaccine A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, Hepatitis B, and Haemophilus influenzae type b. Kallan Roan, Oliver He DTaP/IPV/HepB/Hib vaccine Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine Live flavivirus chimera vaccine YH PreveNile a bacterial vaccine against S. equi infection YH Streptococcus equi vaccine a bacterial vaccine against Mycoplasma gallisepticum infection YH Mycoplasma gallisepticum vaccine Salmonella typhi-Hepatitis A vaccine Baculovirus recombinant E2 protein without emulsion YH Bayovac CSF E2 Tick-borne virus vaccine Dhori virus vaccine Pharyngeal mucosal route is an oral route of administration. TT, YH pharyngeal mucosal route Chimera virus on NDV backbone; field trials in 2007 YH Intervet Avian Influenza virus vaccine host survival to pathogen challenge after vaccination a B. abortus vaccine that uses a conjugate vaccine format YH Brucella abortus conjugate vaccine a B. abortus vaccine that uses a recombinant vector. YH Brucella abortus recombinant vector vaccine A vaccine that protects against Herpes simplex virus type 1 and 2. YH, ZX Herpes simplex virus type 1 and 2 Herpes simplex virus type 1 vaccine YH killed infectious bursal disease Virus vaccine YH live attenuated infectious bursal disease virus vaccine An E. coli vaccine that uses a live mutant by knocking out one gene(s) from a wild type E. coli. YH recombinant E. coli mutant vaccine an E. coli vaccine that uses toxoid antigen YH E. coli toxoid vaccine YH PubMed: http://www.ncbi.nlm.nih.gov/pubmed/9682399 potato expressed E. coli LB-T vaccine VIOLIN Vaccine ID: 276 An E. coli vaccine that uses a recombinant vaccine vector to express an E. coli antigen(s) recombinant vaccine vector E. coli vaccine YH PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23035176 rBCG -Stx2B A DNA vaccine plasmid vector that has the plasmid label pBLUESCRIPT. Rebecca Racz, Yongqun He Davidson College - pBLUESCRIPT: Plasmids and Phages Combine For pBluescript [http://www.bio.davidson.edu/Courses/Molbio/MolStudents/spring2003/Keogh/plasmids.html] Derived from pUC vectors; cross between phages and plasmids and therefore in a special category called "phagemids" (Davidson College - pBLUESCRIPT) The plasmid length is: 2961 pBLUESCRIPT DNA vaccine plasmid DNAVaxDB Plasmid ID: 180 A DNA vaccine plasmid vector that has the plasmid label nkCMVint. Rebecca Racz, Yongqun He A pUC-18-based plasmid; also contains intron A and an SV40 polyadenylation termination signal sequence. It has a CMV promoter. nkCMVint DNA vaccine plasmid DNAVaxDB Plasmid ID: 181 PMID: 9234529 YH E. coli Tir protein Vaccine VIOLIN Vaccine ID: 3087 YH luteinizing hormone-releasing hormone LHRH YH E. coli Shiga toxin 2B vaccine VIOLIN Vaccine ID: 282 inactivated E. coli vaccine An E. coli vaccine against uropathogenic E. coli infections YH UPEC vaccine uropathogenic E. coli vaccine An E. coli vaccine against extraintestinal pathogenic E. coli infections YH ExPEC vaccine extraintestinal pathogenic E. coli vaccine An E. coli vaccine against enterohemorrhagic E. coli infections YH EHEC vaccine enterohemorrhagic E. coli vaccine Kallan Roan, Yongqun He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm Flublok Influenza Vaccine Protein Sciences Corporation For active immunization against disease caused by influenza virus subtypes A and type B contained in the vaccine. Flublok is approved for use in persons 18 years of age and older. 125285 Flublok Live or inactivated gE-deleted marker vaccine YH Bovilis IBR Marker Kallan Roan, Yongqun He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328629.htm FLUCELVAX Influenza Vaccine Seqirus, Inc. For active immunization of persons 4 years of age and older for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM329134.pdf 125408 Flucelvax Baculovirus recombinant E2 protein without emulsion YH Porcilis Pesti YH FluMist Quadrivalent YH Fluarix Quadrivalent a tetanus vaccine manusfactured by Sanofi Pasteur Inc. that is only for booster use (not recommended for primary immunization) YH WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142732.pdf Tetanus Toxoid (for Boost use Only) by Sanofi Pasteur Inc a viral vaccine that is used to protect against fowl pox virus infection YH fowl pox vaccine YL avian influenza vaccine YH bovine rhinotracheitis vaccine Infection followed by drug treatment YH Theileria parva vaccine by local veterinary institutes YL bovine parainfluenza 3 vaccine A DNA vaccine plasmid vector that has the plasmid label pDONR221. The plasmid length is 4762. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2394/ Invitrogen: http://tools.invitrogen.com/content/sfs/manuals/gateway_pdonr_vectors.pdf pDONR221 Sequence: http://tools.invitrogen.com/content/sfs/vectors/pdonr221_seq.txt pDONR221 DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pCN3. The plasmid promoter is CMV. Rebecca Racz, Yongqun He pCN3 DNA vaccine plasmid PMID: 19596416; PMID: 21059395. A DNA vaccine plasmid vector that has the plasmid label V1R. Rebecca Racz, Yongqun He V1R DNA vaccine plasmid PMID: 11797011; PMID: 15258286 YH Toxoplasma gondii vaccine A DNA vaccine plasmid vector that has the plasmid label pVAC1 3.0. The manufacturer is Invitrogen. Rebecca Racz, Yongqun He pVAC1 3.0 DNA vaccine plasmid PMID: 20884037 SpayVac is a contraceptive vaccine that has proven highly effective in deer and can be used to control populations. Refernce: http://terramar.bc.ca/. Crude ZPA preparation; supplied to research groups only no longer available YH SpayVac A DNA vaccine plasmid vector that has the plasmid label pSin-CMV-Vac. The promoter is CMV. Rebecca Racz, Yongqun He pSin-CMV-Vac DNA vaccine plasmid PMID: 22702835; PMID: 23637502 A DNA vaccine plasmid vector that has the plasmid label pGACAG. The promoter is CAG and the antibiotics resistance gene is kanamycin. Rebecca Racz, Yongqun He pGACAG DNA vaccine plasmid PMID: 17203206 A DNA vaccine plasmid vector that has the plasmid label pVCL1012. The promoter is HCMV and the manufacturer is Vical Inc. Rebecca Racz, Yongqun He pVCL1012 DNA vaccine plasmid PMID: 15652666 A DNA vaccine plasmid vector that has the plasmid label pSCA1. Rebecca Racz, Yongqun He pSCA1 DNA vaccine plasmid PMID: 22819169 A DNA vaccine plasmid vector that has the plasmid label phCMV1. This plasmid is 4200 base pairs long, has a CMV promoter, contains kanamycin and neomycin antibiotics resistance genes, and is manufactured by Genlantis. Rebecca Racz, Yongqun He WEB: http://www.genlantis.com/faq-phcmv.html phCMV1 DNA vaccine plasmid PMID: 19540885 A DNA vaccine plasmid vector that has the plasmid label pCJ-3. This plasmid has a CMV promoter and a kanamycin resistance gene. Rebecca Racz, Yongqun He pCJ-3 DNA vaccine plasmid PMID: 16949850 A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/V5-His. This plasmid has a CMV promoter. Rebecca Racz, Yongqun He pcDNA3.1/V5-His DNA vaccine plasmid PMID: 22445688 A DNA vaccine plasmid vector that has the plasmid label pSecTag2 C. This plasmid is 5167 base pairs long, has a CMV promoter and ampicillin and zeocin resistance genes. Rebecca Racz, Yongqun He WEB: http://tools.invitrogen.com/content/sfs/manuals/psectag2_man.pdf pSecTag2 C DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pBC12/CMV/IL-2. Rebecca Racz, Yongqun He NIH AIDS Reagent Program - pBC12/CMV/IL-2: [https://www.aidsreagent.org/reagentdetail.cfm?t=expression_vectors&id=159] Derived from plasmid pBC12/CMV; expresses IL-2 (NIH AIDS Reagent Program - pBC12/CMV/IL-2). Its length is: 4732. pBC12/CMV/IL-2 DNA vaccine plasmid DNAVaxDB Plasmid ID: 182 Cultured trophozoites, reduces disease and cyst shedding YH Giardiavax The plant-based Newcastle disease virus vaccine is a Newcastle disease virus vaccine that is developed by Dow AgroSciences LLC. It uses technology discovered at Washington University. It is the first plant-made animal vaccine approved for sale in the United States. HN recombinant produced in plant cell lines (registered but not on market) YH plant-based Newcastle disease virus vaccine YH classical swine fever virus vaccine A Measles-Mumps-Rubella vaccine that is manufactured by Sanofi Aventis. YH Morupar a live attenuated quality of a bacterial vaccine strain. YH bacterial vaccine organism live attenuated a live attenuated quality of a virus vaccine strain. YH viral vaccine organism live attenuated Fowlpox virus vectored YH Vectormune FP-ND A vaccine that protects against Marek's; disease virus. YH, ZX Marek's; disease virus live attenuated Marek's disease virus vaccine A viral vaccine that protects aganist Newcastle disease virus infection. YH live attenuated Newcastle disease virus vaccine an avian reovirus vaccine that using live attenauted reovirus. YL live attenuated avian reovirus vaccine Sporulated oocysts of several or all of the avian species YH Advent Coccivac Immucox Nobilis Cox ATM Paracox a feline panleukopenia virus vaccine where the virus used is live attenuated. YH live attenuated feline panleukopenia virus vaccine Megan Vac1 is a Salmoneela vaccine that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is designed for protection of broilers to reduce Salmonella contamination. YH WEB: http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf Megan Vac1 a bacterial vaccine vector that uses TB vaccine BCG as the vector. YH BCG vaccine vector NCBI Taxonomy ID: 33892 an avian influenza vaccine that uses inactivated viral organism YH inactivated avian influenza vaccine a viral vaccine vector that uses a vesicular stomatitis virus (VSV) as the vector. YH vesicular stomatitis virus vaccine vector NCBI Taxonomy ID: 11276 Killed oral vaccine YH AquaVac Furuvac a parasite vaccine vector using a live attenuated Leishmania tarentolae strain. Yongqun He, Carly Mantin Leishmania tarentolae vaccine vector NCBI Taxonomy ID: 5689 PubMed:23969885 autologous dendritic cell melanoma vaccine vaccine-induced mouse immune response WEB: http://www.ncbi.nlm.nih.gov/pubmed/21907709 a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261. Yongqun He, Carly Mantin Salmonella typhimurium SL3261 vaccine vector WEB: http://www.ncbi.nlm.nih.gov/pubmed/21964456 a bacterial vaccine vector using a live attenuated Edwardsiella tarda strain EIB202 Yongqun He, Carly Mantin Edwardsiella tarda EIB202 vaccine vector NCBI Taxonomy ID: 498217 YH Babesia bigemina vaccine a vaccine vector that uses a parasite as the vector. Yongqun He, Carly Martin parasite vaccine vector a bacterial vaccine against Yersinia ruckeri infection YH Yersinia ruckeri vaccine WEB: http://www.ncbi.nlm.nih.gov/pubmed/23403993 a bacterial vaccine vector using a live attenuated Streptococcus gordonii vaccine vector. Yongqun He, Carly Mantin Streptococcus gordonii vaccine vector NCBI Taxonomy ID: 1302 WEB: http://www.ncbi.nlm.nih.gov/pubmed/16823926 a bacterial vaccine vector using a live attenuated Bordetella pertussis BPZE as a vaccine vector. Yongqun He, Carly Mantin Bordetella pertussis BPZE vaccine vector WEB: http://www.ncbi.nlm.nih.gov/pubmed/9767712 a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. Yongqun He, Carly Mantin Actinobacillus pleuropneumoniae HS93Tox vaccine vector an Avipox virus vaccine vector that uses a fowlpox virus as the vector Yongqun He, Shunzhou Deng fowlpox virus vaccine vector NCBI Taxonomy ID: 10261 pmid: 10729156 A Listeria monocytogenes vaccine vector that uses the highly attenuated LM1-2 strain YH PMID: 23027427 L. monocytogenes LM1-2 vaccine vector Yongqun He, Shunzhou Deng BHV-4 vaccine vector bovine herpesvirus 4 vaccine vector PMID: 23830977; PMID: 23300989; PMID: 21320537; PMID: 24752229 BoHV-4 vaccine vector NCBI Taxonomy ID: 10385 an Avipox virus vaccine vector that uses an attenuated canarypox virus strain Yongqun He, Shunzhou Deng Poulet et al. 2007, PubMed PMID: 17227690. WEB: http://en.wikipedia.org/wiki/Canarypox canarypox vaccine vector NCBI Taxonomy ID: 44088 a bacterial vaccine vector that uses an attenuated Vibrio cholerae strain Yongqun He, Shunzhou Deng PMID: 9529093 Vibrio cholerae vaccine vector NCBI Taxonomy ID: 666 a viral vaccine vector that uses an avian paramyxovirus strain Yongqun He, Shunzhou Deng avian paramyxovirus type 3 vaccine vector PMID: 21525340 APMV-3 vaccine vector NCBI Taxonomy ID: 207246 a herpesvirus vaccine vector that uses a herpes simplex virus strain Yongqun He, Shunzhou Deng HSV vaccine vector PMID: 22713696; PMID: 19428888; PMID: 20835362; PMID: 16996101 Herpes simplex virus vaccine vector an adenovirus vaccine vector that uses the simian adenovirus ChAd63 strain. Yongqun He, Shunzhou Deng PMID: 22275401; PMID: 23526949; PMID: 22363582 simian adenovirus ChAd63 vaccine vector NCBI Taxonomy ID: 413684 an orthopoxvirus vaccine vector that uses an attenuated Raccoon poxvirus strain Yongqun He, Shunzhou Deng PMID: 22921740 raccoon poxvirus vaccine vector NCBI Taxonomy ID: 10256 Live temperature-sensitive mutant strain; eye drop administration YH Vaxsafe MS A herpesevirus vaccine vector that uses an established live-virus vaccine against Aujeszky's disease of swine, pseudorabies virus (PrV) strain Bartha (PrV-Ba), to serve as vector. Yongqun He, Shunzhou Deng PrV vaccine vector Suid herpesvirus 1 strain Bartha vaccine vector PMID: 24431235 pseudorabies virus strain Bartha vaccine vector NCBI Taxonomy ID: 1006205 an adenovirus vaccine vector that uses a porcine adenovirus 3 strain Yongqun He, Shunzhou Deng PAV3 vaccine vector PMID: 11402666; PMID: 21179494; PMID: 10091994; PMID: 12954206; PMID: 17565687 porcine adenovirus 3 vaccine vector NCBI Taxonomy ID: 35265 a viral vaccine vector that uses a poliovirus strain Yongqun He, Shunzhou Deng PV vaccine vector PMID: 19003009; PMID: 12423772; PMID: 17196342 poliovirus vaccine vector NCBI Taxonomy ID: 138950 In vitro-cultured supernatant antigens, reduce clinical disease YH Nobivac Piro Live submucosal vaccine; deletions in aroA gene YH Equilis StrepE an adenovirus vaccine vector that uses a chimpanzee adenovirus strain Yongqun He, Shunzhou Deng chimpanzee adenovirus vaccine vector NCBI Taxonomy ID: 310542 a viral vaccine vector that uses a measles virus strain Yongqun He, Shunzhou Deng MV vaccine vector PMID: 24084235; PMID: 24606680; PMID: 23642239; PMID: 23550539; PMID: 23516477 measles virus vaccine vector NCBI Taxonomy ID: 11234 a viral vaccine vector that uses a Coxsackievirus strain Yongqun He, Shunzhou Deng PMID: 20824074; PMID: 11115722; PMID: 19053211; PMID: 20088713; PMID: 21389776; PMID: 19941986; PMID: 11160741 Coxsackievirus vaccine vector NCBI Taxonomy ID: 12066 a poxvirus vaccine vector that uses an attenuated Oka varicella virus strain Yongqun He, Shunzhou Deng Human herpesvirus 3 strain Oka vaccine vaccine PMID: 10720546; PMID: 16615495; PMID: 18053621 Oka varicella vaccine vector NCBI Taxonomy ID: 341980 a viral vaccine vector that uses a NewCastle virus strain Yongqun He, Shunzhou Deng NDV vaccine vector PMID: 23845804 Newcastle disease virus vaccine vector NCBI Taxonomy ID: 11176 YH Theileria parva vaccine a viral vaccine vector that uses a myxoma virus strain Yongqun He, Shunzhou Deng PMID: 10627521; PMID: 12951040; PMID: 14972520; PMID: 8719525; PMID: 12057600; PMID: 18474552; PMID: 21835800; PMID: 22244980 myxoma virus vaccine vector NCBI Taxonomy ID: 10273 a viral vaccine vector that uses a Maraba virus strain Yongqun He, Shunzhou Deng PMID: 24322333 Maraba virus vaccine vector NCBI Taxonomy ID: 1046251 a bacterial vaccine vector that uses an attenuated Mycobacterium smegmatis strain Yongqun He, Shunzhou Deng PMID: 22546648; PMID: 21900527 Mycobacterium smegmatis vaccine vector NCBI Taxonomy ID: 1772 YH Neospora caninum vaccine a bacterial vaccine vector that uses an attenuated Lactobacillus gasseri strain Yongqun He, Shunzhou Deng PMID: 21375708; PMID: 20722604; PMID: 21900526 Lactobacillus gasseri vaccine vector NCBI Taxonomy ID: 1596 Yongqun He, Shunzhou Deng HVT vaccine vector Meleagrid herpesvirus 1 vaccine vector PMID: 22845318 herpesvirus of turkey vaccine vector NCBI Taxonomy ID: 37108 A Herpes simplex virus vaccine vector that uses a virus type 1 strain Yongqun He, Shunzhou Deng HSV-1 vaccine vector PMID: 19428888 Herpes simplex virus vaccine 1 vector NCBI Taxonomy ID: 10298 a bacterial vaccine vector that uses an E. coli strain Yongqun He, Shunzhou Deng PMID: 24746937 E. coli vaccine vector NCBI Taxonomy ID: 562 Killed oral vaccine Reference: http://www.spaquaculture.com/default.aspx?pageid=553 YH AquaVac Vibrio a viral vaccine vector that uses a duck enteritis virus strain Yongqun He, Shunzhou Deng Anatid herpesvirus 1 vaccine vector PMID: 23267833 duck enteritis virus vector NCBI Taxonomy ID: 104388 a herpesvirus vaccine vector that uses a CMV virus strain Yongqun He, Shunzhou Deng Cytomegalovirus vaccine vector PMID: 23811402 CMV vaccine vector NCBI Taxonomy ID: 10358 YH Babesia canis vaccine a bacterial vaccine vector that uses a Salmonella typhi strain Yongqun He, Shunzhou Deng Salmonella typhi vaccine vector NCBI Taxonomy ID: 90370 a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is a natural host for the vector. Yongqun He WEB: http://www.biosafety.be/GT/Regulatory/Veterinary_vaccines/EMEA_000404en.pdf recombinant homologous vector vaccine a bacterial vaccine against Mycoplasma synoviae infection YH Mycoplasma synoviae vaccine a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is not one of the natural hosts for the vector. Yongqun He WEB: http://www.biosafety.be/GT/Regulatory/Veterinary_vaccines/EMEA_000404en.pdf recombinant heterologous vector vaccine YH Androstenedione an adenovirus vaccine vector that uses an Adenovirus serotype 5 strain. Yongqun He human adenovirus 5 vaccine vector adenovirus serotype 5 vaccine vector NCBI Taxonomy ID: 28285 an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions. Yongqun He PMID: 17989172 AcMNPV vector autographa californica multicapsid Nucleopolyhedrovirus vaccine vector NCBI Taxonomy ID: 46015 protozoan vaccine that is used to protect against Giardia intestinalis infection YH Giardia duodenalis vaccine a viral vaccine vector that uses a baculovirus as the vector YH PMID: 22705893 baculovirus vaccine vector NCBI Taxonomy ID: 10469 a Chlamydia bacterial vaccine against C. abortus infection YH Chlamydophila abortus vaccine an adenovirus vaccine vector that uses a complex adenovirus as the vector strain. Yongqun He CAdVax vaccine vector PMID: 19776190; PMID: 18480438; PMID: 17634508; PMID: 18216185; PMID: 16501083 complex adenovirus vaccine vector an adenovirus vaccine vector that uses a human adenovirus as the vector strain. Yongqun He HAd vaccine vector PMID: 16297508; PMID: 15761255 human adenovirus vaccine vector a viral vaccine vector that uses a murine leukemia virus as the vaccine vector YH WEB: http://en.wikipedia.org/wiki/Murine_leukemia_virus murine leukemia viral vector vaccine NCBI Taxonomy ID: 11786 YH, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm CDC recommendation of the use of Influenza A (h1N1) 2009 vaccine a population group that have priority for vaccination when a vaccine is first available. YH, XZ vaccination target group vaccinee priority group Chimera H5N3 virus, inactivated in oil-based adjuvant YH Poulvac FluFend I AI H5N3 RG YH USDA a vaccinia vaccine vector that uses the highly attenuated NYVAC as vector A highly attenuated vaccinia virus strain, NYVAC (vP866), was derived from a plaque-cloned isolate of the Copenhagen vaccine strain by the precise deletion of 18 open reading frames (ORFs) from the viral genome. Source: http://www.ncbi.nlm.nih.gov/pubmed/1566575 Yongqun He PMID: 22930439;; PMID: 24069354; PMID: 1566575 NYVAC vaccine vector NCBI Taxonomy ID: 10249 (for Vaccinia virus Copenhagen) XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm pregnant women passive immunization by injecting a recipient with pre-made antibody, antitoxin, epitope, etc. YL passive immunization by injecting pre-made immune element A vaccine used to increase the fecundity in breeding ewes. Ovastim increases the number of multiple ovulations and therefore the number of multiple births. Increased ovulation/twinning YH WEB: http://www.virbac.co.nz/p-virbacnzpuben/display.aspx?srv=p-virbacnz&typ=pub&lang=en&cmd=view&style=styles/specie.xsl&select=PRODUCT[@ID$eq$PRODUCT_264]&affp=& Ovastim Canarypox virus-vectored vaccine (HA and F antigens) YH RECOMBITEK rDistemper XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm persons living with or providing care for infants aged <6 months XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm health-care and emergency medical services personnel XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm persons aged 6 months--24 years XY, XZ WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm persons aged 25--64 years with medical conditions at higher risk for influenza-related complications a viral vaccine vector that uses a retroviral strain Yongqun He PMID: 2839718 retroviral vaccine vector NCBI Taxonomy ID: 11632 Vaxvec: 23 YH, MC, and XZ inactivation is a processual entity that produces inactive material. inactivation Yongqun He a retroviral vaccine vector where a Rous sarcoma virus (a retrovirus) is used Rous sarcoma virus vaccine vector NCBI Taxonomy ID: 11886 Vaxvec: 20 a bacterial vaccine against Lawsonia intracellularis infection YH Lawsonia intracellularis vaccine a poxvirus vaccine vector that uses a swinepox virus as the vector Yongqun He, Shunzhou Deng swinepox virus vaccine vector NCBI Taxonomy ID: 10276 PMID: 22515033; PMID: 21807055; PMID: 22884664; PMID: 23135159 a vaccinia virus vector that uses the Modified Vaccinia Ankara (MVA) virus. YH PMID: 24933081 Modified Vaccinia Ankara (MVA) virus vaccine vector NCBI Taxonomy ID: 467144 a poxvirus vaccine vector that uses an ORF virus which is a parapoxvirus. Shunzhou Deng, Yongqun He ORF virus vaccine vector NCBI Taxonomy ID: 10258 a vaccinia virus vector that uses the MVTT vaccine strain as the vector. MVTT is an attenuated vaccine strain. Shunzhou Deng, Yongqun He vaccinia virus TianTan vaccine vector MVTT vaccine vector NCBI Taxonomy ID: 10253 a fertility vaccine that enhance fertility in sheep. Linked to human serum albumin; increased ovulation/twinning withdrawn YH WEB: http://www.journals.elsevierhealth.com/periodicals/anirep/article/PII0378432093901125/abstract Fecundin A poxvirus vaccine vector that uses an attenuated lumpy skin disease virus as the vector. Yongqun He, Shunzhou Deng LSDV vaccine vector lumpy skin disease virus vaccine vector NCBI Taxonomy ID: 59509 a viral vaccine vector that uses a bovine parainfluenza virus strain as vector Yongqun He, Shunzhou Deng PMID: 22570186; PMID: 24478424. bovine parainfluenza virus vaccine vector NCBI Taxonomy ID: 11215 Gametocyte antigen(s); transmission blocking through maternal antibody transfer YH CoxAbic a Bordetella bacterial vaccine against infection of B. avium YH Bordetella avium vaccine a poxvirus vaccine vector that uses an attenuated capripoxvirus strain as the vaccine vector Yongqun He, Shunzhou Deng capripoxvirus vaccine vector NCBI Taxonomy ID: 10265 survival of live vaccine inside host is a processual entity that represents the survival of a live vaccine inside its host. The time of the survival is often important for the success of the live vaccine. YH survival of live vaccine inside host persistence of vaccine induced immune response is a processual entity that indicates the persistence of an immune reponse induced by a vaccine in a vaccinated host. YH persistence of vaccine induced immune response a bacterial vaccine vector that uses a Corynebacterium pseudotuberculosis strain as the vaccine vector Yongqun He, Shunzhou Deng Corynebacterium pseudotuberculosis vaccine vector NCBI Taxonomy ID: 1719 Killed tachyzoites, reduces abortion YH Bovilis Neoguard a viral vaccine vector that uses a rhabdovirus-based viral strain as the vaccine vector Yongqun He, Shunzhou Deng rhabdovirus-based vaccine vector NCBI Taxonomy ID: 11270 a recombinant vaccine vector that uses Saccharomyces cerevisiae as the vaccine vector Yongqun He, Shunzhou Deng Saccharomyces cerevisiae vaccine vector NCBI Taxonomy ID: 4932 Modified live virus YH RECOMBITEK Canine Parvo a viral vaccine vector that uses a Venezuelan equine encephalitis virus strain as the vaccine vector Yongqun He, Shunzhou Deng Venezuelan equine encephalitis virus vaccine vector VEE vaccine vector NCBI Taxonomy ID: 11036 YH Eimeria maxima vaccine Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm192126.htm Agriflu Influenza Virus Vaccine Novartis Vaccines and Diagnostics Inc. Active immunization of adults 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. BL 125297/32 Agriflu CVX: 140 live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella infection. YH live attenuated Brucella vaccine CVX: 135 a canarypox vaccine vector that uses an attenuated canarypox virus strain ALVAC. The ALVAC vector is a canarypox virus clone obtained after four rounds of plaque purification of a strain from a vaccine for canaries. Yongqun He, Shunzhou Deng ALVAC WEB: http://www.ncbi.nlm.nih.gov/pubmed/17227690 ALVAC vaccine vector an adenovirus vaccine vector that is not able to replicate. Yongqun He non-replicating adenovirus accine vector a bacterial vaccine against A. pleuropneumoniae infection YH Actinobacillus pleuropneumoniae vaccine an adenovirus vaccine vector that is able to replicate. Yongqun He replicating adenovirus accine vector assay of CFU reduction in liver is a CFU reduction assay that is measured using the extracted liver as the tissue for isolation of infected pathogens. YH assay of CFU reduction in liver assay of CFU reduction in lung is a CFU reduction assay that is measured using the extracted lung as the tissue for isolation of infected pathogens. YH assay of CFU reduction in lung live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella abortus infection. YH live attenuated Brucella abortus vaccine live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection. YH live attenuated Brucella melitensis vaccine live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection. YH live attenuated Brucella suis vaccine YH Eimeria tenella vaccine S48 strain with a lost ability to form cysts after passages in mice YH Ovilis Toxovax vaccine viability is a viability of a vaccine organism. YH, ZX vaccine organism viability DNA vaccine YH West Nile-Innovator DNA a recombinant vaccine vector that uses a fungus as the vaccine vector Yongqun He fungal vaccine vector NCBI Taxonomy ID: 4751 YH Leishmania donovani vaccine a poxvirus vaccine vector that uses an avipox virus as the vector Yongqun He Avipox virus vaccine vector NCBI Taxonomy ID: 10260 YH pCIBLSOmp31 Brucella DNA vaccine encoding chimera BLSOmp31 PMID: 17600596 YH, ZX vaccine being viable is a vaccine viability that indicates a vaccine uses live organism. vaccine organism live a poxvirus vaccine vector that uses an orthopox virus as the vector Yongqun He Orthopoxvirus vaccine vector NCBI Taxonomy ID: 10242 A cytokine vaccine adjuvant that contains IL-12. Allen Xiang Oliver He IL-12 vacince adjuvant YH, ZX no vaccine protection YH, ZX significant vaccine protection YH, ZX enhanced significant protection bacterial vaccine that is used to protect against Piscirickettsia salmonis infection generated using OntoRat YL Piscirickettsia salmonis vaccine An E. coli vaccine against enterotoxigenic E. coli infections YH ETEC vaccine enterotoxigenic E. coli vaccine Increased ovulation/twinning YH Androvax B. abortus L7/L12 is a B. abortus subunit vaccine using L7/L12 that is formed by recombinant Human Serum Albumin (HAS)-L7/L12 fusion protein. YH Brucella abortus Human serum albumin (HAS)-L7/L12 PMID: 19293473 B. abortus HSA-L7/L12 An E. coli vaccine against Shiga toxin-producing E. coli (STEC) infections YH STEC vaccine WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2238053/ Shiga toxin-producing E. coli vaccine a vaccine against avian pathogenic Escherichia coli (APEC) infection, a major problem for the poultry industry in the world. YH APEC vaccine avian pathogenic E. coli vaccine YH an E. coli vaccine against O157 E. coli strain infections E. coli O157 vaccine Extracted ApxI, ApxII, ApxIII, and outer membrane proteins YH Porcilis APP PUREVAX Ferret Distemper is a lyophilized ferret vaccine of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus. Reference: http://www.drugs.com/vet/purevax-ferret-distemper.html. Canarypox virus-vectored vaccine YH PUREVAX Ferret Distemper YH, ZX vaccination dose specification YH, ZX challenge dose specification specification of time interval after vaccination for challenge is a plan specification that specifies the time interval after vacciation for challenge YH, ZX specification of vaccination-challenge interval pathogen challenge protocol is a protocol that is used for a pathogen challenge process. YH, ZX pathogen challenge protocol reduction of colony-forming unit (CFU) is a titer measurement of viable bacterial or fungal numbers. It equals to a reduction of a CFU count from another CFU count. This term is often used as a measurement of a vaccine protection study. YH, ZX reduction of colony forming unit intraperitoneal pathogen challenge is a pathogen challenge process that occurs in the intraperitoneal site of a host. YH, ZX intraperitoneal pathogen challenge a vaccination process that occurs in the intraperitoneal route YH, ZX intraperitoneal vaccination YH KLH-s-FimH1-25 with CFA and then IFA VIOLIN Vaccine ID: 4329 an E. coli subunit vaccine that uses E. coli FimH adhesin protein as teh antigen, and uses the complete Freund's adjuvant (CFA) in the first vaccination and the incomplete Freund's adjuvant (IFA) in the boost vaccination. YH PubMed: http://www.ncbi.nlm.nih.gov/pubmed/9110982 E. coli FimH with CFA and then IFA VIOLIN Vaccine ID: 4330 E. coli DNA vaccine is a DNA vaccine that protects against an E. coli infection. YH E. coli DNA vaccine a vaccine organism that is a specific strain YH vaccine strain B. melitensis bp26 and omp31 deletion vaccine is a Brucella melitensis vaccine that has double deletions of bp26 and omp31. YH CGV2631 PMID: 17070627 B. melitensis Rev. 1 with bp26 and omp31 deletions YH pCIOmp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pCI plasmid. PMID: 16177328 pCIOmp31 YH pTargeTomp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pTargeT mammalian expression system vector (Promega, USA). PMID: 17014873 pTargeTomp31 B. abortus L7/L12 fused to MBP is a B. abortus subunit vaccine using L7/L12 that uses recombinant L7/L12 fused on maltose binding protein MBP. YH PMID: 8873388 B. abortus L7/L12 fused to MBP inactivated influenza vaccine is an inactivated viral vaccine that targets at influenza viral infections. YH inactivated influenza vaccine Precocious and egg-passaged lines YH Livacox live attenuated influenza vaccine is a live attenuated vaccine that protects against influenza viral infection. YH live attenuated influenza vaccine laboratory test Live temperature-sensitive mutant strain; eye drop administration YH Vaxsafe MG a vaccine role that is borne by an organism strain serving as a vaccine YH vaccine strain role Peptide conjugated to keyhole limpet hemocyanin in mycobacterium-oil adjuvant (AdjuVac); contraceptive vaccine to control wildlife registration reported to be in progress YH WEB: http://www.aphis.usda.gov/wildlife_damage/nwrc/research/reproductive_control/gonacon.shtml a contraceptive vaccine that is used in wildlife population GonaCon vaccine protection ANOVA In ovo delivery using proprietary platform injection system YH Inovocox A data set that represents a set of data for a list of variables (e.g., vaccination dose) for the data analysis of an vaccine investigation study. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccine investigation data set a vaccination that occurs in the intramuscular route. YH, YL intramuscular vaccination a measurement datum that represents a vaccine strain. Different strains can be represented using distinct digital numbers. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccine strain datum a measurement datum that represents vaccine viability. 0 = live; 1 = irradiated; 2 = killed. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccine viability datum a measurement datum that indicates the usage of a vaccine adjuvant. Different digital numbers can be used to represent different adjuvants. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccine adjuvant usage datum a measurement datum that represents a specific protective antigen used in a vaccine. The antigen can be represented by a described digit. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccine protective antigen datum a measurement datum that represents a specific mutated gene from a vaccine strain. The mutated can be represented by a described digit. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. mutated gene in vaccine strain datum a measurement datum that represents a specific mouse strain used for vaccination. Different strains can be represented using discretized digitals. For example, 0 = BALB/c; 1 = CD1; 2 = mixed/outbred; 3 = C57BL/6; 4 = OF1; 5 = 129/Sv; 6 = Swiss albino. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccination mouse strain datum A measurement datum that represents the biological sex of an animal. The result can be represented using a discretized digit, for example, 0 = female; 1 = male. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. biological sex datum a measurement datum that represents a specific route (e.g., i.p.) used for vaccination. Different routes can be represented using discretized digitals. 0 = IP; 1 = PO; 2 = SC; 3 = IM; 4 = IN; 6 = IG; 7 = IV; 8 = ID. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccination route datum a vaccination dose that is used with the unit of colony forming units (CFU). YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccination dose (unit: CFU) A measurement datum that represents the animal age (unit: day) at the time of vaccination. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. animal age at vaccination in days a measurement datum that represents a specific pathogen strain used for animal challenge study. Different pathogen strains can be represented using discretized digitals. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. pathogen strain for challenge datum a measurement datum that represents a specific pathogen used for animal challenge study. Different pathogens can be represented using discretized digitals. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. pathogen challenge datum Native fucose-mannose-ligand antigen complex YH Leishmune Live oral vaccine YH Enterisol Ileitis a challenge dose that is represented with the unit of colony forming units (CFU). YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. challenge dose (unit: CFU) a measurement datum that represents a length of days as the interval between a vaccination and a challenge in a specific vaccine protection study. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccination-challenge interval in days A colony forming unit (CFU) from the sample of mouse spleen. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. CFU per spleen a reduction of CFU that was measured with the unit of colony forming units (CFU) from the sample of mouse spleen. YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. CFU reduction per spleen a measurement datum that represents a type of vaccine protection efficacy as an outcome of a vaccine protection study. The result can be represented as a digit, for example, 0 = no protection, and 1 = protection (determined by a p-value cutoff). YH He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026. vaccine protection efficacy datum A Chlamydia bacterial vaccine against Chlamydia trachomatis infection YH, RS, NF Chlamydia trachomatis vaccine B. abortus BLS-L7/L12 is a B. abortus subunit vaccine using L7/L12 that is made as a recombinant BLS-L7/L12 fusion protein vaccine. YH recombinant Brucella BLS-L7/L12 fusion protein vaccine recombinant Brucella lumazine synthase and L7/L12 fusion protein vaccine PMID: 19596411 B. abortus BLS-L7/L12 vaccine protection efficacy measurement is an assay that measures the protection efficayc of a vaccine. YH vaccine protection efficacy measurement YH a subunit vaccien that uses LPS as protective antigen lipopolysaccharide subunit vaccine viral vaccine that is used to protect against African swine fever virus infection YH, RS, NF African swine fever virus vaccine A viral vaccine that protects against infection with Foot-and-mouth disease virus. YH, RS, NF Foot-and-mouth disease virus vaccine a bacterial vaccine that uses inactivated bacterial organism. YH inactivated bacterial vaccine an anti-reproductive vaccine for cattle. The vaccine is based on the established principle that antibodies to the hypothalamic releasing hormone, gonadotrophin releasing hormone (GnRH) block the action of GnRH on pituitary secretion of luteinizing hormone and follicle stimulating hormone, leading to gonadal atrophy in mammals. The vaccine comprises an immunogenic GnRH:ovalbumin conjugate formulated in a novel double adjuvant system and is administered in a two-dose treatment regimen. LHRH peptide conjugated to ovalbumin; oil emulsion adjuvant withdrawn in 1996 YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/1370000 Vaxstrate A viral vaccine that protects against infection with Lymphocytic choriomeningitis mammarenavirus YH, RS, NF Lymphocytic choriomeningitis mammarenavirus vaccine a bacterial vaccine that is live and attenuated YH live attenuated bacterial vaccine Veterinary vaccine is a vaccine that is used for animals (excluding humans), for example, pet, domestic, wildlife, and livestock animals. YH veterinary vaccine a viral vaccine that is live attenuated YH This term has an equivalent class: 'viral vaccine' and ('has quality at some time' some 'vaccine organism live attenuated') However, running the reasoner takes time. As a way to reducing the time, I have tentatively made tern two subclasses instead of equivalent class. If needed, the equivalent class can be used in SPARQL or converted back in VO. --Oliver live attenuated viral vaccine YH a B. abortus vaccine that uses subunit antigen Brucella abortus subunit vaccine A viral vaccine that protects aganist Newcastle disease virus infection. YH Newcastle disease virus vaccine YH Brucella melitensis subunit vaccine A viral vaccine that protects against infection with Viral hemorrhagic septicemia virus YH, RS, NF Viral hemorrhagic septicemia virus vaccine YH Brucella abortus DNA vaccine YH Brucella melitensis DNA vaccine A viral vaccine that protects against infection with Human herpesvirus 5. YH, RS, NF Human betaherpesvirus 5 vaccine A viral vaccine that protects against infection with Coxsackievirus YH, RS, NF Coxsackievirus vaccine A protozoan vaccine that protects against infection with Schistosoma japonicum YH, RS, NF Schistosoma japonicum vaccine a bacterial vaccine against Treponema pallidum infection YH, RS Treponema pallidum vaccine A vaccine that protects against Leishmania major. YH, RS Leishmania major vaccine YH, ZX protective antigen A vaccine preparation that results in the generation of a viral vaccine YH, ZX viral vaccine preparation A vaccine preparation that results in the generation of a protozoan vaccine YH, ZX protozoan vaccine preparation A vaccine preparation that results in the generation of a fungal vaccine YH, ZX fungal vaccine preparation A vaccine preparation that results in the generation of a cancer vaccine preparation of cancer vaccine A microbial derivative vaccine adjuvant compsed of CpG DNA. Oliver He PMID:12899580 CpG DNA vaccine adjuvant An emulsion vaccine adjuvant that is a stable oil-in-water emulsion. Samantha G. Sayers http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=M6661%7CSIGMA&N25=0&QS=ON&F=SPEC Ribi vaccine adjuvant A synthetic vaccine adjuvant named RC529 that is a lipid A mimetic. Samantha G. Sayers PMID:16204643 RC529 vaccine adjuvant An aluminum vaccine adjuvant that is aluminum potassium sulfate (AlK(SO4)2). Allen Xiang Samantha G. Sayers aluminum potassium sulfate adjuvant An aluminum hydroxide vaccine adjuvant that is a gel that is made by precipitation of aluminum hydroxide Al(OH)3 under alkaline conditions. Allen Xiang Samantha G. Sayers Alhydrogel PMID:7551218 Alhydrogel vaccine adjuvant A cholera toxin derived vaccine adjuvant made of the B subunit of the cholera toxin from Vibrio cholerae. Samantha G. Sayers CTB cholera toxin B cholera toxin B subunit vaccine adjuvant Allen Xiang, Oliver He, Kallan Roan https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm https://www.prevnar13.com/ Prevnar 13 Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Wyeth Pharmaceuticals, Inc - Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children 6 weeks through 5 years of age (prior to the 6th birthday). - Active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A In children 6 weeks through 5 years of age (prior to the 6th birthday). - Active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children 6 years through 17 years of age (prior to the 18th birthday). - Active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults 18 years of age and older. - Limitations: Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM574852.pdf 125324 Prevnar 13 CVX: 133 VIOLIN Vaccine ID: 1114 SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia). ZX WEB: http://www.gsk.ca/english/docs-pdf/product-monographs/Synflorix.pdf Synflorix VIOLIN Vaccine ID: 1115 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201342.htm Menveo Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine Novartis Vaccines and Diagnostics, Inc. For active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 when administered to individuals 2 months to 55 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf 125300 Menveo CVX: 136 VIOLIN Vaccine ID: 1113 AREPANRIX H1N1 VIOLIN Vaccine ID: 1116 Intanza VIOLIN Vaccine ID: 1117 An aqueous formula of the synthetic vaccine adjuvant RC529. RC529-AF can be obtained from Corixa Corporation (Seattle, WA). RC529 vaccine adjuvant in an aqueour formulation PMID: 15308371 RC529-AF vaccine adjuvant A microbial derivative vaccine adjuvant derived from the lipopolysaccharide (LPS) of Salmonella minnesota R595. Samantha G. Sayers 3-O-deacylated monophosphoryl lipid A vaccine adjuvant 3D-MLA MPL vaccine adjuvant PMID:7551218 https://www.frontiersin.org/articles/10.3389/fimmu.2020.577823 monophosphoryl lipid A vaccine adjuvant PMID:10768940 An E. coli LT toxin derived vaccine adjuvant that is a mutant form of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant. LTK63 is an enzymatically inactive mutant of the heat-labile enterotoxin of Escherichia coli. It can be used as a potent mucosal adjuvant. Samantha G. Sayers PMID:9607006 LTK63 vaccine mutant PMID:10790422 PMID:17920733 is a bacterial toxin (usually an exotoxin) whose toxicity has been weakened or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained. YH WEB: http://en.wikipedia.org/wiki/Toxoid toxoid YH capsular polysaccharide subunit vaccine YH capsular polysaccharide of pathogen organism as vaccine component a subunit vaccine that uses polysaccharide as protective antigen YH polysaccharide subunit vaccine YH polysaccharide of pathogen organism as vaccine component YH is the specification of an objective to prevent a disorder. prevention of disorder objective YH is the specification of an objective to ameliorate a disorder. amelioration of disorder objective A microbial derivative vaccine adjuvant derived from heat-killed Corynebacterium parvum. Samantha G. Sayers PMID:5483667 killed Corynebacterium parvum vaccine adjuvant PMID:4596278 PMID:7591056 An emulsion vaccine adjuvant which is a water-in-oil adjuvant with CRL-8300 (a block copolymer), squalene, and sorbitan monooleate. Samantha G. Sayers Titermax Gold Titermax Gold vaccine adjuvant URL: http://www.titermax.com/i_gold4.htm A synthetic vaccine adjuvant that is dimethyldioctadecylammonium bromide (DDA), a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen. Samantha G. Sayers Dimethyl dioctadecyl ammonium bromide DDA vaccine adjuvant PMID:1439129 A liposome-based vaccine adjuvant that have a positive surface charge. Samantha G. Sayers cationic liposomal vaccine adjuvant DDA:TDB PMID:19874860 A tenosactive compound vaccine adjuvant that contains purified extract from the bark of the South American tree Quillaja saponaria Molina. Samantha G. Sayers PMID:7551218 QuilA vaccine adjuvant A combination vaccine adjuvant comprised of monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion. monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion. Samantha G. Sayers AS02 vaccine adjuvant PMID:15187142 PMID:15780441 A combination vaccine adjuvant that is a combination of 50 μg of the immunoenhancer MPL (3-O-desacyl-4′-monophosphoryl lipid A) with 500 μg of aluminium salt. Samantha G. Sayers PMID:21527299 AS04 vaccine adjuvant An emulsion vaccine adjuvant which is an emulsion plus DDA. Samantha G. Sayers Emulsigen D VSA-3 PMID:16187717 VSA-3 vaccine adjuvant A tensoactive compound vaccine adjuvant that is derived from saponin, a compound that is an immunostimulator found in the plant P. senega. saponin vaccine adjuvant A Montanide vaccine adjuvant that is formulated as water-in-oil emulsions and induces high antibody titers in several animal species. It is a vaccine adjuvant composed of metabolizable oil and a surfactant system designed to make a water-in-oil emulsion. It has been used since 1992 in more than 50 clinical trials related to therapeutic vaccines against various diseases such as cancer and malaria. Oliver He Samantha G. Sayers Montanide ISA 720 Montanide ISA 720 VG WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-720-@/view-1044-seproduit.html?menuid=,979,&lang=en Montanide ISA 720 vaccine adjuvant PMID:15752840 A Montanide vaccine adjuvant that is a mineral oil adjuvant. Montanide incomplete Seppic adjuvant A Montanide vaccine adjuvant that is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion. Samantha G. Sayers Montanide ISA51 WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-51-@/view-1042-seproduit.html?menuid=,979,&lang=en Montanide ISA51 vaccine adjuvant An emulsion vaccine adjuvant developed by Montanide. Oliver He Samantha G. Sayers http://www.montanide.com/ Montanide vaccine adjuvant An E. coli LT toxin derived vaccine adjuvant composed of the B subunit of E. coli heat-labile toxin. Oliver He Samantha G. Sayers B subunit of E. coli heat-labile enterotoxin EtxB vaccine adjuvant A synthetic vaccine adjuvant with the tradename Polygen. Oliver He Samantha G. Sayers Polygen vaccine adjuvant URL: http://www.mvp-technologies.com/adjuvants/Polygen%20Final%20Technical%20Bulletin.pdf a role of host that contains vaccine. It is a role that inheres in an organism that is the target of a vaccine administration (vaccination process). YH, ZX vaccine host role YH, ZX a role that represents a target (i.e., some disorder) of immunization. immunization target role YH, ZX bacterial vaccine immunization YH, ZX viral vaccine immunization YH, ZX cancer vaccine immunization YH, ZX parasite vaccine immunization immunization target role of pathogen YH, ZX immunization target role of bacterial pathogen YH, ZX immunization target role of viral pathogen YH, ZX immunization target role of parasite pathogen YH, ZX immunization target role of fungal pathogen A carbohydrate vaccine adjuvant, which enhances both humoral and cell-mediated immunity to oligopeptides in experimental animal models. Samantha G. Sayers PMID:7551218 Algal Glucan vaccine adjuvant A combination vaccine adjuvant that suspension of 1-2Œºm ovoids of immune stimulant gamma inulin (g-IN) in which alum is embedded as a carrier for protein or other anionic antigens. Samantha G. Sayers PMID:1887671 Algammulin vaccine adjuvant A synthetic vaccine adjuvant that is Bay R1005 (N-(2-Deoxy-2-L-leucylamino β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate ). Samantha G. Sayers BAY R1005 N-( 2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate PMID:7551218 BAY R1005 vaccine adjuvant A synthetic vaccine adjuvant that is N, N-dioctadecyl-N′, N′-bis( 2-hydroxyethyl) propanediamine (Avridine). Samantha G. Sayers Avridine CP20,96 N, N-dioctadecyl-N′, N′-bis( 2-hydroxyethyl) propanediamine PMID:7551218 Avridine vaccine adjuvant A calcium phosphate vaccine adjuvant that is a gel prepared by precipitating soluable calcium and phosphate salts. Samantha G. Sayers calcium phosphate gel PMID:7551218 calcium phosphate gel vaccine adjuvant A microbial derivative vaccine adjuvant composed of the CTA1-DD fusion protein. Samantha G. Sayers CTA1-DD gene fusion protein PMID:7551218 cholera toxin A1-subunit-ProteinA D-fragment fusion protein A mineral salt vaccine adjuvant that is composed of Deoxycholic acid sodium salt (DOC) complexed with aluminum hydroxide. Samantha G. Sayers DOC/Alum Complex PMID:7551218 DOC/Alum Complex vaccine adjuvant A carbohydrate adjuvant that is a highly specific activator of the alternative pathway of complement in vitro and in vivo, and is composed of linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose. Samantha G. Sayers PMID:3265692 PMID:7551218 gamma Inulin vaccine adjuvant A combination vaccine adjuvant that is comprised of a mixture of GMDP, DDA, and Zinc L-proline salt complex (ZnPro8). Samantha G. Sayers PMID:15953835 PMID:7551218 Gerbu vaccine adjuvant A cytokine vaccine adjuvant that includes GM-CSF. Oliver He Samantha G. Sayers GM-CSF vaccine adjuvant A synthetic vaccine adjuvant containing GMDP, a higly effective primary adjuvant. Samantha G. Sayers GMDP N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine PMID:7551218 GMDP vaccine adjuvant An IFN-gamma vaccine adjuvant that is composed of recombinant hIFN-gamma. Oliver He Samantha G. Sayers recombinant hIFN-gamma/Interferon-g vaccine adjuvant A cytokine vaccine adjuvant that includes IL-1b. Oliver He Samantha G. Sayers interleukin-1b vaccine adjuvant A cytokine vaccine adjuvant that includes IL-2. Oliver He Samantha G. Sayers IL-2 vaccine adjuvant interleukin-2 vaccine adjuvant A cytokine vaccine adjuvant that includes IL-7. Oliver He Samantha G. Sayers IL-7 vaccine adjuvant interleukin-7 vaccine adjuvant A synthetic vaccine adjuvant that includes loxoribine which is a guanosine analog derivatized at position N7 and C8, and activates TLR-7. Samantha G. Sayers 7-allyl-8-oxoguanosine Loxoribine PMID:7551218 Loxoribine vaccine adjuvant An emulsion vaccine adjuvant consisting of an oil (squalene)-in-water nano emulsion. Samantha G. Sayers MF59 PMID:20488726 MF59 vaccine adjuvant A liposome-based vaccine adjuvant that consists of liposomes containing the synthetic lipophilic analog of muramyl dipeptide, muramyl tripeptide phosphatidylethanolamine (MTP-PE). Samantha G. Sayers MTP-PE MTP-PE Liposomes PMID:1431559 MTP-PE Liposomes vaccine adjuvant A synthetic vaccine adjuvant made of murametide that has adjuvant activity similar to MDP. Samantha G. Sayers Murametide Nac-Mur-L-Ala-D-Gln-OCH3 PMID:7551218 Murametide vaccine adjuvant A synthetic vaccine adjuvant called murapalmitine. Samantha G. Sayers Murapalmitine Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl PMID:7551218 Murapalmitine vaccine adjuvant A synthetic vaccine adjuvant that includes an MDP analog called D-Murapalmitine. Samantha G. Sayers D-Murapalmitine Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl PMID:7551218 D-Murapalmitine vaccine adjuvant A synthetic vaccine adjuvant that is composed of neuraminidase-galactose oxidase (NAGO) a mixture of mixture of the two enzymes-neuraminidase and galactose oxidase. Samantha G. Sayers NAGO Neuraminidase-galactose oxidase PMID:7551218 NAGO vaccine adjuvant A synthetic vaccine adjuvant consisting of multi-lamellar vesicles comprising a mixture of non-ionic surfactant (e.g., 1-monopalmitoyl-rac-glycerol), cholesterol and dicetyl phosphate used as a primary vaccine adjuvant for entrapped antigen. Samantha G. Sayers NISV non-ionic surfactant vesicles PMID:7551218 non-ionic surfactant vesicles vaccine adjuvant A synthetic vaccine adjuvant made from the emulsion polymerization of methyl methacrylate. Samantha G. Sayers PMMA Polymethyl methacrylate PMID:7551218 PMMA vaccine adjuvant A synthetic vaccine adjuvant synthesized from stable protein phospholipid-calcium precipitates. Samantha G. Sayers protein cochleates PMID:7551218 protein cochleates vaccine adjuvant A saponin vaccine adjuvant that is composed of extracts from the bark of the Quillaja saponaria Molina tree. Specifically, it is an acylated 3, 28-bisdesmodic triterpene glycosides (1,3) or ‚Äö√Ñ√∫saponin‚Äö√Ñ√π with a molecular formula of C92O46H148 and molecular weight of 1990 Da. QS-21 is one of the active fractions of the bark of Chilean tree, Quillaja saponaria, purified using a reverse-phase chromatography (RP-HPLC). Oliver He Randi Vita Samantha G. Sayers QS-21 Stimulon™ QS-21 Adjuvant PMID:27213168 PMID:7551218 QS-21 vaccine adjuvant An aluminum vaccine adjuvant that is a synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation. Samantha G. Sayers Rehydragel HPA PMID:7551218 Rehydragel HPA vaccine adjuvant An aluminum hydroxide vaccine adjuvant that is a low visosity aluminum hydroxide gel. Samantha G. Sayers Rehydragel LV PMID:7551218 Rehydragel LV vaccine adjuvant A cytokine vaccine adjuvant that contains the 163-171 peptide of IL-1β. Oliver He Samantha G. Sayers IL-1β 163-171 peptide vaccine adjuvant Sclavo peptide Sclavo peptide vaccine adjuvant An emulsion vaccine adjuvant that is a water-in-oil emulsion that is used as an adjuvant and has immunostimulating properties similar to Freund's complete adjuvant (FCA). Samantha G. Sayers Specol PMID:1439130 Specol vaccine adjuvant An emulsion vaccine adjuvant that is an emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen. Samantha G. Sayers PMID:7551218 SPT (Antigen Formulation) A synthetic vaccine adjuvant stearyl tyrosine is considered an "organic equivelant" of aluminum hydroxide. Samantha G. Sayers stearyl tyrosine PMID:7551218 stearyl tyrosine vaccine adjuvant A synthetic vaccine adjuvant called Theramide that is composed of N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP). Samantha G. Sayers Theramide PMID:7551218 Theramide vaccine adjuvant A synthetic vaccine adjuvant that is a copolymer (CRL1005), based on a 12 kDa polyoxypropylene (POP) core with 5% POE. Samantha G. Sayers CRL1005 PMID:10717336 CRL1005 vaccine adjuvant An emulsion vaccine adjuvant and is made from non-toxic lipid droplets a few hundred nanometers in diameter and made from surfactants approved for human consumption and common food substances that are 'Generally Recognized as Safe' (GRAS) by the FDA. Samantha G. Sayers http://nano.med.umich.edu/platforms/Nanoemulsions.html nanoemulsion vaccine adjuvant An emusion vaccine adjuvant that contains Œ±-tocopherol and squalene, two biodegradable polyprenyls, in an oil-in-water emulsion. Samantha G. Sayers AS03 PMID:21256188 AS03 vaccine adjuvant An E. coli LT toxin derived vaccine adjuvant that is a mutant form of E.coli heat-labile toxin. Samantha G. Sayers LTR192G PMID:11803061 LTR192G vaccine adjuvant A microbial derivative vaccine adjuvant containing E. coli heat-labile toxin. Samantha G. Sayers E. coli heat-labile toxin, LT LT Oral Adjuvant LT-OA PMID:7551218 E. coli heat-labile toxin vaccine adjuvant An aluminum vaccine adjuvant that is a a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants. Samantha G. Sayers AAHSA Merck Aluminum Adjuvant PMID:17581283 amorphous aluminum hydroxyphosphate sulfate adjuvant Matrix-S Matrix-S vaccine adjuvant Brucella BFR antigen vaccine recombinant Brucella abortus Bfr protein vaccine Brucella abortus subunit vaccine using Bfr PMID: 11447155 Brucella abortus Omp16 vaccine Brucella abortus subunit vaccine using Omp16 PMID: 18981242 B. melitensis DNA vaccine encoding Bp26 and Tf A synthetic vaccine adjuvant contiaing imiquimod a imidazoquinoline. Samantha G. Sayers 1-(2-methypropyl)-IH-imidazo[4,5-c]quinolin-4-amine Aldara™ R-837 S26308 PMID:18566444 PMID:7551218 imiquimod vaccine adjuvant A synthetic vaccine adjuvant, resiquimod is a chemical analog of imiquimod. Samantha G. Sayers PMID:15068862 resiquimod vaccine adjuvant An emulsion vaccine adjuvant containing 2.5% squalene. Samantha G. Sayers PMID:20193791 AF03 vaccine adjuvant A microbial derivative vaccine adjuvant composed of flagellin from gram-negative bacteria. Samantha G. Sayers FliC PMID:16428759 PMID:21048152 Flagellin vaccine adjuvant A synthetic vaccine adjuvant containing Poly(I:C), a synthetic double stranded analog of RNA. Samantha G. Sayers polyriboinosinic-polyribocytidylic acid WEB: http://en.wikipedia.org/wiki/Polyinosinic:polycytidylic_acid poly(I:C) vaccine adjuvant A particulate antigen delivery system that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen. ISCOMATRIX is identical to ISCOMs except that it does not contain antigen. Ref: PMID: 17336431. Samantha G. Sayers PMID:19450632 ISCOMATRIX vaccine adjuvant A saponin vaccine adjuvant that is made from highly purified saponins. Oliver He Samantha G. Sayers WEB: http://www.isconova.com/products/abisco-research-reagent/abisco-100.aspx Abisco-100 vaccine adjuvant A particulate antigen delivery system that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC. Samantha G. Sayers PMID:16734558 albumin-heparin microparticles vaccine adjuvant A combination vaccine adjuvant and is based on the combination of Monophosphoryl Lipid A(MPL), QS21 (a purified fraction of Saponin extracted from Quillarja Saponaria), and a proprietary oil in water emulsion. Samantha G. Sayers http://www.pasteur.fr/applications/euroconf/vaccins/vaccins-abs.html AS-2 vaccine adjuvant A cytokine vaccine adjuvant that includes B7-2. Oliver He Samantha G. Sayers B7-2 vaccine adjuvant A synthetic vaccine adjuvant that is a local anaesthetic drug belonging to the amino amide group, and is used as a vaccine adjuvant in DNA vaccines. Samantha G. Sayers PMID:15246629 WEB: http://en.wikipedia.org/wiki/Bupivacaine Bupivacaine vaccine adjuvant A liposome-based vaccine adjuvant that is composed of virus sized liposomes that contain a DNA plasmid. Samantha G. Sayers cationic liposome-DNA complex JVRS-100 PMID:19285425 cationic liposome-DNA complex JVRS-100 vaccin adjuvant A synthetic vaccine adjuvant that is DHEA, which is relatively stable and can be directly incorporated into vaccine formulations. Samantha G. Sayers 5-androsten-3β-ol-17-one DHA Dehydroepiandrosterone androstenolone prasterone transdehydroandrosterone PMID:7551218 DHEA vaccine adjuvant A synthetic vaccine adjuvant that is PLGA, which has been used in the controlled delivery of peptide drugs. Samantha G. Sayers PLGA PLGA microspheres Polyester poly (DL-lactide-co-glycolide) PMID:15560948 DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant A cytokine vaccine adjuvant that uses the adjuvant effect of cytokine IL-15. Oliver He Samantha G. Sayers IL-15 vaccine adjuvant A liposome-based vaccine adjuvant which is prepared from dehydration-rehydration vesicles (DRVs). Samantha G. Sayers PMID:7551218 immunoliposomes containing antibodies to costimulatory molecules An E. coli LT toxin derived vaccine adjuvant that is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala ‚Üí Arg in position 72 of the A subunit. Samantha G. Sayers PMID:9529328 LTK72 vaccine adjuvant A microbial derivative vaccine adjuvant containing MPL and squalene. Samantha G. Sayers PMID:12213399 MPL-SE vaccine adjuvant a vaccine preservative that contains formaldehyde. YH, SGS WEB: http://www.mja.com.au/public/issues/184_04_200206/eld10500_fm.pdf formaldehyde vaccine preservative A microbial derived vaccine adjuvant made of E112K mC, a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112. Samantha G. Sayers mCT non-toxic mutant E112K of Cholera Toxin mCT-E112K PMID:11251876 non-toxic mutant E112K of Cholera Toxin mCT-E112K vaccine adjuvant A microbial derivative vaccine adjuvant that is derived from cholera toxin. Oliver He Samantha G. Sayers cholera toxin derived vaccine adjuvant A combination vaccine adjuvant that is composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic¬Æ L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)]. Samantha G. Sayers PMID:7551218 SAF-1 vaccine adjuvant A liposome-based vaccine adjuvant that includes the glycoproteins of Sendai virus. Samantha G. Sayers PMID:7551218 Sendai Proteoliposomes, Sendai-containing Lipid Matrices A synthetic vaccine adjuvant that is threonyl muramyl dipeptide (TMDP). Samantha G. Sayers N-acetyl muramyl-L-threonyl-D-isoglutamine Termurtide™ [thr1 ]-MDP PMID:7551218 threonyl muramyl dipeptide (TMDP) vaccine adjuvant A microbial derivative vaccine adjuvant made of virus like particles (VLPS) containing the yeast retrotransposon Ty which has the amino acids 1-381 of the pI protein encoded. Samantha G. Sayers Ty-VLPs PMID:7551218 ty particles vaccine adjuvant A vaccine adjuvant that contains active cytokine compound. Oliver He Samantha G. Sayers cytokine vaccine adjuvant A vaccine adjuvant that is composed of differnt compounds under more than one category. Oliver He Samantha G. Sayers combination vaccine adjuvant emulsion vaccine adjuvant A vaccine adjuvant that serves as a particulate antigen delivery system. Oliver He Samantha G. Sayers particulate antigen delivery system A vaccine adjuvant that contains synthetic material. Oliver He Philip Huang Samantha G. Sayers synthetic vaccine adjuvant A vaccine adjuvant that includes tensioactive material. Tensioactive materials, surfactants or active surface agents are chemical substances with a polar-non polar structure. These substances have a tendency to locate themselves at the surface creating an adsorbed monomolecular layer on the interface. Oliver He Samantha G. Sayers tensioactive compound vaccine adjuvant WEB: http://www.citt.ufl.edu/team/sepulveda/html/en_tensioactivos.htm tensoactive compound vaccine adjuvant A vaccine adjuvant that is primarily composed of carbohydrates. Oliver He Samantha G. Sayers carbohydrate vaccine adjuvant A cytokine vaccine adjuvant that includes IFN-gamma. Oliver He Samantha G. Sayers IFN-gamma vaccine adjuvant a role that is inherenced in a gene that can be mutated in a virulent pathogen, leading to an attenuated strain serving as a live attenuated vaccine strain. YH, YL virmugen role a vaccine that targets for allergy. YL,YH YL, YH allergy vaccine bacterial vaccine that is used to protect against Clostridium perfringens infection generated using OntoRat YL Clostridium perfringens vaccine human immunization objective A viral vaccine that protects against infection with CCHF virus YH, RS, NF CCHF vaccine Crimean-Congo Haemorrhagic Fever vaccine A viral vaccine that protects against infection with Caprine herpesvirus type 1 virus YH, RS, NF Caprine herpesvirus type 1 vaccine an inactivation vaccine that is prepared by heat inactivation. YH, YL heat-killed vaccine an inactivation vaccine that is prepared by irradiation inactivation. YH, YL irradiation-inactivated vaccine an inactivation vaccine that is prepared by H2O2 inactivation. YH, YL H2O2-killed vaccine an inactivation vaccine that is prepared by formalin inactivation. YH, YL formalin-killed vaccine A vaccine prepraration process that is performed by H2O2 inactivation of virulent pathogen. YH preparation of vaccine using H2O2 inactivation an organismal quality that indicates an organism (e.g., human) is not yet immunized against a disease. YH unimmunized an organismal quality that indicates an organism (e.g., human) is immunized against a disease through vaccination with a licensed vaccine. YH immunized by vaccination with a licensed vaccine an organism that is vaccinated with a vaccine vaccinated organism YH, YL, MC vaccinee A Streptococcus vaccine against Streptococcus agalactiae infection. YH, RS Streptococcus agalactiae vaccine an organismal quality that indicates an organism (e.g., human) is vaccinated with a vaccine. YH vaccinated an organismal quality that indicates an organism (e.g., human) is unvaccinated with any vaccine. YH unvaccinated a vaccinated quality that indicates an organism is vaccinated with a licensed vaccine. YH vaccinated with a licensed vaccine a unvaccinated quality that indicates an organism has not been vaccinated with a licensed vaccine. YH unvaccinated with a licensed vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:8306370 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3066 https://github.com/vaccineontology/VO/issues/295 3066 Research B16 Vaccine adjuvanted by Loxoribine an organism that is immunized for a disease YH, YL, MC immunized organism A viral vaccine that protects against infection with Rabbit hemorrhagic disease virus YH, RS, NF rabbit hemorrhagic disease virus vaccine an organism that is unvaccinated with a vaccine YH, YL, MC unvaccinated organism a bacterial gene from Actinobacillus pleuropneumoniae. YH, RR Actinobacillus pleuropneumoniae gene A vaccine that protects against Trypanosoma cruzi. YH T. cruzi vaccine Trypanosoma cruzi vaccine A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi CRP-10 protein. YH T. cruzi DNA vaccine encoding CRP-10 VIOLIN Vaccine ID: 803 A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G2 protein. YH T. cruzi DNA vaccine encoding G2 VIOLIN Vaccine ID: 807 A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G4 protein. YH T. cruzi DNA vaccine encoding G4 VIOLIN Vaccine ID: 809 A T. cruzi DNA vaccine that uses a DNA plasmid expressing T. cruzi TSA-1 protein. YH T. cruzi DNA vaccine encoding TSA-1 VIOLIN Vaccine ID: 812 A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi TSA-1 protein. YH T. cruzi DNA vaccine pGFP-TSA1 VIOLIN Vaccine ID: 811 A T. cruzi subunit vaccine that uses T. cruzi PAR1 protein as protective antigen. YH T. cruzi PAR1 protein vaccine VIOLIN Vaccine ID: 806 A T. cruzi subunit vaccine that uses T. cruzi PAR2 protein as protective antigen. YH T. cruzi PAR2 protein vaccine VIOLIN Vaccine ID: 810 A T. cruzi vaccine that uses attenuated Salmonella to express T. cruzi Cruzipain protein. YH T. cruzi vaccine using attenuated Salmonella expressing T. cruzi Cruzipain VIOLIN Vaccine ID: 804 A T. cruzi vaccine that uses Sendai virus vector to express T. cruzi amastigote surface protein-2. YH T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2 VIOLIN Vaccine ID: 802 a vaccine that contains two or more individual vaccines. YH cocktail vaccine a cocktail vaccine that contains both subunit vaccine and inactivated whole organism vaccines. YH cocktail vaccine containing subunit vaccine and inactivated whole organism vaccine a prime-boost vaccine with DNA vaccine priming that contains a subunit vaccine for boosting YH vaccine containing DNA vaccine for priming and subunit vaccine for boosting a prime-boost vaccine with a DNA vaccine priming that contains a Ad vector vaccine for boosting YH vaccine containing DNA vaccine for priming and Ad vector vaccine for boosting a conjugate vaccine that conjugate more than one open reading frames of protective antigens or conjugate a protective antigen to a carrier protein. An example of fusion protein vaccine is Mtb72f fusion protein vaccine. Reference: PubMed: 15187142. YH fusion protein vaccine fusion conjugate protein vaccine A Brucella gene that is from B. melitensis. YH, RR Brucella melitensis gene A Brucella gene that is from B. suis. YH Brucella suis gene A bacterial gene that is from Bacillus anthracis. YH, RR Bacillus anthracis gene A bacterial gene that is from Listeria monocytogenes. YH, RR Listeria monocytogenes gene A bacterial gene that is from Mycobacterium avium. YH, RR Mycobacterium avium gene A bacterial gene that is from Staphylococcus aureus. YH, RR Staphylococcus aureus gene A bacterial gene that is from Aeromonas hydrophila. YH, RR Aeromonas hydrophila gene A bacterial gene that is from Bordetella bronchiseptica. YH, RR Bordetella bronchiseptica gene A bacterial gene that is from Aeromonas salmonicida. YH, RR Aeromonas salmonicida gene A bacterial gene that is from Bordetella pertussis. YH, RR Bordetella pertussis gene A bacterial gene that is from Borrelia burgdorferi. YH, RR Borrelia burgdorferi gene A bacterial gene that is from Burkholderia pseudomallei. YH, RR Burkholderia pseudomallei gene A bacterial gene that is from Burkholderia pseudomallei. YH, RR Edwardsiella ictaluri gene A bacterial gene that is from Edwardsiella tarda. YH, RR Edwardsiella tarda gene A bacterial gene that is from Francisella tularensis. YH, RR Francisella tularensis gene A bacterial gene that is from Mannheimia haemolytica. YH, RR Mannheimia haemolytica gene A bacterial gene that is from Mycoplasma gallisepticum. YH, RR Mycoplasma gallisepticum gene A bacterial gene that is from Neisseria meningitidis. YH, RR Neisseria meningitidis gene A bacterial gene that is from Pasteurella multocida. YH, RR Pasteurella multocida gene A bacterial gene that is from Salmonella Typhi. YH, RR Salmonella Typhi gene A bacterial gene that is from Salmonella Gallinarum. YH, RR Salmonella Gallinarum gene A bacterial gene that is from Salmonella Typhimurium. YH, RR 'Salmonella Typhimurium gene A bacterial gene that is from Salmonella Enteritidis. YH, RR Salmonella Enteritidis gene A bacterial gene that is from Vibrio cholerae. YH, RR Vibrio cholerae gene A viral gene that is from Bovine herpesvirus 1. YH, RR Bovine herpesvirus 1 gene A bacterial gene that is from Yersinia enterocolitica. YH, RR Yersinia enterocolitica gene A bacterial gene that is from Yersinia pestis. YH, RR Yersinia pestis gene A bacterial gene that is from Yersinia pseudotuberculosis. YH, RR Yersinia pseudotuberculosis gene A bacterial gene that is from Yersinia ruckeri. YH, RR Yersinia ruckeri gene A viral gene that is from Bovine Respiratory Syncytial Virus. YH, RR Bovine Respiratory Syncytial Virus gene A viral gene that is from Classical swine fever virus. YH, RR Classical swine fever virus gene A viral gene that is from Equid herpesvirus 1. YH, RR Equid herpesvirus gene A viral gene that is from Feline herpesvirus 1. YH, RR Feline herpesvirus 1 gene A viral gene that is from Feline immunodeficiency virus. YH, RR Feline immunodeficiency virus gene A viral gene that is from Feline infectious peritonitis virus. YH, RR Feline infectious peritonitis virus gene A viral gene that is from Gallid herpesvirus 1. YH, RR Gallid herpesvirus 1 gene A viral gene that is from Hepatitis B virus. YH, RR Hepatitis B virus gene A viral gene that is from Human herpesvirus 1. YH, RR Human herpesvirus 1 gene A viral gene that is from Human metapneumovirus. YH, RR Human metapneumovirus gene A viral gene that is from Human Respiratory Syncytial Virus. YH, RR Human Respiratory Syncytial Virus gene A viral gene that is from Infectious Hematopoietic Necrosis Virus. YH, RR Infectious Hematopoietic Necrosis Virus gene A viral gene that is from Porcine respiratory and reproductive syndrome virus. YH, RR Porcine respiratory and reproductive syndrome virus gene A viral gene that is from Pseudorabies virus. YH, RR Suid herpesvirus 1 gene Pseudorabies virus gene A viral gene that is from Rabies virus. YH, RR Rabies virus gene A viral gene that is from SARS-CoV. YH, RR SARS-CoV gene A viral gene that is from Simian Immunodeficiency Virus. YH, RR Simian Immunodeficiency Virus gene A viral gene that is from Tick-borne Encephalitis Virus. YH, RR Tick-borne Encephalitis Virus gene A viral gene that is from VEE Virus. YH, RR VEE Virus gene A viral gene that is from West Nile virus. YH, RR West Nile virus gene A viral gene that is from Western equine encephalomyelitis virus. YH, RR Western equine encephalomyelitis virus gene A protozoan gene that is from Leishmania donovani. YH, RR Leishmania donovani gene A Plasmodium gene that is from Plasmodium berghei. YH, RR Plasmodium berghei gene A Plasmodium gene that is from Plasmodium yoelii. YH, RR Plasmodium yoelii gene A protozoan gene that is from Toxoplasma gondii. YH, RR Toxoplasma gondii gene A viral gene that is from Human herpesvirus 2. YH, RR 'Human herpesvirus 2 gene' A viral vaccine that protects against infection with Rinderpest virus YH, RS, NF rinderpest virus vaccine bacterial vaccine that is used to protect against Erysipelothrix rhusiopathiae infection generated using OntoRat YL Erysipelothrix rhusiopathiae vaccine protozoan vaccine that is used to protect against Tritrichomonas suis infection generated using OntoRat YL Trichomonas foetus vaccine protozoan vaccine that is used to protect against Eimeria spp. (Eimeria) infection generated using OntoRat YL Eimeria spp. vaccine viral vaccine that is used to protect against Orf Virus infection generated using OntoRat YL Orf Virus vaccine Vaccine that used for immunizing Aves. YL. Aves vaccine vaccine that used for immunizing fishes YL. fish vaccine viral vaccine that is used to protect against Fowlpox virus infection generated using OntoRat YL Fowl pox vaccine Fowlpox virus vaccine vaccine that used for immunizing carnivora. YL carnivora vaccine vaccine that used for immunizing cat (felis catus) cat vaccine cattle vaccine dog vaccine chicken vaccine Ducks vaccine catfish vaccine gray wolf vaccine horse vaccine parrot vaccine pig vaccine sei whale vaccine sheep vaccine vaccine that used for immunizing salmoninae (tourts, salmons & chars ) YL salmoninae vaccine turkey vaccine The objective that intends to produce vaccine via the vaccine preparation process. YH vaccine target specification A viral vaccine that protects against infection with African horse sickness virus YH, RS, NF African horse sickness virus vaccine viral vaccine that is used to protect against Pigeonpox virus infection generated using OntoRat YL Pigeonpox virus vaccine viral vaccine that is used to protect against Bovine herpesvirus 1 infection YL, YH BHV-1 vaccine Bovine rhinotracheitis vaccine bovine herpesvirus 1 vaccine A viral vaccine that protects against infection with Borna disease virus YH, RS, NF Borna disease virus vaccine A viral vaccine that protects against infection with Caprine herpesvirus 1 YH, RS, NF Caprine herpesvirus 1 vaccine A vaccine licensed in the USA Oliver He, Kallan Roan https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm USA licensed vaccine viral vaccine that is used to protect against Equid herpesvirus 1 infection generated using OntoRat YL Equid herpesvirus 1 vaccine viral vaccine that is used to protect against Feline herpesvirus 1 (Felid herpesvirus 1) infection YL, YH Feline herpesvirus 1 vaccine viral vaccine that is used to protect against Gallid herpesvirus 1 infection YL, YH, RS, NF https://en.wikipedia.org/wiki/Gallid_herpesvirus_1 Gallid herpesvirus 1 vaccine viral vaccine that is used to protect against Canine adenovirus type 1 (Canine adenovirus 1) infection generated using OntoRat YL canine adenovirus type 1 vaccine viral vaccine that is used to protect against Canine Adenovirus Type 2 (Canine adenovirus 2) infection generated using OntoRat YL canine adenovirus Type 2 vaccine viral vaccine that is used to protect against Bovine papillomavirus infection generated using OntoRat YL Bovine papillomavirus vaccine viral vaccine that is used to protect against Avian Polyomavirus infection generated using OntoRat YL avian polyomavirus vaccine viral vaccine that is used to protect against Mink enteritis virus infection generated using OntoRat YL Mink enteritis virus vaccine viral vaccine that is used to protect against Porcine parvovirus infection generated using OntoRat YL Porcine parvovirus vaccine viral vaccine that is used to protect against Porcine rotavirus infection generated using OntoRat YL Porcine rotavirus vaccine viral vaccine that is used to protect against Equine rotavirus infection generated using OntoRat YL Equine rotavirus vaccine viral vaccine that is used to protect against Infectious Bursal Disease Virus (IBDV) infection YL, YH, RS, NF IBDV vaccine infectious bursal disease virus vaccine viral vaccine that is used to protect against Eastern Equine Encephalitis Virus infection generated using OntoRat YL Eastern Equine Encephalitis Virus vaccine viral vaccine that is used to protect against VEE Virus (Venezuelan equine encephalitis virus) infection generated using OntoRat YL VEE Virus vaccine viral vaccine that is used to protect against Equine arteritis virus infection generated using OntoRat YL Equine arteritis virus vaccine viral vaccine that is used to protect against Bovine viral diarrhea virus 1 infection generated using OntoRat YL Bovine viral diarrhea virus 1 vaccine viral vaccine that is used to protect against Infectious Bronchitis Virus (IBV) infection generated using OntoRat YL Infectious Bronchitis Virus vaccine viral vaccine that is used to protect against Bovine coronavirus infection generated using OntoRat YL bovine coronavirus vaccine viral vaccine that is used to protect against Feline infectious peritonitis virus infection YL, YH Feline infectious peritonitis virus vaccine viral vaccine that is used to protect against Transmissible gastroenteritis virus infection generated using OntoRat YL Transmissible gastroenteritis virus vaccine viral vaccine that is used to protect against Bovine Parainfluenza 3 Virus (BPIV-3) (Bovine parainfluenza virus 3) infection YL, YH Bovine Parainfluenza 3 Virus vaccine viral vaccine that is used to protect against Bovine Respiratory Syncytial Virus infection generated using OntoRat YL Bovine Respiratory Syncytial Virus vaccine viral vaccine that is used to protect against Feline immunodeficiency virus infection generated using OntoRat YL Feline immunodeficiency virus vaccine viral vaccine that is used to protect against Feline calicivirus infection YL, YH Feline calicivirus vaccine viral vaccine that is used to protect against Chicken Anemia Virus infection generated using OntoRat YL chicken anemia virus vaccine viral vaccine that is used to protect against Porcine respiratory and reproductive syndrome virus (Porcine reproductive and respiratory syndrome virus) infection generated using OntoRat YL Porcine respiratory and reproductive syndrome virus vaccine bacterial vaccine that is used to protect against Riemerella anatipestifer infection generated using OntoRat YL Riemerella anatipestifer vaccine viral vaccine that is used to protect against Avian Reovirus (Avian orthoreovirus) infection generated using OntoRat YL avian reovirus vaccine viral vaccine that is used to protect against Avian pneumovirus (Avian metapneumovirus) infection generated using OntoRat YL avian pneumovirus vaccine viral vaccine that is used to protect against Bluetongue virus infection generated using OntoRat YL Bluetongue virus vaccine viral vaccine that is used to protect against Turkey hemorrhagic enteritis virus (Turkey adenoirus 3) infection generated using OntoRat YL Turkey hemorrhagic enteritis virus vaccine viral vaccine that is used to protect against Canarypox virus infection generated using OntoRat YL Canarypox virus vaccine viral vaccine that is used to protect against Psittacid herpesvirus 1 infection generated using OntoRat YL Psittacid herpesvirus 1 vaccine A vaccine that protects against infection with Mycobacterium bovis YH, RS, NF Mycobacterium bovis vaccine viral vaccine that is used to protect against Infectious salmon anemia virus infection generated using OntoRat YL Infectious salmon anemia virus vaccine An Edwardsiella bacterial vaccine that is used to protect against Edwardsiella ictaluri infection generated using OntoRat YL Edwardsiella ictaluri vaccine viral vaccine that is used to protect against Avian Encephalomyelitis Virus infection YL, YH avian encephalomyelitis virus vaccine SNOMEDCT: 35283005; UMLS_CUI:C0310667 bacterial vaccine that is used to protect against Mannheimia haemolytica infection generated using OntoRat YL Mannheimia haemolytica vaccine viral vaccine that is used to protect against Porcine circovirus 2 infection YL, YH porcine circovirus 2 vaccine viral vaccine that is used to protect against Duck enteritis virus (Anatid herpesvirus 1) infection generated using OntoRat YL Duck enteritis virus vaccine viral vaccine that is used to protect against Canine parainfluenza virus infection generated using OntoRat YL canine parainfluenza virus vaccine viral vaccine that is used to protect against Avian Paramyxovirus infection generated using OntoRat YL avian paramyxovirus vaccine viral vaccine that is used to protect against Duck hepatitis virus 1 (Duck hepatitis A virus) infection generated using OntoRat YL Duck hepatitis virus 1 vaccine generated using OntoRat YL Canary Pox Modified Live Virus Vaccine (USDA: 1623.10) USDA: 1623.10 violinID:1557 generated using OntoRat YL Pigeon Pox Live Virus Vaccine (USDA: 1881.10) USDA: 1881.10 violinID:2092 generated using OntoRat YL Pigeon Pox Live Virus Vaccine (USDA: 1881.12) USDA: 1881.12 violinID:2093 generated using OntoRat YL Pigeon Pox Live Virus Vaccine (USDA: 1881.14) USDA: 1881.14 violinID:2094 generated using OntoRat YL Quail Pox Live Virus Vaccine (USDA: 18E1.10) USDA: 18E1.10 violinID:2111 generated using OntoRat YL Fox Encephalitis Killed Virus Vaccine (USDA: 1635.20) USDA: 1635.20 violinID:1925 generated using OntoRat YL Mink Distemper Modified Live Virus Vaccine (USDA: 1451.00) USDA: 1451.00 violinID:1967 generated using OntoRat YL Mink Distemper Modified Live Virus Vaccine (USDA: 1451.01) USDA: 1451.01 violinID:1968 generated using OntoRat YL Mink Distemper Modified Live Virus Vaccine (USDA: 1451.20) USDA: 1451.20 violinID:1969 generated using OntoRat YL Mink Enteritis Vaccine violinID:1972 generated using OntoRat YL Feline calicivirus Killed Virus Vaccine (USDA: 15C5.21) USDA: 15C5.21 violinID:1766 generated using OntoRat YL Feline calicivirus Modified Live Virus Vaccine (USDA: 15C1.22) USDA: 15C1.22 violinID:1765 generated using OntoRat YL Feline immunodeficiency virus Killed Virus Vaccine (USDA: 15A5.21) USDA: 15A5.21 violinID:1767 generated using OntoRat YL Feline immunodeficiency virus Killed Virus Vaccine (USDA: 15A5.23) USDA: 15A5.23 violinID:1768 generated using OntoRat YL Feline Infectious Peritonitis Modified Live Virus Vaccine (USDA: 15A1.20) USDA: 15A1.20 violinID:1771 generated using OntoRat YL Feline Leukemia Killed Virus Vaccine (USDA: 1555.20) USDA: 1555.20 violinID:1772 generated using OntoRat YL Feline Leukemia Killed Virus Vaccine (USDA: 1555.21) USDA: 1555.21 violinID:1773 generated using OntoRat YL Feline Leukemia Killed Virus Vaccine (USDA: 1555.22) USDA: 1555.22 violinID:1774 generated using OntoRat YL Feline Leukemia Killed Virus Vaccine (USDA: 1555.R1) USDA: 1555.R1 violinID:1775 generated using OntoRat YL Feline Leukemia Live Canarypox Vector Vaccine (USDA: 1555.R3) USDA: 1555.R3 violinID:1776 generated using OntoRat YL Feline Panleukopenia Killed Virus Vaccine (USDA: 1565.20) USDA: 1565.20 violinID:1819 generated using OntoRat YL Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.00) USDA: 1561.00 violinID:1815 generated using OntoRat YL Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.20) USDA: 1561.20 violinID:1816 generated using OntoRat YL Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.21) USDA: 1561.21 violinID:1817 generated using OntoRat YL Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.23) USDA: 1561.23 violinID:1818 generated using OntoRat YL Feline Rhinotracheitis Modified Live Virus Vaccine (USDA: 16A1.22) USDA: 16A1.22 violinID:1820 generated using OntoRat YL Edwardsiella ictaluri Avirulent Live Culture Vaccine (USDA: 1531.00) USDA: 1531.00 violinID:1714 generated using OntoRat YL Anthrax Spore live culture Vaccine (USDA: 1011.00) USDA: 1011.00 violinID:1122 generated using OntoRat YL Bovine Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1095.20) USDA: 1095.20 violinID:1179 generated using OntoRat YL Bovine Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1095.21) USDA: 1095.21 violinID:1180 generated using OntoRat YL Bovine Respiratory Syncytial Virus Vaccine Modified Live Virus (USDA: 1091.20) USDA: 1091.20 violinID:1178 generated using OntoRat YL Bovine Rhinotracheitis Killed Virus Vaccine (USDA: 1105.20) USDA: 1105.20 violinID:1186 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.00) USDA: 1101.00 violinID:1181 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.20) USDA: 1101.20 violinID:1182 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.21) USDA: 1101.21 violinID:1183 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.22) USDA: 1101.22 violinID:1184 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.B0) USDA: 1101.B0 violinID:1185 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.00) USDA: 1205.00 violinID:1354 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.20) USDA: 1205.20 violinID:1355 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.21) USDA: 1205.21 violinID:1356 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.22) USDA: 1205.22 violinID:1357 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.25) USDA: 1205.25 violinID:1358 generated using OntoRat YL Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.00) USDA: 1201.00 violinID:1351 generated using OntoRat YL Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.20) USDA: 1201.20 violinID:1352 generated using OntoRat YL Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.22) USDA: 1201.22 violinID:1353 generated using OntoRat YL Brucella Abortus Strain 19, Live Culture Vaccine (USDA: 1251.01) USDA: 1251.01 violinID:1383 generated using OntoRat YL Brucella Abortus Strain 19, Live Culture, Reduced Dose Vaccine (USDA: 1251.02) USDA: 1251.02 violinID:1384 generated using OntoRat YL Brucella Abortus Strain RB-51, Live Culture Vaccine (USDA: 1261.00) USDA: 1261.00 violinID:1385 generated using OntoRat YL Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1841.00) USDA: 1841.00 violinID:2077 generated using OntoRat YL Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1841.20) USDA: 1841.20 violinID:2078 generated using OntoRat YL Salmonella Choleraesuis Avirulent Live Culture Vaccine (USDA: 19A1.00) USDA: 19A1.00 violinID:2121 generated using OntoRat YL Salmonella Choleraesuis Avirulent Live Culture Vaccine (USDA: 19A1.01) USDA: 19A1.01 violinID:2122 generated using OntoRat YL Salmonella Dublin Live Culture Vaccine (USDA: 19D1.R0) USDA: 19D1.R0 violinID:2123 generated using OntoRat YL Trichomonas Foetus Killed Protozoa Vaccine (USDA: 1859.00) USDA: 1859.00 violinID:2143 generated using OntoRat YL Wart Vaccine (Colorado Serum) Wart Killed Virus Vaccine (USDA: 1985.50) USDA: 1985.50 violinID:2144 generated using OntoRat YL Avian Encephalomyelitis Killed Virus Vaccine (USDA: 1015.I0) USDA: 1015.I0 violinID:1124 generated using OntoRat YL Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.10) USDA: 1051.10 violinID:1125 generated using OntoRat YL Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.11) USDA: 1051.11 violinID:1126 generated using OntoRat YL Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.12) USDA: 1051.12 violinID:1127 generated using OntoRat YL Avian Influenza H10N9 Subtype, Killed Virus Vaccine (USDA: 1057.H0) USDA: 1057.H0 violinID:1147 generated using OntoRat YL Avian Influenza H2N2 Subtype, Killed Virus Vaccine (USDA: 1057.H2) USDA: 1057.H2 violinID:1149 generated using OntoRat YL Avian Influenza H3N4 Subtype, Killed Virus Vaccine (USDA: 1057.H3) USDA: 1057.H3 violinID:1150 generated using OntoRat YL Avian Influenza H4N6 Subtype, Killed Virus Vaccine (USDA: 1057.H4) USDA: 1057.H4 violinID:1151 generated using OntoRat YL Avian Influenza H5N2 Subtype, Killed Virus Vaccine (USDA: 1057.H5) USDA: 1057.H5 violinID:1152 generated using OntoRat YL Avian Influenza H5N9 Subtype, Killed Virus Vaccine (USDA: 1057.14) USDA: 1057.14 violinID:1146 generated using OntoRat YL Avian Influenza H6N8 Subtype, Killed Virus Vaccine (USDA: 1057.H6) USDA: 1057.H6 violinID:1153 generated using OntoRat YL Avian Influenza H7N2 Subtype, Killed Virus Vaccine (USDA: 10F5.12) USDA: 10F5.12 violinID:1158 generated using OntoRat YL Avian Influenza H7N3 Subtype, Killed Virus Vaccine (USDA: 1057.H7) USDA: 1057.H7 violinID:1154 generated using OntoRat YL Avian Influenza H7N3 Subtype, Killed Virus Vaccine (USDA: 10F5.13) USDA: 10F5.13 violinID:1159 generated using OntoRat YL Avian Influenza H1N1 Subtype, Killed Virus Vaccine (USDA: 1057.H1) USDA: 1057.H1 violinID:1148 generated using OntoRat YL Avian Influenza H5N2 Subtype, Killed Virus Vaccine (USDA: 10F5.10) USDA: 10F5.10 violinID:1157 generated using OntoRat YL Avian Influenza H5N3 Subtype, Killed Virus Vaccine (USDA: 1057.R3) USDA: 1057.R3 violinID:1156 generated using OntoRat YL Avian Influenza H9N2 Subtype, Killed Virus Vaccine (USDA: 1057.H9) USDA: 1057.H9 violinID:1155 generated using OntoRat YL Avian Paramyxovirus Type 1, Killed Virus Vaccine (USDA: 10C5.11) USDA: 10C5.11 violinID:1163 generated using OntoRat YL Avian Paramyxovirus Type 3, Killed Virus Vaccine (USDA: 10C5.10) USDA: 10C5.10 violinID:1162 generated using OntoRat YL Avian Pneumovirus Modified Live Virus Vaccine (USDA: 1A31.20) USDA: 1A31.20 violinID:1164 generated using OntoRat YL Avian Reovirus Killed Virus Vaccine (USDA: 1045.00) USDA: 1045.00 violinID:1166 generated using OntoRat YL Avian Reovirus Killed Virus Vaccine (USDA: 1045.01) USDA: 1045.01 violinID:1167 generated using OntoRat YL Avian Reovirus Killed Virus Vaccine (USDA: 1045.02) USDA: 1045.02 violinID:1168 generated using OntoRat YL Avian Reovirus Killed Virus Vaccine (USDA: 1045.30) USDA: 1045.30 violinID:1169 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.11) USDA: 1231.11 violinID:1361 generated using OntoRat YL Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.1M) USDA: 1231.1M violinID:1373 generated using OntoRat YL Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.20) USDA: 1231.20 violinID:1375 generated using OntoRat YL Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.21) USDA: 1231.21 violinID:1376 generated using OntoRat YL Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.22) USDA: 1231.22 violinID:1377 generated using OntoRat YL Bronchitis Conn Type, Live Virus Vaccine (USDA: 1231.15) USDA: 1231.15 violinID:1365 generated using OntoRat YL Bronchitis Delaware Type, Modified Live Virus Vaccine (USDA: 1231.1D) USDA: 1231.1D violinID:1368 generated using OntoRat YL Bronchitis Georgia Type, Live Virus Vaccine (USDA: 1231.1J) USDA: 1231.1J violinID:1371 generated using OntoRat YL Bronchitis Georgia Type, Live Virus Vaccine (USDA: 1231.1L) USDA: 1231.1L violinID:1372 generated using OntoRat YL Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1235.15) USDA: 1235.15 violinID:1382 generated using OntoRat YL Bronchitis Mass & Ark Types, Live Virus Vaccine (USDA: 1231.13) USDA: 1231.13 violinID:1363 generated using OntoRat YL Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA: 1231.14) USDA: 1231.14 violinID:1364 generated using OntoRat YL Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA: 1231.1G) USDA: 1231.1G violinID:1370 generated using OntoRat YL Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA:1231.1N) USDA:1231.1N violinID:1374 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.12) USDA: 1231.12 violinID:1362 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.18) USDA: 1231.18 violinID:1366 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.1A) USDA: 1231.1A violinID:1367 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.1F) USDA: 1231.1F violinID:1369 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1232.10) USDA: 1232.10 violinID:1378 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1232.15) USDA: 1232.15 violinID:1379 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1233.10) USDA: 1233.10 violinID:1380 generated using OntoRat YL Bronchitis Mass Type, Live Virus Vaccine (USDA: 1235.10) USDA: 1235.10 violinID:1381 generated using OntoRat YL Bursal Disease Killed Virus Vaccine (USDA: 1275.00) USDA: 1275.00 violinID:1403 generated using OntoRat YL Bursal Disease Killed Virus Vaccine (USDA: 1275.02) USDA: 1275.02 violinID:1404 generated using OntoRat YL Bursal Disease Killed Virus Vaccine (USDA: 1275.20) USDA: 1275.20 violinID:1405 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.00) USDA: 1271.00 violinID:1386 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.01) USDA: 1271.01 violinID:1387 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.02) USDA: 1271.02 violinID:1388 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.04) USDA: 1271.04 violinID:1389 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.0A) USDA: 1271.0A violinID:1390 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.10) USDA: 1271.10 violinID:1391 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.11) USDA: 1271.11 violinID:1392 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.12) USDA: 1271.12 violinID:1393 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.13) USDA: 1271.13 violinID:1394 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.16) USDA: 1271.16 violinID:1396 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.17) USDA: 1271.17 violinID:1397 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.18) USDA: 1271.18 violinID:1398 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.19) USDA: 1271.19 violinID:1399 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.40) USDA: 1271.40 violinID:1400 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1271.41) USDA: 1271.41 violinID:1401 generated using OntoRat YL Bursal Disease Live Virus Vaccine (USDA: 1272.00) USDA: 1272.00 violinID:1402 generated using OntoRat YL Bursal Disease Modified Live VirusVaccine (USDA: 1271.15) USDA: 1271.15 violinID:1395 generated using OntoRat YL Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.01) USDA: 12B5.01 violinID:1409 generated using OntoRat YL Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.40) USDA: 12B5.40 violinID:1410 generated using OntoRat YL Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.41) USDA: 12B5.41 violinID:1411 generated using OntoRat YL Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.4A) USDA: 12B5.4A violinID:1412 generated using OntoRat YL Bursal Disease Standard & Variant, Live Virus Vaccine (USDA: 12B1.00) USDA: 12B1.00 violinID:1407 generated using OntoRat YL Bursal Disease Standard & Variant, Live Virus Vaccine (USDA: 12B1.01) USDA: 12B1.01 violinID:1408 generated using OntoRat YL Bursal Disease Variant, Killed Virus Vaccine (USDA: 12A5.00) USDA: 12A5.00 violinID:1406 generated using OntoRat YL Bursal Disease Variant, Live Virus Vaccine (USDA: 12L1.00) USDA: 12L1.00 violinID:1413 generated using OntoRat YL Chicken Anemia Virus Live Virus Vaccine (USDA: 10A1.00) USDA: 10A1.00 violinID:1697 generated using OntoRat YL Chicken Anemia Virus Live Virus Vaccine (USDA: 10A1.01) USDA: 10A1.01 violinID:1698 generated using OntoRat YL Chicken Anemia Virus Modified Live Virus Vaccine (USDA: 10A1.10) USDA: 10A1.10 violinID:1699 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.50) USDA: 1431.50 violinID:1702 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.51) USDA: 1431.51 violinID:1703 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.56) USDA: 1431.56 violinID:1705 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.57) USDA: 1431.57 violinID:1706 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.58) USDA: 1431.58 violinID:1707 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.59) USDA: 1431.59 violinID:1708 generated using OntoRat YL Coccidiosis Live Oocysts Vaccine (USDA: 1431.5C) USDA: 1431.5C violinID:1709 generated using OntoRat YL Coccidiosis Live Oocysts, Chicken Isolates Vaccine (USDA: 1431.55) USDA: 1431.55 violinID:1704 generated using OntoRat YL Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.01) USDA: 1601.01 violinID:1903 generated using OntoRat YL Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.02) USDA: 1601.02 violinID:1904 generated using OntoRat YL Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.11) USDA: 1601.11 violinID:1905 generated using OntoRat YL Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.13) USDA: 1601.13 violinID:1906 generated using OntoRat YL Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.14) USDA: 1601.14 violinID:1907 generated using OntoRat YL Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.15) USDA: 1601.15 violinID:1908 generated using OntoRat YL Fowl Pox Live Virus Vaccine (USDA: 1621.00) USDA: 1621.00 violinID:1913 generated using OntoRat YL Fowl Pox Live Virus Vaccine (USDA: 1621.10) USDA: 1621.10 violinID:1914 generated using OntoRat YL Fowl Pox Live Virus Vaccine (USDA: 1621.11) USDA: 1621.11 violinID:1915 generated using OntoRat YL Fowl Pox Live Virus Vaccine (USDA: 1621.13) USDA: 1621.13 violinID:1916 generated using OntoRat YL Fowl Pox Live Virus Vaccine (USDA: 1621.14) USDA: 1621.14 violinID:1917 YL Fowl Pox Live Virus Vaccine (USDA: 1622.00) USDA: 1622.00 violinID:1918 generated using OntoRat YL Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.00) USDA: 16L1.00 violinID:1945 generated using OntoRat YL Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.04) USDA: 16L1.04 violinID:1948 generated using OntoRat YL Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.09) USDA: 16L1.09 violinID:1952 generated using OntoRat YL Marek's Disease Serotype 2, Live Virus Vaccine (USDA: 1631.00) USDA: 1631.00 violinID:1934 generated using OntoRat YL Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.00) USDA: 1641.00 violinID:1936 generated using OntoRat YL Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.01) USDA: 1641.01 violinID:1937 generated using OntoRat YL Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.06) USDA: 1641.06 violinID:1938 generated using OntoRat YL Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 16L1.06) USDA: 16L1.06 violinID:1949 generated using OntoRat YL Marek's Disease Serotypes 1 & 2 & 3, Live Virus Vaccine (USDA: 16L1.01) USDA: 16L1.01 violinID:1946 generated using OntoRat YL Marek's Disease Serotypes 1 & 3, Live Herpesvirus Chimera Vaccine (USDA: 1631.R0) USDA: 1631.R0 violinID:1935 generated using OntoRat YL Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16G1.02) USDA: 16G1.02 violinID:1944 generated using OntoRat YL Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16L1.02) USDA: 16L1.02 violinID:1947 generated using OntoRat YL Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16L1.08) USDA: 16L1.08 violinID:1951 generated using OntoRat YL Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.00) USDA: 1651.00 violinID:1939 generated using OntoRat YL Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.01) USDA: 1651.01 violinID:1940 generated using OntoRat YL Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.02) USDA: 1651.02 violinID:1941 generated using OntoRat YL Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.05) USDA: 1651.05 violinID:1942 generated using OntoRat YL Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 16G1.00) USDA: 16G1.00 violinID:1943 generated using OntoRat YL Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 16L1.07) USDA: 16L1.07 violinID:1950 generated using OntoRat YL Mycoplasma Gallisepticum Live Culture Vaccine (USDA: 1751.00) USDA: 1751.00 violinID:1973 generated using OntoRat YL Mycoplasma Gallisepticum Live Culture Vaccine (USDA: 1751.01) USDA: 1751.01 violinID:1974 generated using OntoRat YL Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.10) USDA: 1711.10 violinID:1981 generated using OntoRat YL Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.12) USDA: 1711.12 violinID:1982 generated using OntoRat YL Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.14) USDA: 1711.14 violinID:1983 generated using OntoRat YL Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.18) USDA: 1711.18 violinID:1984 generated using OntoRat YL Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 17A2.10) USDA: 17A2.10 violinID:1991 generated using OntoRat YL Newcastle Disease B1 Type, C2 Strain, Live VirusVaccine (USDA: 17B1.10) USDA: 17B1.10 violinID:1993 generated using OntoRat YL Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.0A) USDA: 1721.0A violinID:1985 generated using OntoRat YL Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.10) USDA: 1721.10 violinID:1986 generated using OntoRat YL Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.11) USDA: 1721.11 violinID:1987 generated using OntoRat YL Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.15) USDA: 1721.15 violinID:1988 generated using OntoRat YL Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.16) USDA: 1721.16 violinID:1989 generated using OntoRat YL Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.17) USDA: 1721.17 violinID:1990 generated using OntoRat YL Newcastle Disease Killed Virus Vaccine (USDA: 1705.10) USDA: 1705.10 violinID:1977 generated using OntoRat YL Newcastle Disease Killed Virus Vaccine (USDA: 1705.11) USDA: 1705.11 violinID:1978 generated using OntoRat YL Newcastle Disease Killed Virus Vaccine (USDA: 1705.13) USDA: 1705.13 violinID:1979 generated using OntoRat YL Newcastle Disease Killed Virus Vaccine (USDA: 1705.15) USDA: 1705.15 violinID:1980 generated using OntoRat YL Newcastle Disease VG/GA Strain, Live Virus Vaccine (USDA: 1701.10) USDA: 1701.10 violinID:1976 generated using OntoRat YL Newcastle Disease VG/GA Strain, Live Virus Vaccine (USDA: 17A2.V1) USDA: 17A2.V1 violinID:1992 generated using OntoRat YL Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.01) USDA: 1871.01 violinID:2087 generated using OntoRat YL Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.02) USDA: 1871.02 violinID:2088 generated using OntoRat YL Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.03) USDA: 1871.03 violinID:2089 generated using OntoRat YL Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.04) USDA: 1871.04 violinID:2090 generated using OntoRat YL Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.05) USDA: 1871.05 violinID:2091 generated using OntoRat YL Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.00) USDA: 19C1.00 violinID:2124 generated using OntoRat YL Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.01) USDA: 19C1.01 violinID:2125 generated using OntoRat YL Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.02) USDA: 19C1.02 violinID:2126 generated using OntoRat YL Tenosynovitis Live Virus Vaccine (USDA: 1951.10) USDA: 1951.10 violinID:2139 generated using OntoRat YL Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.01) USDA: 1951.01 violinID:2135 generated using OntoRat YL Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.02) USDA: 1951.02 violinID:2136 generated using OntoRat YL Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.03) USDA: 1951.03 violinID:2137 generated using OntoRat YL Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.04) USDA: 1951.04 violinID:2138 generated using OntoRat YL Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.11) USDA: 1951.11 violinID:2140 generated using OntoRat YL Tenosynovitis Modified Live Virus Vaccine (USDA: 1952.01) USDA: 1952.01 violinID:2141 generated using OntoRat YL Duck Virus Enteritis Modified Live Virus Vaccine (USDA: 1461.10) USDA: 1461.10 violinID:1712 generated using OntoRat YL Duck Virus Hepatitis Modified Live Virus Vaccine (USDA: 14B1.10) USDA: 14B1.10 violinID:1713 generated using OntoRat YL Riemerella Anatipestifer Avirulent Live Culture Vaccine (USDA: 1811.00) USDA: 1811.00 violinID:2120 generated using OntoRat YL Flavobacterium Columnare Avirulent Live Culture Vaccine (USDA: 17F1.00) USDA: 17F1.00 violinID:1902 generated using OntoRat YL Bordetella Bronchiseptica Avirulent Live Culture Vaccine (USDA: 1081.00) USDA: 1081.00 violinID:1172 generated using OntoRat YL Bordetella Bronchiseptica Avirulent Live Culture Vaccine (USDA: 1081.01) USDA: 1081.01 violinID:1173 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.20) USDA: 14P5.20 violinID:1562 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.21) USDA: 14P5.21 violinID:1563 generated using OntoRat YL Canine Coronavirus Modified Live Virus Vaccine (USDA: 14P1.20) USDA: 14P1.20 violinID:1561 generated using OntoRat YL Canine Influenza H3N8, Killed Virus Vaccine (USDA: 15K5.20) USDA: 15K5.20 violinID:1691 generated using OntoRat YL Canine Parainfluenza Modified Live Virus Vaccine (USDA: 1421.21) USDA: 1421.21 violinID:1692 generated using OntoRat YL Distemper Live Canarypox Vector Vaccine (USDA: 1471.R0) USDA: 1471.R0 violinID:1711 generated using OntoRat YL Distemper Modified Live Virus Vaccine (USDA: 1471.10) USDA: 1471.10 violinID:1710 generated using OntoRat YL Giardia Lamblia Killed Protozoa Vaccine (USDA: 18G5.00) USDA: 18G5.00 violinID:1926 generated using OntoRat YL Neospora Caninum Killed Protozoa Vaccine (USDA: 1N11.00) USDA: 1N11.00 violinID:1975 generated using OntoRat YL Parvovirus Killed Virus Vaccine (USDA: 18P5.20) USDA: 18P5.20 violinID:2085 generated using OntoRat YL Parvovirus Killed Virus Vaccine (USDA: 18P5.21) USDA: 18P5.21 violinID:2086 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine (USDA: 18M1.20) USDA: 18M1.20 violinID:2079 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine (USDA: 18M1.21) USDA: 18M1.21 violinID:2080 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine (USDA: 18M1.22) USDA: 18M1.22 violinID:2081 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine (USDA: 18M1.23) USDA: 18M1.23 violinID:2082 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine (USDA: 18M1.25) USDA: 18M1.25 violinID:2083 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine (USDA: 18M1.29) USDA: 18M1.29 violinID:2084 generated using OntoRat YL Rabies Killed Virus Vaccine (USDA: 1905.20) USDA: 1905.20 violinID:2115 generated using OntoRat YL Rabies Killed Virus Vaccine (USDA: 1905.21) USDA: 1905.21 violinID:2116 generated using OntoRat YL Rabies Killed Virus Vaccine (USDA: 1905.22) USDA: 1905.22 violinID:2117 generated using OntoRat YL Rabies Killed Virus Vaccine (USDA: 1905.23) USDA: 1905.23 violinID:2118 generated using OntoRat YL Rabies Killed Virus Vaccine (USDA: 1905.24) USDA: 1905.24 violinID:2119 generated using OntoRat YL Rabies Live Canarypox Vector Vaccine (USDA: 1901.R1) USDA: 1901.R1 violinID:2113 generated using OntoRat YL Rabies Live Canarypox Vector Vaccine (USDA: 1901.R6) USDA: 1901.R6 violinID:2114 generated using OntoRat YL Rabies Live Vaccinia Vector Vaccine (USDA: 1901.R0) USDA: 1901.R0 violinID:2112 generated using OntoRat YL Equine Arteritis Modified Live Virus Vaccine (USDA: 1531.20) USDA: 1531.20 violinID:1731 generated using OntoRat YL Equine Influenza Killed Virus Vaccine (USDA: 1505.10) USDA: 1505.10 violinID:1735 generated using OntoRat YL Equine Influenza Killed Virus Vaccine (USDA: 1505.20) USDA: 1505.20 violinID:1736 generated using OntoRat YL Equine Influenza Killed Virus Vaccine (USDA: 1505.21) USDA: 1505.21 violinID:1737 generated using OntoRat YL Equine Influenza Killed Virus Vaccine (USDA: 1505.24) USDA: 1505.24 violinID:1738 generated using OntoRat YL Equine Influenza Killed Virus Vaccine (USDA: 1505.25) USDA: 1505.25 violinID:1739 generated using OntoRat YL Equine Influenza Killed Virus Vaccine (USDA: 1505.28) USDA: 1505.28 violinID:1740 generated using OntoRat YL Equine Influenza Live Canarypox Vector Vaccine (USDA: 1501.R0) USDA: 1501.R0 violinID:1734 generated using OntoRat YL Equine Influenza Modified Live Virus Vaccine (USDA: 1501.10) USDA: 1501.10 violinID:1732 generated using OntoRat YL Equine Influenza Modified Live Virus Vaccine (USDA: 1501.20) USDA: 1501.20 violinID:1733 generated using OntoRat YL Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.20) USDA: 1525.20 violinID:1742 generated using OntoRat YL Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.21) USDA: 1525.21 violinID:1743 generated using OntoRat YL Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.22) USDA: 1525.22 violinID:1744 generated using OntoRat YL Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.24) USDA: 1525.24 violinID:1745 generated using OntoRat YL Equine Rhinopneumonitis Modified Live Virus Vaccine (USDA: 1521.20) USDA: 1521.20 violinID:1741 generated using OntoRat YL Equine Rotavirus Killed Virus Vaccine (USDA: 1E15.20) USDA: 1E15.20 violinID:1756 generated using OntoRat YL Streptococcus Equi Live Culture Vaccine (USDA: 1831.00) USDA: 1831.00 violinID:2127 generated using OntoRat YL Avian Polyomavirus Killed Virus Vaccine (USDA: 1A15.00) USDA: 1A15.00 violinID:1165 generated using OntoRat YL Chlamydia Psittaci Killed Chlamydia Vaccine (USDA: 1585.20) USDA: 1585.20 violinID:1701 generated using OntoRat YL Chlamydia Psittaci Modified Live Chlamydia Vaccine (USDA: 1581.20) USDA: 1581.20 violinID:1700 generated using OntoRat YL Pacheco's Disease Killed Virus Vaccine (USDA: 18C5.00) USDA: 18C5.00 violinID:2076 generated using OntoRat YL Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.00) USDA: 1541.00 violinID:1757 generated using OntoRat YL Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.01) USDA: 1541.01 violinID:1758 generated using OntoRat YL Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.02) USDA: 1541.02 violinID:1759 generated using OntoRat YL Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.03) USDA: 1541.03 violinID:1760 generated using OntoRat YL Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.04) USDA: 1541.04 violinID:1761 generated using OntoRat YL Haemophilus Parasuis Avirulent Live Culture Vaccine (USDA: 19J1.00) USDA: 19J1.00 violinID:1927 generated using OntoRat YL Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.00) USDA: 10L1.00 violinID:1929 generated using OntoRat YL Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.01) USDA: 10L1.01 violinID:1930 generated using OntoRat YL Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.02) USDA: 10L1.02 violinID:1931 generated using OntoRat YL Porcine Circovirus Type 2, Killed Virus Vaccine (USDA: 19K5.20) USDA: 19K5.20 violinID:2095 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome Reproductive & Respiratory Form, Modified Live Virus Vaccine (USDA: 19T1.20) USDA: 19T1.20 violinID:2102 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome Reproductive & Respiratory Form, Modified Live Virus Vaccine (USDA: 19T1.21) USDA: 19T1.21 violinID:2103 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome Reproductive Form, Killed Virus Vaccine (USDA: 19S5.20) USDA: 19S5.20 violinID:2101 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome Reproductive Form, Modified Live Virus Vaccine (USDA: 19Q1.20) USDA: 19Q1.20 violinID:2098 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine (USDA: 19S1.20) USDA: 19S1.20 violinID:2099 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine (USDA: 19S1.21) USDA: 19S1.21 violinID:2100 generated using OntoRat YL Porcine Rotavirus Modified Live Virus Vaccine (USDA: 19E1.20) USDA: 19E1.20 violinID:2104 generated using OntoRat YL Pseudorabies Modified Live Virus Vaccine (USDA: 1891.20) USDA: 1891.20 violinID:2107 generated using OntoRat YL Pseudorabies Modified Live Virus Vaccine (USDA: 1891.22) USDA: 1891.22 violinID:2108 generated using OntoRat YL Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R2) USDA: 1891.R2 violinID:2109 generated using OntoRat YL Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R4) USDA: 1891.R4 violinID:2110 generated using OntoRat YL Swine Influenza pH1N1, Killed Virus Vaccine (USDA: 19A5.2P) USDA: 19A5.2P violinID:2134 generated using OntoRat YL Transmissible Gastroenteritis Modified Live Virus Vaccine (USDA: 1961.20) USDA: 1961.20 violinID:2142 generated using OntoRat YL West Nile Virus Killed Virus Vaccine (USDA: 1995.20) USDA: 1995.20 violinID:2147 generated using OntoRat YL West Nile Virus Killed Virus Vaccine (USDA: 1995.22) USDA: 1995.22 violinID:2148 generated using OntoRat YL West Nile Virus Live Canarypox Vector Vaccine (USDA: 1991.R0) USDA: 1991.R0 violinID:2145 generated using OntoRat YL West Nile Virus Live Flavivirus Chimera Vaccine (USDA: 1991.R1) USDA: 1991.R1 violinID:2146 generated using OntoRat YL Bluetongue Modified Live Virus Vaccine (USDA: 1061.00) USDA: 1061.00 violinID:1170 YH WEB: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM518295.pdf http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5554 5554 Trade Name: Afluria Quadrivalent Afluria Quadrivalent CVX: 150 generated using OntoRat YL Arthrobacter Live Culture Vaccine (USDA: 1K11.00) USDA: 1K11.00 violinID:1123 generated using OntoRat YL Bordetella Avium Avirulent Live Culture Vaccine (USDA: 1021.01) USDA: 1021.01 violinID:1171 generated using OntoRat YL Escherichia coli avirulent live culture vaccine (USDA: 1551.02) USDA: 1551.02 violinID:1762 generated using OntoRat YL Escherichia coli avirulent live culture vaccine (USDA: 15R1.00) USDA: 15R1.00 violinID:1764 YL Escherichia coli live culture vaccine (USDA: 1551.R0) USDA: 1551.R0 violinID:1763 generated using OntoRat YL Hemorrhagic Enteritis Live Virus Vaccine (USDA: 17E1.20) USDA: 17E1.20 violinID:1928 generated using OntoRat YL Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine (USDA: 19K5.R0) USDA: 19K5.R0 violinID:2096 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.12) USDA: 19A5.12 violinID:2128 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.22) USDA: 19A5.22 violinID:2129 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.23) USDA: 19A5.23 violinID:2130 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.24) USDA: 19A5.24 violinID:2131 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.26) USDA: 19A5.26 violinID:2132 YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.29) USDA: 19A5.29 violinID:2133 generated using OntoRat YL Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine (USDA: 1679.31) USDA: 1679.31 violinID:1970;1971 generated using OntoRat YL Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid (USDA: 4929.31) USDA: 4929.31 violinID:2884;2885;2886 generated using OntoRat YL Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 4949.20) USDA: 4949.20 violinID:2887;28882889;2890 generated using OntoRat YL Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 4949.31) USDA: 4949.31 violinID:2891;2892;2893;2894 generated using OntoRat YL Mink Distemper-Enteritis Modified Live Virus & Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4929.20) USDA: 4929.20 violinID:2881;2882;2883 generated using OntoRat YL Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4955.20) USDA: 4955.20 violinID:2895;2896 generated using OntoRat YL Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4955.21) USDA: 4955.21 violinID:2897;2898 generated using OntoRat YL Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 49A5.20) USDA: 49A5.20 violinID:2899;2900;2901 generated using OntoRat YL Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 49A5.21) USDA: 49A5.21 violinID:2902;2903;2904 generated using OntoRat YL Feline Immunodeficiency-Leukemia Virus Killed Virus Vaccine (USDA: 15D5.R0) USDA: 15D5.R0 violinID:1769;1770 generated using OntoRat YL Feline Leukemia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1A69.20) USDA: 1A69.20 violinID:1777;1778 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 15B5.20) USDA: 15B5.20 violinID:1779;1780;1781;1782 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 15B5.21) USDA: 15B5.21 violinID:1783;1784;1785;1786 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 15B9.20) USDA: 15B9.20 violinID:1787;1788;1789;1790 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 15B9.21) USDA: 15B9.21 violinID:1791;1792;1793;1794 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.20) USDA: 1559.20 violinID:1795;1796;1797;1798;1799 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.23) USDA: 1559.23 violinID:1800;1801;1802;1803;1804 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live & Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.2C) USDA: 1559.2C violinID:1810;1811;1812;1813;1814 generated using OntoRat YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live & Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1559.2B) USDA: 1559.2B violinID:1805;1806;1807;1808;1809 generated using OntoRat YL Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.20) USDA: 16F1.20 violinID:1821;1822;1823 generated using OntoRat YL Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.21) USDA: 16F1.21 violinID:1824;1825;1826 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 16D5.20) USDA: 16D5.20 violinID:1839;1840;1841 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 16D5.23) USDA: 16D5.23 violinID:1842;1843;1844 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 16D9.20) USDA: 16D9.20 violinID:1851;1852;1853 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.20) USDA: 16D1.20 violinID:1827;1828;1829 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.22) USDA: 16D1.22 violinID:1830;1831;1832 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.23) USDA: 16D1.23 violinID:1833;1834;1835 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.24) USDA: 16D1.24 violinID:1836;1837;1838 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D8.20) USDA: 16D8.20 violinID:1845;1846;1847 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D8.21) USDA: 16D8.21 violinID:1848;1849;1850 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 16E5.20) USDA: 16E5.20 violinID:1862;1863;18641865 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 16E5.23) USDA: 16E5.23 violinID:1866;1867;1868;1869 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Killed Chlamydia Vaccine (USDA: 16E6.20) USDA: 16E6.20 violinID:1870;1871;1872;1873 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E1.20) USDA: 16E1.20 violinID:1854;1855;1856;1857 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E1.24) USDA: 16E1.24 violinID:1858;1859;1860;1861 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E8.20) USDA: 16E8.20 violinID:1874;1875;1876;1877 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live & Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1619.20) USDA: 1619.20 violinID:1878;1879;1880;1881 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live Virus and Chlamydia, Canarypox Vector Vaccine (USDA: 1619.R1) USDA: 1619.R1 violinID:1883;18841885;1886;1887 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live & Killed Virus Vaccine (USDA: 16T9.20) USDA: 16T9.20 violinID:1888;1889;1890;1891 generated using OntoRat YL Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live Virus, Canarypox Vector Vaccine (USDA: 16T9.R0) USDA: 16T9.R0 violinID:1892;1893;1894;1895 generated using OntoRat YL Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.20) USDA: 16C1.20 violinID:1896;1897 generated using OntoRat YL Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.21) USDA: 16C1.21 violinID:1898;1899 generated using OntoRat YL Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.22) USDA: 16C1.22 violinID:1899;1900 generated using OntoRat YL Bovine Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1161.00) USDA: 1161.00 violinID:1174;1175 generated using OntoRat YL Bovine Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1161.20) USDA: 1161.20 violinID:1176;1177 generated using OntoRat YL Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45H5.20) USDA: 45H5.20 violinID:2152;2153;2154;2155 generated using OntoRat YL Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45H5.21) USDA: 45H5.21 violinID:2156;2157;2158;2159 generated using OntoRat YL Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid (USDA: 4109.20) USDA: 4109.20 violinID:2160;2161;2162;2163;2164 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4019.00) USDA: 4019.00 violinID:2165;2166 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4059.00) USDA: 4059.00 violinID:2167;2168 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Hardjo-Pomona Bacterin (USDA: 4069.20) USDA: 4069.20 violinID:2169;2170 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4089.00) USDA: 4089.00 violinID:2171;2172 generated using OntoRat YL Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4089.20) USDA: 4089.20 violinID:2173;2174 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Killed Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin (USDA: 4265.00) USDA: 4265.00 violinID:2187;2188;2189;2190 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.00) USDA: 1121.00 violinID:1187;1188 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.20) USDA: 1121.20 violinID:1189;1190 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.21) USDA: 1121.21 violinID:1191;1192 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.24) USDA: 1121.24 violinID:1193;1194 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.31) USDA: 1121.31 violinID:1195;1196 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 4139.20) USDA: 4139.20 violinID:2175;2176;2177 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4129.00) USDA: 4129.00 violinID:2178;2179;2180 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4179.00) USDA: 4179.00 violinID:2181;2182;2183 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4209.00) USDA: 4209.00 violinID:2184;2185;2186 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.00) USDA: 1071.00 violinID:1197;1198;1199 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.20) USDA: 1071.20 violinID:1200;1201;1202 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.21) USDA: 1071.21 violinID:1203;1204;1205 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.22) USDA: 1071.22 violinID:1206;1207;1208 generated using OntoRat YL Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.23) USDA: 1071.23 violinID:1209;1210;1211 generated using OntoRat YL Bovine Rhinotracheitis-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 11B5.20) USDA: 11B5.20 violinID:1213;1214 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine (USDA: 1155.20) USDA: 1155.20 violinID:1224;1225 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine (USDA: 1155.30) USDA: 1155.30 violinID:1226;1227 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4145.20) USDA: 4145.20 violinID:2195;2196;2197;2198 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4145.21) USDA: 4145.21 violinID:2199;2200;2201;2202 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 43S5.20) USDA: 43S5.20 violinID:2203;22042205;2206;2207 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid (USDA: 43T5.20) USDA: 43T5.20 violinID:2208;2209;2210;2211;2212;2213 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4335.20) USDA: 4335.20 violinID:2214;2215;2216 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4336.30) USDA: 4336.30 violinID:2217;2218;2219 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.00) USDA: 1151.00 violinID:1214;1215 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.20) USDA: 1151.20 violinID:1216;1217 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.22) USDA: 1151.22 violinID:1218;1219 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.23) USDA: 1151.23 violinID:1220;1221 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.26) USDA: 1151.26 violinID:1222;1223 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4141.20) USDA: 4141.20 violinID:2191;2192;2193;2194 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4339.00) USDA: 4339.00 violinID:2220;2221;2222 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4359.00) USDA: 4359.00 violinID:2223;2224;2225 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Hardjo-Pomona Bacterin (USDA: 4399.20) USDA: 4399.20 violinID:2226;2227;2228 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.00) USDA: 4389.00 violinID:2229;2230;2231 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.20) USDA: 4389.20 violinID:2232;2233;2234 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.21) USDA: 4389.21 violinID:2235;2236;2237 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Killed Virus Vaccine (USDA: 1175.20) USDA: 1175.20 violinID:1252;1253;1254 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4435.20) USDA: 4435.20 violinID:2252;2253;2254;2255 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.00) USDA: 1171.00 violinID:1228;1229;1230 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.20) USDA: 1171.20 violinID:1231;1232;1233 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.22) USDA: 1171.22 violinID:1234;1235;1236 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.24) USDA: 1171.24 violinID:1237;1238;1239 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.25) USDA: 1171.25 violinID:1240;1241;1242 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.26) USDA: 1171.26 violinID:1243;1244;1245 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.27) USDA: 1171.27 violinID:1246;1247;1248 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.30) USDA: 1171.30 violinID:1249;1250;1251 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4560.24) USDA: 4560.24 violinID:2238;2239;2240;2241 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4560.25) USDA: 4560.25 violinID:2242;2243;2244;2245 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Haemophilus somnus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4489.30) USDA: 4489.30 violinID:2246;2247;2248;2249;2250;2251 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4439.00) USDA: 4439.00 violinID:2256;2257;2258;2259 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4439.20) USDA: 4439.20 violinID:2260;2261;2262;2263 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4479.00) USDA: 4479.00 violinID:2264;2265;2266;2267 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4509.00) USDA: 4509.00 violinID:2268;2269;2270;2271 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Mannheimia Haemolytica Bacterin (USDA: 44A5.20) USDA: 44A5.20 violinID:2486;2487;2488;2489 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.00) USDA: 1181.00 violinID:1255;1256;1257;1258 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.20) USDA: 1181.20 violinID:1259;1260;1261;1262 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.21) USDA: 1181.21 violinID:1263;1263;1265;1266 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.22) USDA: 1181.22 violinID:1267;1268;1269;1270 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.23) USDA: 1181.23 violinID:1271;1272;1273;1274 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.24) USDA: 1181.24 violinID:1275;1276;1277;1278 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.25) USDA: 1181.25 violinID:1279;1280;1281;1282 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.26) USDA: 1181.26 violinID:1283;1284;1285;1286 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.28) USDA: 1181.28 violinID:1287;1288;1289;1290 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.30) USDA: 1181.30 violinID:1291;1292;1293;1294 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1185.20) USDA: 1185.20 violinID:1295;1296;1297;1298 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1185.22) USDA: 1185.22 violinID:1299;1300;1301;1302 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44M5.20) USDA: 44M5.20 violinID:2277;2278;2279;2280;2281;2282 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44M5.22) USDA: 44M5.22 violinID:2283;2284;2285;2286;2287;2288 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B5.20) USDA: 44B5.20 violinID:2313;2314;2315;2316;2317;2318 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B6.20) USDA: 44B6.20 violinID:2319;2320;2321;2322;2323;2324 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B6.21) USDA: 44B6.21 violinID:2325;2326;2327;2328;2329;2330 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C5.20) USDA: 44C5.20 violinID:2343;2344;2345;2346 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C7.20) USDA: 44C7.20 violinID:2347;2348;2349;2350 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44D5.20) USDA: 44D5.20 violinID:2367;2368;2369;2370 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D7.20) USDA: 44D7.20 violinID:2375;2376;2377;2378;2379 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D7.22) USDA: 44D7.22 violinID:2380;2381;2382;2383;2384 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica Bacterin (USDA: 4477.20) USDA: 4477.20 violinID:2405;2406;2407;2408;2409 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.20) USDA: 4465.20 violinID:2426;2427;2428;2429 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.21) USDA: 4465.21 violinID:2430;2431;2432;2433 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.22) USDA: 4465.22 violinID:2434;2435;2436;2437 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4466.20) USDA: 4466.20 violinID:2438;2439;2440;2441 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4466.21) USDA: 4466.21 violinID:2442;2443;2444;2445 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona-Mannheimia Haemolytica Bacterin (USDA: 4475.20) USDA: 4475.20 violinID:2482;2483;2484;2485 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.20) USDA: 1187.20 violinID:1303;1304;1305;1306 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.21) USDA: 1187.21 violinID:1307;1308;1309;1310 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.22) USDA: 1187.22 violinID:1311;1312;1313;1314 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.25) USDA: 1187.25 violinID:1315;1316;1317;1318 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.00) USDA: 1189.00 violinID:1319;1320;1321;1322 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.21) USDA: 1189.21 violinID:1323;1324;1325;1326 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.30) USDA: 1189.30 violinID:1327;1328;1329;1330 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B9.21) USDA: 44B9.21 violinID:2331;2332;2333;2334;2335 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B9.22) USDA: 44B9.22 violinID:2337;2338;2339;2340;2341;2342 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44F9.20) USDA: 44F9.20 violinID:2371;2372;2373;2374 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.20) USDA: 4469.20 violinID:2454;2455;2456;2457 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.22) USDA: 4469.22 violinID:2458;2459;2460;2461 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.25) USDA: 4469.25 violinID:2470;2471;2472;2473 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.30) USDA: 4469.30 violinID:2478;2479;2480;2481 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.20) USDA: 44B1.20 violinID:2289;2290;2291;2292;2293;2294 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.22) USDA: 44B1.22 violinID:2295;2296;2297;2298;2299;2300 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.23) USDA: 44B1.23 violinID:2301;2302;2303;2304;2305;2306 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.25) USDA: 44B1.25 violinID:2307;2308;2309;2310;2311;2312 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.20) USDA: 44C9.20 violinID:2351;2352;2353;2354 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.21) USDA: 44C9.21 violinID:2355;2356;2357;2358 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.23) USDA: 44C9.23 violinID:2359;2360;2361;2362 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.24) USDA: 44C9.24 violinID:2363;2364;2365;2366 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.20) USDA: 44D9.20 violinID:2385;2386;2387;2388;2389 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.21) USDA: 44D9.21 violinID:2390;2391;2392;2393;2394 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.23) USDA: 44D9.23 violinID:2395;2396;2397;2398;2399 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.24) USDA: 44D9.24 violinID:2400;2401;2402;2403;2404 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.20) USDA: 4461.20 violinID:2410;2411;2412;2413 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.21) USDA: 4461.21 violinID:2414;2415;2416;2417 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.22) USDA: 4461.22 violinID:2418;2419;2420;2421 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.25) USDA: 4461.25 violinID:2422;2423;2424;2425 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.00) USDA: 4469.00 violinID:2446;2447;2448;2449 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.01) USDA: 4469.01 violinID:2450;2451;2452;2453 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.23) USDA: 4469.23 violinID:2462;2463;2464;2465 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.24) USDA: 4469.24 violinID:2466;2467;2468;2469 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.26) USDA: 4469.26 violinID:2474;2475;2476;2477 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Hardjo Bacterin (USDA: 4L49.20) USDA: 4L49.20 violinID:2272;2273;2274;2275;2276 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica Toxoid (USDA: 4X49.20) USDA: 4X49.20 violinID:2490;2491;2492;2493 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica Toxoid (USDA: 4X49.21) USDA: 4X49.21 violinID:2494;2495;2496;2497 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45B9.20) USDA: 45B9.20 violinID:2498;2499;2500;2501;2502 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45B9.21) USDA: 45B9.21 violinID:2503;2504;2505;2506;2507 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus-Mannheimia Haemolytica-Pasteurella Multocida Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 11A8.22) USDA: 11A8.22 violinID:1331;1332;1333;1334;1335;1336 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 11A5.20) USDA: 11A5.20 violinID:1346;1347;1348 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.20) USDA: 11A1.20 violinID:1337;1338;139 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.26) USDA: 11A1.26 violinID:1340;1341;1342 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.30) USDA: 11A1.30 violinID:1343;1344;1345 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.20) USDA: 4367.20 violinID:2508;2509;2510;2511 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.26) USDA: 4367.26 violinID:2512;2513;2514;2515 generated using OntoRat YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.30) USDA: 4367.30 violinID:2516;2517;2518;2519 generated using OntoRat YL Bovine Rotavirus-Coronavirus Modified Killed Virus Vaccine (USDA: 1935.20) USDA: 1935.20 violinID:1350 generated using OntoRat YL Bovine Rotavirus-Coronavirus Modified Live Virus Vaccine (USDA: 1931.20) USDA: 1931.20 violinID:1349 generated using OntoRat YL Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 4570.20) USDA: 4570.20 violinID:2520;2521;2522;2523 generated using OntoRat YL Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 4570.22) USDA: 4570.22 violinID:2524;2525;2526;2527 generated using OntoRat YL Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Types C & D-Escherichia Coli Bacterin-Toxoid (USDA: 4575.20) USDA: 4575.20 violinID:2528;2529;2530;2531 generated using OntoRat YL Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Escherichia Coli Bacterin (USDA: 4585.20) USDA: 4585.20 violinID:2532;2533;2534 generated using OntoRat YL Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Escherichia Coli Bacterin (USDA: 4585.22) USDA: 4585.22 violinID:2535;2536;2537 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 45B5.21) USDA: 45B5.21 violinID:2538;2539;2540 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 4C95.20) USDA: 4C95.20 violinID:2541;2542;2543;2544 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4595.21) USDA: 4595.21 violinID:2545;2546 generated using OntoRat YL Bovine Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4595.25) USDA: 4595.25 violinID:2547;2548 generated using OntoRat YL Bovine Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4599.00) USDA: 4599.00 violinID:2549;2550 generated using OntoRat YL Bovine Virus Diarrhea-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 12A5.20) USDA: 12A5.20 violinID:1360 generated using OntoRat YL Mannheimia Haemolytica-Pasteurella Multocida Avirulent Live Culture Vaccine (USDA: 1861.01) USDA: 1861.01 violinID:1932;1933 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox-Mycoplasma Gallisepticum Live Fowl Pox Vector, Live Virus Vaccine (USDA:1D61.R0) USDA:1D61.R0 violinID:1143;1145;1144 generated using OntoRat YL Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: ) USDA: violinID:1437;1438 generated using OntoRat YL Avian Influenza-Fowl Pox H5 Subtype, Live Fowl Pox Vector Vaccine (USDA: 1061.R0) USDA: 1061.R0 violinID:1161;1160 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.10 ) USDA: 10M1.10 violinID:1131;1130 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.11) USDA: 10M1.11 violinID:1133;1132 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.13) USDA: 10M1.13 violinID:1135;1134 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.14) USDA: 10M1.14 violinID:1137;1136 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.40) USDA: 10M1.40 violinID:1139;1138 generated using OntoRat YL Avian Encephalomyelitis-Fowl Pox-Laryngotracheitis Live Virus, Live Fowl Pox Vector Vaccine (USDA: 10S1.R0) USDA: 10S1.R0 violinID:1141;1140;1142 generated using OntoRat YL Avian Encephalomyelitis-Chicken Anemia Virus-Fowl Pox Live and Modified Live Virus Vaccine (USDA: 10T1.40) USDA: 10T1.40 violinID:1129;1128 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 1 & 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1281.R0) USDA: 1281.R0 violinID:1415;1416 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 1 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1281.R1) USDA: 1281.R1 violinID:1417;1418 generated using OntoRat YL Bursal Disease-Marek's Disease Variant, Serotype 3, Live Virus Vaccine (USDA: 1282.50) USDA: 1282.50 violinID:1419;1420 generated using OntoRat YL Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1288.42) USDA: 1288.42 violinID:1421;1422 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.43) USDA: 1288.43 violinID:1423;1424 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.44) USDA: 1288.44 violinID:1425;1426 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.45) USDA: 1288.45 violinID:1427;1428 generated using OntoRat YL Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1288.4A) USDA: 1288.4A violinID:1429;1430 generated using OntoRat YL Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.50) USDA: 12C2.50 violinID:1431;1432 generated using OntoRat YL Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.51) USDA: 12C2.51 violinID:1433;1434 generated using OntoRat YL Bursal Disease-Marek's Disease Variant Strain, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.52) USDA: 12C2.52 violinID:1435;1436 generated using OntoRat YL Bursal Disease-Marek's Disease Standard & Variant, Serotype 3, Live Virus Vaccine (USDA: 12C8.40) USDA: 12C8.40 violinID:1439;1440 generated using OntoRat YL Bursal Disease-Marek's Disease Standard & Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C8.42) USDA: 12C8.42 violinID:1441;1442 generated using OntoRat YL Bursal Disease-Marek's Disease Standard & Variant, Serotype 3, Live Virus Vaccine (USDA: 12C8.43) USDA: 12C8.43 violinID:1443;1444 generated using OntoRat YL Bursal Disease-Marek's Disease Standard & Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C8.44) USDA: 12C8.44 violinID:1445;1446 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.01) USDA: 12D5.01 violinID:1539;1540 generated using OntoRat YL Bursal Disease-Reovirus Killed Virus Vaccine (USDA: 12D5.02) USDA: 12D5.02 violinID:1541;1542 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.03) USDA: 12D5.03 violinID:1543;1544 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.04) USDA: 12D5.04 violinID:1545;1546 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.30) USDA: 12D5.30 violinID:1547;1548 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12D5.45) USDA: 12D5.45 violinID:1467;1465;1466 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.E0) USDA: 12D5.E0 violinID:1549;1550 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F0) USDA: 12D5.F0 violinID:1551;1552 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F1) USDA: 12D5.F1 violinID:1553;1554 generated using OntoRat YL Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.T0) USDA: 12D5.T0 violinID:1555;1556 generated using OntoRat YL Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.10) USDA: 12G5.10 violinID:1457;1458 generated using OntoRat YL Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.11) USDA: 12G5.11 violinID:1459;1460 generated using OntoRat YL Bursal Disease-Newcastle Disease Standard & Variant, Killed Virus Vaccine (USDA: 12G5.42) USDA: 12G5.42 violinID:1461;1462 generated using OntoRat YL Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.43) USDA: 12G5.43 violinID:1463;1464 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 12H1.4M) USDA: 12H1.4M violinID:1469;1468;1470 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 12H1.67) USDA: 12H1.67 violinID:1471;1473;1472 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.40) USDA: 12J5.40 violinID:1475;1474;1476 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.43) USDA: 12J5.43 violinID:1477;1479;1478 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12J5.61) USDA: 12J5.61 violinID:1481;1480;1482 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.62) USDA: 12J5.62 violinID:1483;1485;1484 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.00) USDA: 12M5.00 violinID:1487;1489;1486;1488 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.01) USDA: 12M5.01 violinID:1491;1493;1490;1492 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.11) USDA: 12M5.11 violinID:1495;1497;1494;1496 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Killed Virus Vaccine (USDA: 12M5.40) USDA: 12M5.40 violinID:1499;1501;1500;1498 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12M5.41) USDA: 12M5.41 violinID:1503;1505;1502;1504 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12M5.42) USDA: 12M5.42 violinID:1507;1509;1506;1508 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.43) USDA: 12M5.43 violinID:1511;1513;1510;1512 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.50) USDA: 12M5.50 violinID:1517;1515;1516;1514 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.90) USDA: 12M5.90 violinID:1519;1521;1518;1520 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.91) USDA: 12M5.91 violinID:1523;1525;1522;1524 generated using OntoRat YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.E0) USDA: 12M5.E0 violinID:1527;1529;1526;1528 generated using OntoRat YL Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.40) USDA: 12P5.40 violinID:1531;1532;1530 generated using OntoRat YL Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.41) USDA: 12P5.41 violinID:1533;1535;1534 generated using OntoRat YL Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.E0) USDA: 12P5.E0 violinID:1537;1536;1538 generated using OntoRat YL Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Modified Live Virus & Avirulent Live Culture Vaccine (USDA: 12X1.20) USDA: 12X1.20 violinID:1559;1558;1560 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.20) USDA: 1331.20 violinID:1657;1659;1658 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.25) USDA: 1331.25 violinID:1661;1660;1662 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.27) USDA: 1331.27 violinID:1665;1663;1664 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.30) USDA: 1331.30 violinID:1667;1666;1668 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus, Canarypox Vector Vaccine (USDA: 1331.R1) USDA: 1331.R1 violinID:1669;1671;1670 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Modified Live Virus Vaccine (USDA: 1341.20) USDA: 1341.20 violinID:1605;1607;1606;1608 generated using OntoRat YL Canine Distemper-Measles Modified Live Virus Vaccine (USDA: 1351.20) USDA: 1351.20 violinID:1685;1686 generated using OntoRat YL Canine Distemper-Hepatitis-Parainfluenza Modified Live Virus Vaccine (USDA: 1381.21) USDA: 1381.21 violinID:1683;1682;1684 generated using OntoRat YL Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine (USDA: 13A1.20) USDA: 13A1.20 violinID:1577;1576 generated using OntoRat YL Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine (USDA: 13A1.27) USDA: 13A1.27 violinID:1579;1578 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza Modified Live Virus Vaccine (USDA: 13C1.20) USDA: 13C1.20 violinID:1609;1611;1610 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.20) USDA: 13D1.20 violinID:1615;1613;1612;1614 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.21) USDA: 13D1.21 violinID:1617;1619;1616;1618 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.22) USDA: 13D1.22 violinID:1621;1623;1620;1622 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.23) USDA: 13D1.23 violinID:1625;1627;1624;1626 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.25) USDA: 13D1.25 violinID:1631;1629;1628;1630 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.27) USDA: 13D1.27 violinID:1633;1635;1632;1634 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.28) USDA: 13D1.28 violinID:1637;1639;1636;1638 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.29) USDA: 13D1.29 violinID:1641;1643;1640;1642 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus, Canarypox Vector Vaccine (USDA: 13D1.R1) USDA: 13D1.R1 violinID:1645;1647;1644;1646 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.T0) USDA: 13D1.T0 violinID:1649;1651;1648;1650 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Modified Live & Killed Virus Vaccine (USDA: 13G9.20) USDA: 13G9.20 violinID:1653;1655;1652;1654;1656 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Modified Live & Killed Virus Vaccine (USDA: 13H9.20) USDA: 13H9.20 violinID:1673;1675;1672;1674 generated using OntoRat YL Canine Distemper-Parvovirus Modified Live Virus Vaccine (USDA: 13P1.20) USDA: 13P1.20 violinID:1687;1688 generated using OntoRat YL Canine Distemper-Parvovirus Modified Live Virus Vaccine (USDA: 13P1.27) USDA: 13P1.27 violinID:1689;1690 A horse Encephalomyelitis-Influenza-West Nile Virus vaccine that is inactivated and manufactured by Wyeth Pharmaceuticals Inc. generated using OntoRat YL Encephalomyelitis-Influenza-West Nile Virus Eastern & Western, Killed Virus Vaccine (USDA: 13W5.20) USDA: 13W5.20 violinID:1717;1719;1718;1720 generated using OntoRat YL Encephalomyelitis Eastern & Western, Killed Virus Vaccine (USDA: 1475.00) USDA: 1475.00 violinID:1715;1716 generated using OntoRat YL Canine Distemper-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14D7.20) USDA: 14D7.20 violinID:1677;1676;1678 generated using OntoRat YL Canine Distemper-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14D9.27) USDA: 14D9.27 violinID:1681;1679;1680 generated using OntoRat YL Canine Parainfluenza-Bordetella Bronchiseptica Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 14M1.20) USDA: 14M1.20 violinID:1693;1694 generated using OntoRat YL Canine Parainfluenza-Bordetella Bronchiseptica Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 14M1.22) USDA: 14M1.22 violinID:1695;1696 generated using OntoRat YL Canine Coronavirus-Parvovirus Modified Live Virus Vaccine (USDA: 14R1.20) USDA: 14R1.20 violinID:1565;1564 generated using OntoRat YL Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.20) USDA: 14R7.20 violinID:1567;1566 generated using OntoRat YL Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.21) USDA: 14R7.21 violinID:1569;1568 generated using OntoRat YL Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.22) USDA: 14R7.22 violinID:1571;1570 generated using OntoRat YL Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.25) USDA: 14R7.25 violinID:1573;1572 generated using OntoRat YL Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.29) USDA: 14R7.29 violinID:1575;1574 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine (USDA: 14W5.22) USDA: 14W5.22 violinID:1721;1723;1722 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine (USDA: 14W5.23) USDA: 14W5.23 violinID:1725;1727;1724;1726 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus, Live Canarypox Vector Vaccine (USDA: 14W7.R0) USDA: 14W7.R0 violinID:1729;1728;1730 generated using OntoRat YL Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.24) USDA: 1515.24 violinID:1747;1746 generated using OntoRat YL Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.26) USDA: 1515.26 violinID:1749;1748 generated using OntoRat YL Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.27) USDA: 1515.27 violinID:1751;1750 generated using OntoRat YL Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.2A) USDA: 1515.2A violinID:1753;1752 generated using OntoRat YL Equine Rhinopneumonitis-Influenza Modified Live & Killed Virus Vaccine (USDA: 1518.20) USDA: 1518.20 violinID:1755;1754 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live Virus; Canarypox Vector Vaccine (USDA: 1591.R1) USDA: 1591.R1 violinID:1583;1581;1582;1584;1580 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.20) USDA: 1599.20 violinID:1585;1587;1589;1586;1588 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.21) USDA: 1599.21 violinID:1591;1593;1590;1592;1594 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.25) USDA: 1599.25 violinID:1599;1595;1597;1598;1596 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.29) USDA: 1599.29 violinID:1601;1603;1600;1602;1604 generated using OntoRat YL Fowl Pox-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 15E2.00) USDA: 15E2.00 violinID:1922;1921 generated using OntoRat YL Fowl Laryngotracheitis-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16J1.R1) USDA: 16J1.R1 violinID:1910;1909 generated using OntoRat YL Fowl Laryngotracheitis-Marek's Disease Serotypes 2 & 3, Modified Live & Live Marek's Disease Vector Vaccine (USDA: 16J1.R2) USDA: 16J1.R2 violinID:1912;1911 generated using OntoRat YL Marek's Disease-Newcastle Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16N1.R0) USDA: 16N1.R0 violinID:1954;1953 generated using OntoRat YL Marek's Disease-Newcastle Disease Serotypes 1 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 16N1.R1) USDA: 16N1.R1 violinID:1956;1955 generated using OntoRat YL Marek's Disease-Newcastle Disease Serotypes 1 & 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 16N1.R2) USDA: 16N1.R2 violinID:1958;1957 generated using OntoRat YL Marek's Disease-Tenosynovitis Serotypes 2 & 3, Live & Modified Live Virus Vaccine (USDA: 16T1.00) USDA: 16T1.00 violinID:1964;1963 generated using OntoRat YL Marek's Disease-Tenosynovitis Serotypes 2 & 3, Live Virus Vaccine (USDA: 16T1.03) USDA: 16T1.03 violinID:1966;1965 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.11) USDA: 1761.11 violinID:1996;1997 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.12) USDA: 1761.12 violinID:1998;1999 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1761.13) USDA: 1761.13 violinID:2000;2001 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.14) USDA: 1761.14 violinID:2002;2003 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.15) USDA: 1761.15 violinID:2004;2005 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.17) USDA: 1761.17 violinID:2006;2007 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.18) USDA: 1761.18 violinID:2008;2009 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.19) USDA: 1761.19 violinID:2010;2011 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1761.1A) USDA: 1761.1A violinID:2012;2013 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1762.11) USDA: 1762.11 violinID:2014;2015 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1762.13) USDA: 1762.13 violinID:2016;2017 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1762.1H) USDA: 1762.1H violinID:2018;2019 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.11) USDA: 1771.11 violinID:2020;2021 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.12) USDA: 1771.12 violinID:2022;2023 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1771.14) USDA: 1771.14 violinID:2024;2025 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1771.17) USDA: 1771.17 violinID:2026;2027 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.18) USDA: 1771.18 violinID:2028;2029 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.19) USDA: 1771.19 violinID:2030;2031 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.1A) USDA: 1771.1A violinID:2032;2033 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1775.10) USDA: 1775.10 violinID:2034;2035 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1775.11) USDA: 1775.11 violinID:2036;2037 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1776.10) USDA: 1776.10 violinID:2038;2039 generated using OntoRat YL Newcastle-Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1785.10) USDA: 1785.10 violinID:2040;2041 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1785.11) USDA: 1785.11 violinID:2042;2043 generated using OntoRat YL Newcastle-Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1785.12) USDA: 1785.12 violinID:2044;2045 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1791.14) USDA: 1791.14 violinID:2046;2047 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1791.15) USDA: 1791.15 violinID:2048;2049 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1791.19) USDA: 1791.19 violinID:2050;2051 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 1791.1X) USDA: 1791.1X violinID:2054;2055;2052;2053 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A1.1M) USDA: 17A1.1M violinID:2056;2057 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A1.1N) USDA: 17A1.1N violinID:2058;2059 generated using OntoRat YL Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A2.1M) USDA: 17A2.1M violinID:2060;2061 generated using OntoRat YL Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types Vaccine (USDA: 17B1.17) USDA: 17B1.17 violinID:2062;2063 generated using OntoRat YL Newcastle Disease-Fowl Pox Live Fowl Pox Vector Vaccine (USDA: 17C1.R0) USDA: 17C1.R0 violinID:1994;1995 generated using OntoRat YL Marek's Disease-Newcastle Disease Serotypes 2 & 3, Live Virus & Live Marek's Disease Vector Vaccine (USDA: 17H1.R1) USDA: 17H1.R1 violinID:1960;1959 generated using OntoRat YL Marek's Disease-Newcastle Disease Serotypes 2 & 3, Live Virus & Live Marek's Disease Vector Vaccine (USDA: 17H1.R2) USDA: 17H1.R2 violinID:1962;1961 generated using OntoRat YL Newcastle-Paramyxovirus Type 3, Killed Virus Vaccine (USDA: 17P5.10) USDA: 17P5.10 violinID:2072;2073 generated using OntoRat YL Newcastle-Bronchitis VG/GA Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 17V1.10) USDA: 17V1.10 violinID:2064;2065 generated using OntoRat YL Newcastle-Bronchitis VG/GA Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 17V1.11) USDA: 17V1.11 violinID:2066;2067 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.12) USDA: 19A5.12 violinID:2128 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.22) USDA: 19A5.22 violinID:2129 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.23) USDA: 19A5.23 violinID:2130 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.24) USDA: 19A5.24 violinID:2131 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.26) USDA: 19A5.26 violinID:2132 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.29) USDA: 19A5.29 violinID:2133 generated using OntoRat YL Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine (USDA: 19H1.20) USDA: 19H1.20 violinID:2106;2105 generated using OntoRat YL Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine (USDA: 19K5.R0) USDA: 19K5.R0 violinID:2096 generated using OntoRat YL Porcine Circovirus Type 1 - Type 2 Chimera, Killed Virus Vaccine (USDA: 19K5.R1) USDA: 19K5.R1 violinID:2097 generated using OntoRat YL Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1A82.50) USDA: 1A82.50 violinID:1447;1448 generated using OntoRat YL Bursal Disease-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 1A88.R0) USDA: 1A88.R0 violinID:1449;1450 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1A88.R1) USDA: 1A88.R1 violinID:1451;1452 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1A88.R2) USDA: 1A88.R2 violinID:1453;1454 generated using OntoRat YL Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1B82.50) USDA: 1B82.50 violinID:1455;1456 generated using OntoRat YL Fowl Pox-Mycoplasma Gallisepticum Live Fowl Pox Vector Vaccine (USDA: 1D51.R0) USDA: 1D51.R0 violinID:1924;1923 generated using OntoRat YL Fowl Pox-Laryngotracheitis Live Fowl Pox Vector Vaccine (USDA: 1F31.R0) USDA: 1F31.R0 violinID:1920;1919 generated using OntoRat YL Newcastle-Bronchitis B1 Type, C2 Strain, Mass Type, Live Virus Vaccine (USDA: 1XB1.10) USDA: 1XB1.10 violinID:2068;2069 generated using OntoRat YL Newcastle-Bronchitis B1 Type, C2 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1XC1.10) USDA: 1XC1.10 violinID:2070;2071 generated using OntoRat YL Bovine Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 40A5.20) USDA: 40A5.20 violinID:2150;2151 generated using OntoRat YL Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4629.20) USDA: 4629.20 violinID:2574;2576;2575 generated using OntoRat YL Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4629.27) USDA: 4629.27 violinID:2572;2573;2571 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.20) USDA: 4637.20 violinID:2698;2697;2696;2700;2699 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.22) USDA: 4637.22 violinID:2704;2702;2705;2701;2703 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.23) USDA: 4637.23 violinID:2706;2708;2710;2707;2709 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 4637.29) USDA: 4637.29 violinID:2672;2674;2671;2673;2675 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.21) USDA: 4639.21 violinID:2712;2714;2711;2713;2715 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.22) USDA: 4639.22 violinID:2716;2718;2720;2717;2719 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 4639.25) USDA: 4639.25 violinID:2676;2678;2680;2677;2679 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4639.27) USDA: 4639.27 violinID:2688;2690;2686;2689;2687 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4639.28) USDA: 4639.28 violinID:2692;2694;2691;2693;2695 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus, Live Canarypox Vector Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.R1) USDA: 4639.R1 violinID:2722;2724;2721;2723;2725 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4659.20) USDA: 4659.20 violinID:2668;2670;2667;2669 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46B9.21) USDA: 46B9.21 violinID:2590;2592;2594;2589;2591;2593;2595 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46D5.27) USDA: 46D5.27 violinID:1154;1159 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46E5.20) USDA: 46E5.20 violinID:1153;1158 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46E5.21) USDA: 46E5.21 violinID:1145;1144 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46E5.23) USDA: 46E5.23 violinID:1150;1151 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46E5.24) USDA: 46E5.24 violinID:1147;1149 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46E5.25) USDA: 46E5.25 violinID:1152;1146 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J7.20) USDA: 46J7.20 violinID:2632;2634;2636;2633;2635;2637 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J7.22) USDA: 46J7.22 violinID:2640;2642;2638;2639;2641;2643 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J8.20) USDA: 46J8.20 violinID:2726;2728;2730;2727;2729 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J9.20) USDA: 46J9.20 violinID:2644;2646;2648;2645;2647;2649 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.21) USDA: 46J9.21 violinID:2614;2616;2618;2615;2617;2619 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46J9.25) USDA: 46J9.25 violinID:2596;2598;2600;2597;2599;2601 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.26) USDA: 46J9.26 violinID:2622;2624;2620;2623;2625;2621 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.27) USDA: 46J9.27 violinID:2626;2628;2630;2627;2629;2631 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46J9.29) USDA: 46J9.29 violinID:2606;2602;2604;2607;2603;2605 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live Virus, Live Canarypox Vector Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J9.R1) USDA: 46J9.R1 violinID:2650;2652;2654;2655;2651;2653 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46L9.27) USDA: 46L9.27 violinID:2656;2658;2660;2657;2659;2661 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46P9.27) USDA: 46P9.27 violinID:2662;2664;2666;2663;2665 generated using OntoRat YL Encephalomyelitis-Influenza-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 46W5.21) USDA: 46W5.21 violinID:2800;2799;2801 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47A5.20) USDA: 47A5.20 violinID:1137;1136 generated using OntoRat YL Canine Parvovirus Modified Live Virus Vaccine-Leptospira Canicola Icterohaemorrhagiae Bacterin (USDA: 47B1.20) USDA: 47B1.20 violinID:2738;2739 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47C5.20) USDA: 47C5.20 violinID:2578;2580;2582;2577;2579;2581 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47C5.29) USDA: 47C5.29 violinID:2584;2586;2588;2583;2585;2587 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 47E5.20) USDA: 47E5.20 violinID:1140;1142;1143 generated using OntoRat YL Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 47E5.21) USDA: 47E5.21 violinID:1139;1138;1141 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin (USDA: 47K1.20) USDA: 47K1.20 violinID:2682;2684;2681;2683;2685 generated using OntoRat YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin (USDA: 47L9.20) USDA: 47L9.20 violinID:2608;2610;2612;2609;2611;2613 generated using OntoRat YL Canine Distemper-Hepatitis-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 47P9.22) USDA: 47P9.22 violinID:2732;2734;2731;2733;2735 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.20) USDA: 4835.20 violinID:2768;2770;2769 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.23) USDA: 4835.23 violinID:2772;2771;2773 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.24) USDA: 4835.24 violinID:2774;2776;2775 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.45) USDA: 4835.45 violinID:2778;2777;2779 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.46) USDA: 4835.46 violinID:2780;2782;2781 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4844.30) USDA: 4844.30 violinID:2804;2802;2805;2803 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.23) USDA: 4845.23 violinID:2806;2808;2810;2807;2809 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.24) USDA: 4845.24 violinID:2812;2814;2811;2813;2815 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.32) USDA: 4845.32 violinID:2820;2816;2818;2817;2819 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.33) USDA: 4845.33 violinID:2822;2824;2821;2823;2825 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.22) USDA: 4847.22 violinID:2826;2828;2830;2827;2829;2831 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.23) USDA: 4847.23 violinID:2832;2834;2836;2837;2833;2835 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.24) USDA: 4847.24 violinID:2838;2840;2842;2839;2841;2843 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.32) USDA: 4847.32 violinID:2844;2846;2848;2845;2847;2849 generated using OntoRat YL Encephalomyelitis-Rhinopneumonitis-Influenza-West Nile Virus Eastern & Western, Killed Virus, Killed Flavivirus Chimera Vaccine-Tetanus Toxoid (USDA: 4855.R2) USDA: 4855.R2 violinID:2854;2850;2852;2853;2855;2851 generated using OntoRat YL Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.00) USDA: 4865.00 violinID:2740;2742;2741 generated using OntoRat YL Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.01) USDA: 4865.01 violinID:2744;2743;2745 generated using OntoRat YL Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.21) USDA: 4865.21 violinID:2746;2748;2747 generated using OntoRat YL Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.23) USDA: 4865.23 violinID:2750;2752;2749;2751 generated using OntoRat YL Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.26) USDA: 4865.26 violinID:2754;2755;2753 generated using OntoRat YL Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.27) USDA: 4865.27 violinID:2756;2758;2757;2759 generated using OntoRat YL Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4867.20) USDA: 4867.20 violinID:2760;2762;2761;2763 generated using OntoRat YL Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4867.21) USDA: 4867.21 violinID:2764;2766;2765;2767 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.23) USDA: 4875.23 violinID:2784;2786;2783;2785 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.24) USDA: 4875.24 violinID:2788;2790;2787;2789 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.A0) USDA: 4875.A0 violinID:2792;2794;2791;2793 generated using OntoRat YL Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.A1) USDA: 4875.A1 violinID:2796;2798;2795;2797 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Mycoplasma Gallisepticum Bacterin (USDA: 48B5.10) USDA: 48B5.10 violinID:2912;2911;2913 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Mycoplasma Gallisepticum Bacterin (USDA: 48B6.10) USDA: 48B6.10 violinID:2914;2916;2915 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.01) USDA: 48C5.01 violinID:2934;2933;2935 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.20) USDA: 48C5.20 violinID:2936;2938;2937 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.21) USDA: 48C5.21 violinID:2940;2939;2941 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.22) USDA: 48C5.22 violinID:2942;2944;2943 generated using OntoRat YL Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D6.10) USDA: 48D6.10 violinID:2918;2919;2917 generated using OntoRat YL Newcastle Disease-Bronchitis Mass & Ark Types, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D7.10) USDA: 48D7.10 violinID:2906;2905;2907 generated using OntoRat YL Newcastle Disease-Bronchitis Mass & Ark Types, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D7.11) USDA: 48D7.11 violinID:2908;2910;2909 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.20) USDA: 48W5.20 violinID:2856;2858;2860;2857;2859 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.21) USDA: 48W5.21 violinID:2862;2864;2861;2863 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.22) USDA: 48W5.22 violinID:2866;2868;2865;2867 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.23) USDA: 48W5.23 violinID:2870;2872;2871;2873;2869 generated using OntoRat YL Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus, Live Canarypox Vector Vaccine-Tetanus Toxoid (USDA: 48W9.R0) USDA: 48W9.R0 violinID:2874;2876;2875;2877 generated using OntoRat YL Rabies Killed Virus Vaccine-Ehrlichia Risticii Bacterin (USDA: 4905.20) USDA: 4905.20 violinID:3010 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4906.20) USDA: 4906.20 violinID:2922;2923 generated using OntoRat YL Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4960.00) USDA: 4960.00 violinID:2952;2951 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.01) USDA: 4975.01 violinID:2946;2945 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.20) USDA: 4975.20 violinID:2948;2947 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.22) USDA: 4975.22 violinID:2950;2949 generated using OntoRat YL Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4989.00) USDA: 4989.00 violinID:2920;2921 generated using OntoRat YL Trichomonas Foetus Vaccine, Killed Protozoa-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4990.00) USDA: 4990.00 violinID:3036;3035;3037 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4993.20) USDA: 4993.20 violinID:3012;3011 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4993.21) USDA: 4993.21 violinID:3014;3013 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.20) USDA: 4994.20 violinID:3016;3015;3017 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.21) USDA: 4994.21 violinID:3018;3020;3019 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.23) USDA: 4994.23 violinID:3022;3021;3023 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.24) USDA: 4994.24 violinID:3024;3026;3025 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.22) USDA: 4995.22 violinID:3028;3027 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.23) USDA: 4995.23 violinID:3030;3029 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.25) USDA: 4995.25 violinID:3032;3031 generated using OntoRat YL Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.26) USDA: 4995.26 violinID:3034;3033 generated using OntoRat YL Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 49B1.21) USDA: 49B1.21 violinID:3004;3006;3003;3005 generated using OntoRat YL Porcine Rotavirus Modified Live Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 49C1.21) USDA: 49C1.21 violinID:2992;2991;2993 generated using OntoRat YL Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.22) USDA: 49F6.22 violinID:2954;2956;2953;2955 generated using OntoRat YL Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.23) USDA: 49F6.23 violinID:2958;2960;2957;2959 generated using OntoRat YL Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.24) USDA: 49F6.24 violinID:2962;2964;2961;2963 generated using OntoRat YL Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.22) USDA: 49G6.22 violinID:2966;2968;2965;2967 generated using OntoRat YL Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.23) USDA: 49G6.23 violinID:2970;2972;2969;2971 generated using OntoRat YL Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.24) USDA: 49G6.24 violinID:2974;2976;2973;2975 generated using OntoRat YL Porcine Rotavirus Modified Live Virus Vaccine-Escherichia Coli Bacterin (USDA: 49K1.20) USDA: 49K1.20 violinID:2994;2995 generated using OntoRat YL Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine- Mycoplasma Hyopneumoniae Bacterin (USDA: 49K5.R1) USDA: 49K5.R1 violinID:2978;2977 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome-Circovirus Reproductive & Respiratory Form, Type 2, Modifed Live Virus,Killed Baculovirus Vector Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 49K9.R0) USDA: 49K9.R0 violinID:2986;2984;2985 generated using OntoRat YL Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Escherichia Coli Bacterin (USDA: 49P1.20) USDA: 49P1.20 violinID:3008;3007;3009 generated using OntoRat YL Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Bordetella Bronchiseptica-Clostridium Perfringens Type C-Erysipelothrix Rhusiopathiae-Escherichia Coli-Pasteurella Multocida Bacterin-Toxoid (USDA: 49T9.21) USDA: 49T9.21 violinID:3002;2996;2998;3000;2997;2999;3001 generated using OntoRat YL Infectious Salmon Anemia Virus Killed Virus Vaccine-Aeromonas Salmonicida-Vibrio Anguillarum-Ordalii-Salmonicida Bacterin (USDA: 4A45.20) USDA: 4A45.20 violinID:2878;2880;2879 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.20) USDA: 4BC5.20 violinID:2924;2926;2925 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.21) USDA: 4BC5.21 violinID:2928;2927;2929 generated using OntoRat YL Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.22) USDA: 4BC5.22 violinID:2930;2932;2931 generated using OntoRat YL Porcine Reproductive & Respiratory Syndrome-Parvovirus Reproductive Form, Modified Live & Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4P19.20) USDA: 4P19.20 violinID:2988;2990;2987;2989 avian encephalomyelitis-chicken anemia virus-fowl pox vaccine YL avian encephalomyelitis-fowl pox vaccine YL avian encephalomyelitis-fowl pox-laryngotracheitis vaccine YL avian encephalomyelitis-fowl pox-Mycoplasma gallisepticum vaccine YL avian influenza-fowl pox vaccine YL Bovine Parainfluenza 3-Respiratory Syncytial Virus Vaccine YL Bovine Rhinotracheitis Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid YL Bovine Rhinotracheitis Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid YL Bovine Rhinotracheitis Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae- Pomona Bacterin YL Bovine Rhinotracheitis Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin YL Bovine Rhinotracheitis Vaccine-Leptospira Hardjo-Pomona Bacterin YL Bovine Rhinotracheitis Vaccine-Leptospira Pomona Bacterin YL Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin YL bovine rhinotracheitis-parainfluenza 3 vaccine YL Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Haemophilus Somnus Bacterin YL Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin YL Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Pomona Bacterin YL Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Vaccine YL Bovine Rhinotracheitis-Respiratory Syncytial Virus Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Campylobacter Fetus-Leptospira CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Hardjo-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Campylobacter Fetus-Haemophilus Somnus-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus-Mannheimia Haemolytica Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL chicken bursal disease-Newcastle disease vaccine YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona-Mannheimia Haemolytica Bacterin YL Bursal Disease-Newcastle Disease-Bronchitis Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Hardjo Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica Toxoid YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus-Mannheimia Haemolytica-Pasteurella Multocida Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Vaccine YL Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Vaccine-Leptospira Pomona Bacterin YL Bovine Rotavirus-Coronavirus Vaccine YL Bovine Rotavirus-Coronavirus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid YL Bovine Rotavirus-Coronavirus Vaccine-Clostridium Perfringens Types C & D-Escherichia Coli Bacterin-Toxoid YL Bovine Rotavirus-Coronavirus Vaccine-Escherichia Coli Bacterin YL Bovine Virus Diarrhea Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin YL Bovine Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid YL Bovine Virus Diarrhea Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Bovine Virus Diarrhea Vaccine-Leptospira Pomona Bacterin YL Bursal Disease-Mareks Disease Vaccine YL Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Vaccine YL chicken Bursal Disease-Newcastle Disease-Reovirus Vaccine YL chicken bursal disease-reovirus vaccine YL Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine YL Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-GrippotyphosaIcterohaemorrhagiae-Pomona Bacterial Extract YL Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract YL Canine Coronavirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract YL Canine Coronavirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract YL Canine Coronavirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract YL Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin YL Canine Coronavirus-Parvovirus Vaccine YL Canine Distemper-Adenovirus Type 2 Vaccine YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine YL Canine Distemper-Adenovirus Type 2 Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract YL Canine Distemper-Adenovirus Type 2 Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Borrelia Burgdorferi Bacterin YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract YL horse EEV, VEV, WEV encephalomyelitis and West Nile Virus vaccine YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parvovirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract YL Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Vaccine YL Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira CanicolaGrippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira CanicolaGrippotyphosa-Icterohaemorrhagiae-Pomona Bacterin YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin YL Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine YL Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Vaccine YL Canine Distemper-Hepatitis-Parainfluenza Vaccine YL Canine Distemper-Measles Vaccine YL Canine Distemper-Parvovirus Vaccine YL canine parainfluenza-bordetella bronchiseptica vaccine YL canine parvovirus vaccine-leptospira canicola icterohaemorrhagiae bacterin YL, YH equine EEV and WEV encephalomyelitis vaccine-tetanus toxoid YL, YH equine rhinopneumonitis-influenza vaccine YL, YH equine EEV and WEV encephalomyelitis-influenza vaccine-tetanus toxoid YL equine EEV and WEV encephalomyelitis-influenza-West Nile virus vaccine-tetanus toxoid a viral vaccine against horse EEV, WEV, and VEE viral infections YL, YH horse encephalomyelitis EEV, VEV, and WEV combination vaccine YL Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin YL Canine Distemper-Hepatitis-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin YL Feline Immunodeficiency-Leukemia Virus Vaccine YL equine EEV and WEV encephalomyelitis-rhinopneumonitis vaccine-tetanus toxoid YL equine EEV and WEV encephalomyelitis-rhinopneumonitis-influenza vaccine-tetanus toxoid YL equine EEV and WEV encephalomyelitis-rhinopneumonitis-influenza-West Nile Virus vaccine-tetanus toxoid YL horse EEV, VEV, WEV encephalomyelitis-West Nile Virus Vaccine-Tetanus Toxoid YL Feline Leukemia-Chlamydia Psittaci Vaccine YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Vaccine YL Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine YL Feline Rhinotracheitis-Calici-Chlamydia Psittaci Vaccine YL Feline Rhinotracheitis-Calici-Panleukopenia Vaccine YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine YL Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Vaccine YL Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Vaccine YL Feline Rhinotracheitis-Calicivirus Vaccine YL Fowl Laryngotracheitis-Mareks Disease Vaccine YL Infectious Salmon Anemia Virus Vaccine-Aeromonas Salmonicida-Vibrio Anguillarum-Ordalii-Salmonicida Bacterin YL Fowl Pox-Laryngotracheitis Vaccine YL Fowl Pox-Mareks Disease Vaccine YL Fowl Pox-Mycoplasma Gallisepticum Vaccine YL Mannheimia Haemolytica-Pasteurella Multocida Vaccine YL Mareks Disease-Newcastle Disease Vaccine YL chicken Mareks disease-tenosynovitis vaccine YL Mink Distemper-Enteritis Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid YL Mink Distemper-Enteritis Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid YL Mink Enteritis Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid YL Mink Enteritis Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid SNOMEDCT: 55262006; UMLS_CUI:C0310936 YL Newcastle Disease-Bronchitis Vaccine-Salmonella Enteritidis Bacterin YL Newcastle-Bronchitis Vaccine-Mycoplasma Gallisepticum Bacterin A viral vaccine that protects against infection with Hirame rhabdovirus YH, RS, NF Hirame rhabdovirus vaccine YL Newcastle Disease-Fowl Pox Vaccine YL Newcastle-Bronchitis Vaccine YL Newcastle-Paramyxovirus Vaccine YL bovine parainfluenza 3 vaccine-Leptospira Pomona vaccine YL Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin YL Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Porcine Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae vaccine YL Parvovirus-Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Parvovirus-Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Leptospira CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Virus Vaccine YL Porcine Circovirus Vaccine- Mycoplasma Hyopneumoniae Bactin YL Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Bordetella Bronchiseptica-Clostridium Perfringens Type C-Erysipelothrix Rhusiopathiae-Escherichia Coli-Pasteurella Multocida Bacterin-Toxoid YL Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid YL Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Escherichia Coli Bacterin YL Porcine Rotavirus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid YL Porcine Reproductive & Respiratory Syndrome-Circovirus Vaccine-Mycoplasma Hyopneumoniae Bacterin YL Porcine Reproductive & Respiratory Syndrome-Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Porcine Rotavirus Vaccine-Escherichia Coli Bacterin YL Porcine Rotavirus-Transmissible Gastroenteritis Vaccine YL Rabies Vaccine-Ehrlichia Risticii Bacterin YL Swine Influenza Vaccine YL, YH Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae Bacterin YL Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin YL, YH Swine Influenza Vaccine-Mycoplasma Hyopneumoniae Bacterin USDA: 4995.22 violinID:3028;3027 YL Trichomonas Foetus-Campylobacter Fetus-Leptospira vaccine YL Canine Distemper-Coronavirus-Parvovirus Vaccine A horse vaccine that protects against EEE, VEE, WEE, influenza virius infection, and West Nile virus infection. YL horse Encephalomyelitis-Influenza-West Nile Virus vaccine YL Mink Distemper-Enteritis Vaccine YL, YH porcine parvovirus-erysipelothrix rhusiopathiae vaccine YL Bovine Virus Diarrhea-Respiratory Syncytial Virus Vaccine YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Pomona Bacterin YL Bovine Respiratory Syncytial Virus Virus Vaccine-Haemophilus somnus Bacterin YL Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Haemophilus somnus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin YL Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Modified Live Virus & Avirulent Live Culture Vaccine (USDA: 12X1.21) USDA: 12X1.21 YL Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46L9.20) USDA: 46L9.20 YL Fowl Laryngotracheitis-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16J1.R3) USDA: 16J1.R3 YL created according to WHO Technical Report Series, No. 927, 2005 Annex 3 Recommendations for the production and control of influenza vaccine (inactivated) influenza vaccine (whole virion, inactivated) YL created according to WHO Technical Report Series, No. 927, 2005 Annex 3 Recommendations for the production and control of influenza vaccine (inactivated) influenza vaccine (split virion, inactivated) YL created according to WHO Technical Report Series, No. 927, 2005 Annex 3 Recommendations for the production and control of influenza vaccine (inactivated) influenza vaccine (surface antigens, inactivated) YL created according to WHO Technical Report Series, No. 927, 2005 Annex 3 Recommendations for the production and control of influenza vaccine (inactivated) influenza vaccine (inactivated, adjuvanted) Influenza A (H1N1) 2009 Monovalent Vaccine (IDB) A vaccine that protects against Listeria monocytogenes. YH, RR Listeria monocytogenes vaccine A vaccine that protects against Mycobacterium avium. YH, RR Mycobacterium avium vaccine A bacterial vaccine that protects against infection with Staphylococcus aureus. YH, RR Staphylococcus aureus vaccine A bacterial gene that is from Streptococcus. YH, RR 'Streptococcus gene' A bacterial gene that is from Streptococcus. YH, RR Streptococcus equi gene A Aeromonas vaccine that protects against Aeromonas hydrophila. An Aeromonas vaccine that protects against Aeromonas hydrophila. YH, RR Aeromonas hydrophila vaccine An Edwardsiella bacterial vaccine that protects against Edwardsiella tarda. YH, RR Edwardsiella tarda vaccine A bacterial vaccine that protects against infections by Salmonella typhimurium species. YH, RR Salmonella typhimurium vaccine A bacterial vaccine that protects against infections by Salmonella enterica subsp. enterica serovar Gallinarum. YH, RR Salmonella gallinarum vaccine A bacterial vaccine that protects against infections by Salmonella enterica subsp. enterica serovar Enteritidis. YH, RR Salmonella enteritidis vaccine A bacterial vaccine that protects against infections by Yersinia pseudotuberculosis. YH, RR Yersinia pseudotuberculosis vaccine A viral vaccine that protects against infection of Human metapneumovirus. YH, RR Human metapneumovirus vaccine A viral vaccine that protects against infection of Human respiratory syncytial virus. YH, RR Human respiratory syncytial virus vaccine a malaria vaccine that protects against malaria caused by Plasmodium berghei. YH, RR Plasmodium berghei vaccine a malaria vaccine that protects against malaria caused by Plasmodium yoelii. YH, RR Plasmodium yoelii vaccine A protozoan gene that is from Leishmania infantum. YH, RR Leishmania infantum gene Rebecca Racz, Yongqun He The mutant strain, with deletion of apxIA gene, obtained in this study offered a level of cross-serovar protection against A. pleuropneumoniae infection in mice and pigs (Reference: PMID: 16930871). apxIA from Actinobacillus pleuropneumoniae NCBI_Gene_ID: 4850247; PMID: 16930871 Rebecca Racz, Yongqun He In the intra-peritoneal mouse model, the virulence of the mutant strain decreased at least 100 fold compared with the parent strain. The mutant was evaluated as a potential vaccine using a vaccination-challenge trial. The death number and lung lesion score in the vaccinated pigs given the serovar 1 challenge were obviously lower than those in the unvaccinated pigs apxIC from Actinobacillus pleuropneumoniae NCBI_Protein_ID: 1477456; PMID: 18062275 Rebecca Racz, Yongqun He Deletion in ureC and apxIIA genes of Actinobacillus pleuropneumoniae serotype 2 prototype provides attenuation and protection in pigs against challenge with the virulent parent strain of A. pleuropneumoniae apxIIA from Actinobacillus pleuropneumoniae NCBI_Protein_ID: 255959000; PMID: 12438394 Rebecca Racz, Yongqun He In the present study, the gene encoding the ApxII-activating protein, apxIIC, was insertionally inactivated on the chromosome of a serovar 7 strain, HS93. Pigs vaccinated with live HS93C-Ampr via the intranasal route were protected against a cross-serovar challenge with a virulent serovar 1 strain of A. pleuropneumoniae apxIIC from Actinobacillus pleuropneumoniae NCBI_Protein_ID: 52630373; PMID: 10085043 Rebecca Racz, Yongqun He In the present study, the gene encoding the ApxII-activating protein, apxIIC, was insertionally inactivated on the chromosome of a serovar 7 strain, HS93. Pigs vaccinated with live HS93C-Ampr via the intranasal route were protected against a cross-serovar challenge with a virulent serovar 1 strain of A. pleuropneumoniae apxIIC from Actinobacillus pleuropneumoniae NCBI_Protein_ID: 52630373; PMID: 10085043 Rebecca Racz, Yongqun He An apxIIIB mutant, in combination with an apxIIID mutation, is highly attenuated in pigs and induces significant protection from challenge with wild type A. pleuropneumoniae. The mutant also was slightly attenuated in mice and induced protection in mice against challenge from the parent strain apxIIIB from Actinobacillus pleuropneumoniae NCBI_Nucleotide_ID: 470686; PMID: 19887737 Rebecca Racz, Yongqun He An apxIIID mutant, in combination with an apxIIIB mutation, is highly attenuated in pigs and induces significant protection from challenge with wild type A. pleuropneumoniae. The mutant also was slightly attenuated in mice and induced protection in mice against challenge from the parent strain apxIIID from Actinobacillus pleuropneumoniae NCBI_Nucleotide_ID: 470687; PMID: 19887737 Rebecca Racz, Yongqun He A precisely defined DeltaapxIICDeltaapxIVA double-deletion mutant of A. pleuropneumoniae was constructed based on HB04C(-) by transconjugation and counterselection. The results demonstrated that the DeltaapxIICDeltaapxIVA double mutant strain was less virulent than HB04C(-). Despite attenuation of virulence, the DeltaapxIICDeltaapxIVA double mutant remains immunogenic and conferred a similar level of protective immunity to pigs against challenge with a lethal dose of a heterologous fully virulent standard serovar 1 strain of A. pleuropneumoniae apxIVA from Actinobacillus pleuropneumoniae NCBI_Protein_ID: 6671152; PMID: 17767980 Rebecca Racz, Yongqun He Deletions were introduced into the ureC and apxIIA genes of an Actinobacillus pleuropneumoniae serotype 2 strain by homologous recombination and counterselection. The double-mutant contains no foreign DNA, is highly attenuated, protects pigs from homologous challenge upon a single aerosol application ureC from Actinobacillus pleuropneumoniae NCBI_Protein_ID: 303253439; PMID: 12438394 Rebecca Racz, Yongqun He An mntA deletion mutant, generated by allelic replacement, in Bacillus anthracis was attenuated and provided protection for guinea pigs against lethal spore dose (60 LD50) of the virulent B. anthracis Vollum strain mntA from Bacillus anthracis NCBI_Gene_ID: 7848141; PMID: 16194238 Rebecca Racz, Yongqun He An actA mutant is attenuated in mice and induced significant protection from challenge with wild type L. monocytogenes actA from Listeria monocytogenes NCBI_Gene_ID: 987035; PMID: 12763691 Rebecca Racz, Yongqun He An actA mutant is attenuated in mice and induced significant protection from challenge with wild type L. monocytogenes actA from Listeria monocytogenes NCBI_Gene_ID: 987035; PMID: 12763691 Rebecca Racz, Yongqun He A plcB mutant, in combination with an actA mutant, is attenuated in mice and induces significant protection from challenge with wild type L. monocytogenes plcB from Listeria monocytogenes NCBI_Gene_ID: 987036; PMID: 12763691 Rebecca Racz, Yongqun He A M. avium relA mutant is attenuated in calves and goats. This mutant also elicited an immune response in goats that limited colonization by challenge wild type M. avium relA from Mycobacterium avium NCBI_Gene_ID: 2717869; PMID: 21565243 Rebecca Racz, Yongqun He A drrC mutant is highly attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis drrC from Mycobacterium tuberculosis NCBI_Gene_ID: 888491; PMID: 14702160 Rebecca Racz, Yongqun He An fadD26 mutant is attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis fadD26 from Mycobacterium tuberculosis NCBI_Gene_ID: 887603; PMID: 15958066 Rebecca Racz, Yongqun He Deletion of leuD gene was shown to be highly attenuated. Immunocompetent BALB/c mice vaccinated with the DleuD auxotroph were protected as well as BCG in terms of survival following an intravenous or aerosol challenge with virulent M. tuberculosis leuD from Mycobacterium tuberculosis NCBI_Gene_ID: 888225; PMID: 10768986 Rebecca Racz, Yongqun He A lysA mutant, in combination with a secA2 mutation, is highly attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis lysA from Mycobacterium tuberculosis NCBI_Gene_ID: 886960; PMID: 21264335 Rebecca Racz, Yongqun He A Mce-2 mutant in Mycobacterium tuberculosis is attenuated and provides protection against challenge for mice mce-2 from Mycobacterium tuberculosis NCBI_Gene_ID: 925014; PMID: 16388878 Rebecca Racz, Yongqun He A mce-3 mutant in Mycobacterium tuberculosis is attenuated and provides protection against challenge for mice mce-3 from Mycobacterium tuberculosis NCBI_Gene_ID: 923491; PMID: 16388878 Rebecca Racz, Yongqun He A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis panC from Mycobacterium tuberculosis NCBI_Gene_ID: 885459; PMID: 12219086 Rebecca Racz, Yongqun He A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis panC from Mycobacterium tuberculosis NCBI_Gene_ID: 885459; PMID: 12219086 Rebecca Racz, Yongqun He A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis panD from Mycobacterium tuberculosis NCBI_Gene_ID: 885596; PMID: 12219086 Rebecca Racz, Yongqun He A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis panD from Mycobacterium tuberculosis NCBI_Gene_ID: 885596; PMID: 12219086 Rebecca Racz, Yongqun He Study evaluated immunogenicity and protection against Mycobacterium tuberculosis in rhesus monkeys with an attenuated M. tuberculosis with a disrupted phoP gene (SO2) as a single-dose vaccine. SO2 treatment showed reduced average lung bacterial counts (1.0 and 1.2 log respectively, compared with 0.4 log for BCG) and significant protective effect by reduction in C-reactive protein levels, body weight loss, and decrease of erythrocyte-associated hematologic parameters (MCV, MCH, Hb, Ht) as markers of inflammatory infection, all relative to non-vaccinated controls phoP from Mycobacterium tuberculosis NCBI_Gene_ID: 888772; PMID: 19367339 Rebecca Racz, Yongqun He A proC mutant is highly attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis that is equal to the protection induced by the current vaccine BCG proC from Mycobacterium tuberculosis NCBI_Gene_ID: 887256; PMID: 11160012 Rebecca Racz, Yongqun He RD1 and panCD mutants in Mycobacterium tuberculosis were attenuated and provided protection in CD4-deficient mice against an aerosol challenge with virulent M. tuberculosis RD1 from Mycobacterium tuberculosis NCBI_Gene_ID: 885777; PMID: 16860907 Rebecca Racz, Yongqun He Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Guérin vaccination secA2 from Mycobacterium tuberculosis NCBI_Gene_ID: 885594; PMID: 17671656 A viral vaccine that protects against infection with Reticuloendotheliosis virus YH, RS, NF Reticuloendotheliosis virus vaccine Rebecca Racz, Yongqun He A sigE mutant is highly attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis, more so than the existing vaccine BCG sigE from Mycobacterium tuberculosis NCBI_Gene_ID: 888751; PMID: 20457786 Rebecca Racz, Yongqun He A trpD mutant is highly attenuated in mice and induces more protection from challenge with wild type M. tuberculosis than that induced by the current vaccine BCG trpD from Mycobacterium tuberculosis NCBI_Gene_ID: 887681; PMID: 11160012 Rebecca Racz, Yongqun He An aroA mutant is attenuated in mice and induced significant protection from challenge with wild type S. aureus aroA from Staphylococcus aureus NCBI_Gene_ID: 8614197; PMID: 16714581 Rebecca Racz, Yongqun He A vicK mutant is attenuated in mice and induced protection from challenge with wild type S. equi vicK from Streptococcus equi NCBI_Gene_ID: 6760966; PMID: 19088917 Rebecca Racz, Yongqun He An A. hydrophila aroA mutant is highly attenuated in trout, and a single immunization conferred significant protection from challenge with wild type A. hydrophila aroA from Aeromonas hydrophila NCBI_Gene_ID: 4489425; PMID: 9573055 Rebecca Racz, Yongqun He The aroA gene was inactivated by inserting a fragment expressing kanamycin resistance within the coding sequence and challenged in fish. The LD50 for unvaccinated fish was 71. In contrast, the LD50 was 1.8 x 104 in fish vaccinated once and 3 x 105 in fish vaccinated twice aroA from Aeromonas salmonicida NCBI_Gene_ID: 4997369; PMID: 8478107 Rebecca Racz, Yongqun He Inactivation of the aroA gene highly attenuates B. bronchiseptica, severely impairing its ability to colonize and survive in the respiratory tract of mice. Upon challenge with wild type B. bronchiseptica, the mice immunised with live attenuated B. bronchiseptica aroA mutant had rapidly reduced numbers of B. bronchiseptica in their respiratory tract aroA from Bordetella bronchiseptica NCBI_Gene_ID: 2659145; PMID: 12009288 Rebecca Racz, Yongqun He Inactivation of the aroA gene highly attenuates B. bronchiseptica, severely impairing its ability to colonize and survive in the respiratory tract of mice. Upon challenge with wild type B. bronchiseptica, the mice immunised with live attenuated B. bronchiseptica aroA mutant had rapidly reduced numbers of B. bronchiseptica in their respiratory tract aroA from Bordetella bronchiseptica NCBI_Gene_ID: 2659145; PMID: 12009288 Rebecca Racz, Yongqun He A double mutant strain of Bordetella Bronchiseptica lacking adenylate cyclase(cyaA gene) and type III secretion(bscN gene) is attenuated and provides protection in mice against 5 × 105 CFU of RB50, the B. Bronchiseptica parent strain bscN from Bordetella bronchiseptica NCBI_Gene_ID: 2662485; PMID: 17452472 Rebecca Racz, Yongqun He A double mutant strain of Bordetella Bronchiseptica lacking adenylate cyclase(cyaA gene) and type III secretion(bscN gene) is attenuated and provides protection in mice against 5 × 105 CFU of RB50, the B. Bronchiseptica parent strain cyaA from Bordetella bronchiseptica NCBI_Gene_ID: 2661688; PMID: 17452472 Rebecca Racz, Yongqun He A dnt mutant in Bordetella bronchiseptica was attenuated and provides protection in guinea pigs against intranasal challenge with strain L3 dnt from Bordetella bronchiseptica NCBI_Gene_ID: 2661538; PMID: 3182989 Rebecca Racz, Yongqun He A trpE mutant, in combination with an aroA mutation, is attenuated in mice and induces significant protection from challenge with wild type B. bronchiseptica trpE from Bordetella bronchiseptica NCBI_Protein_ID: 8515760; PMID: 12694904 Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in mice and induces significant protection from challenge with wild type B. pertussis aroA from Bordetella pertussis NCBI_Protein_ID: 144037; PMID: 2407655 Rebecca Racz, Yongqun He A live attenuated B. pertussis vaccine strain BPZE1, developed by deleting dnt gene, protects mice upon a single intranasal administration dnt from Bordetella pertussis NCBI_Gene_ID: 2666936; PMID: 18762220 Rebecca Racz, Yongqun He A flagella-less mutant of Borrelia burgdorferi (HB19Fla-) was attenuated in immunodeficient SCID mice. Mice were challenged 28 days later with virulent strain Sh. 2 and were protected from challenge fla from Borrelia burgdorferi NCBI_Protein_ID: 435009; PMID: 8627071 Rebecca Racz, Yongqun He A asp24 mutation in Brucella abortus is attenuated and provides significant protection in mice asp24 from B. abortus NCBI_Protein_ID: 2353000; PMID: 17664263 Rebecca Racz, Yongqun He A bp26 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice bp26 from B. melitensis NCBI_Protein_ID: 265991532; PMID: 15246618 Rebecca Racz, Yongqun He Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308. This demonstrated that ExsA is critical for full bacterial virulence. The B. abortus exsA deletion mutant was used as a live vaccine candidate. Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51 exsA from B. abortus NCBI_Gene_ID: 3787220; PMID: 12183550 Rebecca Racz, Yongqun He Unmarked rough B. abortus and B. melitensis deletion mutants of manBA (including manA and manB) were attenuated. These mutants provided protection against virulent Brucella challenge in mice manA from B. melitensis NCBI_Protein_ID: 260563601; PMID: 16790778 Rebecca Racz, Yongqun He Mutants manB and manA were attenuated in Brucella melitensis and provided protection against challenge in mice's livers manB from B. melitensis NCBI_Gene_ID: 1198671; PMID: 17664263 Rebecca Racz, Yongqun He A mucR mutant has a significantly reduced degree of colonization in mice and protects against wild type B. melitensis 16M mucR from B. melitensis NCBI_Gene_ID: 1197075; PMID: 21708998 Rebecca Racz, Yongqun He A omp25 mutant is attenuated and provides protection against challenge in mice omp25 from B. melitensis NCBI_Gene_ID: 1196960; PMID: 12151196 Rebecca Racz, Yongqun He A omp31 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice omp31 from B. melitensis NCBI_Gene_ID: 7676420; PMID: 15246618 Rebecca Racz, Yongqun He A pgk mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus pgk from B. abortus NCBI_Gene_ID: 3788256; PMID: 20194591 Rebecca Racz, Yongqun He A pgm mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus pgm from B. abortus NCBI_Gene_ID: 3788847; PMID: 14573645 Rebecca Racz, Yongqun He Mice infected with delta purE201 developed only five to eight times normal spleen weight at 1 week p.i. and produced no interleukin-6 in their serum, which is much lower than the mice infected with the parental strain (16M) purE from B. melitensis NCBI_Gene_ID: 1196006; PMID: 8675325 Rebecca Racz, Yongqun He A purE/purK mutant of B. melitensis 16M was attenuated in mice when given intraperitoneally. Nine weeks after immunization, mice were protected from challenge with wild type B. melitensis purK from B. melitensis NCBI_Protein_ID: 20141763; PMID: 7642258 Rebecca Racz, Yongqun He A virB2 mutant is attenuated in Brucella melitensis and provides protection in mice virB2 from B. abortus NCBI_Gene_ID: 3827981; PMID: 17664263 Rebecca Racz, Yongqun He The deletion of vjbR gene in Brucella melitensis strain 16M made a live attenuated vaccine and provided significance protection against mice vjbR from B. melitensis NCBI_Gene_ID: 1198888; PMID: 21530111 Rebecca Racz, Yongqun He Deletion of gene znuA attenuates Brucella abortus and this live attenuated vaccine was challenged in mice. These mice showed significantly fewer spenic CFU znuA from Brucella spp. NCBI_Gene_ID: 3827700; PMID: 16790759 Rebecca Racz, Yongqun He The aroC deletion in the resultant mutant, designated A2ΔaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compounds. The constructed unmarked aroC mutant of B. pseudomallei is attenuated in both BALB/c and C57Bl/6 mice and is able to confer significant protection in C57Bl/6 mice aroC from Burkholderia pseudomallei NCBI_Gene_ID: 4899749; PMID: 19323044 Rebecca Racz, Yongqun He An asd mutant is highly attenuated in mice. This mutant was also able to protect against acute inhalation melioidosis caused by challenge with wild type B. pseudomallei asd from Burkholderia pseudomallei NCBI_Protein_ID: 2358232; PMID: 21807903 Rebecca Racz, Yongqun He Mice that were challenged with a higher dose of mutant 56:65 purM were protected purM from Burkholderia pseudomallei NCBI_Gene_ID: 3092877; PMID: 19121696 Rebecca Racz, Yongqun He Although 30:93a purN -immunized mice were challenged with a 10-fold higher dose of WT E8, mice were strongly protected and showed no signs of clinical illness until the experiment was terminated purN from Burkholderia pseudomallei NCBI_Gene_ID: 3092878; PMID: 19121696 Rebecca Racz, Yongqun He A crp mutant is attenuated in zebrafish and catfish that were immunized intramuscularly and intracoelomically, respectively. Six weeks after immunization, both zebrafish and catfish were protected from challenge with wild type E. ictaluri crp from Edwardsiella ictaluri NCBI_Gene_ID: 7962173; PMID: 22015784 Rebecca Racz, Yongqun He An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3% aroC from Edwardsiella tarda NCBI_Gene_ID: 8608790; PMID: 21777261 Rebecca Racz, Yongqun He An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3% aroC from Edwardsiella tarda NCBI_Gene_ID: 8608790; PMID: 21777261 Rebecca Racz, Yongqun He An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3% aroC from Edwardsiella tarda NCBI_Gene_ID: 8608790; PMID: 21777261 Rebecca Racz, Yongqun He An esrB mutant is highly attenuated in fish (turbot), with an LD50 of 10(8.1)cfu/fish. Vaccination with this mutant elicited significant protection from wild type E. tarda esrB from Edwardsiella tarda NCBI_Gene_ID: 8607237; PMID: 17478097 Rebecca Racz, Yongqun He An aroC and esrC mutant is attenuated in zebra fish. This mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 71.3% esrC from Edwardsiella tarda NCBI_Gene_ID: 8607212; PMID: 21777261 Rebecca Racz, Yongqun He An aroC and slyA mutant is attenuated in zebra fish. This mutant is also protective against challenge from wild type E. tarda, resulting in a relative percent survival of 80.1% slyA from Edwardsiella tarda NCBI_Gene_ID: 8608031; PMID: 21777261 Rebecca Racz, Yongqun He A carAB mutant is attenuated in turkeys and induces significant protection from challenge with wild type E. coli carA from Escherichia coli NCBI_Gene_ID: 949025; PMID: 8063392 Rebecca Racz, Yongqun He A carAB mutant is attenuated in turkeys and induces significant protection from challenge with wild type E. coli carB from Escherichia coli NCBI_Gene_ID: 944775; PMID: 8063392 Rebecca Racz, Yongqun He A ler deletion mutant derived from wild-type EHEC O157:H7 86-24 was constructed by use of suicide vector pCVD442. Following challenge of 7-day-old suckling mice with O157:H7 EDL933, 75.2% born to group B mothers (immunized with F25) sur- vived, as did 83.0% born to group C mothers (immunized with F105). The surviving suckling mice consistently gained body weight. Only 16.8% of sucking mice born to control group mice survived the challenge ler from Escherichia coli NCBI_Gene_ID: 8219269; PMID: 19682616 Rebecca Racz, Yongqun He Deletion of waaL results in a strain that stimulates enhanced urothelial cytokine secretion, which is an enhanced innate immune response. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted ⩾8 weeks rfaL from Escherichia coli NCBI_Gene_ID: 948148; PMID: 19522648 Rebecca Racz, Yongqun He There was a deletion in gene capB of F. tularensis live vaccine strain. LVS capB, while much less virulent than LVS, induces potent protective immunity against lethal LVS i.n. challenge in mice, comparable to that induced by LVS capB from Francisella tularensis NCBI_Gene_ID: 3952402; PMID: 20643859 Rebecca Racz, Yongqun He A clpB mutant in Francisella tularensis subspecies tularensis strain SCHU S4 was attenuated and provided protection against aerosol challenge in mice clpB from Francisella tularensis NCBI_Gene_ID: 3192509; PMID: 20018266 Rebecca Racz, Yongqun He A FTL0552 mutant in Francisella tularensis was attenuated and provided partial protection in mice against challenge with a lethal dose of the virulent SchuS4 strain when compared to naive mice FTL0552 from Francisella tularensis NCBI_Gene_ID: 3952730; PMID: 18613792] Rebecca Racz, Yongqun He An FTT0918 mutant showed significantly reduced virulence in mice. Mice that recovered from infection with the mutant were protected 2 months later from challenge with wild type F. tularensis FTT0918 from Francisella tularensis NCBI_Gene_ID: 3191684; PMID: 16299332 Rebecca Racz, Yongqun He A galU mutant is attenuated in mice, with only transient weight loss observed. Two months after inoculation, mice were challenge with wild type F. tularensis and were protected, once again only experiencing transient weight loss galU from Francisella tularensis NCBI_Gene_ID: 3191600; PMID: 21819572 Rebecca Racz, Yongqun He A guaA mutant is highly attenuated in mice and induces significant protection from challenge with parent strain F. tularensis LVS guaA from Francisella tularensis NCBI_Gene_ID: 3951701; PMID: 19368784 Rebecca Racz, Yongqun He A guaB mutant is attenuated in mice and induces significant protection from challenge with parent strain F. tularensis LVS guaB from Francisella tularensis NCBI_Gene_ID: 3952496; PMID: 19368784 Rebecca Racz, Yongqun He Intranasal vaccination with KKF235 (F. tularensis subsp. novicida mutant (DeltaiglB) ) protected mice from subsequent homotypic challenge with U112 as well as heterotypic challenge with F. tularensis subsp. holarctica (LVS). Most significantly, oral immunization with KKF235 protected mice from a highly lethal subsp. tularensis (SCHU S4) pulmonary challenge iglB from Francisella tularensis NCBI_Gene_ID: 4548125; PMID: 20016043 Rebecca Racz, Yongqun He An iglC mutant is highly attenuated in mice. Inoculated mice were challenged 30 days later with wild type F. tularensis and were highly protected iglC from Francisella tularensis NCBI_Gene_ID: 4548124; PMID: 16552035 Rebecca Racz, Yongqun He A purMCD mutant in Francisela tularensis was attenuated. A low dosage of F. tularensis LVS delta purMCD mutant provided protection against challenge in mice purC/purD from Francisella tularensis NCBI_Gene_ID: 3952576; PMID: 16861631 Rebecca Racz, Yongqun He Mice, which had been immunized with at least 6.95×103 cfu of F. tularensis U112 purF::Cm, were protected against the subsequent F. tularensis subspecies novicida challenge purF from Francisella tularensis NCBI_Gene_ID: 4548578; PMID: 16930871 Rebecca Racz, Yongqun He A purMCD mutant in Francisella tularensis was attenuated. A low dose of the F. tularensis LVS delta purMCD mutant provided protection against subsequent lethal challenge with the LVS parental strain purM from Francisella tularensis NCBI_Gene_ID: 3952575; PMID: 16861631 Rebecca Racz, Yongqun He C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. SodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice sodB from Francisella tularensis NCBI_Gene_ID: 4548021; PMID: 18692537 Rebecca Racz, Yongqun He A sodC mutant in Francisella tularensis subspecies holarctica was attenuated and provided protection and cleared the infection against lethal challenge in nearly 50% of the mice infected with the ΔsodC mutant sodC from Francisella tularensis NCBI_Protein_ID: 1314283; PMID: 19684141 Rebecca Racz, Yongqun He A wbtA mutant in Francisella tularensis was attenuated and provided protection in mice against challenge with an otherwise lethal dose of either F. tularensis LVS or a fully virulent clinical isolate of F. tularensis type B wbtA from Francisella tularensis NCBI_Gene_ID: 3191939; PMID: 17296751 Rebecca Racz, Yongqun He A wbtI mutant is attenuated in mice. The mutant protected against a low dose challenge with the parental strain, but was less effective against higher doses. However, increasing the immunization dose increased the resistance to higher challenge doses wbtI from Francisella tularensis NCBI_Gene_ID: 5522688; PMID: 17768257 Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in mice and induced significant protection after two doses from challenge with wild type M. haemolytica aroA from Mannheimia haemolytica NCBI_Protein_ID: 451485; PMID: 7839583 Rebecca Racz, Yongqun He An lpd mutant is highly attenuated in chickens and induces significant protection from challenge with wild type M. gallisepticum lpd from Mycoplasma gallisepticum NCBI_Gene_ID: 1089767; PMID: 18342996 Rebecca Racz, Yongqun He A metH mutant, in combination with a siaD mutation, is attenuated in mice and induces significant protection from challenge with wild type N. meningitidis metH from Neisseria meningitidis NCBI_Gene_ID: 903064; PMID: 14688114 Rebecca Racz, Yongqun He An rfaF mutant, in combination with a siaD mutation, is attenuated in mice and induces significant protection from challenge with wild type N. meningitidis rfaF from Neisseria meningitidis NCBI_Gene_ID: 904029; PMID: 14688114 Rebecca Racz, Yongqun He A siaD mutant, in combination with either a metH or rfaF mutation, is attenuated in mice and induces protection from challenge with wild type N. meningitidis siaD from Neisseria meningitidis NCBI_Gene_ID: 903210; PMID: 14688114 Rebecca Racz, Yongqun He A siaD mutant, in combination with either a metH or rfaF mutation, is attenuated in mice and induces protection from challenge with wild type N. meningitidis siaD from Neisseria meningitidis NCBI_Gene_ID: 903210; PMID: 14688114 Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in calves and induces significant protection from challenge with wild type P. multocida aroA from Pasteurella multocida NCBI_Protein_ID: 581456; PMID: 17875632 Rebecca Racz, Yongqun He An aroA mutant is attenuated in mice and induced significant protection from challenge with wild type S. typhi Ty2 aroA from Salmonella spp. NCBI_Gene_ID: 1068996; PMID: 3039297 Rebecca Racz, Yongqun He Inactivation of AroC results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908" aroC from Salmonella spp. NCBI_Gene_ID: 1069415; PMID: 17582563 Rebecca Racz, Yongqun He Inactivation of AroC results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908" aroC from Salmonella spp. NCBI_Gene_ID: 1069415; PMID: 17582563 Rebecca Racz, Yongqun He Inactivation of AroD results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908" aroD from Salmonella spp. NCBI_Gene_ID: 1070649; PMID: 17582563 Rebecca Racz, Yongqun He An asd mutant, alone or in combination with a rfc mutation, is attenuated in mice and induces significant protection from challenge with wild type Salmonella typhimurium asd from Salmonella spp. NCBI_Protein_ID: 267995764; PMID: 20799091 Rebecca Racz, Yongqun He An asd mutant, alone or in combination with a rfc mutation, is attenuated in mice and induces significant protection from challenge with wild type Salmonella typhimurium asd from Salmonella spp. NCBI_Protein_ID: 267995764; PMID: 20799091 Rebecca Racz, Yongqun He An atpA mutant is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium atpA from Salmonella spp. NCBI_Protein_ID: 301160399; PMID: 19649318 Rebecca Racz, Yongqun He A cbiA mutant, in combination with a cobS mutation, is attenuated in chickens and induces significant protection from challenge with wild type S. Gallinarum. This mutant was also able to provide some protection against S. Enteritidis cbiA from Salmonella spp. NCBI_Gene_ID: 6923268; PMID: 20153354 Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1941) is attenuated in mice after oral immunization. This mutant is also protective, and had a vaccine efficacy of 76% against challenge with wild type Salmonella Enteritidis clpP from Salmonella spp. NCBI_Gene_ID: 6950532; PMID: 21807911 Rebecca Racz, Yongqun He A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium clpP from Salmonella spp. NCBI_Gene_ID: 1251968; PMID: 2496146 Rebecca Racz, Yongqun He A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium clpP from Salmonella spp. NCBI_Gene_ID: 1251968; PMID: 2496146 Rebecca Racz, Yongqun He A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium clpP from Salmonella spp. NCBI_Gene_ID: 1251968; PMID: 2496146 Rebecca Racz, Yongqun He A cobS mutant, in combination with a cbiA mutation, is attenuated in chickens and induces significant protection from challenge with wild type S. Gallinarum. This mutant was also able to provide some protection against S. Enteritidis cobS from Salmonella spp. NCBI_Gene_ID: 6923296; PMID: 20153354 Rebecca Racz, Yongqun He A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs cpxA from Salmonella spp. NCBI_Gene_ID: 1255585; PMID: 15542179 Rebecca Racz, Yongqun He A cpxR mutant, in combination with a lon mutation, is highly attenuated in mice and induces significant protection from challenge with wild type S. gallinarum cpxR from Salmonella spp. NCBI_Gene_ID: 6923307; PMID: 20487719 Rebecca Racz, Yongqun He A cya and crp mutant is attenuated in mice. Thirty days after immunization, mice were protected from oral challenge with wild type S. typhimurium crp from Salmonella spp. NCBI_Gene_ID: 1254989; PMID: 3316029 Rebecca Racz, Yongqun He A crp mutant is attenuated in mice and induces significant protection from challenge with wild type S. gallinarum crp from Salmonella spp. NCBI_Protein_ID: 46811321; PMID: 17488512 Rebecca Racz, Yongqun He A cya and crp mutant is attenuated in mice. Thirty days after immunization, mice were protected from oral challenge with wild type S. typhimurium cya from Salmonella spp. NCBI_Protein_ID: 581756; PMID: 3316029 Rebecca Racz, Yongqun He A fliC mutant, in combination with a guaB mutant, is attenuated in mice and chickens and induces significant protection from challenge with wild type S. enterica fliC from Salmonella spp. NCBI_Protein_ID: 119351647; PMID: 17261603 Rebecca Racz, Yongqun He A guaBA, clpP, and fliD mutant (CVD 1923) is attenuated in mice after oral immunization. This mutant is also protective, with a vaccine efficacy of 80% in mice against wild type challenge from Salmonella Typhimurium fliD from Salmonella spp. NCBI_Gene_ID: 1253481; PMID: 21807911 Rebecca Racz, Yongqun He A gal E mutant in strain Ty2 was isolated, attenuated, and protected mice against lethal challenge galE from Salmonella spp. NCBI_Gene_ID: 1067209; PMID: 1092768 Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1941) is attenuated in mice after oral immunization. This mutant is also protective in mice and had a vaccine efficacy of 76% against challenge with wild type Salmonella Enteritidis guaA from Salmonella spp. NCBI_Gene_ID: 6948075; PMID: 21807911 Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium guaA from Salmonella spp. NCBI_Gene_ID: 1254032; PMID: 21807911 Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium guaA from Salmonella spp. NCBI_Gene_ID: 1254032; PMID: 21807911 Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium guaB from Salmonella spp. NCBI_Gene_ID: 1254033; PMID: 21807911 Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium guaB from Salmonella spp. NCBI_Gene_ID: 1254033; PMID: 21807911 Rebecca Racz, Yongqun He A guaB mutant, in combination with a fliC mutant, is attenuated in mice and chickens and induced significant protection from challenge with wild type S. enterica guaB from Salmonella spp. NCBI_Gene_ID: 6949287; PMID: 17261603 Rebecca Racz, Yongqun He A guaB mutant, in combination with a fliC mutant, is attenuated in mice and chickens and induced significant protection from challenge with wild type S. enterica guaB from Salmonella spp. NCBI_Gene_ID: 6949287; PMID: 17261603 Rebecca Racz, Yongqun He A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs gyrA from Salmonella spp. NCBI_Gene_ID: 1253794; PMID: 15542179 Rebecca Racz, Yongqun He Oral immunization with the Salmonella hfq deletion mutant efficiently protects mice against subsequent oral challenge with virulent strain of Salmonella Typhimurium hfq from Salmonella spp. NCBI_Gene_ID: 1255887; PMID: 21347426 Rebecca Racz, Yongqun He A htrA mutant in Salmonella typhimurium is attenuated and provides protection in mice against an oral challenge with virulent S. typhimurium SL1344 htrA from Salmonella spp. NCBI_Protein_ID: 301156836; PMID: 1584006] Rebecca Racz, Yongqun He A lon mutant, in combination with a cpxR mutation, is highly attenuated in mice and induces significant protection from challenge with wild type S. gallinarum lon from Salmonella spp. NCBI_Gene_ID: 6923289; PMID: 20487719 Rebecca Racz, Yongqun He An lppA mutant, in combination with an lppB/msbB mutation, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium lppA from Salmonella spp. NCBI_Protein_ID: 323129647; PMID: 17997275 Rebecca Racz, Yongqun He An lppB mutant, in combination with an msbB mutant or an msbB/lppA mutant, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium lppB from Salmonella spp. NCBI_Protein_ID: 267993263; PMID: 17997275 Rebecca Racz, Yongqun He An lppB mutant, in combination with an msbB mutant or an msbB/lppA mutant, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium lppB from Salmonella spp. NCBI_Protein_ID: 267993263; PMID: 17997275 Rebecca Racz, Yongqun He An msbB mutant, in combination with an lppB or lppAB mutation, is attenuated in mice and induces significant protection from challenge with S. Typhimurium msbB from Salmonella spp. NCBI_Protein_ID: 4104731; PMID: 17997275 Rebecca Racz, Yongqun He An msbB mutant, in combination with an lppB or lppAB mutation, is attenuated in mice and induces significant protection from challenge with S. Typhimurium msbB from Salmonella spp. NCBI_Protein_ID: 4104731; PMID: 17997275 Rebecca Racz, Yongqun He In a pig infection experiment including two oral immunizations with SalmoporcDeltaompD (OmpD, nmpC) and challenge with a multiresistant S. enterica serovar Typhimurium DT104 clinical isolate, we confirmed the protective efficacy of SalmoporcDeltaompD in pigs, showing a significant reduction of both clinical symptoms and colonization of lymph nodes and intestinal tract nmpC from Salmonella spp. NCBI_Protein_ID: 517159; PMID: 17296750 Rebecca Racz, Yongqun He A nuoG mutant is attenuated in chickens and induced significant protection from challenge with wild type S. Gallinarum nuoG from Salmonella spp. NCBI_Gene_ID: 6924283; PMID: 9682335 Rebecca Racz, Yongqun He An ompR mutant is attenuated in mice after oral challenge. Twenty eight days after immunization, mice were challenged with wild type S. typhimurium and were significantly protected ompR from Salmonella spp. NCBI_Protein_ID: 301160045; PMID: 2543631 Rebecca Racz, Yongqun He Three S. typhi deletion mutants (phoP, rpoS, and rpoS-phoP double mutant) were constructed and characterized with respect to invasiveness, virulence, and protective immune response compared with wild-type Ty2. All S. typhi mutants showed an increase in the specific serum IgG levels and T-cell-mediated immunity, and showed equal protection abilities against a wild-type Ty2 challenge after two rounds of immunization in BALB/c mice phoP from Salmonella spp. NCBI_Gene_ID: 1071307; PMID: 17725620 Rebecca Racz, Yongqun He A poxA mutant is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium poxA from Salmonella spp. NCBI_Gene_ID: 1255870; PMID: 9826331 Rebecca Racz, Yongqun He A ppGpp-defective Salmonella Gallinarum, which is attained by mutating the relA and spoT genes, is attenuated in chickens and induces protection from oral challenge with wild type S. Gallinarum relA from Salmonella spp. NCBI_Gene_ID: 6922678; PMID: 21046347 Rebecca Racz, Yongqun He An rfc mutant, in combination with an asd mutation, is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium rfc from Salmonella spp. NCBI_Protein_ID: 267993210; PMID: 20799091 Rebecca Racz, Yongqun He A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs rpoB from Salmonella spp. NCBI_Gene_ID: 255679; PMID: 15542179 Rebecca Racz, Yongqun He Immunizations with Salmonella typhimurium rpoS and rpoS aroA mutants protected susceptible BALB/c mice against subsequent oral challenge with virulent S. typhimurium. When administered orally or intraperitoneally, rpoS derivatives of the mouse-virulent S. typhimurium strains, C52 and SL1344, were highly attenuated and were efficient single-dose live vaccines rpoS from Salmonella spp. NCBI_Protein_ID: 301159483; PMID: 8899717 Rebecca Racz, Yongqun He A ruvB mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium ruvB from Salmonella spp. NCBI_Gene_ID: 1253415; PMID: 20670908 Rebecca Racz, Yongqun He A ppGpp-defective Salmonella Gallinarum, which is attained by mutating the relA and spoT genes, is attenuated in chickens and induces protection from oral challenge with wild type S. Gallinarum spoT from Salmonella spp. NCBI_Gene_ID: 6924903; PMID: 21046347 Rebecca Racz, Yongqun He A surA mutant (BRD1115) is attenuated in BALB/c mice and induces protection from challenge with wild type S. typhimurium surA from Salmonella spp. NCBI_Gene_ID: 1251610; PMID: 10678914 Rebecca Racz, Yongqun He A tolA mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium tolA from Salmonella spp. NCBI_Protein_ID: 301157338; PMID: 19118362 Rebecca Racz, Yongqun He A trxA mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium trxA from Salmonella spp. NCBI_Protein_ID: 301160436; PMID: 19884329 Rebecca Racz, Yongqun He A wecA mutant (DSM645) is attenuated in C57BL/6J mice through i.p. and oral immunization. This mutant also protects against challenge with S. typhimurium strains TML and SL1344 30 days after immunization wecA from Salmonella spp. NCBI_Protein_ID: 20140863; PMID: 22025511 Rebecca Racz, Yongqun He A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium znuA from Salmonella spp. NCBI_Gene_ID: 253412; PMID: 21219981 Rebecca Racz, Yongqun He A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium znuB from Salmonella spp. NCBI_Gene_ID: 1253414; PMID: 21219981 Rebecca Racz, Yongqun He A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium znuC from Salmonella spp. NCBI_Gene_ID: 1253413; PMID: 21219981 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri aroA from Shigella NCBI_Gene_ID: 1077373; PMID: 7927802 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri aroA from Shigella NCBI_Gene_ID: 1077373; PMID: 7927802 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri aroA from Shigella NCBI_Gene_ID: 1077373; PMID: 7927802 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri aroA from Shigella NCBI_Gene_ID: 1077373; PMID: 7927802 Rebecca Racz, Yongqun He An aroD mutant is highly attenuated in monkeys and induces significant protection from challenge with wild type S. flexneri aroD from Shigella NCBI_Gene_ID: 1078189; PMID: 8356844 Rebecca Racz, Yongqun He An aroD mutant is highly attenuated in monkeys and induces significant protection from challenge with wild type S. flexneri aroD from Shigella NCBI_Gene_ID: 1078189; PMID: 8356844 Rebecca Racz, Yongqun He An envZ mutant (SC433) is greatly decreased in virulence in macaque monkeys, though some mild clinical signs were still recorded. This mutant is also highly protective against a challenge of wild type S. flexneri delivered 1 month after inoculation envZ from Shigella NCBI_Gene_ID: 4207729; PMID: 1887672 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri icsA/virG from Shigella NCBI_Gene_ID: 1238021; PMID: 7927802 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri icsA/virG from Shigella NCBI_Gene_ID: 1238021; PMID: 7927802 Rebecca Racz, Yongqun He A virG, senA, senB, and msbB2 mutant (WRSs3) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs3 is comparable to live attenuated vaccine strain WRSS1 msbB2 from Shigella NCBI_Gene_ID: 3670926; PMID: 19932216] Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 senA from Shigella NCBI_Gene_ID: 3671021; PMID: 19932216 Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 senA from Shigella NCBI_Gene_ID: 3671021; PMID: 19932216 Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 senB from Shigella NCBI_Gene_ID: 3668265; PMID: 19932216 Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 senB from Shigella NCBI_Gene_ID: 3668265; PMID: 19932216 Rebecca Racz, Yongqun He A virG mutant (WRSS1) is attenuated in guinea pigs and induced significant protection from challenge with wild type Shigella sonnei virG from Shigella NCBI_Gene_ID: 3670887; PMID: 9712824 Rebecca Racz, Yongqun He A virG mutant (WRSS1) is attenuated in guinea pigs and induced significant protection from challenge with wild type Shigella sonnei virG from Shigella NCBI_Gene_ID: 3670887; PMID: 9712824 Rebecca Racz, Yongqun He A hemA mutant is highly attenuated in mice and rabbits and induces protection from challenge with wild type V. cholerae in rabbits hemA from Vibrio cholerae NCBI_Protein_ID: 12656010; PMID: 16102875 Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in mice, and after 3 doses induces significant protection from challenge with wild type Y. enterocolitica aroA from Yersinia enterocolitica NCBI_Gene_ID: 4713234; PMID: 2777382 Rebecca Racz, Yongqun He A htrA mutant in Yersinia enterocolitica was attenuated and provided partial protection against challenge in mice htrA from Yersinia enterocolitica NCBI_Gene_ID: 4715899; PMID: 8675311 Rebecca Racz, Yongqun He A ompR mutant in Yersinia enterocolitica was attenuated and provided a partial protection from challenge in mice ompR from Yersinia enterocolitica NCBI_Gene_ID: 4716266; PMID: 9711851 Rebecca Racz, Yongqun He A sodA mutant in Yersinia enterocolitica was highly attenuated and mice immunized with a single oral dose of the mutant strain were protected against a lethal oral-challenge infection with wild-type Y. enterocolitica sodA from Yersinia enterocolitica NCBI_Gene_ID: 4716532; PMID: 10496939 Rebecca Racz, Yongqun He A guaBA mutant is attenuated in mice and induced significant protection from challenge with wild type Y. pestis guaA from Yersinia pestis NCBI_Gene_ID: 1146310; PMID: 0096773 Rebecca Racz, Yongqun He A guaBA mutant is attenuated in mice and induced significant protection from challenge with wild type Y. pestis guaB from Yersinia pestis NCBI_Gene_ID: 1146309; PMID: 0096773 Rebecca Racz, Yongqun He An IpxM mutant is attenuated in mice and guinea pigs. This mutant also conferred modest protection from challenge with wild type Y. pestis in Balb/c mice and significant protection in guinea pigs and outbred mice ipxM from Yersinia pestis NCBI_Gene_ID: 1174901; PMID: 17913308 Rebecca Racz, Yongqun He An nlpD mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis nlpD from Yersinia pestis NCBI_Protein_ID: 224483371; PMID: 19759820 Rebecca Racz, Yongqun He A pcm mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis pcm from Yersinia pestis NCBI_Protein_ID: 224483370; PMID: 14742535 Rebecca Racz, Yongqun He An smpB mutant, in combination with an ssrA mutation, is attenuated in mice and induces significant protection from challenge with wild type Y. pestis smpB from Yersinia pestis NCBI_Gene_ID: 1173949; PMID: 20065026 Rebecca Racz, Yongqun He An smpB mutant, in combination with an ssrA mutation, is attenuated in mice and induces significant protection from challenge with wild type Y. pestis ssrA from Yersinia pestis NCBI_Gene_ID: 1173948; PMID: 20065026 Rebecca Racz, Yongqun He A yopH mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis yopH from Yersinia pestis NCBI_Gene_ID: 1172712; PMID: 17652523 Rebecca Racz, Yongqun He A phoP mutant in Yersinia pseudotuberculosis (Yptb) was attenuated and provided protection against oral challenge with virulent Yptb in mice phoP from Yersinia pseudotuberculosis NCBI_Gene_ID: 2956268; PMID: 17194509 Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in rainbow trout and induces significant protection from challenge with wild type Y. ruckeri aroA from Yersinia ruckeri NCBI_Protein_ID: 15420539; PMID: 16083447 Rebecca Racz, Yongqun He A thymidine kinase-deficient mutant (B8-D53) showed no detectable thymidine kinase-inducing activity and was attenuated in calves. B8-D53 also induced protection from challenge with wild type BHV-1 UL23 from Bovine herpesvirus 1 NCBI_Gene_ID: 1487380; PMID: 2994602 Rebecca Racz, Yongqun He A deletion of BHV-1 gE gene in strain A is considered as a live attenuated vaccine. After challenge, vaccinated calves were protected against disease and virus shedding was reduced US8 from Bovine herpesvirus 1 NCBI_Gene_ID: 1487407; PMID: 8023552 Rebecca Racz, Yongqun He A glycoprotein G deletion in bovine respiratory syncytial virus(rBRSV) and recombinant rBRSV was attenuated and provided protection against a BRSV challenge infection in calves glycoprotein G from Bovine Respiratory Syncytial Virus NCBI_Gene_ID: 1489813; PMID: 12414977 Rebecca Racz, Yongqun He An N269A/Q mutation in the E(rns) protein created an attenuated mutant in swine. This mutant was able to induce effective protection in swine against challenge with wild type CSFV E(rns) from Classical swine fever virus NCBI_Protein_ID: 130457; PMID: 17904607 Rebecca Racz, Yongqun He An N to A amino acid substitution was made in the N594 site of the E1 glycoprotein, resulting in attenuation of the virus in swine. This attenuated virus induced protection against challenge with wild type CSFV E1 from Classical swine fever virus NCBI_Protein_ID: 325461; PMID: 19203774 Rebecca Racz, Yongqun He A E2 mutant in Classical swine fever virus is attenuated and provides protection in pigs after oronasal vaccination (not intradermal vaccination) against lethal challenge dose of CSFV strain Eystrup E2 from Classical swine fever virus NCBI_Gene_ID: 920146; PMID: 15837238 Rebecca Racz, Yongqun He A glycoprotein E mutant is attenuated in mice and hamsters and induced significant protection from challenge with wild type Equid herpesvirus in mice gE from Equid herpesvirus NCBI_Protein_ID: 330789; PMID: 17085880 Rebecca Racz, Yongqun He A glycoprotein I mutant is attenuated in mice and hamsters and induced significant protection from challenge with wild type Equid herpesvirus in mice gI from Equid herpesvirus NCBI_Protein_ID: 330788; PMID: 17085880 Rebecca Racz, Yongqun He A thymidine kinase-deficient mutant (PR1) is attenuated in mice and induced significant protection from challenge with wild type EHV-1 5 weeks after vaccination. In foals, PR1 also showed attenuation; however, the mutant induced only partial protection from challenge with EHV-1 TK from Equid herpesvirus NCBI_Protein_ID: 59214; PMID: 16930871 Rebecca Racz, Yongqun He A thymidine kinase-deficient mutant (C7301dlTK) is attenuated in cats and induced significant protection from wild type FHV-1 4 weeks after vaccination UL23 from Feline herpesvirus 1 NCBI_Gene_ID: 8658565; PMID: 8645090 Rebecca Racz, Yongqun He Feline immunodeficiency virus (FIV) made defective in the accessory gene ORF-A were previously shown to be greatly attenuated in its ability to replicate in lymphocytes but to grow normally or near normally in other cell types. 3/9 vaccinees (cats) showed no evidence of the challenge virus over a 15-month observation period. In the other vaccinees, the challenge virus was predominant for various periods of time, but pre-existing viral loads and CD4 lymphocyte counts were either unaffected or altered only marginally and transiently ORF-A from Feline immunodeficiency virus NCBI_Gene_ID: 1724707; PMID: 15680433 Rebecca Racz, Yongqun He A vif mutant in feline immunodeficiency virus was attenuated and FIV-pPPRΔvif proviral DNA protected cats against challenge with the homologous FIV-PPR biological isolate. vif from Feline immunodeficiency virus NCBI_Gene_ID: 1724709; PMID: 10891409 Rebecca Racz, Yongqun He A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens 3a from Feline infectious peritonitis virus NCBI_Gene_ID: 10040181; PMID: 15047802 Rebecca Racz, Yongqun He A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens 3b from Feline infectious peritonitis virus NCBI_Gene_ID: 10040182; PMID: 15047802 Rebecca Racz, Yongqun He A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens 3c from Feline infectious peritonitis virus NCBI_Gene_ID: 10040183; PMID: 15047802 Rebecca Racz, Yongqun He A 7ab deletion mutant in Feline infectious peritonitis virus is attenuated and provides protection against virulent FIPV strain 79-1146 challenge in kittens 7a from Feline infectious peritonitis virus NCBI_Gene_ID: 10040187; PMID: 15047802 Rebecca Racz, Yongqun He A 7ab deletion mutant in Feline infectious peritonitis virus is attenuated and provides protection against virulent FIPV strain 79-1146 challenge in kittens 7b from Feline infectious peritonitis virus NCBI_Gene_ID: 10040188; PMID: 15047802 Rebecca Racz, Yongqun He A UL0 mutant in infectious laryngotracheitis virus (ILTV) was attenuated. Chickens immunized with UL0-negative ILTV were protected from clinical disease after subsequent infection with virulent ILTV UL0 from Gallid herpesvirus 1 NCBI_Gene_ID: 3239037; PMID: 14645915 Rebecca Racz, Yongqun He A thymidine-kinase mutant is attenuated in chickens and induced protection from challenge with wild type GHV-1 UL23 from Gallid herpesvirus 1 NCBI_Gene_ID: 3239035; PMID: 12021870 Rebecca Racz, Yongqun He A UL47 mutant in avian infectious laryngotracheitis virus is attenuated and provides protection in chicken against subsequent challenge infection with virulent ILTV UL47 from Gallid herpesvirus 1 NCBI_Gene_ID: 3239064; PMID: 17325345 Rebecca Racz, Yongqun He Researchers generated a series of woodchuck hepatitis virus (WHV) X mutants. Woodchucks inoculated with X mutants, including those with no serologic evidence of infection, were protected from later challenge with infectious Woodchuck Hepatitis Virus, suggesting previous infection with resulting protective immunity HBVgp3 X protein from Hepatitis B virus NCBI_Gene_ID: 944566; PMID: 11714744 Rebecca Racz, Yongqun He KOS-gDA3C is attenuated with mutations in gD gene in causing skin lesions at the inoculation and zosteriform sites, yet it is as effective as rKOS-gDA3C in protecting mice against HSV-1 challenge gD from Herpes simplex virus type 1 and 2 NCBI_Protein_ID: 19548971; PMID: 18243431 Rebecca Racz, Yongqun He A gH mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 gH from Herpes simplex virus type 1 and 2 NCBI_Protein_ID: 138315; PMID: 8289395 Rebecca Racz, Yongqun He A live-attenuated HSV-2 ICP0 virus provides significant protection against wild-type HSV-2 (MS strain) challenge in mice iCP0 from Herpes simplex virus type 1 and 2 NCBI_Gene_ID: 1487289; PMID: 21412438 Rebecca Racz, Yongqun He A thymidine kinase-deficient (TK) mutant was found to be attenuated in mice. This mutant induced complete protection from challenge with wild type HSV TK from Herpes simplex virus type 1 and 2 NCBI_Gene_ID: 2703374; PMID: 212476 Rebecca Racz, Yongqun He A UL29 mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 UL29 from Herpes simplex virus type 1 and 2 NCBI_Gene_ID: 2703458; PMID: 8289372 Rebecca Racz, Yongqun He An HSV-1 gE (Us8) deletion strain, NS-gEnull, was used as a live attenuated vaccine. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice US8 from Herpes simplex virus type 1 and 2 NCBI_Gene_ID: 2703448; PMID: 18562543 Rebecca Racz, Yongqun He A G mutant is attenuated in African green monkeys and induces protection from challenge with wild type HMPV G protein from Human metapneumovirus NCBI_Protein_ID: 75549950; PMID: 16160190 Rebecca Racz, Yongqun He An M2-2 mutant is attenuated in African green monkeys and induced protection from challenge with wild type HMPV M2-2 from Human metapneumovirus NCBI_Protein_ID: 75549952; PMID: 16160190 Rebecca Racz, Yongqun He An M2-2 mutant of human respiratory syncytial virus A2 is attenuated in African green monkeys. When challenged with wild type RSV, two doses provided complete protection against challenge in the lower respiratory tract and a significant reduction of the challenge virus in the upper respiratory tract M2-2 from Human Respiratory Syncytial Virus NCBI_Protein_ID: 81925031; PMID: 12922094 Rebecca Racz, Yongqun He A mutation in the non-virion protein of IHNV causes attenuated growth in rainbow trout and is able to provide significant protection from subsequent challenge with wild type IHNV NV from Infectious Hematopoietic Necrosis Virus NCBI_Gene_ID: 1489849; PMID: 15047826 Rebecca Racz, Yongqun He Mutant influenza virus that lacks the transmembrane and cytoplasmic tail domains of M2 (M2 knockout [M2KO]) from Influenza A virus (A/Puerto Rico/8/34(H1N1)) is attenuated in both cell culture and mice. Mice intranasally vaccinated with M2KO virus developed protective immune responses and survived a lethal challenge with the wild-type virus, suggesting that the M2KO virus has potential as a live attenuated vaccine M2 from Influenza virus NCBI_Gene_ID: 956528; PMID: 19321619 Rebecca Racz, Yongqun He Intranasal inoculation of mice, pigs, horses, and macaques with NS1-modified influenza virus strains induced robust humoral and cellular immune responses, and generated immune protection against challenge with wild-type virus NS1 from Influenza virus NCBI_Protein_ID: 505039; PMID: 19768406 Rebecca Racz, Yongqun He A mutation in the GP5 protein attenuates HP-PRRSV in piglets. This mutant (HuN4-F112) induces protection against challenge with wild type HP-PRRSV GP5 protein from Porcine respiratory and reproductive syndrome virus NCBI_Protein_ID: 149389584; PMID: 19339125 Rebecca Racz, Yongqun He A glycoprotein E mutant, in combination with UL23 and glycoprotein G mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV glycoprotein E from Pseudorabies virus NCBI_Protein_ID: 307634504; PMID: 12488067 Rebecca Racz, Yongqun He A glycoprotein G mutant, in combination with UL23 and glycoprotein E mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV glycoprotein G from Pseudorabies virus NCBI_Protein_ID: 15422177; PMID: 12488067 Rebecca Racz, Yongqun He A glycoprotein M, gM, deletion in pseudorabies virus was attenuated and induced protection in piglets against intranasal challenge with 108 p.f.u. of the highly virulent PrV strain NIA-3 glycoprotein M from Pseudorabies virus NCBI_Protein_ID: 1478255; PMID: 9292000 Rebecca Racz, Yongqun He A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3 gp50 from Pseudorabies virus NCBI_Gene_ID: 2952548; PMID: 8178562 Rebecca Racz, Yongqun He A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3 gp63 from Pseudorabies virus NCBI_Gene_ID: 2952540; PMID: 8178562 Rebecca Racz, Yongqun He A UL23 mutant, in combination with mutations in glycoproteins G and E, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV UL23 from Pseudorabies virus NCBI_Gene_ID: 2952559; PMID: 12488067 Rebecca Racz, Yongqun He A UL50 mutant is attenuated in pseudorabies virus and induces significant protection in pigs from challenge with the highly virulent NIA-3 strain of PrV UL50 from Pseudorabies virus NCBI_Gene_ID: 2952537; PMID: 9228681 Rebecca Racz, Yongqun He Researchers intranasally inoculated pigs, the natural host of this virus, with mutant PRV strains in which the genes encoding the protein kinase (US3) proteins were inactivated. After challenge infection with the virulent PRV strain NIA-3, no virus was excreted by wt PRV- and PK- mutant-immunized animals, indicating complete protective immunity US3 from Pseudorabies virus NCBI_Gene_ID: 2952561; PMID: 7975253 Rebecca Racz, Yongqun He A glycoprotein G mutant in rabies virus is attenuated. After a one-dose intramuscular vaccination, the ERAg3m virus protected 100% of mice and hamsters from lethal challenge. In co-infections, using a lethal dose of street rabies virus mixed with ERAg3m, 100% of hamsters and 90% of mice survived and were protected against subsequent infection glycoprotein G from Rabies virus NCBI_Gene_ID: 1489856; PMID: 21514343 Rebecca Racz, Yongqun He A P gene mutant is attenuated in mice and induces significant protection from challenge with wild type Rabies virus P protein from Rabies virus NCBI_Protein_ID: 291220682; PMID: 15896403 Rebecca Racz, Yongqun He An E mutant is attenuated in hamsters and induces significant protection from challenge with wild type SARS E from SARS-CoV NCBI_Gene_ID: 1489671; PMID: 18463152 Rebecca Racz, Yongqun He A SIV nef mutant is attenuated in rhesus monkeys and induces protection from challenge with wild type SIV nef from Simian Immunodeficiency Virus NCBI_Gene_ID: 1490008; PMID: 1470917 Rebecca Racz, Yongqun He A virus with a mutation in protein C is attenuated in mice and induced protection from challenge with wild type TBE virus C protein from Tick-borne Encephalitis Virus (TBEV) NCBI_Protein_ID: 206570298; PMID: 11884577 Rebecca Racz, Yongqun He A VEE mutant with a PE2 cleavage signal mutation and a suppressor mutation in E1 is highly attenuated in mice and provides complete protection against challenge with wild type VEE E1 glycoprotein from VEE Virus NCBI_Protein_ID: 798795; PMID: 7676619 Rebecca Racz, Yongqun He A VEE mutant with a PE2 cleavage signal mutation and a suppressor mutation in E1 is highly attenuated in mice and provides complete protection against challenge with wild type VEE PE2 from VEE Virus NCBI_Protein_ID: 229558446; PMID: 7676619 Rebecca Racz, Yongqun He A virus with a C protein mutation is attenuated in mice and induces significant protection from challenge with wild type West Nile virus C protein from West Nile virus NCBI_Protein_ID: 158516889; PMID: 20600500 Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur E1 from Western equine encephalomyelitis virus NCBI_Protein_ID: 17148717; PMID: 12641414 Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur E1 from Western equine encephalomyelitis virus NCBI_Protein_ID: 17148717; PMID: 12641414 Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E2 (WE2102) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur E2 from Western equine encephalomyelitis virus NCBI_Protein_ID: 29611992; PMID: 12641414 Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E2 (WE2102) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur E2 from Western equine encephalomyelitis virus NCBI_Protein_ID: 29611992; PMID: 12641414 Rebecca Racz, Yongqun He A PE2 mutant combined with either a deletion in E2 (WE2102) or E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of these two strains would occur PE2 from Western equine encephalomyelitis virus NCBI_Protein_ID: 90811336; PMID: 12641414 Rebecca Racz, Yongqun He A PE2 mutant combined with either a deletion in E2 (WE2102) or E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of these two strains would occur PE2 from Western equine encephalomyelitis virus NCBI_Protein_ID: 90811336; PMID: 12641414 Rebecca Racz, Yongqun He A cen1 mutant is attenuated in mice and hamsters and induces significant protection from challenge with wild type L. donovani cen1 from Leishmania donovani NCBI_Protein_ID: 15488542; PMID: 19592661 Rebecca Racz, Yongqun He A Leishmania infantum deletion mutant of HSP70-II gene is attenuated and provides protection against Leishmania infection in the L. major-BALB/c infection model. Also, DeltaHSP70-II is a safe live vaccine as immunodeficient SCID mice, and hamsters, infected with mutant parasites did not develp any sign of pathology HSP70 II from Leishmania infantum NCBI_Gene_ID: 5073319; PMID: 21794145 Rebecca Racz, Yongqun He A genetically attenuated parasite (GAP) with a mutation in the FabB/FabF gene is attenuated in mice by arresting in the late liver stage. It also conferred complete protection in mice from challenge with wild type Plasmodium fabB/fabF from Plasmodium spp. NCBI_Gene_ID: 3885996; PMID: 21669394 Rebecca Racz, Yongqun He Genetically attenuated P36p-deficient Plasmodium berghei sporozoites provide protection against sporozoites challenge in mice p36p from Plasmodium spp. NCBI_Gene_ID: 3424772; PMID: 7604034 Rebecca Racz, Yongqun He A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites py36 from Plasmodium spp. NCBI_Protein_ID: 23479924; PMID: 17517871 Rebecca Racz, Yongqun He A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites py52 from Plasmodium spp. NCBI_Protein_ID: 15193062; PMID: 17517871 Rebecca Racz, Yongqun He Deletion of UIS3 in Plasmodium yoelii provided attenuation and full protection in mice by Pyuis3(-) sporozoites required at least 2 immunizations against challenges with infectious sporozoites UIS3 from Plasmodium spp. NCBI_Gene_ID: 3830198; PMID: 17624848 Rebecca Racz, Yongqun He A mic2 mutant is attenuated in mice and induces protection from challenge with wild type T. gondii mic2 from Toxoplasma gondii NCBI_Protein_ID: 1923217; PMID: 16933991 Rebecca Racz, Yongqun He An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii OMPDC from Toxoplasma gondii NCBI_Gene_ID: 7899615; PMID: 20605980 Rebecca Racz, Yongqun He An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii OMPDC from Toxoplasma gondii NCBI_Gene_ID: 7899615; PMID: 20605980 Rebecca Racz, Yongqun He A UP mutant, in combination with an OMPDC mutation, is attenuated in mice and induces significant protection from wild type T. gondii UP from Toxoplasma gondii NCBI_Gene_ID: 900273; PMID: 20605980 Rebecca Racz, Yongqun He The mutant strain, with deletion of apxIA gene, obtained in this study offered a level of cross-serovar protection against A. pleuropneumoniae infection in mice and pigs (Reference: PMID: 16930871). Actinobacillus pleuropneumoniae apxIA mutant vaccine Rebecca Racz, Yongqun He In the intra-peritoneal mouse model, the virulence of the mutant strain decreased at least 100 fold compared with the parent strain. The mutant was evaluated as a potential vaccine using a vaccination-challenge trial. The death number and lung lesion score in the vaccinated pigs given the serovar 1 challenge were obviously lower than those in the unvaccinated pigs Actinobacillus pleuropneumoniae ApxIC mutant vaccine Rebecca Racz, Yongqun He Deletion in ureC and apxIIA genes of Actinobacillus pleuropneumoniae serotype 2 prototype provides attenuation and protection in pigs against challenge with the virulent parent strain of A. pleuropneumoniae Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine Rebecca Racz, Yongqun He In the present study, the gene encoding the ApxII-activating protein, apxIIC, was insertionally inactivated on the chromosome of a serovar 7 strain, HS93. Pigs vaccinated with live HS93C-Ampr via the intranasal route were protected against a cross-serovar challenge with a virulent serovar 1 strain of A. pleuropneumoniae Actinobacillus pleuropneumoniae apxIIC and apxIVA double deletion mutant vaccine Rebecca Racz, Yongqun He In the present study, the gene encoding the ApxII-activating protein, apxIIC, was insertionally inactivated on the chromosome of a serovar 7 strain, HS93. Pigs vaccinated with live HS93C-Ampr via the intranasal route were protected against a cross-serovar challenge with a virulent serovar 1 strain of A. pleuropneumoniae A. pleuropneumoniae HS93C-Ampr Rebecca Racz, Yongqun He An apxIIIB mutant, in combination with an apxIIID mutation, is highly attenuated in pigs and induces significant protection from challenge with wild type A. pleuropneumoniae. The mutant also was slightly attenuated in mice and induced protection in mice against challenge from the parent strain Actinobacillus pleuropneumoniae apxIIIB and apxIIID double mutant vaccine Rebecca Racz, Yongqun He An apxIIID mutant, in combination with an apxIIIB mutation, is highly attenuated in pigs and induces significant protection from challenge with wild type A. pleuropneumoniae. The mutant also was slightly attenuated in mice and induced protection in mice against challenge from the parent strain Actinobacillus pleuropneumoniae apxIIIB and apxIIID double mutant vaccine Rebecca Racz, Yongqun He A precisely defined DeltaapxIICDeltaapxIVA double-deletion mutant of A. pleuropneumoniae was constructed based on HB04C(-) by transconjugation and counterselection. The results demonstrated that the DeltaapxIICDeltaapxIVA double mutant strain was less virulent than HB04C(-). Despite attenuation of virulence, the DeltaapxIICDeltaapxIVA double mutant remains immunogenic and conferred a similar level of protective immunity to pigs against challenge with a lethal dose of a heterologous fully virulent standard serovar 1 strain of A. pleuropneumoniae. (Reference: PubMed: 17767980) Actinobacillus pleuropneumoniae apxIIC and apxIVA double deletion mutant vaccine Rebecca Racz, Yongqun He Deletions were introduced into the ureC and apxIIA genes of an Actinobacillus pleuropneumoniae serotype 2 strain by homologous recombination and counterselection. The double-mutant contains no foreign DNA, is highly attenuated, protects pigs from homologous challenge upon a single aerosol application Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine Rebecca Racz, Yongqun He An mntA deletion mutant, generated by allelic replacement, in Bacillus anthracis was attenuated and provided protection for guinea pigs against lethal spore dose (60 LD50) of the virulent B. anthracis Vollum strain Bacillus anthracis mntA deletion mutant vaccine Rebecca Racz, Yongqun He An actA mutant is attenuated in mice and induced significant protection from challenge with wild type L. monocytogenes Listeria monocytogenes actA mutant vaccine Rebecca Racz, Yongqun He An actA mutant is attenuated in mice and induced significant protection from challenge with wild type L. monocytogenes Listeria monocytogenes actA/plcB mutant vaccine Rebecca Racz, Yongqun He A plcB mutant, in combination with an actA mutant, is attenuated in mice and induces significant protection from challenge with wild type L. monocytogenes Listeria monocytogenes actA/plcB mutant vaccine Rebecca Racz, Yongqun He A M. avium relA mutant is attenuated in calves and goats. This mutant also elicited an immune response in goats that limited colonization by challenge wild type M. avium Mycobacterium avium relA mutant vaccine Rebecca Racz, Yongqun He A drrC mutant is highly attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis Mycobacterium tuberculosis drrC mutant vaccine Rebecca Racz, Yongqun He An fadD26 mutant is attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis Mycobacterium tuberculosis fadD26 mutant vaccine Rebecca Racz, Yongqun He Deletion of leuD gene was shown to be highly attenuated. Immunocompetent BALB/c mice vaccinated with the DleuD auxotroph were protected as well as BCG in terms of survival following an intravenous or aerosol challenge with virulent M. tuberculosis Mycobacterium tuberculosis leuD mutant vaccine Rebecca Racz, Yongqun He A lysA mutant, in combination with a secA2 mutation, is highly attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis Mycobacterium tuberculosis lysA/secA2 mutant vaccine Rebecca Racz, Yongqun He A Mce-2 mutant in Mycobacterium tuberculosis is attenuated and provides protection against challenge for mice Mycobacterium tuberculosis mce-2/mce-3 mutant vaccine A viral vaccine that protects against infection with Chikungunya virus YH, RS, NF chikungunya virus vaccine Rebecca Racz, Yongqun He A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis Mycobacterium tuberculosis panCD mutant vaccine RD1 and panCD mutants in Mycobacterium tuberculosis were attenuated and provided protection in CD4-deficient mice against an aerosol challenge with virulent M. tuberculosis Rebecca Racz, Yongqun He A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis Mycobacterium tuberculosis RD1/panCD mutant vaccine a bacterial vaccine against Streptococcus suis infection YH, RS, NF Streptococcus suis vaccine a diphtheria vaccine against infection with Corynebacterium pseudotuberculosis YH, RS, NF Corynebacterium pseudotuberculosis vaccine Rebecca Racz, Yongqun He Study evaluated immunogenicity and protection against Mycobacterium tuberculosis in rhesus monkeys with an attenuated M. tuberculosis with a disrupted phoP gene (SO2) as a single-dose vaccine. SO2 treatment showed reduced average lung bacterial counts (1.0 and 1.2 log respectively, compared with 0.4 log for BCG) and significant protective effect by reduction in C-reactive protein levels, body weight loss, and decrease of erythrocyte-associated hematologic parameters (MCV, MCH, Hb, Ht) as markers of inflammatory infection, all relative to non-vaccinated controls M. tuberculosis phoP mutant SO2 Rebecca Racz, Yongqun He A proC mutant is highly attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis that is equal to the protection induced by the current vaccine BCG Mycobacterium tuberculosis proC mutant vaccine A protozoan vaccine against Trichinella spiralis infection YH, RS, NF Trichinella spiralis vaccine A vaccine that prevents or treats atherosclerosis disease. YH, RS http://www.onlinejacc.org/content/64/25/2779 atherosclerosis vaccine Rebecca Racz, Yongqun He Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Guérin vaccination M. tuberculosis secA2 mutant Rebecca Racz, Yongqun He A sigE mutant is highly attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis, more so than the existing vaccine BCG Mycobacterium tuberculosis sigE mutant vaccine Rebecca Racz, Yongqun He A trpD mutant is highly attenuated in mice and induces more protection from challenge with wild type M. tuberculosis than that induced by the current vaccine BCG Mycobacterium tuberculosis trpD mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is attenuated in mice and induced significant protection from challenge with wild type S. aureus Staphylococcus aureus aroA mutant vaccine Rebecca Racz, Yongqun He A vicK mutant is attenuated in mice and induced protection from challenge with wild type S. equi Streptococcus equi vicK mutant vaccine Rebecca Racz, Yongqun He An A. hydrophila aroA mutant is highly attenuated in trout, and a single immunization conferred significant protection from challenge with wild type A. hydrophila Aeromonas hydrophila aroA mutant vaccine Rebecca Racz, Yongqun He The aroA gene was inactivated by inserting a fragment expressing kanamycin resistance within the coding sequence and challenged in fish. The LD50 for unvaccinated fish was 71. In contrast, the LD50 was 1.8 x 104 in fish vaccinated once and 3 x 105 in fish vaccinated twice A. salmonicida live-attenuated vaccine encoding AroA Rebecca Racz, Yongqun He Inactivation of the aroA gene highly attenuates B. bronchiseptica, severely impairing its ability to colonize and survive in the respiratory tract of mice. Upon challenge with wild type B. bronchiseptica, the mice immunised with live attenuated B. bronchiseptica aroA mutant had rapidly reduced numbers of B. bronchiseptica in their respiratory tract Bordetella bronchiseptica aroA mutant vaccine (strain BBS18) Rebecca Racz, Yongqun He Inactivation of the aroA gene highly attenuates B. bronchiseptica, severely impairing its ability to colonize and survive in the respiratory tract of mice. Upon challenge with wild type B. bronchiseptica, the mice immunised with live attenuated B. bronchiseptica aroA mutant had rapidly reduced numbers of B. bronchiseptica in their respiratory tract Bordetella bronchiseptica aroA/trpE mutant vaccine Rebecca Racz, Yongqun He A double mutant strain of Bordetella Bronchiseptica lacking adenylate cyclase(cyaA gene) and type III secretion(bscN gene) is attenuated and provides protection in mice against 5 × 105 CFU of RB50, the B. Bronchiseptica parent strain Bordetella bronchiseptica bscN and cyaA double mutant vaccine Rebecca Racz, Yongqun He A double mutant strain of Bordetella Bronchiseptica lacking adenylate cyclase(cyaA gene) and type III secretion(bscN gene) is attenuated and provides protection in mice against 5 × 105 CFU of RB50, the B. Bronchiseptica parent strain Bordetella bronchiseptica bscN and cyaA double mutant vaccine Rebecca Racz, Yongqun He A dnt mutant in Bordetella bronchiseptica was attenuated and provides protection in guinea pigs against intranasal challenge with strain L3 Bordetella bronchiseptica dnt mutant vaccine Rebecca Racz, Yongqun He A trpE mutant, in combination with an aroA mutation, is attenuated in mice and induces significant protection from challenge with wild type B. bronchiseptica Bordetella bronchiseptica aroA/trpE mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in mice and induces significant protection from challenge with wild type B. pertussis Bordetella pertussis aroA mutant vaccine Rebecca Racz, Yongqun He A live attenuated B. pertussis vaccine strain BPZE1, developed by deleting dnt gene, protects mice upon a single intranasal administration Bordetella pertussis dnt mutant vaccine Rebecca Racz, Yongqun He A flagella-less mutant of Borrelia burgdorferi (HB19Fla-) was attenuated in immunodeficient SCID mice. Mice were challenged 28 days later with virulent strain Sh. 2 and were protected from challenge Borrelia burgdorferi fla mutant vaccine Rebecca Racz, Yongqun He A asp24 mutation in Brucella abortus is attenuated and provides significant protection in mice B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA A vaccine that prevents or treats diabetes. YH, RS https://www.ncbi.nlm.nih.gov/pubmed/12956615 diabetes vaccine Rebecca Racz, Yongqun He Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308. This demonstrated that ExsA is critical for full bacterial virulence. The B. abortus exsA deletion mutant was used as a live vaccine candidate. Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51 Brucella abortus exsA mutant vaccine A vaccine that prevents or treats a non-infectious disease. YH, RS https://www.ncbi.nlm.nih.gov/pubmed/12831367 There are mainly five types of non-infectious diseases, which are diabetes, allergies, cardiovascular diseases, cancer and genetic diseases. URL: http://www.ychlpyss.edu.hk/~bio/share/0405/f6homework/Non-infectious%20disease/noninfectiousdisease(ths).htm non-infectious disease vaccine Rebecca Racz, Yongqun He Mutants manB and manA were attenuated in Brucella melitensis and provided protection against challenge in mice's livers Unmarked rough B. abortus and B. melitensis deletion mutants of manBA (including manA and manB) were attenuated. These mutants provided protection against virulent Brucella challenge in mice B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA Rebecca Racz, Yongqun He A mucR mutant has a significantly reduced degree of colonization in mice and protects against wild type B. melitensis 16M B. melitensis mucR mutant vaccine Rebecca Racz, Yongqun He A omp25 mutant is attenuated and provides protection against challenge in mice B. melitensis omp25 mutant vaccine Rebecca Racz, Yongqun He A omp31 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice B. melitensis omp31 mutant vaccine Rebecca Racz, Yongqun He A pgk mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus Brucella abortus pgk mutant vaccine Rebecca Racz, Yongqun He A pgm mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus Brucella abortus pgm mutant vaccine Rebecca Racz, Yongqun He Mice infected with delta purE201 developed only five to eight times normal spleen weight at 1 week p.i. and produced no interleukin-6 in their serum, which is much lower than the mice infected with the parental strain (16M) B. melitensis WR201 (16MΔpurEK) Rebecca Racz, Yongqun He A purE/purK mutant of B. melitensis 16M was attenuated in mice when given intraperitoneally. Nine weeks after immunization, mice were protected from challenge with wild type B. melitensis B. melitensis WR201 (16MΔpurEK) Rebecca Racz, Yongqun He A virB2 mutant is attenuated in Brucella melitensis and provides protection in mice B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA A vaccine that prevents or treats arthritis. YH, RS https://www.ncbi.nlm.nih.gov/pubmed/12956615 arthritis vaccine Rebecca Racz, Yongqun He Deletion of gene znuA attenuates Brucella abortus and this live attenuated vaccine was challenged in mice. These mice showed significantly fewer spenic CFU live attenuated B. abortus with deletion of znuA Rebecca Racz, Yongqun He The aroC deletion in the resultant mutant, designated A2ΔaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compounds. The constructed unmarked aroC mutant of B. pseudomallei is attenuated in both BALB/c and C57Bl/6 mice and is able to confer significant protection in C57Bl/6 mice Burkholderia pseudomallei aroC deletion mutant vaccine Rebecca Racz, Yongqun He An asd mutant is highly attenuated in mice. This mutant was also able to protect against acute inhalation melioidosis caused by challenge with wild type B. pseudomallei Burkholderia pseudomallei asd mutant vaccine Rebecca Racz, Yongqun He Mice that were challenged with a higher dose of mutant 56:65 purM were protected Burkholderia pseudomallei purM mutant vaccine Rebecca Racz, Yongqun He Although 30:93a purN -immunized mice were challenged with a 10-fold higher dose of WT E8, mice were strongly protected and showed no signs of clinical illness until the experiment was terminated Burkholderia pseudomallei purN mutant vaccine Rebecca Racz, Yongqun He A crp mutant is attenuated in zebrafish and catfish that were immunized intramuscularly and intracoelomically, respectively. Six weeks after immunization, both zebrafish and catfish were protected from challenge with wild type E. ictaluri E. ictaluri crp mutant vaccine Rebecca Racz, Yongqun He An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3% Edwardsiella tarda aroC mutant vaccine Rebecca Racz, Yongqun He An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3% Edwardsiella tarda aroC/slyA mutant vaccine Rebecca Racz, Yongqun He An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3% Edwardsiella tarda aroC/esrC mutant vaccine Rebecca Racz, Yongqun He An esrB mutant is highly attenuated in fish (turbot), with an LD50 of 10(8.1)cfu/fish. Vaccination with this mutant elicited significant protection from wild type E. tarda Edwardsiella tarda esrB mutant vaccine Rebecca Racz, Yongqun He An aroC and esrC mutant is attenuated in zebra fish. This mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 71.3% Edwardsiella tarda aroC/esrC mutant vaccine Rebecca Racz, Yongqun He An aroC and slyA mutant is attenuated in zebra fish. This mutant is also protective against challenge from wild type E. tarda, resulting in a relative percent survival of 80.1% Edwardsiella tarda aroC/slyA mutant vaccine Rebecca Racz, Yongqun He A carAB mutant is attenuated in turkeys and induces significant protection from challenge with wild type E. coli Escherichia coli carAB mutant vaccine A vaccine that prevents or treats an autoimmune disease. YH, RS https://www.ncbi.nlm.nih.gov/pubmed/15196997 autoimmune disease vaccine Rebecca Racz, Yongqun He A ler deletion mutant derived from wild-type EHEC O157:H7 86-24 was constructed by use of suicide vector pCVD442. Following challenge of 7-day-old suckling mice with O157:H7 EDL933, 75.2% born to group B mothers (immunized with F25) sur- vived, as did 83.0% born to group C mothers (immunized with F105). The surviving suckling mice consistently gained body weight. Only 16.8% of sucking mice born to control group mice survived the challenge Escherichia coli ler mutant vaccine Rebecca Racz, Yongqun He Deletion of waaL results in a strain that stimulates enhanced urothelial cytokine secretion, which is an enhanced innate immune response. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted ⩾8 weeks Escherichia coli rfaL mutant vaccine Rebecca Racz, Yongqun He There was a deletion in gene capB of F. tularensis live vaccine strain. LVS capB, while much less virulent than LVS, induces potent protective immunity against lethal LVS i.n. challenge in mice, comparable to that induced by LVS Francisella tularensis capB mutant vaccine Rebecca Racz, Yongqun He A clpB mutant in Francisella tularensis subspecies tularensis strain SCHU S4 was attenuated and provided protection against aerosol challenge in mice Francisella tularensis clpB mutant vaccine Rebecca Racz, Yongqun He A FTL0552 mutant in Francisella tularensis was attenuated and provided partial protection in mice against challenge with a lethal dose of the virulent SchuS4 strain when compared to naive mice Francisella tularensis FTL0552 mutant vaccine Rebecca Racz, Yongqun He An FTT0918 mutant showed significantly reduced virulence in mice. Mice that recovered from infection with the mutant were protected 2 months later from challenge with wild type F. tularensis Francisella tularensis FTT0918 mutant vaccine Rebecca Racz, Yongqun He A galU mutant is attenuated in mice, with only transient weight loss observed. Two months after inoculation, mice were challenge with wild type F. tularensis and were protected, once again only experiencing transient weight loss Francisella tularensis galU mutant vaccine Rebecca Racz, Yongqun He A guaA mutant is highly attenuated in mice and induces significant protection from challenge with parent strain F. tularensis LVS Francisella tularensis guaA mutant vaccine Rebecca Racz, Yongqun He A guaB mutant is attenuated in mice and induces significant protection from challenge with parent strain F. tularensis LVS Francisella tularensis guaB mutant vaccine Rebecca Racz, Yongqun He Intranasal vaccination with KKF235 (F. tularensis subsp. novicida mutant (DeltaiglB) ) protected mice from subsequent homotypic challenge with U112 as well as heterotypic challenge with F. tularensis subsp. holarctica (LVS). Most significantly, oral immunization with KKF235 protected mice from a highly lethal subsp. tularensis (SCHU S4) pulmonary challenge Francisella tularensis IglB mutant vaccine Rebecca Racz, Yongqun He An iglC mutant is highly attenuated in mice. Inoculated mice were challenged 30 days later with wild type F. tularensis and were highly protected KKF24 Rebecca Racz, Yongqun He A purMCD mutant in Francisela tularensis was attenuated. A low dosage of F. tularensis LVS delta purMCD mutant provided protection against challenge in mice Francisella tularensis purMCD mutant vaccine Rebecca Racz, Yongqun He Mice, which had been immunized with at least 6.95×103 cfu of F. tularensis U112 purF::Cm, were protected against the subsequent F. tularensis subspecies novicida challenge Francisella tularensis purF mutant vaccine Rebecca Racz, Yongqun He A purMCD mutant in Francisella tularensis was attenuated. A low dose of the F. tularensis LVS delta purMCD mutant provided protection against subsequent lethal challenge with the LVS parental strain Francisella tularensis purMCD mutant vaccine A Streptococcus vaccine against Streptococcus pyogenes infection. YH, RS Streptococcus pyogenes vaccine Rebecca Racz, Yongqun He A sodC mutant in Francisella tularensis subspecies holarctica was attenuated and provided protection and cleared the infection against lethal challenge in nearly 50% of the mice infected with the ΔsodC mutant Francisella tularensis sodC mutant vaccine Rebecca Racz, Yongqun He A wbtA mutant in Francisella tularensis was attenuated and provided protection in mice against challenge with an otherwise lethal dose of either F. tularensis LVS or a fully virulent clinical isolate of F. tularensis type B Francisella tularensis wbtA mutant vaccine Rebecca Racz, Yongqun He A wbtI mutant is attenuated in mice. The mutant protected against a low dose challenge with the parental strain, but was less effective against higher doses. However, increasing the immunization dose increased the resistance to higher challenge doses Francisella tularensis wbtI mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in mice and induced significant protection after two doses from challenge with wild type M. haemolytica Mannheimia haemolytica aroA mutant vaccine Rebecca Racz, Yongqun He An lpd mutant is highly attenuated in chickens and induces significant protection from challenge with wild type M. gallisepticum Mycoplasma gallisepticum lpd mutant vaccine Rebecca Racz, Yongqun He A metH mutant, in combination with a siaD mutation, is attenuated in mice and induces significant protection from challenge with wild type N. meningitidis Neisseria meningitidis metH/siaD mutant vaccine Rebecca Racz, Yongqun He An rfaF mutant, in combination with a siaD mutation, is attenuated in mice and induces significant protection from challenge with wild type N. meningitidis Neisseria meningitidis rfaF/siaD mutant vaccine Rebecca Racz, Yongqun He A siaD mutant, in combination with either a metH or rfaF mutation, is attenuated in mice and induces protection from challenge with wild type N. meningitidis Neisseria meningitidis metH/siaD mutant vaccine Rebecca Racz, Yongqun He A siaD mutant, in combination with either a metH or rfaF mutation, is attenuated in mice and induces protection from challenge with wild type N. meningitidis Neisseria meningitidis rfaF/siaD mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in calves and induces significant protection from challenge with wild type P. multocida Pasteurella multocida aroA mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is attenuated in mice and induced significant protection from challenge with wild type S. typhi Ty2 Salmonella typhi aroA mutant vaccine Rebecca Racz, Yongqun He Inactivation of AroC results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908" Aro-deleted S. Typhi Rebecca Racz, Yongqun He Inactivation of AroC results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908" CVD 908-htrA Rebecca Racz, Yongqun He Inactivation of AroD results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908" Aro-deleted S. Typhi Rebecca Racz, Yongqun He An asd mutant, alone or in combination with a rfc mutation, is attenuated in mice and induces significant protection from challenge with wild type Salmonella typhimurium Salmonella Typhimurium asd mutant vaccine Rebecca Racz, Yongqun He An asd mutant, alone or in combination with a rfc mutation, is attenuated in mice and induces significant protection from challenge with wild type Salmonella typhimurium Salmonella Typhimurium asd/rfc mutant vaccine Rebecca Racz, Yongqun He An atpA mutant is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium Salmonella Typhimurium atpA mutant vaccine Rebecca Racz, Yongqun He A cbiA mutant, in combination with a cobS mutation, is attenuated in chickens and induces significant protection from challenge with wild type S. Gallinarum. This mutant was also able to provide some protection against S. Enteritidis Salmonella Gallinarum cbiA/cobS mutant vaccine Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1941) is attenuated in mice after oral immunization. This mutant is also protective, and had a vaccine efficacy of 76% against challenge with wild type Salmonella Enteritidis Salmonella Enteritidis guaBA/clpP mutant vaccine Rebecca Racz, Yongqun He A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium Salmonella Typhimurium clpP mutant vaccine Rebecca Racz, Yongqun He A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium Salmonella Typhimurium guaBA/clpP mutant vaccine Rebecca Racz, Yongqun He A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine Rebecca Racz, Yongqun He A cobS mutant, in combination with a cbiA mutation, is attenuated in chickens and induces significant protection from challenge with wild type S. Gallinarum. This mutant was also able to provide some protection against S. Enteritidis Salmonella Gallinarum cbiA/cobS mutant vaccine Rebecca Racz, Yongqun He A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine Rebecca Racz, Yongqun He A cpxR mutant, in combination with a lon mutation, is highly attenuated in mice and induces significant protection from challenge with wild type S. gallinarum Salmonella Gallinarum cpxR/Ion mutant vaccine Rebecca Racz, Yongqun He A cya and crp mutant is attenuated in mice. Thirty days after immunization, mice were protected from oral challenge with wild type S. typhimurium Salmonella Typhimurium cya/crp mutant vaccine Rebecca Racz, Yongqun He A crp mutant is attenuated in mice and induces significant protection from challenge with wild type S. gallinarum Salmonella Gallinarum crp mutant vaccine Rebecca Racz, Yongqun He A cya and crp mutant is attenuated in mice. Thirty days after immunization, mice were protected from oral challenge with wild type S. typhimurium Salmonella Typhimurium cya/crp mutant vaccine Rebecca Racz, Yongqun He A fliC mutant, in combination with a guaB mutant, is attenuated in mice and chickens and induces significant protection from challenge with wild type S. enterica Salmonella enterica fliC/guaB mutant vaccine Rebecca Racz, Yongqun He A guaBA, clpP, and fliD mutant (CVD 1923) is attenuated in mice after oral immunization. This mutant is also protective, with a vaccine efficacy of 80% in mice against wild type challenge from Salmonella Typhimurium Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine Rebecca Racz, Yongqun He A gal E mutant in strain Ty2 was isolated, attenuated, and protected mice against lethal challenge Salmonella Typhi galE mutant vaccine Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1941) is attenuated in mice after oral immunization. This mutant is also protective in mice and had a vaccine efficacy of 76% against challenge with wild type Salmonella Enteritidis Salmonella Enteritidis guaBA/clpP mutant vaccine Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium Salmonella Typhimurium guaBA/clpP mutant vaccine Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium Salmonella Typhimurium guaBA/clpP mutant vaccine Rebecca Racz, Yongqun He A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine Rebecca Racz, Yongqun He A guaB mutant, in combination with a fliC mutant, is attenuated in mice and chickens and induced significant protection from challenge with wild type S. enterica Salmonella enterica fliC/guaB mutant vaccine Rebecca Racz, Yongqun He A guaB mutant, in combination with a fliC mutant, is attenuated in mice and chickens and induced significant protection from challenge with wild type S. enterica Salmonella Enteritidis guaBA/clpP mutant vaccine Rebecca Racz, Yongqun He A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine Rebecca Racz, Yongqun He Oral immunization with the Salmonella hfq deletion mutant efficiently protects mice against subsequent oral challenge with virulent strain of Salmonella Typhimurium Salmonella Typhimurium hfq mutant vaccine Rebecca Racz, Yongqun He A htrA mutant in Salmonella typhimurium is attenuated and provides protection in mice against an oral challenge with virulent S. typhimurium SL1344 Salmonella Typhimurium htrA mutant vaccine Rebecca Racz, Yongqun He A lon mutant, in combination with a cpxR mutation, is highly attenuated in mice and induces significant protection from challenge with wild type S. gallinarum Salmonella Gallinarum cpxR/Ion mutant vaccine Rebecca Racz, Yongqun He An lppA mutant, in combination with an lppB/msbB mutation, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium Salmonella Typhimurium IppA/IppB/msbB Rebecca Racz, Yongqun He An lppB mutant, in combination with an msbB mutant or an msbB/lppA mutant, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium Salmonella Typhimurium IppA/IppB/msbB Rebecca Racz, Yongqun He An lppB mutant, in combination with an msbB mutant or an msbB/lppA mutant, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium Salmonella Typhimurium IppB/msbB mutant vaccine Rebecca Racz, Yongqun He An msbB mutant, in combination with an lppB or lppAB mutation, is attenuated in mice and induces significant protection from challenge with S. Typhimurium Salmonella Typhimurium IppA/IppB/msbB Rebecca Racz, Yongqun He An msbB mutant, in combination with an lppB or lppAB mutation, is attenuated in mice and induces significant protection from challenge with S. Typhimurium Salmonella Typhimurium IppB/msbB mutant vaccine Rebecca Racz, Yongqun He In a pig infection experiment including two oral immunizations with SalmoporcDeltaompD (OmpD, nmpC) and challenge with a multiresistant S. enterica serovar Typhimurium DT104 clinical isolate, we confirmed the protective efficacy of SalmoporcDeltaompD in pigs, showing a significant reduction of both clinical symptoms and colonization of lymph nodes and intestinal tract Salmonella Typhimurium ompD/nmpC mutant vaccine Rebecca Racz, Yongqun He A nuoG mutant is attenuated in chickens and induced significant protection from challenge with wild type S. Gallinarum Salmonella Gallinarum nuoG mutant vaccine Rebecca Racz, Yongqun He An ompR mutant is attenuated in mice after oral challenge. Twenty eight days after immunization, mice were challenged with wild type S. typhimurium and were significantly protected Salmonella Typhimurium ompR mutant vaccine Rebecca Racz, Yongqun He Three S. typhi deletion mutants (phoP, rpoS, and rpoS-phoP double mutant) were constructed and characterized with respect to invasiveness, virulence, and protective immune response compared with wild-type Ty2. All S. typhi mutants showed an increase in the specific serum IgG levels and T-cell-mediated immunity, and showed equal protection abilities against a wild-type Ty2 challenge after two rounds of immunization in BALB/c mice Salmonella Typhi phoP mutant vaccine Rebecca Racz, Yongqun He A poxA mutant is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium Salmonella Typhimurium poxA mutant vaccine Rebecca Racz, Yongqun He A ppGpp-defective Salmonella Gallinarum, which is attained by mutating the relA and spoT genes, is attenuated in chickens and induces protection from oral challenge with wild type S. Gallinarum Salmonella Gallinarum relA/spoT mutant vaccine Rebecca Racz, Yongqun He An rfc mutant, in combination with an asd mutation, is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium Salmonella Typhimurium asd/rfc mutant vaccine Rebecca Racz, Yongqun He A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine Rebecca Racz, Yongqun He Immunizations with Salmonella typhimurium rpoS and rpoS aroA mutants protected susceptible BALB/c mice against subsequent oral challenge with virulent S. typhimurium. When administered orally or intraperitoneally, rpoS derivatives of the mouse-virulent S. typhimurium strains, C52 and SL1344, were highly attenuated and were efficient single-dose live vaccines Salmonella Typhimurium rpoS mutant vaccine Rebecca Racz, Yongqun He A ruvB mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium Salmonella Typhimurium ruvB mutant vaccine Rebecca Racz, Yongqun He A ppGpp-defective Salmonella Gallinarum, which is attained by mutating the relA and spoT genes, is attenuated in chickens and induces protection from oral challenge with wild type S. Gallinarum Salmonella Gallinarum relA/spoT mutant vaccine Rebecca Racz, Yongqun He A surA mutant (BRD1115) is attenuated in BALB/c mice and induces protection from challenge with wild type S. typhimurium Salmonella Typhimurium surA mutant vaccine Rebecca Racz, Yongqun He A tolA mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium Salmonella Typhimurium tolA mutant vaccine Rebecca Racz, Yongqun He A trxA mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium Salmonella Typhimurium trxA mutant vaccine Rebecca Racz, Yongqun He A wecA mutant (DSM645) is attenuated in C57BL/6J mice through i.p. and oral immunization. This mutant also protects against challenge with S. typhimurium strains TML and SL1344 30 days after immunization Salmonella Typhimurium wecA mutant vaccine Rebecca Racz, Yongqun He A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium Salmonella Typhimurium znuABC mutant vaccine Rebecca Racz, Yongqun He A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium Salmonella Typhimurium znuABC mutant vaccine Rebecca Racz, Yongqun He A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium Salmonella Typhimurium znuABC mutant vaccine Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri CVD 1204(pGA1-CS2) Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri S. dysenteriae 1 strain WRSd1 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri S. flexneri 2a strain CVD 1203 Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri S. sonnei strain WRSS1 Rebecca Racz, Yongqun He An aroD mutant is highly attenuated in monkeys and induces significant protection from challenge with wild type S. flexneri S. flexneri strain Sfl 124 Rebecca Racz, Yongqun He An aroD mutant is highly attenuated in monkeys and induces significant protection from challenge with wild type S. flexneri Shigella flexneri aroD mutant vaccine Rebecca Racz, Yongqun He An envZ mutant (SC433) is greatly decreased in virulence in macaque monkeys, though some mild clinical signs were still recorded. This mutant is also highly protective against a challenge of wild type S. flexneri delivered 1 month after inoculation Shigella flexneri envZ mutant vaccine a Brucella vaccine against infection wtih B. ovis YH Brucella ovis vaccine Rebecca Racz, Yongqun He An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri SC602 Rebecca Racz, Yongqun He A virG, senA, senB, and msbB2 mutant (WRSs3) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs3 is comparable to live attenuated vaccine strain WRSS1 Shigella sonnei virG/senA/senB/msbB2 mutant vaccine Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 Shigella sonnei virG/senA/senB mutant vaccine Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 Shigella sonnei virG/senA/senB/msbB2 mutant vaccine Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 Shigella sonnei virG/senA/senB mutant vaccine Rebecca Racz, Yongqun He A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1 Shigella sonnei virG/senA/senB/msbB2 mutant vaccine Rebecca Racz, Yongqun He A virG mutant (WRSS1) is attenuated in guinea pigs and induced significant protection from challenge with wild type Shigella sonnei Shigella sonnei virG/senA/senB mutant vaccine Rebecca Racz, Yongqun He A virG mutant (WRSS1) is attenuated in guinea pigs and induced significant protection from challenge with wild type Shigella sonnei Shigella sonnei virG/senA/senB/msbB2 mutant vaccine Rebecca Racz, Yongqun He A hemA mutant is highly attenuated in mice and rabbits and induces protection from challenge with wild type V. cholerae in rabbits Vibrio cholerae hemA mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in mice, and after 3 doses induces significant protection from challenge with wild type Y. enterocolitica Yersinia enterocolitica aroA mutant vaccine Rebecca Racz, Yongqun He A htrA mutant in Yersinia enterocolitica was attenuated and provided partial protection against challenge in mice Yersinia enterocolitica htrA mutant vaccine Rebecca Racz, Yongqun He A ompR mutant in Yersinia enterocolitica was attenuated and provided a partial protection from challenge in mice Yersinia enterocolitica ompR mutant vaccine Rebecca Racz, Yongqun He A sodA mutant in Yersinia enterocolitica was highly attenuated and mice immunized with a single oral dose of the mutant strain were protected against a lethal oral-challenge infection with wild-type Y. enterocolitica Yersinia enterocolitica sodA mutant vaccine Rebecca Racz, Yongqun He A guaBA mutant is attenuated in mice and induced significant protection from challenge with wild type Y. pestis Yersinia pestis guaBA mutant vaccine Rebecca Racz, Yongqun He A guaBA mutant is attenuated in mice and induced significant protection from challenge with wild type Y. pestis Yersinia pestis guaBA mutant vaccine Rebecca Racz, Yongqun He An IpxM mutant is attenuated in mice and guinea pigs. This mutant also conferred modest protection from challenge with wild type Y. pestis in Balb/c mice and significant protection in guinea pigs and outbred mice Yersinia pestis IpxM mutant vaccine Rebecca Racz, Yongqun He An nlpD mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis Yersinia pestis nlpD mutant vaccine Rebecca Racz, Yongqun He A pcm mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis Yersinia pestis pcm mutant vaccine Rebecca Racz, Yongqun He An smpB mutant, in combination with an ssrA mutation, is attenuated in mice and induces significant protection from challenge with wild type Y. pestis Yersinia pestis smpB/ssrA mutant vaccine Rebecca Racz, Yongqun He An smpB mutant, in combination with an ssrA mutation, is attenuated in mice and induces significant protection from challenge with wild type Y. pestis Yersinia pestis smpB/ssrA mutant vaccine Rebecca Racz, Yongqun He A yopH mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis Yersinia pestis yopH mutant vaccine Rebecca Racz, Yongqun He A phoP mutant in Yersinia pseudotuberculosis (Yptb) was attenuated and provided protection against oral challenge with virulent Yptb in mice Yersinia pseudotuberculosis phoP mutant vaccine Rebecca Racz, Yongqun He An aroA mutant is highly attenuated in rainbow trout and induces significant protection from challenge with wild type Y. ruckeri Yersinia ruckeri aroA mutant vaccine Rebecca Racz, Yongqun He A thymidine kinase-deficient mutant (B8-D53) showed no detectable thymidine kinase-inducing activity and was attenuated in calves. B8-D53 also induced protection from challenge with wild type BHV-1 Bovine herpesvirus 1 UL23 mutant vaccine Rebecca Racz, Yongqun He A deletion of BHV-1 gE gene in strain A is considered as a live attenuated vaccine. After challenge, vaccinated calves were protected against disease and virus shedding was reduced Bovine herpesvirus 1 US8 (gE) mutant vaccine Rebecca Racz, Yongqun He A glycoprotein G deletion in bovine respiratory syncytial virus(rBRSV) and recombinant rBRSV was attenuated and provided protection against a BRSV challenge infection in calves Bovine respiratory syncytial virus glycoprotein G mutant vaccine Rebecca Racz, Yongqun He An N269A/Q mutation in the E(rns) protein created an attenuated mutant in swine. This mutant was able to induce effective protection in swine against challenge with wild type CSFV Classical swine fever virus E(rns) mutant vaccine Rebecca Racz, Yongqun He An N to A amino acid substitution was made in the N594 site of the E1 glycoprotein, resulting in attenuation of the virus in swine. This attenuated virus induced protection against challenge with wild type CSFV Classical swine fever virus E1 mutant vaccine Rebecca Racz, Yongqun He A E2 mutant in Classical swine fever virus is attenuated and provides protection in pigs after oronasal vaccination (not intradermal vaccination) against lethal challenge dose of CSFV strain Eystrup Classical swine fever virus E2 mutant vaccine Rebecca Racz, Yongqun He A glycoprotein E mutant is attenuated in mice and hamsters and induced significant protection from challenge with wild type Equid herpesvirus in mice Equid herpesvirus gE mutant vaccine Rebecca Racz, Yongqun He A glycoprotein I mutant is attenuated in mice and hamsters and induced significant protection from challenge with wild type Equid herpesvirus in mice Equid herpesvirus gI mutant vaccine Rebecca Racz, Yongqun He A thymidine kinase-deficient mutant (PR1) is attenuated in mice and induced significant protection from challenge with wild type EHV-1 5 weeks after vaccination. In foals, PR1 also showed attenuation; however, the mutant induced only partial protection from challenge with EHV-1 Equid herpesvirus TK mutant vaccine Rebecca Racz, Yongqun He A thymidine kinase-deficient mutant (C7301dlTK) is attenuated in cats and induced significant protection from wild type FHV-1 4 weeks after vaccination Feline herpesvirus 1 UL23 mutant vaccine Rebecca Racz, Yongqun He Feline immunodeficiency virus (FIV) made defective in the accessory gene ORF-A were previously shown to be greatly attenuated in its ability to replicate in lymphocytes but to grow normally or near normally in other cell types. 3/9 vaccinees (cats) showed no evidence of the challenge virus over a 15-month observation period. In the other vaccinees, the challenge virus was predominant for various periods of time, but pre-existing viral loads and CD4 lymphocyte counts were either unaffected or altered only marginally and transiently Feline immunodeficiency virus ORF-A mutant vaccine Rebecca Racz, Yongqun He A vif mutant in feline immunodeficiency virus was attenuated and FIV-pPPRΔvif proviral DNA protected cats against challenge with the homologous FIV-PPR biological isolate. Feline immunodeficiency virus vif mutant vaccine Rebecca Racz, Yongqun He A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens Feline infectiour peritonitis virus 3abc mutant vaccine Rebecca Racz, Yongqun He A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens Feline infectiour peritonitis virus 3abc mutant vaccine Rebecca Racz, Yongqun He A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens Feline infectiour peritonitis virus 3abc mutant vaccine Rebecca Racz, Yongqun He A 7ab deletion mutant in Feline infectious peritonitis virus is attenuated and provides protection against virulent FIPV strain 79-1146 challenge in kittens Feline infectious peritonitis virus 7ab mutant vaccine Rebecca Racz, Yongqun He A 7ab deletion mutant in Feline infectious peritonitis virus is attenuated and provides protection against virulent FIPV strain 79-1146 challenge in kittens Feline infectious peritonitis virus 7ab mutant vaccine Rebecca Racz, Yongqun He A UL0 mutant in infectious laryngotracheitis virus (ILTV) was attenuated. Chickens immunized with UL0-negative ILTV were protected from clinical disease after subsequent infection with virulent ILTV Gallid herpesvirus 1 UL0 mutant vaccine Rebecca Racz, Yongqun He A thymidine-kinase mutant is attenuated in chickens and induced protection from challenge with wild type GHV-1 Gallid herpesvirus 1 UL23 mutant vaccine Rebecca Racz, Yongqun He A UL47 mutant in avian infectious laryngotracheitis virus is attenuated and provides protection in chicken against subsequent challenge infection with virulent ILTV Gallid herpesvirus 1 UL47 mutant vaccine Rebecca Racz, Yongqun He Researchers generated a series of woodchuck hepatitis virus (WHV) X mutants. Woodchucks inoculated with X mutants, including those with no serologic evidence of infection, were protected from later challenge with infectious Woodchuck Hepatitis Virus, suggesting previous infection with resulting protective immunity Hepatitis B virus X protein mutant vaccine Rebecca Racz, Yongqun He KOS-gDA3C is attenuated with mutations in gD gene in causing skin lesions at the inoculation and zosteriform sites, yet it is as effective as rKOS-gDA3C in protecting mice against HSV-1 challenge Herpes simplex virus 1 gD mutant vaccine Rebecca Racz, Yongqun He A gH mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 Herpes simplex virus 1 gH mutant vaccine Rebecca Racz, Yongqun He A live-attenuated HSV-2 ICP0 virus provides significant protection against wild-type HSV-2 (MS strain) challenge in mice Herpes simplex virus 2 ICP0 mutant vaccine Rebecca Racz, Yongqun He A thymidine kinase-deficient (TK) mutant was found to be attenuated in mice. This mutant induced complete protection from challenge with wild type HSV Herpes simplex virus 1 TK mutant vaccine Rebecca Racz, Yongqun He A UL29 mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 Herpes simplex virus 1 UL29 mutant vaccine Rebecca Racz, Yongqun He An HSV-1 gE (Us8) deletion strain, NS-gEnull, was used as a live attenuated vaccine. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice Herpes simplex virus type 1 DNA vaccine encoding GE Rebecca Racz, Yongqun He A G mutant is attenuated in African green monkeys and induces protection from challenge with wild type HMPV Human metapneumovirus G protein mutant vaccine Rebecca Racz, Yongqun He An M2-2 mutant is attenuated in African green monkeys and induced protection from challenge with wild type HMPV Human metapneumovirus M2-2 mutant vaccine Rebecca Racz, Yongqun He An M2-2 mutant of human respiratory syncytial virus A2 is attenuated in African green monkeys. When challenged with wild type RSV, two doses provided complete protection against challenge in the lower respiratory tract and a significant reduction of the challenge virus in the upper respiratory tract Human Respiratory Syncytial Virus M2-2 mutant vaccine Rebecca Racz, Yongqun He A mutation in the non-virion protein of IHNV causes attenuated growth in rainbow trout and is able to provide significant protection from subsequent challenge with wild type IHNV Infectious Hematopoietic Necrosis Virus NV mutant vaccine Rebecca Racz, Yongqun He Mutant influenza virus that lacks the transmembrane and cytoplasmic tail domains of M2 (M2 knockout [M2KO]) from Influenza A virus (A/Puerto Rico/8/34(H1N1)) is attenuated in both cell culture and mice. Mice intranasally vaccinated with M2KO virus developed protective immune responses and survived a lethal challenge with the wild-type virus, suggesting that the M2KO virus has potential as a live attenuated vaccine Influenza virus CTA1-3M2e-DD protein vaccine Rebecca Racz, Yongqun He Intranasal inoculation of mice, pigs, horses, and macaques with NS1-modified influenza virus strains induced robust humoral and cellular immune responses, and generated immune protection against challenge with wild-type virus Influenza virus NS1 mutant vaccine Rebecca Racz, Yongqun He A mutation in the GP5 protein attenuates HP-PRRSV in piglets. This mutant (HuN4-F112) induces protection against challenge with wild type HP-PRRSV Porcine respiratory and reproductive syndrome virus GP5 protein mutant vaccine Rebecca Racz, Yongqun He A glycoprotein E mutant, in combination with UL23 and glycoprotein G mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine Rebecca Racz, Yongqun He A glycoprotein G mutant, in combination with UL23 and glycoprotein E mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine Rebecca Racz, Yongqun He A glycoprotein M, gM, deletion in pseudorabies virus was attenuated and induced protection in piglets against intranasal challenge with 108 p.f.u. of the highly virulent PrV strain NIA-3 Psuedorabies virus glycoprotein M mutant vaccine Rebecca Racz, Yongqun He A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3 Pseudorabies virus gp50/gp63 mutant vaccine Rebecca Racz, Yongqun He A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3 Pseudorabies virus gp50/gp63 mutant vaccine Rebecca Racz, Yongqun He A UL23 mutant, in combination with mutations in glycoproteins G and E, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine Rebecca Racz, Yongqun He A UL50 mutant is attenuated in pseudorabies virus and induces significant protection in pigs from challenge with the highly virulent NIA-3 strain of PrV Pseudorabies virus UL50 mutant vaccine Rebecca Racz, Yongqun He Researchers intranasally inoculated pigs, the natural host of this virus, with mutant PRV strains in which the genes encoding the protein kinase (US3) proteins were inactivated. After challenge infection with the virulent PRV strain NIA-3, no virus was excreted by wt PRV- and PK- mutant-immunized animals, indicating complete protective immunity Pseudorabies virus US3 mutant vaccine Rebecca Racz, Yongqun He A glycoprotein G mutant in rabies virus is attenuated. After a one-dose intramuscular vaccination, the ERAg3m virus protected 100% of mice and hamsters from lethal challenge. In co-infections, using a lethal dose of street rabies virus mixed with ERAg3m, 100% of hamsters and 90% of mice survived and were protected against subsequent infection Rabies virus glycoprotein G mutant vaccine Rebecca Racz, Yongqun He A P gene mutant is attenuated in mice and induces significant protection from challenge with wild type Rabies virus Rabies virus P protein mutant vaccine Rebecca Racz, Yongqun He An E mutant is attenuated in hamsters and induces significant protection from challenge with wild type SARS SARS-CoV E gene mutant vaccine Rebecca Racz, Yongqun He A SIV nef mutant is attenuated in rhesus monkeys and induces protection from challenge with wild type SIV Simian Immunodeficiency Virus nef mutant vaccine Rebecca Racz, Yongqun He A virus with a mutation in protein C is attenuated in mice and induced protection from challenge with wild type TBE virus ick-borne Encephalitis Virus C protein mutant vaccine Rebecca Racz, Yongqun He A VEE mutant with a PE2 cleavage signal mutation and a suppressor mutation in E1 is highly attenuated in mice and provides complete protection against challenge with wild type VEE VEE Virus PE2/E1 mutant vaccine Rebecca Racz, Yongqun He A VEE mutant with a PE2 cleavage signal mutation and a suppressor mutation in E1 is highly attenuated in mice and provides complete protection against challenge with wild type VEE VEE Virus PE2/E1 mutant vaccine Rebecca Racz, Yongqun He A virus with a C protein mutation is attenuated in mice and induces significant protection from challenge with wild type West Nile virus West Nile virus C protein mutant vaccine Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur WEEV DNA Vaccine encoding 6K-E1 Protein Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur Western equine encephalomyelitis virus PE2/E1 mutant vaccine Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E2 (WE2102) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur WEEV Subunit E2 Protein Vaccine Rebecca Racz, Yongqun He A PE2 mutant combined with a deletion in E2 (WE2102) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur Western equine encephalomyelitis virus PE2/E2 mutant virus Rebecca Racz, Yongqun He A PE2 mutant combined with either a deletion in E2 (WE2102) or E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of these two strains would occur Western equine encephalomyelitis virus PE2/E1 mutant vaccine Rebecca Racz, Yongqun He A PE2 mutant combined with either a deletion in E2 (WE2102) or E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of these two strains would occur Western equine encephalomyelitis virus PE2/E2 mutant virus Rebecca Racz, Yongqun He A cen1 mutant is attenuated in mice and hamsters and induces significant protection from challenge with wild type L. donovani Leishmania donovani cen1 mutant vaccine Rebecca Racz, Yongqun He A Leishmania infantum deletion mutant of HSP70-II gene is attenuated and provides protection against Leishmania infection in the L. major-BALB/c infection model. Also, DeltaHSP70-II is a safe live vaccine as immunodeficient SCID mice, and hamsters, infected with mutant parasites did not develp any sign of pathology Leishmania infantum HSP70 II mutant vaccine Rebecca Racz, Yongqun He A genetically attenuated parasite (GAP) with a mutation in the FabB/FabF gene is attenuated in mice by arresting in the late liver stage. It also conferred complete protection in mice from challenge with wild type Plasmodium Plasmodium FabB/FabF mutant vaccine Rebecca Racz, Yongqun He Genetically attenuated P36p-deficient Plasmodium berghei sporozoites provide protection against sporozoites challenge in mice P. berghei p36p mutant vaccine Rebecca Racz, Yongqun He A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites P. yoelii p36/p52 mutant vaccine Rebecca Racz, Yongqun He A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites P. yoelii p36/p52 mutant vaccine Rebecca Racz, Yongqun He Deletion of UIS3 in Plasmodium yoelii provided attenuation and full protection in mice by Pyuis3(-) sporozoites required at least 2 immunizations against challenges with infectious sporozoites P. yoelii UIS3 mutant vaccine Rebecca Racz, Yongqun He A mic2 mutant is attenuated in mice and induces protection from challenge with wild type T. gondii Toxoplasma gondii mic2 mutant vaccine Rebecca Racz, Yongqun He An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii Toxoplasma gondii OMPDC mutant vaccine Rebecca Racz, Yongqun He An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii Toxoplasma gondii OMPDC/UP mutant vaccine Rebecca Racz, Yongqun He A UP mutant, in combination with an OMPDC mutation, is attenuated in mice and induces significant protection from wild type T. gondii Toxoplasma gondii OMPDC/UP mutant vaccine route of administration that located in the stomach, so that the material is taken into body through stomach directly. YL I.G. intragastric route a intragastric route that has a vaccine injection site located in stomach. YL intragastric injection route vaccination that occurs in the intagastric route. YL intragastric vaccination YL vaccination process that occurs in intradermal route. intradermal vaccination vaccination process that occurs in intranasal route YL intranasal vaccination vaccination process that occurs in oral route. YL oral vaccination vaccination process that occurs in the subcutaneous route YL subcutaneous vaccination a vaccine prepration process that mixes vaccine lyophilized powder and diluent liquid. The process forms a vaccine that can be used for administration. This term can also be considered as a child term of OBI term 'material combination'. WEB: http://www.thehaiticonnection.org/medical/reconstitution.pdf YL, YH A vaccine may include vaccine powder and solvent. When the two mix, we get a vaccine solution, which can be used to inject. Examples: http://www.medicines.org.uk/guides/acwy%20vax/Vaccinations%20%28all%29/ http://www.medicines.org.uk/guides/menitorix/Vaccinations%20%28all%29/ http://www.medicines.org.uk/guides/priorix/Vaccinations%20%28all%29/ Use only the specific diluent provided by the manufacturer for each type of vaccine to ensure adequate potency and safety of the resulting mixture. vaccine reconstitution a vaccine powder that is freeze-dried and lyophilized. YL,YH lyophilized vaccine powder a role inheres in the vaccine component when it is added into vaccine's formulation, it tends to stabilizes an emulsion by increasing its kinetic stablity. YL vaccine emulsifier role a role inheres in vaccine component when added into vaccine's formulation, it tends to inhibit the reaction between two or more other vaccine substances in the final vaccine formulation; it also helps to protect the vaccine from adverse conditions such as the freeze-drying process or heat. YL vaccine stabilizer role a protein vaccine stablizer that is specifically human serum albumin. YL human serum albumin vaccine additive the serum albumin that is part of human it is subclass of 'serum albumin (PR:000003918)' YL human serum albumin UniProtKB:P02768 a vaccine stabilizer that is gelatin. YL gelatin vaccine stabilizer Gelatin is a mixture of peptides and proteins produced by partial hydrolysis of collagen extracted from the skin, boiled crushed bones, connective tissues, organs and some intestines of animals such as domesticated cattle, chicken, and pigs.(wikipedia) YL gelatin a vaccine-induced host gene response that represents a vaccine adverse event response associated with a host susceptibility gene. YH host susceptibility gene response to VAE host susceptibility gene response to vaccine adverse event host immune factor-induced control of intracellular replication of live attenuated vaccine a protein vaccine stablizer that is specifically bovine serum albumin. YH, YL bovine serum albumin vaccine additive a vaccine stabilizer that is specifically made by a sugar. YH, YL sugar vaccine stabilizer a vaccine stabilizer that is generated based on amino acids. YH, YL amino acid vaccine stabilizer a vaccine stabilizer that is specifically made by a sucrose. YH, YL sucrose vaccine stabilizer a vaccine stabilizer that is specifically made by a lactose. YH, YL lactose vaccine stabilizer a vaccine stabilizer that is a protein. YH, YL protein vaccine stabilizer a polysorbate 20 vaccine stabilizer that is Alkest TW20. YH, YL Alkest TW 20 vaccine stabilizer a polysorbate 20 vaccine stabilizer that is Tween 20. YH, YL Tween 20 vaccine stabilizer an antibiotics vaccine residual that has the antibiotics of neomycin. YL, YH neomycin residual the vaccine antiegn that induces protective immune response. YL, YH protective vaccine antigen A viral vaccine against infection of an Sindbis virus. YH, RS Sindbis virus vaccine A viral vaccine against infection of a Lymphocytic choriomeningitis virus. YH, RS Lymphocytic choriomeningitis virus vaccine RB51 induced protection against B.suis A protozoan vaccine against Schistosoma mansoni YH, RS Schistosoma mansoni vaccine A protozoan vaccine against Schistosoma infection YH, RS Schistosoma vaccine when the vaccination of a significant portion of a population (or herd), in contagious diseases that are transmitted from individual to individual, chains of infection are likely to be disrupted, so the large numbers of a population are immue or less susceptible to the disease. YL http://en.wikipedia.org/wiki/Herd_immunity vaccine-induced herd immunity The conjugate protein is a part of a conjugate vaccine and acts as a carrier protein that is covalently attached to a vaccine antigen with poor antigenicity (e.g., a polysaccharide). A conjugate protein is able to induce T-cell-dependent immune responses and stimulate the production of immune memory. YL,YH vaccine conjugate protein role inheres in a material eneitity that union itself chemically with a relative weak vaccine antigen to form a new whole that can create an effective miinuogen. The YL vaccine conjugate role YL epicutaneous (application onto the skin), e percutaneous route Administration of a drug by the way of absorption through the skin, usually for systemic action. The route allows sustained therapeutic plasma drug levels and avoids first pass effect. Simplicity of administration tends to result in high patient compliance. YL percutaneous vaccination intravesical route The injection of a given substance directly into the bladder via a urethral catheter instead of being injected under the skin. YL intravesical vaccination A viral vaccine against infection of a Lymphocytic choriomeningitis virus. YH, RS Infectious pancreatic necrosis virus vaccine A viral vaccine against infection of a viral haemorrhagic septicaemia virus. YH, RS viral haemorrhagic septicaemia virus vaccine an vaccine-induced host response that shows augmented protection and cellular immunity after a host protein is used as adjuvant. YH, RR augmented protection and cellular immunity using host protein as adjuvant A vaccine that protects against Mycobacterium marinum. YH, RS Mycobacterium marinum vaccine A viral vaccine that protects against infection with Hepatitis D virus. YH Hepatitis D virus vaccine viral vaccine that is used to protect against Monkeypox virus infection YH, RS Monkeypox virus vaccine viral vaccine that is used to protect against Bovine viral diarrhea virus 2 infection YH, RS Bovine viral diarrhea virus 2 vaccine A viral vaccine that protects against infection with Murine Cytomegalovirus (or called murid herpesvirus 1). YH, RS, NF murine cytomegalovirus vaccine Murid herpesvirus 1 vaccine RB51 induced protection against B.abortus RB51 induced protection against B.canis RB51 induced protection against B.Melitensis Kallan Roan, Oliver He, OT http://purl.bioontology.org/ontology/RXNORM/1601403 https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm431374.htm BEXSERO Meningococcal Group B Vaccine Novartis Vaccines and Diagnostics, Inc Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf BL 125546 1601403 Bexsero CVX: 163 VIOLIN Vaccine ID: 5576 OT, YH https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM524684.pdf Trade Name: Flublok Quadrivalent Flublok Quadrivalent CVX: 155 VIOLIN Vaccine ID: 5556 RB51 induced host immune response OT, YH. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM502899.pdf Trade Name: Flucelvax Quadrivalent Flucelvax Quadrivalent CVX: 171 VIOLIN Vaccine ID: 5561 Kallan Roan, Oliver He https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM404086.pdf https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm366061.htm FluLaval Influenza Virus Vaccine GlaxoSmithKline Biological (Parent Organization) ID Biomedical Corporation of Quebec For active immunization of persons 6 months of age and older for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM619548.pdf BL 125163 FluLaval Quadrivalent CVX: 158 VIOLIN Vaccine ID: 5562 OT, YH http://ca.gsk.com/media/590283/flulaval-tetra.pdf Product Name: Quadrivalent Influenza Vaccine (Split Virion, Inactivated) Trade Name: FluLaval Tetra FluLaval Tetra VIOLIN Vaccine ID: 5563 Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm356091.htm Fluzone Quadrivalent Influenza Virus Vaccine Sanofi Pasteur Inc. For active immunization of persons 6 months of age and older for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM356094.pdf BL 103914 Fluzone Quadrivalent CVX: 158 VIOLIN Vaccine ID: 5566 OT, YH https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM513242.pdf Product Name: Influenza Virus Vaccine Trade Name: Fluzone Quadrivalent Southern Hemisphere Fluzone Quadrivalent - Southern Hemisphere Formulation CVX: 158 VIOLIN Vaccine ID: 5568 Kallan Roan, Oliver He, Omar Tibi, Khadeejah Khan http://purl.bioontology.org/ontology/RXNORM/1597095 https://www.cancer.org/latest-news/fda-approves-gardasil-9-hpv-vaccine.html https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm Gardasil 9 Human Papillomavirus 9-valent Vaccine, Recombinant Merck & CO., Inc. Indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: - Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58. (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and 11. (1.1) And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ (AIS). (1.1) - Cervical intraepithelial neoplasia (CIN) grade 1. (1.1) - Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3. (1.1) - Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3. (1.1) - Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.1) GARDASIL 9 is indicated in boys and men 9 through 45 years of age for the prevention of the following diseases: - Anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58. (1.2) - Genital warts (condyloma acuminata) caused by HPV types 6 and 11. (1.2) And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2) https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf 125508 1597095 Gardasil 9 CVX: 165 VIOLIN Vaccine ID: 5546 RB51 induced protection against B. ovis OT, YH http://www.pfizer.ca/sites/g/files/g10028126/f/201604/Nimenrix_PM_184020_23Mar2016_E.pdf Nimenrix VIOLIN Vaccine ID: 5578 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593136 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm421020.htm TRUMENBA Meningococcal Group B Vaccine Wyeth Pharmaceuticals, Inc. Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf BL 125549 1593136 Trumenba CVX: 162 VIOLIN Vaccine ID: 5577 OT, YH http://purl.bioontology.org/ontology/RXNORM/1812946 https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM506235.pdf 1812946 Vaxchora CVX: 174 VIOLIN Vaccine ID: 5569 OT, YH H5N1 vaccine GSK https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM376464.pdf Product Name: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted by GSK CVX: 160 VIOLIN Vaccine ID: 5553 OT, YH H1N1 vaccine GSK https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190377.pdf Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine Influenza A (H1N1) 2009 Monovalent Vaccine (GlaxoSmithKline) VIOLIN Vaccine ID: 5552 OT, YH https://www.vaccineshoppecanada.com/document.cfm?file=adacel-polio_e.pdf Trade Name: Adacel-Polio Adacel-Polio VIOLIN Vaccine ID: 5549 RB51 induced immune protection RB51 induced immune response without protection OT, YH https://ca.gsk.com/media/589683/boostrix-polio.pdf Trade Name: Boostrix-Polio Boostrix-Polio VIOLIN Vaccine ID: 5550 This vaccine is given to provide protection against diphtheria, tetanus, and pertussis in children between 6 weeks and 7 years old. Kallan Roan, Oliver He https://www.drugs.com/mmx/tri-immunol.html https://www.hendricks.org/HealthLibrary/default.aspx?sid=1&pTitle=%2CDrug&ContentTypeID=26&ContentID=215&alpha=T&AdditionalTitle=Tri-Immunol discontinued now Tri-Immunol Influenza virus vaccine is used to prevent infection caused by influenza virus types A and B. Kallan Roan, Oliver He https://www.drugs.com/mtm/fluogen-injectable.html Fluogen monovalent vaccine agianst poliomyelitis for infants 6-12 weeks of age, all immunized children up to 18 years of age, and high risk adults. Kallan Roan, Oliver He https://www.rxlist.com/orimune-drug.htm Oral Poliovirus Vaccine Orimune vaccine A malaria vaccine that consists of hepatitis B surface antigen virus-like particles, incorporating a portion of the Plasmodium falciparum-derived circumsporozoite protein and a liposome-based adjuvant. YH, Randi Vita PMID:20078211 https://en.wikipedia.org/wiki/RTS,S https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829262/ Mosquirix In July 2015, RTS,S/AS01 was approved by the European Medicines Agency for immunization of children aged 6 weeks to 17 months against malaria under Article 58,12. P. falciparum RTS,S/AS01 Pnu-Imune vaccine Revaxis is a Diphtheria, Tetanus and Poliomyelitis (inactivated) vaccine manufactured by Sanofi Pasteur. This vaccine helps boost protection against diphtheria, tetanus and poliomyelitis (polio). 3-in-1 diphtheria, polio and tetanus vaccine (Revaxis) http://www.netdoctor.co.uk/medicines/infections/a8594/revaxis-diphtheria-polio-and-tetanus-vaccine/ https://www.medicines.org.uk/emc/files/pil.5581.pdf https://www.medicines.org.uk/emc/product/5581/smpc https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166496/ Dose: 0.5-mL suspension for injection in a pre-filled syringe Active ingredients: Purified diphtheria toxoid ≥2 IU (5 Lf) Purified tetanus toxoid ≥20 IU (10 Lf) Inactivated poliovirus type 1 40 DU Inactivated poliovirus type 2 8 DU Inactivated poliovirus type 3 32 DU Adsorbant: Aluminum hydroxide. 0.35 mg (as aluminum) 0.5-mL suspension for injection in a pre-filled syringe Revaxis is used for preventing diphtheria, tetanus and polio in children from six years of age, adolescents and adults. Revaxis is used for a booster vaccination against these diseases. It is given to teenagers at 14 years of age as part of the British childhood immunisation schedule. Revaxis a Diphthpheria-Tetanus Absorbed vaccine for children 7 years of age and adults. Kallan Roan, Oliver He http://drug-info.in/ditanrix-diphtheria-tetanus-vaccine-adsorbed-glaxosmithkline TD Absorbed and DT Absorbed Vaccine Ditanrix A rotavirus vaccine against severe diarrheal disease. Kallan Roan, Oliver He https://web.stanford.edu/~siegelr/ShadmanRotashieldPaper.pdf Amphotericin B, Monosodium Glutamate (MSG), Sucrose, Bovine (cow) serum, Potassium Phosphate, Potassium monophosphate. discontinued in 2008 Rotashield vaccine A more attenuated measles vaccine that targets measles virus strain Moraten. Kallan Roan, Oliver He http://apps.who.int/iris/bitstream/handle/10665/266590/PMC2554544.pdf?sequence=1&isAllowed=y https://jamanetwork.com/journals/jama/article-abstract/341314 Developed sometime in 1968 therefore assumed to be discontinued Moraten vaccine An inactIve vaccine used to prevent tetanus. Kallan Roan, Oliver He http://www.catalog.md/drugs/tevax.html https://www.atoute.org/n/IMG/pdf/Constituants_des_vaccins_version-actualisee.pdf Discontinued in 2003 Tevax vaccine An active immunization against cholera, indicated only for individuals traveling to or residing in countries where cholera is endemic or epidemic. Kallan Roan, Oliver He https://www.rxlist.com/cholera-vaccine-drug.htm#indications Cholera Vaccine, USP a hexavalent vaccine that has been withrawn on June 2012 by the European commission Hexavac Vaccine http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2012/08/WC500130968.pdf Hexavax A vaccine used to help prevent rabies infection in people who either have been, or are at risk of being bitten, licked or scratched by an animal infected with rabies virus. Kallan Roan, Oliver He http://www.who.int/immunization_standards/vaccine_quality/Rabipur_Product_Insert.pdf Amphotericin B, Neomycin, Sucrose, Chlortetracycline hydrochloride, Sodium chloride, Bovine (cow) serum, Trometamol, Polygeline, Virus: Rabies, Disodium edentate (EDTA), Monopotassium glutamate Rabies Virus Vaccine Rabipur vaccine https://www.ndrugs.com/?s=rabiesvax Rabiesvax vaccine LYMErix [Lyme Disease Vaccine (Recombinant OspA)] is a noninfectious recombinant vaccine developed and manufactured by SmithKline Beecham Biologicals. The vaccine contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. Discontinued in 2002 Kallan Roan, Oliver He lipoprotein outer surface a vaccine https://wayback.archive-it.org/7993/20170405164754/https://www.fda.gov/ohrms/dockets/ac/01/briefing/3680b2_03.pdf https://www.rxlist.com/lymerix-drug.htm Lymerix DTP vaccine DTwP vaccine diphtheria, tetanus and whole cell pertussis vaccine A human diploid cell vaccine against rabies, a viral infectious disease. Kallan Roan, Oliver He https://www.researchgate.net/publication/27190851_Vaccination_against_rabies_and_protective_antibodies_-_Comparison_of_ELISA_and_fluorescent_antibody_virus_neutralization_FAVN_assays Rabivac This absorbed recombinant hepatitis B vaccine is indicated for active immunization against hepatitis B virus infection caused by all known subtypes in subjects of any age considered at risk of exposure to the virus. Genhevac B Pasteur https://www.mesvaccins.net/web/vaccines/48-genhevac-b-pasteur https://www.ncbi.nlm.nih.gov/pubmed/8106774 Discontinued in 2016 Kallan Roan, Oliver He Genhevac B HPV77/DE5 strain Kallan Roan, Oliver He http://americanhistory.si.edu/collections/search/object/nmah_733733 Older version of Meruvax II Meruvax I A vaccine for indivuduals who at risk or recently exposed to rabies. Kallan Roan, Oliver He https://onlinelibrary.wiley.com/doi/pdf/10.1002/0471704210.app4 https://www.redalyc.org/html/579/57912962006/ Rabie-Vax Kallan Roan, Oliver He A vaccine for individuals to protect against mumps virus. https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_M)/MUMPSVAX.html Mumpsvax II Kallan Roan, Oliver He http://www.meppo.com/pdf/drugs/1538-RUDIVAX-1321626694.pdf A live RA 27/3 strain rubella vaccine https://www.ncbi.nlm.nih.gov/pubmed/6531969 Rudivax An adsorbed diphtheria, tetanus, pertussis and inactivated poliomyelitis vaccine. https://www.mesvaccins.net/web/vaccines/63-tetracoq https://www.researchgate.net/publication/289445706_Efficacy_and_safety_of_Tetracoq_vaccine European/French vaccine Often administered with a HIB vaccine. Tetracoq A vaccine for Diphtheria, haemophilus influenzae, pertussis, and tetanus diseases. https://www.drugs.com/mtm/trihibit.html Discontinued in 2011 Trihibit A vaccine against flu (influenza) in adults, especially in those who run an increased risk of experiencing associated complications in case they fall ill with flu. Kallan Roan, Oliver He https://www.medicines.org.uk/emc/files/pil.6163.pdf Seasonal The vaccine targets three strains of influenza virus, and is free of chicken/egg protein. Optaflu A vaccine used to prevent diphtheria and tetanus in individuals over 6 years of age. http://www.catalog.md/drugs/td-rix.html https://www.impfkritik.de/upload/pdf/fachinfo/Td-Rix-GSK-2006-07.pdf European/German vaccine TD-Rix A combined live virus vaccine used to prevent measles, mumps, and rubella. http://vacvine.com/Vaccines/Details/319 need better source Virivac A vaccine used to protect against measles, mumps, and rubella for 12-15 month-old individuals. Kallan Roan, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/18400341 M-M-R I Active immunization against Haemophilius influenzae type b in recommended routinely for children at 24 months of age and for children at 15 months of age enrolled in child care facilities. Kallan Roan, Oliver He HIBIMUNE https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745871/ https://www.ndrugs.com/?s=hib-imune Discontinued in 1988 Hib-Imune Oliver He, Randi Vita MVA expressing antigen 85A modified vaccinia virus Ankara expressing antigen 85A https://www.ncbi.nlm.nih.gov/pubmed/15502839 MVA85A A Haemophilus influenzae type B conjugate vaccine manufactured by GSB. https://www.drugs.com/mtm/omnihib.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745871/ Discontinued Vaccine OmniHIB A vaccine against diphtheria, tetanus, and pertussis. Kallan Roan, Oliver He A vaccine indicated for active immunization against diphtheria, tetanus, and pertussis (whooping cough) in infants and children 6 weeks to 7 years of age (prior to seventh birthday). https://www.rxlist.com/certiva-drug.htm Certiva obsolete Fluogen true A TB vaccine that uses attenuated fowlpox strain FP9 to express mycobacterial mycolyl transferase Ag85A. YH http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=172 https://www.ncbi.nlm.nih.gov/pubmed/15196215 FP85A Pharmacotherapeutic group (ATC code): J 07 AN 01. Oliver He, Randi Vita http://www.immune.org.nz/vaccines/available-vaccines/bcg-vaccine-ssi https://www.hse.ie/eng/health/immunisation/hcpinfo/vaccineordering/bcgpil14.pdf Freeze-dried powder containing live attenuated bacteria of the type Mycobacterium bovis BCG, Danish strain 1331. Sodium glutamate, magnesium sulphate heptahydrate, dipotassium phosphate, l-asparagine monohydrate, ferric ammonium citrate, glycerol 85%, citric acid, monohydrate and water for injections Mycobacterium bovis BCG (Bacillus Calmette-Guérin), Danish strain 1331, live attenuated, 2–8 × 10^5 CFU per dose. BCG Vaccine SSI A TB vaccine that uses BCG as vaccine vector. YH recombinant BCG vaccine A TB vaccine that recombinant BCG strain with the replacment of its urease C encoding gene with the listeriolysin encoding gene from Listeria monocytogenes. Oliver He, Randi Vita BCGΔureC::hly https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610719/ VPM1002 The MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine is a replication-incompetent adenovirus type 5-vectored vaccine that elicits cell-mediated immunity against conserved human immunodeficiency virus proteins. Oliver He, Randi Vita PMID: 18433307 https://www.ncbi.nlm.nih.gov/pubmed/18433307 equal parts of 3 recombinant Ad5 vectors: MRKAd5gag, MRKAd5pol, and MRKAd5nef. E1 region of the Ad5 vector was deleted, which rendered the virus incapable of growing in human cells, and was replaced with a transgene construct that consisted of the human cytomegalovirus promoter; the HIV-1 clade B gag, pol, or nef open reading frame; and the bovine growth hormone poly A MRKAd5 HIV-1 gag/pol/nef YH A Yellow fever virus vaccine that uses the live attenated 17D strain. YF-17D vaccine A Yellow fever virus vaccine that uses the live attenated 17DD strain. Oliver He, Randi Vita https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903908/ Two distinct strains of live attenuated yellow fever virus vaccine, 17D and 17DD, have been widely used. They have the same origin, from a yellow fever virus isolated from a patient with non fatal yellow fever named Asibi, from Ghana, in 1927. The 17D strain, used for vaccine production, corresponds to passage level 235–240 and the 17DD to a passage level 286–287. The comparison of the nucleotide sequences of all 17D vaccines showed an overall homology of 99.2%. YF-17DD vaccine A YF-17DD vaccine t hat is manufactured by Bio-Manguinhos Oliver He, Randi Vita YF 17DD-YFV a licensed N. meningitidis vaccine that includes meningococcal polysaccharides from Groups A, C, Y and W-135 combined, and is manufactured by GSK. Oliver He, Randi Vita ACWYVax http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con425089.pdf Meningococcal polysaccharides (groups A, C, W135 and Y polysaccharides) Lactose ACWY Vax It is live attenuated YFV vaccine strain 17D manufactured in China, France, Senegal, and the USA. In powder and solvent for suspension for injection in pre-filled syringe. Oliver He, Randi Vita 17D-204 https://www.medicines.org.uk/emc/product/1683/smpc Yellow fever virus (produced in specified pathogen-free chick embryos), 17D strain (live, attenuated): not less than 1000 IU Lactose, sorbitol, L-histidine hydrochloride, L-alanine, sodium chloride, potassium chloride, sodium phosphate-dibasic dihydrate, potassium phosphate-monobasic, calcium chloride, magnesium sulfate and water for injections. Stamaril A cancer vaccine against non-small cell lung cancer (NSCLC) NSCLC vaccine non-small cell lung cancer vaccine A non-small cell lung cancer mRNA-derived vaccine that contains modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Oliver He Randi Vita https://www.cancer.gov/publications/dictionaries/cancer-drug/def/non-small-cell-lung-cancer-mrna-derived-vaccine-cv9201 CV9201 A vaccine role that indicates a clinical trial status of a vaccine YH clinical trial vaccine role licensed influenza vaccine Oliver He, Randi Vita https://www.medicines.org.uk/emc/product/6355/smpc influenza vaccine (surface antigen, inactivated): (haemagglutinin and neuraminidase) of the following strains*: (A/Singapore/GP1908/2015, IVR-180) 15 micrograms HA, (A/Singapore/INFIMH-16-0019/2016, NIB-104) 15 micrograms HA, (B/Maryland/15/2016, NYMC BX-69A) 15 micrograms HA potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate and water for injections Imuvac LIPO-5 is a therapeutic HIV vaccine made up of lipopeptides, Study Names: VRI02/ANRS 149 LIGHT; NCT01492985 Oliver He, Randi Vita ANRS HIV-LIPO-5, HIV-LIPO-5 https://aidsinfo.nih.gov/drugs/572/lipo-5/0/patient 5 synthetic HIV-1 peptide fragments, which contain multiple CD8 and CD4 cell epitopes: Gag (amino acids 17 to 35), Gag (amino acids 253 to 284), Pol (amino acids 325 to 355), Nef (amino acids 66 to 97), and Nef (amino acids 116 to 145). The peptides are covalently attached to a palmitoyl-lysylamide moiety that facilitates entry into antigen-presenting DCs and enhances vaccine immunogenicity LIPO-5 is in Phase II development as a therapeutic HIV vaccine. (LIPO-5 is also being studied as a preventive HIV vaccine.) LIPO-5 A Hepatitis B virus vaccine that uses recombinant Hepatitis B surface antigen as the antigen Oliver He, Kallan Roan http://purl.bioontology.org/ontology/RXNORM/797752 https://en.wikipedia.org/wiki/Hepatitis_B_vaccine 797752 Hepatitis B Surface Antigen Vaccine CUI: C0062527 RXAUI: 2850925 TUI: T116, T129, T121 Hepatitis B surface antigen vaccine A Hepatitis B surface antigen viral vaccine that utilizes a cytidine-phosphate-guanosine oligodeoxynucleotide (CpGODN) 1018, as an adjuvant. Oliver He, Randi Vita, Kallan Roan HBsAg-1018 http://purl.bioontology.org/ontology/RXNORM/1994348 https://www.ncbi.nlm.nih.gov/pubmed/22342916 1994348 HEPLISAV-B A CpG DNA vaccine adjuvant that is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC). ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression. ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. It is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma. Kallan Roan Oliver He ISS 1018 CpG ODN ISS 1018 CpG oligodeoxynucleotide ISS-1018 https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iss-1018-cpg-oligodeoxynucleotide https://www.drugbank.ca/drugs/DB05463 ISS 1018 CpG ODN vaccine adjuvant DrugBank Accession number: DB05463 Oliver He, Kallan Roan, Randi Rita A recombinant vesicular stomatitis virus Indiana serotype (rVSV) vector vaccine taht expresses Zaire GP https://www.ncbi.nlm.nih.gov/pubmed/15937495 rVSV-ZEBOV A human paillomavirus vaccine that has the vaccine antigen ingredient of monovalent non-infectious, L1 recombinant HPV-like particles (VLP). Oliver He, Kallan Roan, Randi Rita https://www.ncbi.nlm.nih.gov/pubmed/12854090 HPV-16 L1 VLP An inactivated Japanese encephalitis vaccine (JVax *) for use by certain travelers to and expatriates in Asia. Kallan Roan, Oliver He https://www.cdc.gov/mmwr/preview/mmwrhtml/00018184.htm J-Vax Kallan Roan, Oliver He A viral vaccine that protects against infection with Poliovirus administered orally. http://polioeradication.org/polio-today/polio-prevention/the-vaccines/opv/ https://www.who.int/biologicals/areas/vaccines/polio/opv/en/ Oral Poliovirus vaccine A combination vaccine that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B. Kallan Roan, Oliver He DTaP-Hib vaccine Contains pertussis in acellular form. Diphtheria-Tetanus-Acellular Pertussis-Haemophilus b vaccine A combination vaccine that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B. Kallan Roan, Oliver He DTP-Hib vaccine Contains killed whole cells of bacterium that causes pertussis. Diphtheria-Tetanus-Whole Cell Pertussis-Haemophilus b vaccine A vaccine used to develop immunity to rabies. Kallan Roan, Oliver He Discontinued Imovax ID A live virus vaccine for immunization against measles and rubella. Kallan Roan, Oliver He https://www.rxlist.com/m-r-vax-ii-drug.htm MR-VAX II Kallan Roan, Oliver He DTP-HepB vaccine Diphtheria-Tetanus-Pertussis-Hepatitis B vaccine Active immunzation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards Kallan Roan, Oliver He Tritanrix HB https://www.ema.europa.eu/en/tritanrix-hb-h-w-3838 Tritanrix A vaccine used to prevent diphtheria, tetanus, pertussis, and Haemophilus type B infections. Kallan Roan, Oliver He https://www.hendricks.org/HealthLibrary/default.aspx?sid=1&pTitle=%2CDrug&ContentTypeID=26&ContentID=1027&alpha=A&AdditionalTitle=ActHIB%C2%AE+With+DTP DTP-ActHIB An oral vaccine against adenovirus serotype 4. https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare/Vaccine-Preventable-Diseases/Adenovirus Kallan Roan, Oliver He The vaccine is in a form of white enteric-coated tablets. It is typically administered with Adenovirus type 7 vaccine. Adenovirus Type 4 An oral vaccine against adenovirus serotype 7. Kallan Roan, Oliver He The vaccine is in a form of peach-colored enteric-coated tablets. It is typically administered with Adenovirus type 4 vaccine. https://health.mil/Military-Health-Topics/Health-Readiness/Immunization-Healthcare/Vaccine-Preventable-Diseases/Adenovirus Adenovirus Type 7 A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b. Kallan Roan, Oliver He DTAP/IPV/ACT-HIB https://insights.ovid.com/pubmed?pmid=9849987 Diphtheria-Tetanus-Pertussis-Poliovirus-ACT-Hib vaccine Active immunization against tetanus, diphtheria, pertussis, and poliomyelitis for individuals between 3 months and 6 years of age. Kallan Roan, Oliver He https://www.impfkritik.de/upload/pdf/fachinfo/quatro-virelon-chiron-behring.pdf Quatro Virelon A vaccine that protects adolescents and adults from tetanus, diphtheria, and pertussis. Kallan Roan, Oliver He https://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.html Tdap is different than the DTaP vaccine, which is given to infants and children in five doses, starting at 2 months of age. TDAP A measles virus vaccine manufactured outside of the U.S. Kallan Roan, Oliver He This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Measles virus vaccine foreign to USA A Mumps-Rubella vaccine manufactured outside of the U.S. Kallan Roan, Oliver He This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Mumps-Rubella Vaccine foreign to USA A Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine manufactured outside of the U.S Kallan Roan, Oliver He This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine foreign to USA A Diphtheria-Tetanus-Pertussis-Poliovirus vaccine manufactured outside of the U.S. Kallan Roan, Oliver He This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Diphtheria-Tetanus-Pertussis-Poliovirus vaccine foreign to USA A Haemophilis influenzae Type b capsular polysaccharide vaccine manufactured outside of the U.S. Kallan Roan, Oliver He https://www.drugs.com/mmx/haemophilus-influenzae-type-b-polysaccharide-vaccine.html This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. HIB Polysaccharide foreign to USA A Hepatitis B vaccine manufactured outside of the U.S. Kallan Roan, Oliver He https://www.ema.europa.eu/documents/product-information/hbvaxpro-epar-product-information_en.pdf This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Hepatitis B vaccine foreign to USA A Diphtheria-Tetanus-Poliovirus vaccine manufactured outside of the U.S. Kallan Roan, Oliver He https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166496/ This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Diphtheria-Tetanus-Poliovirus vaccine foreign to USA A Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine manufactured outside of the U.S. Kallan Roan, Oliver He https://www.ema.europa.eu/medicines/human/EPAR/hexyon DTaP/IPV/HepB/Hib vaccine foreign to USA This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine foreign to USA A seasonal Influenza virus vaccine manufactured outside of the U.S. Kallan Roan, Oliver He http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/types-of-seasonal-influenza-vaccine This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Seasonal Influenza virus vaccine foreign to USA A Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine manufactured outside of the U.S Kallan Roan, Oliver He DTaP/IPV/Hib vaccine foreign to USA https://ca.gsk.com/media/590970/infanrix-ipv-hib.pdf This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine foreign to USA Kallan Roan, Oliver He http://vk.ovg.ox.ac.uk/ppv A pneumococcal vaccine manufactured outside of the U.S. This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Pneumococcal vaccine foreign to USA An active immunizing combination agent that is used to prevent infection caused by certain groups of meningococcal bacteria and Haemophilus influenza type b (Hib) bacteria. Kallan Roan, Oliver He https://www.mayoclinic.org/drugs-supplements/meningococcal-vaccine-and-haemophilus-b-vaccine-intramuscular-route/description/drg-20075601 Meningococcal Conjugate and Haemophilis B Vaccine A Meningicoccal Conjugate and Haemophilis B Vaccine manufactured outside of the U.S. Kallan Roan, Oliver He This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Meningococcal Conjugate and Haemophilis B Vaccine foreign to USA A tick-borne encephalitis virus vaccine used to prevent subtype Far Eastern tick-borne encephalitis virus (formerly known as Russian Spring Summer encephalitis virus). Kallan Roan, Oliver He https://www.who.int/immunization/sage/1_TBE_PP_Draft_13_Mar_2011_SAGE_apr_2011.pdf?ua=1 Spring Summer Encephalitis Vaccine A polysaccharide vaccine to prevent typhoid caused Salmonella typhi. Acetone is used to inactivate culture, and dried. Kallan Roan, Oliver He https://www.cdc.gov/mmwr/pdf/rr/rr4314.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2366340 Acetone-Dried Typhoid Vi Polysaccharide vaccine acellular pertussis vaccine, inactivated http://purl.bioontology.org/ontology/RXNORM/798302 798302 inactivated acellular pertussis vaccine A vaccine to protect individuals against infections caused by hepatitis A virus and typhoid fever bacteria. Kallan Roan, Oliver He Hepatitis A and Vi Polysaccharide typhoid vaccine foreign to USA https://www.ncbi.nlm.nih.gov/pubmed/9772328 This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. Hepatitis A virus-Typhoid vaccine foreign to USA B. pertussis pertactin vaccine Bordetella pertussis pertactin vaccine http://purl.bioontology.org/ontology/RXNORM/1300380 1300380 Bordetella pertussis pertactin vaccine, inactivated Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300186 1300186 Bordetella pertussis toxoid vaccine, inactivated Bordetella pertussis filamentous hemagglutinin vaccine, inactivated Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300182 1300182 Bordetella pertussis fimbriae 2/3 vaccine, inactivated Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300380 1300380 Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300185 1300185 Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657600 1300365 Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300366 1300366 Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300381 1300381 Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300187 1300187 Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300307 1300307 Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1988802 1988802 Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML A monovalent vaccine used to protect against H1N1 influenza virus. Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181950.htm H1N1 Influenza Monovalent Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854930 854930 pneumococcal capsular polysaccharide type 1 vaccine Kallan Roan, Oliver He DP+IPV vaccine Diphtheria Toxoid-Pertussis-Poliovirus vaccine DT+IPV+HIB+HEPB vaccine Diphtheria-Tetanus-Poliovirus-Haemophilus B-Hepatitis B vaccine Seasonal Influenza A27:H29 vaccine For the prevention of influenza caused by Influenza Virus, Types A and B. For the Southern Hemisphere 2017 season, the vaccine is indicated for use only in persons aged 5 years and over. Kallan Roan, Oliver He https://www.medsafe.govt.nz/profs/Datasheet/f/Fluvaxinj.pdf Fluvax Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854934 854934 pneumococcal capsular polysaccharide type 11A vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854936 854936 pneumococcal capsular polysaccharide type 12F vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854938 854938 pneumococcal capsular polysaccharide type 14 vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854940 854940 pneumococcal capsular polysaccharide type 15B vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854942 854942 pneumococcal capsular polysaccharide type 17F vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854944 854944 pneumococcal capsular polysaccharide type 18C vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854944 854944 pneumococcal capsular polysaccharide type 19A vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854948 854948 pneumococcal capsular polysaccharide type 19F vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854950 854950 pneumococcal capsular polysaccharide type 2 vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854952 854952 pneumococcal capsular polysaccharide type 20 vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854954 854954 pneumococcal capsular polysaccharide type 22F vaccine 1 ML Recombivax 0.04 MG/ML Injection RECOMBIVAX HB dialysis formulation vaccine 1 ML Injection Recombivax HB 40 MCG per 1 ML Injection Recombivax HB, Hepatitis B vaccine (recombinant) Dialysis Formulation 40 MCG per 1 ML Injection http://purl.bioontology.org/ontology/RXNORM/830263 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [Recombivax] Hepatitis A virus-Typhoid vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830260 Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1994352 1994352 CUI: C4534702 RXAUI: 9712934, 9712933, 9712931, 9712937 TUI: T200 0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [Heplisav-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854962 854962 pneumococcal capsular polysaccharide type 4 vaccine 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection 0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657331 1657331 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML A vaccine which helps prevent hepatitis A and typhoid fever. This vaccine should only be given to adults and teenagers aged 15 years and above. Kallan Roan, Oliver He https://www.hpra.ie/img/uploaded/vaccines/PIL_PA1077099001.pdf Hepatyrix Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830212 830212 Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [Recombivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658155 1658155 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [Recombivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830245 830245 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Recombivax] BCG Vaccine (by Organon Teknika) Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658150 1658150 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [Recombivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657683 1657683 Hepatitis B Surface Antigen Vaccine Injection [Recombivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830244 830244 Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Recombivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830253 830253 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Recombivax] This may just be a synonym of Recombivax HB: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110114.pdf because all the vaccine is injectable RECOMBIVAX HB® Hepatitis B Vaccine (Recombinant) Suspension for intramuscular injection Initial U.S. Approval: 1986 Recombivax Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854970 854970 pneumococcal capsular polysaccharide type 8 vaccine The site that is the part of the host body and the entrance point where a vaccine is administered. YL it is not the natural anatomical part where the body has access toward outside, such as mouth or nose. But rather the holes on the skin made by needdles used for vaccination. vaccination site Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854958 854958 pneumococcal capsular polysaccharide type 3 vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854960 854960 pneumococcal capsular polysaccharide type 33F vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854966 854966 pneumococcal capsular polysaccharide type 6B vaccine A trivalent inactive influenza virus vaccine. Kallan Roan, Oliver He Flu-imune https://cvi.asm.org/content/cdli/1/1/16.full.pdf Vaccine sold for 1993-1994 influenza season. Flu-Imune Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854956 854956 pneumococcal capsular polysaccharide type 23F vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854968 854968 pneumococcal capsular polysaccharide type 7F vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854972 854972 pneumococcal capsular polysaccharide type 9N vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854972 854972 pneumococcal capsular polysaccharide type 5 vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797753 797753 Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830236 830236 Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798427 798427 Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Engerix-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658156 1658156 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658708 1658708 influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML A quadrivalent influenza vaccine against two influenza A strains and two influenza B strains. Kallan Roan, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/24022123 QIV Dresden Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658142 1658142 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798422 798422 Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Engerix-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798428 798428 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658157 1658157 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658144 1658144 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798430 798430 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] A combination vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b (Hib). Kallan Roan, Oliver He https://www.mesvaccins.net/web/vaccines/15-infanrixquinta Infanrix Quinta Oliver He, Khadeejah Khan http://purl.bioontology.org/ontology/RXNORM/854937 854937 pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML http://purl.bioontology.org/ontology/RXNORM/1994350 1994350 Hepatitis B Surface Antigen Vaccine Injection [Heplisav-B] A combination vaccine against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus. Kallan Roan, Oliver He http://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/28/FileName/700FA5039310414550A80719A7B644CD/PI_Infanrix_Penta.pdf Infanrix Penta http://purl.bioontology.org/ontology/RXNORM/1292432 1292432 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Injection http://purl.bioontology.org/ontology/RXNORM/1292422 1292422 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain http://purl.bioontology.org/ontology/RXNORM/1658006 1658006 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection http://purl.bioontology.org/ontology/RXNORM/1292423 1292423 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML http://purl.bioontology.org/ontology/RXNORM/1292457 1292457 0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection http://purl.bioontology.org/ontology/RXNORM/1292424 1292424 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Product http://purl.bioontology.org/ontology/RXNORM/1292436 1292436 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML http://purl.bioontology.org/ontology/RXNORM/1292430 1292430 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML http://purl.bioontology.org/ontology/RXNORM/1292432 1292432 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Injection http://purl.bioontology.org/ontology/RXNORM/1658013 1658013 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Zostavax] http://purl.bioontology.org/ontology/RXNORM/1292433 1292433 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML [Zostavax] http://purl.bioontology.org/ontology/RXNORM/1292435 1292435 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Injection [Zostavax] pneumococcal capsular polysaccharide vaccine Streptococcus pneumoniae capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901622 901622 Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901627 901627 Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901630 901630 Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901621 901621 Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901635 901635 Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901638 901638 Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901626 901626 Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901629 901629 Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901632 901632 Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901634 901634 Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901625 901625 Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901623 901623 Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901637 901637 Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Khadeejah Khan, Oliver He L1 protein, Human papillomavirus Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798268 798268 L1 protein, Human papillomavirus type 6 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798262 798262 L1 protein, Human papillomavirus type 11 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798266 798266 L1 protein, Human papillomavirus type 18 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798264 798264 L1 protein, Human papillomavirus type 16 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1596930 1596930 L1 protein, Human papillomavirus type 31 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1596931 1596931 L1 protein, Human papillomavirus type 33 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1596932 1596932 L1 protein, Human papillomavirus type 45 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1596933 1596933 L1 protein, Human papillomavirus type 52 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1596934 1596934 L1 protein, Human papillomavirus type 58 Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854957 854957 pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854939 854939 pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854969 854969 pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854965 854965 pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854935 854935 pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854933 854933 pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML A combination vaccine against diphtheria, tetanus, acellular pertussis, and inactivated poliomyelitis for individuals ages from 16 months to 13 years of age. Kallan Roan, Oliver He https://www.mesvaccins.net/web/vaccines/51-infanrixtetra Infanrix Tetra A vaccine that can be given to children after the age of 2 months up to 2 years to prevent infectious diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC) bacteria. Kallan Roan, Oliver He https://www.medicines.org.uk/emc/files/pil.167.pdf Menitorix Kallan Roan, Oliver He SHINGRIX Zoster Vaccine Recombinant, Adjuvanted Indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581605.pdf 125614 Shingrix A vaccine against tetanus, diphtheria, pertussis, and inactivated poliovirus manufactured outside of the U.S. Kallan Roan, Oliver He https://www.nhsinform.scot/healthy-living/immunisation/vaccines/the-4-in-1-vaccine This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. TDAP/IPV vaccine foreign to USA Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854941 854941 pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML Oliver He, Khadeejah Khan http://purl.bioontology.org/ontology/RXNORM/854943 854943 pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML Oliver He, Khadeejah Khan http://purl.bioontology.org/ontology/RXNORM/854945 854945 pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854947 854947 pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854931 854931 pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854949 854949 pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854951 854951 pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854953 854953 pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854955 854955 pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854959 854959 pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854961 854961 pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854963 854963 pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854971 854971 pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854973 854973 pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901636 901636 Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901620 901620 Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798220 798220 Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine a vaccine-induced down-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine. YH, RR live attenuated vaccine-induced down-regulated gene expression compared to infection with wild type pathogen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798222 798222 Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901624 901624 Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798224 798224 Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He vhttp://purl.bioontology.org/ontology/RXNORM/798226 798226 Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901628 901628 Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798228 798228 Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901631 901631 Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901633 901633 Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798230 798230 Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798232 798232 Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593128 1593128 meningococcal group B vaccine a vaccine-induced up-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine. YH, RR live attenuated vaccine-induced up-regulated gene expression compared to infection with wild type pathogen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601397 1601397 meningococcal group B vaccine 0.1 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593133 1593133 meningococcal group B vaccine Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593132 1593132 meningococcal group B vaccine Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300181 1300181 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094070.htm Vivotif Typhoid Vaccine Live Oral Ty21a Berna Biotech, Ltd. For immunization of adults and children greater than 6 years of age against disease caused by Salmonella typhi. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807.pdf 103123 Vivotif CVX: 25 Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762601 762601 Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule [Vivotif] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762602 762602 Typhoid Vaccine Live Ty21a 2000000000 UNT Delayed Release Oral Capsule [Vivotif] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1187406 1187406 Vivotif Oral Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1187407 1187407 Vivotif Pill Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601405 1601405 meningococcal group B vaccine Prefilled Syringe [Bexsero] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601231 1601231 Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601398 1601398 Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601233 1601233 Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601399 1601399 Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601236 1601236 Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601400 1601400 Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593127 1593127 Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593129 1593129 Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593130 1593130 Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593131 1593131 Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601232 1601232 Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804187 804187 Yellow-Fever Virus Vaccine, 17D-204 strain Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1876704 1876704 Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1876705 1876705 0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300183 1300183 Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1162391 1162391 Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1876709 1876709 Stamaril Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1876708 1876708 Yellow-Fever Virus Vaccine, 17D-204 strain Injection [Stamaril] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1876710 1876710 0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injection [Stamaril] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658238 1658238 Yellow-Fever Virus Vaccine, 17D-204 strain Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658239 1658239 0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804188 804188 Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1292826 1292826 Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injectable Suspension Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798305 798305 diphtheria toxoid vaccine, inactivated 5 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798306 798306 tetanus toxoid vaccine, inactivated Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798307 798307 tetanus toxoid vaccine, inactivated 10 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300379 1300379 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300364 1300364 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1988801 1988801 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML Khadeejah Khan, Oliver He Acellular Pertussis Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798302 798302 acellular pertussis vaccine, inactivated Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/829893 829893 acellular pertussis vaccine, inactivated 0.116 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/801826 801826 acellular pertussis vaccine, inactivated 96 UNT/ML A trivalent influenza vaccine contianing two A influenza strains and one B influenza strain. Kallan Roan, Oliver He https://www.clinicalleader.com/doc/results-phase-presented-gsks-quadrivalent-influenza-vaccines-0001 TIV Dresden Kallan Roan, Oliver He An inactivated quadrivalent influenza vaccine against 2 influenza A strains and 2 influenza B strains for infants 6 months up to 23 months, and if needed it can be administered to children 2 to 17 years old with compromised immune systems and those considered vulnerable and high risk. https://globalnews.ca/news/2254967/a-first-for-flu-season-a-new-more-robust-four-strain-vaccine/ QIV Quebec Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/805373 805373 diphtheria toxoid vaccine, inactivated 30 UNT/ML A clostridium tetani vaccine that consists of formaldehyde inactivated tetanospasmin (aka tetanus toxoid). Oliver He, Hector Guzman-Orozco https://en.wikipedia.org/wiki/Clostridium_tetani tetanus toxoid vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/374054 374054 tetanus toxoid vaccine, inactivated Injectable Solution Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/374444 374444 tetanus toxoid vaccine, inactivated Injectable Suspension Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1164846 1164846 tetanus toxoid vaccine, inactivated Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/792155 792155 tetanus toxoid vaccine, inactivated Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/801712 801712 tetanus toxoid vaccine, inactivated 20 UNT/ML Khadeejh khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/792156 792156 0.5 ML tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/204527 204527 tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/205262 205262 tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/318242 318242 tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/316782 316782 tetanus toxoid vaccine, inactivated 8 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/331444 331444 tetanus toxoid vaccine, inactivated 4 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798444 798444 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657731 1657731 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1159739 1159739 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798447 798447 0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657733 1657733 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injection [PedvaxHIB] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798445 798445 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798451 798451 0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injection [PedvaxHIB] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1160330 1160330 Hepatitis B Surface Antigen Vaccine Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798420 798420 Hepatitis B Surface Antigen Vaccine Injectable Suspension Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830237 830237 Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Suspension Mumps-Rubella Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798425 798425 Hepatitis B Surface Antigen Vaccine Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798426 798426 1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657681 1657681 Hepatitis B Surface Antigen Vaccine Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830243 830243 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798438 798438 Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830252 830252 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798429 798429 0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658149 1658149 1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658154 1658154 0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799447 1799447 Typhoid Vaccine Live Ty21a 2000000000 UNT [Vivotif] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/807271 807271 diphtheria toxoid vaccine, inactivated 4 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1160325 1160325 Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798362 798362 Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798476 798476 Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798361 798361 Hepatitis A Vaccine (Inactivated) Strain HM175 Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/803362 803362 Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658057 1658057 Hepatitis A Vaccine (Inactivated) Strain HM175 Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658065 1658065 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658058 1658058 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799445 1799445 Typhoid Vaccine Live Ty21a 2000000000 UNT Fluzone Intradermal A trivalent influenza vaccine containing two strains of influenza A and one strain of influenza B for use in people 18 years to 64 years for use during the 2012-2013 season. Kallan Roan, Oliver He http://www.news.sanofi.us/2014-12-12-Sanofi-Pasteur-Announces-FDA-Approval-of-Fluzone-R-Intradermal-Quadrivalent-Influenza-Vaccine-for-Adults Fluzone Intradermal Trivalent Meningococcal conjugate vaccine, which contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y), is used to prevent infection caused by meningococcal bacteria. Kallan Roan, Oliver He https://www.everydayhealth.com/drugs/meningococcal-conjugate-vaccine meningococcal conjugate vaccine A DTaP vaccine used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past. Kallan Roan, Oliver He https://www.cdc.gov/mmwr/preview/mmwrhtml/00048610.htm Acel-Imune Typhoid Vi Polysaccharide vaccine This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine. https://wonder.cdc.gov/wonder/help/vaers.html vaccine foreign to USA Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762598 762598 Typhoid Vaccine Live Ty21a 2000000000 UNT Delayed Release Oral Capsule Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762595 762595 Typhoid Vaccine Live Ty21a Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762597 762597 Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1159372 1159372 Typhoid Vaccine Live Ty21a Pill Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1159371 1159371 Typhoid Vaccine Live Ty21a Oral Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660921 1660921 influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1186748 1186748 Twinrix Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1724009 1724009 influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657222 1657222 influenza A virus A/Christchurch/16/2010 (H1N1) antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798305 798305 diphtheria toxoid vaccine, inactivated 13.4 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798304 798304 diphtheria toxoid vaccine, inactivated Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/801709 801709 diphtheria toxoid vaccine, inactivated 50 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/807414 807414 diphtheria toxoid vaccine, inactivated 25 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658102 1658102 1 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Injection [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/802012 802012 Hepatitis A Vaccine, Inactivated 50 UNT/ML [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/836636 836636 0.5 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Prefilled Syringe [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658106 1658106 0.5 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Injection [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1187568 1187568 Vaqta Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/836634 836634 1 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Prefilled Syringe [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/253174 253174 Hepatitis A Vaccine, Inactivated Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/836633 836633 Hepatitis A Vaccine, Inactivated Prefilled Syringe [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658101 1658101 Hepatitis A Vaccine, Inactivated Injection [Vaqta] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658099 1658099 Hepatitis A Vaccine, Inactivated Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1160328 1160328 Hepatitis A Vaccine, Inactivated Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657223 1657223 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657224 1657224 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658709 1658709 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657225 1657225 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1723999 1723999 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1664468 1664468 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657130 1657130 influenza A virus A/South Australia/55/2014 (H3N2) antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657132 1657132 influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657127 1657127 influenza A virus A/Brisbane/10/2010 (H1N1) antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799398 1799398 influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657226 https://www.fludb.org/brc/fluStrainDetails.spg?strainName=B/Brisbane/60/2008&decorator=influenza 1657226 influenza B virus B/Brisbane/60/2008 antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657227 1657227 influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1664469 1664469 influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661110 1661110 influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801177 1801177 influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML vaccine against Neisseriales vaccine against Neisseriales bacterial infection https://en.wikipedia.org/wiki/Neisseriaceae Neisseriales vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946982 1946982 influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657133 1657133 influenza B virus B/Utah/9/2014 antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657135 1657135 influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657228 1657228 influenza B virus B/Phuket/3073/2013 antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657229 1657229 influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660923 1660923 influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658710 1658710 influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946983 1946983 influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1664470 1664470 influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML A vaccine that is used against an infection by a pathogen under Spirochaetes. https://en.wikipedia.org/wiki/Spirochaete vaccine against Spirochaetes Spirochaetes vaccine Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term influenza vaccines Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1116738 1116738 Influenza Virus Vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1303851 1303851 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term Influenza A (H1N1) Virus Vaccine Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term Influenza A (H1N1)-like Virus Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term Influenza A (H3N2)-like Virus Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term Influenza A (H3N2) Virus Vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1541617 1541617 Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1541618 1541618 Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1005931 1005931 Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1005932 1005932 Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1111368 1111368 Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304122 1304122 Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304300 1304300 Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304309 1304309 Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304123 1304123 Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1303851 1303851 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304299 1304299 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304308 1304308 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1005929 1005929 Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1005930 1005930 Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1111367 1111367 Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1006250 1006250 Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain A vaccine that is used against an infection by a pathogen under Borreliella. https://en.wikipedia.org/wiki/Borrelia vaccine against Borreliella Borreliella vaccine Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term Influenza B Virus Vaccine Khadeejah Khan, Oliver He NOT IN RxNorm Empty Parent Term Influenza B-like Virus Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1303855 1303855 Influenza B virus vaccine, B-Wisconsin-1-2010-like virus Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1304310 1304310 Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/857921 857921 Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/857922 857922 Influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1111369 1111369 Influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427022 1427022 Influenza B virus vaccine, B-Massachusetts-2-2012-like virus Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427023 1427023 Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1429576 1429576 Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1429589 1429589 Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1543760 1543760 Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML Kallan Roan, Oliver He Proteobacteria vaccine Betaproteobacteria vaccine A vaccine that is used against an infection by a pathogen under Yersiniaceae. vacccine against Yersiniaceae https://en.wikipedia.org/wiki/Yersiniaceae Yersiniaceae vaccine A vaccine that is used against an infection by a pathogen under Corynebacterium. vaccine against Corynebacterium https://en.wikipedia.org/wiki/Corynebacterium Corynebacterium vaccine Gammaproteobacteria vaccine A vaccine that is used against an infection by a pathogen under Bacillus. vaccine against Bacillus https://en.wikipedia.org/wiki/Bacillus Bacillus vaccine A vaccine that is used against an infection by a pathogen under Varicellovirus. vaccine against Varicellovirus https://en.wikipedia.org/wiki/Varicellovirus Varicellovirus vaccine A vaccine that is used against an infection by a pathogen under Papillomaviridae. https://en.wikipedia.org/wiki/Papillomaviridae vaccine against Papillomaviridae Papillomaviridae vaccine A vaccine that is used against an infection by a pathogen under Orthopoxvirus. https://en.wikipedia.org/wiki/Orthopoxvirus vaccine against Orthopoxvirus Orthopoxvirus vaccine A vaccine that is used against an infection by a pathogen under Orthohepadnavirus. https://en.wikipedia.org/wiki/Orthohepadnavirus vaccine against Orthohepadnavirus Orthohepadnavirus vaccine A vaccine that is used against an infection by a pathogen under Reoviridae. vaccine against Reoviridae https://en.wikipedia.org/wiki/Reoviridae Reoviridae vaccine A vaccine that is used against an infection by a pathogen under Sedoreovirinae. vaccine against Sedoreovirinae https://en.wikipedia.org/wiki/Sedoreovirinae Sedoreovirinae vaccine A vaccine that is used against an infection by a pathogen under Morbillivirus. vaccine against Morbillivirus https://en.wikipedia.org/wiki/Morbillivirus Morbillivirus vaccine A vaccine that is used against an infection by a pathogen under Rubulavirus. vaccine against Rubulavirus https://en.wikipedia.org/wiki/Rubulavirus Rubulavirus vaccine A vaccine that is used against an infection by a pathogen under Lyssavirus. vaccine against Lyssavirus https://en.wikipedia.org/wiki/Lyssavirus Lyssavirus vaccine A vaccine that is used against an infection by a pathogen under Flaviviridae. https://en.wikipedia.org/wiki/Flaviviridae vaccine against Flaviviridae Flaviviridae vaccine A vaccine that is used against an infection by a pathogen under Enterovirus. vaccine against Enterovirus https://en.wikipedia.org/wiki/Enterovirus Enterovirus vaccine A vaccine that is used against an infection by a pathogen under Hepatovirus. vaccine against Hepatovirus https://en.wikipedia.org/wiki/Hepatitis_A#Virology Hepatovirus vaccine A vaccine that is used against an infection by a pathogen under Rubivirus. vaccine against Rubivirus https://en.wikipedia.org/wiki/Rubella_virus Rubivirus vaccine Alphaproteobacteria vaccine Enterobacterales vaccine Enterobacteriaceae vaccine Spirochaetia vaccine Firmicutes vaccine Bacilli vaccine Lactobacillales vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/901644 901644 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Prefilled Syringe [Prevnar 13] Prevnar 13 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854974 854974 pneumococcal capsular polysaccharide type 9V vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854975 854975 pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1182409 1182409 CUI: C3236244 RXAUI: 3843751 RXN STRENGTH: 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML TUI: T200 Pneumovax 23 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658471 1658471 pneumococcal capsular polysaccharide type 1 vaccine / pneumococcal capsular polysaccharide type 10A vaccine / pneumococcal capsular polysaccharide type 11A vaccine / pneumococcal capsular polysaccharide type 12F vaccine / pneumococcal capsular polysaccharide type 14 vaccine / pneumococcal capsular polysaccharide type 15B vaccine / pneumococcal capsular polysaccharide type 17F vaccine / pneumococcal capsular polysaccharide type 18C vaccine / pneumococcal capsular polysaccharide type 19A vaccine / pneumococcal capsular polysaccharide type 19F vaccine / pneumococcal capsular polysaccharide type 2 vaccine / pneumococcal capsular polysaccharide type 20 vaccine / pneumococcal capsular polysaccharide type 22F vaccine / pneumococcal capsular polysaccharide type 23F vaccine / pneumococcal capsular polysaccharide type 3 vaccine / pneumococcal capsular polysaccharide type 33F vaccine / pneumococcal capsular polysaccharide type 4 vaccine / pneumococcal capsular polysaccharide type 5 vaccine / pneumococcal capsular polysaccharide type 6B vaccine / pneumococcal capsular polysaccharide type 7F vaccine / pneumococcal capsular polysaccharide type 8 vaccine / pneumococcal capsular polysaccharide type 9N vaccine / pneumococcal capsular polysaccharide type 9V vaccine Injection [Pneumovax 23] CUI: C4033793 RXAUI: 7253076 TUI: T200 Pneumovax 23 Injection Kallan Roan, Oliver He Pneumovax 23 (Pneumococcal vaccine polyvalent) 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/1658472 1658472 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML Injection [Pneumovax 23] CUI: C3887855 RXAUI: 7253077, 7253108, 7253095 RXN STRENGTH: 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML TUI: T200 PNEUMOVAX 23 0.5 ML Injection Kallan Roan, Oliver He Pneumovax 23 (Pneumococcal vaccine polyvalent) Injectable Solution http://purl.bioontology.org/ontology/RXNORM/854981 854981 pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23] CUI: C1154308 RXAUI: 2977679, 7253371, 3270831 RXN STRENGTH: 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML TUI: T200 PNEUMOVAX 23 vaccine Injectable Solution Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1547581 1547581 pneumococcal capsular polysaccharide type 1 vaccine / pneumococcal capsular polysaccharide type 10A vaccine / pneumococcal capsular polysaccharide type 11A vaccine / pneumococcal capsular polysaccharide type 12F vaccine / pneumococcal capsular polysaccharide type 14 vaccine / pneumococcal capsular polysaccharide type 15B vaccine / pneumococcal capsular polysaccharide type 17F vaccine / pneumococcal capsular polysaccharide type 18C vaccine / pneumococcal capsular polysaccharide type 19A vaccine / pneumococcal capsular polysaccharide type 19F vaccine / pneumococcal capsular polysaccharide type 2 vaccine / pneumococcal capsular polysaccharide type 20 vaccine / pneumococcal capsular polysaccharide type 22F vaccine / pneumococcal capsular polysaccharide type 23F vaccine / pneumococcal capsular polysaccharide type 3 vaccine / pneumococcal capsular polysaccharide type 33F vaccine / pneumococcal capsular polysaccharide type 4 vaccine / pneumococcal capsular polysaccharide type 5 vaccine / pneumococcal capsular polysaccharide type 6B vaccine / pneumococcal capsular polysaccharide type 7F vaccine / pneumococcal capsular polysaccharide type 8 vaccine / pneumococcal capsular polysaccharide type 9N vaccine / pneumococcal capsular polysaccharide type 9V vaccine Prefilled Syringe [Pneumovax 23] CUI: C3855233 RXAUI: 6400287 TUI: T200 PNEUMOVAX 23 vaccine Prefilled Syringe Kallan Roan, Oliver He Pneumovax 23 (Pneumococcal vaccine polyvalent) 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1547582 0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML Prefilled Syringe [Pneumovax 23] CUI: C3853732 RXAUI: 7253508, 6400288, 6400291 RXN STRENGTH: 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML / 0.05 MG/ML TUI: T200 PNEUMOVAX 23 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1177656 1177656 CUI: C3231573 RXAUI: 3844071 RXN STRENGTH: 0.0044 MG/ML / 0.0044 MG/ML / 0.0044 MG/ML / 0.0044 MG/ML / 0.0044 MG/ML / 0.0088 MG/ML / 0.0044 MG/ML / 0.0044 MG/ML TUI: T200 Prevnar 13 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901643 901643 Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe [Prevnar 13] CUI: C2746125 RXAUI: 3060990 TUI: T200 Prevnar 13 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854967 854967 CUI: C2709771 RXAUI: 2977666 pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1179526 1179526 CUI: C3233397 RXAUI: 3844185 TUI: T200 ProQuad Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658000 1658000 Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [ProQuad] CUI: C4033818 RXAUI: 7252149 TUI: T200 ProQuad vaccine Injection Kallan Roan, Oliver He ProQuad Measles, Mumps, Rubella, and Varicella Virus Vaccine Live 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/1292443 1292443 0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML Injection [ProQuad] CUI: C1698231 RXAUI: 7252150, 7250950, 7253644 TUI: T200 ProQuad vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854979 854979 CUI: C2709781 RXAUI: 2977677 TUI: T200 pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML [Pneumovax 23] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901642 901642 CUI: C2746124 RXAUI: 3060989 TUI: T200 Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML [Prevnar 13] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1292441 1292441 CUI: C2364511 RXAUI: 4609906 TUI: T200 Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML [ProQuad] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658703 1658703 CUI: C4033722 RXAUI: 7253467 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427028 1427028 CUI: C3645245 RXAUI: 5473440 TUI: T116, T121 Fluzone Quadrivalent 2013-2014 Formula Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658712 1658712 CUI: C4033721 RXAUI: 7253478 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML [Fluzone 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658713 1658713 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2015-2016] CUI: C4033789 RXAUI: 7253479 TUI: T200 Fluzone 2015-2016 High-Dose vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658714 1658714 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2015-2016] CUI: C4026367 RXAUI: 7253480, 7253494, 7707297 TUI: T200 Fluzone 2015-2016 High-Dose vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He Fluzone 2015-2016 45 MCG (15 MCG x 3) in 0.5 ML Injectable Suspension http://purl.bioontology.org/ontology/RXNORM/1658706 1658706 CUI: C4033789 RXAUI: 7264732, 7253470, 7264735 TUI: T200 Fluzone 2015-2016 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801179 1801179 CUI: C4271565 RXAUI: 8237155 TUI: T116, T129, T121 Fluzone 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801180 1801180 CUI: C4271631 RXAUI: 8237156 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML [Fluzone 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801182 1801182 CUI: C4271735 RXAUI: 8237158 TUI: T200 Fluzone 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801181 1801181 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2016-2017] CUI: C4271674 RXAUI: 8237157 TUI: T200 Fluzone 2016-2017 High-Dose vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801183 1801183 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2016-2017] CUI: C4270825 RXAUI: 8237163, 8237162, 8237159 TUI: T200 Fluzone 2016-2017 High-Dose vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928340 1928340 CUI: C4490427 RXAUI: 9198824 TUI: T116 Fluzone 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928343 1928343 CUI: C4490430 RXAUI: 9198827 TUI: T200 Fluzone 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928341 1928341 CUI: C4490428 RXAUI: 9198825 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML [Fluzone 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928342 1928342 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2017-2018] CUI: C4490429 RXAUI: 9198826 TUI: T200 Fluzone 2017-2018 high-dose vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928344 1928344 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2017-2018] CUI: C4325062 RXAUI: 9198828, 9198831, 9198832 TUI: T200 Fluzone 2017-2018 high-dose vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050419 2050419 CUI: C4719042 RXAUI: 10289780 TUI: T109 Fluzone 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050422 2050422 CUI: C4719045 RXAUI: 10289783 RXN STRENGTH: 0.12 MG/ML (expressed as influenza A virus A/Michigan/45/2015 (H1N1) antigen) / 0.12 MG/ML (expressed as influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen) / 0.12 MG/ML (expressed as influenza B virus B/Maryland/15/2016 antigen) TUI: T200 Fluzone 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050420 2050420 CUI: C4719043 RXAUI: 10289781 TUI: T200 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML [Fluzone 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050421 2050421 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2018-2019] CUI: C4719044 RXAUI: 10289782 TUI: T200 Fluzone 2018-2019 high-dose vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050423 2050423 0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2018-2019] CUI: C4719046 RXAUI: 10289784, 10289785, 10289786 TUI: T200 Fluzone 2018-2019 high-dose vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1794331 1794331 CUI: C4256803 RXAUI: 8222490 TUI: T116, T129, T121 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928289 1928289 CUI: C4490394 RXAUI: 9198755 TUI: T116, T129, T121 influenza A virus A/Michigan/45/2015 (H1N1) antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048564 2048564 CUI: C4704008 RXAUI: 10279285 TUI: T116, T129, T121 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048563 2048563 CUI: C4704007 RXAUI: 10279284 TUI: T116, T129, T121 influenza B virus B/Maryland/15/2016 antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050417 2050417 CUI: C4719040 RXAUI: 10289778 RXN STRENGTH: 0.12 MG/ML TUI: T200 influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928338 1928338 CUI: C4490425 RXAUI: 9198822 RXN STRENGTH: 0.12 MG/ML TUI: T200 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050416 2050416 CUI: C4719039 RXAUI: 10289777 RXN STRENGTH: 0.12 MG/ML TUI: T200 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801176 1801176 CUI: C4271783 RXAUI: 8237152 RXN STRENGTH: 0.12 MG/ML TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427031 1427031 CUI: C3645248 RXAUI: 5473443 TUI: T200 Fluzone Quadrivalent 2013-2014 Formula Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427029 1427029 CUI: C3645246 RXAUI: 5473441 TUI: T200 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / Influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone Quadrivalent 2013-2014 Formula] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427038 1427038 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Brisbane-60-2008-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula] CUI: C3645252 RXAUI: 5473453 TUI: T200 Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1427052 1427052 0.25 ML Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / Influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula] CUI: C3537276 RXAUI: 5488148, 5473470, 5473464 TUI: T200 Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537557 1537557 CUI: C3817309 RXAUI: 6338534 TUI: T116, T121 Fluzone Quadrivalent 2014-2015 Formula Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537560 1537560 CUI: C3819823 RXAUI: 6338537 TUI: T200 Fluzone Quadrivalent 2014-2015 Formula Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1598360 1598360 CUI: C3872179 RXAUI: 6821895 TUI: T200 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Quadrivalent 2014-2015 Formula] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537559 1537559 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Brisbane-60-2008-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula] CUI: C3819658 RXAUI: 6338536 TUI: T200 Fluzone Quadrivalent 2014-2015 Formula Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1598361 1598361 0.1 ML Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula] CUI: C3871481 RXAUI: 6821896, 6821899 TUI: T200 Fluzone Quadrivalent 2014-2015 Formula 0.1 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659725 1659725 CUI: C4026655 RXAUI: 7255357 TUI: T116, T129, T121 Fluzone Quadrivalent 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659728 1659728 CUI: C4047088 RXAUI: 7255360 TUI: T200 Fluzone Quadrivalent 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659726 1659726 CUI: C4046959 RXAUI: 7255358 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661112 1661112 CUI: C4046937 RXAUI: 7258293 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659747 1659747 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2015-2016] CUI: C4047035 RXAUI: 7255391 TUI: T200 Fluzone Quadrivalent 2015-2016 Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659748 1659748 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2015-2016] CUI: C4046210 RXAUI: 7255392, 7707326 TUI: T200 Fluzone Quadrivalent 2015-2016 vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659729 1659729 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2015-2016] CUI: C4018869 RXAUI: 7707300, 7255361 TUI: T200 Fluzone Quadrivalent 2015-2016 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659736 1659736 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2015-2016] CUI: C4047037 RXAUI: 7255373 TUI: T200 Fluzone Quadrivalent 2015-2016 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661113 1661113 0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016] CUI: C4032740 RXAUI: 7707304, 7258294 TUI: T200 Fluzone Quadrivalent 2015-2016 vaccine 0.1 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659755 1659755 0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016] CUI: C4026368 RXAUI: 7255401, 7707633 TUI: T200 Fluzone Quadrivalent 2015-2016 vaccine 0.25 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659737 1659737 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016] CUI: C4046211 RXAUI: 7707379, 7255374 TUI: T200 Fluzone Quadrivalent 2015-2016 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801071 1801071 CUI: C4224224 RXAUI: 8236907 TUI: T116, T129, T121 Fluzone Quadrivalent 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801074 1801074 CUI: C4271738 RXAUI: 8236910 TUI: T200 Fluzone Quadrivalent 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801173 1801173 CUI: C4271632 RXAUI: 8237145 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801072 1801072 CUI: C4271637 RXAUI: 8236908 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801188 1801188 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2016-2017] CUI: C4271673 RXAUI: 8237172 TUI: T200 Fluzone Quadrivalent 2016-2017 Formula Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801189 1801189 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2016-2017] CUI: C4270930 RXAUI: 8237177, 8237176, 8237173 RXN STRENGTH: 0.03 MG/ML (expressed as influenza A virus A/California/7/2009 (H1N1) antigen) / 0.03 MG/ML (expressed as influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen) / 0.03 MG/ML (expressed as influenza B virus B/Brisbane/60/2008 antigen) / 0.03 MG/ML (expressed as influenza B virus B/Phuket/3073/2013 antigen) TUI: T200 Fluzone Quadrivalent 2016-2017 Formula 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801193 1801193 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2016-2017] CUI: C4224210 RXAUI: 8237184, 8237186, 8237185 RXN STRENGTH: 0.03 MG/ML (expressed as influenza A virus A/California/7/2009 (H1N1) antigen) / 0.03 MG/ML (expressed as influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen) / 0.03 MG/ML (expressed as influenza B virus B/Brisbane/60/2008 antigen) / 0.03 MG/ML (expressed as influenza B virus B/Phuket/3073/2013 antigen) TUI: T200 Fluzone Quadrivalent 2016-2017 Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801073 1801073 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2016-2017] CUI: C4271678 RXAUI: 8236909 TUI: T200 Fluzone Quadrivalent 2016-2017 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801075 1801075 0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017] CUI: C4270829 RXAUI: 8236914, 8237166, 8236911 TUI: T200 Fluzone Quadrivalent 2016-2017 vaccine 0.1 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801174 1801174 0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017] CUI: C4224209 RXAUI: 8237169, 8237148, 8237146 TUI: T200 Fluzone Quadrivalent 2016-2017 vaccine 0.25 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801186 1801186 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017] CUI: C4270931 RXAUI: 8237168, 8237167, 8237165 TUI: T200 Fluzone Quadrivalent 2016-2017 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928313 1928313 CUI: C4325215 RXAUI: 9198781 TUI: T116, T129, T121 Fluzone Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928316 1928316 CUI: C4490411 RXAUI: 9198784 TUI: T200 Fluzone Quadrivalent 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928314 1928314 CUI: C4490409 RXAUI: 9198782 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928469 1928469 CUI: C4490475 RXAUI: 9199188 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928315 1928315 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2017-2018] CUI: C4490410 RXAUI: 9198783 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928317 1928317 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2017-2018] CUI: C4490412 RXAUI: 9198785, 9198856, 9198855 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928356 1928356 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2017-2018] CUI: C4319521 RXAUI: 9198884, 9198850, 9198885 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928331 1928331 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2017-2018] CUI: C4490420 RXAUI: 9198810 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928359 1928359 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018] CUI: C4490439 RXAUI: 9198872, 9198871, 9198873 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928332 1928332 0.25 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018] CUI: C4325067 RXAUI: 9198880, 9198881, 9198811 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine 0.25 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928470 1928470 0.1 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018] CUI: C4325068 RXAUI: 9199192, 9199191, 9199189 TUI: T200 Fluzone Quadrivalent 2017-2018 vaccine 0.1 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050773 2050773 CUI: C4719179 RXAUI: 10290520 TUI: T116, T129, T121 Fluzone Quadrivalent 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050776 2050776 CUI: C4719182 RXAUI: 10290523 TUI: T200 Fluzone Quadrivalent 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050774 2050774 CUI: C4719180 RXAUI: 10290521 TUI: T200 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050781 2050781 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2018-2019] CUI: C4719187 RXAUI: 10290530 TUI: T200 Fluzone Quadrivalent 2018-2019 vaccine Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050782 2050782 0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2018-2019] CUI: C4719188 RXAUI: 10290531, 10290534, 10290535 TUI: T200 Fluzone Quadrivalent 2018-2019 vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050787 2050787 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2018-2019] CUI: C4553813 RXAUI: 10290540, 10290538, 10290539 TUI: T200 Fluzone Quadrivalent 2018-2019 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050775 2050775 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2018-2019] CUI: C4719181 RXAUI: 10290522 TUI: T200 Fluzone Quadrivalent 2018-2019 Vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050789 2050789 0.25 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2018-2019] CUI: C4719194 RXAUI: 10290543, 10290544, 10290545 TUI: T200 Fluzone Quadrivalent Pediatric Dose for 6-35 Months of Age 2018-2019 Vaccine 0.25 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050777 2050777 0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2018-2019] RXAUI: 10290524, 10290528, 10290527 TUI: T200 Fluzone Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe CUI: C4719183 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660922 1660922 CUI: C4047148 RXAUI: 7258095 TUI: T200 influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1794431 1794431 CUI: C4257282 RXAUI: 8222590 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801069 1801069 CUI: C4271787 RXAUI: 8236905 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928310 1928310 CUI: C4490406 RXAUI: 9198778 TUI: T200 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928291 1928291 CUI: C4490396 RXAUI: 9198757 TUI: T200 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048958 2048958 CUI: C4704185 RXAUI: 10279935 TUI: T200 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048959 2048959 CUI: C4704186 RXAUI: 10279936 TUI: T200 influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Kallan Roan, Oliver He RXAUI: 3850144 http://purl.bioontology.org/ontology/RXNORM/1186641 1186641 CUI: C3240393 TUI: T200 YF-Vax Injectable Product Kallan Roan, Oliver He 1658240 Yellow-Fever Virus Vaccine, 17D-204 strain Injection [YF-Vax] CUI: C4033799 RXAUI: 7252581 TUI: T200 YF-VAX Injection Kallan Roan, Oliver He 0.5 ML YF-Vax 4000 UNT/ML Injection http://purl.bioontology.org/ontology/RXNORM/1658241 1658241 0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injection [YF-Vax] CUI: C4019051 RXAUI: 7252591, 7252583, 7252590, 7252582 TUI: T200 YF-VAX 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1292828 1292828 YF-Vax 4000 UNT/ML Injectable Suspension CUI: C0710788 RXAUI: 4610776, 4610775, 7251861 TUI: T200 YF-Vax 4000 UNT/ML Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1292827 1292827 Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Suspension [YF-Vax] CUI: C2356379 RXAUI: 4610774 TUI: T200 YF-Vax Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804191 804191 CUI: C2356378 RXAUI: 2860284 TUI: T200 Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML [YF-Vax] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1184551 1184551 CUI: C3238354 RXAUI: 3843231 TUI: T200 PedvaxHIB Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798449 798449 CUI: C2344386 RXAUI: 2851572 TUI: T200 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML [PedvaxHIB] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657733 1657733 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injection [PedvaxHIB] CUI: C4033832 RXAUI: 7251648 TUI: T200 PedvaxHIB vaccine Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798451 798451 0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML Injection [PedvaxHIB] CUI: C1237239 RXAUI: 7251650, 7251649, 7253595, 7251196 TUI: T200 PedvaxHIB vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657326 1657326 CUI: C4026630 RXAUI: 7251220 TUI: T116, T129, T121 Fluvirin 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657329 1657329 CUI: C4033912 RXAUI: 7251223 TUI: T200 Fluvirin 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657327 1657327 CUI: C4033751 RXAUI: 7251221 TUI: T200 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluvirin 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657330 1657330 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluvirin 2015-2016] CUI: C4026364 RXAUI: 7251224, 7251264 TUI: T200 Fluvirin 2015-2016 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659982 1659982 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluvirin 2015-2016] CUI: C4047024 RXAUI: 7255800 TUI: T200 Fluvirin 2015-2016 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659983 1659983 0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2015-2016] CUI: C4026365 RXAUI: 7255801, 7255804 TUI: T200 Fluvirin 2015-2016 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801153 1801153 CUI: C4224219 RXAUI: 8237127 TUI: T116, T129, T121 Fluvirin 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801156 1801156 CUI: C4271736 RXAUI: 8237130 TUI: T200 Fluvirin 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801154 1801154 CUI: C4271633 RXAUI: 8237128 TUI: T200 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluvirin 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801157 1801157 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension [Fluvirin 2016-2017] CUI: C4224195 RXAUI: 8237131, 8237133, 8237132 TUI: T200 Fluvirin 2016-2017 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801162 1801162 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluvirin 2016-2017] CUI: C4271675 RXAUI: 8237137 TUI: T200 Fluvirin 2016-2017 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801163 1801163 0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2016-2017] CUI: C4270826 RXAUI: 8237141, 8237142, 8237138 TUI: T200 Fluvirin 2016-2017 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928970 1928970 CUI: C4325210 RXAUI: 9199995 TUI: T116, T129, T121 Fluvirin 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928973 1928973 CUI: C4490746 RXAUI: 9199998 TUI: T200 Fluvirin 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928971 1928971 CUI: C4490744 RXAUI: 9199996 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluvirin 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928974 1928974 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension [Fluvirin 2017-2018] CUI: C4325059 RXAUI: 9200000, 9199999, 9200001 TUI: T200 Fluvirin 2017-2018 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928978 1928978 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluvirin 2017-2018] CUI: C4490747 RXAUI: 9200007 TUI: T200 Fluvirin 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928982 1928982 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2017-2018] CUI: C4325061 RXAUI: 9200013, 9200018, 9200017 TUI: T200 Fluvirin 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657232 1657232 CUI: C4026648 RXAUI: 7251209 TUI: T116, T129, T121 Fluarix Quadrivalent 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657235 1657235 CUI: C4033913 RXAUI: 7251212 TUI: T200 Fluarix Quadrivalent 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657233 1657233 CUI: C4033752 RXAUI: 7251210 TUI: T200 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657234 1657234 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2015-2016] CUI: C4033850 RXAUI: 7251211 TUI: T200 FLUARIX QUADRIVALENT 2015-2016 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657236 1657236 0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2015-2016] CUI: C4026362 RXAUI: 7707241, 7251213 TUI: T200 FLUARIX QUADRIVALENT 2015-2016 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799119 1799119 CUI: C4224221 RXAUI: 8233865 TUI: T116, T129, T121 Fluarix Quadrivalent 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799122 1799122 CUI: C4271754 RXAUI: 8233868 TUI: T200 Fluarix Quadrivalent 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799120 1799120 CUI: C4271658 RXAUI: 8233866 TUI: T200 influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799121 1799121 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2016-2017] CUI: C4271699 RXAUI: 8233867 TUI: T200 FLUARIX QUADRIVALENT 2016-2017 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799123 1799123 0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2016-2017] CUI: C4224206 RXAUI: 8233903, 8233902, 8233869 TUI: T200 FLUARIX QUADRIVALENT 2016-2017 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928303 1928303 CUI: C4490400 RXAUI: 9198769 TUI: T116, T129, T121 Fluarix Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928306 1928306 CUI: C4490403 RXAUI: 9198772 TUI: T200 Fluarix Quadrivalent 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928304 1928304 CUI: C4490401 RXAUI: 9198770 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928305 1928305 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2017-2018] CUI: C4490402 RXAUI: 9198771 TUI: T200 Fluarix Quadrivalent 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928307 1928307 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2017-2018] CUI: C4325064 RXAUI: 9198814, 9198808, 9198773 TUI: T200 Fluarix Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048962 2048962 CUI: C4704189 RXAUI: 10279939 TUI: T116, T129, T121 Fluarix Quadrivalent 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048965 2048965 CUI: C4704192 RXAUI: 10279942 TUI: T200 Fluarix Quadrivalent 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048963 2048963 CUI: C4704190 RXAUI: 10279940 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048964 2048964 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2018-2019] CUI: C4704191 RXAUI: 10279941 TUI: T200 FLUARIX QUADRIVALENT 2018-2019 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048966 2048966 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2018-2019] CUI: C4704193 RXAUI: 10279943, 10279945, 10279944 TUI: T200 FLUARIX QUADRIVALENT 2018-2019 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928290 1928290 CUI: C4490395 RXAUI: 9198756 TUI: T116, T129, T121 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928300 1928300 CUI: C4490397 RXAUI: 9198766 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661803 1661803 CUI: C4020099 RXAUI: 7264715 TUI: T129, T121 Afluria 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661806 1661806 CUI: C4047061 RXAUI: 7264718 TUI: T200 Afluria 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661804 1661804 CUI: C4046916 RXAUI: 7264716 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661812 1661812 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria 2015-2016] CUI: C4018775 RXAUI: 7264729, 7707306, 7264733 TUI: T200 afluria 2015-2016 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661805 1661805 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2015-2016] CUI: C4046988 RXAUI: 7264717 TUI: T200 Afluria 2015-2016 Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1661807 1661807 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2015-2016] CUI: C4018774 RXAUI: 7264719, 7264723, 7707305 TUI: T200 Afluria 2015-2016 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799399 1799399 CUI: C4224216 RXAUI: 8234382 TUI: T116, T129, T121 Afluria 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799402 1799402 CUI: C4271746 RXAUI: 8234385 TUI: T200 Afluria 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799400 1799400 CUI: C4271652 RXAUI: 8234383 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Afluria 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799413 1799413 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension [Afluria 2016-2017] CUI: C4224196 RXAUI: 8234404, 8234405, 8234406 TUI: T200 Afluria 2016-2017 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799401 1799401 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2016-2017] CUI: C4271691 RXAUI: 8234384 TUI: T200 Afluria 2016-2017 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799403 1799403 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2016-2017] CUI: C4224214 RXAUI: 8236926, 8234386, 8236927 TUI: T200 afluria 2016-2017 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942128 1942128 CUI: C4325193 RXAUI: 9267473 TUI: T129, T121 Afluria 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942131 1942131 CUI: C4519949 RXAUI: 9267476 TUI: T200 Afluria 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942129 1942129 CUI: C4519947 RXAUI: 9267474 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML [Afluria 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942158 1942158 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Injectable Suspension [Afluria 2017-2018] CUI: C4325058 RXAUI: 9267492, 9267490, 9267491 TUI: T200 Afluria 2017-2018 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942130 1942130 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2017-2018] CUI: C4519948 RXAUI: 1942130 TUI: T200 Afluria 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942132 1942132 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2017-2018] CUI: C4325060 RXAUI: 9267481, 9267480, 9267477 TUI: T200 Afluria 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050767 2050767 CUI: C4719173 RXAUI: 10290502 TUI: T116, T129, T121 Afluria 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050770 2050770 CUI: C4719176 RXAUI: 10290505 TUI: T200 Afluria 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050768 2050768 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Afluria 2018-2019] CUI: C4719174 RXAUI: 10290503 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Afluria 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050771 2050771 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Injectable Suspension [Afluria 2018-2019] CUI: C4719177 RXAUI: 10290510, 10290509, 10290506 TUI: T200 afluria 2018-2019 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050802 2050802 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2018-2019] CUI: C4719203 RXAUI: 10290573 TUI: T200 Afluria 2018-2019 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050803 2050803 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2018-2019] CUI: C4719204 RXAUI: 10292876, 10290577, 10292877 TUI: T200 Afluria 2018-2019 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1858962 1858962 CUI: C4293490 RXAUI: 8698886 TUI: T200 Afluria Quadrivalent 2016-2017 Formula Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1858960 1858960 CUI: C4293406 RXAUI: 8698884 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2016-2017 Formula] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1858966 1858966 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2016-2017 Formula] CUI: C4293383 RXAUI: 8698910, 8698890, 8698911 TUI: T200 Afluria Quadrivalent 2016-2017 Formula Influenza Virus Vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1858961 1858961 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2016-2017 Formula] CUI: C4293449 RXAUI: 8698885 TUI: T200 Afluria Quadrivalent 2016-2017 Formula Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1858963 1858963 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2016-2017 Formula] CUI: C4283663 RXAUI: 8698892, 8698891, 8698887 TUI: T200 Afluria Quadrivalent 2016-2017 Formula 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1858959 1858959 CUI: C4293360 RXAUI: 8698883 TUI: T116, T129, T121 Afluria Quadrivalent 2016-2017 Formula Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942162 1942162 CUI: C4325196 RXAUI: 9267495 TUI: T129, T121 Afluria Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942165 1942165 CUI: C4519959 RXAUI: 9267498 TUI: T200 Afluria Quadrivalent 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942163 1942163 CUI: C4519957 RXAUI: 9267496 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942173 1942173 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2017-2018] CUI: C4325066 RXAUI: 9267520, 9267517, 9267516 TUI: T200 Afluria Quadrivalent 2017-2018 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942164 1942164 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2017-2018] CUI: C4519958 RXAUI: 9267497 TUI: T200 Afluria Quadrivalent 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1942166 1942166 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2017-2018] CUI: C4325063 RXAUI: 9272502, 9267499, 9272501 TUI: T200 Afluria Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050791 2050791 CUI: C4719195 RXAUI: 10290555 TUI: T116, T129, T121 Afluria Quadrivalent 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050794 2050794 CUI: C4719198 RXAUI: 10290558 TUI: T200 Afluria Quadrivalent 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050792 2050792 CUI: C4719196 RXAUI: 10290556 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050795 2050795 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2018-2019] CUI: C4553815 RXAUI: 10322944, 10290561, 10290559 TUI: T200 Afluria Quadrivalent 2018-2019 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050796 2050796 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2018-2019] CUI: C4719199 RXAUI: 10290562 TUI: T200 Afluria Quadrivalent 2018-2019 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050797 2050797 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2018-2019] CUI: C4553814 RXAUI: 10322943, 10322942, 10290563 TUI: T200 Afluria Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799102 1799102 CUI: C4224220 RXAUI: 8233849 TUI: T116, T129, T121 Flulaval Quadrivalent 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799105 1799105 CUI: C4271755 RXAUI: 8233852 TUI: T200 Flulaval Quadrivalent 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799103 1799103 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2016-2017] CUI: C4271659 RXAUI: 8233850 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799205 1799205 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2016-2017] CUI: C4224211 RXAUI: 1799205 TUI: T200 FLULAVAL QUADRIVALENT 2016-2017 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799104 1799104 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2016-2017] CUI: C4271700 RXAUI: 8233851 TUI: T200 Flulaval Quadrivalent 2016-2017 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799106 1799106 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2016-2017] CUI: C4255281 RXAUI: 8233853, 8233905, 8233906 TUI: T200 Flulaval Quadrivalent 2016-2017 vaccine 0.5 Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657335 1657335 CUI: C4026650 RXAUI: 7251229 TUI: T116, T129, T121 FluLaval Quadrivalent 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657338 1657338 CUI: C4033911 RXAUI: 7251232 TUI: T200 FluLaval Quadrivalent 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657336 1657336 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [FluLaval Quadrivalent 2015-2016] CUI: C4033750 RXAUI: 7251230 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [FluLaval Quadrivalent 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657339 1657339 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [FluLaval Quadrivalent 2015-2016] CUI: C4018811 RXAUI: 7251233, 7707287 TUI: T200 FLULAVAL QUADRIVALENT 2015-2016 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928325 1928325 CUI: C4325209 RXAUI: 9198793 TUI: T116, T129, T121 Flulaval Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928328 1928328 CUI: C4490418 RXAUI: 9198796 TUI: T200 Flulaval Quadrivalent 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928326 1928326 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2017-2018] CUI: C4490416 RXAUI: 9198794 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928329 1928329 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2017-2018] CUI: C4319520 RXAUI: 9198867, 9198866, 9198797 TUI: T200 FLULAVAL QUADRIVALENT 2017-2018 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928335 1928335 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2017-2018] CUI: C4490423 RXAUI: 9198815 TUI: T200 Flulaval Quadrivalent 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928336 1928336 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2017-2018] CUI: C4319519 RXAUI: 9198862, 9198816, 9198863 TUI: T200 Flulaval Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048970 2048970 CUI: C4704197 RXAUI: 10279949 TUI: T116, T129, T121 Flulaval Quadrivalent 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048973 2048973 CUI: C4704200 RXAUI: 10279952 TUI: T200 Flulaval Quadrivalent 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048971 2048971 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2018-2019] CUI: C4704198 RXAUI: 10279950 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2018-2019] Kallan Roan, Oliver He 2048974 http://purl.bioontology.org/ontology/RXNORM/2048974 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2018-2019] CUI: C4552692 RXAUI: 10279953, 10279956, 10279954 TUI: T200 Flulaval Quadrivalent 2018-2019 vaccine Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048975 2048975 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2018-2019] CUI: C4704201 RXAUI: 10279957 TUI: T200 Flulaval Quadrivalent 2018-2019 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2048976 2048976 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2018-2019] CUI: C4552691 RXAUI: 10279960, 10279959, 10279958 TUI: T200 Flulaval Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657140 1657140 CUI: C4026649 RXAUI: 7251081 TUI: T116, T129, T121 Flucelvax 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657143 1657143 CUI: C4033914 RXAUI: 7251084 TUI: T200 Flucelvax 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657141 1657141 influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax 2015-2016] CUI: C4033757 RXAUI: 7251082 TUI: T200 influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657142 1657142 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax 2015-2016] CUI: C4033857 RXAUI: 7251083 TUI: T200 FLUCELVAX 2015-2016 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657144 1657144 0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax 2015-2016] CUI: C4026363 RXAUI: 7251085, 8725354, 7707232 TUI: T200 FLUCELVAX 2015-2016 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801607 1801607 CUI: C4276115 RXAUI: 8238453 TUI: T129, T121 Flucelvax Quadrivalent 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801610 1801610 CUI: C4276265 RXAUI: 8238456 TUI: T200 Flucelvax Quadrivalent 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801608 1801608 influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2016-2017] CUI: C4276184 RXAUI: 8238454 TUI: T200 influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801609 1801609 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2016-2017] CUI: C4276248 RXAUI: 8238455 TUI: T200 FLUCELVAX QUADRIVALENT 2016-2017 Prefilled Syringe Kallan Roan, Oliver He 1801611 0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2016-2017] CUI: C4256265 RXAUI: 8238461, 8238460, 8238457 TUI: T200 FLUCELVAX QUADRIVALENT 2016-2017 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801603 1801603 CUI: C4276030 RXAUI: 8238449 TUI: T116, T129, T121 influenza B virus B/Hong Kong/259/2010 antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801604 1801604 CUI: C4276333 RXAUI: 8238450 TUI: T200 influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928533 1928533 CUI: C4325207 RXAUI: 9199341 TUI: T116, T129, T121 Flucelvax Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928536 1928536 CUI: C4490504 RXAUI: 9199344 TUI: T200 Flucelvax Quadrivalent 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928534 1928534 CUI: C4490502 RXAUI: 9199342 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928537 1928537 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2017-2018] CUI: C4490505 RXAUI: 9199345, 9199362, 9199359 TUI: T200 FLUCELVAX Quadrivalent 2017-2018 Injectable Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928539 1928539 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2017-2018] CUI: C4490507 RXAUI: 9199347 TUI: T200 Flucelvax Quadrivalent 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928540 1928540 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2017-2018] CUI: C4325069 RXAUI: 9199352, 9199361, 9199348 TUI: T200 Flucelvax Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1986826 1986826 CUI: C4530100 RXAUI: 9698281 TUI: T129, T121 Shingrix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1986827 1986827 CUI: C4530101 RXAUI: 9698282 TUI: T200 Varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML [Shingrix] Kallan Roan, Oliver He 0.5 ML Shingrix 0.1 MG/ML Injection http://purl.bioontology.org/ontology/RXNORM/1986830 1986830 0.5 ML Varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection [Shingrix] RXAUI: 9698706, 9698285, 9698287, 9698286 TUI: T200 Shingrix vaccine 0.5 ML Injection 0.5 ML Shingrix 0.1 MG/ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1986821 1986821 CUI: C0061673 RXAUI: 9698276 TUI: T116, T129, T121 Varicella zoster virus glycoprotein E Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1986820 1986820 CUI: C4530095 RXAUI: 9698275 TUI: T116, T129, T121 Varicella zoster virus glycoprotein E, recombinant http://purl.bioontology.org/ontology/RXNORM/1986822 1986822 CUI: C4530096 RXAUI: 9698277 TUI: T200 Varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML http://purl.bioontology.org/ontology/RXNORM/1664639 1664639 CUI: C4026651 RXAUI: 7266972 TUI: T116, T129, T121 influenza A virus A/Bolivia/559/2013 (H1N1) antigen http://purl.bioontology.org/ontology/RXNORM/1664467 1664467 CUI: C4050818 RXAUI: 7266777 TUI: T200 influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML http://purl.bioontology.org/ontology/RXNORM/1664639 1664639 CUI: C4026651 RXAUI: 7266972 TUI: T116, T129, T121 Flumist 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801825 1801825 CUI: C4276113 RXAUI: 8238995 TUI: T116, T129, T121 Flumist Quadrivalent 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946970 1946970 CUI: C4529647 RXAUI: 9278624 TUI: T116, T129, T121 Flumist Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1664644 1664644 influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray [Flumist 2015-2016] CUI: C4026361 RXAUI: 7266797, 7266977, 7266796 TUI: T200 FluMist Quadrivalent, 2015-2016 Formula Nasal Spray Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1664640 1664640 CUI: C4050879 RXAUI: 7266973 TUI: T200 influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML [Flumist 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801767 1801767 CUI: C4276025 RXAUI: 8238906 TUI: T116, T129, T121 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801822 1801822 CUI: C4276331 RXAUI: 8238992 TUI: T200 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801826 1801826 CUI: C4276182 RXAUI: 8238996 TUI: T200 influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML [Flumist Quadrivalent 2016-2017] Kallan Roan, Oliver He FluMist Quadrivalent, Live Attenuated, 2016-2017 Formula Nasal Spray http://purl.bioontology.org/ontology/RXNORM/1801830 1801830 influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray [Flumist Quadrivalent 2016-2017] CUI: C4224207 RXAUI: 8239001, 8239002, 8239000 TUI: T200 FluMist Quadrivalent, 2016-2017 Formula Nasal Spray Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946985 1946985 CUI: C4529659 RXAUI: 9278648 TUI: T200 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [Flumist Quadrivalent 2017-2018] Kallan Roan, Oliver He FluMist Quadrivalent, Live Attenuated, 2017-2018 Formula Nasal Spray http://purl.bioontology.org/ontology/RXNORM/1946986 1946986 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [Flumist Quadrivalent 2017-2018] CUI: C4522486 RXAUI: 9278652, 9278649, 9278653 TUI: T200 FluMist Quadrivalent, 2017-2018 Formula Nasal Spray Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946980 1946980 CUI: C4529654 RXAUI: 9278643 TUI: T200 influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946964 1946964 CUI: C4522494 RXAUI: 9278618 TUI: T116, T129, T121 influenza A virus A/Slovenia/2903/2015 (H1N1) antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1946981 1946981 CUI: C4529655 RXAUI: 9278644 TUI: T200 influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2054182 2054182 CUI: C4719703 RXAUI: 10329701 TUI: T116, T129, T121 Flumist Quadrivalent 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2054177 2054177 CUI: C4719701 RXAUI: 10329696 TUI: T116, T129, T121 influenza B virus B/Colorado/06/2017 antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2054271 2054271 CUI: C4719748 RXAUI: 10329902 TUI: T200 influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML http://purl.bioontology.org/ontology/RXNORM/2054273 2054273 CUI: C4719750 RXAUI: 10329904 TUI: T200 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [Flumist Quadrivalent 2018-2019] FluMist Quadrivalent, Live Attenuated, 2018-2019 Formula Nasal Spray http://purl.bioontology.org/ontology/RXNORM/2054274 2054274 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [Flumist Quadrivalent 2018-2019] CUI: C4719751 RXAUI: 10329907, 10329905, 10329906 TUI: T200 FluMist Quadrivalent, 2018-2019 Formula Nasal Spray Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2054270 2054270 CUI: C4719747 RXAUI: 10329901 TUI: T200 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1166526 1166526 CUI: C3220746 RXAUI: 3837627 TUI: T200 Havrix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798365 798365 CUI: C2344345 RXAUI: 2851478 TUI: T200 Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML [Havrix] Kallan Roan, Oliver He 0.5 ML Havrix 1440 UNT/ML Injection Havrix 720 UNT per 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/1658066 1658066 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injection [Havrix] CUI: C3888157 RXAUI: 7252248, 7252247, 7253517, 7252251 TUI: T200 HAVRIX pediatric/adolescent vaccine 720 UNT in 0.5 ML Injection Kallan Roan, Oliver He 1 ML Havrix 1440 UNT/ML Injection Havrix 1440 UNT per 1 ML Injection http://purl.bioontology.org/ontology/RXNORM/1658060 1658060 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injection [Havrix] CUI: C1637805 RXAUI: 7252240, 7253646, 7252252, 7252239 TUI: T200 HAVRIX adult vaccine 1440 UNT in 1 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658059 1658059 Hepatitis A Vaccine (Inactivated) Strain HM175 Injection [Havrix] CUI: C4033811 RXAUI: 7252238 TUI: T200 HAVRIX Injection Kallan Roan, Oliver He HAVRIX pediatric/adolescent vaccine 720 UNT in 0.5 ML Prefilled Syringe Havrix 720 UNT per 0.5 ML Prefilled Syringe, 0.5 ML http://purl.bioontology.org/ontology/RXNORM/798482 798482 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] CUI: C2344406 RXAUI: 3271879, 7253645, 3066070, 2851611 TUI: T200 Havrix, Hepatitis A Vaccine (Inactivated), (Pediatric Dose) 0.5 ML Prefilled Syringe Kallan Roan, Oliver He 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] HAVRIX adult vaccine 1440 UNT in 1 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/798479 798479 CUI: C1322283 RXAUI: 2851606, 7239762, 7253516 TUI: T200 Havrix, Hepatitis A Vaccine (Inactivated), (Adult Dose) 1 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798478 798478 Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Havrix] CUI: C2344405 RXAUI: 2851605 TUI: T200 Havrix Prefilled Syringe poliovirus vaccine inactivated Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763096 763096 CUI: C2242156 RXAUI: 5026693 TUI: T129, T121 poliovirus vaccine inactivated, type 1 (Mahoney) Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763098 763098 CUI: C2242158 RXAUI: 5026694 TUI: T129, T121 poliovirus vaccine inactivated, type 2 (MEF-1) Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763100 763100 CUI: C2242160 RXAUI: 5026695 TUI: T129, T121 poliovirus vaccine inactivated, type 3 (Saukett) http://purl.bioontology.org/ontology/RXNORM/1178815 1178815 CUI: C3232713 RXAUI: 3842767 TUI: T200 PEDIARIX Injectable Product http://purl.bioontology.org/ontology/RXNORM/829972 829972 CUI: C2586685 RXAUI: 5027365 TUI: T200 acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [PEDIARIX] http://purl.bioontology.org/ontology/RXNORM/829988 829988 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [PEDIARIX] CUI: C2586690 RXAUI: 5027414 TUI: T200 PEDIARIX vaccine Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/829989 829989 0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [PEDIARIX] CUI: C2586691 RXAUI: 3634543, 7253748, 5027677 TUI: T200 PEDIARIX vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763097 763097 CUI: C2242157 RXAUI: 5027171 TUI: T200 poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763099 763099 CUI: C2242159 RXAUI: 5027167 TUI: T200 poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763101 763101 CUI: C2242161 RXAUI: 5027168 TUI: T200 poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML http://purl.bioontology.org/ontology/RXNORM/1300806 1300806 CUI: C2719943 RXAUI: 4626294 TUI: T116, T129, T121 Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1176753 1176753 CUI: C3230691 RXAUI: 3838525 TUI: T200 Ipol Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763104 763104 CUI: C2242163 RXAUI: 5027360 TUI: T200 poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML [Ipol] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/763106 763106 poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Ipol] CUI: C1877934 RXAUI: 5027670, 6816444, 7253746 TUI: T200 IPOL vaccine Injectable Solution Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/807219 807219 CUI: C0078221 RXAUI: 2863812 TUI: T116, T129, T121 Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1187511 1187511 CUI: C3241253 RXAUI: 3848865 TUI: T200 Typhim VI Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/807223 807223 CUI: C2365227 RXAUI: 2863816 TUI: T200 Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Typhim VI] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/807225 807225 Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] CUI: C0711001 RXAUI: 7251850, 2863819, 2863818 TUI: T200 Typhim Vi Injectable Solution Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1486495 1486495 Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe [Typhim VI] CUI: C3701103 RXAUI: 5937066 TUI: T200 Typhim VI Prefilled Syringe Kallan Roan, Oliver He 0.5 ML Typhim VI 0.05 MG/ML Prefilled Syringe Typhim VI 25 MCG per 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1486496 1486496 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] CUI: C0980908 RXAUI: 7252822, 5937069, 5937068, 5937067 TUI: T200 Typhim Vi 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/807220 807220 CUI: C2365225 RXAUI: 2863813 TUI: T200 Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1361664 1361664 CUI: C3528060 RXAUI: 5037103 TUI: T200 Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830464 830464 CUI: C2586803 RXAUI: 5026921 TUI: T129, T121 rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830465 830465 CUI: C2586804 RXAUI: 5027213 TUI: T200 rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659733 1659733 CUI: C4047087 RXAUI: 7255368 TUI: T200 Imovax Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1659731 1659731 CUI: C4046958 RXAUI: 7255366 TUI: T200 rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML [Imovax] Kallan Roan, Oliver He IMOVAX rabies vaccine 2.5 UNT in 1 ML Injection Imovax Rabies, Wistar Rabies Virus Strain PM-1503-3M (Human) 2.5 UNT per 1 ML Injection http://purl.bioontology.org/ontology/RXNORM/830470 CUI: C0711018 RXAUI: 7253451, 7250938, 7255369, 7255370 TUI: T200 1 ML Imovax 2.5 UNT/ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830457 830457 CUI: C2586798 RXAUI: 2939884 TUI: T129, T121 rabies virus vaccine flury-lep strain Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830458 830458 CUI: C2586799 RXAUI: 2939885 TUI: T200 rabies virus vaccine flury-lep strain 2.5 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1177669 1177669 CUI: C3231586 RXAUI: 3844818 TUI: T200 RabAvert Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830461 830461 CUI: C2586802 RXAUI: 2939888 TUI: T200 rabies virus vaccine flury-lep strain 2.5 UNT/ML [RabAvert] Kallan Roan, Oliver He RabAvert 2.5 UNT in 1 ML Injection RabAvert 2.5 UNT per 1 ML Injection http://purl.bioontology.org/ontology/RXNORM/830463 830463 1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection [RabAvert] CUI: C0711019 RXAUI: 7253136, 7250934, 7252193, 7252192 TUI: T200 1 ML RabAvert 2.5 UNT/ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1169861 1169861 CUI: C3223997 RXAUI: 3837729 TUI: T200 Hiberix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300809 1300809 CUI: C2719732 RXAUI: 4626297 TUI: T200 Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML [Hiberix] Kallan Roan, Oliver He 0.5 ML Hiberix 0.07 MG/ML Injection Hiberix (Haemophilus influenzae type b strain 20,752, capsular polysaccharide (10 MCG) inactivated tetanus toxoid (25 MCG) conjugate vaccine) per 0.5 ML Injection Hiberix (Haemophilus influenzae type b strain 20,752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine) 35 MCG per 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/1300810 1300810 0.5 ML Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection [Hiberix] CUI: C2719734 RXAUI: 7252256, 7252207, 7253591, 7252257, 7252206 TUI: T200 HIBERIX vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300807 1300807 CUI: C2719728 RXAUI: 4626295 TUI: T200 Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML http://purl.bioontology.org/ontology/RXNORM/1170172 1170172 CUI: C3224301 RXAUI: 3831445 TUI: T200 COMVAX Injectable Product Comvax (Haemophilus influenzae b (Ross strain) capsular polysaccharide (7.5 MCG) Meningococcal Protein (125 MCG) Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine 5 MCG) per 0.5 ML Injection Comvax, Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine Injection http://purl.bioontology.org/ontology/RXNORM/798443 798443 Preferred Name 0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML / Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [COMVAX] CUI: C0714228 RXAUI: 7251580, 7251337, 7253592, 7251338 TUI: T200 COMVAX Injection 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/798441 798441 CUI: C2344381 RXAUI: 3020182 TUI: T200 Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.265 MG/ML / Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [COMVAX] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1367001 1367001 CUI: C3531472 RXAUI: 5048926 TUI: T116, T121 Flublok 2012-2013 Formula Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1367004 1367004 CUI: C3531475 RXAUI: 5048929 TUI: T200 Flublok 2012-2013 Formula Injectable Product Kallan Roan, Oliver He 1367005 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Injectable Solution [Flublok 2012-2013 Formula] CUI: C3531476 RXAUI: 5048931, 5048930 TUI: T200 Flublok 2012-2013 Formula Influenza Virus Vaccine Injectable Solution Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1367002 1367002 CUI: C3531473 RXAUI: 5048927 TUI: T200 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML [Flublok 2012-2013 Formula] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1442206 1442206 CUI: C3692550 RXAUI: 5532833 TUI: T116, T121 Flublok 2013-2014 Formula Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1442209 1442209 CUI: C3692553 RXAUI: 5532836 TUI: T200 Flublok 2013-2014 Formula Injectable Product http://purl.bioontology.org/ontology/RXNORM/1442210 1442210 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Injectable Solution [Flublok 2013-2014 Formula] CUI: C3651109 RXAUI: 5532837, 5532838 TUI: T200 Flublok 2013-2014 Formula Influenza Virus Vaccine Injectable Solution http://purl.bioontology.org/ontology/RXNORM/1442207 1442207 CUI: C3692551 RXAUI: 5532834 TUI: T200 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2013-2014 Formula] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537517 1537517 CUI: C3817315 RXAUI: 6338485 TUI: T116, T121 Flublok 2014-2015 Formula Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537520 1537520 CUI: C3819829 RXAUI: 6338488 TUI: T200 Flublok 2014-2015 Formula Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537521 1537521 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Injectable Solution [Flublok 2014-2015 Formula] CUI: C3817268 RXAUI: 6338489, 6338490 TUI: T200 Flublok 2014-2015 Formula Influenza Virus Vaccine Injectable Solution Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1537518 1537518 CUI: C3819293 RXAUI: 6338486 TUI: T200 Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2014-2015 Formula] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660925 1660925 CUI: C4020135 RXAUI: 7258098 TUI: T129, T121 Flublok 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660928 1660928 CUI: C4047076 RXAUI: 7258101 TUI: T200 Flublok 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660926 1660926 CUI: C4046941 RXAUI: 7258099 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1660929 1660929 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection [Flublok 2015-2016] CUI: C4019692 RXAUI: 7258105, 7258102 TUI: T200 Flublok 2015-2016 vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1803020 1803020 CUI: C4224215 RXAUI: 8241253 TUI: T116, T129, T121 Flublok 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1803023 1803023 CUI: C4276258 RXAUI: 8241256 TUI: T200 Flublok 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1803021 1803021 CUI: C4276177 RXAUI: 8241254 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML [Flublok 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1803024 1803024 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2016-2017] CUI: C4224212 RXAUI: 8241260, 8241257, 8241263 TUI: T200 Flublok 2016-2017 vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928876 1928876 CUI: C4490679 RXAUI: 9199818 TUI: T116, T129, T121 Flublok 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928879 1928879 CUI: C4490682 RXAUI: 9199821 TUI: T200 Flublok 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928877 1928877 CUI: C4490680 RXAUI: 9199819 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML [Flublok 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928880 1928880 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2017-2018] CUI: C4490683 RXAUI: 9199203, 9199204, 9199822 TUI: T200 Flublok 2017-2018 vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928347 1928347 CUI: C4490433 RXAUI: 9198836 TUI: T116, T129, T121 Flublok Quadrivalent 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928350 1928350 CUI: C4490435 RXAUI: 9198839 TUI: T200 Flublok Quadrivalent 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928361 1928361 CUI: C4490441 RXAUI: 9198889 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928362 1928362 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2017-2018] CUI: C4490442 RXAUI: 9198860, 9198861, 9198890 TUI: T200 Flublok Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928349 1928349 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2017-2018] CUI: C4490434 RXAUI: 9198838 TUI: T200 Flublok Quadrivalent 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050378 2050378 CUI: C4719023 RXAUI: 10289675 TUI: T200 Flublok Quadrivalent 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050381 2050381 CUI: C4719026 RXAUI: 10289678 TUI: T200 Flublok Quadrivalent 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050379 2050379 CUI: C4719024 RXAUI: 10289676 TUI: T200 influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050380 2050380 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2018-2019] CUI: C4719025 RXAUI: 10289677 TUI: T200 Flublok Quadrivalent 2018-2019 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050382 2050382 0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2018-2019] CUI: C4719027 RXAUI: 10289680, 10289679, 10289681 TUI: T200 Flublok Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/2050374 2050374 CUI: C4719019 RXAUI: 10289671 TUI: T200 influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML http://purl.bioontology.org/ontology/RXNORM/2050375 2050375 CUI: C4719020 RXAUI: 10289672 TUI: T200 influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1724002 1724002 CUI: C4060062 RXAUI: 7710863 TUI: T116, T121 FLUAD 2015-2016 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801078 1801078 CUI: C4271566 RXAUI: 8236918 TUI: T116, T129, T121 Fluad 2016-2017 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928961 1928961 CUI: C4325205 RXAUI: 9199981 TUI: T116, T129, T121 Fluad 2017-2018 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050759 2050759 CUI: C4719165 RXAUI: 10290487 TUI: T116, T129, T121 Fluad 2018-2019 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1723997 1723997 CUI: C4059934 RXAUI: 7710856 TUI: T116, T129, T121 influenza B virus B/Brisbane/9/2014 antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1724000 1724000 CUI: C4060367 RXAUI: 7710861 TUI: T200 influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1724005 1724005 CUI: C4060278 RXAUI: 7710866 TUI: T200 FLUAD 2015-2016 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1724011 1724011 CUI: C4060159 RXAUI: 7710874 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML [FLUAD 2015-2016] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1724004 1724004 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [FLUAD 2015-2016] CUI: C4060234 RXAUI: 7710865 TUI: T200 FLUAD 2015-2016 vaccine Prefilled Syringe Kallan Roan, Oliver He FLUAD 2015-2016 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1724012 1724012 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe [FLUAD 2015-2016] CUI: C4059806 RXAUI: 7710870, 7710875, 7716409 TUI: T200 FLUAD 2015-2016 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801081 1801081 CUI: C4271737 RXAUI: 8236921 TUI: T200 Fluad 2016-2017 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801079 1801079 C4271636 RXAUI: 8236919 TUI: T200 influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluad 2016-2017] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801080 1801080 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2016-2017] CUI: C4271677 RXAUI: 8236920 TUI: T200 Fluad 2016-2017 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1801082 1801082 0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2016-2017] CUI: C4270828 RXAUI: 8236922, 8236925, 8236924 TUI: T200 Fluad 2016-2017 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928964 1928964 CUI: C4490740 RXAUI: 9199984 TUI: T200 Fluad 2017-2018 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928962 1928962 CUI: C4490738 RXAUI: 9199982 TUI: T200 influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluad 2017-2018] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928963 1928963 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2017-2018] CUI: C4490739 RXAUI: 9199983 TUI: T200 Fluad 2017-2018 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1928965 1928965 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2017-2018] CUI: C4325070 RXAUI: 9199987, 9199985, 9199986 TUI: T200 Fluad 2017-2018 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050762 2050762 CUI: C4719168 RXAUI: 10290491 TUI: T200 Fluad 2018-2019 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050760 2050760 CUI: C4719166 RXAUI: 10290488 TUI: T200 influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Fluad 2018-2019] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050761 2050761 influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2018-2019] CUI: C4719167 RXAUI: 10290490 TUI: T200 Fluad 2018-2019 vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050763 2050763 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2018-2019] CUI: C4719169 RXAUI: 10290492, 10290493, 10290494 TUI: T200 Fluad 2018-2019 vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1176026 1176026 CUI: C3229980 RXAUI: 3836903 TUI: T200 Gardasil Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798272 798272 CUI: C2344300 RXAUI: 2851350 TUI: T200 L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.04 MG/ML [Gardasil] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1656961 1656961 L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injection [Gardasil] CUI: C2344301 RXAUI: 7250795 TUI: T200 GARDASIL Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798274 798274 0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.04 MG/ML Injection [Gardasil] CUI: C1714255 RXAUI: 7250530, 6836567, 7251909 TUI: T200 GARDASIL 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798277 798277 L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Prefilled Syringe [Gardasil] CUI: C2344303 RXAUI: 2851356 TUI: T200 GARDASIL Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798278 798278 0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.04 MG/ML Prefilled Syringe [Gardasil] CUI: C1725928 RXAUI: 2851357, 2980898, 6836565 TUI: T200 GARDASIL 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798265 798265 CUI: C2344294 RXAUI: 2851343 TUI: T200 L1 protein, Human papillomavirus type 16 Vaccine 0.08 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798269 798269 CUI: C2344298 RXAUI: 2851347 TUI: T200 L1 protein, Human papillomavirus type 6 Vaccine 0.04 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1301885 1301885 CUI: C2724165 RXAUI: 4627784 TUI: T116, T121 Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1301887 1301887 CUI: C2724167 RXAUI: 4627786 TUI: T116, T129, T121 Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1301886 1301886 CUI: C2725255 RXAUI: 4627785 TUI: T200 Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1301888 1301888 CUI: C3474821 RXAUI: 4627787 TUI: T200 Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1167355 1167355 CUI: C3221549 RXAUI: 3832040 TUI: T200 Cervarix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1301890 1301890 CUI: C2725256 RXAUI: 4627789 TUI: T200 Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML [Cervarix] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/867488 867488 L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Prefilled Syringe [Cervarix] CUI: C2723809 RXAUI: 2999023 TUI: T200 CERVARIX Prefilled Syringe Kallan Roan, Oliver He Cervarix Human Papillomavirus bivalent (types 16 and 18) vaccine, recombinant 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1301891 1301891 CUI: C2724157 RXAUI: 3266660, 4627790, 7236130 TUI: T200 CERVARIX 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/845525 845525 CUI: C1579318 RXAUI: 2963098 TUI: T129, T121 Japanese encephalitis virus vaccine, inactivated Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300779 1300779 CUI: C3474322 RXAUI: 4626258 TUI: T129, T121 Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300780 1300780 CUI: C2682867 RXAUI: 4626259 TUI: T200 Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML http://purl.bioontology.org/ontology/RXNORM/1167200 1167200 CUI: C3221394 RXAUI: 3838660 TUI: T200 Ixiaro Injectable Product http://purl.bioontology.org/ontology/RXNORM/1300782 1300782 CUI: C2682871 RXAUI: 4626261 TUI: T200 Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML [Ixiaro] http://purl.bioontology.org/ontology/RXNORM/845531 845531 Japanese encephalitis virus vaccine, inactivated Prefilled Syringe [Ixiaro] CUI: C2682872 RXAUI: 2963104 TUI: T200 Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) Prefilled Syringe Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) 0.012 MG/ML 0.5 ML Prefilled Syringe Ixiaro 6 MCG per 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1300783 1300783 0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro] CUI: C2682873 RXAUI: 6833047, 4626263, 2984288, 4626262, 2994485 TUI: T200 0.5 ML Ixiaro 0.012 MG/ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1812935 1812935 CUI: C4291328 RXAUI: 8262960 TUI: T116, T129, T121 vibrio cholerae CVD 103-HGR strain live antigen Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1812935 1812935 CUI: C4291328 RXAUI: 8262960 TUI: T200 vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1812950 1812950 CUI: C4291505 RXAUI: 8262971 TUI: T200 Vaxchora Oral Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1172748 1172748 CUI: C3226798 RXAUI: 3838385 TUI: T200 Infanrix Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/854946 854946 pneumococcal capsular polysaccharide type 10A vaccine Neisseria meningitidis vaccine antigen replication defective simian adenoviral vector expressing KH, a self-cleaving polyprotein comprising L. donovani KMP-11 and HASPB Randi Vita, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/28498840 5712 KH, a self-cleaving polyprotein comprising L. donovani HASPB and KMP-11 Proteins ChAd63-KH vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1812948 1812948 Cholera Vaccine Oral Suspension [Vaxchora] CUI: C4291477 RXAUI: 8262969 TUI: T200 Vaxchora Oral Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1812951 1812951 vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML Oral Suspension [Vaxchora] CUI: C4271028 RXAUI: 8262973, 8262974, 8262972 TUI: T200 Vaxchora 1,200,000,000 UNT per 100 ML Oral Suspension Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1812947 1812947 CUI: C4291443 RXAUI: 8262968 TUI: T200 vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML [Vaxchora] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050058 2050058 CUI: C4718905 RXAUI: 9712930 TUI: T200 Heplisav-B Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/2050058 2050058 Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Heplisav-B] CUI: C4718905 RXAUI: 10287780 TUI: T200 HEPLISAV-B Prefilled Syringe Kallan Roan, Oliver He 0.5 ML Heplisav-B 0.04 MG/ML Prefilled Syringe HEPLISAV-B 20 MCG in 0.5 ML Prefilled Syringe Heplisav-B 0.04 MG/ML per 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/2050059 2050059 0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B] CUI: C4553167 RXAUI: 10287788, 10287789, 10287781, 10287783, 10287782 TUI: T200 HEPLISAV-B 20 MCG per 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1994349 1994349 CUI: C4541386 RXAUI: 9712928 TUI: T200 Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Heplisav-B] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/801829 801829 CUI: C2346335 RXAUI: 5027208 TUI: T200 Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML http://purl.bioontology.org/ontology/RXNORM/1184583 1184583 CUI: C3238386 RXAUI: 3843263 TUI: T200 Pentacel Injectable Product http://purl.bioontology.org/ontology/RXNORM/805376 805376 CUI: C2364460 RXAUI: 5027344 TUI: T200 acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Pentacel] http://purl.bioontology.org/ontology/RXNORM/1657397 1657397 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Pentacel] CUI: C4033845 RXAUI: 7251281 TUI: T200 Pentacel vaccine Injection Pentacel DTaP-IPV/Hib (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)) 0.5 ML Injection 805378 0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel] CUI: C2346346 RXAUI: 7251683, 7253749, 7250887 TUI: T200 Pentacel vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1171400 1171400 CUI: C3225481 RXAUI: 3838975 TUI: T200 Kinrix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830550 830550 CUI: C2586836 RXAUI: 5027347 TUI: T200 acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Kinrix] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657886 1657886 CUI: C4033746 RXAUI: 7251903 TUI: T200 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Kinrix] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/830556 830556 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Kinrix] CUI: C2586841 RXAUI: 5027411 TUI: T200 KINRIX vaccine Prefilled Syringe Kallan Roan, Oliver He KINRIX DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/830557 830557 0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Kinrix] CUI: C2586842 RXAUI: 7253751, 5027675, 3634544 TUI: T200 KINRIX vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657887 1657887 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Kinrix] CUI: C2586837 RXAUI: 7251904 TUI: T200 KINRIX vaccine Injection Kallan Roan, Oliver He KINRIX DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) 0.5 ML Injection 830552 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Kinrix] CUI: C2586838 RXAUI: 7250882, 7251905, 7253750 TUI: T200 KINRIX vaccine 0.5 ML Injection 1168164 CUI: C3222333 RXAUI: 3833478 TUI: T200 http://purl.bioontology.org/ontology/RXNORM/1168164 Daptacel Injectable Product http://purl.bioontology.org/ontology/RXNORM/1300309 1300309 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Daptacel] CUI: C2609933 RXAUI: 5027355 TUI: T200 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Daptacel] Daptacel DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Injection http://purl.bioontology.org/ontology/RXNORM/1300310 1300310 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Daptacel] CUI: C1169838 RXAUI: 7251885, 7250857, 7250858, 7253754 TUI: T200 DAPTACEL vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1169952 1169952 CUI: C3224088 RXAUI: 3828634 TUI: T200 Adacel Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300190 1300190 CUI: C2587006 RXAUI: 5027353 TUI: T200 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Adacel] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/904262 904262 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Adacel] CUI: C2746860 RXAUI: 5027415 TUI: T200 Adacel Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300191 1300191 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Adacel] CUI: C2746861 RXAUI: 4625204, 7252705, 5027658, 4625563 TUI: T200 Adacel 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657767 1657767 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adacel] CUI: C4033829 RXAUI: 7251690 TUI: T200 Adacel Injection Kallan Roan, Oliver He Adacel (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 5 MCG / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 5 MCG / Bordetella pertussis pertactin vaccine, inactivated 3 MCG / Bordetella pertussis toxoid vaccine, inactivated 2.5 MCG / Diphtheria Toxoid Vaccine 2 UNT / Tetanus Toxoid Vaccine 5 UNT) per 0.5 ML Injection Adacel Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Injection http://purl.bioontology.org/ontology/RXNORM/1300206 1300206 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Adacel] CUI: C1639148 RXAUI: 7250855, 7251691, 7252702, 7250854 TUI: T200 Adacel 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300383 CUI: C3152863 RXAUI: 5027354 TUI: T200 1300383 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Infanrix] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657878 1657878 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Infanrix] CUI: C2368976 RXAUI: 7251893 TUI: T200 INFANRIX vaccine Injection Kallan Roan, Oliver He Infanrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.025 MG / Bordetella pertussis pertactin vaccine, inactivated 0.008 MG / Bordetella pertussis toxoid vaccine, inactivated 0.025 MG / diphtheria toxoid vaccine, inactivated 25 UNT / tetanus toxoid vaccine, inactivated 10 UNT) per 0.5 ML Injection Infanrix DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Injection http://purl.bioontology.org/ontology/RXNORM/1300386 1300386 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Infanrix] CUI: C0710622 RXAUI: 7250871, 7251894, 7250870, 7253756 TUI: T200 INFANRIX vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/824539 824539 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Infanrix] CUI: C2368973 RXAUI: 5027387 TUI: T200 INFANRIX vaccine Prefilled Syringe Kallan Roan, Oliver He Infanrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 25 MCG / Bordetella pertussis pertactin vaccine, inactivated 8 MCG / Bordetella pertussis toxoid vaccine, inactivated 25 MCG / diphtheria toxoid vaccine, inactivated 25 UNT / tetanus toxoid vaccine, inactivated 10 UNT) per 0.5 ML Prefilled Syringe Infanrix DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1300384 1300384 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Infanrix] CUI: C2368974 RXAUI: 5027659, 7253755, 3633959, 4625557 TUI: T200 INFANRIX vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1175718 1175718 CUI: C3229697 RXAUI: 3831021 TUI: T200 Boostrix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657603 1657603 CUI: C4033749 RXAUI: 7251494 TUI: T200 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Boostrix] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300369 1300369 CUI: C2364904 RXAUI: 5027356 TUI: T200 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Boostrix] Kallan Roan, Oliver He acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix] http://purl.bioontology.org/ontology/RXNORM/1657466 1657466 CUI: C2364905 RXAUI: 7251319 TUI: T200 BOOSTRIX vaccine Injection Kallan Roan, Oliver He Boostrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 8 MCG / Bordetella pertussis pertactin vaccine, inactivated 2.5 MCG / Bordetella pertussis toxoid vaccine, inactivated 8 MCG / diphtheria toxoid vaccine, inactivated 2.5 UNT / tetanus toxoid vaccine, inactivated 5 UNT) per 0.5 ML Injection Boostrix Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Injection http://purl.bioontology.org/ontology/RXNORM/1300378 1300378 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Boostrix] CUI: C2364906 RXAUI: 7250865, 7251497, 7253758, 7250866 TUI: T200 BOOSTRIX vaccine 0.5 ML Injection RS, NF, YH Brucella melitensis bp26 mutant vaccine violinID: 3259 RS, NF, YH Brucella melitensis omp25 mutant vaccine violinID: 3261 RS, NF, YH Brucella melitensis omp31 mutant vaccine violinID: 3262 RS, NF, YH Pseudorabies recombinant vector vaccine encoding gp50 protein violinID: 826 RS, NF, YH BoNT/C violinID: 91 RS, NF, YH S. pneumoniae CbpA Protein Vaccine violinID: 787 RS, NF, YH S. pneumoniae ClpP protein Vaccine violinID: 789 RS, NF, YH S. pneumoniae PspA Protein Vaccine violinID: 795 RS, NF, YH S. pneumoniae SrtA Protein Vaccine violinID: 798 RS, NF, YH N. caninum NcPDI Protein Vaccine violinID: 937 RS, NF, YH N. caninum NcDG1 protein vaccine violinID: 944 RS, NF, YH N. meningitidis ExbB Protein Vaccine violinID: 947 RS, NF, YH N. meningitidis LctP Protein Vaccine violinID: 948 RS, NF, YH N. meningitidis NspA Protein Vaccine violinID: 956 RS, NF, YH N. miningitidis TBP2 Protein Vaccine violinID: 957 RS, NF, YH Influenza virus DNA vaccine encoding HA from Influenza A virus (A/Hong Kong/1/68(H3N2)) violinID: 998 RS, NF, YH Influenza virus DNA vaccine encoding HA from Influenza A virus (A/environment/Hong Kong/156/1997(H5N1)) violinID: 999 RS, NF, YH Influenza virus HA protein vaccine (Influenza A virus (A/Yamagata/120/1986(H1N1))) violinID: 1003 RS, NF, YH Influenza virus HA protein vaccine (Influenza A virus (A/Fukuoka/C29/85(H3N2))) violinID: 1004 RS, NF, YH Influenza virus DNA vaccine encoding HA from Influenza B virus (B/Ibaraki/2/85) violinID: 1005 RS, NF, YH Influenza virus DNA vaccine encoding HA from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) violinID: 1012 RS, NF, YH Influenza virus DNA vaccine encoding HA from Influenza A virus (A/equine/Kentucky/1/1981(H3N8)) violinID: 1014 RS, NF, YH L. donovani GRP-78 Protein Vaccine violinID: 1029 RS, NF, YH L. donovani Beta-tubulin Protein Vaccine violinID: 1031 RS, NF, YH T. pallidum GlpQ Protein Vaccine violinID: 1069 RS, NF, YH T. pallidum TmpB Protein Vaccine violinID: 1070 RS, NF, YH T. pallidum Tp92 Protein Vaccine violinID: 1071 RS, NF, YH B. burgdorferi DbpA Protein Vaccine violinID: 1072 RS, NF, YH B. burgdorferi OspA Protein Vaccine violinID: 1074 RS, NF, YH B. burgdorferi OspB Protein Vaccine violinID: 1075 RS, NF, YH B. burgdorferi OspC Protein Vaccine violinID: 1076 RS, NF, YH L. monocytogenes DNA Vaccine encoding hly violinID: 1077 RS, NF, YH L. monocytogenes p60 Protein Vaccine violinID: 1078 RS, NF, YH L. donovani Hsp70 Protein Vaccine violinID: 1109 RS, NF, YH F. tularensis FopB Protein Vaccine violinID: 1111 RS, NF, YH M. tuberculosis DNA vaccine ESAT-6 violinID: 3543 RS, NF, YH Ebola virus DNA vaccine EBOV GP violinID: 3576 RS, NF, YH Ebola virus EBOV NP violinID: 3577 RS, NF, YH Nontypeable H. influenzae NucA Protein vaccine violinID: 192 RS, NF, YH Psuedorabies DNA vaccine encoding IE180 protein violinID: 822 RS, NF, YH Pseudorabies Subunit gI Protein Vaccine violinID: 829 RS, NF, YH Pseudorabies Subunit gB Protein Vaccine violinID: 830 RS, NF, YH S. neurona SAG1 Protein Vaccine violinID: 835 RS, NF, YH Rotavirus VP6 Protein Vaccine violinID: 877 RS, NF, YH L. major PSA-2 Protein Vaccine violinID: 1006 RS, NF, YH L. major H2B Protein Vaccine violinID: 1009 RS, NF, YH L. major DNA Vaccine encoding Gp63 violinID: 1013 RS, NF, YH S. aureus ClfA Protein Vaccine violinID: 1082 RS, NF, YH S. aureus CNA Protein Vaccine violinID: 1083 RS, NF, YH S. aureus FnbA Protein Vaccine violinID: 1084 RS, NF, YH S. agalactiae BPS Protein Vaccine violinID: 1086 RS, NF, YH S. agalactiae Rib Protein Vaccine violinID: 1087 RS, NF, YH S. agalactiae Sip Protein Vaccine violinID: 1088 RS, NF, YH S. pyogenes Emm1 Protein Vaccine violinID: 1089 RS, NF, YH S. pyogenes FbaA Protein Vaccine violinID: 1090 RS, NF, YH S. pyogenes FBP54 Protein Vaccine violinID: 1091 RS, NF, YH S. pyogenes SfbI Protein Vaccine violinID: 1092 RS, NF, YH S. pyogenes Sib35 Protein Vaccine violinID: 1093 RS, NF, YH M. tuberculosis DNA Vaccine encoding KatG violinID: 1094 RS, NF, YH M. tuberculosis HBHA Protein Vaccine violinID: 1095 RS, NF, YH H. pylori HspA Protein Vaccine violinID: 1097 RS, NF, YH H. pylori HspB Protein Vaccine violinID: 1098 RS, NF, YH H. pylori GltA Protein Vaccine violinID: 1099 RS, NF, YH S. pneumoniae PhpA-79 Protein Vaccine violinID: 1100 RS, NF, YH N. meningitidis TbpA Protein Vaccine violinID: 1101 RS, NF, YH P. berghei MSP1 Protein Vaccine violinID: 1105 RS, NF, YH L. infantum SMT Protein Vaccine violinID: 1108 RS, NF, YH L. donovani HASPB1 Protein Vaccine violinID: 1028 RS, NF, YH S. pneumoniae GtS Protein Vaccine violinID: 790 RS, NF, YH S. pneumoniae 6PGD Protein Vaccine violinID: 792 RS, NF, YH S. pneumoniae PiaA Protein Vaccine violinID: 793 RS, NF, YH S. pneumoniae RASV synthesizing PsaA violinID: 794 RS, NF, YH Ebola virus recombinant adenovirus vector vaccine ADV-GP/NP violinID: 61 RS, NF, YH GP and NP violinID: 71 RS, NF, YH BoNT/A(Hc) violinID: 74 RS, NF, YH PBT violinID: 75 RS, NF, YH BoNT/F(Hc) violinID: 76 RS, NF, YH BoNT/B(Hc) violinID: 78 RS, NF, YH VRP violinID: 82 RS, NF, YH V-LSN violinID: 83 RS, NF, YH V-LSG violinID: 84 RS, NF, YH V-LSG1 + V- LSG2 violinID: 85 RS, NF, YH V-LSG + V-LSN violinID: 86 RS, NF, YH V-LSG/N violinID: 87 RS, NF, YH HC of type C and D violinID: 88 RS, NF, YH ML29 violinID: 89 RS, NF, YH V-LSGPC violinID: 90 RS, NF, YH VSV[Delta]G/LVGPC violinID: 92 RS, NF, YH YFV17D/LAS-GPC violinID: 93 RS, NF, YH ACAM1000 violinID: 95 RS, NF, YH CCSV violinID: 97 RS, NF, YH LC16m8 violinID: 98 RS, NF, YH MVA violinID: 99 RS, NF, YH NYVAC violinID: 100 RS, NF, YH dVV-L violinID: 101 RS, NF, YH IMV-EEV violinID: 102 RS, NF, YH Smallpox DNA Vaccine violinID: 103 RS, NF, YH MVA-BN violinID: 106 RS, NF, YH LC16m0 violinID: 107 RS, NF, YH pABFHc2 violinID: 108 RS, NF, YH Inactivated C. jejuni whole-cell (CWC) violinID: 114 RS, NF, YH MBP fused on Campylobacter FlaA (MBP-FlaA) violinID: 124 RS, NF, YH Recombinant DOBV nucleocapsid protein (rDOBV N) violinID: 140 RS, NF, YH Truncated Recombinant DoBV Nucleocapsid Proteins (Dob-N rNp) violinID: 141 RS, NF, YH VEE virus complex-specific monoclonal antibody violinID: 167 RS, NF, YH Live attenuated vaccine TC-83 violinID: 168 RS, NF, YH http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=172 https://www.ncbi.nlm.nih.gov/pubmed/15196215 MVA85A prime and BCG boost violinID: 172 RS, NF, YH http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=174 BCG expressing MSP violinID: 174 RS, NF, YH Mtb72f fusion protein violinID: 175 RS, NF, YH Recombinant RNA replicons from attenuated VEE virus violinID: 181 RS, NF, YH Nontypeable H. influenzae Outer Membrane Protein P1 vaccine violinID: 182 RS, NF, YH Chimeric SIN/VEE Virus SIN-83 violinID: 183 RS, NF, YH Live attenuated VEE vaccines violinID: 184 RS, NF, YH Live attenuated V3526 virus violinID: 185 RS, NF, YH Nontypeable H. influenzae outer membrane recombinant P4 vaccine violinID: 187 RS, NF, YH Non-typeable H. influenzae dLOS–P6 vaccine violinID: 196 RS, NF, YH Defective adenovirus expressing VEEV E2 glycoprotein violinID: 197 RS, NF, YH Marburg virus-like particles violinID: 216 RS, NF, YH Adenovirus vectors expressing Marburg virus glycoprotein violinID: 217 RS, NF, YH DNA vaccine encoding ANDV glycoproteins violinID: 218 RS, NF, YH Chimaeric HBV core particles carrying Puumala virus nucleocapsid protein fragments violinID: 219 RS, NF, YH Avirulent Salmonella vaccine strain carrying C. jejuni cjaA gene violinID: 220 RS, NF, YH BCG auxotroph expressing HIV-1 clade immunogen violinID: 224 RS, NF, YH M. tuberculosis DNA vaccine pAK4-sod violinID: 225 RS, NF, YH deltaphoP/Q S. typhimurium strains expressing PEB1-ss violinID: 226 RS, NF, YH Recombinant VEE Replicons expressing MBGV GP violinID: 227 RS, NF, YH Recombinant VEE Replicons expressing MBGV NP violinID: 228 RS, NF, YH Irradiated MBGV antigen violinID: 229 RS, NF, YH Marburg virus glycoprotein expressed by baculovirus recombinants violinID: 230 RS, NF, YH Q-VAX violinID: 237 RS, NF, YH Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus violinID: 238 RS, NF, YH M-44 violinID: 240 RS, NF, YH Chloroform-methanol residue (CMR) violinID: 241 RS, NF, YH P1-HspB (fusion of protein 1 and heat-shock protein B) violinID: 242 RS, NF, YH Coxevac violinID: 243 RS, NF, YH Chlamyvax FQ violinID: 244 RS, NF, YH VSV-based vaccine expressing MBGV GP violinID: 245 RS, NF, YH Heterologous MARV Protein VLP violinID: 246 RS, NF, YH CVD 909 violinID: 250 RS, NF, YH CVD 915 violinID: 253 RS, NF, YH Broilact Chick Salmonella vaccine violinID: 255 RS, NF, YH Zoosaloral H. violinID: 256 RS, NF, YH Salmonella vacT violinID: 257 RS, NF, YH S. flexneri 2a strain CVD 1205 violinID: 261 RS, NF, YH E. coli heat-labile enterotoxin B-subunit (LB-T) Vaccine violinID: 276 RS, NF, YH Shiga Toxin 2 B Subunit Vaccine violinID: 282 RS, NF, YH Brucella ovis Microparticle Subunit Vaccine violinID: 296 RS, NF, YH Live, Attenuated Rifampin-Resistant Rough Mutants of Brucella melitensis violinID: 297 RS, NF, YH DNA vaccine co-expressing A85A and caspase-3 violinID: 303 RS, NF, YH Recombinant vaccinia A27L, D8L, and B5R Proteins with adjuvant MPL-TDM violinID: 305 RS, NF, YH Killed Vaccinia Virus with Adjuvant NanoEmulsion violinID: 311 RS, NF, YH Yellow Fever NS1 Protein Vaccine violinID: 781 RS, NF, YH vP869 violinID: 783 RS, NF, YH Varicella Subunit Vaccine encoding gI and gE glycoproteins violinID: 785 RS, NF, YH TBEV DNA vaccine encoding E protein violinID: 814 RS, NF, YH Pseduorabies Subunit Glycoprotein C Vaccine violinID: 820 RS, NF, YH Pseudorabies recombinant vector vaccine encoding gp50 and gII protein violinID: 827 RS, NF, YH Y. pestis YscF Protein Vaccine violinID: 886 RS, NF, YH Y. pestis DNA vaccine encoding dfF1 Protein violinID: 906 RS, NF, YH RASV expressing Y. pestis Psn violinID: 908 RS, NF, YH Rotavirus VP2/VP 6 Protein Vaccine violinID: 914 RS, NF, YH Rotavirus VP4/VP7 Protein Vaccine violinID: 917 RS, NF, YH P. yoelii DNA vaccine encoding PyHEP17 Protein violinID: 927 RS, NF, YH N. caninum DNA vaccine encoding NcSAG1 and NcSRS2, combined with recombinant NcSAG1 and NcSRS2 Proteins violinID: 935 RS, NF, YH N. caninum MIC10 and p24 protein vaccine violinID: 946 RS, NF, YH CCPS-P64kR violinID: 953 RS, NF, YH C. botulinum DNA vaccine pSCARSA/BHc violinID: 983 RS, NF, YH Influenza virus DNA vaccine encoding HA of Equine influenza virus H3N8 violinID: 991 RS, NF, YH Recombinant vesicular stomatitis virus encoding HA from Influenza A virus (A/WSN/1933(H1N1)) violinID: 992 RS, NF, YH Recombinant baculovirus encoding HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1)) violinID: 995 RS, NF, YH Recombinant vaccinia virus encoding HA from Influenza B virus (Strain B/England/222/82) violinID: 996 RS, NF, YH L. major DNA Vaccine encoding LACKp24, TSA, LmSTI1 and CPa violinID: 1000 RS, NF, YH L. major DNA Vaccine encoding SP violinID: 1001 RS, NF, YH pCAGGoptiHA violinID: 1002 RS, NF, YH BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) violinID: 1007 RS, NF, YH Flagellin-based HA globular head fusion vaccine using HA protein from Influenza A virus (A/Viet Nam/1203/2004(H5N1)) violinID: 1010 RS, NF, YH L. major H1 Protein Vaccine violinID: 1011 RS, NF, YH Influenza virus DNA vaccine encoding M1 from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) violinID: 1015 RS, NF, YH AdH5-FluA NP violinID: 1021 RS, NF, YH L. donovani LD31 Protein Vaccine violinID: 1030 RS, NF, YH Leishmania vaccine using recombinant L. tarentolae strain expressing A2 antigen violinID: 1032 RS, NF, YH T. annulata Tams1 Protein Vaccine violinID: 1055 RS, NF, YH S. typhi DnaJ Protein Vaccine violinID: 1056 RS, NF, YH S. typhi GroEL Protein Vaccine violinID: 1057 RS, NF, YH Salmonella IroN Protein Vaccine violinID: 1060 RS, NF, YH Salmonella DNA vaccine encoding SopB Protein violinID: 1062 RS, NF, YH S. typimurium Vi4072 violinID: 1063 RS, NF, YH Measles Virus vaccine VEE/SIN-H violinID: 1068 RS, NF, YH B. burgdorferi DbpA and OspA Protein Vaccine violinID: 1073 RS, NF, YH P. aeruginosa DNA Vaccine encoding OprF violinID: 1079 RS, NF, YH P. aeruginosa OprI Protein Vaccine violinID: 1080 RS, NF, YH P. aeruginosa PcrV Protein Vaccine violinID: 1081 RS, NF, YH S. aureus DNA Vaccine encoding PBP2a Protein violinID: 1085 RS, NF, YH P. falciparum LSA-3 Protein Vaccine violinID: 1096 RS, NF, YH P. chabaudi AMA1 Protein Vaccine violinID: 1102 RS, NF, YH P. falciparum CS expressed in irradiated P. berghei as Vaccine violinID: 1103 RS, NF, YH P. falciparum DNA Vaccine encoding EBA-175 violinID: 1104 RS, NF, YH pcDNA3-LiP0 violinID: 1106 RS, NF, YH VVr expressing L. infantum P36/LACK violinID: 1107 RS, NF, YH L. amazonensis CP Protein Vaccine violinID: 1110 RS, NF, YH S. agalactiae BipA Protein Vaccine violinID: 1112 RS, NF, YH J5dLPS/OMP violinID: 1118 RS, NF, YH C. muridarum Tarp subunit vaccine violinID: 1119 RS, NF, YH C. jejuni PorA protein vaccine violinID: 1120 RS, NF, YH P. falciparum pfCelTos protein vaccine violinID: 1121 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/806594 806594 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix] CUI: C2364909 RXAUI: 5027374 TUI: T200 BOOSTRIX vaccine Prefilled Syringe Kallan Roan, Oliver He Boostrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 8 MCG / Bordetella pertussis pertactin vaccine, inactivated 2.5 MCG / Bordetella pertussis toxoid vaccine, inactivated 8 MCG / diphtheria toxoid vaccine, inactivated 2.5 UNT / tetanus toxoid vaccine, inactivated 5 UNT) per 0.5 ML Prefilled Syringe Boostrix Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1300370 1300370 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Boostrix] CUI: C2364910 RXAUI: 5027662, 7253757, 4625540, 4625564 TUI: T200 BOOSTRIX vaccine 0.5 ML Prefilled Syringe http://purl.bioontology.org/ontology/RXNORM/1300365 1300365 CUI: C3474172 RXAUI: 4625526 TUI: T200 Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1368371 1368371 CUI: C3535682 RXAUI: 5068281 TUI: T116, T129, T121 BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS RS, NF, YH Ovine Ecthyma Live Virus Vaccine violinID: 2074 RS, NF, YH Ovine Ecthyma Live Virus Vaccine violinID: 2075 RS, NF, YH West Nile Virus DNA Vaccine (USDA: 1995.D0) violinID: 2149 RS, NF, YH Canine Parainfluenza Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 47A9.20) violinID: 2736; violinID: 2737 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799961 1799961 CUI: C4271790 RXAUI: 8235199 TUI: T200 BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML RS, NF, YH Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine-Erysipelothrix Rhusiopathiae-Haemophilus Parasuis Bacterin (USDA: 49V9.20) violinID: 2979; violinID: 2980; violinID: 2981 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1174360 1174360 CUI: C3228377 RXAUI: 3830942 TUI: T200 Biothrax Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1799963 1799963 CUI: C4271638 RXAUI: 8235201 TUI: T200 BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML [Biothrax] RS, NF, YH Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine-Haemophilus Parasuis Bacterin (USDA: 49Q9.20) violinID: 2982; violinID: 2983 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/832681 832681 Anthrax Vaccine Adsorbed Injectable Suspension [Biothrax] CUI: C2608510 RXAUI: 2943547 TUI: T200 Biothrax Injectable Suspension RS, NF, YH T. gondii DNA vaccine encoding MIC8 violinID: 3038 RS, NF, YH S. aureus IsdB subunit vaccine (V710) violinID: 3039 RS, NF, YH P. multocida rOmpH Vaccine violinID: 3040 RS, NF, YH Inactivated PMV-3 Vaccine with Specol violinID: 3046 RS, NF, YH B. anthracis rPA Vaccine with Rehydragel HPA adjuvant violinID: 3047 RS, NF, YH Rotavirus Chimeric VP6 protein Vaccine violinID: 3048 RS, NF, YH BHV1 gD subunit vaccine violinID: 3050 RS, NF, YH BVDV Inactivated Vaccine violinID: 3051 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:9725239 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3053 https://github.com/vaccineontology/VO/issues/369 1489079 3053 Clinical trial Gene name: E7 Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:10931134 PubMed:9725239 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3054 https://github.com/vaccineontology/VO/issues/370 1489079 3054 Licensed Gene name: E7 Cancer Vaccine using E7 protein of human papillomavirus 16 and Quil-A RS, NF, YH E. maxima oocysts with Arlacel A vaccine violinID: 3056 RS, NF, YH Tetanus Toxoid with Calcium Phosphate violinID: 3057 RS, NF, YH Tetanus Toxoid with Stearyl Tyrosine violinID: 3058 RS, NF, YH V3 VLPs with Gamma inulin adjuvant violinID: 3059 RS, NF, YH gp120 recominant with GMDP adjuvant violinID: 3061 RS, NF, YH gp120 recominant with MDP adjuvant violinID: 3062 RS, NF, YH rHA with IL-1Beta adjuvant violinID: 3063 RS, NF, YH rHA with IL-2 adjuvant violinID: 3064 RS, NF, YH rHA with IL-7 adjuvant violinID: 3065 RS, NF, YH gp140, Gag and Tat Protein Vaccine with MF59 violinID: 3067 RS, NF, YH HBsAg Liposomal MTP-PE Vaccine violinID: 3068 RS, NF, YH Synthetic OMP1 Vaccine violinID: 3069 RS, NF, YH L. donovani Recombinant Ld-Gamma-GCS in NIV system Vaccine violinID: 3070 RS, NF, YH Inactivated HIV-2 Vaccine with PMMA violinID: 3071 RS, NF, YH P. falciparum MSP4 with AFCo1 Adjuvant violinID: 3072 RS, NF, YH Inactivated split Mem 71 Virus with SPT adjuvant violinID: 3073 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3074 3074 Recombinant Colorectal cancer antigen GA733 Vaccine RS, NF, YH Anthrax vaccine adsorbed with Squalene adjuvant violinID: 3076 RS, NF, YH Group A streptococcal recombinant fusion peptide Vaccine violinID: 3077 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3078 3078 Recombinant NY-ESO-1 Protein vaccine adjuvanted with Imiquimod RS, NF, YH Mutagrip Vaccine with P40 Adjuvant violinID: 3080 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:28706878 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3081 https://github.com/vaccineontology/VO/issues/241 1489079 3081 Clinical trial Gene name: E7 attenuated Listeria expressing cancer antigen vaccine RS, NF, YH recombinant S gene Hepatitis B Vaccine with rIFN-gamma violinID: 3082 RS, NF, YH Y. pestis F1 antigen Vaccine with Flagellin violinID: 3083 RS, NF, YH Inactivated H1N1(2009) Vaccine with AF03 adjuvant violinID: 3084 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3085 3085 Recombinant NY-ESO-1 ISCOMATRIX Vaccine RS, NF, YH Recombinant PA with Poly(I:C) Adjuvant violinID: 3086 RS, NF, YH Recombinant Tir Protein Vaccine violinID: 3087 RS, NF, YH C. muridarum PmpG-1, PmpE/F-2, and MOMP Proteins Vaccine violinID: 3089 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3091 3091 Synthetic MUC1 Peptide Vaccine RS, NF, YH HIV-2 DNA vaccine violinID: 3092 RS, NF, YH Hepatitis B surface antigen (HBsAg) with JVRS-1000 violinID: 3093 RS, NF, YH live TC-83 VEE Vaccine with DHEA violinID: 3094 RS, NF, YH E. coli CS3 in PLGA microspheres violinID: 3095 RS, NF, YH MVA/IL-15/5Mtb vaccine violinID: 3096 RS, NF, YH rgp120 HIV Vaccine with immunoliposomes violinID: 3097 RS, NF, YH pneumococcal polysaccharide conjugate vaccine serotype 1 (PNC-1) violinID: 3098 RS, NF, YH LEISH-F1+MPL-SE vaccine violinID: 3099 RS, NF, YH HSV glycoproteins subunit vaccine violinID: 3100 RS, NF, YH HIV-1 gp120 with mCT E112K violinID: 3101 RS, NF, YH P. falciparum MSA-2 subunit vaccine violinID: 3103 RS, NF, YH B. anthracis PA protein Vaccine with TMDP violinID: 3104 RS, NF, YH P. yoelii TyCS-VLP Vaccine violinID: 3105 RS, NF, YH pVAX-P1 DNA vaccine violinID: 3106 RS, NF, YH YopE(67-77) Protein Vaccine violinID: 3107 RS, NF, YH HIV recombinant gp160 Protein Vaccine violinID: 3108 RS, NF, YH human apo B-100 peptide-2 protein vaccine violinID: 3110 RS, NF, YH MDA-modified human apo B-100 peptide Vaccine violinID: 3111 RS, NF, YH Brucella melitensis mucR mutant vaccine violinID: 3117 RS, NF, YH Tick-borne Encephalitis Virus C protein mutant vaccine violinID: 3147 RS, NF, YH Mycobacterium tuberculosis mce-2 mutant vaccine violinID: 3207 RS, NF, YH Aflunov violinID: 3285 RS, NF, YH Fluad violinID: 3286 RS, NF, YH Focetria violinID: 3287 RS, NF, YH Brucella abortus S19 vjbR mutant vaccine violinID: 3288 RS, NF, YH African Swine Fever Virus 9GL mutant vaccine violinID: 3289 RS, NF, YH Recombinant B. abortus CobB protein with CFA/IFA adjuvant violinID: 3292 RS, NF, YH Recombinant B. abortus AsnC protein with CFA/IFA adjuvant violinID: 3293 RS, NF, YH M2 mutant from Influenza A violinID: 3294 RS, NF, YH Mycobacterium tuberculosis mce-3 mutant vaccine violinID: 3296 RS, NF, YH Bovine Respiratory Syncytial Virus recombinant vector vaccine BHVl/BRSVG encoding the G protein violinID: 3299 RS, NF, YH Influenza virus DNA vaccine BacPAKHA encoding EqfKY HA violinID: 3301 RS, NF, YH Influenza virus DNA vaccine p188 encoding H7 violinID: 3303 RS, NF, YH Influenza virus DNA vaccine pCMV/Hl encoding H1 violinID: 3304 RS, NF, YH Influenza virus DNA vaccine pCMV/H7 violinID: 3305 RS, NF, YH Influenza virus DNA vaccine pIRES/HA encoding HA violinID: 3306 RS, NF, YH Influenza virus DNA vaccine pIRES/NA expressing NA violinID: 3307 RS, NF, YH Influenza virus DNA vaccine pIRES/HA/IL-2 expressing HA violinID: 3308 RS, NF, YH Influenza virus DNA vaccine pIRES/NA/IL-2 encoding NA violinID: 3309 RS, NF, YH Influenza virus DNA vaccine pIRES/HA/GM-CSF encoding HA violinID: 3310 RS, NF, YH Influenza virus DNA vaccine pIRES/NA/GM-CSF encoding NA violinID: 3311 RS, NF, YH Influenza virus DNA vaccine pIRES/HA/IL-12p35 + pIRES/NA/IL-12p40 violinID: 3312 RS, NF, YH Influenza virus DNA vaccine pRSV-NP encoding the coding sequence from influenza virus A/PR/8/34. violinID: 3316 RS, NF, YH Influenza virus DNA vaccine pHA/NP147–155 encoding NP147-155 violinID: 3318 RS, NF, YH Influenza virus DNA vaccine pBK-SFV-NP violinID: 3320 RS, NF, YH Influenza virus DNA vaccine pBK-SFV-HA violinID: 3322 RS, NF, YH Influenza virus DNA vaccine HA-DNA violinID: 3324 RS, NF, YH Influenza virus DNA vaccine d1TTFC-NP encoding NP violinID: 3327 RS, NF, YH Influenza virus DNA vaccine A/NP violinID: 3330 RS, NF, YH Influenza virus DNA vaccine NP DNA violinID: 3331 RS, NF, YH Influenza virus DNA vaccine HA DNA violinID: 3332 RS, NF, YH Influenza virus DNA vaccine NA-DNA violinID: 3333 RS, NF, YH Influenza virus DNA vaccine H5 DNA violinID: 3338 RS, NF, YH T. gondii DNA vaccine pSAG1-ROP2-SAG2 violinID: 3342 RS, NF, YH T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2 violinID: 3343 RS, NF, YH Y. pestis DNA vaccine F1-V DNA violinID: 3344 RS, NF, YH Bovine herpesvirus 1 DNA vaccine pRSVgIV violinID: 3349 RS, NF, YH Bovine herpesvirus 1 recombinant vector vaccine BHVl/BRSVG violinID: 3350 RS, NF, YH Bovine herpesvirus 1 DNA vaccine pMASIAtgB encoding a truncated, secreted form of gB violinID: 3357 RS, NF, YH Bovine herpesvirus 1 recombinant vector vaccine rLaSota/gDFL encoding gD violinID: 3359 RS, NF, YH Bovine herpesvirus 1 recombinant vector vaccine rLaSota/gDF encoding gD violinID: 3360 RS, NF, YH Foot and mouth disease DNA vaccine pWRMHX encoding a minimal self-cleaving ribozyme violinID: 3366 RS, NF, YH IHNV DNA vaccine pCMV4-G violinID: 3369 RS, NF, YH IHNV DNA vaccine pCMV4-N encoding the nucleoprotein violinID: 3370 RS, NF, YH Murine cytomegalovirus DNA vaccine pcDNA-89 encoding pp89 violinID: 3372 RS, NF, YH Newcastle disease virus DNA vaccine pCAGF encoding the F protein violinID: 3373 RS, NF, YH PRRSV DNA vaccine GST-ORF5 encoding GP5 violinID: 3374 RS, NF, YH Rabies virus DNA vaccine pSG5rab.gp violinID: 3375 RS, NF, YH Lymphocytic choriomeningitis virus DNA vaccine pCMV-NP violinID: 3376 RS, NF, YH Human papillomavirus DNA vaccine VlJns-Ll encoding L1 violinID: 3379 RS, NF, YH Human papillomavirus DNA vaccine Pe7(pcDNA3-Sig/sE7/LAMP) encoding E7 violinID: 3380 RS, NF, YH Human papillomavirus DNA vaccine pC16-L1 encoding L1 violinID: 3383 RS, NF, YH Human papillomavirus DNA vaccine CRT/E7 DNA violinID: 3384 RS, NF, YH Human papillomavirus DNA vaccine E7IR violinID: 3388 RS, NF, YH Human papillomavirus DNA vaccine E7SH DNA violinID: 3389 RS, NF, YH Ebola virus DNA vaccine GP DNA violinID: 3392 RS, NF, YH Ebola virus recombinant rAD-GP encoding GP violinID: 3393 RS, NF, YH Ebola virus recombinant VSVdeltaG-GP encoding GP violinID: 3394 RS, NF, YH Ebola virus recombinant vector vaccine EBO7 encoding GP from SEBOV and ZEBOV violinID: 3395 RS, NF, YH VHSV DNA vaccine pCMV-vhsG encoding glycoprotein G violinID: 3396 RS, NF, YH VHSV DNA vaccine pCMV-vhsN encoding nucleocapsid protein N and glycoprotein G violinID: 3397 RS, NF, YH Classical swine fever virus DNA vaccine pCI-gp55 violinID: 3398 RS, NF, YH Human cytomegalovirus DNA vaccine VCL-CB01 encoding phosphoprotein 65 and gB violinID: 3401 RS, NF, YH HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag violinID: 3426 RS, NF, YH SIV DNA vaccine pVacc4 encoding env from mac239 violinID: 3430 RS, NF, YH HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) violinID: 3439 RS, NF, YH HIV DNA vaccine pCMN160 violinID: 3449 RS, NF, YH SIV DNA vaccine pSIVgag and pmacIL-15 encoding SIV core protein violinID: 3468 RS, NF, YH HIV recombinant vector vaccine MVA-gag encoding gag violinID: 3478 RS, NF, YH HIV DNA vaccine pHIS-SHIV-B violinID: 3481 RS, NF, YH HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost violinID: 3485 RS, NF, YH HIV recombinant vector vaccine MVA.HIVA encoding env and rev violinID: 3491 RS, NF, YH HIV DNA vaccine VlJns-tPA-gp120 violinID: 3497 RS, NF, YH Hepatitis B DNA vaccine PLGA-CTAB-DNA encoding the small envelope gene violinID: 3510 RS, NF, YH Duck hepatitis B DNA vaccine pcDNA I-S encoding small S proteins violinID: 3516 RS, NF, YH Hepatitis B DNA vaccine pRc/CMV-HBs(S) encoding HBsAg violinID: 3519 RS, NF, YH Influenza virus DNA vaccine pDNA encoding M2 and NP violinID: 3520 RS, NF, YH M. tuberculosis DNA vaccine pcDNA3.1+/Ag85A DNA encoding Ag85A violinID: 3522 RS, NF, YH Hepatitis B DNA vaccine pS encoding major envelope proteins violinID: 3524 RS, NF, YH Hepatitis B DNA vaccine pCMV-HBs encoding HBsAg violinID: 3525 RS, NF, YH Hepatitis B DNA vaccine pCEA/HBsAg encoding CEA and HBsAg violinID: 3528 RS, NF, YH Hepatitis B DNA vaccine pCMV-S2.S encoding the HBV(ayw Strain) envelope protein. violinID: 3533 RS, NF, YH Coxsackievirus DNA vaccine pCMV/VPl encoding VP1 violinID: 3538 RS, NF, YH M. tuberculosis DNA vaccine encoding Ag85B, MPT64 and MPT83 violinID: 3540 RS, NF, YH M. tuberculosis DNA vaccine (containing the ESAT-6, MPT-64, MPT-83, and KatG constructs) violinID: 3546 RS, NF, YH M. tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag violinID: 3547 RS, NF, YH Herpes simplex virus DNA vaccine gD-2 encoding gD violinID: 3548 RS, NF, YH Herpes simplex virus DNA vaccine Delta-gB-2 encoding gB violinID: 3549 RS, NF, YH Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27 violinID: 3550 RS, NF, YH Herpes simplex virus DNA vaccine gB-DNA encoding gB violinID: 3551 RS, NF, YH Herpes simplex virus DNA vaccine gBDNA encoding gB violinID: 3552 RS, NF, YH Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis violinID: 3553 RS, NF, YH Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G violinID: 3555 RS, NF, YH Rabies virus DNA vaccine encoding the ERA glycoprotein violinID: 3556 RS, NF, YH Leishmania major DNA vaccine KMP-11 violinID: 3557 RS, NF, YH T. cruzi DNA vaccine encoding TSA-1, ASP-1, ASP-2 violinID: 3558 RS, NF, YH T. cruzi DNA vaccine encoding ASP-2 violinID: 3559 RS, NF, YH T. cruzi DNA vaccine pUB-ASP-2 violinID: 3560 RS, NF, YH T. cruzi DNA vaccine pTS encoding T. cruzi antigens violinID: 3561 RS, NF, YH Lassa fever virus recombinant vector vaccine V-LSG encoding the glycoprotein violinID: 3565 RS, NF, YH Lassa fever virus recombinant vector vaccine V-LSG/N encoding the glycoprotein and the nucleoprotein violinID: 3567 RS, NF, YH Lassa fever virus recombinant vector vaccine YFV17D/LASV-GPC encoding the glycoprotein precursor violinID: 3570 RS, NF, YH Ebola virus recombinant vector vaccine pVSVXN2-Delta-G/ZEBOVsGP encoding GP violinID: 3574 RS, NF, YH Ebola virus recombinant adenovirus vaccine AdC7-ZGP encoding GP violinID: 3579 RS, NF, YH Ebola virus recombinant vector vaccine Ad-CMVZGP encoding the glycoprotein violinID: 3580 RS, NF, YH Ebola virus recombinant vector vaccine Ad-CAGoptZGP encoding the envelope glycoprotein violinID: 3581 RS, NF, YH Ebola virus DNA vaccine DNA/rAd5 encoding ZEBOV and SEBOV antigens violinID: 3591 RS, NF, YH B. anthracis DNA vaccine PA violinID: 3593 RS, NF, YH Marburg virus DNA vaccine MARV GP encoding GP violinID: 3594 RS, NF, YH Marburg virus recombinant vector vaccine CAdVax-Panfilo violinID: 3596 RS, NF, YH Marburg virus DNA prime/boost vaccine DNA/rAd5-GP encoding GP from strain Angola violinID: 3598 RS, NF, YH Marburg virus DNA vaccine DNA-GP encoding GP violinID: 3599 RS, NF, YH Marburg virus recombinant vector vaccine MBGV GP violinID: 3600 RS, NF, YH B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein violinID: 3605 RS, NF, YH B. abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD violinID: 3607 RS, NF, YH B. melitensis DNA vaccine pCI-Omp31 violinID: 3611 RS, NF, YH B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein) violinID: 3613 RS, NF, YH B. melitensis DNA vaccine p-Omp25 violinID: 3615 RS, NF, YH B. melitensis DNA vaccine p-ialB violinID: 3616 NF Oliver He RS 3617 Lymphoma DNA vaccine V-Alpha-V-Beta-V-Beta-FrC RS, NF, YH P. falciparum recombinant vector vaccine MVA.ME-TRAP violinID: 3628 An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3643 https://github.com/vaccineontology/VO/issues/175 3643 Clinical trial Glypican-3-derived peptide vaccine for human hepatocellular carcinoma RS, NF, YH EAE DNA vaccine pZZ/MBP68-85 encoding MBP violinID: 3647 RS, NF, YH EAU DNA vaccine IRBP-DNA encoding IRBP violinID: 3649 RS, NF, YH Autoimmune diabetes DNA vaccine pND2-SGAD55 violinID: 3652 RS, NF, YH Autoimmune diabetes DNA vaccine pCMV-1/rGAD65 encoding GAD violinID: 3653 RS, NF, YH Autoimmune diabetes DNA vaccine pND2-GAD65-BAX encoding GAD and BAX violinID: 3655 RS, NF, YH Insulin-dependent diabetes mellitus DNA vaccine JwGAD65 + IL-4 violinID: 3656 RS, NF, YH Adjuvant arthritis DNA vaccine pCMV3.65 encoding HSP65 violinID: 3661 RS, NF, YH Pristane-induced arthritis DNA vaccine DNA-hsp65 encoding Mycobacterium leprae 65-kDa heat shock protein violinID: 3662 RS, NF, YH Adjuvant arthritis DNA vaccine CII encoding type II collagen violinID: 3663 RS, NF, YH Adjuvant arthritis DNA vaccine pcDNA-CCOL2A1 encoding type II collagen violinID: 3664 RS, NF, YH Herpes simplex virus DNA vaccine pSIN-gB encoding gB violinID: 3665 RS, NF, YH Herpes simplex virus DNA vaccine pCI-gB encoding gB violinID: 3666 RS, NF, YH B. burgdorferi DNA vaccine pCMV-ZS7/TPA encoding OspC from Borrelia burgdorferi sensu lato violinID: 3669 RS, NF, YH C. tetani DNA vaccine pcDNA3tetC encoding fragment C violinID: 3672 RS, NF, YH West Nile virus DNA vaccine pCBWN encoding prM and E violinID: 3673 RS, NF, YH B. anthracis DNA vaccine pDNA encoding PA violinID: 3677 RS, NF, YH B. anthracis DNA vaccine LF pDNA encoding LF violinID: 3678 RS, NF, YH E. acervulina DNA vaccine 3-1E violinID: 3681 RS, NF, YH H. rhabdovirus DNA vaccine pHRV-G encoding HIRRV and VHSV G proteins violinID: 3682 RS, NF, YH IHNV DNA vaccine pCDNA-G encoding G violinID: 3687 RS, NF, YH VEE virus DNA vaccine VEEV IA/B parent encoding structural genes violinID: 3689 RS, NF, YH VEE virus recombinant vector vaccine RAd/VEEV violinID: 3690 RS, NF, YH VEE virus recombinant vector vaccine RAd/VEEV#2 violinID: 3691 RS, NF, YH VEE virus recombinant vector vaccine RAd/VEEV#3 encoding TC-83 violinID: 3692 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15879128 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3695 https://github.com/vaccineontology/VO/issues/316 8132375 3695 Research Gene name: Fragment C from tetanus toxin Cancer DNA vaccine p.DOM-AH1 encoding fragment C Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:18273615 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3696 https://github.com/vaccineontology/VO/issues/378 21423 3696 Research Gene name: E2A Carcinoma DNA vaccine pVAX/E2A Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12384547 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3698 https://github.com/vaccineontology/VO/issues/292 1945467 3698 Clinical trial Gene name: Immunoglobulin B-cell lymphoma DNA vaccine VCL-1642.XXX encoding a chimeric immunoglobulin molecule onsisting of tumor-specific variable (Id) regions Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12231517 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3699 https://github.com/vaccineontology/VO/issues/387 1048 128168861 3699 Research Gene name: S|CEA Colorectal cancer DNA vaccine pCEA/HBsAg encoding carcinoembryonic antigen and hepatitis B surface antigen Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12496961 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3700 https://github.com/vaccineontology/VO/issues/294 22178 7306 3700 Research Gene name: TYRP1|Gene name: Tyrp1 B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12496961 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3701 https://github.com/vaccineontology/VO/issues/293 22178 7306 3701 Research Gene name: TYRP1|Gene name: Tyrp1 B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3705 3705 Melanoma DNA vaccine TA2M encoding tyrosinase peptides Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3713 https://github.com/vaccineontology/VO/issues/518 3713 Gene name: Survivin Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3717 https://github.com/vaccineontology/VO/issues/512 2922 3717 Gene name: GRP Melanoma DNA vaccine pCR3.1-VS-HSP65-TP-GRP6-M2 encoding 6 tandem repeats of GRP Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3718 https://github.com/vaccineontology/VO/issues/514 12981 4100 3718 Gene name: GM-CSF|Gene name: MAGEA1 Melanoma DNA vaccine pNL3-MAGE-1-GM Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3719 https://github.com/vaccineontology/VO/issues/513 12981 4100 3719 Gene name: GM-CSF|Gene name: MAGEA1 Melanoma DNA vaccine pN4a-MAGE-1-GM Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3720 https://github.com/vaccineontology/VO/issues/516 84004 3720 Gene name: Mcam Melanoma DNA vaccine SINCp c-muMUC18 encoding MCAM/MUC18 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3723 https://github.com/vaccineontology/VO/issues/485 17829 4582 3723 Clinical trial Gene name: MUC1|Gene name: Muc1 Lung metastasis DNA vaccine pCEP4-MUC1 encoding MUC1 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3724 https://github.com/vaccineontology/VO/issues/511 6490 3724 Gene name: gp100 Melanoma DNA vaccine hugp100 encoding gp100 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3726 https://github.com/vaccineontology/VO/issues/519 20431 3726 Gene name: Pmel17 Melanoma DNA vaccine VR1012/mPmel17 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3727 https://github.com/vaccineontology/VO/issues/509 1067130 1638 3727 Gene name: HUMGP 75|Gene name: TRP-2 Melanoma DNA vaccine gp75 DNA encoding melanosomal membrane glycoproteins, gp75 Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3728 https://github.com/vaccineontology/VO/issues/521 22178 3728 Gene name: TRP-1 Melanoma recombinant vector vaccine rVVmTRP-1 encoding TRP-1 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3729 https://github.com/vaccineontology/VO/issues/510 6490 3729 Gene name: gp100 Melanoma DNA vaccine hTRP2 encoding TRP-2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3730 https://github.com/vaccineontology/VO/issues/515 104042 55118 3730 Gene name: Ubiquitin|Gene name: Trp2 Melanoma DNA vaccine pUB-TRP-2 encoding a fusion protein linking murine ubiquitin (UB) to the N-terminus of the full-length mTRP-2 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3731 3731 Neuroblastoma DNA vaccine HuDsec NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3736 3736 Prostate cancer DNA vaccine pcDNA3-STEAP encoding six-transmembrane epithelial antigen NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3737 3737 Prostate cancer DNA vaccine hPSMAt encoding PSMA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3738 3738 Prostate cancer DNA vaccine rPSMAt encoding PSMA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3740 3740 Prostate cancer DNA vaccine pVax-PSA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3742 3742 Prostate cancer DNA vaccine psig-3P-Fc encoding 3P(hPSM, hPAP, or hPSA)-Fc fusion protein NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3744 3744 Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3745 3745 Prostate cancer DNA vaccine encoding PSCA NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3746 3746 Prostate cancer DNA vaccine pmPSCA encoding PSCA RS, NF, YH T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain) violinID: 3754 RS, NF, YH T. gondii DNA vaccine pVR1020-GRA1 violinID: 3755 RS, NF, YH T. gondii DNA vaccine T.g.HSP70 violinID: 3756 RS, NF, YH Chinese S. japonicum DNA vaccine pCMV-Sjc97 encoding paramyosin violinID: 3757 RS, NF, YH Chinese S. japonicum DNA vaccine pVAX/SjFABP encoding FABP violinID: 3758 RS, NF, YH Chinese S. japonicum DNA vaccine SjCTPI violinID: 3760 RS, NF, YH Chinese S. japonicum DNA vaccine SjCTPI-Hsp70 violinID: 3761 RS, NF, YH Chinese S. japonicum DNA vaccine pVIVO2-IL12-Sj23 encoding Sj23 and IL-12 violinID: 3762 RS, NF, YH S. mansoni DNA vaccine Sm23-pcDNA encoding Sm23 violinID: 3763 RS, NF, YH S. mansoni DNA vaccine pcDNA/CTSOD encoding SOD violinID: 3764 RS, NF, YH S. mansoni DNA vaccine pcDNA/GPXbb encoding glutathione-S-peroxidase, GPX violinID: 3765 RS, NF, YH S. mansoni DNA vaccine Sm-p80-pcDNA3 encoding the large subunit of S. mansoni calpain violinID: 3767 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3768 https://github.com/vaccineontology/VO/issues/520 7299 3768 Gene name: Tyrosinase Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase RS, NF, YH Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4 violinID: 3770 RS, NF, YH Dengue virus DNA vaccine sB encoding E violinID: 3771 RS, NF, YH Dengue virus DNA vaccine sC encoding prM and E violinID: 3772 RS, NF, YH Dengue virus DNA vaccine sABC encoding prM and E violinID: 3773 RS, NF, YH Dengue virus DNA vaccine D1ME encoding prM and E violinID: 3778 RS, NF, YH Dengue virus DNA vaccine pE1D2 encoding E from Dengue Virus 2 strain New Guinea C violinID: 3779 RS, NF, YH Dengue virus DNA vaccine pcTPANS1 encoding NS1 fused to the tissue plasminogen activator signal sequence violinID: 3781 RS, NF, YH Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein violinID: 3783 RS, NF, YH Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain violinID: 3784 RS, NF, YH Human papillomavirus DNA vaccine hCRTE6E7L2 DNA encoding CRT linked to E6, E7 and L2 violinID: 3785 RS, NF, YH B. anthracis DNA vaccine pTPA-PA63 violinID: 3792 RS, NF, YH B. anthracis DNA vaccine pLAMP1-PA63 violinID: 3793 RS, NF, YH B. anthracis DNA vaccine pTPA-P violinID: 3795 RS, NF, YH B. anthracis DNA vaccine pIMS-120 encoding PA violinID: 3796 RS, NF, YH B. anthracis DNA vaccine pCPA violinID: 3801 RS, NF, YH B. anthracis DNA vaccine PA83 furin violinID: 3802 RS, NF, YH Vaccinia virus DNA vaccine A33R from strain IHD-J violinID: 3805 RS, NF, YH Vaccinia virus DNA vaccine B5R violinID: 3808 RS, NF, YH Vaccinia virus DNA vaccine pWRG/L1R violinID: 3810 RS, NF, YH Vaccinia virus DNA vaccine 4pox violinID: 3814 RS, NF, YH Vaccinia virus DNA vaccine wtD8L violinID: 3815 RS, NF, YH Vaccinia virus DNA vaccine tPA-D8L violinID: 3816 RS, NF, YH VEE virus DNA vaccine encoding 26S violinID: 3822 RS, NF, YH WEE virus DNA vaccine pVHX-6 encoding 26S violinID: 3823 RS, NF, YH VEE virus DNA vaccine pSTU-TRDF encoding VEEV E3-E2-6K violinID: 3829 RS, NF, YH Sindbis virus DNA vaccine encoding E2 violinID: 3830 RS, NF, YH FeLV DNA vaccine gag/pol and env violinID: 3831 RS, NF, YH IPNV DNA vaccine pEGFP-N1-SegA and pEGFP-N1-VP2 violinID: 3834 RS, NF, YH VHSV DNA vaccine pVHS-G encoding glycoproteins violinID: 3836 RS, NF, YH IHNV DNA vaccine pIHN-G encoding glycoproteins violinID: 3837 RS, NF, YH M. marinum pCMV-85A violinID: 3838 RS, NF, YH Avian influenza virus DNA vaccine pH5HA violinID: 3839 RS, NF, YH Avian influenza virus DNA vaccine pN1NA encoding N1 neuraminidase violinID: 3840 RS, NF, YH Avian influenza virus DNA vaccine pNP violinID: 3841 RS, NF, YH Influenza virus DNA vaccine pCMVH5HA violinID: 3842 RS, NF, YH Influenza virus DNA vaccine p-Beta-actinH7HA violinID: 3844 RS, NF, YH Influenza virus DNA vaccine pCAGGoptiHA violinID: 3845 RS, NF, YH Influenza virus DNA vaccine pCAGGHA violinID: 3846 RS, NF, YH Avian influenza DNA vaccine pCMV-M violinID: 3847 RS, NF, YH Avian influenza virus DNA vaccine pCMV-HA violinID: 3848 RS, NF, YH PRRSV DNA vaccine pCA-U-optiGP5 violinID: 3849 RS, NF, YH PRRSV DNA vaccine pIRESorf5/IFN-Gamma violinID: 3852 RS, NF, YH PRRSV DNA vaccine pIRESorf5/IL-2 violinID: 3853 RS, NF, YH PRRSV DNA vaccine pIRESorf7/IL-2 violinID: 3854 RS, NF, YH PRRSV DNA vaccine pCI-ORF5/ORF6 violinID: 3857 RS, NF, YH Chinese S. japonicum DNA vaccine SjC23-Hsp70 violinID: 3860 RS, NF, YH Chinese S. japonicum DNA vaccine SjC23 violinID: 3861 RS, NF, YH B. burgdorferi DNA vaccine encoding strain B31 OspA violinID: 3863 RS, NF, YH DNA vaccine expressing the E2 protein violinID: 3864 RS, NF, YH pCgap DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase violinID: 3865 RS, NF, YH DNA vaccine expressing PspA violinID: 3867 RS, NF, YH PsaA DNA Vaccine violinID: 3868 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3869 3869 B16 melanoma DNA vaccine pSin-mTRP-1 RS, NF, YH Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21 violinID: 3870 RS, NF, YH Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP violinID: 3871 RS, NF, YH Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2 violinID: 3872 RS, NF, YH Herpes Simplex Virus 2 DNA Vaccine encoding gD violinID: 3873 RS, NF, YH Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L violinID: 3874 RS, NF, YH Classical Swine Fever Virus DNA Vaccine pcDNA/E2 with TRIF violinID: 3876 RS, NF, YH Avian pneumovirus DNA Vaccine expressing the F gene violinID: 3878 RS, NF, YH Murine cytomegalovirus DNA vaccine pgM-pgN violinID: 3880 RS, NF, YH E. maxima DNA vaccine pcDNA-Gam56 violinID: 3881 RS, NF, YH T. gondii DNA vaccine pVAX-TgMIC13 violinID: 3882 RS, NF, YH Hepatitis D DNA vaccine pcDNA3p27/Ad5F35p27 violinID: 3883 RS, NF, YH L. major DNA vaccine pcLACK + IL-22 violinID: 3884 RS, NF, YH T. gondii DNA vaccine ROP8-pVAX-1 violinID: 3885 RS, NF, YH T. cruzi DNA vaccine encoding TSA-1 and Tc24 violinID: 3886 RS, NF, YH IBDV DNA vaccine pCAGoptiVP2/rVP2 violinID: 3887 RS, NF, YH IBDV DNA vaccine pCAGVP243-IL-18 violinID: 3888 RS, NF, YH IBV DNA vaccine pVAX1-16S1/M/N violinID: 3889 RS, NF, YH P. multocida DNA vaccine pcDNA-OMPH + pcDNA-OMPA violinID: 3890 RS, NF, YH P. multocida DNA vaccine pcDNA-OMPH/OMPA violinID: 3891 RS, NF, YH BVDV DNA vaccine encoding E2 violinID: 3892 RS, NF, YH E. rhusiopathiae DNA vaccine pcD-ACSC violinID: 3893 RS, NF, YH M. avium DNA vaccine DNA-Av35/p2AIL12 violinID: 3894 RS, NF, YH S. aureus DNA vaccine pClfaSrtD13 violinID: 3895 RS, NF, YH S. aureus DNA vaccine encoding Efb, FnbpA, ClfA, Cna violinID: 3896 RS, NF, YH B. anthracis DNA Vaccine expressing PA violinID: 3897 RS, NF, YH A. pleuropneumoniae DNA vaccine pcDNA-apxIA/pcDNA-apxIIA violinID: 3898 RS, NF, YH B. pertussis DNA vaccine pcDNA/S1 violinID: 3899 RS, NF, YH B. abortus DNA vaccine pVF278 violinID: 3900 RS, NF, YH Dengue Virus DNA Vaccine expressing prM/E proteins violinID: 3902 RS, NF, YH Dengue Virus DNA Vaccine D1ME-VRP violinID: 3903 RS, NF, YH Dengue Virus DNA Vaccine encoding NS1 violinID: 3904 RS, NF, YH Feline immunodeficiency virus recombinant vector vaccine FIV-Delta-RT violinID: 3906 RS, NF, YH Foot-and-Mouth Disease Virus DNA Vaccine pSinCMV-Vac-MEG990 violinID: 3907 RS, NF, YH Foot-and-Mouth Disease Virus Cationic Microparticle-coated DNA Vaccine violinID: 3908 RS, NF, YH FMDV DNA Vaccine encoding P1 and non-structural proteins 2A, 3C, and 3D violinID: 3909 RS, NF, YH C. trachomatis DNA vaccine pWRG7079::MOMP violinID: 3910 RS, NF, YH C. pneumoniae DNA vaccine pHSP-60 violinID: 3911 RS, NF, YH E. tarda DNA vaccine pCE18 violinID: 3912 RS, NF, YH E. tarda DNA vaccine pCE6 violinID: 3913 RS, NF, YH E. tarda DNA vaccine pCEsa1 violinID: 3914 RS, NF, YH H. pylori DNA vaccine poipA violinID: 3915 RS, NF, YH H. pylori DNA vaccine pcDNA3.1-hspA violinID: 3916 RS, NF, YH H. pylori DNA vaccine pcDNA3.1-hspB violinID: 3917 RS, NF, YH Leptospira interrogans DNA vaccine ompL1-pcDNA3.1(+) violinID: 3918 RS, NF, YH Leptospira interrogans DNA vaccine pTARGET/ LigBrep violinID: 3919 RS, NF, YH SIV recombinant vector vaccine rAd5/rLCMV violinID: 3920 RS, NF, YH Laryngotracheitis DNA Vaccine encoding gB violinID: 3921 RS, NF, YH Marburg virus recombinant vector vaccine MBGV GP/MBGV NP violinID: 3922 RS, NF, YH H. rhabdovirus DNA Vaccine encoding N and G violinID: 3923 RS, NF, YH Influenza virus DNA vaccine M2-DNA/M2-Ad violinID: 3924 RS, NF, YH N. meningitidis DNA vaccine P3A violinID: 3926 RS, NF, YH P. aeruginosa DNA vaccine pGACAG-OprF/OprI violinID: 3927 RS, NF, YH P. aeruginosa DNA vaccine pGACAG-PcrV violinID: 3928 RS, NF, YH P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA violinID: 3929 RS, NF, YH Y. pestis DNA vaccine YscF-2 violinID: 3930 RS, NF, YH BRSV DNA vaccine VCL-Fb violinID: 3931 RS, NF, YH Duck hepatitis virus 1 DNA vaccine pSCA/VP1 violinID: 3932 RS, NF, YH Hantavirus DNA vaccine pWRG/HTN-M violinID: 3933 RS, NF, YH RHDV DNA vaccine pcDNA-VP60 violinID: 3934 RS, NF, YH HSV 2 DNA vaccine pVAX-HSV-2gD-HSP70 violinID: 3935 RS, NF, YH HRSV DNA vaccine DRF-412 violinID: 3936 RS, NF, YH HRSV DNA vaccine pND-G violinID: 3937 RS, NF, YH IBV DNA vaccine pVAX1-N violinID: 3938 RS, NF, YH IBV DNA vaccine pVAX-S1 with GM-CSF adjuvant violinID: 3939 RS, NF, YH H. rhabdovirus DNA Vaccine encoding G violinID: 3940 RS, NF, YH Infectious Bronchitis Virus DNA Vaccine encoding S1, N, and M violinID: 3941 RS, NF, YH Infectious Bursal Disease Virus DNA Vaccine expressing VP2 violinID: 3942 RS, NF, YH Japanese encephalitis virus DNA Vaccine P-JEV violinID: 3943 RS, NF, YH Japanese encephalitis virus DNA Vaccine pCJ-3/E encoding E violinID: 3944 RS, NF, YH REV DNA vaccine VP22/gag and VP22/env violinID: 3946 RS, NF, YH P. yoelii DNA vaccine pDIP/PyCSP. 1 violinID: 3947 RS, NF, YH P. yoelii DNA vaccine encoding PySSP2 violinID: 3948 RS, NF, YH P. berghei DNA vaccine encoding PbCSP violinID: 3949 RS, NF, YH P. yoelii DNA vaccine pPyHsp60-VR1012 violinID: 3950 RS, NF, YH P. yoelii DNA vaccine encoding MSP1 violinID: 3951 RS, NF, YH P. berghei DNA vaccine CSP-3p28 violinID: 3952 RS, NF, YH P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42 violinID: 3953 RS, NF, YH SHIV DNA vaccine encoding env and gag violinID: 3954 RS, NF, YH SHIV(Ba-L) DNA vaccine encoding env and gag violinID: 3955 RS, NF, YH GSK1437173A violinID: 3956 RS, NF, YH Human cytomegalovirus DNA vaccine pcGB violinID: 3958 RS, NF, YH rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine violinID: 3960 RS, NF, YH S. pneumoniae pspA-rBCG Vector Vaccine violinID: 3961 RS, NF, YH T. gondii recombinant vaccine vector rBCGpMV361-TgCyP violinID: 3962 RS, NF, YH AE-Poxine violinID: 3963 A dendritic cell vaccine consisting of dendritic cells (DCs) electroporated with mRNA encoding three adjuvants, CD40 ligand (CD40L), a constitutively active TLR4, and CD70 (all together termed TriMix); coelectroporated with full-length mRNA encoding MAGE-A3, MAGE-C2, Tyrosinase and gp100; and linked to DC-LAMP, with potential immunostimulating activity. Upon vaccination, the DCs may stimulate the immune system to mount an antigen-specific cytotoxic T-lymphocyte (CTL) response against the melanoma antigens. This may decrease cellular proliferation of melanoma cells expressing these antigens. Electroporation with the adjuvants CD40L and TLR4 allows for the generation of mature and active DCs; electroporation with CD70 provides a costimulatory signal to CD27+ naive T cells thereby supporting T-cell proliferation and inhibiting T-cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5238 https://github.com/vaccineontology/VO/issues/286 4102 51438 6490 7099 7299 959 970 5238 Clinical trial Gene name: gp100 (PMEL)|Gene name: MAGEA3|Gene name: MAGEC2|Gene name: CD40LG|Gene name: Tyrosinase|Gene name: TLR4|Gene name: CD70 Autologous TriMix-DC Melanoma Vaccine RS, NF, YH SL3261 expressing T. spiralis Ag30 violinID: 3969 RS, NF, YH Aeromonas hydrophila LSA34 vector vaccine WED/pUTDgap violinID: 3970 RS, NF, YH Actinobacillus pleuropneumoniae HS93Tox-/pIG-T1K vectored vaccine violinID: 3972 RS, NF, YH Bordetella pertussis BPZE vectored vaccine violinID: 3973 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3987 3987 pCR3.1-VS-HSP65-TP-GRP6-M2 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4001 4001 SRL172 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4019 4019 VMCL NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4025 4025 Newcastle disease virus lysate NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4044 4044 smallpox vaccine NF Oliver He RS Yuying Pan PubMed:22896657 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4054 4054 mRNA-electroporated dendritic cells encoding gp100 and tyrosinase as melanoma vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4057 4057 pcDNA3-MCC/ST The approach focuses on the use of five primary patient derived melanoma cells (MEL-2, MEL-V, 3MM, KFM, and GLM-2). These cells display differential in vitro migratory and invasive properties as well as have the ability to form solid tumors when implanted into BALB/c nude mice. The retention of the innate phenotype of these primary patient derived cells together with the expression of a multitude repertoire of melanoma associated antigens offers a novel opportunity to target melanoma so as to avoid immune evasion Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4064 https://github.com/vaccineontology/VO/issues/557 2315 6490 4064 Gene name: MLANA|Gene name: gp100 Multivalent immunotherapeutic vaccine NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4079 4079 short overlapping peptides and full-length recombinant protein RS, NF, YH BCG-DHTM violinID: 4082 RS, NF, YH rSPV-PCV2-cap violinID: 4083 RS, NF, YH vFP89-H5 violinID: 4084 RS, NF, YH vNDV-H5 violinID: 4085 RS, NF, YH fp-IBD1 violinID: 4087 RS, NF, YH rDEV-re6 (H5) violinID: 4088 RS, NF, YH FPV-LT vaccine violinID: 4089 RS, NF, YH rFPV-IBDV-VP2 violinID: 4091 RS, NF, YH LT-BCG- Ag85B /Rv3425 violinID: 4092 RS, NF, YH L. T -PpSP15 violinID: 4095 RS, NF, YH A2-CPA-CPB(-CTE)-recombinant L. tarentolae violinID: 4096 RS, NF, YH L. T -HIV-1 Gag violinID: 4097 RS, NF, YH AdC68- rabies virus glycoprotein violinID: 4099 RS, NF, YH rAd-GP (Ebola virus) violinID: 4100 RS, NF, YH HVT-ND violinID: 4102 RS, NF, YH rHVT-H5 violinID: 4103 RS, NF, YH rHVT-H5 (clade 2.2 H5N1 HPAIV) violinID: 4104 RS, NF, YH rSPV-MRP (Streptococcus suis) violinID: 4106 RS, NF, YH rSPV-HA1 (Swine influenza virus H1N1) violinID: 4107 RS, NF, YH HS93Tox-/pIG-T1K violinID: 4108 RS, NF, YH ALVAC-SIV/gp120 violinID: 4110 RS, NF, YH ALVAC-rabies violinID: 4111 RS, NF, YH E. coli-CPPs (Edwardsiella tarda) violinID: 4112 RS, NF, YH CAdVax-ZEBOV/SEBOV violinID: 4113 RS, NF, YH CAdVax-RVFV glycoprotein violinID: 4114 RS, NF, YH CAdVax-Den12/Den34 violinID: 4115 RS, NF, YH CAdVax-Filoviruses (Ebola ) violinID: 4116 RS, NF, YH CAdVa-Filoviruses (EbMarburg viruses) violinID: 4117 RS, NF, YH cAdVaxM(fus) violinID: 4118 RS, NF, YH cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species) violinID: 4119 RS, NF, YH RB51-SRS2 violinID: 4120 RS, NF, YH RB51--MIC3/GRA6/MIC1/SRS2 violinID: 4121 RS, NF, YH BPZE1- FHA (H1N1/PR8 influenza A virus) violinID: 4122 RS, NF, YH BV-RVG/RVG violinID: 4124 RS, NF, YH BV-Dual-S1 violinID: 4125 RS, NF, YH AcHERV-sH1N1-HA violinID: 4126 RS, NF, YH BV-H5/H7/H9 violinID: 4128 RS, NF, YH BacMam-sHAPQ violinID: 4129 RS, NF, YH rBCGpMV361-TgCyP violinID: 4130 RS, NF, YH rBCG -Stx2B (Escherichia coli ) violinID: 4131 RS, NF, YH rDEV-us78HA violinID: 4136 RS, NF, YH VSV-DeltaG-H5 (H5N1) violinID: 4137 An Ebola virus vaccine that uses a recombinant vesicular stomatitis virus (rVSV) vector expressing an Ebola filovirus glycoprotein Oliver He, Kallan Roan http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4140 rVSV-EBOV violinID: 4140 RS, NF, YH rVSV- SEBOV-GP and -VP40 violinID: 4141 RS, NF, YH rVSVDeltaG-ANDV-GPC violinID: 4142 RS, NF, YH rMVA-GnGc (Rift Valley fever virus) violinID: 4143 RS, NF, YH rMVA-SIV-CD40L violinID: 4144 RS, NF, YH rMVA-CCHF violinID: 4145 RS, NF, YH MVA-CHIKV violinID: 4146 RS, NF, YH MVTT-HA-QH violinID: 4149 RS, NF, YH S. gordonii -M6-Sj-F1 violinID: 4150 RS, NF, YH Streptococcus gordonii-TTFC violinID: 4151 RS, NF, YH S. gordonii-PT violinID: 4152 RS, NF, YH SL3261-L. major violinID: 4153 RS, NF, YH SL3261-L. donovani violinID: 4154 NF Oliver He RS 4155 SL3261-GFP expression and mIL-12 gene integration RS, NF, YH SL3261-P. aeruginosa serogroup O11 O antigen violinID: 4156 RS, NF, YH SL3261- UreA and UreB violinID: 4157 RS, NF, YH SL3261 expressing streptococcal M protein violinID: 4158 RS, NF, YH Schmidt-Ruppin Rous sarcoma virus-H7 (H7N7) violinID: 4159 RS, NF, YH http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4160 https://pubmed.ncbi.nlm.nih.gov/18708674/ RBD-rAAV-SARS-CoV violinID: 4160 RS, NF, YH http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4161 https://pubmed.ncbi.nlm.nih.gov/18289745/ RBD-rAAV-SARS-CoV prime/RBD-specific T cell peptide boost violinID: 4161 RS, NF, YH rNDV-ILTV-gD violinID: 4162 RS, NF, YH rNDV-H5 violinID: 4163 RS, NF, YH rNDV-H5 ( HPAI H5N1 challenge in mule ducks) violinID: 4164 RS, NF, YH rNDV-H6 violinID: 4165 RS, NF, YH rAPMV3-F (newcastle disease) violinID: 4167 RS, NF, YH BoHV-4-A-gD(cp)gD(106)DeltaTK violinID: 4168 RS, NF, YH BoHV-4-A-IgK-VP2gD violinID: 4169 RS, NF, YH HSVT[VP7/6/2] violinID: 4172 RS, NF, YH M. S- H. pylori -opm26 violinID: 4173 RS, NF, YH M.S-Delta-esx-3-IKEPLUS (M. tuberculosis) violinID: 4174 RS, NF, YH YF17D- HIV-1 p24 violinID: 4175 RS, NF, YH RCN-HA (H5N1) violinID: 4176 RS, NF, YH RCN-F1-V (Yersinia pestis F1 and V) violinID: 4177 RS, NF, YH RCN-rabies-G violinID: 4178 RS, NF, YH RCN-IRES-tPA-YpF1( Yersinia pestis) violinID: 4179 RS, NF, YH PAV3-HA (H5N1) violinID: 4180 RS, NF, YH PAV3-HA (A/Hanoi/30408/2005 H5N1) violinID: 4181 RS, NF, YH rAd-P97c violinID: 4182 RS, NF, YH PrV-HA (swine-origin H1N1) violinID: 4183 RS, NF, YH PrV-PCV2-ORF2 violinID: 4184 RS, NF, YH rAdV-SFV-E2 violinID: 4185 RS, NF, YH Typhi strain Ty21a-LPS-Shigella violinID: 4186 RS, NF, YH Typhi strain Ty21a-PA (Bacillus anthracis) violinID: 4187 RS, NF, YH Ty21a-O-Ps (Shigella dysenteriae ) violinID: 4188 RS, NF, YH SabRV-SIV violinID: 4189 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4190 4190 Poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope RS, NF, YH SG33-VP2/5 violinID: 4191 RS, NF, YH Myxoma-FCV violinID: 4192 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4193 https://github.com/vaccineontology/VO/issues/496 727897 4193 Gene name: MUC5B Maraba virus MG1 Vaccine RS, NF, YH rvOka-HN (mumps virus) violinID: 4194 RS, NF, YH rOka-gD2- HSV-2 violinID: 4195 RS, NF, YH rMV- SARS-CoV -S/Ssol violinID: 4196 RS, NF, YH rMV- WNV violinID: 4197 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4198 4198 rMeV- SCD RS, NF, YH rMV-Ed-G violinID: 4199 RS, NF, YH rLAG- PA-DCpep violinID: 4200 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4201 4201 rMCMV-TRP2 RS, NF, YH rCMV- EBOV violinID: 4202 RS, NF, YH rCMV-TT violinID: 4203 RS, NF, YH CVB4/p24(73(3)) violinID: 4204 RS, NF, YH rVCG- Chlamydia-cholera violinID: 4205 RS, NF, YH CVD 103-HgR- REPEC violinID: 4206 RS, NF, YH rVCG- MOMP/HSV-2-gD violinID: 4207 RS, NF, YH pRP-RSV-HSV-1-gB violinID: 4208 RS, NF, YH RSV-H7 violinID: 4209 RS, NF, YH ALVAC-AHSV violinID: 4210 RS, NF, YH ALVAC-BTV-VP2/VP5 violinID: 4211 RS, NF, YH ALVAC-HIV-2 violinID: 4212 RS, NF, YH ALVAC-RV violinID: 4213 RS, NF, YH FP-AI-H5(H5N1) violinID: 4214 RS, NF, YH ALVAC-AI-H5(H5N1) violinID: 4215 RS, NF, YH ALVAC-WNV-prM/E violinID: 4216 RS, NF, YH ALVAC-BTV-CP(VP2/VP5) violinID: 4218 RS, NF, YH ALVAC-NiV-G violinID: 4219 RS, NF, YH ALVAC-NiV-F violinID: 4220 RS, NF, YH ALVAC-EIV (equine influenza virus H3N8) violinID: 4221 RS, NF, YH ALVAC-WNV-PrM/E (dogs and cats) violinID: 4222 RS, NF, YH ALVAC-HIV-2- env/gag/pol violinID: 4223 RS, NF, YH ALVAC-RHDV (vCP309) violinID: 4224 Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12006514 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4225 7157 4225 Clinical trial Gene name: TP53 (P53) ALVAC-P53 Vaccine RS, NF, YH ALVAC-FL- env/gag violinID: 4226 RS, NF, YH ALVAC-MV-HA/F violinID: 4227 RS, NF, YH FP-IBDV-VP2 violinID: 4228 RS, NF, YH rFPV-AI-H5A-IL6 violinID: 4229 RS, NF, YH rFPV-ILTV violinID: 4230 RS, NF, YH vFP89-HA (H5N1 HPAI virus) violinID: 4231 RS, NF, YH rFPV-H5AI-L2 violinID: 4232 RS, NF, YH ALVAC-AI-H5 violinID: 4233 RS, NF, YH rPFV-CSFV-E0 violinID: 4234 RS, NF, YH rMDV-IBDV-VP2 violinID: 4237 RS, NF, YH rFPV-IBDV-VP 2.4.3 violinID: 4239 RS, NF, YH rFPV-NDV-H/F violinID: 4240 RS, NF, YH rFP-RPV-H/F violinID: 4241 RS, NF, YH Ac-CMV-S1 (infectious bronchitis virus) violinID: 4242 RS, NF, YH BV-GD-ORF2 violinID: 4243 RS, NF, YH rSPV/H3-2A-H1 violinID: 4244 RS, NF, YH HVT-ILT(FC-126 strain) violinID: 4245 RS, NF, YH rBCG-Ag85A/Ag85B violinID: 4246 RS, NF, YH rMVA- AHS-VP2 violinID: 4248 RS, NF, YH rMVTT-HA-QH (H5N1) violinID: 4249 RS, NF, YH rMVTT-SIV-gpe violinID: 4250 NF Oliver He RS VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4251 4251 rMVTT- HPV16-E6/E7 RS, NF, YH rLSDV-Rabies-gP violinID: 4253 RS, NF, YH rLSDV-RPV violinID: 4254 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4255 https://github.com/vaccineontology/VO/issues/527 4100 4255 Gene name: MAGEA1 MG1-hDCT Vaccine RS, NF, YH rORFV-D1701-V-HAh5n (H5N1) violinID: 4256 RS, NF, YH rORFV-RabG violinID: 4257 RS, NF, YH rORFV-RHDV-VP60 violinID: 4258 RS, NF, YH rORFV-CSFV-E2 violinID: 4259 RS, NF, YH rORFV-p40(Borna disease virus) violinID: 4260 RS, NF, YH rORFV-PRV-gC/gD violinID: 4261 RS, NF, YH NYVAC-EHV-1- vP1014 violinID: 4262 RS, NF, YH NYVAC- CDV-H/F violinID: 4263 RS, NF, YH ALVAC- CDV-H/F violinID: 4264 RS, NF, YH NYVAC-HIV-1 violinID: 4265 RS, NF, YH NYVAC-HIV-2 violinID: 4266 RS, NF, YH NYVAC-JEV violinID: 4267 RS, NF, YH ALVAC-JEV violinID: 4268 RS, NF, YH NYVAC-PRV- gII/ gp50 violinID: 4270 RS, NF, YH NYVAC-SIV violinID: 4271 RS, NF, YH NYVAC-JEV- prM/E/ NS1 violinID: 4274 RS, NF, YH VC-TetC/Tcf violinID: 4275 RS, NF, YH rAdV-SjTPI.opt violinID: 4280 RS, NF, YH rPIV5-H3 (influenza virus) violinID: 4282 RS, NF, YH rVEE-HA(H1N1) violinID: 4288 RS, NF, YH rS.C-APP-ApxI/ApxII violinID: 4289 RS, NF, YH rS.C-APP-ApxIIA violinID: 4290 RS, NF, YH dVV-HA5(H5N1) violinID: 4293 RS, NF, YH rCPV-BTV-Cpox violinID: 4295 RS, NF, YH rBCG-SIVgag violinID: 4299 RS, NF, YH rBCG-S1PT violinID: 4300 RS, NF, YH rBCGMSP1-15 violinID: 4301 RS, NF, YH rMVA-SIV-CD40L violinID: 4302 RS, NF, YH HVT-LT violinID: 4304 RS, NF, YH NYVAC-Pf7 violinID: 4306 RS, NF, YH Toxminus-PLD toxoid violinID: 4308 RS, NF, YH MVA-PvTRAP violinID: 4309 RS, NF, YH ChAd63 -PvTRAP violinID: 4310 RS, NF, YH NILV-Py CSP violinID: 4311 RS, NF, YH SAd-ME.TRAP violinID: 4312 RS, NF, YH NYVAC-CSP (malaria) violinID: 4313 RS, NF, YH BDES-PfCSP (baculovirus dual expression system) violinID: 4314 RS, NF, YH HDAd-sFsyn violinID: 4315 RS, NF, YH LM1-2-E7 violinID: 4316 RS, NF, YH BL21(DE3)/pUTa-E + pET28a-FT violinID: 4317 RS, NF, YH rVEE-Ebola-NP violinID: 4318 RS, NF, YH M. bovis DNA vaccine pCI-Ag85B violinID: 4319 RS, NF, YH Bacillus Calmette-Guérin Danish (BCG) violinID: 4320 RS, NF, YH APSV Wetvax violinID: 4321 RS, NF, YH http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4322 A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), B/Florida/4/2006; Sanofi-Pasteur 2008-2009 trivalent influenza vaccine violinID: 4322 2010-2011 trivalent seasonal inactivated influenza vaccine 2010 consisting of Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008) RS, NF, YH, RV 2010-2011 trivalent seasonal inactivated influenza vaccine (A/California/7/09 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008) https://www.ncbi.nlm.nih.gov/pubmed/25596819 https://www.ncbi.nlm.nih.gov/pubmed/27317456 2011–2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008) violinID: 4324 RS, NF, YH Recombinant Aeromonas hydrophila vaccine (Aera) violinID: 4325 RS, NF, YH C-KCE (vBAC-C-KCE) violinID: 4326 RS, NF, YH v2RVFH violinID: 4327 Kallan Roan, Oliver He Biothrax (anthrax vaccine adsorbed) 0.5 ML Injectable Suspension http://purl.bioontology.org/ontology/RXNORM/832682 832682 BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML Injectable Suspension [Biothrax] CUI: C1877319 RXAUI: 7241001, 8235202, 8235203, 8231134 TUI: T200 Biothrax 0.5 ML Injectable Suspension http://purl.bioontology.org/ontology/RXNORM/805573 805573 CUI: C2364569 RXAUI: 2861602 TUI: T129, T121 Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain http://purl.bioontology.org/ontology/RXNORM/805574 805574 CUI: C2364570 RXAUI: 2861603 TUI: T200 Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/805577 805577 CUI: C2364572 RXAUI: 2861607 TUI: T200 Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML [Rotarix] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/805579 805579 Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 UNT/ML Oral Suspension [Rotarix] CUI: C2343398 RXAUI: 8728820, 8728821, 2861609 TUI: T200 Rotarix, Rotavirus, live attenuated (RV1) G1P[8] Oral Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1182565 1182565 CUI: C3236400 RXAUI: 3845652 TUI: T200 Rotarix Oral Liquid Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798292 798292 CUI: C2344315 RXAUI: 2851375 TUI: T116, T129, T121 Human-Bovine Reassortant Rotavirus Strain G4 Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798293 798293 CUI: C2344316 RXAUI: 2851376 TUI: T200 Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798294 798294 CUI: C2344317 RXAUI: 2851377 TUI: T116, T129, T121 Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798288 798288 CUI: C2344311 RXAUI: 2851371 TUI: T116, T129, T121 Human-Bovine Reassortant Rotavirus Strain G2 Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798290 798290 CUI: C2344313 RXAUI: 2851373 TUI: T116, T129, T121 Human-Bovine Reassortant Rotavirus Strain G3 Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798286 798286 CUI: C2344309 RXAUI: 2851369 TUI: T116, T129, T121 Human-Bovine Reassortant Rotavirus Strain G1 Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798291 798291 CUI: C2344314 RXAUI: 2851374 TUI: T200 Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798287 798287 CUI: C2344310 RXAUI: 2851370 TUI: T200 Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798295 798295 CUI: C2344318 RXAUI: 2851378 TUI: T200 Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798289 798289 CUI: C2344312 RXAUI: 2851372 TUI: T200 Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1182563 1182563 CUI: C3236398 RXAUI: 3845650 TUI: T200 RotaTeq Oral Liquid Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798298 798298 CUI: C2344321 RXAUI: 2851381 TUI: T200 Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML [RotaTeq] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798300 798300 Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 1400000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 1100000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 1000000 UNT/ML / Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 1150000 UNT/ML Oral Suspension [RotaTeq] CUI: C1698233 RXAUI: 8728818, 8728828, 2851383 TUI: T200 RotaTeq, Rotavirus, live pentavalent (RV5) Oral Vaccine Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1607807 1607807 CUI: C4018289 RXAUI: 6839906 TUI: T200 Quadracel Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1988804 1988804 CUI: C4530672 RXAUI: 9702160 TUI: T200 Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Quadracel] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1607808 1607808 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel] CUI: C4018290 RXAUI: 7253752, 9702161 TUI: T200 Quadracel vaccine 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/901509 901509 CUI: C2741588 RXAUI: 3060734 TUI: T129, T121 Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine http://purl.bioontology.org/ontology/RXNORM/901507 901507 CUI: C2741586 RXAUI: 3060732 TUI: T129, T121 Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine http://purl.bioontology.org/ontology/RXNORM/901511 901511 CUI: C2741590 RXAUI: 3060736 TUI: T129, T121 Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine http://purl.bioontology.org/ontology/RXNORM/901505 901505 CUI: C2741584 RXAUI: 3060730 TUI: T129, T121 Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine http://purl.bioontology.org/ontology/RXNORM/901516 901516 CUI: C2741589 RXAUI: 3060735 TUI: T200 Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML http://purl.bioontology.org/ontology/RXNORM/901508 901508 CUI: C2741587 RXAUI: 3060733 TUI: T200 Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML http://purl.bioontology.org/ontology/RXNORM/901512 901512 CUI: C2741591 RXAUI: 3060737 TUI: T200 Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML http://purl.bioontology.org/ontology/RXNORM/901506 901506 CUI: C2741585 RXAUI: 3060731 TUI: T200 Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1184384 1184384 CUI: C3238199 RXAUI: 3840481 TUI: T200 Menveo Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901516 901516 CUI: C2741595 RXAUI: 3060741 TUI: T200 Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Menveo] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/901518 901518 0.5 ML Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection [Menveo] CUI: C2741597 RXAUI: 7253602, 7251512, 7250930 TUI: T200 MENVEO vaccine 0.5 ML Injection Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593139 1593139 CUI: C3859502 RXAUI: 6809461 TUI: T200 Trumenba Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593137 1593137 CUI: C3859500 RXAUI: 6809459 TUI: T200 Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML [Trumenba] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593138 1593138 meningococcal group B vaccine Prefilled Syringe [Trumenba] CUI: C3859501 RXAUI: 6809460 TUI: T200 Trumenba vaccine Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1593140 1593140 0.5 ML Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe [Trumenba] CUI: C3859503 RXAUI: 6809462, 6809488, 7253600, 6809470 TUI: T200 Trumenba vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601406 1601406 CUI: C3883559 RXAUI: 6827964 TUI: T200 Bexsero Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601404 1601404 CUI: C3883499 RXAUI: 6827962 TUI: T200 meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML [Bexsero] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1601407 1601407 0.5 ML meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe [Bexsero] CUI: C3882668 RXAUI: 7253601, 6827965, 6827966, 6827968, 6827967 TUI: T200 BEXSERO vaccine 0.5 ML Prefilled Syringe Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/833079 833079 CUI: C2608637 RXAUI: 2944708 TUI: T116, T121 smallpox vaccine live vaccinia virus Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/833080 833080 CUI: C2608638 RXAUI: 2944709 TUI: T200 smallpox vaccine live vaccinia virus 500000000 UNT/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1165898 1165898 CUI: C3220139 RXAUI: 3828366 TUI: T200 ACAM2000 Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/833086 833086 smallpox vaccine live vaccinia virus 500000000 UNT/ML Injectable Solution [ACAM2000] CUI: C2608644 RXAUI: 2944716, 2944715, 7252433 TUI: T200 ACAM2000 smallpox (vaccinia) vaccine, live Injectable Solution Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/833084 833084 CUI: C2608642 RXAUI: 2944713 TUI: T200 smallpox vaccine live vaccinia virus 500000000 UNT/ML [ACAM2000] Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/29503 29503 CUI: C0065944 RXAUI: 436480, 5945194, 6410398 TUI: T109, T129, T121 meningococcal group C polysaccharide Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/314725 314725 CUI: C0982276 RXAUI: 1473942 TUI: T109, T129, T121 MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437844 1437844 C3666861 RXAUI: 5495920 TUI: T200 meningococcal group C polysaccharide 0.01 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/350967 350967 CUI: C1167603 RXAUI: 1545436 TUI: T200 meningococcal group C polysaccharide 0.1 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437845 1437845 CUI: C3666862 RXAUI: 5495921 TUI: T200 MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.01 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/350966 350966 CUI: C1167602 RXAUI: 1545435 TUI: T200 MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437915 1437915 CUI: C3666883 RXAUI: 5496016 TUI: T200 MenHibrix Injectable Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1437913 1437913 CUI: C3666881 RXAUI: 5496014 TUI: T200 Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.01 MG/ML [MenHibrix] Kallan Roan, Oliver He MenHibrix (meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine) 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/1437916 1437916 0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.01 MG/ML Injection [MenHibrix] CUI: C3537927 RXAUI: 7253596, 7251659, 7250946 TUI: T200 MENHIBRIX vaccine 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/1437843 1437843 CUI: C3666860 RXAUI: 5495919 TUI: T200 Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML http://purl.bioontology.org/ontology/RXNORM/1299785 1299785 CUI: C3159361 RXAUI: 4624424 TUI: T129, T121 HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 http://purl.bioontology.org/ontology/RXNORM/1183840 1183840 CUI: C3237660 RXAUI: 3840468 TUI: T200 Menomune A/C/Y/W-135 Injectable Product http://purl.bioontology.org/ontology/RXNORM/1802483 1802483 CUI: C4083103 RXAUI: 8240118 TUI: T129, T121 HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1153474 1153474 CUI: C3207956 RXAUI: 3814359 TUI: T200 Adenovirus Type 4 Vaccine Live Oral Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1153475 1153475 CUI: C3207957 RXAUI: 3814360 TUI: T200 Adenovirus Type 4 Vaccine Live Pill Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1099935 1099935 CUI: C3153709 RXAUI: 6337850 TUI: T200 Adenovirus Type 4 Vaccine Live Delayed Release Oral Tablet Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1099936 1099936 CUI: C3153710 RXAUI: 6337174, 6364229 TUI: T200 Adenovirus Type 4 Vaccine Live 32000 UNT Delayed Release Oral Tablet Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1099934 1099934 CUI: C3153708 RXAUI: 3638491 TUI: T200 Adenovirus Type 4 Vaccine Live 32000 UNT Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1153476 1153476 CUI: C3207958 RXAUI: 3814361 TUI: T200 Adenovirus Type 7 Vaccine Live Oral Product Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1153661 1153661 CUI: C3208141 RXAUI: 3814362 TUI: T200 Adenovirus Type 7 Vaccine Live Pill Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1099939 1099939 CUI: C3153712 RXAUI: 6337292 TUI: T200 Adenovirus Type 7 Vaccine Live Delayed Release Oral Tablet Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1099940 1099940 CUI: C3153713 RXAUI: 6337842, 6364883 TUI: T200 Adenovirus Type 7 Vaccine Live 32000 UNT Delayed Release Oral Tablet Kallan Roan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1099938 1099938 CUI: C3153711 RXAUI: 3638495 TUI: T200 Adenovirus Type 7 Vaccine Live 32000 UNT http://purl.bioontology.org/ontology/RXNORM/568054 568054 CUI: C1600470 RXAUI: 2283589 TUI: T200 meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML [Menomune A/C/Y/W-135] http://purl.bioontology.org/ontology/RXNORM/1658227 1658227 meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [Menomune A/C/Y/W-135] CUI: C4033800 RXAUI: 7252552 TUI: T200 Menomune A/C/Y/W-135 Vaccine Injection http://purl.bioontology.org/ontology/RXNORM/1658228 1658228 CUI: C3887764 RXAUI: 7253594, 7252562, 7252553 TUI: T200 Menomune A/C/Y/W-135 Vaccine 0.5 ML Injection http://purl.bioontology.org/ontology/RXNORM/207269 207269 meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML Injectable Solution [Menomune A/C/Y/W-135] CUI: C0708576 RXAUI: 3051640, 7253593, 5944304, 1155623 TUI: T200 Menomune A/C/Y/W-135 Vaccine Injectable Solution http://purl.bioontology.org/ontology/RXNORM/314724 314724 CUI: C0982275 RXAUI: 1473937 TUI: T200 MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 http://purl.bioontology.org/ontology/RXNORM/350965 350965 CUI: C1167601 RXAUI: 1545434 TUI: T200 MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML http://purl.bioontology.org/ontology/RXNORM/29501 29501 CUI: C0065942 RXAUI: 436468, 6410396, 2719265, 5945192 TUI: T200 meningococcal group A polysaccharide http://purl.bioontology.org/ontology/RXNORM/328467 328467 CUI: C1123385 RXAUI: 1505209 TUI: T200 meningococcal group A polysaccharide 0.1 MG/ML The gH1-Qbeta vaccine is a novel pandemic-influenza vaccine produced by covalently linking the globular head domain of haemagglutinin (gH1) from A/California/07/09 produced in E. coli to VLPs from the bacteriophage Qbeta Randi Vita, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/30573748 15 µg HA from Influenza A virus (A/California/7/2009(H1N1)) VLPs from the bacteriophage Qbeta gH1-Qbeta vaccine https://www.ncbi.nlm.nih.gov/pubmed/29535712 100 µg CN54gp140 GLA-AF A recombinant uncleaved clade C HIV-1 envelope gp140 protein (CN54gp140) CN54gp140 + GLA Fluenz™ is a seasonal trivalent live attenuated influenza vaccine (LAIV) administered intranasally. The vaccine contained A/California/07/2009 (H1N1) pdm09-like strain, A/Victoria/361/2011 (H3N2)-like strain, and B/Massachusetts/2/2012-like strain. Randi Rita, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/26148331 Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Victoria/361/2011(H3N2)), Influenza B virus (B/Massachusetts/02/2012 Fluenz quadrivalent seasonal inactivated influenza vaccine 2014 consisting of Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008), Influenza B virus (B/Massachusetts/02/2012) Randi Rita, Olilver He Avey et al 2019, paper submitted Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008), Influenza B virus (B/Massachusetts/02/2012) quadrivalent seasonal inactivated influenza vaccine 2014 ‘F’ (intended to refer to a female biological sex), ‘Female’, ‘Woman’, ‘0’ (intended to refer to a female biological sex) A biological sex datum that represents the biological sex of an animal (including human) as being female. Paul Fabry, Oliver He female biological sex datum ‘I’ (intended to refer to an intersex biological sex), ‘Intersex’, ‘Hermaphrodite’, ‘Pseudo-hermaphrodite’, ‘2’ (intended to refer to an intersex biological sex) A biological sex datum that represents the biological sex of an animal (including human) as being intersex. Paul Fabry, Oliver He intersex biological sex datum A vaccine against coronavirus infection Hong Yu, Oliver He coronavirus vaccine Oliver He https://www.fludb.org/brc/fluStrainDetails.spg?strainName=A/Perth/16/2009(H3N2)&decorator=influenza Recommended by WHO for Vaccines: 2011-2012 Northern Hemisphere 2010 Southern Hemisphere 2011 Southern Hemisphere 2012 Southern Hemisphere 2010-2011 Northern Hemisphere Influenza A virus A/Perth/16/2009 (H3N2) antigen 2012-2013 trivalent seasonal inactivated influenza vaccine 2012-2013 Influenza A virus (A/California/7/2009 (H1N1)), Influenza A virus (A/Victoria/361/2011 (H3N2)), and Influenza B virus (B/Wisconsin/1/2010) Randi Vita, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/?term=30843873 2012-2013 seasonal trivalent inactivated influenza vaccine (A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Wisconsin/1/2010) MERS-CoV vaccine MERS vaccine Oliver He https://www.drugbank.ca/drugs/DB14396 influenza B virus B/Wisconsin/1/2010 antigen Oliver He https://www.fludb.org/brc/fluStrainDetails.spg?strainName=A/Victoria/361/2011(H3N2)&decorator=influenza Recommended by WHO for Vaccines: 2013 Southern Hemisphere 2014 Southern Hemisphere 2012-2013 Northern Hemisphere 2013-2014 Northern Hemisphere influenza A virus A/Victoria/361/2011 (H3N2) antigen Inactivated monovalent influenza A/H5N1 (3.75 mcg hemagglutinin [HA] A/Indonesia/05/2005) split-virus (SV) vaccine (Sanofi) Randi Vita, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/28099485 https://www.ncbi.nlm.nih.gov/pubmed/30566602 Inactivated monovalent influenza A/H5N1 (3.75 mcg hemagglutinin [HA] A/Indonesia/05/2005) split-virus (SV) vaccine (Sanofi) https://www.fludb.org/brc/fluStrainDetails.spg?strainName=A/Indonesia/5/2005(H5N1)&tabName=17535101%20No2&decorator=influenza&context=1544988803656 Influenza A virus (A/Indonesia/05/2005) antigen https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884803/ MERS-CoV S protein with alum and CpG adjuvant MERS-CoV protein MERS-CoV S protein A coronavirus vaccine against the infection of SARS-CoV-2 (cause of COVID-19) Oliver He, Philip Huang, Anthony Huffman SARS-CoV-2 vaccine https://en.wikipedia.org/wiki/COVID-19_vaccine https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines COVID-19 vaccine A Plasmodium falciparum vaccine that is composed of aseptic, purified, live (metabolically active), radiation-attenuated, cryopreserved Plasmodium falciparum sporozite. Randi Vita, Oliver He Plasmodium falciparum sporozite Vaccine https://www.ncbi.nlm.nih.gov/pubmed/26469720 https://www.ncbi.nlm.nih.gov/pubmed/28216244 Sanaria Inc., Rockville, MD PfSPZ Vaccine The fully infectious PfSPZ are attenuated in vivo by concomitant administration of an anti-malarial drug (chloroquine). Chloroquine kills disease-associated blood stages but does not affect pre-erythrocytic (sporozoite or liver) stages, which are exposed to the host's immune system. Sporozoites-induced protection is mediated by immunity against pre-erythrocytic stages. Randi Vita, Oliver He PfSPZ Chemoprophylaxis Vaccine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775905/ https://www.ncbi.nlm.nih.gov/pubmed/26469720 https://www.ncbi.nlm.nih.gov/pubmed/28199305 Sanaria Inc., Rockville, MD PfSPZ-CVac Sanaria® PfSPZ-GA1 consists of purified, aseptic, cryopreserved Pf sporozoites (NF54 strain) genetically attenuated by removal of the b9 and slarp genes to halt development in the early liver stages. Randi Vita, Oliver He https://www.ncbi.nlm.nih.gov/pubmed/26469720 Sanaria Inc., Rockville, MD The parasite line was generated by the Leiden University Medical Center (LUMC) and RUMC in collaboration with Sanaria. PfΔb9Δslarp parasites invade hepatocytes but are incapable of sustaining liver stage development, similar to radiation-attenuated PfSPZ. The potential advantages of PfSPZ-GA1 are that (1) the PfSPZ are homogenous and have a precisely characterized genetic basis for attenuation; (2) manufacturing PfSPZ-GA1 cannot result in accidental exposure of staff to infectious parasites, thereby simplifying the approach to safety of operators and lowering costs. PfSPZ-GA1 also has the potential to induce more efficient protection than the radiation-attenuated PfSPZ Vaccine due to a different pattern of developmental arrest and antigen expression. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077156/ PfSPZ-GA1 a vaccine role that inheres in a vaccine using virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines. Anthony Huffman, Oliver He virus like particle vaccine role https://pubmed.ncbi.nlm.nih.gov/20923267/ virus-like particle vaccine role A vaccine that uses virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines. Anthony Huffman, Oliver He virus like particle vaccine https://pubmed.ncbi.nlm.nih.gov/20923267/ virus-like particle vaccine vaccine-induced T-helper 1 type immune response that is indicated by the presence of Interferon-gamma production Anthony Huffman, Oliver He vaccine specific interferon-γ immune response vaccine-induced T-helper 1 type immune response that is indicated by the presence of interleukin-2 production Anthony Huffman, Oliver He vaccine specific IL-2 immune response vaccine-induced T-helper 2 type immune response that is indicated by the presence of interleukin-4 production Anthony Huffman, Oliver He vaccine specific interleukin-4 response vaccine-induced T-helper 2 type immune response that is indicated by the presence of interleukin-10 production Anthony Huffman, Oliver He vaccine specific interleukin-10 response vaccine-induced T-helper 1 type immune response that is indicated by the presence of IgG2a production Anthony Huffman, Oliver He https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101669/ vaccine specific Th1 immune response indicated by IgG2a production vaccine-induced T-helper 2 type immune response that is indicated by the presence of IgG1 production Anthony Huffman, Oliver He https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101669/ vaccine specific Th2 immune response indicated by IgG1 production Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. human age Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. child age Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. adolescence age Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. adult age Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. senior age Anna Maria Masci, Anthony Huffman, Oliver He age range at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. human age range at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human child age range at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human adult age range at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human senior age range at vaccination Anna Maria Masci, Anthony Huffman, Oliver He human age 13 to 18 years at vaccination https://www.cdc.gov/vaccines/vpd/vaccines-age.html The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. human adolescence age range at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 1 to 2 months at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 4 months at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 11 to 12 years at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 4 to 6 years at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 7 to 11 months at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 12 to 23 months at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 2 to 3 years at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 6 months at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 7 to 10 years at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 19 to 26 years at vaccination Anna Maria Masci, Anthony Huffman, Oliver He The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age 27 to 59 years at vaccination The age with the range from the birth to one month after birth at when a vaccination is taken. HepB vaccination is sometimes taken within 12 hours after birth. Anna Maria Masci, Anthony Huffman, Oliver He, Jie Zheng newborn age range at human vaccination https://www.cdc.gov/vaccines/parents/diseases/hepb.html The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855. https://www.cdc.gov/vaccines/vpd/vaccines-age.html human age within one month at vaccination A SARS-CoV-2 RNA vaccine formed from a lipid nanoparticle-formulated trimerized SARS-CoV-2 receptor-binding domain Philip Huang, Rohit Goru, Oliver He BNT162b2 PF-07302048 Tozinameran PubMed: 32839784 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://en.wikipedia.org/wiki/Tozinameran https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine https://www.fda.gov/media/144246/download Comirnaty Oliver He, Philip Huang SARS-CoV-2 protein Replaced term with S protein of SARS-CoV-2 Wuhan strain (PR_P0DTC2) for ontology harmonization Anthony Huffman S protein of SARS-CoV-2 true E protein of SARS-CoV-2 BBV152 (also known as Covaxin) is an inactivated COVID-19 vaccine that is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research. Philip Huang, Rohit Guru, Oliver He BBV152 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://en.wikipedia.org/wiki/BBV152 https://go.drugbank.com/drugs/DB15847 COVAXIN A recombinant coronavirus-like particle SARS-CoV-2 vaccine developed by Medicago Philip Huang NCT04636697 CoVLP A P. falciparum malaria vaccine that is formed by tull length CS-expressing replication-deficient recombinant human adenovirus 35. Randi Vita, Oliver He PMID:18455276 This is a term requested by Randi for the HIPC/ImmPort work Ad35.CS.01 malaria vaccine A SARS-CoV-2 trimeric S protein subunit vaccine. Philip Huang NCT04405908 SCB-2019 A SARS-CoV-2 S1-RBD-protein based vaccine developed by Vaxxinity Philip Huang NCT04545749 UB-612 A SARS-CoV-2 replication-defective human adenovirus type 5/35 vector based vaccine expressing the S protein. Philip Huang NCT04666012 AdCLD-CoV19 A SARS-CoV-2-RBD-Fc fusion protein designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein. Philip Huang https://www.akstonbio.com/programs/covid-19-vaccine/ AKS-452 A DNA vaccine plasmid vector that has the plasmid label pCAGGSP7. This plasmid has a polylinker containing KpnI, XhoI, ClaI, EcoRV, SmaI, Not1 and Sac1 sites inserted into the EcoRI site of pCAGGS. Rebecca Racz, Yongqun He pCAGGSP7 DNA vaccine plasmid PMID:9711802 A DNA vaccine plasmid vector that has the plasmid label pCAGGS/MCS. This plasmid has a chicken beta-actin promoter, contains a multiple cloning site between the EcoRI and BglII sites of the rabbit beta-globin gene, and has restriction sites for the enzymes SacI, ClaI, NsiI, Asp718, SmaI, SphI, XhoI, and NheI. Rebecca Racz, Yongqun He pCAGGS/MCS DNA vaccine plasmid PMID: 9261394 A DNA vaccine plasmid vector that has the plasmid label pWRG. This plasmid is a eukaryotic expression plasmid that contains the immediate early promoter and intron A of human cytomegalovirus. Rebecca Racz, Yongqun He pWRG DNA vaccine plasmid PMID: 10403592 A DNA vaccine plasmid vector that has the plasmid label pHW2000. This plasmid is derived from pHW12 and contains part of the human pol I promoter and murine terminator sequences, a CMV promoter, and the polyadenylation signal of the gene encoding bovine growth hormone. Rebecca Racz, Yongqun He pHW2000 DNA vaccine plasmid PMID: 10662626 A DNA vaccine plasmid vector that has the plasmid label pCMV/R. This plasmid is a mammalian expression vector with a CMV promoter. Rebecca Racz, Yongqun He pCMV/R DNA vaccine plasmid PMID: 20660192 A DNA vaccine plasmid vector that has the plasmid label VRC-9123. Rebecca Racz, Yongqun He This plasmid was prepared under Good Manufacturing Practices at 4 mg/mL in phosphate buffered saline (PBS). VRC-9123 DNA vaccine plasmid PMID: 21975270 A DNA vaccine plasmid vector that has the plasmid label pPJV7563. This plasmid has a human cytomegalovirus immediate early promoter. Rebecca Racz, Yongqun He pPJV7563 DNA vaccine plasmid PMID: 20544035 A DNA vaccine plasmid vector that has the plasmid label p188. This plasmid is a replication-defective derivative of pP1/H7. Rebecca Racz, Yongqun He p188 DNA vaccine plasmid PMID: 8212843 A DNA vaccine plasmid vector that has the plasmid label VR10551. This plasmid contains a human cytomegalovirus immediate early 1 promoter, a kanamycin resistance gene, intron A and a modified rabbit b-globin terminator. Rebecca Racz, Yongqun He VR10551 DNA vaccine plasmid PMID: 17637571 A DNA vaccine plasmid vector that has the plasmid label VCL-1632. This plasmid contains a CMV promoter, kanamycin resistance gene, the murine κ constant region sequence, a translational enhancer, the murine IgG2a heavy-chain sequence, and a translation terminator. This plasmid is derived from pUC-18. Rebecca Racz, Yongqun He VCL-1632 DNA vaccine plasmid PMID: 12384547 A DNA vaccine plasmid vector that has the plasmid label pSport-B-gal. This plasmid contains a CMV promoter. Rebecca Racz, Yongqun He pSport-B-gal DNA vaccine plasmid PMID: 12496961 A DNA vaccine plasmid vector that has the plasmid label pSin-B-gal. This plasmid contains a CMV promoter. Rebecca Racz, Yongqun He pSin-B-gal DNA vaccine plasmid PMID: 10646851 A DNA vaccine plasmid vector that has the plasmid label pLXSHD. This plasmid has a murine leukemia virus enhancer-promoter LTR. Rebecca Racz, Yongqun He pLXSHD DNA vaccine plasmid PMID: 7533183 A DNA vaccine plasmid vector that has the plasmid label WRG/BEN. This plasmid is based off of pWRG7077. It contains a CMV promoter and a kanamycin resistance gene. Rebecca Racz, Yongqun He WRG/BEN DNA vaccine plasmid PMID: 9739060 A DNA vaccine plasmid vector that has the plasmid label pNGVL4a. This plasmid has a CMV promoter and kanamycin and ampicillin resistance genes. Rebecca Racz, Yongqun He There is an extra immunostimulatory sequence (450 bp) in pNGVL4a plasmid compared to pNGVL3 pNGVL4a DNA vaccine plasmid PMID: 11818167 A DNA vaccine plasmid vector that has the plasmid label pNGVL3. This plasmid has a CMV promoter and kanamycin and ampicillin resistance genes. Rebecca Racz, Yongqun He pNGVL3 DNA vaccine plasmid PMID: 11818167 A DNA vaccine plasmid vector that has the plasmid label SINCp B-gal. This plasmid contains a CMV promoter. Rebecca Racz, Yongqun He SINCp B-gal DNA vaccine plasmid PMID: 17024104 A DNA vaccine plasmid vector that has the plasmid label Synchotrope TA2M. This plasmid is 3683 base pairs in length and has two copies of the murine CpG immune stimulatory sequence AACGTT inserted. Rebecca Racz, Yongqun He It has been shown that plasmid half-life in human serum in vitro is 20 minutes Synchotrope TA2M DNA vaccine plasmid PMID: 12833467 A DNA vaccine plasmid vector that has the plasmid label pCMV/myc/ER. This plasmid is 5066 base pairs in length and contains a CMV promoter and ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2236/ pCMV/myc/ER DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pPA63-LAMP1. Rebecca Racz, Yongqun He pPA63-LAMP1 DNA vaccine plasmid PMID: 19130551 A DNA vaccine plasmid vector that has the plasmid label pSecTag2B. This plasmid is 5163 base pairs in length and contains a CMV promoter and ampicillin resistance gene. Rebecca Racz, Yongqun He Invitrogen:http://tools.invitrogen.com/content/sfs/manuals/psectag2_man.pdf; Sequence: http://tools.invitrogen.com/content/sfs/vectors/psectag2b_seq.txt pSecTag2B DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pTPA-PA63-LAMP1. Rebecca Racz, Yongqun He pTPA-PA63-LAMP1 DNA vaccine plasmid PMID: 19130551 A DNA vaccine plasmid vector that has the plasmid label pTPA-PA63. Rebecca Racz, Yongqun He pTPA-PA63 DNA vaccine plasmid PMID: 19130551 A DNA vaccine plasmid vector that has the plasmid label VR2210. This plasmid contains a CMV promoter and kanamycin resistance gene. It was created through ligation of fragments of digested plasmid VR1012, hTPA, and B. burgdorferi B31 ospA. Rebecca Racz, Yongqun He VR2210 DNA vaccine plasmid PMID: 8985201 A DNA vaccine plasmid vector that has the plasmid label pCMV-TPA/ZS7. This plasmid contains a CMV promoter and is generated from pCMV-ZS7 by attaching hTPA to ospC ZS7. Rebecca Racz, Yongqun He pCMV-TPA/ZS7 DNA vaccine plasmid PMID: 12941385; PMID: 10580194 A DNA vaccine plasmid vector that has the plasmid label pABB-CRS2. This plasmid is a derivative of pCVD442 and contains a chloramphenicol resistance gene. Rebecca Racz, Yongqun He pABB-CRS2 DNA vaccine plasmid PMID: 11562461 A DNA vaccine plasmid vector that has the plasmid label pMASIA-tgD. This plasmid is based off of pMASIA and contains a CMV promoter and kanamycin resistance gene. Rebecca Racz, Yongqun He pMASIA-tgD DNA vaccine plasmid PMID: 12466473 A DNA vaccine plasmid vector that has the plasmid label pCMVi-UB. This plasmid was built from pCMV-5 and contains a CMV promoter. Rebecca Racz, Yongqun He pCMVi-UB DNA vaccine plasmid PMID: 10433551 A DNA vaccine plasmid vector that has the plasmid label pCI30. This plasmid contains a CMV promoter, ampicillin resistance gene, T7 RNA polymerase promoter, a multiple cloning region and a 6xHis tag coding sequence. Rebecca Racz, Yongqun He pCI30 DNA vaccine plasmid PMID: 17239501; PMID: 11567754 A DNA vaccine plasmid vector that has the plasmid label pCP15/60. Rebecca Racz, Yongqun He pCP15/60 DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pUMVC3. This plasmid is 4030 base pairs in length and contains a CMV promoter and kanamycin resistance gene. Rebecca Racz, Yongqun He Aldevron: http://www.aldevron.com/products/dnas/umvc_expression/ pUMVC3 DNA vaccine plasmid PMID: 12654810 A DNA vaccine plasmid vector that has the plasmid label pcDNA1. This plasmid is 4000 base pairs in length and contains a CMV promoter. Rebecca Racz, Yongqun He Addgene: https://www.addgene.org/vector-database/2089/ pcDNA1 DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pCAT. This plasmid is 4364 base pairs in length and contains an ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2051/ pCAT DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pGT36. This plasmid is a derivative of pcDNA3 and contains a CMV promoter and a kanamycin resistance gene. Rebecca Racz, Yongqun He pGT36 DNA vaccine plasmid PMID: 9569471] A DNA vaccine plasmid vector that has the plasmid label VR1040. This plasmid contains four copies of the mouse immunostimulatory sequence and is similar to VR1012. Rebecca Racz, Yongqun He VR1040 DNA vaccine plasmid PMID: 11883007 A DNA vaccine plasmid vector that has the plasmid label pcTPA. This plasmid is based on pcDNA3 and contains the hTPA signal sequence. Rebecca Racz, Yongqun He pcTPA DNA vaccine plasmid PMID: 16122850 A DNA vaccine plasmid vector that has the plasmid label pMV10.1. This plasmid contains a CMV promoter and a kanamycin resistance gene. Rebecca Racz, Yongqun He pMV10.1 DNA vaccine plasmid PMID: 16125280 A DNA vaccine plasmid vector that has the plasmid label pET11d. This plasmid is 5674 base pairs in length and contains an ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2628/ pET11d DNA vaccine plasmid PMID: 16520093 A DNA vaccine plasmid vector that has the plasmid label pUMVC4b. This plasmid is 4478 base pairs in length and contains a CMV promoter and kanamycin and ampicillin resistance genes. Rebecca Racz, Yongqun He Aldevron: http://www.aldevron.com/products/dnas/umvc_expression/; Sequence: https://system.netsuite.com/c.606687/pUMVC4a.txt pUMVC4b DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pRC. This plasmid is 7400 base pairs in length and contains CMV and RSV promoters. Rebecca Racz, Yongqun He pRC DNA vaccine plasmid PMID: 9879611 A DNA vaccine plasmid vector that has the plasmid label pAK-4. This plasmid is 6600 base pairs in length and contains a CMV promoter and kanamycin and ampicillin resistance genes. Rebecca Racz, Yongqun He pAK-4 DNA vaccine plasmid PMID: 16157425 A DNA vaccine plasmid vector that has the plasmid label pCMVi(-H3)Ubs. This plasmid contains a CMV promoter. Rebecca Racz, Yongqun He pCMVi(-H3)Ubs DNA vaccine plasmid PMID: 10438054 A DNA vaccine plasmid vector that has the plasmid label Auxo-GTU. Rebecca Racz, Yongqun He patent applications, PCT/FI02/00379 filed 03.05.2002 and PCT/FI2004/ 000540 filed 15.09.2004 Auxo-GTU DNA vaccine plasmid PMID: 16359234 A DNA vaccine plasmid vector that has the plasmid label pCMN160. This plasmid has a CMV promoter. Rebecca Racz, Yongqun He pCMN160 DNA vaccine plasmid PMID: 9142121 A DNA vaccine plasmid vector that has the plasmid label V1Jns. This plasmid contains the human CMV promoter, enhancer and intron A as well as the polyadenylation sequences of bovine growth hormone. Rebecca Racz, Yongqun He V1Jns DNA vaccine plasmid PMID: 9127013 A DNA vaccine plasmid vector that has the plasmid label pND-14. This plasmid contains a CMV promoter, ampicillin resistance gene, a tissue plasminogen activator leader sequence, a bovine growth hormone terminator, and constitutive transport element from simian retrovirus. Rebecca Racz, Yongqun He pND-14 DNA vaccine plasmid PMID: 15149785 A DNA vaccine plasmid vector that has the plasmid label pSecTag2A. This plasmid is 5159 base pairs in length and contains a CMV promoter and ampicillin reisistance gene. Rebecca Racz, Yongqun He Invitrogen: http://tools.invitrogen.com/content/sfs/manuals/psectag2_man.pdf; Sequence: http://tools.invitrogen.com/content/sfs/vectors/psectag2a_seq.txt pSecTag2A DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pRc/CMV-HBs(S). This plasmid is 5618 base pairs in length and contains a CMV promoter and ampicillin resistance gene. Rebecca Racz, Yongqun He Bioresearch Online: http://www.bioresearchonline.com/doc/pRcCMV-HBsS-0001 Also known as pCMV-S pRc/CMV-HBs(S) DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pcDNA. Rebecca Racz, Yongqun He pcDNA DNA vaccine plasmid PMID: 15839423 A DNA vaccine plasmid vector that has the plasmid label proVAX. This plasmid contains a CMV promoter and a hCG-β leader sequence. Rebecca Racz, Yongqun He proVAX DNA vaccine plasmid PMID: 17310492 A DNA vaccine plasmid vector that has the plasmid label p1012. Rebecca Racz, Yongqun He p1012 DNA vaccine plasmid PMID: 11117750 A DNA vaccine plasmid vector that has the plasmid label pUSE-. This plasmid is a mammalian expression vector derived from pCI-neo. Rebecca Racz, Yongqun He pUSE- DNA vaccine plasmid PMID: 11507187 A DNA vaccine plasmid vector that has the plasmid label APL023. Rebecca Racz, Yongqun He APL023 DNA vaccine plasmid PMID: 17241713 A DNA vaccine plasmid vector that has the plasmid label pEGFP-N1. This plasmid is 4733 base pairs in length and contains a CMV promoter and kanamycin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2491/ pEGFP-N1 DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pCDL-SRa296. This plasmid is 3700 base pairs in length and contains a SRalpha promoter. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2084/ pCDL-SRa296 DNA vaccine plasmid PMID: 2827008 A DNA vaccine plasmid vector that has the plasmid label pUSK. Rebecca Racz, Yongqun He pUSK DNA vaccine plasmid PMID: 15121294 A DNA vaccine plasmid vector that has the plasmid label pUBIQ. This plasmid is derived from pGEM3 and contains a CMV promoter and an ampicillin resistance gene. Rebecca Racz, Yongqun He pUBIQ DNA vaccine plasmid PMID: 12922097 A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/Hygro(-). This plasmid is 5596 base pairs in length and contains a CMV promoter and an ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2105/ Differs from other pcDNA3.1 in drug resistance; +/- refers to orientation of f1 ori pcDNA3.1/Hygro(-) DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pCMV3ISS. This plasmid is a eukaryotic expression vector. Rebecca Racz, Yongqun He pCMV3ISS DNA vaccine plasmid PMID: 18951941 A DNA vaccine plasmid vector that has the plasmid label pWRG7079. This plasmid contains a CMV promoter and a kanamycin resistance gene and differs from pWRG7077 by the insertion of a TPA sequence. Rebecca Racz, Yongqun He pWRG7079 DNA vaccine plasmid PMID: 12922144 A DNA vaccine plasmid vector that has the plasmid label pVR1020. This plasmid contains a CMV promoter and kanamycin resistance gene. Rebecca Racz, Yongqun He pVR1020 DNA vaccine plasmid PMID: 11292786 A DNA vaccine plasmid vector that has the plasmid label nkCMVintpolyli. This plasmid contains a CMV promoter. Rebecca Racz, Yongqun He nkCMVintpolyli DNA vaccine plasmid PMID: 8666931 A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/V5-His-TOPO. This plasmid is 5523 base pairs in length and contains a CMV promoter and ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/5587/ pcDNA3.1/V5-His-TOPO DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pIRES1neo. This plasmid is 5257 base pairs in length and contains an ampicillin resistance gene. Rebecca Racz, Yongqun He Metalife: http://www.metalife.com/Genbank/1899169 pIRES1neo DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pRc/RSV. This plasmid is 5224 base pairs in length and contains a RSV LTR promoter and ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/3908/ pRc/RSV DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pCI-TPA. This plasmid contains the N-terminal signal sequence of TPA. Rebecca Racz, Yongqun He pCI-TPA DNA vaccine plasmid PMID: 19428891 A DNA vaccine plasmid vector that has the plasmid label pCSIVgag. Rebecca Racz, Yongqun He pCSIVgag DNA vaccine plasmid PMID: 18000037 A DNA vaccine plasmid vector that has the plasmid label pVacc4. This plasmid is a derivative of pVacc1 and contains a CMV promoter. Rebecca Racz, Yongqun He pVacc4 DNA vaccine plasmid PMID: 15004179 A DNA vaccine plasmid vector that has the plasmid label pBC12B1. This plasmid is a eukaryotic expression vector. Rebecca Racz, Yongqun He pBC12B1 DNA vaccine plasmid PMID: 10948115 A DNA vaccine plasmid vector that has the plasmid label pGFP. This plasmid is 3300 base pairs in length and contains a lac promoter and an ampicillin resistance gene. Rebecca Racz, Yongqun He Clontech: http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=17740 pGFP DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pCMV-beta. This plasmid is 7164 base pairs in length and contains a CMV promoter and ampicllin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2245/ pCMV-beta DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pSW3891. This plasmid contains a CMV promoter. Rebecca Racz, Yongqun He pSW3891 DNA vaccine plasmid PMID: 16919703 A DNA vaccine plasmid vector that has the plasmid label pJW4304. This plasmid is 5132 base pairs in length and contains a CMV promoter. Rebecca Racz, Yongqun He NIH AIDS Reagent Program: https://www.aidsreagent.org/reagentdetail.cfm?t=cloning_vectors&id=76 pJW4304 DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pGT146-mIL-12. Rebecca Racz, Yongqun He pGT146-mIL-12 DNA vaccine plasmid PMID: 18694965 A DNA vaccine plasmid vector that has the plasmid label pDNAVACC. Rebecca Racz, Yongqun He pDNAVACC DNA vaccine plasmid PMID: 21134447 A DNA vaccine plasmid vector that has the plasmid label VR1055. This plasmid is derived from pUC19 and contains a CMV promoter, kanamycin resistance gene, a cloning polylinker, and a transcriptional terminator region derived from the rabbit beta-globin gene. Rebecca Racz, Yongqun He VR1055 DNA vaccine plasmid PMID: 9990062 A DNA vaccine plasmid vector that has the plasmid label pRSC. Rebecca Racz, Yongqun He pRSC DNA vaccine plasmid PMID: 21185849 A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1(Zeo)+. This plasmid is 5015 base pairs in length and contains a zeocin selectable marker, a CMV promoter, and an ampicillin resistance gene. Rebecca Racz, Yongqun He Addgene: http://www.addgene.org/vector-database/2110/ pcDNA3.1(Zeo)+ DNA vaccine plasmid A DNA vaccine plasmid vector that has the plasmid label pVF. Rebecca Racz, Yongqun He Also known as pVAX-Flag pVF DNA vaccine plasmid PMID: 23026687 A SARS-CoV-2 vaccine consisting of autologous dendritic cells previously loaded ex vivo with spike protein. Philip Huang NCT04386252 AV-COVID-19 A SARS-CoV-2 vaccine that includes a protein antigen, SARS-CoV-2 Spike RBD, adsorbed to the adjuvant Alhydrogel (Alum), in combination with another approved adjuvant, CpG 1018 Philip Huang https://www.biologicale.com/news.html Corbevax A SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB). Philip Huang CIGB-66 https://rpcec.sld.cu/en/trials/RPCEC00000345-En Abdala A SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB). Philip Huang https://rpcec.sld.cu/en/trials/RPCEC00000345-En CIGB-669 A SARS-CoV-2 inactivated virus vaccine by Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Co. Philip Huang, Oliver He NCT04852705 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php KCONVAC A stabilised pre-fusion SARS-CoV-2 spike protein vaccine produced in a baculovirus expression system and manufactured by Sanofi Pasteur and GlaxoSmithKline Philip Huang CoV2 preS dTM PubMed ID: 33887209 VAT00002 An influenza virus vector SARS-CoV-2 vaccine administered as an intranasal spray manufactured by University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy. Philip Huang http://www.chictr.org.cn/showprojen.aspx?proj=55421 DelNS1-2019-nCoV-RBD-OPT1 A SARS-CoV-2 protein subunit vaccine that relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). Philip Huang NCT04527575 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php EpiVacCorona A SARS-CoV-2 plasmid DNA vaccine developed by GeneOne Life Science. Philip Huang NCT04673149 GLS-5310 A rVSV-SARS-CoV-2-S vaccine developed by the Israel Institute for Biological Research (IIBR) Philip Huang Brilife NCT04608305 IIBR-100 A SARS-CoV-2 recombinant vector vaccine by Shenzhen Geno-Immune Medical Institute Philip Huang NCT04276896 LV-SMENP-DC A SARS-CoV-2 subunit vaccine with recombinant SARS-CoV-2 spike (S) protein and aluminum phosphate adjuvant Philip Huang NCT04683484 Nanocovax A SARS-CoV-2 inactivated vaccine manufactured by the Research Institute for Biological Safety Problems (Republic of Kazakhstan) Philip Huang QazCovid-in NCT04691908 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php QazVac A SARS-CoV-2 virus-like particle vaccine that contains the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike (S) protein and is adjuvanted with aluminum. Philip Huang ACTRN12620001308987 RBD-HBsAg VLP A SARS-CoV-2 protein subunit vaccine by West China Hospital Philip Huang NCT04640402 Recombinant SARS-CoV-2 vaccine (Sf9 cell) Philip Huang A SARS-CoV-2 recombinant protein vaccine that uses the Baculovirus expression vector system https://www.shionogi.com/content/dam/shionogi/global/news/pdf/2020/12/e-201216.pdf S-268019 A SARS-CoV-2 subunit vaccine developed by Finlay Vaccine Institute (IFV) Philip Huang FINLAY-FR-2 https://rpcec.sld.cu/en/trials/RPCEC00000347-En Soberana 02 A SARS-CoV-2 vaccine candidate that uses a measles virus vector platform, and is made by Merck. Development of the vaccine was discontinued on January 25, 2021. Philip Huang, Oliver He https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/ V591 A SARS-CoV-2 inactivated, Vero-cell based vaccine adjuvanted with aluminum and CpG 1018. It uses the manufacturing platform of Valneva’s commercial Japanese encephalitis (JE) vaccine Philip Huang https://valneva.com/research-development/covid-19-vla2001/ VLA2001 'A SARS DNA vaccine that is made from recombinant plasmid containing nucleocapsid protein (N) sequence constructed then expressed and purified from E. coli bacteria’ Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5732 PubMed ID:16423399 SARS N protein DNA vaccine VIOLIN ID: 5732 'A SARS DNA combination vaccine that is made from recombinant plasmids’ containing membrane protein (M) and nucleocapsid protein (N) sequences constructed then expressed and purified from E. coli bacteria’ Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5733 PubMed ID:16423399 SARS N + SARS M DNA vaccine VIOLIN ID: 5733 'A SARS DNA vaccine that is made from recombinant plasmid containing membrane protein (M) sequence constructed then expressed and purified from E. coli bacteria’ Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5731 PubMed ID:16423399 SARS M protein DNA vaccine VIOLIN ID: 5731 'A SARS DNA vaccine that is made from oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained CTLA4HingeSARS800 with SARS-CoV S protein‘ Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5738 PubMed ID:15993989 Salmonella-CTLA4-S SARS DNA vaccine VIOLIN ID: 5738 A SARS DNA vaccine that is made from intraperitoneal recombinant spike polypeptide generated by amplififying gene encoding amino acids residues 14-667 of S protein that was cloned BamHI and KpnI sites of vector pQE-31 that was generated by Escherichia coli Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5734 PubMed ID:15993989 Recombinant SARS spike polypeptide vaccine VIOLIN ID: 5734 A SARS DNA vaccine that is made from CTLA4HingeSARS800 DNA with SARS-CoV S protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5737 PubMed ID:15993989 SARS CTLA4-S DNA vaccine VIOLIN ID: 5737 A SARS DNA vaccine that is made from tpa-optimize800 DNA with SARS-CoV S protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5736 PubMed ID:15993989 SARS tPA-S DNA vaccine VIOLIN ID: 5736 A SARS DNA vaccine made from CTLA4HingeSARS800 DNA with SARS-CoV S protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5739 PubMed ID:15993989 Salmonella-tPA-S SARS DNA vaccine VIOLIN ID: 5739 A SARS recombinant vector vaccine that is made from of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5729 PubMed ID:23142821 SARS MA-ExoN vaccine VIOLIN ID: 5729 A SARS recombinant vector vaccine that is made from recombinant MA15 virulent mouse-adapted SARS-CoV (MA15) background of E-deleted vaccine candidate (rMA15-ΔE) Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5728 PubMed ID:16423399 SARS rMA15-ΔE vaccine VIOLIN ID: 5728 A SARS recombinant vector vaccine that is made from a recombinant live-attenuated modified vaccinia virus Ankara (MVA) that had a full-length SARS-CoV envelope Spike (S) glycoprotein gene introduced into the deletion III region of the MVA genome. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5726 PubMed ID:15708987 SARS ADS-MVA vaccine VIOLIN ID: 5726 A MERS subunit vaccine that has a combined adjuvant of aluminum hydroxide and CpG oligodeoxynucleotides. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5714 PubMed ID:29618723 MERS-CoV S vaccine adjuvanted with CpG and Alum VIOLIN ID: 5714 A MERS inactivated whole virus vaccine that has a combined adjuvant that has a combined adjuvant of aluminum hydroxide and CpG oligodeoxynucleotides. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5721 PubMed ID:29618723 Inactivated whole MERS-CoV (IV) vaccine with CpG and Alum VIOLIN ID: 5721 A SARS recombinant vector vaccine made from a recombinant form of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5725 PubMed ID:15096611 SARS MVA/S vaccine VIOLIN ID: 5725 A SARS inactivated vaccine made from whole killed (inactivated by beta-propiolactone) SARS-CoV Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5730 PubMed ID:16476986 β-propiolactone-inactivated SARS-CoV vaccine VIOLIN ID: 5730 A SARS recombinant vector vaccine made of combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5727 PubMed ID:16476986 SARS Ad S/N vaccine VIOLIN ID: 5727 A MERS recombinant vector vaccine made of a recombinant adenoviral vector encoding the the S1 extracellular domain of S protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5719 PubMed ID:25192975 Ad5.MERS-S1 vaccine VIOLIN ID: 5719 A MERS recombinant vector vaccine made of a recombinant adenoviral vector encoding the full-length MERS-CoV S protein (Ad5.MERS-S) Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5720 PubMed ID:25192975 Ad5.MERS-S vaccine VIOLIN ID: 5720 A MERS DNA vaccine made of plasmid that encoded S1 subunit only Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5715 PubMed ID:26218507 MERS England1 S1 protein subunit Vaccine VIOLIN ID: 5715 A MERS combination vaccine made of made of the VRC8400 plasmid that encodes the full-length, membrane anchore MERS spike protein and a DNA vaccine that is a plasmid that encoded S1 subunit Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5717 PubMed ID:26218507 MERS England1 S DNA + England1 S protein subunit vaccine VIOLIN ID: 5717 A MERS DNA vaccine made of the VRC8400 plasmid that encodes the full-length, membrane anchore MERS spike protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5716 PubMed ID:26218507 MERS England1 S DNA Vaccine VIOLIN ID: 5716 A MERS subunit vaccine made of neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the ribosomal binding domain (RBD) of the MERS-CoV S protein that was expressed by baculovirus-insect cell sf9-derived recombinant MERS-CoV. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5723 PubMed ID:28536429 MERS rRBD plus alum vaccine VIOLIN ID: 5723 A MERS DNA vaccine made of plasmid that encodes the first 725 amino acids of S from MERS-CoV Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5718 PubMed ID:28314561 MERS-CoV pcDNA3.1-S1 DNA vaccine VIOLIN ID: 5718 A MERS recombinant vector virus made from chimeric virus based on the vesicular stomatitis virus (VSV) in which the G gene was replaced by MERS-CoV S gene (VSVΔG-MERS). Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5722 PubMed ID:29246504 VSVΔG-MERS vaccine VIOLIN ID: 5722 A MERS subunit vaccine made of a neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the N-terminal domain (NTD) of the MERS-CoV S1 subunit that was expressed by baculovirus-insect cell sf9-derived recombinant MERS-CoV. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5724 PubMed ID:28536429 MERS rNTD vaccine VIOLIN ID: 5724 A SARS inactivated vaccine made from inactivated whole virus by formalin and Ultraviolet radiation, hence Double Inactivated (DI) Vaccine Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5742 PubMed ID:22536382 inactivated whole (formalin and UV radiation) SARS-CoV vaccine VIOLIN ID: 5742 A SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5743 PubMed ID:22536382 recombinant SARS DNA spike protein vaccine VIOLIN ID: 5743 A SARS VLP vaccine made from the SARS-CoV spike protein (S) and the Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV) Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5747 PubMed ID:22536382 Viral-like-particle S-MHV SARS vaccine VIOLIN ID: 5747 A SARS inactivated vaccine made from SARS-CoV inactivated by ultraviolet radiation and a Toll-Like Receptor Agonist Adjuvant is added to prevent eosinophilic immunopathology Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5741 PubMed ID:22536382 UV-Inactivated SARS + TLR agonist vaccine VIOLIN ID: 5741 A SARS inactivated vaccine made from SARS-CoV inactivated by ultraviolet radiation Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5740 PubMed ID:22536382 UV-Inactivated SARS vaccine VIOLIN ID: 5740 A MERS recombinant vector made from Venezuelan equine encephalitis replicons bearing epitopes of N protein from MERS. Crosslisted as SARS vaccine (VIOLINID:5754). Efficacy higher intranasally than subcutaneously. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5748 PubMed ID:26954467 VRP-MERS-N vaccine VIOLIN ID: 5748 A SARS recombinant vector vaccine made from Venezuelan equine encephalitis replicons (VRP) encoding a SARS-CoV CD4+ T cell epitope vaccinated intranasally. Crosslisted as MERS vaccine (VIOLINID:5789). Efficacy higher intranasally than subcutaneously. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5749 PubMed ID:26954467 VRP-SARS-N vaccine VIOLIN ID: 5749 A MERS DNA vaccine made of plasmid vaccines that encoded S1 subunit only Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5750 PubMed ID:26954467 rVV-SARS vaccine VIOLIN ID: 5750 A MERS recombinant vector vaccine made of live-attenuated measles virus (MV) vaccine encoding the MERS-CoV spike protein (MERS-S). Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5757 PubMed ID:26355094 MVvac2-MERS-S(H) vaccine VIOLIN ID: 5757 A MERS recombinant vector vaccine made of live-attenuated measles virus (MV) vaccine encoding the MERS-CoV nucleocapsid protein (MERS-N). Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5760 PubMed ID:29902727 MVvac2-MERS-N vaccine VIOLIN ID: 5760 A MERS recombinant vector made of Chimpanzee adenovirus Oxford 1 vector expressing S protein from MERS-CoV’ Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5751 PubMed ID:29263883 ChAdOx1-MERS-S vaccine VIOLIN ID: 5751 A MERS recombinant vector made of Adenovirus type 41 used as vector for MERS-CoV S protein.’ Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5760 PubMed ID:25762305 Ad41.MERS vaccine VIOLIN ID: 5760 A MERS VLP vaccine made from a recombinant baculovirus co-expresssing the spike S, envelope (E), and membrane (M) proteins of MERS. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5758 PubMed ID:23986586 MVA-MERS vaccine VIOLIN ID: 5758 A SARS DNA vaccine made from encoding calrectulin linked to a SARS-CoV N protein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5753 PubMed ID:15078946 CRT-N SARS vaccine VIOLIN ID: 5753 A SARS recombinant vector vaccine made from a line attenuated and recombinant SARS-CoV lacking the E gene Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3155 PubMed ID:18463152 rSARS-CoV-ΔE vaccine VIOLIN ID: 3155 A MERS recombinant vector made of MVvac2 (measle virus) expressing a soluble, truncated version of spike glycoprotein of MERS-CoV in its full length cloned into the MVvac2 genome and rescued. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5759 PubMed ID:26355094 MVvac2-MERS-solS vaccine VIOLIN ID: 5759 A SARS-CoV-2 whole virus vaccine made from a purified inactivated SARS-CoV-2 virus. Anthony Huffman, Philip Huang, Rohit Goru, Oliver He PiCoVacc VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5761 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://en.wikipedia.org/wiki/CoronaVac PubMed ID:32376603 CoronaVac VIOLIN ID: 5761 A SARS-CoV-2 subunit vaccine composed of the SARS-CoV-2 S protein receptor-binding domain produced in Chinese hamster ovary (CHO) cells and adjuvant aluminum hydroxide. Anthony Huffman, Philip Huang VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5764 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php ZF2001 VIOLIN ID: 5764 A SARS-CoV-2 RNA vaccine made of self-coding RNA encoding SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle. Anthony Huffman, Philip Huang VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5771 PubMed ID:32647131 LNP-nCoVsaRNA VIOLIN ID: 5771 A SARS-CoV-2 vaccine made from a recombinant adinvorius type-5 expressing SARS-CoV-2 S protein. A SARS-CoV-2 vaccine made of self-coding RNA encoding SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle. Anthony Huffman, Philip Huang VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5768 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php PubMed ID:32450106 Ad5-nCoV VIOLIN ID: 5768 A MERS DNA Vaccine that is made of the plasmid pGX9109 expressing MERS S protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5769 PubMed ID:32450106 MERS GLS-5300 vaccine VIOLIN ID: 5769 A SARS DNA vaccine made of a single closed plasmid DNA marcromolecule (VRC-8138) that produces a deletion mutant of the SARS Spike glycoprotein Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5770 PubMed ID:18824060 VRC-SRSDNA015-00-VP vaccine VIOLIN ID: 5770 A SARS-CoV recombinant vector vaccine that is made from the Newcastle disease virus from the mesogenic Beaudette C strainexpressing SARS-CoV S protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5766 PubMed ID:17535926 SARS NDV-BC/S vaccine VIOLIN ID: 5766 A SARS-CoV recombinant vector vaccine that is made from the Newcastle disease virus from the lentogenic LaSota strain expressing SARS-CoV S protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5767 PubMed ID:17535926 SARS NDV-VF/S vaccine VIOLIN ID: 5767 A SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5745 PubMed ID:16497416 rDNA-expressed S SARS protein vaccine VIOLIN ID: 5745 A SARS DNA vaccine made up of arecombinat vector vaccine made from recombinant measles virus expressing S protein and recombinant measles virus expressing N protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5762 PubMed ID:18346823 rMV-S + rMV-N vaccine VIOLIN ID: 5762 A SARS-CoV recombinant vector made from a baculovirus vector expressing SARS-CoV S protein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5763 PubMed ID:22536382 SARS-CoV Baculovirus S protein Vaccine VIOLIN ID: 5763 A MERS recombinant vector made of recombinant modified vaccinia virus Ankara (rMVA) vaccine vector carrying full MERS-CoV spike glycoprotein. Anthony Huffman VIOLIN: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5752 PubMed ID:32325037 MVA-MERS-S vaccine VIOLIN ID: 5752 A SARS-CoV-2 single dose intranasal vaccine manufactured by Altimmune in collaboration with the University of Alabama-Birmingham. This vaccine was discontinued after a Phase 1 trial. Philip Huang https://altimmune.com/adcovid/ AdCOVID A plasmid pCI-N, encoding the full-length N gene of SARS-CoV, was constructed and expressed in Escherichia coli DH5alpha [PubMed: 15582659] SARS-CoV pCI-N DNA vaccine VIOLIN ID: 5735 A SARS-CoV 2 (rSARS-CoV-2) subunit vaccine made of nanoparticles composed of a trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M1 adjuvant. Anthony Huffman, Philip Huang Covovax PubMed:32376603 NVX-CoV2373 A SARS-CoV-2 RNA vaccine that has a lipid nanoparticle (LNP) platform and Spike protein antigen Anthony Huffman, Philip Huang NCT04758962 CoV2 SAM A SARS-CoV2 RNA vaccine made of lipid nanoparticle with mRNA which encodes the S-2P antigen, made of the SARS-CoV-2 glycoprotein with a transmembrane anchor and intact S1-S2 cleavage site. Anthony Huffman, Philip Huang, Rohit Goru, Oliver He COVID-19 Vaccine Moderna CX-024414 mRNA-1273 PubMed:32663912 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://en.wikipedia.org/wiki/MRNA-1273 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine Moderna COVID-19 vaccine A SARS-CoV2 recombinat vector vaccine made of a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein Anthony Huffman, Philip Huang AZD1222 COVID-19 Vaccine AstraZeneca ChAdOx1 nCoV-19 PubMed:32702298 https://en.wikipedia.org/wiki/AZD1222 Covishield Oxford–AstraZeneca COVID-19 vaccine violinID:2020-001072-15, 2020-001228-32, ISRCTN89951424 A SARS-CoV-2 recombinant viral vector vaccine composed of Ad26 vector expressing S protein. Anthony Huffman, Philip Huang, Oliver He Ad26COVS1 JNJ-78436735 Johnson & Johnson COVID-19 vaccine PubMed:32731257 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php Ad26.COV2.S A SARS-CoV-2 inactivated whole virus vaccine that is developed by the Wuhan Institute of Biological Products. Anthony Huffman, Philip Huang PubMed:32789505 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php WIBP-CorV A SARS-CoV-2 mRNA vaccine made of lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 manufactured by Academy of Military Science (AMS), Walvax Biotechnology, and Suzhou Abogen Biosciences. Anthony Huffman, Philip Huang PubMed:32795413 ARCoV A SARS-CoV-2 plasmid DNA vaccine that encodes the envelope protein. Anthony Huffman PubMed:32800805 ZyCoV-D A SARS-CoV-2 recombinant viral vector vaccine composed of Ad26 and Ad5 vectors expressing S protein that lyophilised. Anthony Huffman, Philip Huang, Rohit Goru, Oliver He PubMed:32896291 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://en.wikipedia.org/wiki/Gam-COVID-Vac Gam-COVID-Vac Sputnik V A SARS-CoV-2 investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle Anthony Huffman, Philip Huang PubMed:32973505 ARCT-021 A SARS-CoV-2 DNA vaccine developed by AnGes. Anthony Huffman NCT04463472 AG0301-COVID19 A SARS-CoV-2 inactivated whole virus vaccine that produced in Vero cells that is developed by the Beijing Institute of Biological Products. Anthony Huffman, Philip Huang ChiCTR2000032459, ChiCTR2000034780 http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://en.wikipedia.org/wiki/BBIBP-CorV https://go.drugbank.com/drugs/DB15807 BBIBP-CorV A SARS-CoV-2 inactivated whole virus vaccine that is developed by the Chinese Academy of Medical Sciences . Anthony Huffman, Philip Huang IMBCAMS COVID-19 vaccine PubMed:32376603 Covidful Chinese Academy of Medical Sciences COVID-19 vaccine A SARS-CoV-2 mRNA vaccine developed by CureVac AG and CEPI. Anthony Huffman, Philip Huang NCT04449276 CVnCoV A SARS-CoV 2 recombinant viral vector using Gorilla Adenovirus that encodes for SARS-CoV-2 Spike protein. Anthony Huffman, Philip Huang https://www.covidx.eu/grad-cov2 GRAd-COV2 A SARS-CoV-2 DNA vaccine expressing the SARS-CoV-2 S protein Anthony Huffman, Philip Huang NCT04445389 GX-19 A SARS-CoV-2 subunit vaccine that is made of a protein subunit made of the RBD domain of the S protein. Philip Huang PMID:32973505 Anthony Huffman KBP-COVID-19 A DNA vaccine that expresses S protein from the pGX9501 vector Philip Huang PMID:32433465 Anthony Huffman INO-4800 A SARS-CoV-2 protein subunit vaccine developed by Adimmune Corporation. AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant. Philip Huang, Oliver He NCT04522089 https://go.drugbank.com/drugs/DB16436 https://www.smartpatients.com/trials/NCT04522089 AdimrSC-2f A SARS-CoV-2 oral DNA vaccine that delivers plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2. Philip Huang NCT04334980 https://www.symvivo.com/covid-19 bacTRL-Spike A SARS-CoV-2 mRNA vaccine manufactured by Chulalongkorn University Philip Huang NCT04566276 ChulaCov19 A synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine Philip Huang NCT04639466 COH04S1 Anthony Huffman gorilla adenovirus vector an adenovirus vaccine vector that uses a gorilla adenovirus. Anthony Huffman adenovirus serotype 26 vaccine vector NCBI Taxonomy ID: 46928 an adenovirus vaccine vector that uses an Adenovirus serotype 26 strain. A nanoparticle vector composed of lipids. PMID: 20402623 Anthony Huffman lipid nanoparticle vector A vaccine component composed of a synthetic component that is solid and spherical structures ranging to around 100 nm in size and prepared from natural or synthetic polymers. PMID: 22353619 Anthony Huffman nanoparticle vector A chimpanzee adenovirus vaccine vector that patented by Oxford and derived from ChAd serotype Y25 that exchanges the native E4 orf4, orf6 and orf6/7 genes for those from HAdV-C5 PMID: 29527232 chimpanzee adenovirus Oxford1 vaccine vector ChAdOx1 A chimpanzee adenovirus vaccine vector developed by Oxford by deleting E1/E3 from ChAd68 with a modified E4 region. PMID: 29527232 chimpanzee adenovirus Oxford2 vaccine vector ChAdOx2 A SARS-CoV-2 DNA vaccine developed by Providence Health & Services. Philip Huang NCT04627675 CORVax12 A SARS-CoV-2 recombinant vector vaccine employing the lentiviral vector system and developed by Shenzhen Geno-Immune Medical Institute. Philip Huang NCT04299724 COVID-19 aAPC vaccine A SARS-CoV-2 refrigerator-stable mRNA vaccine by Moderna that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD) Philip Huang NCT04813796 https://investors.modernatx.com/news-releases/news-release-details/first-participants-dosed-phase-1-study-evaluating-mrna-1283 mRNA-1283 A prophylactic plasmid DNA Vaccine for SARS CoV-2 by Entos Pharmaceuticals Philip Huang NCT04591184 Covigenix VAX-001 A SARS-CoV-2 live, attenuated vaccine manufactured by Codagenix, Inc. Philip Huang NCT04619628 COVI-VAC A SARS-CoV-2 inactivated vaccine developed by Health Institutes of Turkey Philip Huang ERUCOV-VAC NCT04691947 Turkovac A SARS-CoV-2 human adenovirus serotype 5 (hAd5) vector vaccine with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain. Philip Huang NCT04591717 hAd5-COVID-19 A SARS-CoV-2 subunit vaccine developed by University Hospital Tuebingen Philip Huang NCT04546841 IMP CoVac-1 A SARS-CoV-2 recombinant vector vaccine that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein (S) Philip Huang NCT04569383 MVA-SARS-2-S A SARS-CoV-2 subunit vaccine that contains the Spike (S) protein with CpG 1018 and aluminum content as adjuvant. Philip Huang NCT04487210 MVC-COV1901 A SARS-CoV-2 protein subunit vaccine developed by Vaxine Pty Ltd and CinnaGen Co. and adjuvanted with Advax Philip Huang SpikoGen NCT04453852 COVAX-19 A SARS-CoV-2 subunit vaccine with the S1 component of the SARS-CoV-2 spike (S) protein and SWE adjuvant. Philip Huang NCT04702178 COVAC A SARS-CoV-2 vaccine that uses a recombinant vesicular stomatitis virus (rVSV) platform, and is made by Merck. Development of the vaccine was discontinued on January 25, 2021. Philip Huang, Oliver He https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/ V590 A SARS-CoV-2 adenoviral vector-based oral vaccine by Vaxart expressing a SARS-CoV-2 antigen and dsRNA adjuvant Philip Huang NCT04563702 VXA-CoV2-1 A SARS-CoV-2 protein subunit vaccine manufactured by SK Bioscience Co., Ltd., and equipped with an aluminum hydroxide adjuvant Philip Huang NCT04750343 SKYCovione Philip Huang, Rohit Goru, Oliver He COVID-19 RNA vaccine Philip Huang, Rohit Goru, Oliver He COVID-19 recombinant vector vaccine Philip Huang, Rohit Goru, Oliver He COVID-19 recombinant adenoviral vector vaccine Philip Huang, Rohit Goru, Oliver He COVID-19 inactivated vaccine Philip Huang COVID-19 subunit vaccine Philip Huang COVID-19 DNA vaccine Philip Huang COVID-19 live, attenuated vaccine Philip Huang COVID-19 virus-like particle vaccine A saponin vaccine adjuvant comprised of 40 nm nanoparticles composed of Quillaja saponins, cholesterol and phospholipid. Philip Huang PMID:22844480 Matrix-M vaccine adjuvant A carbohydrate vaccine adjuvant derived from delta inulin Chemical Nature: Carbohydrate Mechanism of Action: Complement, Dendritic cells (unknown receptor), Other, Unknown Immune profile induced: mixed Th1/Th2 By routes: IM, IN, IP, SQ, inhalation, Point of Contact: Nikolai Petrovsky, Vaxine https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889 https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500 https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637 https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620 https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245 https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367 https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758 https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440 https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451 https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269 https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559 https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742 https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913 https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687 https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531 https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701 https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480 https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134 https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724 https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215 https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356 https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015 https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608 https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380 https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494 https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344 https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225 https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225 https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153 https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280 https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280 https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330 https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480 https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000 https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914 https://www.ncbi.nlm.nih.gov/pubmed/?term=12 Nikolai Petrovsky Oliver He Philip Huang Wolfgang Leitner PMID:22728225 https://vac.niaid.nih.gov/view?id=37 https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000 https://www.ncbi.nlm.nih.gov/pubmed/?term=12 https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440 https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134 https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758 https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215 https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913 https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330 https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225 https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367 https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724 https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620 https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245 https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701 https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153 https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531 https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480 https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500 https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269 https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451 https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480 https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344 https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914 https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280 https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608 https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380 https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637 https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687 https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742 https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015 https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356 https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889 https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280 https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494 https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559 37 Advax vaccine adjuvant A SARS-CoV-2 protein subunit vaccine manufactured by the Razi Vaccine and Serum Research Institute with a Spike protein antigen Philip Huang Razi Cov Pars A SARS-CoV-2 recombinant adenoviral vector vaccine that is manufactured by Bharat Biotech International Ltd. and administered intranasally Philip Huang NCT04751682 BBV154 A SARS-CoV-2 Chimpanzee Adenovirus serotype 6 vector vaccine manufactured by Gritstone Oncology and the National Institute of Allergy and Infectious Diseases Philip Huang NCT04776317 ChAdV68-S A SARS-CoV-2 inactivated vaccine by Shifa Pharmed Philip Huang https://en.irct.ir/trial/52701 COVIran Barakat A SARS-CoV-2 plasmid DNA vaccine manufactured by Takis and Rottapharm Biotech Philip Huang https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003734-20/IT COVID-eVax A SARS-CoV-2 DNA vaccine manufactured by University of Sydney, Bionet Co., and Technovalia Philip Huang NCT04742842 COVIGEN A SARS-CoV-2 protein subunit vaccine by EuBiologics Co., Ltd. Philip Huang NCT04783311 EuCorVac-19 A SARS-CoV-2 lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant Philip Huang NCT04785144 mRNA-1273.351 A SARS-CoV-2 protein subunit vaccine by SK Bioscience Philip Huang NCT04760743 NBP2001 A SARS-CoV-2 recombinant viral vector vaccine by Mahidol University Philip Huang NCT04764422 NDV-HXP-S A SARS-CoV-2 mRNA vaccine by Providence Therapeutics Philip Huang NCT04765436 PTX-COVID19-B A SARS-CoV-2 protein subunit vaccine manufactured by Walter Reed Army Institute of Research Philip Huang NCT04784767 SpFN A SARS-CoV-2 virus-like particle vaccine that expresses a modified version of the SARS-CoV-2 spike (S) glycoprotein and is equipped with an aluminum phosphate adjuvant. It is manufactured by VBI Vaccines Inc. and is delivered intramuscularly. Philip Huang NCT04773665 VBI-2902a A SARS-CoV-2 inactivated vaccine developed by Organization of Defensive Innovation and Research in Iran Philip Huang https://en.irct.ir/trial/54133 FAKHRAVAC A SARS-CoV-2 live, attenuated vaccine manufactured by Meissa Vaccines, Inc. that expresses the spike (S) protein of SARS-CoV-2. Philip Huang NCT04798001 MV-014-212 A SARS-CoV-2 mRNA vaccine that is manufactured by Sanofi Pasteur Philip Huang NCT04798027 MRT5500 A SARS-CoV-2 inactivated whole virus vaccine developed by the Chumakov Centre at the Russian Academy of Sciences Philip Huang http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php CoviVac A SARS-CoV-2 protein subunit vaccine manufactured by Instituto Finlay de Vacunas. It is used as a booster dose for the Soberana 02 COVID-19 vaccine Philip Huang https://rpcec.sld.cu/trials/RPCEC00000366-En Soberana Plus A SARS-CoV-2 mRNA vaccine manufactured by Daiichi Sankyo Co., Ltd. Philip Huang Daiichi Sankyo Co., Ltd. DS-5670a A SARS-CoV-2 recombinant Newcastle Disease Virus vector vaccine expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein Philip Huang NCT04830800 COVIVAC A SARS-CoV-2 subunit vaccine developed by Livzon Mabpharm Inc. Philip Huang ChiCTR2100045107 V-01 A SARS-CoV-2 subunit vaccine developed by the National Vaccine and Serum Institute of China Philip Huang NCT04869592 COVID-19 subunit vaccine by National Vaccine and Serum Institute of China A SARS-COV-2 temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. Philip Huang NCT04863131 Elixirgen Therapeutics, Inc. EXG-5003 A SARS-CoV-2 inactivated vaccine developed by KM Biologics Co., Ltd. Philip Huang jRCT2071200106 KD-414 A COVID-19 virus-like particle vaccine developed by the Scientific and Technological Research Council of Turkey Philip Huang NCT04818281 COVID-19 VLP vaccine by the Scientific and Technological Research Council of Turkey A SARS-CoV-2 subunit vaccine by Jiangsu Rec-Biotechnology Co., Ltd. Philip Huang NCT04818801 ReCOV A SARS-CoV-2 inactivated virus vaccine by Kocak Farma Philip Huang NCT04838080 Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine A SARS-CoV-2 recombinant adenoviral vector vaccine by Tetherex Pharmaceutical Corporation Philip Huang NCT04839042 SC-Ad6-1 A COVID-19 virus-like particle vaccine developed by Radboud University Philip Huang NCT04839146 ABNCoV2 A SARS-CoV-2 Lipid-Inorganic Nanoparticle (LION™) formulated replicating mRNA vaccine that encodes for a full-length spike (S) protein of the SARS-CoV-2 virus Philip Huang NCT04844268 HDT-301 A SARS-CoV-2 inactivated virus vaccine by the Scientific and Technological Research Council of Turkey adjuvanted by aluminum hydroxide and CpG ODN Philip Huang NCT04866069 COVID-19 inactivated vaccine by the Scientific and Technological Research Council of Turkey An MF59-adjuvanted SARS-CoV-2 subunit vaccine based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp (spike glycoprotein-clamp [sclamp]) Philip Huang PubMed ID: 33887208 MF59-adjuvanted SARS-CoV-2 Sclamp vaccine A recombinant Newcastle Disease Virus vectored vaccine for SARS-CoV-2 by Laboratorio Avi-Mex Philip Huang NCT04871737 COVID-19 rNDV vector vaccine by Laboratorio Avi-Mex A SARS-CoV-2 mRNA vaccine by Shanghai East Hospital and Stemirna Therapeutics Philip Huang ChiCTR2100045984 COVID-19 mRNA vaccine by Shanghai East Hospital and Stemirna Therapeutics A SARS-CoV-2 subunit vaccine by OSE Immunotherapeutics Philip Huang NCT04885361 CoVepiT A SARS-CoV-2 recombinant viral vector vaccine by the German Center for Infection Research Philip Huang NCT04895449 MVA-SARS-2-ST A SARS-CoV-2 subunit vaccine that is orally administered and manufactured by Syneos Health Philip Huang NCT04893512 Syneos Health CoV2-OGEN1 A COVID-19 vaccine that is authorized for emergent use, which is typically authorized based on an Emergency Use Authorization (EUA). Oliver He http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines authorized COVID-19 vaccine Oliver He http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php authorized COVID-19 RNA vaccine Oliver He http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php authorized inactivated COVID-19 vaccine Oliver He http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php authorized COVID-19 recombinant vector vaccine Oliver He authorized COVID-19 recombinant adenoviral vector vaccine Oliver He, Philip Huang http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php authorized COVID-19 subunit vaccine A vaccine adjuvant that includes IV270, which is a low–molecular weight TLR7 agonist conjugated to a phospholipid and is a highly potent and stable immune activator. Chemical Nature: Small molecule Receptor: TLR7 Mechanism of Action: Activation of innate immune pathways Immune profile induced: Th1-biased Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody affinity maturation, (6) Promotes antibody epitope spreading By routes: intramuscular and intranasal. Point of Contact: Dennis Carson, UCSD Dennis Carson Oliver He Wolfgang Leitner 1V270 PMID:25568203 PMID:28724768 PMID:32636840/ https://vac.niaid.nih.gov/view?id=6 6 1V270 vaccine adjuvant Chemical Nature: Small molecule Receptor: TLR4 Mechanism of Action: Innate immune activation Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Anti-inflammatory, (3) Promotes antibody epitope spreading. By routes: intramuscular and intranasal. Point of Contact: Dennis Carson, UCSD Amogh Madireddi Dennis Carson Oliver He Wolfgang Leitner 2B182C https://vac.niaid.nih.gov/view?id=7 https://www.ncbi.nlm.nih.gov/pubmed/?term=25568203 https://www.ncbi.nlm.nih.gov/pubmed/?term=28724768 https://www.ncbi.nlm.nih.gov/pubmed/?term=32636840 7 2B182C vaccine adjuvant A role of a material entity that binds to TLR7 and activates the receptor for pathogen recognition and activation of innate immunity. TLR7 agonist role Oliver He Toll-like receptor 7 agonist role https://en.wikipedia.org/wiki/TLR7 TLR7 receptor role A SARS-CoV-2 protein subunit vaccine manufactured by the Research Institute for Biological Safety Problems in Kazakhstan Philip Huang NCT04930003 QazCoVac-P https://en.wikipedia.org/wiki/T_helper_cell Th1 immunity stimulatory role https://en.wikipedia.org/wiki/T_helper_cell Th2 immunity stimulatory role A SARS-CoV-2 self-amplifying RNA vaccine sponsored by MRC/UVRI and LSHTM Uganda Research Unit Philip Huang NCT04934111 LNP-nCOV saRNA-02 A multivalent SARS-CoV-2 mRNA booster vaccine which combines mRNA-1273, Moderna’s authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine at the 50 µg dose level and lower. Philip Huang https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine mRNA-1273.211 A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. In (H115D)VHL35 peptide, histidine is substituted for an aspartic acid in position 115. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5304 https://github.com/vaccineontology/VO/issues/77 5304 Clinical trial (H115D)VHL35 Peptide Vaccine Chemical Nature: Small molecule Receptor: Dendritic cells (unknown receptor) Mechanism of Action: Innate immune activation Immune profile induced: Th1-biased Other Features/Characteristics: Other. Specify: Co-adjuvant for TLR4 ligands Point of Contact: Dennis Carson, UCSD Amogh Madireddi Dennis Carson Oliver He Wolfgang Leitner 2.00E+151 https://vac.niaid.nih.gov/view?id=9 9 2E151 vaccine adjuvant Chemical Nature: Small molecule Receptor: CLR (Dectin, Mincle) Mechanism of Action: None/Unknown Immune profile induced: Th17-component Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune Amogh Madireddi Kendal Ryter Oliver He Wolfgang Leitner UM-1098 https://vac.niaid.nih.gov/view?id=27 UM-1098 vaccine adjuvant Chemical Nature: Small molecule and Synthetic derivative of natural compound Receptor: Unknown and NLRP3 Mechanism of Action: Presumably the same as QS-21 in the absence of dose-limiting toxicity Immune profile induced: Th1-biased Other Features/Characteristics: None Point of Contact: Melissa Malhame, Adjuvance Technologies Amogh Madireddi Melissa Malhame Oliver He Wolfgang Leitner TQL-1055 https://vac.niaid.nih.gov/view?id=36 TQL-1055 vaccine adjuvant Chemical Nature: Emulsion Receptor: TLR2 and TLR4 Mechanism of Action: Activation of mucosal and systemic immunity Immune profile induced: Th1/Th17 Other Features/Characteristics: Promotes antibody affinity maturation Point of Contact: Ali Fattom, BlueWillow Biologics Ali Fattom Amogh Madireddi Oliver He Wolfgang Leitner NanoVax/NE01 https://vac.niaid.nih.gov/view?id=22 https://www.ncbi.nlm.nih.gov/pubmed/?term=31495593 https://www.ncbi.nlm.nih.gov/pubmed/?term=31515143 NanoVax/NE01 vaccine adjuvant Chemical Nature: Other Receptor: TLR4 Mechanism of Action: TLR4 agonist Immune profile induced: Th1-biased Other Features/Characteristics: None/Unknown Point of Contact: Darrick Carter, PAI Life Sciences Amogh Madireddi Darrick Carter Oliver He Wolfgang Leitner MiT4 https://vac.niaid.nih.gov/view?id=16 MiT4 vaccine adjuvant Chemical Nature: (1) Natural compound, (2) Carbohydrate, (3) Combination adjuvant Receptor: CLR (Dectin, Mincle) and NAIP Mechanism of Action: Activation of Dectin-2-expressing innate immune cells; dual targeting of injection site and draining lymph node. Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: Promotes antibody epitope spreading Point of Contact: Ivan Zanoni, Boston Children's Hospital Amogh Madireddi Ivan Zanoni Oliver He Wolfgang Leitner https://vac.niaid.nih.gov/view?id=14 Mannadjuvant Chemical Nature: Combination Adjuvant Receptor: TLR4 Mechanism of Action: TLR4 agonist plus potential inflammasome Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None/Unknown Point of Contact: Darrick Carter, PAI Life Sciences Amogh Madireddi Darrick Carter Oliver He Wolfgang Leitner LiT4 https://vac.niaid.nih.gov/view?id=20 LiT4 vaccine adjuvant Chemical Nature: Small molecule Receptor: TLR7 and TLR8 Mechanism of Action: None/Unknown Immune profile induced: Th1-biased Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune Amogh Madireddi Kendal Ryter Oliver He Wolfgang Leitner INI-4001 https://vac.niaid.nih.gov/view?id=28 INI-4001 vaccine adjuvant Chemical Nature: Small molecule Receptor: TLR4 Mechanism of Action: None/Unknown Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune Amogh Madireddi Kendal Ryter Oliver He Wolfgang Leitner INI-2004 https://vac.niaid.nih.gov/view?id=26 INI-2004 vaccine adjuvant Chemical Nature: Small molecule Receptor: TLR4 Mechanism of Action: None/Unknown Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune Amogh Madireddi Kendal Ryter Oliver He Wolfgang Leitner INI-2002 https://vac.niaid.nih.gov/view?id=29 INI-2002 vaccine adjuvant Chemical Nature: Small molecule and Combination adjuvant Receptor: TLR4 and TLR7 Mechanism of Action: Activation of antigen presenting cells and stimulating B cell proliferation Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody epitope spreading. By routes: intramuscular and intranasal. Point of Contact: Dennis Carson, UCSD Amogh Madireddi Dennis Carson Oliver He Wolfgang Leitner Fos47 https://vac.niaid.nih.gov/view?id=5 https://www.ncbi.nlm.nih.gov/pubmed/?term=25568203 https://www.ncbi.nlm.nih.gov/pubmed/?term=28724768 https://www.ncbi.nlm.nih.gov/pubmed/?term=32636840 Fos47 vaccine adjuvant Chemical Nature: Emulsion Receptor: TLR4 Mechanism of Action: Squalene emulsion plus TLR4 Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Sciences Amogh Madireddi Darrick Carter Oliver He Wolfgang Leitner EmT4 https://vac.niaid.nih.gov/view?id=17 EmT4 vaccine adjuvant Chemical Nature: Emulsion Receptor: Unknown Mechanism of Action: Squalene emulsion possibly triggering inflammasome or through extracellular ATP Immune profile induced: None Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Sciences Amogh Madireddi Darrick Carter Oliver He Wolfgang Leitner Em https://vac.niaid.nih.gov/view?id=18 Em vaccine adjuvant Chemical Nature: (1) Synthetic derivative of natural compound, (2) Nucleic acid Receptor: TLR3 Mechanism of Action: TLR3, possibly RIG-I - agonist Immune profile induced: Th1-biased Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection. By routes: SQ, IM. Point of Contact: Carolina Lopez, University of Washington at St Louis Amogh Madireddi Carolina Lopez Oliver He Wolfgang Leitner DDO DDO (Defective viral genome-Derived Oligonucleotide) Defective viral genome-Derived Oligonucleotide https://vac.niaid.nih.gov/view?id=30 https://www.ncbi.nlm.nih.gov/pubmed/?term=24099876 https://www.ncbi.nlm.nih.gov/pubmed/?term=29861183 DDO (Defective viral genome-Derived Oligonucleotide) vaccine adjuvant Chemical Nature: Synthetic derivative of natural compound Receptor: Unknown Mechanism of Action: (1) Antigen carrier, (2) Innate immune enhancer/activator Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection, (4) Other, (5) Promotes antibody affinity maturation, (6) High stability. By routes: IM, IN, IP, IN, ID, IVag. Specify: Safe for systemic or mucosal administration Point of Contact: Tulin Morcol, Captivate Pharma Amogh Madireddi Oliver He Tulin Morcol Wolfgang Leitner CaPNP (CaPtivant)(TM) https://vac.niaid.nih.gov/view?id=11 https://www.ncbi.nlm.nih.gov/pubmed/?term=11063495 https://www.ncbi.nlm.nih.gov/pubmed/?term=12204953 https://www.ncbi.nlm.nih.gov/pubmed/?term=28716554 https://www.ncbi.nlm.nih.gov/pubmed/?term=28933657 https://www.ncbi.nlm.nih.gov/pubmed/?term=31591662 11 CaPNP (CaPtivant)(TM) vaccine adjuvant Chemical Nature: Small molecule, other Receptor: TLR4 Mechanism of Action: None Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: Other Point of Contact: Robert Ernst, University of Maryland - Baltimore Amogh Madireddi Oliver He Robert Ernst Wolfgang Leitner BECC470b https://vac.niaid.nih.gov/view?id=32 https://www.ncbi.nlm.nih.gov/pubmed/?term=28487429 https://www.ncbi.nlm.nih.gov/pubmed/?term=29861179 https://www.ncbi.nlm.nih.gov/pubmed/?term=33309485 32 BECC470b vaccine adjuvant Chemical Nature: (1) Synthetic derivative of natural compound, (2) other Receptor: TLR4 Mechanism of Action: None Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Robert Ernst, University of Maryland-Baltimore Amogh Madireddi Oliver He Robert Ernst Wolfgang Leitner BECC438s https://vac.niaid.nih.gov/view?id=33 33 BECC438s vaccine adjuvant Chemical Nature: Small molecule, other Receptor: TLR4 Mechanism of Action: None Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Robert Ernst, University of Maryland Baltimore Amogh Madireddi Oliver He Robert Ernst Wolfgang Leitner BECC438b https://vac.niaid.nih.gov/view?id=31 https://www.ncbi.nlm.nih.gov/pubmed/?term=28487429 https://www.ncbi.nlm.nih.gov/pubmed/?term=29861179 https://www.ncbi.nlm.nih.gov/pubmed/?term=33309485 31 BECC438b vaccine adjuvant Chemical Nature: Combination adjuvant Receptor: TLR4 Mechanism of Action: TLR4 and potentially inflammasome Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Services Amogh Madireddi Darrick Carter Oliver He Wolfgang Leitner AlT4 https://vac.niaid.nih.gov/view?id=19 19 AlT4 vaccine adjuvant Chemical Nature: Combination adjuvant Receptor: TLR3 Mechanism of Action: TLR3 agonist plus potential inflammasome Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Services Amogh Madireddi Darrick Carter Oliver He Wolfgang Leitner AlT3 https://vac.niaid.nih.gov/view?id=21 21 AlT3 vaccine adjuvant Chemical Nature: Small molecule Receptor: (1) TLR7, (2) TLR8 Mechanism of Action: TLR7/8 dual agonist - lymph node delivery Immune profile induced: Th1-biased Other Features/Characteristics: Promotes antibody affinity maturation Point of Contact: Sunil David, Virovax Amogh Madireddi Oliver He Sunil David Wolfgang Leitner Alhydroxiquim-II https://vac.niaid.nih.gov/view?id=12 https://www.ncbi.nlm.nih.gov/pubmed/?term=33521604 https://www.ncbi.nlm.nih.gov/pubmed/?term=33654090 12 Alhydroxiquim-II vaccine adjuvant Chemical Nature: (1) Synthetic derivative of natural compound, (2) Emulsion, (3) Combination adjuvant, (4) Other Receptor: TLR4 Mechanism of Action: Adjuplex enhances cross presentation to CD8 T cells and GLA stimulates TLR4 signaling Immune profile induced: Mixed Th1/Th17 Other Features/Characteristics: None Point of Contact: Marulasiddappa Suresh, UW Madison Amogh Madireddi Marulasiddappa Suresh Oliver He Wolfgang Leitner Adjuplex+GLA https://vac.niaid.nih.gov/view?id=15 https://www.ncbi.nlm.nih.gov/pubmed/?term=32984856 https://www.ncbi.nlm.nih.gov/pubmed/?term=33444400 https://www.ncbi.nlm.nih.gov/pubmed/?term=33767689 15 Adjuplex+GLA vaccine adjuvant Chemical Nature: Small molecule Receptor: Dendritic cells (unknown receptor) Mechanism of Action: Innate immune activation/enhancer Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Dennis Carson, UCSD Amogh Madireddi Dennis Carson Oliver He Wolfgang Leitner 2F52 https://vac.niaid.nih.gov/view?id=8 https://www.ncbi.nlm.nih.gov/pubmed/?term=29751735 8 2F52 vaccine adjuvant A role of a material entity that binds to TLR4 and activates the receptor for pathogen recognition and activation of innate immunity. TLR4 agonist role Oliver He, Amogh Madireddi Toll-like receptor 4 agonist role https://en.wikipedia.org/wiki/TLR4 TLR4 receptor role A role of a material entity that binds to TLR3 and activates the receptor for pathogen recognition and activation of innate immunity. TLR3 agonist role Oliver He, Amogh Madireddi Toll-like receptor 3 agonist role https://en.wikipedia.org/wiki/TLR3 TLR3 receptor role A role of a material entity that binds to TLR8 and activates the receptor for pathogen recognition and activation of innate immunity. TLR8 agonist role Oliver He, Amogh Madireddi Toll-like receptor 8 agonist role https://en.wikipedia.org/wiki/TLR8 TLR8 receptor role A role of a material entity that binds to TLR2 and activates the receptor for pathogen recognition and activation of innate immunity. TLR2 agonist role Oliver He, Amogh Madireddi Toll-like receptor 2 agonist role https://en.wikipedia.org/wiki/TLR2 TLR2 receptor role immune response profile A biased immune profile that is characterized by the presense of T help cells Type 1 T helper (Th1) cells that produce interferon-gamma, interleukin (IL)-2, and tumour necrosis factor (TNF)-beta, which activate macrophages and are responsible for cell-mediated immunity and phagocyte-dependent protective responses. Oliver He, Amogh Madireddi https://en.wikipedia.org/wiki/T_helper_cell https://pubmed.ncbi.nlm.nih.gov/10579123/ Th1-biased immune profile A baised immune profile that is characterized by the presense of T type 2 Th (Th2) cells that produce IL-4, IL-5, IL-10, and IL-13, which are responsible for strong antibody production, eosinophil activation, and inhibition of several macrophage functions, thus providing phagocyte-independent protective responses. Oliver He, Amogh Madireddi https://en.wikipedia.org/wiki/T_helper_cell https://pubmed.ncbi.nlm.nih.gov/10579123/ Th2-biased immune profile An immune profile that is characterized by the presense of both Type 1 and Type 2 T helper (Th1 and Th2) cells. Oliver He, Amogh Madireddi https://en.wikipedia.org/wiki/T_helper_cell https://pubmed.ncbi.nlm.nih.gov/10579123/ Th1/Th2 mixed immune profile An immune profile that is characterized by the presense of T helper 17 cells (Th17) that a subset of pro-inflammatory T helper cells defined by their production of interleukin 17 (IL-17). They are related to T regulatory cells and the signals that cause Th17s to differentiate actually inhibit Treg differentiation. Oliver He, Amogh Madireddi https://en.wikipedia.org/wiki/T_helper_17_cell Th17 immune profile An immune profile that is characterized by the presense of both Type 1 and Type 17 T helper (Th1 and Th17) cells. Oliver He, Amogh Madireddi https://en.wikipedia.org/wiki/T_helper_cell Th1/Th17 mixed immune profile A SARS-CoV-2 subunit vaccine by Clover Biopharmaceuticals AUS Pty Ltd that contains the S protein from the B.1.351 variant. Philip Huang NCT04950751 SCB-2020S A SARS-CoV-2 subunit vaccine by Bagheiat-allah University of Medical Sciences Philip Huang https://en.irct.ir/trial/56987 Noora A SARS-CoV-2 subunit vaccine by Baiya Phytopharm Co., Ltd. Philip Huang NCT04953078 Baiya SARS-CoV-2 Vax 1 A SARS-CoV-2 recombinant vector vaccine manufactured by CyanVac LLC Philip Huang NCT04954287 CVXGA1 A SARS-CoV-2 recombinant vector vaccine by AstraZeneca and Oxford University against variant strain B.1.351 Philip Huang NCT04973449 AZD2816 A SARS-CoV-2 subunit vaccine manufactured by Shanghai Zerun Biotechnology, Walvax Biotechnology, and CEPI Philip Huang NCT04990544 202-CoV A SARS-CoV-2 protein subunit vaccine by Laboratorios HIPRA Philip Huang NCT05007509 COVID-19 subunit vaccine by HIPRA A SARS-CoV-2 DNA vaccine developed by AnGes. Philip Huang NCT04993586 AG0302-COVID19 Oliver He http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php authorized COVID-19 DNA vaccine An Advax-CpG vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide CpG55.2. Pubmed References:Chemical Nature: (1) combination adjuvant Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1 Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability By routes: SQ, IM Point of Contact: Nikolai Petrovsky, Vaxine LTD Nikolai Petrovsky Oliver He Wolfgang Leitner Advax-CpG55.2 https://pubmed.ncbi.nlm.nih.gov/32636840/ https://vac.niaid.nih.gov/view?id=38 https://www.ncbi.nlm.nih.gov/pubmed/?term=32849580 https://www.ncbi.nlm.nih.gov/pubmed/?term=33301675 https://www.ncbi.nlm.nih.gov/pubmed/?term=34069575 38 Advax-CpG55.2 vaccine adjuvant A vaccine adjuvant that is synthesized by derivatizing a natural Momordica saponin in one step. VSA-2 is chemically stable. VSA-2 is much less toxic than QS-21. VSA-2 is more Th1-biased than QS-21. Momordica saponins are isolated from widely available and sustainable sources. Pubmed References: Chemical Nature: (1) Synthetic derivative of natural compound Mechanism of Action: unknown Immune profile induced: mixed Th1/Th2 Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21 By routes: SQ Point of Contact: Pengfei Wang, University of Alabama https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001 Oliver He Pengfei Wang Wolfgang Leitner VSA-2 https://vac.niaid.nih.gov/view?id=42 https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001 42 VSA-2 vaccine adjuvant A vaccine adjuvant that is prepared by derivatizing a natural Momordica saponin in one chemical step. VSA-1 is chemically more stable than QS-21. VSA-1 is much less toxic than QS-21. The Momordica saponins are from sustainable sources and widely available. Pubmed References: Chemical Nature: (1) Synthetic derivative of natural compound Mechanism of Action: unknown Immune profile induced: mixed Th1/Th2 Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21 By routes: SQ Point of Contact: Pengfei Wang, University of Alabama https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920 Oliver He Pengfei Wang Wolfgang Leitner VSA-1 https://vac.niaid.nih.gov/view?id=41 https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920 41 VSA-1 vaccine adjuvant A vaccine adjuvant that is a potent adjuvant for antibody and cellular responses to protein, polypeptide and small peptide antigens. rOv-ASP-1 stands for Recombinant Onchocerca volvulus activation-associated secreted protein-1. Pubmed References: Chemical Nature: (1) Protein Mechanism of Action: unknown Immune profile induced: Th1 Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation. By routes: IM Point of Contact: Sara Lustigman, New York Blood Center Oliver He Sara Lustigman Wolfgang Leitner Recombinant O. volvulus activation-associated secreted protein-1 rOv-ASP-1 https://vac.niaid.nih.gov/view?id=43 https://www.ncbi.nlm.nih.gov/pubmed/?term=1583768 https://www.ncbi.nlm.nih.gov/pubmed/?term=18341617 https://www.ncbi.nlm.nih.gov/pubmed/?term=18675867 https://www.ncbi.nlm.nih.gov/pubmed/?term=22615877 https://www.ncbi.nlm.nih.gov/pubmed/?term=24681229 https://www.ncbi.nlm.nih.gov/pubmed/?term=25736195 https://www.ncbi.nlm.nih.gov/pubmed/?term=26795365 https://www.ncbi.nlm.nih.gov/pubmed/?term=29764680 https://www.ncbi.nlm.nih.gov/pubmed/?term=32471056 43 rOv-ASP-1 vaccine adjuvant A vaccine adjuvant that includes double mutant of heat-labile E. coli toxin (LT) at R192G/L211A or LT(R192G/L211A) Chemical Nature: protein Mechanism of Action: CGM1 ganglioside, cAMP, inflammasome Immune profile induced: mixed Th1/Th17 Other Features/Characteristics: Induces mucosal immunity (IM, ID, SQ, SL, oral, , transcutaneous), Induces epitope spreading, Promotes antibody affinity maturation, Effective in newborns, promotes antibody epitope spreading By routes: IM, ID, SL, oral, SQ, IN, IP, intragastric, transcutaneous, transdermal, buccal, intrarectal Point of Contact: Elizabeth Norton, Tulane University https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994 https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349 https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197 https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082 https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793 https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827 https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241 https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122 https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825 https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621 https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536 https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379 https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125 https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441 https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067 https://www.ncbi.nlm.nih.gov/pubmed/?term=25944298 https://www.ncbi.nlm.nih.gov/pubmed/?term=6424635 https://www.ncbi.nlm.nih.gov/pubmed/?term=3916310 https://www.ncbi.nlm.nih.gov/pubmed/?term=4826740 https://www.ncbi.nlm.nih.gov/pubmed/?term=2884428 https://www.ncbi.nlm.nih.gov/pubmed/?term=30778066 https://www.ncbi.nlm.nih.gov/pubmed/?term=4893257 https://www.ncbi.nlm.nih.gov/pubmed/?term=28063704 https://www.ncbi.nlm.nih.gov/pubmed/?term=4375349 https://www.ncbi.nlm.nih.gov/pubmed/?term=28792004 https://www.ncbi.nlm.nih.gov/pubmed/?term=25765967 https://www.ncbi.nlm.nih.gov/pubmed/?term=25483682 https://www.ncbi.nlm.nih.gov/pubmed/?term=30638799 https://www.ncbi.nlm.nih.gov/pubmed/?term=21326197 https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774 https://www.ncbi.nlm.nih.gov/pubmed/?term=31427449 https://www.ncbi.nlm.nih.gov/pubmed/?term=6957164 https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933 https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933 https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933 https://www.ncbi.nlm.nih.gov/pubmed/?term=31641151 https://www.ncbi.nlm.nih.gov/pubmed/?term=27133878 https://www.ncbi.nlm.nih.gov/pubmed/?term=27676456 https://www.ncbi.nlm.nih.gov/pubmed/?term=27226279 https://www.ncbi.nlm.nih.gov/pubmed/?term=22406456 https://www.ncbi.nlm.nih.gov/pubmed/?term=30787109 https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527 https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527 https://www.ncbi.nlm.nih.gov/pubmed/?term=30563789 https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774 https://www.ncbi.nlm.nih.gov/pubmed/?term=30473185 https://www.ncbi.nlm.nih.gov/pubmed/?term=30248001 https://www.ncbi.nlm.nih.gov/pubmed/?term=24049109 https://www.ncbi.nlm.nih.gov/pubmed/?term=30797634 https://www.ncbi.nlm.nih.gov/pubmed/?term=31482013 https://www.ncbi.nlm.nih.gov/pubmed/?term=29771685 https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774 https://www.ncbi.nlm.nih.gov/pubmed/?term=25444830 Clinical trials: https://clinicaltrials.gov/ct2/show/NCT03922061 https://clinicaltrials.gov/ct2/show/NCT04232943 https://clinicaltrials.gov/ct2/show/NCT02531685 https://clinicaltrials.gov/ct2/show/NCT02052934 https://clinicaltrials.gov/ct2/show/NCT02531802 https://clinicaltrials.gov/ct2/show/NCT01147445 https://clinicaltrials.gov/ct2/show/NCT03548064 https://clinicaltrials.gov/ct2/show/ NCT01739231 https://clinicaltrials.gov/ct2/show/NCT03404674 https://clinicaltrials.gov/ct2/show/NCT03729219 https://clinicaltrials.gov/ct2/show/NCT04826094 Elizabeth Norton Oliver He Wolfgang Leitner dmLT https://vac.niaid.nih.gov/view?id=13 https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067 https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994 https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122 https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621 https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241 https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827 https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825 https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536 https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793 https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197 https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125 https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082 https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441 https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379 https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349 13 dmLT vaccine adjuvant Chemical Nature: (1) other (Peptide) Mechanism of Action: C5aR1 on mononuclear phagocytes Immune profile induced: mixed Th1/Th2 Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation. By routes: SQ, IP, IV. Point of Contact: Joseph Vetro, University of Nebraska Medical Center https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/10516626/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/12538044/, https://pubmed.ncbi.nlm.nih.gov/19428909/, https://pubmed.ncbi.nlm.nih.gov/21723901/ Joseph Vetro Oliver He Wolfgang Leitner CPDI-01 https://pubmed.ncbi.nlm.nih.gov/10516626/ https://pubmed.ncbi.nlm.nih.gov/10799917/ https://pubmed.ncbi.nlm.nih.gov/12538044/ https://pubmed.ncbi.nlm.nih.gov/19428909/ https://pubmed.ncbi.nlm.nih.gov/21723901/ https://pubmed.ncbi.nlm.nih.gov/9013982/ https://vac.niaid.nih.gov/view?id=39 39 CPDI-01 vaccine adjuvant A recombiant vector vaccine that is has a viral vector. Anthony Huffman recombinant viral vector vaccine A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc. Philip Huang NCT05037097 ARCT-165 A SARS-CoV-2 monovalent protein subunit vaccine by Novavax immunizing against the B.1.351 (Beta) variant and containing the Matrix-M1 adjuvant Philip Huang NCT05029856 SII B.1.351 A SARS-CoV-2 bivalent protein subunit vaccine by Novavax containing antigen for both the ancestral strain and B.1.351 (Beta) variant. Philip Huang NCT05029856 SII Bivalent A SARS-CoV-2 monovalent protein subunit vaccine by Novavax immunizing against the B.1.617.2 (Delta) variant and containing the Matrix-M1 adjuvant Philip Huang NCT05029856 SII B.1.617.2 A SARS-CoV-2 recombinant viral vector vaccine by Biocad Philip Huang NCT05037188 AAV5-RBD-S A vaccine adjuvant that includes UM-3005, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile. Chemical Nature: (1) small molecule Mechanism of Action: TLR7/8 agonist Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, InImmune Ani M. Bernardi Helene Bazin-Lee Oliver He Wolfgang Leitner UM-3005 https://vac.niaid.nih.gov/view?id=47 https://www.ncbi.nlm.nih.gov/pubmed/32210973 47 UM-3005 vaccine adjuvant A SARS-CoV-2 subunit vaccine by Sinocelltech Ltd. Philip Huang NCT05043311 SCTV01C A SARS-CoV-2 replication deficient human adenovirus vector vaccine expressing the spike, nucleocapsid and RNA polymerase proteins. Philip Huang NCT05094609 Ad5-triCoV/Mac A SARS-CoV-2 DNA vaccine developed by Vaccibody AS encoding the receptor-binding domain Philip Huang NCT05069623 VB10.2129 A SARS-CoV-2 T-Cell-based DNA vaccine developed by Vaccibody AS Philip Huang NCT05069623 VB10.2210 A SARS-CoV-2 replication deficient chimpanzee adenovirus 68 vector vaccine expressing the spike, nucleocapsid and RNA polymerase proteins. Philip Huang NCT05094609 ChAd-triCoV/Mac A SARS-CoV-2 subunit vaccine by PT Bio Farma Philip Huang NCT05067894 COVID-19 subunit vaccine by PT Bio Farma A SARS-CoV-2 DNA vaccine developed by Scancell Ltd. Philip Huang NCT05047445 COVIDITY A SARS-CoV-2 subunit vaccine by Yisheng Biopharma Philip Huang ACTRN12621001009808 PIKA Recombinant COVID-19 Vaccine A SARS-CoV-2 DNA vaccine developed by University of Hong Kong and Immuno Cure 3 Limited Philip Huang NCT05102643 COVID-19 DNA vaccine by the University of Hong Kong and Immuno Cure 3 Limited A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc. Philip Huang ISRCTN15779782 ARCT-154 A COVID-19 virus-like particle vaccine developed by Yantai Patronus Biotech Co., Ltd. Philip Huang NCT05137444 LYB001 A SARS-CoV-2 inactivated vaccine developed by the National Research Centre of Egypt Philip Huang NCT05128721 Covi Vax A SARS-CoV-2 subunit vaccine containing a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle. Philip Huang NCT05113862 naNO-COVID A SARS-CoV-2 subunit vaccine by HK inno.N Corporation Philip Huang NCT05113849 IN-B009 A SARS-CoV-2 RNA vaccine manufactured by VLP Therapeutics Japan, LLC Philip Huang jRCT2071210067 VLPCOV-01 A vaccine adjuvant that includes UM-3004, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile. Chemical Nature: (1) small molecule Mechanism of Action: TLR7/8 agonist Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, University of Montana Ani M. Bernardi Helene Bazin-Lee Oliver He Wolfgang Leitner UM-3004 https://vac.niaid.nih.gov/view?id=46 https://www.ncbi.nlm.nih.gov/pubmed/32210973 46 UM-3004 vaccine adjuvant A vaccine adjuvant that includes UM-3003, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile. Chemical Nature: (1) small molecule Mechanism of Action: TLR7/8 agonist Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, University of Montana Ani M. Bernardi Helene Bazin-Lee Oliver He Wolfgang Leitner UM-3003 https://vac.niaid.nih.gov/view?id=45 https://www.ncbi.nlm.nih.gov/pubmed/32210973 45 UM-3003 vaccine adjuvant A vaccine adjuvant made from the A subunit of heat-labile (LT) enterotoxin of Enterotoxigenic Escherichia coli (ETEC). This LTA1 adjuvant is able to induce Th1, Th2, and Th17 immune responses. Chemical Nature: (1) Protein Mechanism of Action: cAMP, inflammasome induction Immune profile induced: mixed Th1/Th2/Th17 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces epitope spreading, (3) Promotes antibody affinity maturation, (4) Promotes antibody epitope spreading, (5) High stability Route of immunization: IM, IN, SL, ID, IP Point of Contact: Elizabeth Norton, Tulane University Ani M. Bernardi Elizabeth Norton Oliver He Wolfgang Leitner LTA1 https://vac.niaid.nih.gov/view?id=44 https://www.ncbi.nlm.nih.gov/pubmed/22526674 https://www.ncbi.nlm.nih.gov/pubmed/26305793 https://www.ncbi.nlm.nih.gov/pubmed/31427449 https://www.ncbi.nlm.nih.gov/pubmed/31641151 https://www.ncbi.nlm.nih.gov/pubmed/31929548 https://www.ncbi.nlm.nih.gov/pubmed/33986280 https://www.ncbi.nlm.nih.gov/pubmed/34516780 https://www.ncbi.nlm.nih.gov/pubmed/6957164 44 LTA1 vaccine adjuvant A carbohydrate vaccine adjuvant that is a glucan carbohydrate microcapsules with a β(1-3)/β(1-6)-linked glucan structure to allow targeting of antigens to macrophages or neutrophils through interactions with the β-glucan receptor found uniquely on the surface of these cell types. Adjuvax-ligand complexes are formed by physically entrapping or crosslinking the ligand within the β-glucan. Oliver He Randi Vita DOI: 10.1021 Adjuvax vaccine adjuvant A vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide (ODN). Pubmed References:Chemical Nature: (1) combination adjuvant Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1 Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability By routes: SQ, IM Point of Contact: Nikolai Petrovsky, Vaxine LTD Nikolai Petrovsky Oliver He Wolfgang Leitner Advax-2 Advax-CpG Advax-SM https://pubmed.ncbi.nlm.nih.gov/32636840/ https://www.ncbi.nlm.nih.gov/pubmed/?term=32849580 https://www.ncbi.nlm.nih.gov/pubmed/?term=33301675 https://www.ncbi.nlm.nih.gov/pubmed/?term=34069575 Advax-CpG vaccine adjuvant A combination vaccine adjuvant includes 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) purified from plant extract Quillaja saponaria Molina, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution. Oliver He Randi Vita https://www.fda.gov/media/107538/download#:~:text=The%20AS01B%20adjuvant%20suspension%20is,DOPC)%20and%20cholesterol%20in%20phosphate%2D AS01B vaccine adjuvant An AS02 vaccine adjuvant contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. As02a https://clinicaltrials.gov/ct2/show/NCT00308061 AS02A vaccine adjuvant A carbohydrate vaccine adjuvant that is aminoglycan consisting of β-(1->4)-linked D-glucosamine residues. Oliver He Randi Vita CHEBI:16261 PMID:24346613 chitosan vaccine adjuvant A Montanide vaccine adjuvant that is a water-dispersed liquid IMS 1313 nanoparticle combined with an immuno-stimulating compound. Oliver He Randi Vita IMS 1313 N VGPR IMS-1313 https://scialert.net/abstract/?doi=ijps.2018.167.174 Montanide IMS 1313 vaccine adjuvant A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound. Oliver He Randi Vita ISA-206 PMID:8961504 Montanide ISA 206 vaccine adjuvant A Montanide vaccine adjuvant that Mannide oleate derivative in a mineral oil solution ( Seppic SA, France). Oliver He Randi Vita ISA-50 http://vetarhiv.vef.unizg.hr/papers/74-2/raman.pdf Montanide ISA 50 vaccine adjuvant A carbohydrate vaccine adjuvant that is tomatidine in which the hydroxy group at position 3 is linked to lycotetraose, a tetrasaccharide composed of two units of D-glucose, one unit of D-xylose, and one unit of D-galactose. Oliver He Randi Vita CHEBI:9630 Tomatine vaccine adjuvant A carbohydrate vaccine adjuvant that polysaccharide prepared from the cell wall of Saccaromyces cerevisiae (bakers' yeast). Oliver He Randi Vita PMID:11380697 Zymosan vaccine adjuvant An emulsion vaccine adjuvant that is oil-based adjuvant (Adjuvant XtendIII®; Grand Laboratories, Larchwood, IA). Oliver He Randi Vita XtendIII vaccine adjuvant A microbial derivative vaccine adjuvant that is monophosphoryl lipid A (detoxified endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM) in 2% oil (squalene)-Tween 80-water. Oliver He Randi Vita Monophosphoryl-lipid A + Trehalose dicorynomycolate https://www.sigmaaldrich.com/US/en/product/sigma/m6536 MPL + TDM vaccine adjuvant A muramyl dipeptide vaccine adjuvant that muramyl dipeptide derivative (threonyl-MDP) in an oil-in-water (o/w) emulsion vehicle. Oliver He Randi Vita SAF https://link.springer.com/protocol/10.1385/1-59259-083-7:229 Syntex Adjuvant Formulation A vaccine adjuvant that diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol. Oliver He Randi Vita DBP CHEBI:34687 PMID:26319029 dibutyl phthalate vaccine adjuvant A vaccine adjuvant that includes naturally occurring trivalent alcohol. Oliver He Randi Vita glycerine, 1, 2, 3-propanetriol https://academic.oup.com/cid/article/45/10/1277/277413 glycerol vaccine adjuvant A vaccine adjuvant includes three palmitic acid groups that are bound in an ester and amide linkage to a cysteine residue. Oliver He Randi Vita Tripalmitoyl-S-glyceryl-cysteine PMID:24130558 Pam3Cys vaccine adjuvant A vaccine adjuvant that is equimolar mixture of the cationic lipid GAP-DMORIE [(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide)] and a neutral colipid DPyPE (1,2-diphytanoyl-sn-glydero-3-phosphoethanolamine). Oliver He Randi Vita PMID:21118032 Vaxfectin vaccine adjuvant A vaccination process that involves adding a vaccine into a host prior to disease. Randi Vita, Oliver He preventive vaccination https://en.wikipedia.org/wiki/Preventive_healthcare preventative vaccination prophylactic vaccination A vaccination process that involves adding a vaccine into a host after a disease has occurred. Randi Vita, Oliver He https://en.wikipedia.org/wiki/Therapeutic_vaccines therapeutic vaccination A vaccine adjuant that is derived from Salmonella enterica serovar typhimurium and is able to induce Th1/Th2/Th17 immune responses through the mechanism of action of TLR4, inflammasome, and DC activation. Chemical Nature: other Mechanism of Action: TLR4; inflammasome; DC activation Immune profile induced: Th1/Th2/Th17 Receptor: TLR4, NLRP3 Storage information: -20 or -80C Point of Contact: Lisa Morici, Tulane University Lisa Morici Oliver He Wolfgang Leitner T-vant https://vac.niaid.nih.gov/view?id=61 https://www.ncbi.nlm.nih.gov/pubmed/?term=33498352 https://www.ncbi.nlm.nih.gov/pubmed/?term=34069796 61 T-vant vaccine adjuvant An immune profile that is characterized by the presense of Type 1 Type 2, and Th17 T helper cells. Oliver He, Amogh Madireddi https://en.wikipedia.org/wiki/T_helper_cell https://pubmed.ncbi.nlm.nih.gov/10579123/ Th1/Th2/Th17 mixed immune profile A role of a material entity that binds to NLRP3. Oliver He https://en.wikipedia.org/wiki/NLRP3 NLRP3 receptor role Chemical Nature: Nucleic Acid Mechanism of Action: TLR/RLR-agonist Immune profile induced: Th1/Th2 Route of immunization: IM and IN Point of Contact: Xiaoliang Ren, Yisheng Bio Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT02657161 https://clinicaltrials.gov/ct2/show/NCT02956421 Oliver He Wolfgang Leitner Xiaoliang Ren PIKA https://vac.niaid.nih.gov/view?id=55 https://www.ncbi.nlm.nih.gov/pubmed/?term=17484805 https://www.ncbi.nlm.nih.gov/pubmed/?term=20538850 https://www.ncbi.nlm.nih.gov/pubmed/?term=21468931 https://www.ncbi.nlm.nih.gov/pubmed/?term=26765968 https://www.ncbi.nlm.nih.gov/pubmed/?term=28118938 https://www.ncbi.nlm.nih.gov/pubmed/?term=29174316 https://www.ncbi.nlm.nih.gov/pubmed/?term=34766005 55 PIKA vaccine adjuvant Chemical Nature: peptide Mechanism of Action: activation of mast cells, epithelial cells, macrophages and dendritic cells Immune profile induced: Th2-biased Route of immunization: IM and IN Point of Contact: Herman Staats, Duke University Herman Staats Oliver He Wolfgang Leitner Mastoparan 7 https://vac.niaid.nih.gov/view?id=53 https://www.ncbi.nlm.nih.gov/pubmed/?term=31068425 https://www.ncbi.nlm.nih.gov/pubmed/?term=32047657 https://www.ncbi.nlm.nih.gov/pubmed/?term=34566991 53 Mastoparan 7 vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: mast cell activation Immune profile induced: Th2-biased Route of immunization: IN Point of Contact: Herman Staats, Duke University Herman Staats Oliver He Wolfgang Leitner Mast cell activator small molecules https://vac.niaid.nih.gov/view?id=54 https://www.ncbi.nlm.nih.gov/pubmed/?term=34566991 54 Mast cell activator small molecules vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children's Hospital Ofer Levy Oliver He Wolfgang Leitner Precision Vaccines Program (PVP)-037 https://vac.niaid.nih.gov/view?id=56 56 Precision Vaccines Program (PVP)-037 vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: TLR4 agonist Immune profile induced: Th1/Th2 Route of immunization: IM and IN Point of Contact: Robert Ernst, University of Maryland - Baltimore Oliver He Robert Ernst Wolfgang Leitner BECC470s https://vac.niaid.nih.gov/view?id=60 60 BECC470s vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, University of Montana Helene Bazin-Lee Oliver He Wolfgang Leitner TRAC478 https://vac.niaid.nih.gov/view?id=48 48 TRAC478 vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1/Th17 Route of immunization: IM and IN Point of Contact: Christopher Fox, AAHI Christopher Fox Oliver He Wolfgang Leitner GLA-3M-052-LS https://vac.niaid.nih.gov/view?id=58 https://www.ncbi.nlm.nih.gov/pubmed/?term=34248966 https://www.ncbi.nlm.nih.gov/pubmed/?term=34795290 58 GLA-3M-052-LS vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Christopher Fox Oliver He Wolfgang Leitner 3M-052-SE https://vac.niaid.nih.gov/view?id=57 https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728 https://www.ncbi.nlm.nih.gov/pubmed/?term=30089691 https://www.ncbi.nlm.nih.gov/pubmed/?term=32213623 https://www.ncbi.nlm.nih.gov/pubmed/?term=34131024 https://www.ncbi.nlm.nih.gov/pubmed/?term=34972105 https://www.ncbi.nlm.nih.gov/pubmed/?term=35572573 57 3M-052-SE vaccine adjuvant Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Clinical trials: https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT04915768 https://clinicaltrials.gov/ct2/show/NCT05197712 Christopher Fox Oliver He Wolfgang Leitner 3M-052-Alum https://vac.niaid.nih.gov/view?id=59 https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326 https://www.ncbi.nlm.nih.gov/pubmed/?term=32561559 https://www.ncbi.nlm.nih.gov/pubmed/?term=33971664 https://www.ncbi.nlm.nih.gov/pubmed/?term=34117252 https://www.ncbi.nlm.nih.gov/pubmed/?term=34266981 59 3M-052-Alum vaccine adjuvant Chemical Nature: (1) emulsion Mechanism of Action: unknown Immune profile induced: Th1/Th17 Route of immunization: IM Point of Contact: Patrice Dubois, Vaccine Formulation Institute Clinical trial: https://clinicaltrials.gov/ct2/show/NCT04702178 Oliver He Patrice Dubois Wolfgang Leitner SWE https://vac.niaid.nih.gov/view?id=50 https://www.ncbi.nlm.nih.gov/pubmed/?term=30849373 https://www.ncbi.nlm.nih.gov/pubmed/?term=32411401 50 SWE vaccine adjuvant Chemical Nature: (1) Emulsion (with Saponin) Mechanism of Action: unknown Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Patrice Dubois, Vaccine Formulation Institute Oliver He Patrice Dubois Wolfgang Leitner SQ https://vac.niaid.nih.gov/view?id=52 https://www.ncbi.nlm.nih.gov/pubmed/?term=33688647 52 SQ vaccine adjuvant Chemical Nature: (1) other (liposome with Saponin) Mechanism of Action: unknown Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Patrice Dubois, Vaccine Formulation Institute Oliver He Patrice Dubois Wolfgang Leitner LQ https://vac.niaid.nih.gov/view?id=51 https://www.ncbi.nlm.nih.gov/pubmed/?term=32156809 https://www.ncbi.nlm.nih.gov/pubmed/?term=33688647 51 LQ vaccine adjuvant A SARS-CoV-2 RNA vaccine by Suzhou Abogen Biosciences Co., Ltd. Philip Huang NCT05434585 ABO1009-DP A SARS-CoV-2 protein subunit vaccine manufactured by ACM Biolabs. Philip Huang NCT05385991 ACM-001 A SARS-CoV-2 DNA vaccine developed by Imam Abdulrahman Bin Faisal University. Philip Huang NCT05171946 Almansour-001 A synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine Philip Huang NCT04639466 ChAdV68-S A SARS-CoV-2 protein subunit vaccine manufactured by the University of Melbourne. Philip Huang NCT05272605 DoCo-Pro-RBD-1 + MF59 A SARS-CoV-2 inactivated vaccine developed by Eva Pharma. Philip Huang NCT05218070 EgyVax A SARS-CoV-2 RNA vaccine by Gritstone Bio, Inc. Philip Huang NCT05435027 GRT-R912 A SARS-CoV-2 RNA vaccine by the University of Melbourne. Philip Huang NCT05272605 MIPSCo-mRNA-RBD-1 A SARS-CoV-2 inactivated vaccine developed by Osve Pharmaceutical Company. Philip Huang IRCT20210622051670N1 Osvid-19 A SARS-CoV-2 protein subunit vaccine manufactured by Speransa Therapeutics. Philip Huang NCT05389319 Prime-2-CoV-Beta A SARS-CoV-2 RNA vaccine by Wuhan Recogen Biotechnology Co., Ltd. Philip Huang NCT05366296 RH109 A SARS-CoV-2 RNA vaccine by Walvax Biotechnology and Shanghai RNACure Biopharma Philip Huang NCT05394012 RQ3013 A SARS-CoV-2 RNA vaccine by RVAC Medicines Philip Huang NCT05420077 RVM-V001 A SARS-CoV-2 protein subunit vaccine manufactured by Vaxxas Pty Ltd Philip Huang ACTRN12622000597796 VXS-1223 A SARS-CoV-2 RNA vaccine by ImmunityBio, Inc. Philip Huang NCT05370040 AAHI-SC2 A SARS-CoV-2 protein subunit vaccine manufactured by Human Stem Cell Institute Philip Huang NCT05270954 Betuvax-CoV2 A SARS-CoV-2 RNA vaccine by CanSino Biologics Inc. Philip Huang NCT05373472 COVID-19 mRNA vaccine by CanSino Biologics A SARS-CoV-2 RNA vaccine by EyeGene Inc. Philip Huang NCT05188469 EG-COVID A SARS-CoV-2 mRNA vaccine by Moderna that combines the mRNA-1273 COVID-19 vaccine and the mRNA-1010 influenza vaccine. Philip Huang NCT05375838 mRNA-1073 A SARS-CoV-2 mRNA vaccine by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Philip Huang NCT05439824 SYS6006 A SARS-CoV-2 inactivated vaccine developed by Airlangga University Philip Huang NCT05226429 UNAIR Inactivated COVID-19 Vaccine A SARS-CoV-2 protein subunit vaccine manufactured by Livzon Pharmaceutical Group Inc. Philip Huang NCT05273528 V-01-351/V-01D Bivalence Vaccine A SARS-CoV-2 mRNA vaccine by Gennova Biopharmaceuticals Limited Philip Huang CTRI/2022/04/041880 GEMCOVAC-19 A SARS-CoV-2 mRNA vaccine by AIM Vaccine Co., Ltd. Philip Huang NCT05428592 LVRNA009 A SARS-CoV-2 bivalent mRNA vaccine by Moderna that contains the mRNA-1273 COVID-19 vaccine and the mRNA-1273.214 Omicron booster Philip Huang NCT05436834 mRNA-1273.214 A SARS-CoV-2 mRNA booster vaccine by Moderna that targets the Omicron variant Philip Huang NCT05249829 mRNA-1273.529 A SARS-CoV-2 inactivated vaccine developed by China National Biotec Group Company Limited Philip Huang NCT05374954 Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited Oliver He http://www.violinet.org/cov19vaxkb/authorizedcov19vax.php authorized COVID-19 virus-like particle vaccine Chemical Nature: other Mechanism of Action: Activation of APCs, activation of T cells and stimulating B cell proliferation (IgG) Immune profile induced: Th1-biased Route of immunization: IM and SQ Point of Contact: Matthew Heath, Allergy Therapeutics (UK) Ltd Ani Bernardi Ari Joffe Matthew Heath Oliver He Wolfgang Leitner MCT MCT vaccine adjuvant MicroCrystalline Tyrosine https://vac.niaid.nih.gov/view?id=25 https://www.ncbi.nlm.nih.gov/pubmed/?term=28347293 https://www.ncbi.nlm.nih.gov/pubmed/?term=28468322 https://www.ncbi.nlm.nih.gov/pubmed/?term=28953265 https://www.ncbi.nlm.nih.gov/pubmed/?term=29592962 25 MicroCrystalline Tyrosine vaccine adjuvant Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329 https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=21816196 https://www.ncbi.nlm.nih.gov/pubmed/?term=21690242 https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869 https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184 https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184 https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649 https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649 https://www.ncbi.nlm.nih.gov/pubmed/?term=22509423 https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687 https://www.ncbi.nlm.nih.gov/pubmed/?term=23904160 https://www.ncbi.nlm.nih.gov/pubmed/?term=23954378 https://www.ncbi.nlm.nih.gov/pubmed/?term=22425788 https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286 https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286 https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057 https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057 https://www.ncbi.nlm.nih.gov/pubmed/?term=23228811 https://www.ncbi.nlm.nih.gov/pubmed/?term=25024362 https://www.ncbi.nlm.nih.gov/pubmed/?term=25030053 https://www.ncbi.nlm.nih.gov/pubmed/?term=24404140 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898 https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898 https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521 https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521 https://www.ncbi.nlm.nih.gov/pubmed/?term=25367751 https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135 https://www.ncbi.nlm.nih.gov/pubmed/?term=25637347 https://www.ncbi.nlm.nih.gov/pubmed/?term=27005808 https://www.ncbi.nlm.nih.gov/pubmed/?term=26656121 https://www.ncbi.nlm.nih.gov/pubmed/?term=26874325 https://www.ncbi.nlm.nih.gov/pubmed/?term=26791076 https://www.ncbi.nlm.nih.gov/pubmed/?term=27466350 https://www.ncbi.nlm.nih.gov/pubmed/?term=27699241 https://www.ncbi.nlm.nih.gov/pubmed/?term=29176865 https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370 https://www.ncbi.nlm.nih.gov/pubmed/?term=29263879 https://www.ncbi.nlm.nih.gov/pubmed/?term=29795025 https://www.ncbi.nlm.nih.gov/pubmed/?term=29983563 https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252 https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252 https://www.ncbi.nlm.nih.gov/pubmed/?term=27895131 https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844 https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075 https://www.ncbi.nlm.nih.gov/pubmed/?term=33705411 https://www.ncbi.nlm.nih.gov/pubmed/?term=35126135 https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214 https://www.ncbi.nlm.nih.gov/pubmed/?term=26731269 https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448 https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448 https://www.ncbi.nlm.nih.gov/pubmed/?term=27456709 https://www.ncbi.nlm.nih.gov/pubmed/?term=32023469 https://www.ncbi.nlm.nih.gov/pubmed/?term=32402293 https://www.ncbi.nlm.nih.gov/pubmed/?term=32348377 https://www.ncbi.nlm.nih.gov/pubmed/?term=32697993 https://www.ncbi.nlm.nih.gov/pubmed/?term=29515589 https://www.ncbi.nlm.nih.gov/pubmed/?term=33046728 https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678 https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937 https://www.ncbi.nlm.nih.gov/pubmed/?term=30567978 https://www.ncbi.nlm.nih.gov/pubmed/?term=31362695 https://www.ncbi.nlm.nih.gov/pubmed/?term=29769270 https://www.ncbi.nlm.nih.gov/pubmed/?term=31521953 https://www.ncbi.nlm.nih.gov/pubmed/?term=28298421 Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT01484548 https://clinicaltrials.gov/ct2/show/NCT01751048 https://clinicaltrials.gov/ct2/show/NCT02071758 https://clinicaltrials.gov/ct2/show/NCT02465216 https://clinicaltrials.gov/ct2/show/NCT01927159 https://clinicaltrials.gov/ct2/show/NCT01599897 https://clinicaltrials.gov/ct2/show/NCT01154049 https://clinicaltrials.gov/ct2/show/NCT03302897 https://clinicaltrials.gov/ct2/show/NCT02465216 https://clinicaltrials.gov/ct2/show/NCT02508376 https://clinicaltrials.gov/ct2/show/NCT03806686 https://clinicaltrials.gov/ct2/show/NCT01949909 https://clinicaltrials.gov/ct2/show/NCT01540474 https://clinicaltrials.gov/ct2/show/NCT02014727 https://clinicaltrials.gov/ct2/show/NCT02647489 https://clinicaltrials.gov/ct2/show/NCT02658253 https://clinicaltrials.gov/ct2/show/NCT01991561 https://clinicaltrials.gov/ct2/show/NCT01596725 https://clinicaltrials.gov/ct2/show/NCT01147068 https://clinicaltrials.gov/ct2/show/NCT03820414 https://clinicaltrials.gov/ct2/show/NCT03220724 https://clinicaltrials.gov/ct2/show/NCT03409276 https://clinicaltrials.gov/ct2/show/NCT01864876 https://clinicaltrials.gov/ct2/show/NCT02115815 https://clinicaltrials.gov/ct2/show/NCT01397604 Ani Bernardi Ari Joffe Christopher Fox Oliver He Wolfgang Leitner GLA-SE https://clinicaltrials.gov/ct2/show/NCT01484548 https://clinicaltrials.gov/ct2/show/NCT01751048 https://clinicaltrials.gov/ct2/show/NCT02071758 https://vac.niaid.nih.gov/view?id=62 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869 https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329 62 GLA-SE vaccine adjuvant Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Mixed Th1/Th2 Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT02508376 https://clinicaltrials.gov/ct2/show/NCT02647489 https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT03589794 Ani Bernardi Ari Joffe Christopher Fox Oliver He Wolfgang Leitner GLA-SLQ https://vac.niaid.nih.gov/view?id=63 https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687 https://www.ncbi.nlm.nih.gov/pubmed/?term=24465426 https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135 https://www.ncbi.nlm.nih.gov/pubmed/?term=26862758 https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937 https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678 https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844 63 GLA-SLQ vaccine adjuvant Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ani Bernardi Ari Joffe Christopher Fox Oliver He Wolfgang Leitner SLA-LSQ https://vac.niaid.nih.gov/view?id=64 https://www.ncbi.nlm.nih.gov/pubmed/?term=30302281 64 SLA-LSQ vaccine adjuvant Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: n/a Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT03820414 https://clinicaltrials.gov/ct2/show/NCT02071758 Ani Bernardi Ari Joffe Christopher Fox Oliver He Wolfgang Leitner SLA-SE https://vac.niaid.nih.gov/view?id=65 https://www.ncbi.nlm.nih.gov/pubmed/?term=30386348 https://www.ncbi.nlm.nih.gov/pubmed/?term=31149350 https://www.ncbi.nlm.nih.gov/pubmed/?term=31891152 https://www.ncbi.nlm.nih.gov/pubmed/?term=32540272 https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225 65 SLA-SE vaccine adjuvant Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT02508376 https://clinicaltrials.gov/ct2/show/NCT02647489 https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT03589794 Ani Bernardi Ari Joffe Christopher Fox Oliver He Wolfgang Leitner GLA-AF https://vac.niaid.nih.gov/view?id=66 https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687 https://www.ncbi.nlm.nih.gov/pubmed/?term=24465426 https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135 https://www.ncbi.nlm.nih.gov/pubmed/?term=26862758 https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937 https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678 https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844 66 GLA-AF vaccine adjuvant A cancer vaccine that is used against prostate cancer. Oliver He Penny Pan https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/immunotherapy-for-prostate-cancer prostate cancer vaccine A cancer vaccine that is used against colorectal cancer Oliver He Penny Pan PubMed:35990683 colorectal cancer vaccine A cancer vaccine that is used against lymphoma. Oliver He Penny Pan http://www.cancer.gov/news-events/cancer-currents-blog/2019/in-situ-vaccine-non-hodgkin-lymphoma lymphoma vaccine A cancer vaccine that is used against brain canceer. Oliver He Penny Pan https://www.criver.com/eureka/brain-cancer-vaccine-gliomas-moves-forward-clinic brain cancer vaccine A cancer vaccine that is used against liver canceer. Oliver He Penny Pan https://www.creative-biolabs.com/vaccine/liver-cancer-vaccines.htm liver cancer vaccine A cancer vaccine that is used against pancreatic canceer. Oliver He Penny Pan https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-vaccine pancreatic cancer vaccine A recombinant viral vaccine vector that uses PVSRIPO, a recombinant nonpathogenic polio-rhinovirus chimera. PVSRIPO is an engineerable oncolytic virus whereas its internal ribosomal entry site element can be substituted to demolish its cytopathogenic effect. PVSRIPO has a natural inherent tropism for antigen-presenting cells (including dendritic cells and macrophages) due to the presence of the CD-155 receptor on their cellular surfaces. This enables it of inducing CD8+ T-cell mediate immune responses. Mina Ashraf, Oliver He https://journals.aai.org/jimmunol/article/172/7/3994/71825/Cutting-Edge-CD96-Tactile-Promotes-NK-Cell-Target https://link.springer.com/article/10.1007/s00109-008-0433-0 https://pubmed.ncbi.nlm.nih.gov/31988324/ https://www.pnas.org/doi/abs/10.1073/pnas.93.6.2370 https://www.pnas.org/doi/full/10.1073/pnas.95.14.8216 https://www.sciencedirect.com/science/article/pii/B978012810514600009X?via%3Dihub PVSRIPO vaccine vector A Comirnaty COVID-19 mRNA vaccine produced by Pfizer-BioNTech,which is a bivalent vaccine that is effective against the original strain of COVID-19 as well as the Omicron BA.1 variant.A non-US vaccine product. Penny Pan, Oliver He Comirnaty Bivalent PMID: 36541943 https://secure.medicalletter.org/TML-article-1665f https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx Comirnaty 520 Authorized by WHO 10/19/2022 - Counted toward immunity in US.Ref:https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech A Comirnaty COVID-19 mRNA vaccine utilizes Lipid Nanoparticle-Self-amplifying RNA technology, available as a bivalent boosters against the original strain of COVID-19 as well as the Omicron BA.1 variant produced by Pfizer (PF) with a dose of 30 mcg/0.3 mL to provide enhanced protection. Penny Pan, Oliver He PMID: 36206167 https://secure.medicalletter.org/TML-article-1660c https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx Comirnaty 300 EUA authorized Pfizer adult bivalent booster ages 12+ yrs, original strain + omicron BA.4/BA.5. Not Authorized by WHO. Non-US Tradename for same formulation (Comirnaty Bivalent) counted toward immunity in US. Ref:https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation A Comirnaty COVID-19 mRNA vaccine utilizing Lipid Nanoparticle-Self-amplifying RNA technology against the original strain of COVID-19 without preservative ,which is produced by Pfizer (PF) with a dose of 30 mcg/0.3 mL. Penny Pan, Oliver He https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx 208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose Passive vaccine is a vaccine that is made of immune globulin and used to immulize an individual against some dieases. passive vaccine anthrax immune globulin anthrax immune globulin passive vaccine CVX code:181 CMVIG cytomegalovirus immune globulin passive vaccine, intravenous CVX code:29 Hepatitis A Immune Globulin passive vaccine is a passive vaccine that provides protection against hepatitis A through the passive transfer of an antibody. Hep A, IG provides temporary immunity to the virus for two to three months, if administered prior to exposure or within two weeks after exposure. Hep A,IG Hepatitis A immune globulin Stapleton, Jack T. "Passive immunization against hepatitis A." Vaccine 10 (1992): S45-S47. Hepatitis A immune globulin passive vaccine CVX code:154 HBIG hepatitis B immune globulin hepatitis B immune globulin passive vaccine CVX code:30 IG immune globulin, intramuscular CVX code:86 IGIV immune globulin, intravenous CVX code:87 IG,unspecified formulation immune globulin, unspecified formulation CVX code:14 rabies immune globulin CVX code:34 RSV-IGIV respiratory syncytial virus immune globulin, intravenous respiratory syncytial virus immune globulin passive vaccine, intravenous CVX code:71 Rho(D) Immune globulin - IM CVX code:157 Rho(D) Immune globulin- IV or IM Rho(D) Immune globulin- IV or IM passive vaccine CVX code:156 Rho(D) Unspecified formulation CVX code:159 tetanus immune globulin CVX code:13 'vaccinia immune globulin' vaccinia immune globulin passive vaccine CVX code:79 varicella zoster immune globulin CVX code:36 varicella zoster immune globulin (Investigational New Drug) CVX code:117 DTP-hepB-Hib plentavalent Non-US Diphtheria-Pertussis-Tetanus-Haemophilus B-Hepatitis B vaccine,(Pentavalent) CVX code:198 DTP-Hib-Hep B DTP--Haemophilus influenzae type b conjugate and hepatitis B vaccine CVX code:107 YY, YH Influenza, injectable, MDCK, quadrivalent, preservative Influenza, injectable,Influenza, injectable, Madin Darby Canine Kidney, quadrivalent with preservative Madin Darby Canine Kidney, quadrivalent with preservative CVX code:186 DTP,unspecified formulation Diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation CVX code:107 DTP-Hib DTP--Haemophilus influenzae type b conjugate vaccine CVX code:22 A viral vaccine that protects against infection with influenza virus. PY,HY Influenza,high-dose,quadrivalent Influenza,high-dose seasonal,quadrivalent,0.7ml dose,preservative free CVX code:197 YY, YH Influenza, injectable,quadrivalent, preservative free, pediatric Influenza, injectable,quadrivalent, preservative free, pediatric CVX code:161 YY, YH influenza, intradermal, quadrivalent, preservative free Influenza, injectable, MDCK, quadrivalent, preservative CVX code:166 A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine. YY,YH OPV bivalent CXX code:178 Non-US bivalent oral polio vaccine (types 1 and 3) A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine. YY,YH OPV ,monovalent, unspecified CXX code:179 Non-US monovalent oral polio vaccine, unspecified formulation YH, YY Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) CVX code:09 YH, YY Td, adsorbed, preservative free, adult use, Lf unspecified tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified CVX code:196 YH, YY Td (adult) tetanus and diphtheria toxoids, not adsorbed, for adult use CVX code:138 A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine. YY,YH OPV CXX code:02 trivalent poliovirus vaccine, live, oral YY,YH DTaP,IPV,Hib,HepB Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine. CVX code:146 A vaccine adjuvant 30:70 (w/w) Water-in-Oil (W/O) emulsion that stimulates a mixed Th1/Th2 response. Chemical Nature: emulsion Mechanism of Action: adjuvanted antigen depot at injection site Immune profile induced: Mixed Th1/Th2 Route of immunization: IM and SQ Point of Contact: Peter Blackburn, MerciaPharma Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760 https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964 https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319 https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT02500680 https://clinicaltrials.gov/ct2/show/NCT02500680 https://clinicaltrials.gov/ct2/show/NCT03624062 https://clinicaltrials.gov/ct2/show/NCT02118077 Ari Joffe Oliver He Peter Blackburn Wolfgang Leitner MAS-1 https://clinicaltrials.gov/ct2/show/NCT02118077 https://clinicaltrials.gov/ct2/show/NCT02500680 https://clinicaltrials.gov/ct2/show/NCT03624062 https://vac.niaid.nih.gov/view?id=68 https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760 https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964 https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319 https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305 68 MAS-1 vaccine adjuvant A vaccine adjuvant that induces CD8 T cells and provides innate protection. Chemical Nature: small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: SQ Point of Contact: Taegyan Kang, Progeneer Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335 Ongoing clinical trials: n/a Ari Joffe Oliver He Taegyan Kang Wolfgang Leitner ProLNG-S https://vac.niaid.nih.gov/view?id=34 https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335 34 ProLNG-S vaccine adjuvant A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response. Chemical Nature: Liposome Mechanism of Action: n/a Immune profile induced: n/a Route of immunization: IN, IP, IM, Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772 https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684 https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03715985 Ari Joffe Gabriel Kristian Pedersen Oliver He Wolfgang Leitner CAF09b https://clinicaltrials.gov/ct2/show/NCT03715985 https://vac.niaid.nih.gov/view?id=76 https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684 https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074 https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772 76 CAF09b vaccine adjuvant A vaccine adjuvant that is a lipid-based nanosuspension of a synthetic TLR7/8 ligand that facilitates adsorption to aluminum oxyhydroxide via the structural properties of the helper lipid employed. Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326 https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326 https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT05781542 https://clinicaltrials.gov/ct2/show/NCT05471076 https://clinicaltrials.gov/ct2/show/NCT04915768 https://clinicaltrials.gov/ct2/show/NCT05781542 Ari Joffe Oliver He Valerie Soza Wolfgang Leitner 3M-052-AF https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT04915768 https://clinicaltrials.gov/ct2/show/NCT05471076 https://clinicaltrials.gov/ct2/show/NCT05781542 https://vac.niaid.nih.gov/view?id=69 https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326 https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085 69 3M-052-AF vaccine adjuvant A vaccine adjuvant that reformulates Alhydrogel as a stable nanoparticle with the anionic polymer polyacrylic acid (PAA), leading to the induction of structure-dependent TH1 response. Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742 https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264 Ari Joffe Oliver He Valerie Soza Wolfgang Leitner NanoAlum https://vac.niaid.nih.gov/view?id=71 https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742 https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264 71 NanoAlum vaccine adjuvant A vaccine adjuvant is a small molecule adjuvant that induces Th1-based immune response and is designed for use with self-amplifying RNA antigens. Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728 https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202 https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388 https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783 https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712 https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT05370040 Ari Joffe Oliver He Valerie Soza Wolfgang Leitner NLC vaccine adjuvant Nanostructured Lipid Carrier Nanostructured Lipid Carrier (NLC) https://clinicaltrials.gov/ct2/show/NCT05370040 https://vac.niaid.nih.gov/view?id=70 https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202 https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388 https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783 https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728 https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666 https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712 70 Nanostructured Lipid Carrier (NLC) vaccine adjuvant AH Giardia spp. protein PFS25/28 in Matrix M a malaria vaccine that protects against malaria caused by Plasmodium knowlesi. Anthony Huffman Plasmodium knowlesi vaccine a malaria vaccine that protects against malaria caused by Plasmodium chabaudi. Anthony Huffman Plasmodium chabaudi vaccine A vaccine adjuvant is an oil-in-water emulsion that induces Th1-based immune response. Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: n/a Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577 https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225 Ari Joffe Oliver He Valerie Soza Wolfgang Leitner SLA-AF https://vac.niaid.nih.gov/view?id=72 https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577 https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225 72 SLA-AF vaccine adjuvant A vaccine adjuvant is a gadoteridol-loaded cationic adjuvant formulation 01 that induced a Th1/Th17 type of immune response. Chemical Nature: Liposome system Mechanism of Action: n/a Immune profile induced: Th1/Th17 Route of immunization: IP, IM, IN, SQ, ID, SC, SL, intratracheal, endotracheal, Fish vaccination Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263 https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488 https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790 https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110 https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776 https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936 https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987 https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731 https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939 https://www.ncbi.nlm.nih.gov/pubmed/?term=33072125 https://www.ncbi.nlm.nih.gov/pubmed/?term=35585969 https://www.ncbi.nlm.nih.gov/pubmed/?term=26494626 https://www.ncbi.nlm.nih.gov/pubmed/?term=26379666 https://www.ncbi.nlm.nih.gov/pubmed/?term=35124896 https://www.ncbi.nlm.nih.gov/pubmed/?term=34358167 https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075 https://www.ncbi.nlm.nih.gov/pubmed/?term=31130946 https://www.ncbi.nlm.nih.gov/pubmed/?term=31906072 https://www.ncbi.nlm.nih.gov/pubmed/?term=32106599 https://www.ncbi.nlm.nih.gov/pubmed/?term=19492047 https://www.ncbi.nlm.nih.gov/pubmed/?term=33422991 https://www.ncbi.nlm.nih.gov/pubmed/?term=28414746 https://www.ncbi.nlm.nih.gov/pubmed/?term=33066267 https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370 https://www.ncbi.nlm.nih.gov/pubmed/?term=23308247 https://www.ncbi.nlm.nih.gov/pubmed/?term=30984200 https://www.ncbi.nlm.nih.gov/pubmed/?term=20505822 https://www.ncbi.nlm.nih.gov/pubmed/?term=27525651 https://www.ncbi.nlm.nih.gov/pubmed/?term=23873630 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT00922363 https://clinicaltrials.gov/ct2/show/NCT01009762 https://clinicaltrials.gov/ct2/show/NCT02787109 https://clinicaltrials.gov/ct2/show/NCT01141205 https://clinicaltrials.gov/ct2/show/NCT03926728 Ari Joffe Gabriel Kristian Pedersen Oliver He Wolfgang Leitner CAF01 https://clinicaltrials.gov/ct2/show/NCT00922363 https://clinicaltrials.gov/ct2/show/NCT01009762 https://clinicaltrials.gov/ct2/show/NCT01141205 https://clinicaltrials.gov/ct2/show/NCT02787109 https://clinicaltrials.gov/ct2/show/NCT03926728 https://vac.niaid.nih.gov/view?id=75 https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936 https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731 https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776 https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939 https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790 https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987 https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488 https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263 https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110 75 CAF01 vaccine adjuvant A cancer vaccine that is developed against breast cancer. Oliver He breast cancer vacine A cancer vaccine that is developed against bladder cancer. Oliver He bladder cancer vacine A cancer vaccine that is developed against lung cancer. Oliver He lung cancer vacine A cancer vaccine that is developed against leukemia. Oliver He leukemia cancer vacine A cancer vaccine that is developed against cervical cancer. Oliver He cervical cancer vacine A cancer vaccine that is developed against cervical cancer. Oliver He colon cancer vacine A cancer vaccine that is developed against gastric cancer Oliver He gastric cancer vacine A cancer vaccine that is developed against mesothelioma cancer. Oliver He mesothelioma cancer vacine A cancer vaccine that is developed against myeloma cancer. Oliver He myeloma cancer vaccine A cancer vaccine that is developed against ovarian cancer. Oliver He ovarian cancer vaccine A cancer vaccine that is developed against renal cancer. Oliver He renal cancer vaccine A cancer vaccine that is developed against sarcoma cancer. Oliver He sarcoma cancer vaccine A cancer vaccine that is developed against esophageal cancer. Jie Zheng Oliver He Yuying Pan esophageal cancer vaccine A cancer vaccine that is developed against head and neck cancer. Jie Zheng Oliver He Yuying Pan head and neck cancer vaccine A cancer vaccine that is developed against nasopharyngeal cancer. Jie Zheng Oliver He Yuying Pan nasopharyngeal cancer vaccine A cancer vaccine that is developed against hepatocellular carcinoma. Jie Zheng Oliver He Yuying Pan hepatocellular carcinoma vaccine Anthony Huffman Plasmodium falciparum MSA2 a grouping class for vaccines for specific diseases vaccine for disease a grouping class for vaccines for specific pathogens vaccine for pathogen a grouping class for vaccines for specific platforms vaccine for platform vaccine by platform type A Inactivated vaccine that immunizes against Neospora caninum protozoa. Anthony Huffman violinID:1975 N. caninum Killed Protozoa Vaccine A Inactivated vaccine that immunizes against Toxoplasma gondii trypmastigote. Anthony Huffman violinID:6065 CTLVECNS A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite. Anthony Huffman violinID:5993 G. lamblia bivalent DNA vaccine encoding a1-giardin and CWP2 A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite. Anthony Huffman violinID:5991 G. lamblia vaccine encoding a-enolase A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite. Anthony Huffman violinID:5989 G. lamblia vaccine encoding a1-giardin A Live attenuated vaccine that immunizes against Giardi lamblia trophozoite. Anthony Huffman violinID:6004 G. lamblia vaccine using attenuated Salmonella vaccine expressing VSPH7 A Live attenuated vaccine that immunizes against Plasmodium falciparum sporozoite. Anthony Huffman violinID:5952 p52(-)/p36(-) GAP A Live attenuated vaccine that immunizes against Plasmodium falciparum sporozoite. Anthony Huffman violinID:5988 Pb(PfCS@UIS4) A Live attenuated vaccine that immunizes against Plasmodium falciparum sporozoite. Anthony Huffman violinID:5950 PfSPZ A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote. Anthony Huffman violinID:6069 RH-AMA1KO A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote. Anthony Huffman violinID:6082 T. gondii GRA17 mutant vaccine A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote. Anthony Huffman violinID:6090 T. gondii irradiated sterilised tachyzoites A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote. Anthony Huffman violinID:6087 T. gondii LDH1 and LDH2 mutant vaccine A Live attenuated vaccine that immunizes against Toxoplasma gondii trypmastigote. Anthony Huffman violinID:6091 UV-attenuated Toxoplasma gondii with DSCG adjuvant adenovirus unspecified formulation adenovirus vaccine unspecified formulation CVX:82 botulinum antitoxin botulinum antitoxin CVX:27 cholera unspecified formulation cholera vaccine unspecified formulation CVX:26 cholera BivWC cholera BivWC CVX:173 cholera live attenuated cholera live attenuated CVX:174 diphtheria antitoxin diphtheria antitoxin CVX:12 Hib unspecified formulation Haemophilus influenzae type b vaccine conjugate unspecified formulation CVX:17 Hib (PRP-D) Haemophilus influenzae type b vaccine PRP-D conjugate CVX:46 Hep A live attenuated Hep A live attenuated-IM CVX:169 Hep A adult hepatitis A vaccine adult dosage CVX:52 Hep A pediatric unspecified formulation hepatitis A vaccine pediatric dosage unspecified formulation CVX:31 Hep A ped/adol 3 dose hepatitis A vaccine pediatric/adolescent dosage 3 dose schedule CVX:84 Hep A unspecified formulation hepatitis A vaccine unspecified formulation CVX:85 HepB recombinant 3-antigen Al(OH)3 Hepatitis B vaccine (recombinant) 3-antigen Al(OH)3 adjuvanted CVX:220 Hep B adolescent/high risk infant hepatitis B vaccine adolescent/high risk infant dosage CVX:42 Hep B unspecified formulation hepatitis B vaccine unspecified formulation CVX:45 Hep C hepatitis C vaccine CVX:58 Hep E hepatitis E vaccine CVX:59 herpes simplex 2 herpes simplex virus type 2 vaccine CVX:60 typhus historical Historical record of a typhus vaccination CVX:131 HPV unspecified formulation HPV unspecified formulation CVX:137 Rabies - IM Diploid cell culture Human Rabies vaccine from human diploid cell culture CVX:175 influenza nasal unspecified formulation influenza nasal unspecified formulation CVX:151 influenza split (incl. purified surface antigen) influenza virus vaccine split virus (incl. purified surface antigen)-retired CODE CVX:15 influenza unspecified formulation influenza virus vaccine unspecified formulation CVX:88 influenza whole influenza virus vaccine whole virus CVX:16 Japanese Encephalitis unspecified formulation Japanese Encephalitis vaccine unspecified formulation CVX:129 Junin virus Junin virus vaccine CVX:63 leprosy leprosy vaccine CVX:65 meningococcal A polysaccharide (non-US) meningococcal A polysaccharide vaccine (non-US) CVX:191 meningococcal AC polysaccharide (non-US) meningococcal AC polysaccharide vaccine (non-US) CVX:192 meningococcal ACWY unspecified formulation meningococcal ACWY vaccine unspecified formulation CVX:108 meningococcal B unspecified meningococcal B unspecified formulation CVX:164 meningococcal C conjugate meningococcal C conjugate vaccine CVX:103 meningococcal unknown serogroups meningococcal vaccine of unknown formulation and unknown serogroups CVX:167 meningococcal polysaccharide (groups A C Y W-135) TT conjugate meningococcal polysaccharide (groups A C Y W-135) tetanus toxoid conjugate vaccine 0.5mL dose preservative free CVX:203 meningococcal MCV4 unspecified formulation Meningococcal MCV4 unspecified conjugate formulation(groups A C Y and W-135) CVX:147 Novel Influenza-H1N1-09 all formulations Novel influenza-H1N1-09 all formulations CVX:128 Novel influenza-H1N1-09 Novel influenza-H1N1-09 injectable CVX:127 Novel Influenza-H1N1-09 nasal Novel Influenza-H1N1-09 live virus for nasal administration CVX:125 Novel influenza-H1N1-09 preservative-free Novel influenza-H1N1-09 preservative-free injectable CVX:126 Pneumococcal conjugate PCV15 polysaccharide CRM197 conjugate adjuvant PF Pneumococcal conjugate vaccine 15-valent (PCV15) polysaccharide CRM197 conjugate adjuvant preservative free CVX:215 c conjugate PCV20 polysaccharide CRM197 conjugate adjuvant PF Pneumococcal conjugate vaccine 20-valent (PCV20) polysaccharide CRM197 conjugate adjuvant preservative free CVX:216 PCV10 pneumococcal conjugate vaccine 10 valent CVX:177 Pneumococcal Conjugate unspecified formulation Pneumococcal Conjugate unspecified formulation CVX:152 rabies intradermal injection rabies vaccine for intradermal injection CVX:40 rabies unspecified formulation rabies vaccine unspecified formulation CVX:90 RSV-MAb (new) respiratory syncytial virus monoclonal antibody (motavizumab) intramuscular CVX:145 RSV-MAb respiratory syncytial virus monoclonal antibody (palivizumab) intramuscular CVX:93 rheumatic fever rheumatic fever vaccine CVX:72 rotavirus unspecified formulation rotavirus vaccine unspecified formulation CVX:122 rotavirus tetravalent rotavirus live tetravalent vaccine CVX:74 COVID-19 D614 recomb preS dTM AS03 adjuvant add PF 10mcg/0.5mL SARS-COV-2 (COVID-19) vaccine D614 prefusion spike recombinant protein subunit (CoV2 preS dTM) AS03 adjuvant added preservative free 10mcg/0.5mL dose CVX:226 COVID-19 D614 recomb preS dTM AS03 adjuvant add PF 5mcg/0.5mL SARS-COV-2 (COVID-19) vaccine D614 prefusion spike recombinant protein subunit (CoV2 preS dTM) AS03 adjuvant added preservative free 5mcg/0.5mL dose CVX:225 COVID-19 mRNA LNP-S bivalent booster PF 10 mcg/0.2 mL SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 10 mcg/0.2 mL dose CVX:230 COVID-19 mRNA LNP-S bivalent booster PF 10 mcg/0.2 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 10 mcg/0.2 mL dose tris-sucrose formulation CVX:301 COVID-19 mRNA LNP-S bivalent booster PF 30 mcg/0.3 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 30 mcg/0.3 mL dose tris-sucrose formulation CVX:300 COVID-19 mRNA LNP-S bivalent booster PF 50 mcg/0.5 mL or 25mcg/0.25 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 50 mcg/0.5 mL or 25 mcg/0.25 mL dose CVX:229 COVID-19 mRNA LNP-S bivalent PF 3 mcg/0.2 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent preservative free 3 mcg/0.2 mL dose tris-sucrose formulation CVX:302 COVID-19 mRNA LNP-S PF 10 mcg/0.2 mL dose tris-sucrose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 10 mcg/0.2mL dose tris-sucrose formulation CVX:218 COVID-19 mRNA LNP-S PF 100 mcg/0.5mL dose or 50 mcg/0.25mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 100 mcg/0.5mL dose or 50 mcg/0.25mL dose CVX:207 COVID-19 mRNA LNP-S PF 3 mcg/0.2 mL dose tris-sucrose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 3 mcg/0.2mL dose tris-sucrose formulation CVX:219 COVID-19 mRNA LNP-S PF 30 mcg/0.3 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose CVX:208 COVID-19 mRNA LNP-S PF 30 mcg/0.3 mL dose tris-sucrose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose tris-sucrose formulation CVX:217 COVID-19 mRNA LNP-S PF 50 mcg/0.5 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 50 mcg/0.5 mL dose CVX:221 COVID-19 mRNA LNP-S PF pediatric 25 mcg/0.25 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 25 mcg/0.25 mL dose CVX:228 COVID-19 mRNA LNP-S PF pediatric 50 mcg/0.5 mL dose SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 50 mcg/0.5 mL dose CVX:227 SARS-COV-2 (COVID-19) vaccine UNSPECIFIED SARS-COV-2 (COVID-19) vaccine UNSPECIFIED CVX:213 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine (Spikevax Bivalent) Moderna SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine (Spikevax Bivalent) Moderna CVX:519 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine Product Pfizer-BioNTech SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine Product (Comirnaty Bivalent) Pfizer-BioNTech CVX:520 COVID-19 Non-US Vaccine Product Unknown SARS-COV-2 COVID-19 Non-US Vaccine Specific Product Unknown CVX:500 COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) CVX:508 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro Chinese Acad of Sciences) SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology Chinese Academy of Sciences) CVX:507 SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Zifivax) SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Zifivax) CVX:513 COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA) CanSino Biological Inc./Beijing Institute of Biotechnology CVX:506 COVID-19 VVnr Non-US Vaccine (Sputnik Light) SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) CVX:504 tetanus toxoid not adsorbed tetanus toxoid not adsorbed CVX:142 tetanus toxoid unspecified formulation tetanus toxoid unspecified formulation CVX:112 Tick-borne encephalitis vaccine (non-US) Tick-borne encephalitis vaccine (non-US) CVX:77 Tick-borne encephalitis inactivated PF 0.25mL Tick-borne encephalitis vaccine inactivated preservative free 0.25mL dose CVX:223 Tick-borne encephalitis inactivated PF 0.5mL Tick-borne encephalitis vaccine inactivated preservative free 0.5mL dose CVX:224 Tick-borne encephalitis unspecified Tick-borne encephalitis vaccine unspecified CVX:222 Typhoid conjugate vaccine (TCV) Typhoid conjugate vaccine (non-US) CVX:190 typhoid parenteral AKD (U.S. military) typhoid vaccine parenteral acetone-killed dried (U.S. military) CVX:53 typhoid parenteral typhoid vaccine parenteral other than acetone-killed dried CVX:41 typhoid unspecified formulation typhoid vaccine unspecified formulation CVX:91 vaccinia (smallpox) diluted vaccinia (smallpox) vaccine diluted CVX:105 Vaccinia smallpox monkeypox vaccine live PF SQ or ID injection Vaccinia smallpox monkeypox vaccine live attenuated preservative free subcutaneous or intradermal injection CVX:206 VEE unspecified formulation Venezuelan equine encephalitis vaccine unspecified formulation CVX:92 VEE inactivated Venezuelan equine encephalitis inactivated CVX:81 dengue fever dengue fever vaccine CVX:56 Ebola unspecified Ebola unspecified CVX:214 A combination vaccine adjuvant that is liposome-based adjuvant of a synthetic TLR agonist and saponin induced a Th1-biased immune response. Chemical Nature: Combination adjuvant Mechanism of Action: n/a Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Maria Lawrenz, Vaccine Formulation Institute Jie Zheng Maria Lawrenz Nilufer kosar Oliver He Wolfgang Leitner LMQ https://www.ncbi.nlm.nih.gov/pubmed/?term=36119058 https://www.ncbi.nlm.nih.gov/pubmed/?term=36634821 https://www.ncbi.nlm.nih.gov/pubmed/?term=37029167 https://github.com/vaccineontology/VO/issues/614 78 LMQ vaccine adjuvant A vaccine adjuvant that is a peptide which is able to induce Th1/Th2/Th17 immune responses through the mechanism of selectively activates C5aR1 on mononuclear phagocytes vs neutrophils. Chemical Nature: Other - Peptide Mechanism of Action: (Primary) Selectively activates C5aR1 on mononuclear phagocytes vs neutrophils Immune profile induced: Th1/Th2/Th17 Route of immunization: IP, IV Point of Contact: Joseph Vetro, University of Nebraska Medical Center Jie Zheng Joseph Vetro Nilufer kosar Oliver He Wolfgang Leitner CPDI-02 https://www.ncbi.nlm.nih.gov/pubmed/?term=11710544 https://www.ncbi.nlm.nih.gov/pubmed/?term=19836478 https://www.ncbi.nlm.nih.gov/pubmed/?term=20965299 https://github.com/vaccineontology/VO/issues/615 40 CPDI-02 vaccine adjuvant A vaccine adjuvant with a Toll-like receptor 9 (TLR9)-active oligonucleotide that is able to induce Th1/Th2 immune responses. Chemical Nature: Nucleic acid Mechanism of Action: TLR9 agonist Immune profile induced: Mixed Th1/Th2 Route of immunization: IM, SQ Point of Contact: Nikolai Petrovsky, Vaxine LTD Jie Zheng Nikolai Petrovsky Nilufer kosar Oliver He Wolfgang Leitner CpG55.2 https://www.ncbi.nlm.nih.gov/pubmed/?term=24554695 https://www.ncbi.nlm.nih.gov/pubmed/?term=27387453 https://www.ncbi.nlm.nih.gov/pubmed/?term=32156809 https://www.ncbi.nlm.nih.gov/pubmed/?term=32418798 https://www.ncbi.nlm.nih.gov/pubmed/?term=33479242 https://www.ncbi.nlm.nih.gov/pubmed/?term=34399628 https://www.ncbi.nlm.nih.gov/pubmed/?term=34420786 https://www.ncbi.nlm.nih.gov/pubmed/?term=34456075 https://github.com/vaccineontology/VO/issues/616 10 CpG55.2 vaccine adjuvant A combination vaccine adjuvant that includes AS01-mimic, Immune Stimulating Complex (ISCOM) with a TLR4 agonist. Chemical Nature: Combination adjuvant Mechanism of Action: Cytokine induction in draining lymph nodes with increased lymph flow and lymph antigen accumulation Immune profile induced: Mixed Th1/Th2 Route of immunization: s.c. / i.m. / i.n. Point of Contact: Katarzyna Kaczmarek Michaels, Massachusetts Institute of Technology Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=34860581 https://www.ncbi.nlm.nih.gov/pubmed/?term=36131022 https://www.ncbi.nlm.nih.gov/pubmed/?term=34878851 Jie Zheng Katarzyna Kaczmarek Michaels Nilufer kosar Oliver He Wolfgang Leitner SMNP https://github.com/vaccineontology/VO/issues/632 77 SMNP vaccine adjuvant A combination vaccine adjuvant that is an AS01-mimic, liposomal adjuvant of a TLR4 agonist and saponin. Chemical Nature: - Natural compound - Synthetic derivative of natural compound - Combination adjuvant Mechanism of Action: MPLA: TLR4 agonist QS21: Sugar-lawn likely recog. by lectins to facilitate uptake by M_, DCs, etc Immune profile induced: Mixed Th1/Th2 Route of immunization: ID, IM Point of Contact: Mangala Rao, Walter Reed Army Institute of Research Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178 https://www.ncbi.nlm.nih.gov/pubmed/?term=31827000 https://www.ncbi.nlm.nih.gov/pubmed/?term=34470866 https://www.ncbi.nlm.nih.gov/pubmed/?term=35632473 https://www.ncbi.nlm.nih.gov/pubmed/?term=36417525 https://www.ncbi.nlm.nih.gov/pubmed/?term=34914540 https://www.ncbi.nlm.nih.gov/pubmed/?term=32881968 https://www.ncbi.nlm.nih.gov/pubmed/?term=26372857 https://www.ncbi.nlm.nih.gov/pubmed/?term=36055874 https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178 https://www.ncbi.nlm.nih.gov/pubmed/?term=36679887 https://www.ncbi.nlm.nih.gov/pubmed/?term=36934088 https://www.ncbi.nlm.nih.gov/pubmed/?term=34903722 https://www.ncbi.nlm.nih.gov/pubmed/?term=31775762 https://www.ncbi.nlm.nih.gov/pubmed/?term=28596090 https://www.ncbi.nlm.nih.gov/pubmed/?term=31151801 https://www.ncbi.nlm.nih.gov/pubmed/?term=34711815 https://www.ncbi.nlm.nih.gov/pubmed/?term=34159328 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT04268420 https://clinicaltrials.gov/ct2/show/NCT04296279 https://clinicaltrials.gov/ct2/show/NCT04784767 https://clinicaltrials.gov/ct2/show/NCT05500417 https://clinicaltrials.gov/ct2/show/NCT04826094 https://clinicaltrials.gov/ct2/show/NCT04658667 https://clinicaltrials.gov/ct2/show/NCT05423418 Jie Zheng Mangala Rao Nilufer kosar Oliver He Wolfgang Leitner ALFQ https://github.com/vaccineontology/VO/issues/633 79 ALFQ vaccine adjuvant A vaccine adjuvant which is a small molecule TLR agonist that drives a mixed Th1/Th2 response. Chemical Nature: Small molecule Mechanism of Action: Innate immune activation Immune profile induced: Mixed Th1/Th2 Route of immunization: IM Point of Contact: Dennis Carson, UCSD Dennis Carson Jie Zheng Nilufer kosar Oliver He Wolfgang Leitner 2G023A https://github.com/vaccineontology/VO/issues/648 81 2G023A vaccine adjuvant A vaccine adjuvant, a small molecule TLR agonist that drives a mixed Th1/Th2 response. Chemical Nature: Small molecule Mechanism of Action: Innate immune activation Immune profile induced: Mixed Th1/Th2 Route of immunization: IM Point of Contact: Dennis Carson, UCSD Dennis Carson Jie Zheng Nilufer kosar Oliver He Wolfgang Leitner 2G053 https://github.com/vaccineontology/VO/issues/649 80 2G053 vaccine adjuvant A combination vaccine adjuvant of a synthetic TLR agonist and aluminum salt. Chemical Nature: - Synthetic derivative of natural compound - Combination adjuvant - Mineral salt Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: SQ, IM Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=37454145 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=28828575 https://www.ncbi.nlm.nih.gov/pubmed/?term=30013570 https://www.ncbi.nlm.nih.gov/pubmed/?term=24211167 https://www.ncbi.nlm.nih.gov/pubmed/?term=23933525 https://www.ncbi.nlm.nih.gov/pubmed/?term=34597297 https://www.ncbi.nlm.nih.gov/pubmed/?term=36996185 https://www.ncbi.nlm.nih.gov/pubmed/?term=28464026 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03910972 https://clinicaltrials.gov/ct2/show/NCT02126462 https://clinicaltrials.gov/ct2/show/NCT02839161 https://clinicaltrials.gov/ct2/show/NCT03110757 https://clinicaltrials.gov/ct2/show/NCT02337855 https://clinicaltrials.gov/ct2/show/NCT01717950 https://clinicaltrials.gov/ct2/show/NCT02476773 https://clinicaltrials.gov/ct2/show/NCT01261130 https://clinicaltrials.gov/ct2/show/NCT01385189 https://clinicaltrials.gov/ct2/show/NCT03172975 Jie Zheng Nilufer kosar Oliver He Valerie Soza Wolfgang Leitner GLA-Alum https://github.com/vaccineontology/VO/issues/650 83 GLA-Alum vaccine adjuvant A combination vaccine adjuvant of a synthetic TLR4 agonist and aluminum salt. Chemical Nature: - Synthetic derivative of natural compound - Combination adjuvant - Mineral salt Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=26901122 https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577 Jie Zheng Nilufer kosar Oliver He Valerie Soza Wolfgang Leitner SLA-Alum https://github.com/vaccineontology/VO/issues/651 82 SLA-Alum vaccine adjuvant An emulsion vaccine adjuvant that includes squalene-based oil-in-water emulsion. Chemical Nature: Emulsion Mechanism of Action: n/a Immune profile induced: Mixed Th1/Th2 Route of immunization: IM, SQ Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214 https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687 https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728 https://www.ncbi.nlm.nih.gov/pubmed/?term=37495191 https://www.ncbi.nlm.nih.gov/pubmed/?term=36256646 https://www.ncbi.nlm.nih.gov/pubmed/?term=28089141 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03330899 https://clinicaltrials.gov/ct2/show/NCT01612000 https://clinicaltrials.gov/ct2/show/NCT02464163 https://clinicaltrials.gov/ct2/show/NCT02464163 Jie Zheng Nilufer kosar Oliver He Valerie Soza Wolfgang Leitner Stable Emulsion (SE) https://github.com/vaccineontology/VO/issues/652 84 Stable Emulsion (SE) vaccine adjuvant A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48412 NCT: https://clinicaltrials.gov/ct2/show/NCT00109655 PubMed:28530155 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5475 https://github.com/vaccineontology/VO/issues/75 1437 5475 Clinical trial Gene name: CSF-2 Oncolytic Adenovirus Encoding GM-CSF Vaccine A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN_2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN_2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C104743 NCT: https://clinicaltrials.gov/ct2/show/NCT02773849 PubMed:28834453 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5047 https://github.com/vaccineontology/VO/issues/322 3440 5047 Clinical trial Gene name: IFNA2 Recombinant Adenovirus-Interferon/Syn3 Vaccine A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2686 NCT: https://clinicaltrials.gov/ct2/show/NCT00072137 PubMed:15780740 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4994 https://github.com/vaccineontology/VO/issues/328 1437 4994 Clinical trial Gene name: GM-CSF Recombinant Fowlpox GM-CSF Vaccine Adjuvant A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C107243 NCT: https://clinicaltrials.gov/ct2/show/NCT02864368 PubMed:31806885 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5259 https://github.com/vaccineontology/VO/issues/118 18826 5259 Clinical trial Gene name: pp65(Lcp 1) PEP-CMV Vaccine A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C69076 NCT: https://clinicaltrials.gov/ct2/show/NCT01498328 PubMed:28844499 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5032 https://github.com/vaccineontology/VO/issues/120 1956 5032 Clinical trial Gene name: EGFR PF-04948568 Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29786 PubMed:21078216 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5192 https://github.com/vaccineontology/VO/issues/324 945006 5192 Clinical trial Gene name: lacZ Recombinant Adenovirus-LacZ Vaccine A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient�s own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116332 NCT: https://clinicaltrials.gov/ct2/show/NCT02149225 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5086 5086 Clinical trial Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2 A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively-personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116331 NCT: https://clinicaltrials.gov/ct2/show/NCT02149225 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5231 1956 5231 Clinical trial Gene name: EGFR Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1 An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C99378 NCT: https://clinicaltrials.gov/ct2/show/NCT02718443 PubMed:29632710 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5521 3791 5521 Clinical trial Gene name: KDR VEGFR-2 DNA Vaccine VXM01 A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C99228 NCT: https://clinicaltrials.gov/ct2/show/NCT02636582 PubMed:33485895 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5363 https://github.com/vaccineontology/VO/issues/54 2064 5363 Clinical trial Gene name: ERBB2 Nelipepimut-S Plus GM-CSF Vaccine A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C121947 NCT: https://clinicaltrials.gov/ct2/show/NCT02427581 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5348 5348 Clinical trial Personalized Synthetic Long Peptide Breast Cancer Vaccine A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61146 NCT: https://clinicaltrials.gov/ct2/show/NCT05163223 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5040 https://github.com/vaccineontology/VO/issues/122 2064 5040 Clinical trial Gene name: ERBB2 pNGVL3-hICD Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29785 PubMed:11590241 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5530 https://github.com/vaccineontology/VO/issues/320 5530 Clinical trial Recombinant Adenovirus-Cre Recombinase Vaccine An�immunotherapeutic�composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against�WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to�WT1.�WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116880 NCT: https://clinicaltrials.gov/ct2/show/NCT01220128 PubMed:30562862 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5297 https://github.com/vaccineontology/VO/issues/326 7490 5297 Clinical trial Gene name: WT1 Recombinant Anti-WT1 Immunotherapeutic GSK2302024A Vaccine A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49177 NCT: https://clinicaltrials.gov/ct2/show/NCT00140738 PubMed:26975189 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5241 2064 5241 Clinical trial Gene name: ERBB2 Recombinant dHER2 Vaccine A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102782 NCT: https://clinicaltrials.gov/ct2/show/NCT00004156 PubMed:9656453 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5077 4582 5077 Clinical trial Gene name: MUC1 Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49087 NCT: https://clinicaltrials.gov/ct2/show/NCT00227474 PubMed:18990081 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5058 https://github.com/vaccineontology/VO/issues/337 7162 5058 Clinical trial Gene name: TPBG Recombinant Modified Vaccinia Ankara-5T4 Vaccine A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen; MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various tumors such as breast, prostate, and ovarian cancers. This vaccine could be used in development of immunotherapeutics against cancers expressing MUC1. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2510 NCT: https://clinicaltrials.gov/ct2/show/NCT00071942 PubMed:9101412 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5281 https://github.com/vaccineontology/VO/issues/338 354 4582 5281 Clinical trial Gene name: MUC1|Gene name: KLK3 Recombinant Vaccinia DF3/MUC1 Vaccine A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2732 NCT: https://clinicaltrials.gov/ct2/show/NCT00071942 PubMed:12898638 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5321 https://github.com/vaccineontology/VO/issues/347 4582 5321 Clinical trial Gene name: MUC1 Recombinant Vaccinia-MUC-1 Vaccine A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1690 NCT: https://clinicaltrials.gov/ct2/show/NCT00003638 PubMed:23983823 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5425 https://github.com/vaccineontology/VO/issues/361 5425 Clinical trial Gene name: sialyl-Tn Sialyl Tn-KLH Vaccine A vaccine comprised of a synthetic Sialyl-Tn antigen linked to the protein carrier, keyhole limpet hemocyanin (KLH), administered with immunostimulant, Detox. Vaccination with STn-KLH plus Detox may elicit an IgG-based anti-STn antibody response and ultimately a cytotoxic T-cell response against STn-expressing cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2501 NCT: https://clinicaltrials.gov/ct2/show/NCT00003638 PubMed:7690215 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5061 https://github.com/vaccineontology/VO/issues/363 5061 Clinical trial Gene name: sialyl-Tn STn-KLH plus Detox Vaccine A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61076 NCT: https://clinicaltrials.gov/ct2/show/NCT00304096 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5271 6007 5271 Clinical trial Gene name: RHD Synthetic Breast Cancer Peptides-Tetanus Toxoid-Montanide ISA-51 Vaccine A vaccine containing a clustered pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Alpha-N-acetylgalactosamine (Tn) is a monosaccharide usually O-linked to serine or threonine residues of mucins found on most epithelial cancers with the highest expression on prostate cancer. This vaccine contains the Tn epitope cluster (c) that is synthesized by linking 3 copies of the Tn epitope on a threonine backbone to achieve the essential immunogenic structure. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition. Vaccination with Tn(c)-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing Tn antigen, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2474 NCT: https://clinicaltrials.gov/ct2/show/NCT00030823 PubMed:9579798 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5025 5025 Clinical trial Tn(c)-KLH Conjugate Vaccine A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma. (NCIT_C85466). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85466 NCT: https://clinicaltrials.gov/ct2/show/NCT00900809 PubMed:18425107 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5026 https://github.com/vaccineontology/VO/issues/50 107653060 5026 Clinical trial Gene name: IL12 Natural Killer Cells ZRx101 vaccine A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2657 NCT: https://clinicaltrials.gov/ct2/show/NCT05479045 PubMed:24397899 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5206 https://github.com/vaccineontology/VO/issues/55 1485 5206 Clinical trial Gene name: CTAG1B NY-ESO-1 peptide vaccine A�plasmid�DNA�encoding an immunogenic peptide derived from the�cancer-testis antigen�NY-ESO-1�with potential immunostimulating and antitumor activities. Upon administration,�NY-ESO-1�plasmid�DNA�cancer�vaccine�may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the�NY-ESO-1�antigen, resulting in tumor cell lysis.�NY-ESO-1�is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62452 NCT: https://clinicaltrials.gov/ct2/show/NCT00199849 PubMed:15102697 PubMed:21900253 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5283 https://github.com/vaccineontology/VO/issues/56 https://github.com/vaccineontology/VO/issues/58 1485 5283 Clinical trial Gene name: CTAG1B NY-ESO-1 plasmid DNA cancer vaccine A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113432 NCT: https://clinicaltrials.gov/ct2/show/NCT02015416 PubMed:31069460 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5445 https://github.com/vaccineontology/VO/issues/85 1485 7099 5445 Clinical trial Gene name: CTAG1B|Gene name: TLR4 NY-ESO-1/GLA-SE vaccine ID-G305AmN A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68999 NCT: https://clinicaltrials.gov/ct2/show/NCT00199836 PubMed:15501973 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5428 https://github.com/vaccineontology/VO/issues/112 1485 5428 Clinical trial Gene name: CTAG1B NY-ESO-1b peptide vaccine A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26680 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5182 https://github.com/vaccineontology/VO/issues/76 1485 5182 Clinical trial Gene name: CTAG1B NY-ESO-B Vaccine An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2830 NCT: https://clinicaltrials.gov/ct2/show/NCT00006106 PubMed:11892945 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5486 https://github.com/vaccineontology/VO/issues/73 7157 5486 Clinical trial Gene name: TP53 ONYX-015 Vaccine A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1986 NCT: https://clinicaltrials.gov/ct2/show/NCT00001827 PubMed:24583792 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5255 7157 5255 Clinical trial Gene name: TP53 p53 Peptide Vaccine A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78820 NCT: https://clinicaltrials.gov/ct2/show/NCT00722839 PubMed:22402037 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5441 5441 Clinical trial PADRE-CMV Fusion Peptide Vaccine A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2786 NCT: https://clinicaltrials.gov/ct2/show/NCT00001386 PubMed:10546852 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5451 https://github.com/vaccineontology/VO/issues/115 5451 Clinical trial PCLUS 3-18MN Vaccine A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2787 NCT: https://clinicaltrials.gov/ct2/show/NCT00001386 PubMed:10546852 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5443 https://github.com/vaccineontology/VO/issues/116 5443 Clinical trial PCLUS 6.1-18MN Vaccine A cancer vaccine consisting of Her2/neu peptides incorporated into microspheres of poly (lactide-co-glycolide) (PLGA), a biodegradable polymer. Poly microsphere encapsulated HER2/neu oral vaccine has been investigated for use in immunotherapy for tumors positive for HER-2/neu, a tumor associated antigen that is overexpressed in various cancers, including breast and ovarian cancer.� Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2718 NCT: https://clinicaltrials.gov/ct2/show/NCT02795988 PubMed:29448628 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5176 2064 5176 Clinical trial Gene name: ERBB2 Poly Microsphere Encapsulated HER2/neu Oral Vaccine A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2438 NCT: https://clinicaltrials.gov/ct2/show/NCT00019006 PubMed:33016924 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5320 https://github.com/vaccineontology/VO/issues/189 3845 5320 Clinical trial Gene name: KRAS RAS Peptide Cancer Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the stimulatory molecule transgene B7-1. Recombinant fowlpox-B7.1 (rF-B7.1) vaccine may enhance antigen presentation and activate antitumoral cytotoxic T-cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2666 NCT: https://clinicaltrials.gov/ct2/show/NCT00030693 PubMed:12969559 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5424 https://github.com/vaccineontology/VO/issues/329 941 5424 Clinical trial Gene name: CD80 Recombinant Fowlpox-B7.1 Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2620 NCT: https://clinicaltrials.gov/ct2/show/NCT00028496 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5049 https://github.com/vaccineontology/VO/issues/330 1048 5049 Clinical trial Gene name: CEACAM5 Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82371 NCT: https://clinicaltrials.gov/ct2/show/NCT00924092 PubMed:22862954 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5152 1048 5152 Clinical trial Gene name: CEACAM5 (CEA) Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207 A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2619 NCT: https://clinicaltrials.gov/ct2/show/NCT00217373 PubMed:27581603 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5037 https://github.com/vaccineontology/VO/issues/342 111518 5037 Clinical trial Gene name: Cea-Mouse Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine An admixture of�recombinant�vaccinia�virus encoding MUC-1 and�recombinant�vaccinia�virus encoding the murine T-cell co-stimulatory molecule�B7.1. MUC-1 is a glycosylated mucin that is overexpressed in breast, lung, pancreatic, prostate, stomach, colon, and ovarian carcinomas. Vaccination with MUC-1 in combination with�B7.1 may enhance the cytotoxic T cell (CTL) immune response to tumors expressing MUC-1, compared to vaccination with MUC-1 alone. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29409 PubMed:9101412 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5326 https://github.com/vaccineontology/VO/issues/348 12519 4582 5326 Clinical trial Gene name: MUC1|Gene name: Cd80 Recombinant Vaccinia-MUC1-B7 Vaccine A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia- NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48419 NCT: https://clinicaltrials.gov/ct2/show/NCT00112957 PubMed:29773080 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5389 https://github.com/vaccineontology/VO/issues/349 1485 5389 Clinical trial Gene name: CTAG1B Recombinant Vaccinia-NY-ESO-1 Vaccine A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49082 NCT: https://clinicaltrials.gov/ct2/show/NCT00505271 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5437 https://github.com/vaccineontology/VO/issues/355 900 5437 Clinical trial Gene name: CCNG1 Retrovector Encoding Mutant Anti-Cyclin G1 Vaccine An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114285 NCT: https://clinicaltrials.gov/ct2/show/NCT00978913 PubMed:16096014 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5180 2064 373110 7157 5180 Clinical trial Gene name: Survivin|Gene name: ERBB2|Gene name: p53 Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95705 NCT: https://clinicaltrials.gov/ct2/show/NCT02334865 PubMed:27576783 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5008 https://github.com/vaccineontology/VO/issues/405 373110 5008 Clinical trial Gene name: Survivin SVN53-67/M57-KLH Peptide Vaccine A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT-encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C120118 NCT: https://clinicaltrials.gov/ct2/show/NCT02960594 PubMed:34230114 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5171 https://github.com/vaccineontology/VO/issues/409 7015 5171 Clinical trial Gene name: TERT Synthetic hTERT DNA Vaccine INO-1400 A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MElanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may sitmulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated antigens upregulated and expressed on the cell surfaces of certain tumor cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C67098 NCT: https://clinicaltrials.gov/ct2/show/NCT00423254 PubMed:21760528 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5496 https://github.com/vaccineontology/VO/issues/412 6277 5496 Clinical trial Gene name: S100A6 Synthetic Peptides E-PRA And E-PSM Vaccine A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 27-35 peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C85462 NCT: https://clinicaltrials.gov/ct2/show/NCT00972309 PubMed:27622067 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5448 https://github.com/vaccineontology/VO/issues/413 445347 5448 Clinical trial Gene name: TARP TARP 27-35 Peptide Vaccine A peptide-based cancer vaccine, consisting of amino acid residues 29 through 37 of T cell receptor gamma alternate reading frame protein (TARP) with a leucine-to-valine substitution at position 9, with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 29-37-9V peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against TARP-expressing tumor cells, which may result in decreased tumor cell proliferation. The leucine-to-valine substitution at position 9 of this peptide improves its immunogenicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C85463 NCT: https://clinicaltrials.gov/ct2/show/NCT02362464 PubMed:27622067 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5242 https://github.com/vaccineontology/VO/issues/414 445347 5242 Clinical trial Gene name: TARP TARP 29-37-9V Peptide Vaccine A cancer vaccine consisting of a recombinant vector encoding the tumor-associated carcinoembryonic antigen (CEA) that is�contaminated�with bovine viral diarrhea virus (BVDV). The carcinoembryonic antigen (CEA) is a prevalent tumor marker expressed by a number of different cancers such as colorectal, breast, lung and ovarian carcinomas; vaccination with vaccinia virus genetically engineered to express�CEA�may generate antitumoral T-cell responses.�BVDV�is an RNA pestivirus that may contaminate vaccines due to its presence in fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29476 PubMed:35380920 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5295 https://github.com/vaccineontology/VO/issues/415 4153 5295 Clinical trial Gene name: MBL2 TBC-CEA-Contaminated W/ BVDV Vaccine A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C91077 NCT: https://clinicaltrials.gov/ct2/show/NCT01095848 PubMed:22862954 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5458 10134 27 3696 3728 6868 7153 780 5458 Clinical trial Gene name: BCAP31|Gene name: TOP2A|Gene name: ADAM17|Gene name: ABL2|Gene name: JUP|Gene name: DDR1|Gene name: IGTB8 Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907 A cancer vaccine containing URLC10 (up-regulated lung cancer 10) epitopes with potential immunostimulatory and antineoplastic activities. Upon administration, URL peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. Up-regulated in lung and esophageal cancers, the function of URLC10 is unknown. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74087 NCT: https://clinicaltrials.gov/ct2/show/NCT00624182 PubMed:27720136 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5115 54742 5115 Clinical trial Gene name: LY6K URLC10 Peptide Vaccine A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74088 NCT: https://clinicaltrials.gov/ct2/show/NCT00632333 PubMed:24708624 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5001 10643 54742 7422 5001 Clinical trial Gene name: LY6K|Gene name: VEGFA|Gene name: IGF2BP3 URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine A highly tumor-selective vaccinia virus (vv) with an engineered double deletion (DD) of the thymidine kinase (tk) and vaccinia growth factor genes and additions of both a cytosine deaminase (CD) gene and a somatostatin receptor (SR) gene with potential oncolytic viral activity. The tk and vaccinia growth factor gene deletions in intratumorally administered vaccinia virus (vvDD-CDSR) help to restrict its replication and cytolytic activity to tumor cells with large nucleotide pools and tumor cells with activation of the EGFR-Ras pathway. Addition of the CD gene to the viral genome allows control of oncolytic viral infection through the administration of the prodrug 5-fluorocytosine (5-FC), converted by CD to the antimetabolite 5-fluorouracil (5-FU) in cells infected with this agent. Addition of the SR gene allows anatomical localization of vaccinia virus (vvDD-CDSR) through the use of octreotide scintigraphy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74089 NCT: https://clinicaltrials.gov/ct2/show/NCT00574977 PubMed:27203445 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5296 45091589 5296 Clinical trial Gene name: cdsR Vaccinia Virus DD-CDSR Vaccine A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61327 NCT: https://clinicaltrials.gov/ct2/show/NCT00285259 PubMed:22237175 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5390 3077579 5390 Clinical trial Gene name: UL83 VCL-CB01 Vaccine A live attenuated bacteria injectable vaccine used to prevent typhoid, which is caused by Salmonella typhi. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97127 NCT: https://clinicaltrials.gov/ct2/show/NCT03294564 PubMed:7487253 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5322 5322 Clinical trial Vi Capsular Polysaccharide Typhoid Vaccine A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C104738 PubMed:16220325 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5430 7490 5430 Clinical trial Gene name: WT1 WT1 124-138 Peptide Vaccine A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61442 NCT: https://clinicaltrials.gov/ct2/show/NCT01842139 PubMed:26492414 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5089 7490 5089 Clinical trial Gene name: WT1 WT1 126-134 Peptide Vaccine A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104734 PubMed:23225417 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5029 7490 5029 Clinical trial Gene name: WT1 WT1 235-243 Peptide Vaccine A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104737 PubMed:16220325 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5468 7490 5468 Clinical trial Gene name: WT1 WT1 247-261 Peptide Vaccine A cancer vaccine consisting of the DNA plasmid pNGVL4a-A encoding calreticulin (CRT) linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, this vaccine may generate a potent cytotoxic T-lymphocyte (CTL) response against E7-expressing tumor cells, resulting in tumor cell death. For E7(detox), the amino acids in E7 at positions 24 (cysteine to glycine) and 26 (glutamic acid to glycine) were substituted. CRT, a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER), may potentiate MHC class I presentation of HPV-16 E7 to E7-specific CD8-positive T cells. In addition, pNGVL4a-A contains two short immunostimulatory DNA sequences (ISS) in the noncoding region, which may elicit the production of IFN- and IL-12 in transfected keratinocytes and dermal antigen presenting cells (APCs), resulting in a potent T helper cell type 1 response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88289 NCT: https://clinicaltrials.gov/ct2/show/NCT00988559 PubMed:26616223 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5011 https://github.com/vaccineontology/VO/issues/123 1489079 5011 Clinical trial Gene name: HPV16 E7 pNGVL4a-CRT/E7(detox) DNA Vaccine An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48418 NCT: https://clinicaltrials.gov/ct2/show/NCT00121173 PubMed:30296681 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5069 https://github.com/vaccineontology/VO/issues/124 1489079 5069 Clinical trial Gene name: HPV16 E7 pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as recombinant human papillomavirus quadrivalent vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61087 NCT: https://clinicaltrials.gov/ct2/show/NCT00411749 PubMed:35997582 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5406 25479185 5406 Clinical trial Gene name: L1 Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.� Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119664 PubMed:26772631 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5342 25479185 7162 5342 Clinical trial Gene name: L1|Gene name: TPBG Recombinant Human Papillomavirus Nonavalent Vaccine A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88326 NCT: https://clinicaltrials.gov/ct2/show/NCT01022346 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5208 https://github.com/vaccineontology/VO/issues/340 1489078 1489079 5208 Clinical trial Gene name: E6|Gene name: E7 Recombinant Vaccinia Viral Vector RO5217790 Vaccine A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C111037 NCT: https://clinicaltrials.gov/ct2/show/NCT02128126 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5186 https://github.com/vaccineontology/VO/issues/410 1489078 1489079 5186 Clinical trial Gene name: E6|Gene name: E7 Synthetic Long E6/E7 Peptides Vaccine HPV-01 A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811 NCT: https://clinicaltrials.gov/ct2/show/NCT00493545 PubMed:16691066 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5542 1489079 3329 5542 Clinical trial Gene name: E7|Gene name: HSPD1 Verpasep Caltespen Vaccine A synthetic vaccine used for cancer immunotherapy also known as Ras(cis 12)-Vaccinia Vaccine, RASVAC-C is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29401 NCT: https://clinicaltrials.gov/ct2/show/NCT00019591 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5504 https://github.com/vaccineontology/VO/issues/190 3845 5504 Clinical trial Gene name: KRAS RASVAC-C Vaccine A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine,�RASVAC-C�is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.� Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29402 NCT: https://clinicaltrials.gov/ct2/show/NCT00019591 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5497 https://github.com/vaccineontology/VO/issues/191 3845 5497 Clinical trial Gene name: KRAS RASVAC-V Vaccine A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2423 NCT: https://clinicaltrials.gov/ct2/show/NCT00002960 PubMed:16082381 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5470 https://github.com/vaccineontology/VO/issues/325 4771 7157 7490 5470 Clinical trial Gene name: NF2|Gene name: WT1|Gene name: TP53 (P53) Recombinant Adenovirus-p53 SCH-58500 Vaccine An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C166939 NCT: https://clinicaltrials.gov/ct2/show/NCT01253837 PubMed:12810649 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5219 https://github.com/vaccineontology/VO/issues/336 100136034 5219 Clinical trial Gene name: tnf-alpha Recombinant Human Fusion Protein L19TNFalpha Vaccine A cancer vaccine containing multiple peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from, URLC10 (up-regulated lung cancer 10), CDCA1 (cell division cycle-associated protein 1), KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-CDCA1-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, CDCA1, KCO1 peptides, resulting in cell lysis and decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95212 NCT: https://clinicaltrials.gov/ct2/show/NCT00681577 PubMed:27720136 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5350 10643 54742 83540 5350 Clinical trial Gene name: LY6K|Gene name: NUF2|Gene name: IGF2BP3 URLC10-CDCA1-KOC1 Multipeptide Vaccine A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.126, with potential antitumor activity. Upon vaccination with p.DOM-WT1-126 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96738 NCT: https://clinicaltrials.gov/ct2/show/NCT01334060 PubMed:27099895 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5165 https://github.com/vaccineontology/VO/issues/69 7490 5165 Clinical trial Gene name: WT1 p.DOM-WT1-126 DNA Vaccine A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.37, with potential antitumor activity. Upon vaccination with p.DOM-WT1-37 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96737 NCT: https://clinicaltrials.gov/ct2/show/NCT01334060 PubMed:27099895 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5471 https://github.com/vaccineontology/VO/issues/61 https://github.com/vaccineontology/VO/issues/62 7490 5471 Clinical trial Gene name: WT1 p.DOM-WT1-37 DNA Vaccine A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2235 NCT: https://clinicaltrials.gov/ct2/show/NCT00004918 PubMed:27654852 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5140 https://github.com/vaccineontology/VO/issues/139 140738 5140 Clinical trial Gene name: TMEM37 PR1 Leukemia Peptide Vaccine A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens (substances isolated from tumor cells). A tumor antigen vaccine may stimulate the body's immune system to find and kill cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2341 NCT: https://clinicaltrials.gov/ct2/show/NCT00100971 PubMed:30348199 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5387 5387 Clinical trial Tumor Cell Derivative Vaccine A�peptide�cancer�vaccine�comprised of a�peptide�derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration,�WT1�peptide�vaccine�OCV-501�may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against�WT1�expressing cells.�WT1�protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106257 NCT: https://clinicaltrials.gov/ct2/show/NCT01961882 PubMed:28321480 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5330 7490 5330 Clinical trial Gene name: WT1 WT1 Peptide Vaccine OCV-501 An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78865 NCT: https://clinicaltrials.gov/ct2/show/NCT00725283 PubMed:16117707 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5354 7490 5354 Clinical trial Gene name: WT1 WT1-A10/AS01B Immunotherapeutic GSK2130579A Vaccine A recombinant vaccinia virus encoding carcinoembryonic antigen (CEA). CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers. Attenuated vaccinia virus is a highly effective immunizing agent that evokes both humoral and cell-mediated responses. Vaccination with this agent may evoke a cytotoxic immune response to CEA-expressing cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2809 NCT: https://clinicaltrials.gov/ct2/show/NCT00081848 PubMed:7629885 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5401 https://github.com/vaccineontology/VO/issues/341 1048 5401 Clinical trial Gene name: CEACAM5 Recombinant Vaccinia-CEA Vaccine Human mesenchymal stem cells (MSCs) harvested from bone marrow of healthy adult donors and expanded ex vivo, with potential immunosuppressive activity. Remestemcel-L cells are hypo-immunogenic due to lack of major histocompatibility II (MHC II) molecule expression, eliciting little, if any, host immune response upon intravenous infusion. Infusion of allogeneic MSCs may result in: a) increased production of anti-inflammatory cytokines, such as interleukin-10, prostaglandin E, and hepatocyte growth factor; b) decreased mononuclear phagocyte expression of indoleamine 2,3,-dioxygenase, which catabolizes L-tryptophan into its pro-inflammatory metabolites; and c) modulated dendritic cell (DC)maturation and disrupted activities of natural killer (NK) cells and CD8+ and CD4+ T cells. In addition, pluripotent MSCs, upon administration, may be recruited to damaged tissue sites, differentiating along specific lineages when stimulated. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C67082 PubMed:32018062 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4993 https://github.com/vaccineontology/VO/issues/353 4993 Clinical trial Remestemcel-L Vaccine A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. OBP-301 contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C119617 NCT: https://clinicaltrials.gov/ct2/show/NCT02293850 PubMed:27673332 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5072 7015 5072 Clinical trial Gene name: TERT Telomerase-specific Type 5 Adenovirus OBP-301 Vaccine A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. OSE 2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26645 NCT: https://clinicaltrials.gov/ct2/show/NCT02654587 PubMed:18382135 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5528 https://github.com/vaccineontology/VO/issues/72 1048 2064 4101 4102 7157 5528 Clinical trial Gene name: TP53|Gene name: CEACAM5|Gene name: ERBB2|Gene name: MAGEA2|Gene name: MAGEA3 EP-2101 Vaccine A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at amino acid position 134. It was used to pulse dendritic cells, which are then used in the adoptive immunotherapy setting and may stimulate the host immune system to mount a specific cytotoxic T lymphocyte response against tumor cells expressing the p35 mutation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38121 NCT: https://clinicaltrials.gov/ct2/show/NCT00049218 PubMed:29301826 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5272 https://github.com/vaccineontology/VO/issues/125 https://github.com/vaccineontology/VO/issues/193 7157 5272 Clinical trial Gene name: TP53 PR-151 Peptide Vaccine An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95024 NCT: https://clinicaltrials.gov/ct2/show/NCT01598454 PubMed:26903265 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5201 https://github.com/vaccineontology/VO/issues/188 3265 3845 4893 5201 Clinical trial Gene name: HRAS|Gene name: NRAS|Gene name: KRAS Racotumomab Vaccine A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49289 NCT: https://clinicaltrials.gov/ct2/show/NCT00062907 PubMed:16581300 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5074 https://github.com/vaccineontology/VO/issues/323 10643 5074 Clinical trial Gene name: IGF2BP3 Recombinant Adenovirus-L523S Vaccine A plasmid DNA encoding human L523S, an RNA-binding protein that belongs to the KOC (K homology domain containing protein overexpressed in cancer) family, with potential antineoplastic activity. Vaccination with L523S DNA may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express the L523S protein. As an oncofetal protein, L523S is normally expressed in early embryonic tissue, but is overexpressed in certain cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49290 NCT: https://clinicaltrials.gov/ct2/show/NCT00062907 PubMed:12750279 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5156 https://github.com/vaccineontology/VO/issues/327 10643 5156 Clinical trial Gene name: IGF2BP3 Recombinant DNA-L523S Vaccine A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70674 NCT: https://clinicaltrials.gov/ct2/show/NCT00516685 PubMed:29661145 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5190 25003478 5190 Clinical trial Gene name: LV28_RS26095 transcriptional regulator RegF Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66985 NCT: https://clinicaltrials.gov/ct2/show/NCT02460367 PubMed:28238782 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5527 5527 Clinical trial Tergenpumatucel-L Vaccine A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073 NCT: https://clinicaltrials.gov/ct2/show/NCT02439450 PubMed:27364122 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5513 7184 5513 Clinical trial Gene name: HSP90B1 Viagenpumatucel-L Vaccine A cancer vaccine consisting of a mixture of a murine lymphoma-derived idiotype and interleukin-2 (IL-2) encapsulated in dimyristoylphosphatidylcholine liposomes. The use of a liposomal carrier confers immunogenicity to the naturally non-immunogenic idiotype. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2783 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5541 https://github.com/vaccineontology/VO/issues/74 107653060 5541 Clinical trial Gene name: IL12 Oncovax-ID/IL-2 Vaccine A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of the maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97951 NCT: https://clinicaltrials.gov/ct2/show/NCT02323230 PubMed:26405584 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5371 https://github.com/vaccineontology/VO/issues/364 373110 5371 Clinical trial Gene name: Survivin Survivin Antigen Vaccine DPX-Survivac A vaccine consisting of lymphoma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated lymphoma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth.� Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2821 PubMed:18715553 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5046 5046 Clinical trial Unconjugated Lymphoma Ig Id Vaccine A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96042 NCT: https://clinicaltrials.gov/ct2/show/NCT01308294 PubMed:25941588 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5305 https://github.com/vaccineontology/VO/issues/48 1485 4102 5305 Clinical trial Gene name: MAGEA3|Gene name: CTAG1B NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17. A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2680 NCT: https://clinicaltrials.gov/ct2/show/NCT01307618 PubMed:16133111 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5323 https://github.com/vaccineontology/VO/issues/49 107653060 2315 4102 6490 5323 Clinical trial Gene name: IL12|Gene name: MAGEA3|Gene name: MLANA|Gene name: PMEL NA17.A2 peptide vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL) and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114380 NCT: https://clinicaltrials.gov/ct2/show/NCT00313508 PubMed:16311731 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5100 1485 2315 4102 6490 7299 5100 Clinical trial Gene name: MAGEA3|Gene name: MLANA|Gene name: PMEL|Gene name: CTAG1B|Gene name: TYR NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1 peptide-pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C120129 NCT: https://clinicaltrials.gov/ct2/show/NCT00798629 PubMed:16311731 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5366 1485 2315 5366 Clinical trial Gene name: CTAG1B|Gene name: MLANA NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine A cancer�vaccine�consisting of�PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration,�PEP-3-KLH�conjugate�vaccine�may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74070 NCT: https://clinicaltrials.gov/ct2/show/NCT00626015 PubMed:14519652 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5480 https://github.com/vaccineontology/VO/issues/117 1956 5480 Clinical trial Gene name: EGFR PEP-3-KLH Conjugate Vaccine A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103192 NCT: https://clinicaltrials.gov/ct2/show/NCT01690377 PubMed:30049538 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5006 https://github.com/vaccineontology/VO/issues/121 170482 3598 51284 54106 8829 5006 Clinical trial Gene name: IL13RA2|Gene name: CLEC4C|Gene name: NRP1|Gene name: TLR9|Gene name: TLR7 Plasmacytoid Dendritic Cell Vaccine rime/boost vaccination proved to be of no advantage or even detrimental in therapeutic settings in B16F1 and transgenic adenocarcinoma of the mouse prostate (TRAMP) models, respectively Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:23539449 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4074 https://github.com/vaccineontology/VO/issues/140 4074 Research prime/boost DC-TRP-2 melanoma vaccine A viral vaccine comprised of a�recombinant�fowlpox�vector construct encoding a modified epitope of the melanoma antigen glycoprotein 100 (gp100), ES-2092M(gp100), containing an endoplasmic reticulum signal sequence targeted to the endoplasmic reticulum apparatus. Vaccination with�recombinant�fowlpox-gp100p209�vaccine may stimulate the host immune system more efficiently to mount a cytotoxic T lymphocyte response against tumor cells expressing the gp100 antigen. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2806 NCT: https://clinicaltrials.gov/ct2/show/NCT00080353 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5274 6490 5274 Clinical trial Gene name: gp100 (PMEL) Recombinant Fowlpox-gp100p209 Vaccine A�vaccine�consisting of a replication-defective�recombinant�fowlpox�virus that encodes for the murine melanoma antigen glycoprotein 100 (mgp100) with potential antineoplastic activity. Vaccination with�recombinant�fowlpox-mgp100�vaccine�may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2805 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5499 https://github.com/vaccineontology/VO/issues/332 5499 Clinical trial Recombinant Fowlpox-Mgp100 Vaccine A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2807 NCT: https://clinicaltrials.gov/ct2/show/NCT00054535 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5518 https://github.com/vaccineontology/VO/issues/335 7299 5518 Clinical trial Gene name: Tyrosinase Recombinant Fowlpox-Tyrosinase Vaccine A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103830 NCT: https://clinicaltrials.gov/ct2/show/NCT01744171 PubMed:12750279 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5359 6490 5359 Clinical trial Gene name: gp100 (PMEL) Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. gp100p209 is a fragment epitope of gp100 in which the threonine in position 2 is replaced with methionine; this modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently.� Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29566 NCT: https://clinicaltrials.gov/ct2/show/NCT00116597 PubMed:15133631 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5393 https://github.com/vaccineontology/VO/issues/344 6490 5393 Clinical trial Gene name: gp100 (PMEL) Recombinant Vaccinia-gp100:209-217 Vaccine A�recombinant�vaccinia�virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. This�recombinant�vaccinia�Mgp100�encodes a fragment epitope of gp100 bearing 2 amino acids substitution; T->M at position 210 and 288 A ->V at position 210. This modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C51978 PubMed:12912944 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5505 https://github.com/vaccineontology/VO/issues/346 6490 5505 Clinical trial Gene name: gp100 (PMEL) Recombinant Vaccinia-Mgp100 Vaccine A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48638 PubMed:30626434 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5232 12524 2315 6490 941 5232 Clinical trial Gene name: Cd86|Gene name: MLANA-Dupli|Gene name: CD80|Gene name: gp100 (PMEL) Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine A recombinant vaccinia virus encoding the melanocyte differentiation antigen tyrosinase-related protein-1 (TRP-1) with potential use in cancer immunotherapy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29564 PubMed:19047169 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5063 https://github.com/vaccineontology/VO/issues/352 22178 5063 Clinical trial Gene name: TRP-1 Recombinant Vaccinia-TRP1 Vaccine A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2430 NCT: https://clinicaltrials.gov/ct2/show/NCT01216436 PubMed:26241951 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5194 https://github.com/vaccineontology/VO/issues/360 1493 8784 5194 Clinical trial Gene name: CTLA4|Gene name: TNFRSF18 Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant A recombinant plasmid DNA vaccine that encodes two peptides, tyrosinase 207�216 and tyrosinase 1�17, both of which are derived from human tyrosinase. Jie Zheng Jimmy Guo Oliver He Virginia He NCT: https://clinicaltrials.gov/ct2/show/NCT00023647 PubMed:12833467 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4002 https://github.com/vaccineontology/VO/issues/406 4002 Research Synchotrope TA2M Vaccine A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2650 NCT: https://clinicaltrials.gov/ct2/show/NCT00023647 PubMed:12833467 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5218 https://github.com/vaccineontology/VO/issues/407 7299 5218 Clinical trial Gene name: Tyrosinase Synchrotope TA2M Plasmid DNA Vaccine A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28549 NCT: https://clinicaltrials.gov/ct2/show/NCT00033228 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5506 https://github.com/vaccineontology/VO/issues/408 2315 7299 5506 Clinical trial Gene name: MLANA-Dupli|Gene name: Tyrosinase Synchrovax SEM Plasmid DNA Vaccine A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48639 NCT: https://clinicaltrials.gov/ct2/show/NCT00116597 PubMed:11874634 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5217 https://github.com/vaccineontology/VO/issues/411 6490 5217 Clinical trial Gene name: PMEL - obsolete Synthetic Melanoma-Associated Antigens Vaccine A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122396 NCT: https://clinicaltrials.gov/ct2/show/NCT02410733 PubMed:21093980 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5114 416115 5114 Clinical trial Gene name: MAGE-1 Tetravalent RNA-lipoplex Cancer Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:23090079 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4004 2315 6409 7299 4004 Research Gene name: MLANA|Gene name: PMEL|Gene name: Tyrosinase TLR-9/GM Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:23509826 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4075 4075 Clinical trial TriMixDC-MEL Vaccine A recombinant peptide consisting of amino acid residues 180 to 188 of the tyrosinase-related protein 2 (TRP2). Expressed by cells of melanocyte origin, TRP2 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP-2: 180-188 peptide may induce cytotoxic T lymphocyte (CTL) responses to melanoma cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2815 NCT: https://clinicaltrials.gov/ct2/show/NCT00022438 PubMed:16906394 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5325 1638 5325 Clinical trial Gene name: TRP-2 TRP-2: 180-188 Peptide Vaccine A recombinant peptide consisting of amino acid residues 1 to 9 of the tyrosinase-related protein 1 (TRP1). Expressed by cells of melanocyte origin, TRP1 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP1(0RF3):1-9 may stimulate cytotoxic T cell responses to melanoma cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2816 NCT: https://clinicaltrials.gov/ct2/show/NCT00019383 PubMed:8027058 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5487 22178 5487 Clinical trial Gene name: TRP-1 TRP1(0RF3):1-9 Peptide Vaccine A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2384 NCT: https://clinicaltrials.gov/ct2/show/NCT00028431 PubMed:21143299 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5060 7299 5060 Clinical trial Gene name: Tyrosinase Tyrosinase-KLH Vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:14581425 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3999 tyrosinase240-251s, 368-376d vaccine 3999 Research tyrosinase240-251S, 368-376D Vaccine Immunotherapy with�VMCL�was not associated with a statistically significant improvement in OS or RFS, with CIs not ruling out important gains from such treatment. Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:12377961 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4007 4007 Research vaccinia melanoma cell lysates (VMCL) vaccine Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:3155379 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4023 4023 Research Vaccinia Melanoma Oncolysates (VMO) Vaccine A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2674 NCT: https://clinicaltrials.gov/ct2/show/NCT00002817 PubMed:8894677 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5508 12981 5508 Clinical trial Gene name: Csf2-Mouse Vaccinia-GM-CSF Vaccine A vaccine consisting of recombinant vaccinia virus, based on the modified vaccinia virus Ankara (MVA) that encodes the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Tyrosinase is a melanoma-specific differentiation agent that catalyzes the synthesis of the melanin precursor L-3,4-dihydroxyphenylalanine (L-DOPA). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531 NCT: https://clinicaltrials.gov/ct2/show/NCT00019734 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5223 7299 5223 Clinical trial Gene name: Tyrosinase Vaccinia-Tyrosinase Vaccine A plasmid DNA vaccine, encoding an epitope of mouse tyrosinase, with potential antineoplastic activity. Administered via intramuscular electroporation, vaccination with xenogeneic tyrosinase DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) immune responses against melanoma cells that express tyrosinase, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68839 NCT: https://clinicaltrials.gov/ct2/show/NCT00471133 PubMed:4019903 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5416 7299 5416 Clinical trial Gene name: Tyrosinase Xenogeneic Tyrosinase DNA Vaccine A recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C28550 NCT: https://clinicaltrials.gov/ct2/show/NCT00066404 PubMed:19893592 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5510 https://github.com/vaccineontology/VO/issues/321 3456 5510 Clinical trial Gene name: IFNB1 Recombinant Adenovirus-hIFN-beta Vaccine A modified recombinant nonapeptide (LMLGEFLKL) derived from the anti-apoptosis protein survivin with potential immunopotentiating and antineoplastic activities. Upon administration, survivin Sur1M2 peptide vaccine may elicit humoral and cellular immune responses against survivin-expressing cancers, resulting in decreased tumor cell proliferation and tumor cell death. The survivin protein inhibits caspase activation and apoptosis; it is undetectable in normal adult tissues but is expressed by several human cancers including lung, colon, breast, pancreas, and prostate cancer as well as hematopoietic malignancies and skin cancers. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71741 NCT: https://clinicaltrials.gov/ct2/show/NCT00499577 PubMed:29057249 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5265 https://github.com/vaccineontology/VO/issues/365 7015 5265 Clinical trial Gene name: TERT Survivin Sur1M2 Peptide Vaccine A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2822 NCT: https://clinicaltrials.gov/ct2/show/NCT00001561 PubMed:4108872 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5391 5391 Clinical trial Unconjugated Myeloma Ig Id Vaccine A peptide vaccine comprised of an epitope of human Wilms tumor 1 (WT-1) with potential antineoplastic activity. WT-1, a transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64635 NCT: https://clinicaltrials.gov/ct2/show/NCT01827137 PubMed:25802083 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5341 7490 5341 Clinical trial Gene name: WT1 WT1 Analog Peptide Vaccine A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C102751 NCT: https://clinicaltrials.gov/ct2/show/NCT01621542 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5027 7490 5027 Clinical trial Gene name: WT1 WT1 Peptide Vaccine WT2725 A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box�binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103823 NCT: https://clinicaltrials.gov/ct2/show/NCT01718899 PubMed:30128502 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5415 22433 57823 6382 5415 Clinical trial Gene name: Xbp1|Gene name: SDC1|Gene name: SLAMF7 XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410 A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113651 NCT: https://clinicaltrials.gov/ct2/show/NCT02033616 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5481 https://github.com/vaccineontology/VO/issues/71 5481 Clinical trial Ovapuldencel-T Vaccine A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48414 NCT: https://clinicaltrials.gov/ct2/show/NCT00091273 PubMed:20445345 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5502 5502 Clinical trial Ovarian Cancer Peptide Vaccine A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96739 NCT: https://clinicaltrials.gov/ct2/show/NCT01334047 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5403 7015 5403 Clinical trial Gene name: TERT Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115105 NCT: https://clinicaltrials.gov/ct2/show/NCT02107950 PubMed:22862954 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5280 3696 3728 780 5280 Clinical trial Gene name: ITGB8|Gene name: JUP|Gene name: DDR1 Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51 with potential immunostimulatory and antitumor activities. Upon administration, p53 synthetic long peptide (70-251) vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against p53-expressing tumor cells. p53, a tumor associated antigen (TAA), may be overexpressed in variety of cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82420 NCT: https://clinicaltrials.gov/ct2/show/NCT00844506 PubMed:26334096 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5278 https://github.com/vaccineontology/VO/issues/59 7157 5278 Clinical trial Gene name: TP53 P53-Synthetic Long Peptides Vaccine A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2428 NCT: https://clinicaltrials.gov/ct2/show/NCT00006216 PubMed:7578411 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5245 https://github.com/vaccineontology/VO/issues/57 79447 5245 Clinical trial Gene name: PAGR1 PA-1-STK Ovarian Carcinoma Vaccine An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71533 NCT: https://clinicaltrials.gov/ct2/show/NCT02562755 PubMed:31413923 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5078 https://github.com/vaccineontology/VO/issues/119 1437 5078 Clinical trial Gene name: hGM-CSF Pexastimogene-devacirepvec Vaccine A plasmid DNA vaccine containing mammalian expression vector pUMVC3, encoding epitopes of human insulin-like growth factor-binding protein 2 (hIGFBP-2) with potential immunostimulating and antineoplastic activities. Upon vaccination, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against hIGFBP-2-expressing cells. The tumor associated antigen (TAA) hIGFBP-2, a member of the insulin like growth factor receptor family, is overexpressed in a number of cancer cell types and its expression has been associated with increased invasiveness. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95727 NCT: https://clinicaltrials.gov/ct2/show/NCT01322802 PubMed:17102977 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5365 https://github.com/vaccineontology/VO/issues/186 3484 5365 Clinical trial Gene name: hIGFBP-2 pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine A recombinant retrovirus containing the modified murine retroviral vector MFG-S encoding a chimeric construct, MOv18-gamma. MOv18 is a murine monoclonal antibody developed against epitope of human folate binding protein, which is overexpressed on more than 90% of non-mucinous epithelial ovarian neoplasms. The chimeric construct (MOv18-gamma) encodes the variable region of MOv18 antibody, and the gamma chain of human T-cell receptor. This virion might be used to transduce autologous T lymphocytes, and reintroduced back to the patient after expansion ex vivo to invoke specific immune response against ovarian cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29192 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5131 https://github.com/vaccineontology/VO/issues/356 2348 5131 Clinical trial Gene name: FOLR1 Retroviral Vector MFGS-MOv18-gamma Vaccine A fowlpox vaccine containing the tumor-associated antigen mucin-1 (MUC1), found in pancreatic tumor cells, and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM), which is designed to enhance antigen presentation and activation of immune responses critical for tumor destruction. Vaccination with this agent may elicit a host immune response against MUC1-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29558 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5477 https://github.com/vaccineontology/VO/issues/357 4582 5477 Clinical trial Gene name: MUC1 rF-MUC1(DF3)/TRICOM Vaccine A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2445 NCT: https://clinicaltrials.gov/ct2/show/NCT00389610 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5340 100137216 5340 Clinical trial Gene name: GM-CSF Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C77895 NCT: https://clinicaltrials.gov/ct2/show/NCT00655785 PubMed:26190488 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5214 2321 5214 Clinical trial Gene name: FLT1 VEGFR1-1084 Peptide Vaccine A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74090 NCT: https://clinicaltrials.gov/ct2/show/NCT00639925 PubMed:15930316 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5419 16542 5419 Clinical trial Gene name: Kdr VEGFR2-169 Peptide Vaccine A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1. Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74066 NCT: https://clinicaltrials.gov/ct2/show/NCT00616291 PubMed:21131422 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5379 https://github.com/vaccineontology/VO/issues/111 1485 30848 5379 Clinical trial Gene name: CTAG1B|Gene name: CTAG2 NY-ESO-1/LAGE-1 peptide vaccine An autologous dendritic cell (DCs) vaccine targeting prostate cancer with immunostimulating activity. The autologous DC vaccine is prepared via transfecting DCs with mRNAs extracted from primary prostate cancer tissue, and mRNAs of human telomerase reverse transcriptase (hTERT) and survivin. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against prostate cancer cells, resulting in tumor cell death. Both hTERT and survivin are essential in neoplastic growth, and are considered to be universal tumor antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95771 NCT: https://clinicaltrials.gov/ct2/show/NCT00345293 PubMed:30505813 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5205 7015 5205 Clinical trial Gene name: TERT Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine This DNA vaccine expressed prostate-specific membrane antigen (PSMA) Jie Zheng Jimmy Guo Oliver He Virginia He PubMed:22729556 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3710 3710 Research Prostate cancer DNA vaccine pDOM-PSMA27 encoding PSMA A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71723 NCT: https://clinicaltrials.gov/ct2/show/NCT00514072 PubMed:22932804 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5351 https://github.com/vaccineontology/VO/issues/141 959 5351 Clinical trial Gene name: CD40 Prostate Cancer Vaccine ONY-P1 A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115106 NCT: https://clinicaltrials.gov/ct2/show/NCT02111577 PubMed:27683469 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5132 354 5132 Clinical trial Gene name: KLK3 Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine A vaccinia virus carrying a copy of the human gene encoding prostate-specific antigen (PSA), contaminated with bovine viral diarrhea virus (BVDV). Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29334 PubMed:27683469 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5260 https://github.com/vaccineontology/VO/issues/142 354 5260 Clinical trial Gene name: KLK3 PROSTVAC-Contaminated W/ BVDV vaccine A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2497 NCT: https://clinicaltrials.gov/ct2/show/NCT00015977 PubMed:27683469 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5087 https://github.com/vaccineontology/VO/issues/143 354 5087 Clinical trial Gene name: KLK3 PSA Prostate Cancer Vaccine An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2236 NCT: https://clinicaltrials.gov/ct2/show/NCT00004211 PubMed:14711334 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5022 https://github.com/vaccineontology/VO/issues/144 354 5022 Clinical trial Gene name: KLK3 PSA RNA-Pulsed Dendritic Cell Vaccine A 30-residue prostate specific antigen (PSA) oligoepitope peptide (OP) vaccine with potential antineoplastic activity. PSA-OP peptide vaccine contains the PSA-1 and PSA-3 HLA-A2 epitopes and the PSA-9 HLA-class I-A3 epitope joined by peptide linker sequences. In an animal model, vaccination with this agent has been shown to elicit a cytotoxic T-lymphocyte immune response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29337 PubMed:9743387 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5234 https://github.com/vaccineontology/VO/issues/179 354 5234 Clinical trial Gene name: KLK3 PSA-OP Peptide Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the prostate-specific tumor associated antigens (TAAs) prostate specific antigen (PSA) and prostate acid phosphatase (PAP), and conjugated to the immunostimulant keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, prostate cancer antigen/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against prostate cancer cells expressing PSA and PAP, which may result in prostate cancer cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C92573 NCT: https://clinicaltrials.gov/ct2/show/NCT01171729 PubMed:12487060 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5353 56318 5353 Clinical trial Gene name: Acpp PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114289 NCT: https://clinicaltrials.gov/ct2/show/NCT02058680 PubMed:12487060 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5109 https://github.com/vaccineontology/VO/issues/180 1437 3558 5109 Clinical trial Gene name: IL-2|Gene name: GM-CSF PSA/IL-2/GM-CSF Vaccine A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C123283 NCT: https://clinicaltrials.gov/ct2/show/NCT02514213 PubMed:32208168 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5252 https://github.com/vaccineontology/VO/issues/181 2346 5252 Clinical trial Gene name: FOLH1 PSA/PSMA DNA Plasmid INO-5150 vaccine A synthetic peptide based on sequence corresponding to positions 154-163 of the amino acids of prostate-specific antigen (PSA), VISNDVCAQV. Upon administration, PSA:154-163 peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2798 NCT: https://clinicaltrials.gov/ct2/show/NCT00004156 PubMed:19483644 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5106 https://github.com/vaccineontology/VO/issues/182 4582 5106 Clinical trial Gene name: MUC1 PSA:154-163 Peptide vaccine A cancer vaccine comprised of a synthetic peptide with an amino acid sequence corresponding to positions 154-163 of the amino acid sequence for prostate-specific antigen (PSA) with a leucine substitution at position 155. Upon administration, PSA:154-163(155L) peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29338 NCT: https://clinicaltrials.gov/ct2/show/NCT00109811 PubMed:19483644 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5155 https://github.com/vaccineontology/VO/issues/183 354 5155 Clinical trial Gene name: KLK3 PSA:154-163(155L) Peptide Vaccine A peptide-based cancer vaccine containing epitopes of T cell receptor gamma-chain alternate reading frame protein (TARP) and prostate-specific membrane antigen (PSMA) in combination with a Poly IC-LC immunoadjuvant, with potential antineoplastic activity. Upon administration, PSMA/TARP peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP- and PSMA-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP and PSMA are commonly expressed in prostate cancer cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78819 NCT: https://clinicaltrials.gov/ct2/show/NCT00694551 PubMed:34494382 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5052 https://github.com/vaccineontology/VO/issues/184 354 5052 Clinical trial Gene name: KLK3 PSMA/TARP Peptide Vaccine A cancer vaccine containing plasmid DNA encoding human prostatic acid phosphatase (PAP) (pTVG-HP) with potential immunostimulatory and antineoplastic activities. Upon administration, pTVG-HP plasmid DNA vaccine may stimulate the host immune system to generate a cytotoxic T lymphocyte (CTL) response against PAP-expressing prostate cancer cells. PAP or prostatic specific acid phosphatase (PSAP) is a tumor associated antigen (TAA) that may be overexpressed in prostate cancer. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82407 NCT: https://clinicaltrials.gov/ct2/show/NCT02499835 PubMed:17102977 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5535 https://github.com/vaccineontology/VO/issues/185 55 5535 Clinical trial Gene name: ACP3 pTVG-HP Plasmid DNA Vaccine A cancer�vaccine�containing xenogenic�DNA�from rhesus macaque (Macaca mulatta) that encodes prostate specific antigen (PSA) with potential immunostimulating and antineoplastic activities. Upon repeated intradermal administration via electroporation,�pVAXrcPSAv53l�vaccine�may induce a cytotoxic T-lymphocyte (CTL) response against PSA-expressing prostate cancer cells. Rhesus PSA is 89% homologous to human PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82352 NCT: https://clinicaltrials.gov/ct2/show/NCT00859729 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5092 https://github.com/vaccineontology/VO/issues/187 354 5092 Clinical trial Gene name: KLK3 pVAXrcPSAv53l DNA Vaccine A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2675 NCT: https://clinicaltrials.gov/ct2/show/NCT00005039 PubMed:17707059 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4988 https://github.com/vaccineontology/VO/issues/333 354 4988 Clinical trial Gene name: KLK3 Recombinant Fowlpox-Prostate Specific Antigen Vaccine A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38708 NCT: https://clinicaltrials.gov/ct2/show/NCT00108732 PubMed:16390546 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5434 https://github.com/vaccineontology/VO/issues/333 12519 3383 354 965 5434 Clinical trial Gene name: KLK3|Gene name: Cd80|Gene name: ICAM1|Gene name: CD58 Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding TRICOM. TRICOM is comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3) that may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2667 NCT: https://clinicaltrials.gov/ct2/show/NCT00450619 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5253 https://github.com/vaccineontology/VO/issues/132 12519 3383 965 5253 Clinical trial Gene name: Cd80|Gene name: ICAM1|Gene name: CD58 Recombinant Fowlpox-TRICOM Vaccine A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433 NCT: https://clinicaltrials.gov/ct2/show/NCT02649439 PubMed:12242725 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5154 https://github.com/vaccineontology/VO/issues/339 354 5154 Clinical trial Gene name: KLK3 Recombinant Vaccinia PSA Vaccine A recombinant vaccinia virus encoding prostate-specific antigen (PSA). Vaccination with recombinant vaccinia-PSA may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for PSA, which may decrease tumor growth. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29945 NCT: https://clinicaltrials.gov/ct2/show/NCT00005039 PubMed:12242725 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5302 https://github.com/vaccineontology/VO/issues/350 354 5302 Clinical trial Gene name: KLK3 Recombinant Vaccinia-Prostate Specific Antigen Vaccine A recombinant vaccinia virus encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) with potential use in cancer immunotherapy. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29563 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5307 https://github.com/vaccineontology/VO/issues/351 2346 354 5307 Clinical trial Gene name: KLK3|Gene name: Prostate-specific membrane antigen Recombinant Vaccinia-PSA/PSMA Vaccine A synthetic fowlpox viral vaccine containing the tumor-associated antigens prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM). Vaccination with this viral vaccine may enhance antigen presentation and activate cytotoxic T-cells against PSA- or PSMA-expressing tumor cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29559 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5005 https://github.com/vaccineontology/VO/issues/358 354 5005 Clinical trial Gene name: KLK3 rF-PSA/PSMA/TRICOM Vaccine A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38681 NCT: https://clinicaltrials.gov/ct2/show/NCT02772562 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5183 https://github.com/vaccineontology/VO/issues/359 12519 3383 354 965 5183 Clinical trial Gene name: ICAM1|Gene name: Cd80|Gene name: KLK3|Gene name: CD58 Rilimogene-galvacirepvec Vaccine A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1985 NCT: https://clinicaltrials.gov/ct2/show/NCT02159950 PubMed:20818862 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5216 https://github.com/vaccineontology/VO/issues/362 55 5216 Clinical trial Gene name: ACP3 Sipuleucel-T Vaccine A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756 NCT: https://clinicaltrials.gov/ct2/show/NCT02855892 PubMed:27941629 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5101 https://github.com/vaccineontology/VO/issues/416 22059 5101 Clinical trial Gene name: Trp53 Telomerase Peptide Vaccine GV1001 A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Jie Zheng Jimmy Guo Oliver He Virginia He NCT: https://clinicaltrials.gov/ct2/show/NCT01784913 PubMed:28391357 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5478 7015 5478 Clinical trial Gene name: TERT UV1 Telomerase Peptide Vaccine An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116879 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5397 8743 5397 Clinical trial Gene name: TNFSF10 Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Vaccine A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70968 NCT: https://clinicaltrials.gov/ct2/show/NCT00523159 PubMed:23899354 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5013 https://github.com/vaccineontology/VO/issues/354 3105 3106 5013 Clinical trial Gene name: HLA-A|Gene name: HLA-B Renal Cell Carcinoma Peptides Vaccine IMA901 A cell-based preparation in which autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. Upon electroporation into autologous DCs, the RNA is translated and processed. BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. When AGS-003-BLD is reintroduced to the patient, the MHC-presented peptides interact with and activate CD8-positive T cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C129522 NCT: https://clinicaltrials.gov/ct2/show/NCT02170389 PubMed:25901286 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5373 958 5373 Clinical trial Gene name: CD40 Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003 Peripheral blood lymphocytes (PBL) harvested from the blood of a renal cancer patient and exposed in vitro to renal tumor-associated antigens (TAA). Introducing these renal tumor-reactive autologous peripheral blood lymphocytes back to the same patient target tumor cells expressing these TAAs and could induce a cytotoxic T-cell-mediated immune response against renal cell cancer. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48816 PubMed:33408117 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5196 5196 Clinical trial Renal Tumor-Reactive Autologous Peripheral Blood Lymphocyte Vaccine A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine substitution at position 74. As a cancer vaccine, VHL-59: 65-76(V74G) may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38122 PubMed:20109232 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5097 7428 5097 Clinical trial Gene name: VHL VHL-42: 65-76(V74G) Peptide Vaccine A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift mutation. As a cancer vaccine, VHL-59: 116-128(FrSh116-128) peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38123 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5172 7428 5172 Clinical trial Gene name: VHL VHL-59: 116-128 Peptide Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point mutation variant of the VHL protein; the mutation is in amino acid position 166. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2741 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5012 7428 5012 Clinical trial Gene name: VHL VHL14 Peptide Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I, is a point mutation variant of the VHL tumor suppressor protein; the mutation is in amino acid position 111. Vaccination with this agent may stimulate a cytotoxic T-cell response in patients with VHL-associated cancers that express this variant of the VHL tumor suppressor protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2740 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5333 7428 5333 Clinical trial Gene name: VHL VHL16 Peptide Vaccine A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2824 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5490 7428 5490 Clinical trial Gene name: VHL VHL2 (Y12M) Peptide Vaccine A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2492 NCT: https://clinicaltrials.gov/ct2/show/NCT00001703 PubMed:20109232 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5127 7428 5127 Clinical trial Gene name: VHL Von Hippel-Lindau Peptide Vaccine A synthetic peptide vaccine based on the sequences of a translocation mutation of 2 transcriptional factor genes, PAX3 and FKHR. PAX3/FKHR fusion proteins are frequently found in patients with rhabdomyosarcomas. Vaccination with PAX3/FKHR peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this PAX3/FKHR fusion protein. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49023 NCT: https://clinicaltrials.gov/ct2/show/NCT00001564 PubMed:15838707 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5484 https://github.com/vaccineontology/VO/issues/114 2308 5077 7422 5484 Clinical trial Gene name: PAX3|Gene name: FOXO1|Gene name: VEGFA PAX3/FKHR Peptide Vaccine A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the�AKT�Gene. The viral vector�RCAS�harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29908 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5044 https://github.com/vaccineontology/VO/issues/192 207 5044 Clinical trial Gene name: AKT1 RCAS-Akt Vaccine A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector,�RCAS�harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29910 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5500 3845 5500 Clinical trial Gene name: KRAS RCAS-Ras Vaccine A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development; its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells. Jie Zheng Jimmy Guo Oliver He Virginia He NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2640 NCT: https://clinicaltrials.gov/ct2/show/NCT00069940 PubMed:11536162 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5098 7015 5098 Clinical trial Gene name: TERT Telomerase: 540-548 Peptide Vaccine To obtain SOCS1-silenced DCs, DCs derived from mouse bone marrow cells ex vivo were induced to differentiation in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, and then transduced with Len-SOCS1-shRNA or control Len-GFP lentiviruses. The SOCS1-silenced DCs were loaded by TRP2 peptide to prepare the DC vaccine, which was induced to mature by LPS. The DCs were analyzed by flow cytometry (FCM) for surface expressions of MHCII and CD86 and by real-time PCR for the expressions of SOCS1, IL-10 as well as IL-12p40. B16 or IL-10-silenced B16 (IL-10(-/-);) cells were inoculated into C57BL/6 mice. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23643168 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4071 https://github.com/vaccineontology/VO/issues/78 4071 Research 1(SOCS1)-silenced dendritic cell (DC) Vaccine A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5, FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5414 https://github.com/vaccineontology/VO/issues/79 5414 Clinical trial 117-126:FGF-5 Peptide Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5418 https://github.com/vaccineontology/VO/issues/80 5418 Clinical trial 12 Melanoma Peptide Vaccine 2 class major histocompatibility complex�restricted melanoma peptides Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21690475 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3978 https://github.com/vaccineontology/VO/issues/81 3978 Research 12MP Vaccine 4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12 MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6 MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6 MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23653149 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4070 https://github.com/vaccineontology/VO/issues/82 4070 Clinical trial 12MP, 12MP/Tet, 12MP/6MHP, or 6MHP Vaccine A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22495394 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5290 https://github.com/vaccineontology/VO/issues/83 2315 6490 7299 5290 Clinical trial Gene name: Tyrosinase|Gene name: gp100|Gene name: MLANA 27-35(27L):MART-1 Peptide Vaccine A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4986 https://github.com/vaccineontology/VO/issues/84 4986 851B Gel Vaccine A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:17000686 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5244 https://github.com/vaccineontology/VO/issues/86 94025 5244 Clinical trial Gene name: MUC16 Abagovomab Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:11860704 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5543 https://github.com/vaccineontology/VO/issues/87 2875 7124 5543 Research Gene name: TNF|Gene name: GPT Ad CMV I kappaB alpha Vaccine A cancer vaccine consisting of a recombinant adenoviral vector encoding the tumor-associated antigen (TAA) human MUC-1 (hMUC-1) linked to the extracellular domain (ecd) of the co-stimulatory molecule CD40 ligand (CD40L) and an adenovirus signal sequence that encodes a secretory signal peptide (Ad-sig) with potential immunostimulating and antineoplastic activities. Due to the presence of the secretory signal peptide expressed by Ad-sig in the vaccine construct, transfected cells may secrete a fusion protein composed of hMUC-1 and the CD40L ecd. The CD40L moiety part of the fusion protein binds to CD40 receptors on dendritic cells (DCs). Subsequently, DCs may be activated and migrate, T-cells may expand, and a cytotoxic T lymphocyte (CTL) response against tumor cells that overexpress hMUC-1 may follow. MUC-1 is a hypoglycosylated TAA overexpressed by epithelial cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5179 https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.3098 https://github.com/vaccineontology/VO/issues/88 4582 959 5179 Clinical trial Gene name: MUC1|Gene name: CD40LG Ad-sig-hMUC-1/ecdCD40L Vaccine A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5308 https://www.cell.com/molecular-therapy-family/oncolytics/pdf/S2372-7705(20)30171-6.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281656/ https://github.com/vaccineontology/VO/issues/89 3592 3593 5308 Clinical trial Gene name: IL12B|Gene name: IL12A Ad5-yCD/mutTKSR39rep-hIL12 Vaccine A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15300212 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5523 https://github.com/vaccineontology/VO/issues/92 5523 Clinical trial Adenovector Encoding MDA7 Vaccine A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4999 https://github.com/vaccineontology/VO/issues/93 2346 4999 Clinical trial Gene name: Prostate-specific membrane antigen Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:25956394 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5137 https://github.com/vaccineontology/VO/issues/94 1048 5137 Clinical trial Gene name: CEACAM5 Adenoviral Vector Ad5-CEA(6D) Vaccine An adenovirus vector engineered to produce CD40 ligand. For use as a possible gene therapy agent. May induce apoptosis through the TNF pathway. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15153545 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5529 https://github.com/vaccineontology/VO/issues/95 5529 Research Adenovirus 5-CD40 Ligand Vaccine Fibroblast growth factor-2-retargeted adenoviral vectors may be used to increase the transduction of GBM-derived endothelial cells, enabling a new and efficient antiangiogenesis strategy for the treatment of malignant gliomas. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:16709032 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5489 https://github.com/vaccineontology/VO/issues/96 2247 5489 Research Gene name: FGF2 Adenovirus 5-Fibroblast Growth Factor 2 Vaccine A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT04111172 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5147 https://github.com/vaccineontology/VO/issues/97 2984 5147 Clinical trial Gene name: GUCY2C Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen. Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5435 https://github.com/vaccineontology/VO/issues/98 941 5435 Research Gene name: CD80 Adenovirus B7-1 Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00307229 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5388 https://github.com/vaccineontology/VO/issues/99 24337 5388 Clinical trial Gene name: Erbb2 Adenovirus Encoding Rat HER-2/neu Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22737604 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5370 https://github.com/vaccineontology/VO/issues/100 2315 4105 7299 5370 Clinical trial Gene name: Tyrosinase|Gene name: MLANA|Gene name: MAGEA6 Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus HER2-transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00197522 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5082 https://github.com/vaccineontology/VO/issues/101 2064 5082 Clinical trial Gene name: ERBB2 Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine A gene viral vector complex comprised of a replication-defective adenovirus and a herpes simplex virus thymidine kinase gene that activates ganciclovir, causing inhibition of DNA synthesis and apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/8985364 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5122 https://github.com/vaccineontology/VO/issues/102 5122 Clinical trial Adenovirus RSV-TK Vaccine A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:33575474 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5285 https://github.com/vaccineontology/VO/issues/103 2346 5285 Clinical trial Gene name: Prostate-specific membrane antigen gene engineering Adenovirus-mediated Human Interleukin-12 Vaccine A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant adenovirus encoding p53 peptide, with potential immunomodulating activity. Intradermal vaccination with adenoviral-p53 transduced dendritic cell vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:20420527 PubMed:29515795 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5256 https://github.com/vaccineontology/VO/issues/104 7157 5256 Clinical trial Gene name: TP53 (P53) Adenovirus-p53 Transduced Dendritic Cell Vaccine A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5010 https://github.com/vaccineontology/VO/issues/105 2346 5010 Clinical trial Gene name: Prostate-specific membrane antigen gene engineering Adenovirus-PSA Prostate Cancer Vaccine A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential antineoplastic and immunostimulating activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of this vaccine leads to an induction of apoptosis through the expression of RTVP-1 and results in a reduction in cellular proliferation in prostate cancer cells. In addition, this cancer-cell based vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor associated antigens, resulting in an immune-mediated prostate cancer cell death. Furthermore, RTVP-1 stimulates CTL and natural killer (NK) cell activities. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5203 https://github.com/vaccineontology/VO/issues/106 11010 5203 Clinical trial Gene name: GLIPR1 AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32323103 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5436 https://github.com/vaccineontology/VO/issues/107 1437 2064 5436 Clinical trial Gene name: GM-CSF|Gene name: ERBB2 AE37 Peptide/GM-CSF Vaccine A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5275 https://github.com/vaccineontology/VO/issues/108 174 5275 Clinical trial Gene name: AFP AFP Gene Hepatocellular Carcinoma Vaccine A cancer vaccine made of a recombinant NY-ESO-1 protein with a TLR7 agonist Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:C5941317 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3991 https://github.com/vaccineontology/VO/issues/109 1485 3991 Clinical trial Gene name: NY-ESO-1 Ag NY-ESO-1 Vaccine A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01461148 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5402 https://github.com/vaccineontology/VO/issues/110 28990 9014 9447 5402 Clinical trial Gene name: AIM2|Gene name: TAF1B|Gene name: ASTE1 AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:26787078 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5422 https://github.com/vaccineontology/VO/issues/145 1048 111518 5422 Clinical trial Gene name: CEACAM5|CEA Algenpantucel-L Vaccine A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5020 https://github.com/vaccineontology/VO/issues/146 5788 945 5020 Clinical trial Gene name: CD33|Gene name: PTPRC Allogeneic AML Antigen-expressing Dendritic Cell Vaccine An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15254047 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4998 https://github.com/vaccineontology/VO/issues/147 941 4998 Clinical trial Gene name: CD80 Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5257 https://github.com/vaccineontology/VO/issues/148 1048 4101 7490 5257 Clinical trial Gene name: CEACAM5|Gene name: WT1|Gene name: MAGEA2 Allogeneic Cellular Vaccine 1650-G A cancer vaccine consisting of allogeneic, immortalized dendritic cells (DCs) loaded with tumor specific antigens and activated, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration of the allogeneic dendritic cell vaccine COMBIG-DC, these activated DCs attract natural killer (NK) cells, induce an anti-inflammatory response leading to the induction of NK-cell-mediated tumor cell death. Upon release of tumor associated antigens (TAAs) from the lysed tumor cells, these antigens are taken up by antigen presenting cells which activate the immune system to elicit a potent cytotoxic T-cell (CTL) response against the TAAs, resulting in the death of TAAs-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01525017 NCT: https://clinicaltrials.gov/ct2/show/NCT01974661 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5446 https://github.com/vaccineontology/VO/issues/149 3458 7124 5446 Clinical trial Gene name: IFNG|Gene name: TNF Allogeneic Dendritic Cell Vaccine COMBIG-DC A cell-based vaccine composed of allogeneic dendritic cells pulsed ex-vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5102 https://github.com/vaccineontology/VO/issues/150 5102 Clinical trial Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5023 https://github.com/vaccineontology/VO/issues/151 7070 5023 Clinical trial Gene name: CD90 Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5327 https://github.com/vaccineontology/VO/issues/152 1437 4102 7490 9947 5327 Clinical trial Gene name: GM-SCF|Gene name: MAGEA3|Gene name: WT1|Gene name: MAGEC1 Allogeneic GM-CSF-Based Myeloma Cell Vaccine An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.A vaccine that is being studied as a way to help the body's immune system kill breast cancer cells. To make the vaccine, the GM-CSF gene is put into breast cancer cells in the laboratory. The cells are then treated with radiation to stop them from growing and injected into the same or a different patient. The GM-CSF protein made by the changed breast cancer cells may help the immune system kill breast cancer cells in the body. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5059 https://github.com/vaccineontology/VO/issues/153 2064 5059 Clinical trial Gene name: ERBB2 Allogeneic GM-CSF-Secreting Breast Cancer Vaccine An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01088789 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5075 https://github.com/vaccineontology/VO/issues/154 5075 Clinical trial Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5515 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2010-01868&r=1 https://github.com/vaccineontology/VO/issues/155 5515 Clinical trial Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo A cancer vaccine, containing human-specific large multivalent immunogens (LMIs) isolated from the membrane fraction of cells from a breast cancer cell line, with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen breast cancer vaccine may stimulate a cytotoxic T lymphocyte (CTL) immune response against tumor cells that express the breast cancer cell-specific LMIs. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5269 https://github.com/vaccineontology/VO/issues/156 1493 5269 Clinical trial Gene name: CTLA4 Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00726739 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5423 https://github.com/vaccineontology/VO/issues/157 2315 6490 5423 Clinical trial Gene name: MLANA|Gene name: gp100 (PMEL) Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307 A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32002306 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5376 https://github.com/vaccineontology/VO/issues/158 216 5376 Clinical trial Gene name: ALDH1A1 Allogeneic Melanoma Vaccine AGI-101H A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5440 https://github.com/vaccineontology/VO/issues/159 10232 5440 Clinical trial Gene name: MSLN Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine A biologic product that consists of undifferentiated stem cells, obtained from adult bone marrow or other non-embryonic tissue sources, that are expanded in vitro and deposited in master cell banks for ""off-the-shelf"" use, with potential hematopoiesis-inducing and immunomodulating activities. Allogeneic multipotent adult progenitor cells (MAPCs) are non-immunogenic due to the lack of major histocompatibility (MHC) molecule expression, and so elicit no immune response upon administration. In vivo, bone marrow-derived adult stem cells are capable of maturing into a broad range of cell types and may help restore the immune system by producing multiple therapeutic molecules in response to inflammation and tissue damage. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5054 https://github.com/vaccineontology/VO/issues/160 5054 Clinical trial Allogeneic Multipotent Adult Progenitor Cells Vaccine A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5358 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)36654-0 https://github.com/vaccineontology/VO/issues/161 941 959 5358 Clinical trial Gene name: CD80|Gene name: CD40LG Allogeneic Renal Cell Carcinoma Vaccine MGN1601 A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5339 https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/allogeneic-tumor-cell-vaccine https://github.com/vaccineontology/VO/issues/162 5339 Clinical trial Allogeneic Tumor Cell Vaccine A vaccine composed of killed glioma cancer cells from another patient for use in immunotherapy Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:24829761 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5119 https://github.com/vaccineontology/VO/issues/163 5119 Clinical trial Allogenic Glioma Cancer Vaccine A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:25041030 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5313 https://github.com/vaccineontology/VO/issues/164 149 5313 Clinical trial Gene name: AFP Alpha Fetoprotein Adenoviral Vector Vaccine An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5349 https://github.com/vaccineontology/VO/issues/165 11605 5349 Clinical trial Gene name: Gla Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:16675576 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5315 https://github.com/vaccineontology/VO/issues/166 174 5315 Clinical trial Gene name: AFP Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12; these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32188702 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5288 https://github.com/vaccineontology/VO/issues/167 5288 Clinical trial Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cell Vaccine A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the ""gold standard"" DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs; as a result it can be used as a cancer vaccine. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5198 https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alpha-type-1-polarized-dendritic-cells https://github.com/vaccineontology/VO/issues/168 2315 6490 7299 5198 Clinical trial Gene name: MLANA|Gene name: gp100 (PMEL)|Gene name: Tyrosinase Alpha-type-1 Polarized Dendritic Cell Vaccine A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection which does not produce symptoms or harm the host. When carrying foreign genes it will cause transient expression of protein. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:16061912 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5334 https://github.com/vaccineontology/VO/issues/169 3458 5334 Clinical trial Gene name: IFNG -Obselete ALVAC Vaccine A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cells, and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28, to augment the host immune response. This agent has been shown to stimulate a host immune response against tumor cells that express CEA. (NCI04) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:12596363 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5444 https://github.com/vaccineontology/VO/issues/210 1048 941 5444 Clinical trial Gene name: CD80|Gene name: CEACAM5 (CEA) ALVAC-B7-CEA Vaccine A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against CEA-positive tumor cells, thereby decreasing tumor growth. (NCI04) Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5003 https://github.com/vaccineontology/VO/issues/212 1048 5003 Clinical trial Gene name: CEACAM5 (CEA) ALVAC-CEA (VCP248) Vaccine A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:18676757 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5125 https://github.com/vaccineontology/VO/issues/213 941 5125 Clinical trial Gene name: CD80 ALVAC-CEA B7.1 Vaccine A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5051 https://github.com/vaccineontology/VO/issues/214 1048 5051 Clinical trial Gene name: CEACAM5 (CEA) ALVAC-CEA Vaccine A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01982487 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5332 https://github.com/vaccineontology/VO/issues/215 1485 5332 Clinical trial Gene name: NY-ESO-1 ALVAC-ESO-1 Vaccine A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00003556 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5181 https://github.com/vaccineontology/VO/issues/216 1493 5181 Clinical trial Gene name: CTLA4 ALVAC-hB7.1 Vaccine A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00612222 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5124 https://github.com/vaccineontology/VO/issues/217 2315 5124 Clinical trial Gene name: MLANA ALVAC-MART-1 Vaccine A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5394 https://github.com/vaccineontology/VO/issues/170 1485 6490 5394 Clinical trial Gene name: gp100 (PMEL)|Gene name: CTAG1B ALVAC(2) Melanoma Multi-antigen Vaccine A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01982487 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5268 https://github.com/vaccineontology/VO/issues/171 1485 3383 941 965 5268 Clinical trial Gene name: NY-ESO-1|Gene name: ICAM1|Gene name: CD80|Gene name: CD58 ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine A cancer vaccine consisting of autologous dendritic cells loaded with separate preparations of acute myelogenous leukemia (AML) cell lysate and AML-specific messenger RNA (mRNA) with potential immunostimulatory and antineoplastic activities. Upon administration, AML mRNA plus lysate loaded autologous dendritic cell vaccine may elicit a potent cytotoxic T-cell (CTL) response against AML cells, resulting in tumor cell death. Autologous dendritic cells doubly-loaded with AML cell lysate and AML-specific mRNA may elicit superior primary, recall, and effector lytic immune responses compared to autologous dendritic cells loaded with tumor lysate or tumor mRNA alone. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5533 https://github.com/vaccineontology/VO/issues/219 5533 Clinical trial AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:19051140 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5243 https://github.com/vaccineontology/VO/issues/220 1489079 5243 Clinical trial Gene name: E7 Amolimogene Bepiplasmid Vaccine A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:32513836 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5331 https://github.com/vaccineontology/VO/issues/221 367 5331 Clinical trial Gene name: AR Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118 A modified vaccinia Ankara (MVA) encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15627214 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3994 https://github.com/vaccineontology/VO/issues/222 3994 Clinical trial Ankara (MVA) Vaccine Recombinant MVA-gp100M and ALVAC(2)-5T4 were constructed to complement existing ALVAC(2)-gp100M and MVA-5T4 vectors. Recombinant TAA expression in chicken embryo fibroblast cells was confirmed by Western blot analysis. 5T4 expression was approximately equal for both viruses, whereas ALVAC-derived gp100 was quickly degraded, at a time point when MVA-derived gp100 was still stable and expressed at high levels Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15627214 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4073 https://github.com/vaccineontology/VO/issues/223 4073 Clinical trial Ankara (MVA) and ALVAC(2) Vaccine An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5199 https://github.com/vaccineontology/VO/issues/224 5199 Clinical trial Anti-CD19/CD3 Tetravalent Antibody AFM11 Vaccine Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5411 https://www.targetedonc.com/view/cd20-cd3-bispecific-antibodies-can-revolutionize-b-cell-lymphoma-therapy https://github.com/vaccineontology/VO/issues/225 931 5411 Clinical trial Gene name: MS4A1 Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells Cancer Vaccine Autologous human peripheral blood lymphocytes (PBLs), transduced with a retroviral vector encoding both the alpha and beta chains of a T cell receptor (TCR) specific for the carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, anti-CEA TCR retroviral vector-transduced autologous lymphocytes bind to tumor cells expressing CEA, which may result in cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. The tumor-associated antigen (TAA) CEA is overexpressed by a variety of cancer cell types, including those of the gastrointestinal tract, lung, and breast. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5536 https://github.com/vaccineontology/VO/issues/226 1048 5536 Clinical trial Gene name: CEACAM5 (CEA) Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5375 https://github.com/vaccineontology/VO/issues/227 1493 5375 Clinical trial Gene name: CTLA4 Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5149 https://github.com/vaccineontology/VO/issues/228 1493 5149 Clinical trial Gene name: CTLA4 Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00895466 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5405 https://github.com/vaccineontology/VO/issues/229 14714 5405 Clinical trial Gene name: Gnhr1 Anti-GnRH Vaccine PEP223 A monoclonal antibody that functionally mimics MUC-1 antigen, a tumor cell surface antigen. Administration of anti-idiotype MUC-1 monoclonal antibody may elicit an anti-idiotype antibody and corresponding T-cell response against MUC-1 expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15550589 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5175 https://github.com/vaccineontology/VO/issues/230 4582 5175 Clinical trial Gene name: MUC1 Anti-idiotype MUC-1 Monoclonal Antibody Vaccine A synthetic antibody produced by a genetically homogenous population of hybrid cells (hybridoma) against determinant idiotypes (Id) which usually mimic human epitopes. Anti-Id vaccines may be effective in the treatment of B-cell lymphomas, resulting in tumor regression. Anti-idiotype vaccine therapy is less likely to induce autoimmunity if the target antigen is not normally expressed on normal tissues. Monoclonal antibodies have become powerful tools for tumor targeting, recognizing different protein markers on certain cancer cells and may be used alone or as delivery agents for drugs, toxins or radioactive material targeted to tumors. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5301 https://github.com/vaccineontology/VO/issues/231 5301 Clinical trial Anti-Idiotype Specified Monoclonal Antibody Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/9816036 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4015 https://github.com/vaccineontology/VO/issues/232 4015 Clinical trial anti-idiotypic (anti-id) mAb MK2-23 + BCG A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that is directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a major surface marker on most human melanoma cells. Due to poor immunogenicity of GD3, anti-Id MoAb BEC2 (Ab2) was raised against a mouse anti-GD3 MoAb, R24 (Ab1). This anti-Id MoAb was shown to be functionally mimicking GD3 in stimulating an immune response to produce Ab3 that may be used in combination with other adjuvants for treatment of melanomas. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5433 https://github.com/vaccineontology/VO/issues/233 5433 Clinical trial Anti-idiotypic Monoclonal Antibody BEC2 Vaccine An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5485 https://github.com/vaccineontology/VO/issues/234 1485 5485 Clinical trial Gene name: NY-ESO-1 Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A Vaccine Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5081 https://github.com/vaccineontology/VO/issues/235 1485 30484 5081 Clinical trial Gene name: NY-ESO-1|Gene name: CTAG2 Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes Vaccine Human autologous peripheral blood lymphocytes (PBLs) transduced with an anti-p53 T cell receptor gene with potential antineoplastic activity. PBLs are harvested from a patient and pulsed with a retroviral vector that encodes the T-cell receptor gene specific for a mutated form of p53. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these modified PBLs express the anti-p53 T cell receptor which binds to mutant p53-overexpressing tumor cells; PBL-mediated tumor growth inhibition may follow. Many tumor cell types overexpress mutant p53 proteins, which are associated with the loss of apoptosis regulation and abnormal cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00393029 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5447 https://github.com/vaccineontology/VO/issues/236 7157 5447 Clinical trial Gene name: TP53 (P53) Anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes Vaccine An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01853878 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5361 https://github.com/vaccineontology/VO/issues/237 23532 5361 Clinical trial Gene name: PRAME Anti-PRAME Immunotherapeutic GSK2302032A Vaccine An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse (""off the shelf"") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5138 https://github.com/vaccineontology/VO/issues/238 6490 5138 Clinical trial Gene name: gp100 (PMEL) Antigen-targeted Personalized Breast Cancer Vaccine A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01133704 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5420 https://github.com/vaccineontology/VO/issues/239 2346 354 55 5420 Clinical trial Gene name: ACPP|Gene name: Prostate|Gene name: KLK3 APC8015F Vaccine A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21509164 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5222 https://github.com/vaccineontology/VO/issues/240 5222 Clinical trial Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells Vaccine A vaccine comprised of autologous epithelial ovarian cells infected with ALVAC-hB7.1 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5319 https://www.clincosm.com/trial/recurrent-ovarian-epithelial-cancer-houston-alvac-hb71-recombinant https://github.com/vaccineontology/VO/issues/242 155971 5319 Clinical trial Gene name: env AUT-OV-ALVAC-hB7.1 Vaccine An autologous tumor cell vaccine containing chronic lymphocytic leukemia (CLL) B cells transduced with an adenoviral vector carrying chimeric CD154 (ad-CD154) with potential antineoplastic activity. Administration of autologous ad-CD154 transduced CLL B cells may result in increases in the numbers of leukemia-specific CD4+ T cells and high serum-levels of IL-12 and IFN-gamma. Due to ligation of CD154 to CD40 on CLL cells, this agent may induce CLL cells to express the proapoptotic molecule BID and death receptors CD95 (Fas) and DR5, rendering CLL B cells first resistant and then sensitive to Fas-mediated apoptosis. In addition, autologous ad-CD154 transduced CLL B cells may induce MHC class I-dependent cytotoxic T lymphocyte (CTL) responses against autologous leukemia cells. CD154 is a type II membrane glycoprotein and ligand for CD40; both molecules are important in cognate co-stimulatory cell-cell interactions. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00779883 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5053 https://github.com/vaccineontology/VO/issues/243 959 5053 Clinical trial Gene name: CD40LG Autologous Ad-CD154-Transduced CLL B Cells Vaccine Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00509496 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5507 https://github.com/vaccineontology/VO/issues/244 6490 5507 Clinical trial Gene name: gp100 (PMEL) Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00509288 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5293 https://github.com/vaccineontology/VO/issues/245 2315 5293 Clinical trial Gene name: MLANA Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes Vaccine A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with CD133-positive autologous brain tumor stem cells (BTSCs) -derived mRNA with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against the CD133-positive BTSCs from which the autologous tumor mRNA is derived. CD133, a tumor-associated antigen (TAA) and neural stem cell marker, has been found on a specific subset of glioblastoma multiforme (GBM) stem cells; its presence has been correlated with resistance to conventional chemotherapy and radiotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5463 https://mhlw-grants.niph.go.jp/system/files/2013/134041/201328051A/201328051A0017.pdf https://github.com/vaccineontology/VO/issues/246 8842 5463 Clinical trial Gene name: PROM1 Autologous CD133-Positive BTSC mRNA-Pulsed Autologous Dendritic Cell Vaccine A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L; TRAP; CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5174 https://github.com/vaccineontology/VO/issues/247 959 5174 Clinical trial Gene name: CD40LG Autologous CD40L-expressing B-CLL Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5150 https://github.com/vaccineontology/VO/issues/248 174 5150 Clinical trial Gene name: AFP Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01995708 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5128 https://github.com/vaccineontology/VO/issues/249 7490 5128 Clinical trial Gene name: WT1 Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22774527 PubMed:31771601 PubMed:34862245 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3967 https://github.com/vaccineontology/VO/issues/250 3967 Clinical trial autologous dendritic cell vaccine (DCV) A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02649829 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5085 https://github.com/vaccineontology/VO/issues/251 958 5058 Clinical trial Gene name: CD40 Autologous Dendritic Cell Vaccine ACT2001 A cancer vaccine comprised of autologous dendritic cells (DCs) that have been transduced ex vivo with an adenoviral vector containing the CCL21 gene with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, autologous dendritic cell-adenovirus CCL21 vaccine expresses the chemokine CCL21, which may induce an antitumoral cytotoxic immune response in the tumor microenvironment. CCL21 [chemokine (C-C motif) ligand 21] has been shown to attract antigen presenting cells (APCs), like leukocytes and DCs, and natural killer (NK) cells and their T-cell effectors to induce a cytotoxic immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT03546361 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5030 https://github.com/vaccineontology/VO/issues/252 6366 5030 Clinical trial Gene name: CCL21 Autologous Dendritic Cell-Adenovirus CCL21 Vaccine An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:20420527 PubMed:29515795 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5088 https://github.com/vaccineontology/VO/issues/253 7157 5088 Clinical trial Gene name: TP53 (P53) Autologous Dendritic Cell-Adenovirus P53 Vaccine A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5495 https://github.com/vaccineontology/VO/issues/254 2315 4102 6490 5495 Clinical trial Gene name: MLANA|Gene name: gp100 (PMEL)|Gene name: MAGEA3 Autologous Dendritic Cell-Allogeneic Melanoma Tumor Cell Lysate Vaccine cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:20884622 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5066 https://github.com/vaccineontology/VO/issues/255 6490 5066 Clinical trial Gene name: gp100 (PMEL) Autologous Dendritic Cell-Autologous Tumor mRNA-Human CD40L Vaccine A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of autologous DC-based immunotherapeutic AV0113, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5284 https://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.2052 https://github.com/vaccineontology/VO/issues/256 5284 Clinical trial Autologous Dendritic Cell-based Immunotherapeutic AV0113 Vaccine A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23685836 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5056 https://github.com/vaccineontology/VO/issues/257 4582 6382 952 5055 Clinical trial Gene name: MUC1|Gene name: CD38|Gene name: SDC1 Autologous Dendritic Cell-Tumor Fusion Vaccine A vaccine consisting of autologous cancer cells modified with the hapten, Dinitrophenyl. The treatment program consists of multiple intradermal injections of irradiated DNP-modified autologous tumor cells mixed with bacillus Calmette-Guerin. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/9400626 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5537 https://github.com/vaccineontology/VO/issues/258 5537 Clinical trial Autologous Dinitrophenyl Vaccine A cancer vaccine consisting of autologous ovarian cancer cell peptide antigens conjugated to the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of autologous dinitrophenyl-modified ovarian cancer vaccine may induce a cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5459 https://github.com/vaccineontology/VO/issues/259 5459 Clinical trial Autologous Dinitrophenyl-Modified Ovarian Cancer Vaccine A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5118 https://github.com/vaccineontology/VO/issues/260 5118 Clinical trial Autologous EBV-Transformed B Lymphoblastoid-Tumor Fusion Cell Vaccine A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5225 https://github.com/vaccineontology/VO/issues/261 1880 5225 Clinical trial Gene name: GPR183 Autologous Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Vaccine Multipotent self-renewing adherent non-hematopoietic stromal cells harvested from a patient's bone marrow and grown in vitro. When injected back into the patient, autologous expanded mesenchymal stem cells OTI-010 may differentiate into various mesenchyme-derived cell types and, in some instances, may augment bone marrow engraftment after whole-body irradiation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5491 https://github.com/vaccineontology/VO/issues/262 5491 Clinical trial Autologous Expanded Mesenchymal Stem Cells OTI-010 Vaccine An autologous tumor cell vaccine containing irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Autologous breast cancer cells are transduced ex vivo with an adenovirus vector encoding the GM-CSF gene and irradiated and then reintroduced into the patient. Upon repeated subcutaneous administration of the vaccine, autologous GM-CSF-secreting breast cancer cells secrete GM-CSF, which may stimulate a tumor-specific cytotoxic T-lymphocyte (CTL) response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5250 https://github.com/vaccineontology/VO/issues/263 2064 5250 Clinical trial Gene name: ERBB2 Autologous GM-CSF-Secreting Breast Cancer Vaccine A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5188 https://github.com/vaccineontology/VO/issues/264 10232 5188 Clinical trial Gene name: MSLN Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5240 https://github.com/vaccineontology/VO/issues/265 1437 7490 5240 Clinical trial Gene name: GM-CSF|Gene name: WT1 Autologous GM-CSF-Secreting Lethally Irradiated Leukemia Cell Vaccine A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5266 https://github.com/vaccineontology/VO/issues/266 3308 5266 Clinical trial Gene name: HSPA4 Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858 A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02211027 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5043 https://github.com/vaccineontology/VO/issues/267 6375 5043 Clinical trial Gene name: XLC1 Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00458679 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5228 https://github.com/vaccineontology/VO/issues/268 12519 3383 942 5228 Clinical trial Gene name: Cd80|Gene name: CD86|Gene name: ICAM1 Autologous IL-2-expressing B-CLL Vaccine A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immunostimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00104819 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5057 https://github.com/vaccineontology/VO/issues/269 3123 5075 Clinical trial Gene name: HLA-DRB1 Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous lymphoma cells with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, autologous lymphoma cell lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against lymphoma cells, which may result in lymphoma cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5248 https://github.com/vaccineontology/VO/issues/270 5248 Clinical trial Autologous Lymphoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine consisting of hybrid cells created by electrofusing allogeneic dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5503 https://github.com/vaccineontology/VO/issues/272 1638 2315 6490 7299 5503 Clinical trial Gene name: gp100 (PMEL)|Gene name: MLANA|Gene name: DCT|Gene name: Tyrosinase Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine A cell-based cancer vaccine consisting of hybrid cells created by electrofusing autologous dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5431 https://github.com/vaccineontology/VO/issues/273 5431 Clinical trial Autologous Lymphoma Cell/Autologous Dendritic Cell Electrofusion Hybrid Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5148 https://github.com/vaccineontology/VO/issues/274 1485 2315 5148 Clinical trial Gene name: NY-ESO-1|Gene name: MLANA-Dupuli Autologous Melanoma Lysate-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5213 https://github.com/vaccineontology/VO/issues/275 3123 5213 Clinical trial Gene name: HLA-DRB1 Autologous Melanoma Lysate/KLH-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5158 https://github.com/vaccineontology/VO/issues/276 1485 5158 Clinical trial Gene name: NY-ESO-1 Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine A vaccine consisting of irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous non-small cell lung cancer (NSCLC)-derived DNA with potential immunostimulatory and antineoplastic activities. Upon administration, autologous NSCLC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses NSCLC tumor-associated antigens (TAAs) in addition to MHC class I-determinants and the co-stimulatory molecule B7.1, which may induce a cytotoxic T-lymphocyte (CTL) response against NSCLC cells. The MRC-5 cell line is a human diploid lung fibroblast cell line extablished in 1966. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5377 https://github.com/vaccineontology/VO/issues/277 5377 Clinical trial Autologous NSCLC DNA-Transfected Semi-Allogeneic Fibroblasts MRC-5 Vaccine A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5311 https://github.com/vaccineontology/VO/issues/278 5311 Clinical trial Autologous NSCLC Peptide-specific Dendritic Cell Vaccine A cancer vaccine consisting of autologous, mature monocyte-derived dendritic cells (DCs) transfected with oncofetal antigen immature laminin receptor protein (OFA-iLRP) RNA, with potential antineoplastic activity. Upon administration, DCs in the OFA-iLRP RNA-transfected autologous dendritic cell vaccine express, process, and present OFA-iLRP to the host immune system, which may mount a potent cytotoxic T-cell (CTL) response against OFA-iLRP-expressing tumor cells. As a highly conserved protein, OFA-iLRP is preferentially expressed in fetal tissues and in many types of cancer, including hematopoietic malignancies, but is not detectable in normal differentiated adult cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00715832 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5368 https://github.com/vaccineontology/VO/issues/279 16785 5368 Clinical trial Gene name: Rspa Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous, irradiated dendritic cells (DCs) pulsed with ovarian tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian tumor cells expressing the patients ovarian tumor cell-specific TAAs, which may result in ovarian tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5427 https://github.com/vaccineontology/VO/issues/280 5427 5427 Clinical trial Gene name: ERBB2 Autologous Ovarian Tumor Cell Lysate-Pulsed Dendritic Cell Vaccine A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5220 https://discovery.lifemapsc.com/regenerative-medicine/cell-therapy-applications/brain-ald451-bone-marrow-derived-cells-for-malignant-glioma https://github.com/vaccineontology/VO/issues/281 216 217 5220 Clinical trial Gene name: ALDH1A1|Gene name: ALDH2 Autologous Pluripotent ALDHbr Stem Cells ALD-451 Vaccine A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5282 https://github.com/vaccineontology/VO/issues/282 2346 928 5282 Clinical trial Gene name: CD40|Gene name: Prostate Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101 A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with renal cell carcinoma (RCC) tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous renal cell carcinoma tumor lysate-dendritic cell vaccine may stimulate anti-tumoral cytotoxic T-lymphocyte (CTL) and antibody responses against RCC tumor cells expressing RCC TAAs, resulting in RCC tumor cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5018 https://github.com/vaccineontology/VO/issues/283 2315863 7015 5018 Clinical trial Gene name: Survivin|Gene name: TERT Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5189 https://github.com/vaccineontology/VO/issues/284 5189 Clinical trial Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02362451 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5024 https://github.com/vaccineontology/VO/issues/285 6862 5024 Clinical trial Gene name: TBXT Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5108 https://github.com/vaccineontology/VO/issues/287 3558 5108 Clinical trial Gene name: IL2 Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22854664 PubMed:32558897 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5396 https://github.com/vaccineontology/VO/issues/288 942 5396 Clinical trial Gene name: CD86 Autologous Tumor Cell Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B). Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:18528294 PubMed:23482679 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5035 https://github.com/vaccineontology/VO/issues/289 53340 54763 728695 8852 9232 5035 Clinical trial Gene name: SPA17|Gene name: ROPN1|Gene name: AKAP4|Gene name: PTTG1|Gene name: SPANXB1 Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine An autologous therapeutic vaccine for the treatment of acute myelogenous leukemia. This vaccine is prepared from blood samples of patients following their first relapse. Tumor cells extracted from blood sample are modified with hapten, a process that makes the cells appear foreign to the patient's body and results in stimulating immune response against the cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5404 https://github.com/vaccineontology/VO/issues/290 2315 4102 5404 Clinical trial Gene name: MAGEA3|Gene name: MLANA Autologous-Cell Leukemia Vaccine An autologous-cell vaccine for melanoma. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5110 https://github.com/vaccineontology/VO/issues/291 5110 Clinical trial Autologous-Cell Melanoma Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21036724 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5230 https://github.com/vaccineontology/VO/issues/296 5230 Clinical trial BCG, Cell Wall Skeleton Vaccine A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:7479929 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5399 https://github.com/vaccineontology/VO/issues/297 598 7306 4671 Clinical trial Gene name: BCL2L1|Gene name: TYRP1 Bcl-Xs Adenovirus Vaccine A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:26211534 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5374 https://github.com/vaccineontology/VO/issues/298 7042 5374 Clinical trial Gene name: TGFB2 Belagenpumatucel-L Vaccine A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15983396 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4992 https://github.com/vaccineontology/VO/issues/299 7157 4992 Clinical trial Gene name: TP53 (P53) Berzofsky Ras/P53 Peptide Vaccine A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5439 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-05711&r=1 https://github.com/vaccineontology/VO/issues/310 925 5439 Clinical trial Gene name: CD8A Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew; vaccination against BITC antigens may kill these cells and may prevent tumor recurrences. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5210 https://github.com/vaccineontology/VO/issues/311 3383 941 965 5210 Clinical trial Gene name: CD58|Gene name: ICAM1|Gene name: CD80 Brain Tumor Initiating Cell Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5309 https://github.com/vaccineontology/VO/issues/312 5309 Clinical trial C29561 Vaccine A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5544 https://github.com/vaccineontology/VO/issues/313 2521 5544 Clinical trial Gene name: FUS Canarypox-hIL-12 Melanoma Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/7629885 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5329 https://github.com/vaccineontology/VO/issues/372 5329 Clinical trial CAP-2 (CEA Peptide 9-mer) Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5380 https://link.springer.com/article/10.1007/s11888-014-0250-5 https://github.com/vaccineontology/VO/issues/373 5380 Clinical trial CAP-3 (CEA Peptide 9-mer) Vaccine 9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with carcinoembryonic antigen peptide 1-6D, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00203892 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5356 https://github.com/vaccineontology/VO/issues/374 1048 5356 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen Peptide 1-6D Vaccine A cancer vaccine, consisting of alphavirus vector-derived virus-like replicon particles expressing the 9-amino-acid carcinoembryonic antigen peptide (CAP) 1-6D, with potential antineoplastic activity. Vaccination with this agent may elicit a cytotoxic T lymphocyte (CTL) immune response against CEA-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22630596 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5129 https://github.com/vaccineontology/VO/issues/375 1048 5129 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen Peptide 1-6D Virus-Like Replicon Particles Vaccine A cancer vaccine comprised of an epitope from the Carcinoembryonic Antigen obtained from cancer cells that can stimulate an immune response against tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:22630596 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5209 https://github.com/vaccineontology/VO/issues/376 1048 5209 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen Peptide-1 Vaccine A vaccine comprised of autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) targeting tumor cells expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21187495 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5041 https://github.com/vaccineontology/VO/issues/377 1048 5041 Clinical trial Gene name: CEACAM5 (CEA) Carcinoembryonic Antigen RNA-pulsed DC Cancer Vaccine A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT). Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5193 https://github.com/vaccineontology/VO/issues/379 1001 2022 4193 4904 6657 5193 Clinical trial Gene name: ENG|Gene name: YBX1|Gene name: SOX2|Gene name: CDH3|Gene name: MDM2 CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT02049489 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5107 https://github.com/vaccineontology/VO/issues/380 8842 5107 Clinical trial Gene name: PROM1 CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine A vaccine comprised of CD80-transfected allogenic breast cancer cells to induce T-cell response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5476 https://github.com/vaccineontology/VO/issues/381 2064 941 5467 Clinical trial Gene name: CD80|Gene name: ERBB2 CD80 Breast Cancer Vaccine Autologous human dendritic cells pulsed with RNA encoding the carcinoembryonic antigen (CEA) are being studied for possible use in the treatment of cancer expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21187495 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5045 https://github.com/vaccineontology/VO/issues/382 1048 5045 Clinical trial Gene name: CEACAM5 (CEA) CEA RNA-pulsed Autologous Human Cultured Dendritic Cells Vaccine A plasmid vaccine encoding wild type human carcinoembryonic antigen (CEA) fused to a tetanus toxoid T helper epitope, with potential antineoplastic activity. Upon vaccination and subsequent intradermal electroporation, CEA/tetanus toxoid T helper epitope fusion protein-expressing DNA plasmid vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA, a tumor associated antigen, is overexpressed in a variety of cancer cell types. The tetanus toxoid helper peptide epitope, obtained from the bacterial Clostridium tetani toxoid, binds to class II MHC molecules and increases the helper T-cell response thereby inducing an increased and long-term immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5367 https://github.com/vaccineontology/VO/issues/383 1048 5367 Research Gene name: CEACAM5 (CEA) CEA/Tetanus Toxoid T Helper Epitope Fusion Protein-Expressing DNA Plasmid Vaccine A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential antineoplastic activity. Upon intralesional injection of enadenotucirev, the adenovirus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation in host cells, which promotes viral replication. Deletion of E1B prevents replication in normal, healthy cells that express wild-type p53. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of the E3 gene, which encodes the adenovirus death protein, enhances the safety profile of the administered adenovirus. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5316 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(05)00564-2 https://github.com/vaccineontology/VO/issues/384 5316 Clinical trial Chimeric Ad11p/Ad3 Oncolytic Virus Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4985 https://academic.oup.com/neuro-oncology/article/22/Supplement_3/iii306/6018727 https://github.com/vaccineontology/VO/issues/385 3077579 4985 Clinical trial Gene name: UL83 CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5306 https://github.com/vaccineontology/VO/issues/386 3077579 5306 Clinical trial Gene name: UL83 CMVpp65/gB Plasmid Vaccine ASP0113 A vaccine composed of synthetic peptides derived from beta-human chorionic gonadotropin (hCG) conjugated to diphtheria toxoid. Vaccination with this peptide may elicit the host immune response against hCG-producing cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/9815634 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5372 https://github.com/vaccineontology/VO/issues/389 11716682 5372 Clinical trial Gene name: tox1 CTP-37-DT Vaccine A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with cyclin B1 peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, cyclin B1 peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and anti-cyclin B1 antibody responses against cyclin B1-expressing cancer cells, resulting in tumor cell lysis. Cyclin B1, a key regulator of the cell cycle and cell division, is overexpressed in a variety of cancer cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT01398124 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5139 https://github.com/vaccineontology/VO/issues/390 931 5139 Clinical trial Gene name: MS4A1 Cyclin B1 Peptide-pulsed Autologous Dendritic Cell Vaccine A preparation of autologous lymphocytes with potential immunopotentiating and antineoplastic activities. Cytokine-induced killer (CIK) cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes, generated ex-vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1, and interferon gamma (IFN-gamma) and then expanded. When reintroduced back to patients after autologous stem cell transplantation, CIK cells may recognize and kill tumor cells associated with minimal residual disease (MRD). CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:23210562 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5070 https://github.com/vaccineontology/VO/issues/391 174 5070 Clinical trial Gene name: AFP Cytokine-Induced Killer Cells Vaccine A vaccine composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:15256471 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5163 https://github.com/vaccineontology/VO/issues/392 5163 Clinical trial Dendritic Cell Tumor Cell Lysate Vaccine A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient. In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen. Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5161 https://github.com/vaccineontology/VO/issues/393 5161 Clinical trial Dendritic Cell-Autologous Lung Tumor Vaccine A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21187495 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5417 https://github.com/vaccineontology/VO/issues/394 1048 5417 Clinical trial Gene name: CEACAM5 (CEA) Dendritic Cell-CEA Peptide Vaccine An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen; both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5067 https://github.com/vaccineontology/VO/issues/395 2315 6490 5067 Clinical trial Gene name: gp100 (PMEL)|Gene name: MLANA Dendritic Cell-gp100-MART-1 Antigen Vaccine A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of MART-1 (melanoma antigen recognized by T-cells), an antigen expressed by melanoma cells. When the altered dendritic cells are returned to the patient, they stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5524 https://github.com/vaccineontology/VO/issues/396 2315 5524 Clinical trial Gene name: MLANA Dendritic Cell-MART-1 Peptide Vaccine A vaccine comprised of autologous dendritic cells pulsed with a recombinant prostate specific membrane antigen. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5000 https://github.com/vaccineontology/VO/issues/397 2346 5000 Clinical trial Gene name: Prostate-specific membrane antigen gene engineering: Dendritic Cell-Recombinant Prostate-Specific Membrane Antigen Vaccine An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5493 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-00926&r=1 https://github.com/vaccineontology/VO/issues/398 1485 5493 Clinical trial Gene name: NY-ESO-1 Dendritic Cell-targeting Lentiviral Vector ID-LV305 Vaccine A cancer vaccine consisting of autologous renal cell carcinoma (RCC) tumor cells modified with the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of DNP-modified autologous renal cell carcinoma tumor cell vaccine may induce a cytotoxic T-lymphocyte (CTL) response against renal cell carcinoma tumor cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5338 https://github.com/vaccineontology/VO/issues/400 5338 Clinical trial Dinitrophenyl-Modified Autologous Renal Cell Carcinoma Tumor cell Vaccine A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of DNA plasmid encoding interleukin-12 INO-9012, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5016 https://jitc.bmj.com/content/9/7/e003019 https://github.com/vaccineontology/VO/issues/401 2902 5016 Clinical trial Gene name: GRIN1 DNA Plasmid Encoding Interleukin-12 INO-9012 Vaccine A DNA-based combination immunotherapeutic, INO-3112, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT03439085 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5136 https://github.com/vaccineontology/VO/issues/402 1489078 1489079 5136 Clinical trial Gene name: E7|Gene name: E6 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:36129459 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5207 https://github.com/vaccineontology/VO/issues/403 1489078 1489079 5207 Clinical trial Gene name: E7|Gene name: E6 DNA Vaccine VB10.16 A cancer vaccine consisting of a DNA plasmid encoding epitopes of the human preferential antigen of melanoma (PRAME) and the prostate specific membrane antigen (PSMA) with potential immunostimulating activity. Upon direct administration of this vaccine into lymph nodes, peptides expressed by DNA plasmid vector pPRA-PSM may activate the immune system, resulting in a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing cells. PRAME and PSMA are tumor associated antigens upregulated in a number of cancer cell types. As part of the MKC1106-PP regimen exploiting the 'prime-boost strategy', this plasmid is responsible for priming the immune response and is used in conjunction with a peptide vaccine consisting of PRAME and PSMA that boosts the immune system against PRAME- and PSMA-expressing tumor cells. Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He NCT: https://clinicaltrials.gov/ct2/show/NCT00423254 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5407 https://github.com/vaccineontology/VO/issues/404 2346 5407 Research Gene name: Prostate-specific membrane antigen DNA Vector pPRA-PSM Vaccine A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5378 https://github.com/vaccineontology/VO/issues/126 4582 1048 5378 Clinical trial Gene name: CEACAM5|Gene name: MUC1 Falimarev vaccine A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5090 https://github.com/vaccineontology/VO/issues/456 7422 5090 Clinical trial Gene name: VEGFA hVEGF26-104/RFASE Peptide Vaccine A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5464 https://github.com/vaccineontology/VO/issues/438 2829163 5464 Clinical trial Gene name: HPV6 E6 HPV-6-targeting Immunotherapeutic Vaccine INO-3106 A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells. (NCIT_C2195). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5103 https://github.com/vaccineontology/VO/issues/65 4582 5103 Clinical trial Gene name: MUC1 Emepepimut-S Vaccine An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of the gp96-Ig-secreting allogeneic bladder cancer cell vaccine HS-410, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5033 https://github.com/vaccineontology/VO/issues/209 7184 5033 Clinical trial Gene name: HSP90B1 gp96-secreting Allogeneic Bladder Cancer Cell Vaccine HS-410 A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5300 https://github.com/vaccineontology/VO/issues/131 1485 5300 Clinical trial Gene name: NY-ESO-1 Fowlpox-NY-ESO-1 Vaccine A cancer vaccine comprised of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides with potential antineoplastic activity. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against GAA peptide-expressing glioma cells, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5096 https://github.com/vaccineontology/VO/issues/137 2548 5096 Clinical trial Gene name: GAA Glioma-Associated Antigen Peptide-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5073 https://github.com/vaccineontology/VO/issues/138 1956 5073 Clinical trial Gene name: EGFR Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5202 https://github.com/vaccineontology/VO/issues/426 55553 5202 Clinical trial Gene name: SOX6 HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5298 https://github.com/vaccineontology/VO/issues/458 3417 5298 Clinical trial Gene name: IDH1 IDH1R132H Mutation-targeting IDH1 Peptide Vaccine A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5461 https://github.com/vaccineontology/VO/issues/459 3417 5461 Clinical trial Gene name: IDH1 IDH1R132H-Specific Peptide Vaccine PEPIDH1M A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine exposes the immune system to undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5215 https://github.com/vaccineontology/VO/issues/494 4100 6490 5215 Gene name: MAGEA1|Gene name: gp100 Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5531 https://github.com/vaccineontology/VO/issues/64 1100818972 5531 Clinical trial Gene name: EGFR EGFRvIII Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5151 https://github.com/vaccineontology/VO/issues/127 5151 Clinical trial Fas-Chimera Transgene-expressing Endothelial Tumor Cell-targeting Adenovector VB-111 Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5277 https://github.com/vaccineontology/VO/issues/457 8842 5277 Clinical trial Gene name: PROM1 ICT-121 Dendritic Cell Vaccine A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5229 https://github.com/vaccineontology/VO/issues/174 4582 2760 5229 Clinical trial Gene name: GM2A|Gene name: MUC1 Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH Conjugate Vaccine A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5237 https://github.com/vaccineontology/VO/issues/306 2064 5237 Clinical trial Gene name: ERBB2 HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4997 https://github.com/vaccineontology/VO/issues/447 1442 7494 4997 Clinical trial Gene name: XBP1|Gene name: CSH1 hTERT/Survivin/CMV Multipeptide Vaccine A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5166 https://github.com/vaccineontology/VO/issues/495 4582 634 5166 Gene name: CEACAM1|Gene name: MUC1 Mammaglobin-A DNA Vaccine A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5036 https://github.com/vaccineontology/VO/issues/530 2064 2315 5036 Gene name: MLANA-Dupli|Gene name: ERBB2 Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor. (NCIT_C62801). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4987 https://github.com/vaccineontology/VO/issues/51 4987 Clinical trial E1M(184V) Peptide Vaccine A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine may elicit an immune response against cancer cells expressing hTERT and survivin by activating cytotoxic T-cells (CTLs), natural killer cells (NKs), and B-lymphocytes. The tumor associated antigens (TAAs) hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and play key roles in tumor cell growth and survival. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5121 https://github.com/vaccineontology/VO/issues/440 7015 5121 Clinical trial Gene name: TERT hTERT mRNA/Survivin Peptide-double-loaded Autologous Dendritic Cell Vaccine A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5516 https://github.com/vaccineontology/VO/issues/441 7015 5516 Clinical trial Gene name: TERT hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5065 https://github.com/vaccineontology/VO/issues/445 7015 5065 Clinical trial Gene name: TERT hTERT Vaccine V934/V935 A poxvirus made non-infectious by ultraviolet light or other inactivation methods in order to reduce its pathogenicity. In cancer gene therapy, inactivated vaccinia virus may be used as a vector to express a protein that kills tumor cells or elicits specific anti-tumor immunity. In a cancer vaccine application, tumor cells taken from the host may be adsorbed with inactivated vaccinia virus and returned to the host, where the modified tumor cells may stimulate an anti-tumor immune response. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5130 https://github.com/vaccineontology/VO/issues/465 5130 Clinical trial Inactivated Vaccinia Virus Vaccine A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5099 https://github.com/vaccineontology/VO/issues/466 1048 4582 5099 Clinical trial Gene name: CEACAM5|Gene name: MUC1 Inalimarev Vaccine A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5258 https://github.com/vaccineontology/VO/issues/472 5258 Clinical trial Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809 Vaccine A conjugate consisting of keyhole-limpet hemocyanin (KLH) and fluorescein isothiocyanate (FITC) with potential immunostimulating activity. Vaccination with KLH-FITC may elicit an immune response against fluorescein and the production of anti-fluorescein IgG antibodies. KLH, a natural protein isolated from the marine mollusk keyhole limpet, is an immunostimulant carrier protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5146 https://github.com/vaccineontology/VO/issues/473 5146 Clinical trial KLH-FITC Vaccine A cell-based vaccine targets tumors expressing the HER2/neu marker. HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers. APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient. These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5538 https://github.com/vaccineontology/VO/issues/475 2064 5538 Clinical trial Gene name: ERBB2 Lapuleucel-T Vaccine A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5187 https://github.com/vaccineontology/VO/issues/525 1234 5187 Gene name: CCR5 Mesothelioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5235 https://github.com/vaccineontology/VO/issues/526 5235 Methanol Extraction Residue of BCG Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5347 https://github.com/vaccineontology/VO/issues/529 5347 Gene name: P10 Mimotope-P10s-PADRE Peptide Vaccine A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope. Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5286 https://github.com/vaccineontology/VO/issues/533 4240 5286 Gene name: MFGE8 Monoclonal Antibody 11D10 Anti-Idiotype Vaccine A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5452 https://github.com/vaccineontology/VO/issues/534 1048 5452 Gene name: CEACAM5 Monoclonal Antibody 3H1 Anti-Idiotype Vaccine An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5308 https://github.com/vaccineontology/VO/issues/536 2583 5308 Gene name: B4GALNT1 Monoclonal Antibody A1G4 Anti-Idiotype Vaccine An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5469 https://github.com/vaccineontology/VO/issues/537 6489 5469 Gene name: ST8SIA1 Monoclonal Antibody GD2 Anti-Idiotype Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5239 https://github.com/vaccineontology/VO/issues/538 5239 Montanide ISA-51/Survivin Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5362 https://github.com/vaccineontology/VO/issues/544 4255 5362 Gene name: MGMT MSCV-MGMT(P140K) Vaccine A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5517 https://github.com/vaccineontology/VO/issues/545 4582 5517 Gene name: MUC1 MUC-1 Peptide Vaccine A peptide vaccine containing human mucin 2 (MUC2) protein conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. MUC2, a secretory or gel forming glycoprotein expressed predominantly in goblet cells of the gastrointestinal and respiratory tracts, is overexpressed as an aberrant or deglycosylated form in various tumors such as gastric carcinomas and some hormone-refractory prostate cancers. MUC2 protein is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with MUC2-KLH may result in the production of antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing MUC2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5169 https://github.com/vaccineontology/VO/issues/547 4583 5169 Gene name: MUC2 MUC-2-KLH Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5123 https://github.com/vaccineontology/VO/issues/548 4582 5123 Gene name: MUC1 MUC1 Antigen/SB AS-2 Vaccine A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5251 https://github.com/vaccineontology/VO/issues/549 4582 5251 Gene name: MUC1 MUC1-KLH Conjugate Vaccine A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity. MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen. Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5160 https://github.com/vaccineontology/VO/issues/550 4582 5160 Gene name: MUC1 MUC1-KLH Vaccine/QS21 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5068 https://github.com/vaccineontology/VO/issues/551 4582 5068 Gene name: MUC1 MUC1-targeted Peptide GO-203-2C Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5522 https://github.com/vaccineontology/VO/issues/552 2348 5522 Gene name: FOLR1 Multi-epitope Folate Receptor Alpha Peptide Vaccine A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5064 https://github.com/vaccineontology/VO/issues/556 10643 54742 5064 Gene name: LY6K |Gene name: IGF2BP3 Multipeptide Vaccine S-588210 A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5364 https://github.com/vaccineontology/VO/issues/559 5364 Mutant p53 Peptide Pulsed Dendritic Cell Vaccine A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5091 https://github.com/vaccineontology/VO/issues/564 4582 5091 Gene name: MUC1 MVA-MUC1-IL2 Vaccine A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may be capable of inducing an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5400 https://github.com/vaccineontology/VO/issues/566 2064 5400 Gene name: ERBB2 MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L. major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L. major capsid proteins or functional L. major capsid protein derivatives. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5449 https://github.com/vaccineontology/VO/issues/450 5449 Clinical trial Human Papilloma Virus L1 Virus-Like Particle V504 Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5408 https://github.com/vaccineontology/VO/issues/478 1489079 2829163 5408 Clinical trial Gene name: HPV6 E6|Gene name: E7 Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5195 https://github.com/vaccineontology/VO/issues/532 1604 5195 Gene name: CD55 Monoclonal Antibody 105AD7 Anti-idiotype Vaccine A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor; VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5164 https://github.com/vaccineontology/VO/issues/486 54742 7422 5164 Clinical trial Gene name: LY6K|Gene name: VEGFA LY6K/VEGFR1/VEGFR2 Multipeptide Vaccine A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5055 https://github.com/vaccineontology/VO/issues/172 11716682 5055 Clinical trial Gene name: tox1 Globo H-DT Vaccine OBI-833 A synthetic peptide derived from the protein ESW/FLI1 type 2 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-2 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 2 fusion protein. (NCIT_C49064). Jie Zheng Justin Song Oliver He Penny Pan PubMed:/2753158 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5432 https://github.com/vaccineontology/VO/issues/63 297374825 5432 Clinical trial Gene name: CD22 EF-2 Peptide Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5421 https://github.com/vaccineontology/VO/issues/554 4100 6490 5421 Gene name: MAGEA1|Gene name: gp100 Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107 A preparation of allogeneic HLA-matched leukocytes treated with a derivative of placental protein 14 (PP14) with potential immunomodulating activity. PP14 derivative-treated HLA-matched donor mononuclear cell-enriched leukocytes contain at least fifty-five percent early-apoptotic T cells; after infusion and when processed by recipient dendritic cells, early-apoptotic T cells may help induce a decrease in the donor effector T-cell responses against the recipient of an allogeneic hematopoietic stem cell (HSC) transplant, thereby minimizing allogeneic HSC transplant-related graft-versus-host disease (GVHD). PP14, a 162 amino acid glycosylated protein secreted by the late secretory phase endometrium, binds to T cells in a carbohydrate fashion and has been shown to induce T-cell apoptosis; maternal immune tolerance to the fetus and pregnancy-related remissions of autoimmune disease may involve PP14-induced T cell apoptosis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5093 https://github.com/vaccineontology/VO/issues/427 5047 5093 Clinical trial Gene name: PAEP HLA-Matched Donor Mononuclear Cell-Enriched Leukocytes Apocell vaccine Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5168 https://github.com/vaccineontology/VO/issues/461 5168 Clinical trial IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051 A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5015 https://github.com/vaccineontology/VO/issues/528 5133 5015 Gene name: PDCD1 MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC) Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5002 https://github.com/vaccineontology/VO/issues/304 3845 5002 Clinical trial Gene name: KRAS HCV DNA Vaccine INO-8000 A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5312 https://github.com/vaccineontology/VO/issues/563 5312 MVA-FCU1 TG4023 Vaccine A synthetic HIV vaccine based on a recombinant canary pox virus vector expressing the human immunodeficiency virus (HIV) glycoprotein gp160. HIVgP160 vaccine has been used to generate in vivo primary T lymphocyte response against HIV antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5360 https://github.com/vaccineontology/VO/issues/308 155971 5360 Clinical trial Gene name: env HIVgP160 Vaccine A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2. Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5474 https://github.com/vaccineontology/VO/issues/429 1489078 5474 Clinical trial Gene name: E6 HPV 16 E6 (18-26) Peptide vaccine A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5184 https://github.com/vaccineontology/VO/issues/431 1489079 5184 Clinical trial Gene name: E7 HPV 16 E7:86-93 Peptide Vaccine A vaccine consisting of human papillomavirus-derived noninfectious virus-like particles (VLPs), containing the L. major capsid protein. Vaccination with HPV 16 L1-VLP results in increases in T cell-proliferative response to HPV 16 L1-VLP, as well as significant increases in cytokine (interferon-gamma, interleukin-5 and -10) responses to L1 VLP. This agent may reduce the incidence of persistent HPV-16 infection, which may be responsible for half of all cases of cervical cancer including high-grade cervical intraepithelial neoplasia. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5520 https://github.com/vaccineontology/VO/issues/432 25479185 5520 Clinical trial Gene name: L1 HPV 16 L1-VLP vaccine A synthetic peptide vaccine consisting of amino acids 13 through 21 of the viral oncoprotein human papillomavirus (HPV) 18 E6. The HPV 18E6 peptide cross-reacts immunologically with both HPV type 16 and HPV type 18, the most common HPV types involved in cervical cancer. Vaccination with HPV-18 E6:13-21 peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV 16 and 18. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5159 https://github.com/vaccineontology/VO/issues/433 5159 Clinical trial HPV 18 E6:13-21 Peptide vaccine Noninfectious, synthetic, virus-like particles (VLP) containing the major viral capsid protein, L1, of the human papillomavirus type 18 with potential immunoprotective activity. Vaccination with HPV 18 L1-VLP may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) response against cells positive for HPV 18, thereby preventing cervical infection upon exposure to HPV type 18. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5247 https://github.com/vaccineontology/VO/issues/434 5247 Clinical trial HPV 18 L1-VLP vaccine A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5226 https://github.com/vaccineontology/VO/issues/435 1489078 1489079 5226 Clinical trial Gene name: E6|Gene name: E7 HPV DNA Plasmids Therapeutic Vaccine VGX-3100 A vaccine directed against Human Papillomavirus Type 11 that causes majority of the genital warts and anogenital cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5227 https://github.com/vaccineontology/VO/issues/437 5227 Clinical trial HPV-11 Vaccine A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms. HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator. This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas. PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5162 https://github.com/vaccineontology/VO/issues/451 1489079 5162 Clinical trial Gene name: E7 Human Papillomavirus 16 E7 Peptide/Padre 965.10 Vaccine A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5233 https://github.com/vaccineontology/VO/issues/452 5233 Clinical trial Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine A vaccinia viral based vaccine, encoding epitopes of E6 and E7 proteins from human papillomavirus (HPV) types 16 and 18, with immunostimulatory and antineoplastic activities. HPV types 16 and 18 account for approximately 70% of cervical cancers. Vaccination with this HPV-TA (tumor antigen) vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for E6 and E7 from either type 16 or 18 HPV, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5279 https://github.com/vaccineontology/VO/issues/453 1489078 1489079 5279 Clinical trial Gene name: E6|Gene name: E7 Human Papillomavirus Tumor Antigen Vaccine A vaccine consisting of noninfectious, recombinant virus-like particles (VLP) containing the major viral capsid protein L1 of nine strains of human papillomavirus (HPV), with potential immunoprotective activity. Vaccination with HPV V503 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells positive for any of these nine strains of HPV, thereby preventing cervical infection upon exposure to certain HPV subtypes. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5167 https://github.com/vaccineontology/VO/issues/454 5167 Clinical trial Gene name: major capsid protein L1 Human Papillomavirus Vaccine V503 A peptide based vaccine consisting of amino acids 12 through 20 of the E7 gene of the Human Papilloma Virus type 16. HPV-16 E7 12-20 peptide vaccine may elicit a specific CD8 T-cell response to the E7 oncogene protein, thereby inhibiting the abrogation of p53 and pRb function and thus prevent tumorigenesis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5079 https://github.com/vaccineontology/VO/issues/430 1489079 5079 Clinical trial Gene name: E7 HPV 16 E7:12-20 Peptide Vaccine A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5083 https://github.com/vaccineontology/VO/issues/436 1489078 1489079 5083 Clinical trial Gene name: E6|Gene name: E7 HPV E6/E7 DNA Vaccine GX-188E A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5262 https://github.com/vaccineontology/VO/issues/455 2346 5262 Clinical trial Gene name: Prostate-specific membrane antigen Human Prostate-Specific Membrane Antigen Plasmid DNA Vaccine A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5105 https://github.com/vaccineontology/VO/issues/540 5105 Mouse Prostate-Specific Membrane Antigen Plasmid DNA Vaccine Early-to late-stage myeloid progenitor cells derived from adult human stem cells with potential hematopoietic activity. Upon infusion, human myeloid progenitor cells CLT-008 proliferate into mature myeloid cells, including granulocytes, macrophages, platelets, and erythrocytes. These myeloid progenitor cells die within forty-five days after a burst of hematopoiesis. This agent cannot create lymphoid cells, including T cells associated with graft-versus-host disease Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5511 https://github.com/vaccineontology/VO/issues/449 5511 Clinical trial Human Myeloid Progenitor Cells CLT-008 vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with corpses of apoptotic leukemic cells, with potential immunostimulatory and antineoplastic activities. Upon vaccination, autologous dendritic cells pulsed with leukemic apoptotic corpse may activate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against leukemic cells expressing leukemia-associated antigens, which may result in leukemic cell lysis and inhibition of tumor cell growth. Apoptotic tumor cell corpses contain an array of tumor associated antigens Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5004 https://github.com/vaccineontology/VO/issues/476 5004 Clinical trial Leukemic Apoptotic Corpse-Pulsed Autologous Dendritic Cells Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5200 https://github.com/vaccineontology/VO/issues/555 3077513 3077579 5200 Gene name: UL83|Gene name: UL123 Multi-peptide CMV-Modified Vaccinia Ankara Vaccine This is an autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine (NCIT_C1979). GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5453 https://github.com/vaccineontology/VO/issues/302 1437 5453 Clinical trial Gene name: GM-CSF GVAX Lung Cancer Vaccine A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5112 https://github.com/vaccineontology/VO/issues/419 3791 5112 Clinical trial Gene name: KDR HLA-A*2402-Restricted VEGFR1 Peptide Vaccine A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5294 https://github.com/vaccineontology/VO/issues/420 3791 5294 Clinical trial Gene name: KDR HLA-A2402-Restricted VEGFR1/2 Multipeptide Vaccine A cancer vaccine consisting of allogeneic neuroblastoma tumor cells have been genetically modified to secrete the human cytokine interleukin-2 (IL-2) and the human chemokine lymphotactin (Lptn) with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 and Lptn are secreted by the IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, potentially enhancing the cytotoxic T lymphocyte (CTL) response elicited by vaccine neuroblastoma tumor-associated antigens (TAAs) against host neuroblastoma tumor cells. Produced by activated progenitor T cells, Lptn belongs to the C chemokine subfamily and is a potent chemotactic factor for lymphocytes; IL-2 stimulates natural killer (NK) cells and may enhance a vaccine-elicited CTL immune response against tumor cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5173 https://github.com/vaccineontology/VO/issues/462 6375 5173 Clinical trial Gene name: XCL1 IL-2/Lptn Gene-Modified Allogeneic Neuroblastoma Tumor Cell Vaccine An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular administration with GSK1572932A may stimulate the immune system to exert both humoral and cellular immune responses against MAGE-A3-expressing tumor cells. MAGE-A3, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and bladder cancer. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5343 https://github.com/vaccineontology/VO/issues/463 4102 5343 Clinical trial Gene name: MAGEA3 Immunotherapeutic GSK1572932A GVAX cancer vaccines are autologous cell vaccines comprised of tumor cells which have been irradiated and genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5211 https://github.com/vaccineontology/VO/issues/301 1493 354 5211 Clinical trial Gene name: CTLA4|Gene name: KLK3 GVAX Cancer Vaccine A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5540 https://github.com/vaccineontology/VO/issues/470 2546420 5540 Clinical trial Gene name: WHcAg Interferon-gamma-expressing Adenovirus Vaccine ASN-002 A vaccine based on anti-idiotype (Id) monoclonal antibodies combined with interleukin-2 (IL-2). Anti-Id vaccines have been shown to be effective in treatment of B-cell lymphoma in animal models and in clinical trials, resulting in tumor regression; the addition of interleukin-2 (IL-2) may augment the therapeutic effect of anti-Id vaccines. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5352 https://github.com/vaccineontology/VO/issues/471 5176180 5352 Clinical trial Gene name: gp72 Interleukin-2 Anti-Idiotype Vaccine A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5519 https://github.com/vaccineontology/VO/issues/474 5519 Clinical trial KLH-Lymphoma Ig Vaccine Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/487 8132375 Clinical trial Gene name: Fragment C from tetanus toxin Lymphoma DNA vaccine V_V_V_-FrC A preparation of autologous peripheral blood mononuclear cells (PBMCs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PBMCs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PBMCs localized in lymphoma tissue. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5212 https://github.com/vaccineontology/VO/issues/467 1048 5212 Clinical trial Gene name: CEACAM5 Indium In 111-Labeled Autologous Peripheral Blood Mononuclear Cells Vaccine A preparation of autologous peripheral polymorphonuclear (PMNLs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PMNLs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PMNLs localized in lymphoma tissue. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5273 https://github.com/vaccineontology/VO/issues/468 5273 Clinical trial Indium In 111-Labeled Autologous Polymorphonuclear Leukocytes Vaccine Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to the same patient to target tumor cells expressing ESO-1. ESO-1 is a human self-antigen expressed by melanomas. The ESO-1 gene encodes several MHC class I- and MHC class II-restricted epitopes that may activate cytotoxic T-cell-mediated tumor destruction Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5178 https://pubmed.ncbi.nlm.nih.gov/?term=ESO-1+Reactive+Autologous+Peripheral+Blood+Lymphocyte https://github.com/vaccineontology/VO/issues/67 1485 5178 Clinical trial Gene name: NY-ESO-1 ESO-1 Reactive Autologous Peripheral Blood Lymphocyte vaccine A recombinant fowlpox virus-based vaccine vector designed to express various tumor-associated peptide antigens. Strong CD8 cytotoxic T cell responses may be induced after prolonged immunization with fowlpox virus vaccines and have been associated with tumor regression. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5042 https://github.com/vaccineontology/VO/issues/130 4582 1048 5042 Clinical trial Gene name: CEACAM5|Gene name: MUC1 Fowlpox Virus Vector Vaccine A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5249 https://github.com/vaccineontology/VO/issues/135 2315 5249 Clinical trial Gene name: MLANA Gag:267-274 Peptide Vaccine An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5410 https://github.com/vaccineontology/VO/issues/136 1493 5410 Clinical trial Gene name: CTLA4 GITRL RNA-transfected Autologous Dendritic Cell Vaccine Used C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) or both. Tumor was transplanted by the injection of wild-type B16 cells. Tumor growth and survival were measured to evaluate the efficacy of vaccination. Specific humoral response and immunoglobulin G (IgG) switch were evaluated measuring total IgG and IgG1 and IgG2a subtypes against tumor membrane proteins of B16 cells Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4061 https://github.com/vaccineontology/VO/issues/176 4061 Clinical trial GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccine A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5111 https://github.com/vaccineontology/VO/issues/177 5111 Clinical trial GM-CSF-encoding Oncolytic Adenovirus CGTG-102 vaccine Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/195 6490 Clinical trial Gene name: gp100 gp100 g209-2M Melanoma Vaccine A vaccine that injected peptides of gp100, MART-1, MAGE-3 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3993 https://github.com/vaccineontology/VO/issues/196 6490 3993 Clinical trial Gene name: gp100 gp100 + Mart-1 + Mart-3 vaccine A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100 adenovirus vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5133 https://github.com/vaccineontology/VO/issues/197 6490 5133 Clinical trial Gene name: gp100 gp100 Adenovirus Vaccine A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF). Vaccination with gp100 and GM-CSF DNA/gold vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive cells, resulting in decreased tumor growth. GM-CSF is thought to increase the induction and activation of antigen-presenting cells (APC), allowing for a reduction in the dose of gp100 administered. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5084 https://github.com/vaccineontology/VO/issues/198 6490 5084 Clinical trial Gene name: gp100 gp100 and GM-CSF DNA/Gold Vaccine A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a valine substitution at position 184. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5482 https://github.com/vaccineontology/VO/issues/199 6490 5482 Clinical trial Gene name: gp100 gp100 Protein (184V) vaccine A cancer vaccine consisting of a recombinant vaccinia virus encoding the gp100 melanoma-melanocyte antigen. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5153 https://github.com/vaccineontology/VO/issues/200 6490 5153 Clinical trial Gene name: gp100 gp100 Vaccinia Vaccine A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic activity. The expression of gp100 may generate a cellular immune response to melanoma cells; this effect is enhanced by the co-administration of interleukin 2 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5135 https://github.com/vaccineontology/VO/issues/201 6490 5135 Clinical trial Gene name: gp100 gp100-Fowlpox Vaccine Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a tumor associated antigen (TAA) commonly expressed by melanoma cells, may increase melanoma-reactive cytotoxic lymphocytes (CTL) in the PBL cell population. Autologous gp100-pulsed PBL have been administered to melanoma patients in order to augment cytotoxic immune responses to melanoma. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5007 https://github.com/vaccineontology/VO/issues/202 6490 5007 Clinical trial Gene name: gp100 gp100-Pulsed Peripheral Blood Mononuclear Cell vaccine Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the same patient to target tumor sites expressing gp100. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4990 https://github.com/vaccineontology/VO/issues/203 6490 4990 Clinical trial Gene name: gp100 gp100-Reactive Autologous Peripheral Blood Lymphocyte vaccine To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials (Hailemichael et al., 2013). Immunization Route: Intramuscular injection (i.m.) Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4078 https://github.com/vaccineontology/VO/issues/204 6490 4078 Clinical trial Gene name: gp100 gp100/IFA vaccine A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5095 https://github.com/vaccineontology/VO/issues/205 6490 5095 Clinical trial Gene name: gp100 gp100: ES209-217(210M) Peptide vaccine A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific T-cell immunity. gp100 antigen is a self-antigen expressed by melanocytes, pigmented retinal cells, and most melanoma lesions and is recognized via class I and II HLA-restricted mechanisms. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5145 https://github.com/vaccineontology/VO/issues/206 6490 5145 Clinical trial Gene name: gp100 gp100:154-162 Peptide Vaccine A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5050 https://github.com/vaccineontology/VO/issues/207 6490 5050 Clinical trial Gene name: gp100 gp100:209-217 Peptide vaccine A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100:280-288 peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5526 https://github.com/vaccineontology/VO/issues/208 6490 5526 Clinical trial Gene name: gp100 gp100:280-288 Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3989 https://github.com/vaccineontology/VO/issues/307 6490 3989 Clinical trial Gene name: gp100 Hexapeptide melanoma vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5185 https://github.com/vaccineontology/VO/issues/423 4100 4102 5185 Clinical trial Gene name: MAGEA3|Gene name: MAGEA1 HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5034 https://github.com/vaccineontology/VO/issues/425 2315 6490 5034 Clinical trial Gene name: gp100 |Gene name: MLANA HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5270 https://github.com/vaccineontology/VO/issues/448 7015 5270 Clinical trial Gene name: TERT hTERT/Survivin/Melanoma Tumor Cell-Derived mRNA-Transfected Dendritic Cell Vaccine A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5143 https://github.com/vaccineontology/VO/issues/484 3845 7157 5143 Clinical trial Gene name: TP53|Gene name: KRAS Long Peptide Vaccine 7 A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5021 https://github.com/vaccineontology/VO/issues/489 4102 5021 Gene name: MAGEA3 MAGE-3.A1 Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4003 https://github.com/vaccineontology/VO/issues/497 6490 4003 Gene name: gp100 MART-1 Vaccine A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that is expressed by certain types of melanoma. Vaccination with MART-1 adenovirus vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against MART-1 positive melanoma cells, resulting in an antitumor effect. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5398 https://github.com/vaccineontology/VO/issues/498 2315 5398 Gene name: MLANA-Dupli MART-1 Adenovirus Vaccine A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes and have been used to immunize patients with advanced melanomas; prolonged immunization may result in a reduction in tumor size. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5254 https://github.com/vaccineontology/VO/issues/502 2315 5254 Gene name: MLANA-Dupli MART-1 Fowlpox Vaccine A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic host immune responses to melanoma cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5204 https://github.com/vaccineontology/VO/issues/503 2315 5204 Gene name: MLANA-Dupli MART-1 Vaccinia Vaccine Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5028 https://github.com/vaccineontology/VO/issues/504 4100 6490 5028 Gene name: gp100|Gene name: MAGEA3 MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5141 https://github.com/vaccineontology/VO/issues/505 2315 6490 5141 Gene name: MLANA|Gene name: gp100 MART-1:26-35(27L) Peptide Vaccine A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5450 https://github.com/vaccineontology/VO/issues/506 2315 5450 Gene name: MLANA MART-1:27-35 Peptide Vaccine A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5142 https://github.com/vaccineontology/VO/issues/507 2315 5142 Gene name: MLANA Melan-A VLP Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5318 https://github.com/vaccineontology/VO/issues/508 2315 4102 5318 Gene name: MLANA|Gene name: MAGEA3 Melan-A/MAGE-3.DP4 Peptide Vaccine Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/517 7299 Gene name: Tyrosinase Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4989 https://github.com/vaccineontology/VO/issues/522 282617 4989 Gene name: IFNL3 Melanoma Theraccine A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5014 https://github.com/vaccineontology/VO/issues/523 5014 Melapuldencel-T Vaccine A multipeptide cancer vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5261 https://github.com/vaccineontology/VO/issues/524 22178 6490 5261 Gene name: gp100|Gene name: TRP-1 MELITAC 12.1 Peptide Vaccine A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5039 https://github.com/vaccineontology/VO/issues/535 2064 5039 Gene name: ERBB2 Monoclonal Antibody 4B5 Anti-Idiotype Vaccine A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5386 https://github.com/vaccineontology/VO/issues/539 20431 5386 Gene name: Pmel17 Mouse gp100 Plasmid DNA Vaccine Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/543 768 Gene name: CA9 mRNA-Electroporated Dendritic Cells Vaccine A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2; this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1). TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5310 https://github.com/vaccineontology/VO/issues/558 1638 5310 Gene name: DCT Murine TYRP2 Plasmid DNA Vaccine A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5276 https://github.com/vaccineontology/VO/issues/446 7015 5276 Clinical trial Gene name: TERT hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1 A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04) (NCIT_C28775). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5264 https://github.com/vaccineontology/VO/issues/66 1485 5264 Clinical trial Gene name: NY-ESO-1 ESO-1 (161-180) Peptide Vaccine A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5473 https://pubmed.ncbi.nlm.nih.gov/?term=ESO-1%3A157-165%28165V%29+Peptide https://github.com/vaccineontology/VO/issues/68 1485 5473 Clinical trial Gene name: NY-ESO-1 ESO-1:157-165(165V) Peptide vaccine A recombinant virus-based vaccine that contains various peptide antigens. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Strong CD8 T cell responses may be induced after prolonged immunization and have been associated with tumor regression. Jie Zheng Justin Song Oliver He Penny Pan PubMed:15757474 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5031 https://github.com/vaccineontology/VO/issues/129 354 634 5031 Clinical trial Gene name: CEACAM1|Gene name: KLK3 Fowlpox Virus Vaccine A peptide vaccine against the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), with potential immunomodulating and antineoplastic activities. Vaccination with indoleamine 2,3-dioxygenase peptide vaccine may activate the immune system to induce an immune response against IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and may eradicate IDO-expressing tumor cells. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression; Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5144 https://github.com/vaccineontology/VO/issues/469 3620 5144 Clinical trial Gene name: IDO1 Indoleamine 2,3-dioxygenase Peptide Vaccine A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity. Jie Zheng Justin Song Oliver He Penny Pan PubMed:22855837 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5317 https://github.com/vaccineontology/VO/issues/128 2348 5317 Clinical trial Gene name: FOLR1 Folate-FITC vaccine A cancer vaccine consisting of a recombinant vaccinia virus encoding the tumor-associated gene MAGE-1 that is contaminated with bovine viral diarrhea virus (BVDV). The MAGE-1 gene is a member of the melanoma antigen-encoding gene family which is expressed in various malignant tumors such as hepatocellular carcinoma and germ cell tumors in addition to melanoma. Vaccination with vaccinia virus expressing human MAGE-1 may generate antitumoral T-cell responses. BVDV is an RNA pestivirus that may contaminate vaccines due to its presence in the fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5157 https://github.com/vaccineontology/VO/issues/488 4100 5157 Gene name: MAGEA1 MAGE-1 Vaccinia Contaminated with BVDV A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5395 https://github.com/vaccineontology/VO/issues/491 4102 5395 Gene name: MAGEA3 MAGE-A3 Peptide Vaccine An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5336 https://github.com/vaccineontology/VO/issues/492 4102 5336 Gene name: MAGEA3 MAGE-A3-expressing Adenovirus Type 5 Vaccine A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. hTERT I540/R572Y/D988Y multipeptide vaccine contains strongly antigenic peptide epitopes I540 (9-mer), R572Y (9-mer) and D988Y (10-mer). Vaccination with this agent may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells. Directly linked to tumorigenesis, telomerase is expressed in the majority of human cancer cells but is infrequently expressed in normal cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5191 https://github.com/vaccineontology/VO/issues/439 7015 5191 Clinical trial Gene name: TERT hTERT I540/R572Y/D988Y Multipeptide Vaccine A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5344 https://github.com/vaccineontology/VO/issues/460 5344 Clinical trial Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020 A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5460 https://github.com/vaccineontology/VO/issues/565 354 55 5460 Gene name: KLK3|Gene name: ACP3 MVA-PSA/PAP Prostate Cancer Vaccine A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT_C91076). Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5314 https://github.com/vaccineontology/VO/issues/560 3783709 5698 5314 Clinical trial Gene name: EBNA-1|Gene name: PSMB9 MVA-EBNA1/LMP2 Vaccine A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5466 https://github.com/vaccineontology/VO/issues/482 5689 5466 Clinical trial Gene name: PSMB9 LMP-2:340-349 Peptide Vaccine A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5479 https://github.com/vaccineontology/VO/issues/483 5689 5479 Clinical trial Gene name: PSMB9 LMP-2:419-427 Peptide Vaccine A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5263 https://github.com/vaccineontology/VO/issues/490 4100 4102 5263 Gene name: MAGEA3|Gene name: MAGEA1 MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine A trivalent cancer vaccine containing the ganglioside lactones GM2, GD2 and GD3 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with GM2 lactone/GD2 lactone/GD3 lactone-KLH conjugate trivalent vaccine may elicit antibodies against tumor cells expressing any of these epitopes, resulting in an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these gangliosides. GM2, GD2 and GD3 are tumor associated antigens (TAAs) that are overexpressed in a variety of tumor cell membranes. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5532 https://github.com/vaccineontology/VO/issues/178 117189 2760 5532 Clinical trial Gene name: GM2A|Gene name: GRDX GM2/GD2/GD3 Lactone-KLH Conjugate Trivalent Vaccine A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from ring finger protein 43 (RNF43); translocase of outer mitochondrial membrane 34 (TOMM34); and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing RNF43, TOMM34, and VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5429 https://github.com/vaccineontology/VO/issues/421 10953 3791 5429 Clinical trial Gene name: KDR|Gene name: TOMM34 HLA-A*2404-Restricted RNF43-TOMM34-VEGFR1-VEGFR2 Multipeptide Vaccine A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5120 https://github.com/vaccineontology/VO/issues/422 5120 Clinical trial Gene name: Survivin HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine A dendritic cell (DC) vaccine containing ex vivo expanded autologous DCs obtained from a patient with leukemia with potential immunostimulating activity. Upon reintroduction into the host, the host dendritic cell vaccine-001 MSSM/BIIR may stimulate the immune system to mount a leukemia-specific cytotoxic T lymphocyte (CTL) response. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5246 https://github.com/vaccineontology/VO/issues/428 1489078 5246 Clinical trial Gene name: E6 Host Dendritic Cell Vaccine-001 MSSM/BIIR A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5048 https://github.com/vaccineontology/VO/issues/464 10983 983 5048 Clinical trial Gene name: CDK1|Gene name: CCNI IMT-1012 Immunotherapeutic Vaccine A cancer vaccine containing four HLA-A0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5355 https://github.com/vaccineontology/VO/issues/309 2064 6490 5355 Clinical trial Gene name: PMEL|Gene name: ERBB2 HLA-A0201-Restricted TRP2-gp100-EphA2-HER2 multipeptide Vaccine A cancer vaccine containing three HLA-A0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5017 https://github.com/vaccineontology/VO/issues/417 3791 54742 5017 Clinical trial Gene name: KDR|Gene name: LY6K HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4991 https://github.com/vaccineontology/VO/issues/480 1485 1956 4991 Clinical trial Gene name: EGFR|Gene name: CTAG1B Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623 A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5104 https://github.com/vaccineontology/VO/issues/173 4582 2760 5104 Clinical trial Gene name: GM2A|Gene name: MUC1 Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH Conjugate Vaccine Peripheral blood lymphocytes (PBL) transfected to express MOv have been designed for possible use in autologous adoptive cellular immunotherapy of ovarian adenocarcinomas that overexpress folate-binding protein. MOv-PBLs express MOv-gamma (MOv), a chimeric receptor gene product derived from a recombinant gene encoding the variable region of murine monoclonal antibody MOv18 against folate-binding protein (FBP), often overexpressed in human ovarian cancer cells, and the human gene encoding the IgG and IgE Fc receptor gamma subunit. Autologous vaccination with these PBLs stimulates a host cytotoxic T lymphocyte response against ovarian cancer cells that overexpress FBP. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5335 https://github.com/vaccineontology/VO/issues/541 4343 5335 Gene name: MOV10 MOv-PBL Vaccine An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5385 https://github.com/vaccineontology/VO/issues/477 5385 Clinical trial Gene name: Tumor Associated Antigen Light-Emitting Oncolytic Vaccinia Virus GL-ONC1 Vaccine A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5413 https://github.com/vaccineontology/VO/issues/418 3791 5413 Clinical trial Gene name: KDR HLA-A*0201-Restricted VEGFR1 Peptide Vaccine A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA) and TRICOM, a combination of three immunostimulants (i.e., B7.1, ICAM-1, and LFA-3). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5038 https://github.com/vaccineontology/VO/issues/132 354 5038 Clinical trial Gene name: KLK3 Fowlpox-PSA-TRICOM Vaccine A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5369 https://github.com/vaccineontology/VO/issues/542 26872 5369 Gene name: STEAP1 mRNA-Derived Prostate Cancer Vaccine CV9103 Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5126 https://github.com/vaccineontology/VO/issues/546 4583 5126 Gene name: MUC2 MUC-2-Globo H-KLH Conjugate Vaccine A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF. Jie Zheng Justin Song Oliver He Penny Pan https://github.com/vaccineontology/VO/issues/194 7124 Clinical trial Gene name: TNF Golnerminogene Pradenovec Vaccine A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5465 https://github.com/vaccineontology/VO/issues/424 2250 5465 Clinical trial Gene name: FGF5 HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine A naturally occurring 9-residue peptide of fibroblast growth factor 5 (FGF-5). Recognized by tumor infiltrating cytotoxic T lymphocytes originally isolated from a renal cell carcinoma that overexpressed FGF-5, FGF-5:172-176/217-220 peptide activates various cytotoxic CD8 lymphocytes in an HLA-restricted manner. Overexpressed in several cancer cell lines, FGF-5 is a tumor-associated antigen that may be useful in cancer immunotherapy. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5498 https://github.com/vaccineontology/VO/issues/134 4108 5498 Clinical trial Gene name: MAGEA9 G250 Peptide Vaccine A synthetic peptide derived from the protein ESW/FLI1 type 1 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-1 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 1 fusion protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5509 https://github.com/vaccineontology/VO/issues/52 253970502 100306940 5509 Clinical trial Gene name: FL1|Gene name: EWSR1 EF-1 Peptide Vaccine A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5488 https://github.com/vaccineontology/VO/issues/479 4582 5488 Clinical trial Gene name: MUC1 Liposomal MUC1/PET-lipid A Vaccine Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5345 https://github.com/vaccineontology/VO/issues/493 4102 5345 Gene name: MAGEA3 MAGE-A3/HPV 16 Peptide Vaccine A peptide derived from the tumor suppressor protein Von Hippel-Lindau (VHL). This peptide, sequence: MEAGRPRPCCAR, was constructed based on a frameshift mutation of one of the VHL gene products; the more abundant protein VHLp18(MEA) (where MEA stands for three amino acids, Met-Glu-Ala). Vaccination with FrSh61(MEA)VHL33 peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5236 https://github.com/vaccineontology/VO/issues/133 7428 5236 Clinical trial Gene name: VHL FrSh61 (MEA) VHL33 Peptide Vaccine A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types. Jie Zheng Justin Song Oliver He Penny Pan VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5442 https://github.com/vaccineontology/VO/issues/305 2064 5442 Clinical trial Gene name: ERBB2 HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5303 5303 Clinical trial Ad5-yCD/mutTKSR39rep-hIL12 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5324 5324 Clinical trial Ad5F35-LMP1/LMP2-Transduced Autologous Dendritic Cell vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5534 5534 Clinical trial Alpha Fetoprotein Plasmid DNA Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4995 4995 Clinical trial ALVAC-CEA (6D)-B7.1 Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5085 5085 Clinical trial Autologous Dendritic Cell Vaccine ACT2001 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5056 5056 Clinical trial Autologous Dendritic Cell-Tumor Fusion Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4051 4051 Clinical trial autologous dendritic cells (DCs) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5057 5057 Clinical trial Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3981 3981 Research autologous monocyte-derived mature DCs pulsed with p53, survivin and telomerase-derived peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4029 4029 Research Bacille Calmette Guerin for melanoma of lower extremity vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4028 4028 Licensed Bacillus Calmette-Guerin (BCG) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4036 4036 Research Bacillus Calmette-Guerin (BCG), C. parvum vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4035 4035 Research Bacillus Calmette-Guerin (BCG), dinitrochlorobenzene (DNCB) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4034 4034 Research bacillus Calmette-Guerin (MER) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4021 4021 Research BCG and chemotherapy for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4022 4022 Clinical trial BCG and Corynebacterium parvum for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4033 4033 Clinical trial BCG treatment after surgical tumor removal vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5399 5399 Clinical trial Bcl-Xs Adenovirus Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4017 4017 Research Biolistic DNA vaccination Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3984 3984 Research Canvaxin Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5476 5476 Clinical trial CD80 Breast Cancer Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4072 4072 Research class I HLA-A0201-restricted gp100209-2M peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5456 5456 Clinical trial Contusugene ladenovec vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3990 3990 Research CpG 7909/PF3512676 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4170 4170 Licensed CVB4/p24(73(3)) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5494 5494 Clinical trial Dendritic Cell-Idiotype-Keyhole Limpet Hemocyanin Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5346 5346 Clinical trial DEPDC1/MPHOSH1 Peptide Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5116 5116 Clinical trial DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4060 4060 Clinical trial DNA Vaccine encoding p42.3 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3998 3998 Research DNP-modified autologous vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4076 4076 Research electroloading of mature dendritic cells with melanoma whole tumor cell lysate vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4067 4067 Research ESAT-6-gpi DNA vaccine combined with B16F10-ESAT-6-gpi/IL-21 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4081 4081 Research Flagrp170 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4018 4018 Licensed FVAX vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4047 4047 Research GM-CSF transfected cells vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4008 4008 Research gp100 Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3974 3974 Clinical trial gp100:209-217(210M) peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5438 5438 Clinical trial gp100:280-288(288V) Peptide Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5062 5062 Clinical trial GVAX Pancreatic Cancer Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4010 4010 Research hapten dinitrophenyl vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3992 3992 Research HCA587 protein vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4053 4053 Clinical trial hMART-IT vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3986 3986 Research HSP65-HER2 fusion peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4058 4058 Research Hsp70 chaperone-based gel composition vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3982 3982 Research HSPPC-96 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3980 3980 Research human leukocyte antigen class I-modified peptide vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4077 4077 Research HUVECs-OK432 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3976 3976 Clinical trial IDD-3 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4009 4009 Research IFN/tremem vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4062 4062 Clinical trial IL-12p70 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3977 3977 Research IMM-101 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4069 4069 Clinical trial Incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4037 4037 Research intralesional bacile Calmette-Guerin (BCG) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4038 4038 Research intralesional bacile Calmette-Guerin (BCG), DTIC, vincristine vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3975 3975 Research Ipilimumab vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4045 4045 Research ipilimumab, vemurafenib vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4012 4012 Research irradiated autologous cell vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4050 4050 Clinical trial irradiated melanoma cells plus BCG vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5472 5472 Clinical trial KSA-KLH Conjugate Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4000 4000 Licensed L612 HuMAb vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3968 3968 Research Large Multivalent Immunogen (LMI) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4048 4048 Research long-peptide vaccine and mAb Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4066 4066 Research mAb PC61 and DC/tumor fusion vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4005 4005 Research MAGE-A12:170-178 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4059 4059 Clinical trial MAGE-A3 + AS15 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4039 4039 Clinical trial MAGE-A3-genetically modified lymphocyte vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4065 4065 Research MCMV-TRP2 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4046 4046 Research mCRT-vGPCR-coated whole-cell vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3996 3996 Research Melacine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3985 3985 Research Melan-A/Mart-1 vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3979 3979 Research Melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5412 5412 Clinical trial Modified Vaccinia Virus Ankara Vaccine Expressing p53 Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4068 4068 Licensed mouse/human gp10025-33 peptide plus CpG adjuvant; mouse/human gp100; mouse/human gp10025-33 peptide-pulsed DCs vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5224 5224 Clinical trial Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4063 4063 Clinical trial Multipeptide melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4030 4030 Research Oral Bacille Calmette-Guerin for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=3983 3983 Research OVA-TEXO vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4032 4032 Clinical trial procarbazine, dactinomycin, velba vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4031 4031 Research Pulmonary BCG immunotherapy for malignant melanoma vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=6075 6075 Research RIPO(H3.3) vaccine Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=4011 4011 Research alpha-GalCer-loaded tumor-cell vaccine A Cp12 protein that is part of Crptosporidium parvum Anthony Huffman Crptosporidium parvum Cp12 A Cp21 protein that is part of Crptosporidium parvum Anthony Huffman Crptosporidium parvum Cp21 A Cp15 protein that is part of Crptosporidium parvum Anthony Huffman Crptosporidium parvum Cp15 A CP60 protein that is part of Crptosporidium parvum Anthony Huffman Crptosporidium parvum CP60 A Cp23 protein that is part of Crptosporidium parvum Anthony Huffman Crptosporidium parvum Cp23 A CpP2 protein that is part of Crptosporidium parvum Anthony Huffman Crptosporidium parvum CpP2 A 3-1E protein that is part of Eimeria acervulina Anthony Huffman Eimeria acervulina 3-1E A gam56 protein that is part of Eimeria maxima Anthony Huffman Eimeria maxima gam56 A a1-giardin protein that is part of Giardia duodenalis Anthony Huffman Giardia duodenalis a1-giardin NCBI Gene ID 5697168 A a1-giardin protein that is part of Giardia lamblia Anthony Huffman Giardia lamblia a1-giardin NCBI Gene ID 5697168 A alpha-enolase protein that is part of Giardia lamblia Anthony Huffman Giardia lamblia alpha-enolase NCBI Gene ID 2023 A CWP2 protein that is part of Giardia lamblia Anthony Huffman Giardia lamblia CWP2 NCBI Gene ID 5703171 A Acen1 protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani Acen1 A Beta-tubulin protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani Beta-tubulin NCBI Gene ID 13392307 A FML protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani FML A Gp63 protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani Gp63 NCBI Gene ID 13389283 A HASPB1 protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani HASPB1 A KH protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani KH A LdyGCS protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani LdyGCS A NH36 protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani NH36 A P1 protein that is part of Leishmania donovani Anthony Huffman Leishmania donovani P1 NCBI Gene ID 13388831 A A2 protein that is part of Leishmania infantum Anthony Huffman Leishmania infantum A2 NCBI Gene ID 13387764 A HSP70 II protein that is part of Leishmania infantum Anthony Huffman Leishmania infantum HSP70 II NCBI Gene ID 5073319 A KMP-11 protein that is part of Leishmania major Anthony Huffman Leishmania major KMP-11 NCBI Gene ID 13387683 A LmSTI1 protein that is part of Leishmania major Anthony Huffman Leishmania major LmSTI1 A LIPO-A protein that is part of Leishmania major Anthony Huffman Leishmania major LIPO-A A P36 protein that is part of Leishmania major Anthony Huffman Leishmania major P36 A PEPCK protein that is part of Leishmania major Anthony Huffman Leishmania major PEPCK NCBI Gene ID 5649768 A LeIF protein that is part of Leishmania major Anthony Huffman Leishmania major LeIF NCBI Gene ID 12981542 A MIC3 protein that is part of Neospora caninum Anthony Huffman Neospora caninum MIC3 A GRA2 protein that is part of Neospora caninum Anthony Huffman Neospora caninum GRA2 A GRA6 protein that is part of Neospora caninum Anthony Huffman Neospora caninum GRA6 A SRS2 protein that is part of Neospora caninum Anthony Huffman Neospora caninum SRS2 A MIC10 protein that is part of Neospora caninum Anthony Huffman Neospora caninum MIC10 A p24 protein that is part of Neospora caninum Anthony Huffman Neospora caninum p24 A PDI protein that is part of Neospora caninum Anthony Huffman Neospora caninum PDI A SAG1 protein that is part of Neospora caninum Anthony Huffman Neospora caninum SAG1 A P36p protein that is part of Plasmodium berghei Anthony Huffman Plasmodium berghei P36p A ABRA protein that is part of Plasmodium falciparum An ABRA protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum ABRA A EBA-175 RII protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum EBA-175 RII A Hsp90 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Hsp90 A MSP1 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum MSP1 A RESA protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum RESA A MSP2 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum MSP2 A MSP4 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum MSP4 A Pf ribosomal protein P0 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Pf ribosomal protein P0 A PfCelTOS protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum PfCelTOS A PfSSP2 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum PfSSP2 A LSA1 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum LSA1 A Pfen protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Pfen A Pfs230 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Pfs230 A Pfs25 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Pfs25 A Pfs48 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Pfs48 A RH5 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum RH5 A TRAP protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum TRAP A Pfs45 protein that is part of Plasmodium falciparum Anthony Huffman Plasmodium falciparum Pfs45 A PkCSP protein that is part of Plasmodium knowlesi Anthony Huffman Plasmodium knowlesi CSP Plasmodium knowlesi PkCSP A PkSSP2 protein that is part of Plasmodium knowlesi A SSP2 protein that is part of Plasmodium knowlesi Anthony Huffman Plasmodium vivax Thrombospondin-related apical merozoite protein Plasmodium knowlesi PkSSP2 Plasmodium knowlesi SSP2 A PkAMA1 protein that is part of Plasmodium knowlesi Anthony Huffman Plasmodium knowlesi AMA1 Plasmodium knowlesi PkAMA1 A PkMSP1 protein that is part of Plasmodium knowlesi A PkMSP1p42 protein that is part of Plasmodium knowlesi Anthony Huffman Plasmodium knowlesi MSP1 Plasmodium knowlesi PkMSP1p42 A CelTOS protein that is part of Plasmodium vivax A PvCelTOS protein that is part of Plasmodium vivax Anthony Huffman Plasmodium vivax CelTOS Plasmodium vivax PvCelTOS A CS protein that is part of Plasmodium vivax A PvCS protein that is part of Plasmodium vivax Anthony Huffman Plasmodium vivax CS Plasmodium vivax PvCS A DBPII protein that is part of Plasmodium vivax A PvDBPII protein that is part of Plasmodium vivax Anthony Huffman Plasmodium vivax PvDBPII A TRAP protein that is part of Plasmodium vivax Anthony Huffman Plasmodium vivax TRAP A HEP17 protein that is part of Plasmodium yoelii Anthony Huffman Plasmodium yoelii HEP17 A HSP60 protein that is part of Plasmodium yoelii Anthony Huffman PMC98419 citation for occurance in all lifestages Plasmodium yoelii HSP60 A SSP2 protein that is part of Plasmodium yoelii Anthony Huffman Plasmodium yoelii SSP2 A ASP-1 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi ASP-1 A CRP protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi CRP NCBI Gene ID 947867 A G1 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi G1 A PAR3 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi PAR3 NCBI Gene ID 3540497 A PFR Ag protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi PFR Ag A rTcENO from H8 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi rTcENO from H8 A Tc24 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi Tc24 A Tc80 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi Tc80 A TcENO protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TcENO A TcSSP4 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TcSSP4 A TcTASV-C protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TcTASV-C A TCTS-154 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TCTS-154 A Trans-salidase protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi Trans-salidase NCBI Gene ID 3537653 A TSA-1 protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TSA-1 NCBI Gene ID 3544076 A TsF protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TsF NCBI Gene ID 3537653 A TSSA protein that is part of Trypanosoma cruzi Anthony Huffman Trypanosoma cruzi TSSA A CDPK1 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii CDPK1 A CDPK6 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii CDPK6 A ROP18 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ROP18 A CST2 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii CST2 A CyP protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii CyP A GRA1 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA1 A GRA16 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA16 A GRA17 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA17 A GRA24 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA24 A GRA23 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA23 A GRA25 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA25 A GRA41 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA41 A GRA6 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA6 A GRA7 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA7 A GRA8 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii GRA8 A hsp70 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii hsp70 A ISP3 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ISP3 A MIC1 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii MIC1 A MIC11 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii MIC11 A MIC13 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii MIC13 A MIC4 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii MIC4 A MIC6 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii MIC6 A MIC8 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii MIC8 A PGAM2 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii PGAM2 A RACK1 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii RACK1 A ROP16 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ROP16 A ROP17 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ROP17 A PLP1 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii PLP1 A ROP38 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ROP38 A ROP8 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ROP8 A ROP2 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii ROP2 A SAG2 protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii SAG2 A SAG5B protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii SAG5B A SAG5C protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii SAG5C A TgADF protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii TgADF A TgNTPase-II protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii TgNTPase-II A TgPF protein that is part of Toxoplasma gondii Anthony Huffman Toxoplasma gondii TgPF YH country USA is a country that exists in north America. YH USA A viral vaccine that protects against infection with Rubella virus. YH Rubella virus vaccine MeSH: D012411 A vaccine regulation for vaccine safety. YH vaccine saftey regulation A vaccine regulatory process that is for vaccine regulatory agent to review vaccine license application from vaccine producer. YH review of vaccine license application YH, ZX todo: Proteins + Conjugate Trade Name: Actacel Actacel YH, ZX todo: Killed virus Trade Name: Avaxim Avaxim YH, ZX todo: Killed virus Trade Name: Avaxim - Pediatric Avaxim - Pediatric YH, ZX todo: Live bacteria Trade Name: BCG Vaccine (Freeze-Dried) BCG Vaccine (Freeze-Dried) (by Sanofi Pasteur) YH, ZX todo: Proteins + killed virus Trade Name: DT Polio Adsorbed DT Polio Adsorbed YH, ZX todo: Proteins + killed bacteria Trade Name: Dukoral Dukoral Kallan Roan, Oliver He https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm110102.htm ENGERIX-B Hepatitis B Vaccine (Recombinant) GlaxoSmithKline Biologicals ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf 103239 Engerix-B CVX: 08 CVX: 44 A Measles-Rubella vaccine that is live attenuated and manufactured by GlaxoSmithKline Biologicals. YH, ZX Trade Name: Eolarix Eolarix YH, ZX todo: Killed virus Trade Name: Epaxal Epaxal todo: assign parent immunogen: TBE YH, ZX todo: Inactivated whole virus Trade Name: FSME - IMMUN FSME - IMMUN Kallan Roan, Oliver He, ZX http://purl.bioontology.org/ontology/RXNORM/683648 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179527.htm HIBERIX Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) GlaxoSmithKline Biologicals For active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b. HIBERIX is approved for use in children 6 weeks through 4 years of age (prior to fifth birthday). https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM179530.pdf 683648 Hiberix CVX: 48 YH, ZX todo: Killed virus Trade Name: Imovax Polio Imovax Polio YH, ZX Trade Name: Imovax Rabies Imovax Rabies (Canada) A poliovirus vaccine that uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine. Oliver He, Allen Xiang, Hector Guzman-Orozco todo: Killed virus Trade Name: Inactived Poliomyelitis Vaccine - IPV Inactivated Poliomyelitis Vaccine - IPV A combination vaccine that protects infants from diphtheria, tetanus, pertussis (whooping cough), polio, hepatitis B and Haemophilus influenzae type b (Hib). YH, ZX http://www.immune.org.nz/vaccines/available-vaccines/infanrix-hexa todo: Proteins + killed viruses + conjugate Trade Name: Infanrix-hexa Infanrix-hexa YH, ZX todo: Proteins + conjugate Trade Name: Infanrix/Hib Infanrix/Hib YH, ZX todo: Proteins + killed virus Trade Name: Infanrix-IPV Infanrix-IPV YH, ZX todo: Proteins + killed virus + conjugate Trade Name: Infanrix -IPV/Hib Infanrix -IPV/Hib CVX: 120 YH, ZX Trade Name: Liquid Pedvax HIB Liquid Pedvax HIB YH, ZX todo: Conjugate Trade Name: Meningitec Meningitec YH, ZX todo: Polysaccharide Trade Name: Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C YH, ZX todo: Conjugate Trade Name: Menjugate Menjugate YH, ZX todo: Polysaccharide Trade Name: Menomune A/C/Y/W-135 Menomune A/C/Y/W-135 A live attenuated V. cholerae vaccine that is manufactured by Berna Biotech, Ltd. This vaccine uses the V. Cholera strain CVD 103-HGR. YH, ZX todo: Live bacteria Trade Name: Mutacol Mutacol YH, ZX todo: Conjugate Trade Name: Neisvac-C Neisvac-C YH, ZX todo: Proteins, killed virus + conjugate Trade Name: Pediacel Pediacel A polyvalent pneumococcal vaccine used to protectsagainst serious infection (e.g., meningitis, bacteria in the blood) due to Streptococcus pneumoniae, and it is manufactured by Sanofi Pasteur. YH, ZX PNEUMO (PNU-IMUNE) Pnu-Imune Pnu-Imune 23 https://www.webmd.com/drugs/2/drug-5547/pnu-imune-injection/details Generic Name: pneumococcal vaccine polyvalent (Intramuscular route, Subcutaneous route) Trade Name: Pneumo 23 Pneumo 23 YH, ZX Trade Name: Pneumovax 23 obsolete Pneumovax 23 (Canada) true YH, ZX https://www.prevnar13.com/ todo: Conjugate Trade Name: Prevnar obsolete Prevnar (Canada) true A MMR vaccine that is manufactured by GlaxoSmithKline Biologicals. YH, ZX Trade Name: Priorix Priorix A Measles-Mumps-Rubella-Vericella vaccine that is live attenuated and manufactured by GlaxoSmithKline Biologicals. YH, ZX Trade Name: Priorix-Tetra Priorix-Tetra YH, ZX http://purl.bioontology.org/ontology/RXNORM/1607804 todo: Proteins + killed virus 1607804 Trade Name: Quadracel Quadracel Kallan Roan, Oliver He https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110098.htm todo: Recombinant protein RECOMBIVAX HB Hepatitis B Vaccine (Recombinant) Merck & Co, Inc RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of hepatitis B virus. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110114.pdf BL 101066 Recombivax HB CVX: 08 CVX: 43 CVX: 44 todo: assign parent immunogen: ROT Kallan Roan, Oliver He, ZX ROTARIX https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133920.htm todo: Live virus Rotarix Rotavirus Vaccine, Live, Oral GlaxoSmithKline Biologicals For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9), for use in infants 6 weeks to 24 weeks of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM133539.pdf BL 125265 Rotarix YH, ZX todo: Proteins Trade Name: Td Adsorbed Td Adsorbed YH, ZX todo: Proteins Trade Name: Tripacel Tripacel YH, ZX todo: Recombinant protein + killed virus Trade Name: Twinrix Junior Twinrix Junior YH, ZX todo: Polysaccharide Trade Name: Typherix Typherix Kallan Roan, Oliver He, ZX VAQTA https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110017.htm todo: Killed virus VAQTA Hepatitis A Vaccine, Inactivated Merck & Co, Inc For active immunization against disease caused by hepatitis A virus in persons 12 months of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110049.pdf BL 103606 Trade Name: Vaqta Vaqta YH, ZX todo: Live virus Trade Name: Varilrix Varilrix YH, ZX todo: Live virus Trade Name: Varivax III Varivax III todo: assign parent immunogen: Typh-I + (HA) YH, ZX todo: Polysaccharide + killed virus Trade Name: ViVaxim ViVaxim YH, ZX todo: Live virus Trade Name: Vivotif Vivotif (Canada) a protein from a bacterium YH, ZX bacterium protein YH, ZX G+ bacterium protein YH, ZX G- bacterium protein a protein from a virus YH, ZX virus protein a protein from a parasite YH, ZX parasite protein a protein from fungus YH, ZX fungus protein YH, ZX Bacillus anthracis protein YH, ZX Brucella protein YH, ZX Yersinia pestis protein YH, ZX Francisella tularensis protein YH, ZX Ebola virus protein YH, ZX Clostridium botulinum protein YH, ZX Lassa Fever Virus protein YH, ZX Variola virus protein YH, ZX Campylobacter jejuni protein YH, ZX Escherichia coli protein YH, ZX Human Immunodeficiency Virus protein YH, ZX Hantavirus protein YH, ZX Marburg Virus protein YH, ZX Mycobacterium tuberculosis protein YH, ZX Plasmodium spp. protein YH, ZX Haemophilus influenzae protein YH, ZX Coxiella burnetii protein YH, ZX VEE Virus protein YH, ZX Clostridium tetani protein YH, ZX Salmonella spp. protein YH, ZX Shigella protein YH, ZX Neisseria meningitidis protein YH, ZX Streptococcus pneumoniae protein YH, ZX Hepatitis A virus protein YH, ZX Hepatitis B virus protein YH, ZX Influenza virus protein YH, ZX Japanese encephalitis virus protein YH, ZX Measles virus protein YH, ZX Mumps virus protein YH, ZX Human papillomavirus protein YH, ZX Poliovirus protein YH, ZX Rabies virus protein YH, ZX Rotavirus protein YH, ZX Rubella virus protein YH, ZX Yellow fever virus protein YH, ZX Varicella-zoster virus protein YH, ZX Tick-borne Encephalitis Virus (TBEV) protein YH, ZX Chlamydophila pneumoniae protein YH, ZX Chlamydia muridarum protein YH, ZX Yersinia pseudotuberculosis protein YH, ZX Bovine Leukemia virus protein YH, ZX Corynebacterium diphtheriae protein YH, ZX Porcine circovirus 2 protein YH, ZX Pseudorabies virus protein YH, ZX Classical swine fever virus protein YH, ZX Bovine herpesvirus 1 protein YH, ZX West Nile virus protein YH, ZX Marek's disease virus protein YH, ZX Newcastle disease virus protein YH, ZX Feline leukemia virus protein YH, ZX Canine parvovirus protein YH, ZX Canine coronavirus protein YH, ZX Canine distemper virus protein YH, ZX Infectious Hematopoietic Necrosis Virus protein YH, ZX Lawsonia intracellularis protein YH, ZX Porphyromonas gulae protein YH, ZX Yersinia ruckeri protein YH, ZX Aeromonas salmonicida protein YH, ZX Vibrio anguillarum (Listonella anguillarum) protein YH, ZX Streptococcus equi protein YH, ZX Chlamydophila abortus protein YH, ZX Mycoplasma synoviae protein YH, ZX Mycoplasma gallisepticum protein YH, ZX Bordetella avium protein YH, ZX Actinobacillus pleuropneumoniae protein YH, ZX Eimeria spp. protein YH, ZX Eimeria tenella protein YH, ZX Theileria parva protein YH, ZX Theileria annulata protein YH, ZX Toxoplasma gondii protein YH, ZX Babesia bovis protein YH, ZX Neospora caninum protein YH, ZX Giardia duodenalis protein YH, ZX Sarcocystis neurona protein YH, ZX Babesia canis protein YH, ZX Leishmania donovani protein YH, ZX Eimeria maxima protein YH, ZX Herpes simplex virus type 1 and 2 protein YH, ZX Leishmania major protein YH, ZX Leishmania infantum protein YH, ZX Leishmania amazonensis protein YH, ZX Trypanosoma cruzi protein YH, ZX Chlamydophila psittaci protein YH, ZX Burkholderia pseudomallei protein YH, ZX Western equine encephalomyelitis virus protein YH, ZX Cryptosporidium parvum protein YH, ZX Hendra virus protein YH, ZX Dengue Virus protein YH, ZX Nipah virus protein YH, ZX Rickettsia spp protein YH, ZX Bordetella pertussis protein YH, ZX Vibrio cholerae protein YH, ZX Rift Valley Fever virus protein YH, ZX SARS-CoV protein YH, ZX Yersinia enterocolitica protein YH, ZX Entamoeba histolytica protein YH, ZX Coccidioides spp. protein YH, ZX Trypanosoma brucei protein YH, ZX Helicobacter pylori protein YH, ZX IMMUNOGENICITY: Induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-alpha but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. Has been used for vaccine development [PubMed: 10816475][PubMed: 11953393][PubMed: 12933826]. MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages [PubMed: 15845493]. SodC from B. abortus strain 2308 VIOLILN Protegen ID: 3; NCBI Protein GI: 83269434; NCBI Protein Accession: YP_418725.1; NCBITaxon: 234 YH, ZX Lef from B. anthracis str. A2012 Protegen ID: 5; NCBI Gene GI: 1158731; NCBI Protein GI: 40646957; NCBI Protein Accession: AAR88323.1; NCBITaxon: 32630 YH, ZX EBOV GP Protegen ID: 10; NCBI Gene GI: 955190 YH, ZX EBOV NP Protegen ID: 11; NCBI Gene GI: 955194; NCBI Protein GI: 22789223; NCBI Protein Accession: NP_690580; NCBITaxon: 186539 YH, ZX VP24 from Reston ebolavirus Protegen ID: 12; NCBI Gene GI: 955193; NCBI Protein GI: 22789228; NCBI Protein Accession: NP_690586; NCBITaxon: 186539 YH, ZX VP40 from Reston ebolavirus Protegen ID: 13; NCBI Gene GI: 955192; NCBI Protein GI: 22789225; NCBI Protein Accession: NP_690582; NCBITaxon: 186539 YH, ZX VP30 from Reston ebolavirus Protegen ID: 14; NCBI Gene GI: 955196; NCBI Protein GI: 22789227; NCBI Protein Accession: NP_690585; NCBITaxon: 186539 YH, ZX VP35 from Reston ebolavirus Protegen ID: 15; NCBI Gene GI: 955189; NCBI Protein GI: 22789224; NCBI Protein Accession: NP_690581; NCBITaxon: 186539 YH, ZX VP35 expressed from alphavirus replicons induced a protective immune response in C57BL/6 mice when challenged with Ebola virus Zaire [PubMed: 11485406]. VP35 from Zaire ebolavirus Protegen ID: 16; NCBI Gene GI: 911827; NCBI Protein GI: 10313992; NCBI Protein Accession: NP_066244; NCBITaxon: 186538 YH, ZX Recombinant Tbp1 and Tbp2 proteins were expressed from Escherichia coli and antisera were raised to the purified proteins. In a passive model of bacteraemia, infant rats were protected from challenge with Hib after transfer of anti-rTbp2 antiserum, but not after anti-rTbp1 antiserum [PubMed: 8830248]. Tbp2 Protegen ID: 277; NCBI Gene GI: 3430457; NCBI Protein GI: 68249580; NCBI Protein Accession: YP_248692; NCBITaxon: 281310 YH, ZX VP24 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406]. VP24 from Zaire ebolavirus Protegen ID: 17; NCBI Gene GI: 911828; NCBI Protein GI: 10313998; NCBI Protein Accession: NP_066250; NCBITaxon: 186538 YH, ZX VP30 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406]. VP30 from Zaire ebolavirus Protegen ID: 18; NCBI Gene GI: 911826; NCBI Protein GI: 10313997; NCBI Protein Accession: NP_066249; NCBITaxon: 186538 YH, ZX Vaccination of BALB/c or C57BL/6 mice with eVLPs, composed of the EBOV glycoprotein and matrix viral protein (VP)40 with a lipid membrane, in conjunction with QS-21 adjuvant resulted in mixed IgG subclass responses, a Th1-like memory cytokine response, and protection from lethal EBOV challenge [PubMed: 16002721]. VP40 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406]. VP40 from Zaire ebolavirus Protegen ID: 19; NCBI Gene GI: 911825; NCBI Protein GI: 10313993; NCBI Protein Accession: NP_066245; NCBITaxon: 186538 YH, ZX HLA-A*0201 mice immunized with either GPC(42-50) from LASVsSgp2 glycoprotein or GPC(60-68) were protected against challenge with a recombinant vaccinia virus that expressed LASV GPC [PubMed: 16912286]. LASVsSgp2 glycoprotein Protegen ID: 20; NCBI Gene GI: 956585; NCBI Protein GI: 23343511; NCBI Protein Accession: NP_694870; NCBITaxon: 11620 YH, ZX Caf1 from Y. pestis biovar Microtus str. 91001 Protegen ID: 23; NCBI Gene GI: 2767670; NCBI Protein GI: 45478667; NCBI Protein Accession: NP_995523; NCBITaxon: 229193 YH, ZX It has previously been shown that a DNA subunit vaccine (4pox) based on four orthopoxvirus immunogens (L1R, B5R, A27L and A33R) can produce protective immunity against lethal orthopoxvirus challenges in mice and nonhuman primates. the immunogenicity of an L1R construct to which a tissue plasminogen activator signal sequence was placed in frame with the full-length L1R gene was tested. When the tPA-L1R construct was substituted for the unmodified L1R gene in the 4pox vaccine, given as a prime and single boost, animals were better protected from lethal challenge with vaccinia virus (VACV) [PubMed: 18485547]. L1R from Monkeypox virus Zaire-96-I-16 Protegen ID: 28; NCBI Gene GI: 928938; NCBI Protein GI: 17974998; NCBI Protein Accession: NP_536512; NCBITaxon: 619591 YH, ZX PagA from B. anthracis str. 'Ames Ancestor' Protegen ID: 32; NCBI Gene GI: 2820165; NCBI Protein GI: 47566476; NCBI Protein Accession: NC_007322.2 YH, ZX Lef from B. anthracis str. Ames Ancestor' Protegen ID: 38; NCBI Gene GI: 2820148; NCBI Protein GI: 47566484; NCBI Protein Accession: NC_007322.2 YH, ZX MAb BA5 protected animals against plague, neutralized the Y. pestis type III secretion pathway and promoted opsonophagocytic clearance of bacteria in blood. LcrV residues 196-225 were necessary and sufficient for MAb BA5 binding. These results identify LcrV residues 196-225 as a linear epitope that is recognized by the murine immune system to confer plague protection [PubMed: 20005318]. LcrV from y. pestis CO92 Protegen ID: 44; NCBI Gene GI: 1172676; NCBI Protein GI: 16082719; NCBI Protein Accession: NP_395165; NCBITaxon: 214092 YH, ZX An LcrV variant lacking amino acid residues 271 to 300 (rV10) elicited immune responses that protected mice against a lethal challenge with Y. pestis [PubMed: 16041032]. LcrV from Y. pestis KIM 10 Protegen ID: 45; NCBI Gene GI: 1149310; NCBI Protein GI: 31795491; NCBI Protein Accession: NP_857946; NCBITaxon: 187410 YH, ZX V antigen Protegen ID: 46; NCBI Gene GI: 4118094 YH, ZX Study evaluated the humoral immune response of mice that survived lethal Y. pestis aerosol challenge after antibiotic treatment. Results indicated that one of the predominant antibody response of mice surviving pneumonic plague after treatment with antibiotics was to pla [PubMed: 10085037]. Pla Protegen ID: 48; NCBI Gene GI: 1172643; NCBI Protein GI: 16082686; NCBI Protein Accession: NP_395233; NCBITaxon: 214092 YH, ZX The type III secretion apparatus encoded on the low-calcium response (LCR) virulence plasmid, pCD1 in strain KIM5, of Y. pestis is a conserved virulence mechanism that is absolutely required for virulence of Y. pestis. YscF is a surface localized protein required both to secrete Yops and to translocate toxins into eukaryotic cells. YscF polymerization is possibly required for a YscF needle to puncture eukaryotic cell membranes. It is also likely that YscF and its homologs function to provide a base that a translocon complex is built upon, or that YscF builds a conduit from the bacterium to the eukaryotic membrane - this suggestion seems more likely given that other proteins such as YopB, YopD, and LcrV are also required for translocation into eukaryotic cells. YscF is thought to be a surface-expressed protein in Y. pestis and is required for virulence. YscF has been found to function as a protective antigen against experimental plague infection [PubMed: 15978133]. YopD from Y. pestis CO92 Protegen ID: 49; NCBI Gene GI: 1172673; NCBI Protein GI: 16082716; NCBI Protein Accession: NP_395162; NCBITaxon: 214092 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatA) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. Note: Part of CP #3 also belongs to gatB GatA Protegen ID: 422; NCBI Protein GI: 62184918; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatB) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. Note: Part of CP #3 also belongs to gatA GatB Protegen ID: 424; NCBI Protein GI: 62147986; NCBITaxon: 218497 YH, ZX The MOMP (omp1) DNA immunization induced a non-specific and partial protection in OF1 outbred mice fetuses against challenge with C. abortus [PubMed: 12488563]. Omp1 Protegen ID: 425; NCBI Protein GI: 40601; NCBITaxon: 83555 YH, ZX In pregnant mice, the dnaK vaccine induced a non-specific partial protection from abortion after challenge with Chlamydophila abortus [PubMed: 12056482]. DnaK Protegen ID: 426; NCBI Protein GI: 26006347; NCBITaxon: 83555 YH, ZX The immunogenicity and protective effect of recombinant LcrE protein combined either with Freund's or Alum adjuvant were investigated in mice. The immunization with both protocols resulted in a significant reduction of the number of viable C. pneumoniae in the lungs after challenge. Results confirm that LcrE induces protective immunity in mice [PubMed: 19451031]. LcrE Protegen ID: 428; NCBI Gene GI: 895078; NCBI Protein GI: 15618244; NCBI Protein Accession: NP_224529; NCBITaxon: 115713 YH, ZX Results of this study showed that intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response. The immunization induced statistically significant protection against intranasal C. pneumoniae challenge, the level of which correlated with the magnitude of CopN-specific lymphocyte proliferation [PubMed: 16949182]. CopN Protegen ID: 429; NCBI Protein GI: 33241669; NCBITaxon: 182082 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0512 showed significant levels of protection when compared to negative control animals. At 9 days following challenge TC0512 showed a 73% reduction in the number of recoverable Chlamydia compared with vector only immunized controls [PubMed: 17239501]. TC0512 outer membrane protein, putative Protegen ID: 430; NCBI Gene GI: 1245872; NCBI Protein GI: 15835130; NCBI Protein Accession: NP_296889; NCBITaxon: 243161 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0757 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. TC0757 hypothetical protein Protegen ID: 431; NCBI Gene GI: 1246122; NCBI Protein GI: 15835371; NCBI Protein Accession: NP_297130; NCBITaxon: 243161 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0439 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. TC0439 adherence factor Protegen ID: 432; NCBI Gene GI: 1245792; NCBI Protein GI: 15835057; NCBI Protein Accession: NP_296816; NCBITaxon: 243161 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0767/768 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. TC0767 hypothetical protein Protegen ID: 433; NCBI Gene GI: 1246132; NCBI Protein GI: 15835381; NCBI Protein Accession: NP_297140; NCBITaxon: 243161 YH, ZX Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0767/768 showed significant levels of protection when compared to negative control animals [PubMed: 17239501]. TC0768 hypothetical protein Protegen ID: 434; NCBI Gene GI: 1246133; NCBI Protein GI: 15835382; NCBI Protein Accession: NP_297141; NCBITaxon: 243161 YH, ZX Female BALB/c mice were immunized with chlamydial major outer membrane protein (MOMP) mixed with cholera toxin and CpG oligodeoxynucleotide adjuvants by either the IN or TCI routes. Both intranasal and transcutaneous immunization protected mice against respiratory challenge with Chlamydia [PubMed: 16153755]. MOMP Protegen ID: 435; NCBI Protein GI: 1518659; NCBITaxon: 83560 YH, ZX Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. Overall, vaccination with DCs transfected with PmpG-1(25-500) exhibited the greatest degree of protective immunity among the four Chlamydia Ags tested [PubMed: 19155509]. PmpG-1 Protegen ID: 436; NCBI Gene GI: 1246433; NCBI Protein GI: 15834883; NCBI Protein Accession: NP_296642; NCBITaxon: 243161 YH, ZX Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. In addition, RplF was able to engender protective immunity against challenge with C. muridarum [PubMed: 19155509]. RplF Protegen ID: 437; NCBI Gene GI: 1246168; NCBI Protein GI: 15835415; NCBI Protein Accession: NP_297174; NCBITaxon: 243161 YH, ZX Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. In addition, pmpE/F-2 was able to engender protective immunity against challenge with C. muridarum [PubMed: 19155509]. PmpE/F-2 Protegen ID: 438; NCBI Gene GI: 1246432; NCBI Protein GI: 15834882; NCBI Protein Accession: NP_296641; NCBITaxon: 243161 YH, ZX IM-ID vaccination with CPn0095 (pknD) generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p0.019). This resulted in the ability of CPN0095 to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129]. PknD Protegen ID: 439; NCBI Gene GI: 895704; NCBI Protein GI: 161353778; NCBI Protein Accession: NP_224303; NCBITaxon: 115713 YH, ZX M-ID vaccination with fabD generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p 0.019). This resulted in the ability of fabD to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129]. FabD Protegen ID: 440; NCBI Gene GI: 894994; NCBI Protein GI: 15618217; NCBI Protein Accession: NP_224502; NCBITaxon: 115713 YH, ZX Mice vaccinated with candidate gene ssb showed significant reduction of spleen chlamydial loads as compared to nave, non-protected control mice (p 0.048). This resulted in the ability of ssb to mediate a modest, but significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129]. Ssb Protegen ID: 441; NCBI Gene GI: 894901; NCBI Protein GI: 15618301; NCBI Protein Accession: NP_224586; NCBITaxon: 115713 YH, ZX Pigs were subjected to challenge infection with a dose of 1x10(5)TCID(50) (50% tissue culture infective dose) virulent CSFV strain. At 1 week post challenge infection, all of the yE2-immunized pigs were alive and without symptoms or signs of CSF. The yeast-expressed E2 protein retains correct immunogenicity and is able to induce a protective immune response against CSFV infection [PubMed: 19625145]. In a seperate study, swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever [PubMed: 7666549]. E2 Protegen ID: 442; NCBI Gene GI: 920146; NCBI Protein GI: 12657942; NCBI Protein Accession: NP_075354; NCBITaxon: 11096 YH, ZX Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever [PubMed: 7666549]. E0 Protegen ID: 443; NCBI Protein GI: 115343287; NCBITaxon: 11096 YH, ZX Intramuscular vaccination of pigs with immunoaffinity-purified E1 (gp55) in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV (Classical swine fever virus) strain Brescia [PubMed: 8350404]. Gp55 Protegen ID: 444; NCBI Protein GI: 1763691; NCBITaxon: 11096 YH, ZX A single dose of ciBoNT/A1 HP provided equivalent or greater protective immunity, not only against the homologous toxin, but also against two distinct toxin subtypes with significant amino acid divergence in mice when challenged with BoNT/A subtypes /A1, /A2, and /A3 from Clostridium botulinum [PubMed: 19450643]. BoNT/A1 from C. botulinum Protegen ID: 445; NCBI Protein GI: 241183337; NCBITaxon: 1491 YH, ZX Purified FHc was used to vaccinate mice and evaluate their survival against challenge with active botulinum neurotoxin serotype F (BoNT/F). Mice that received one injection of 5 microg or two injections of >or=0.04 microg of FHc were completely protected [PubMed: 18845829]. FHc Protegen ID: 446; NCBI Protein GI: 166236883; NCBITaxon: 32630 YH, ZX A completely synthetic gene encoding fragment C, a approximately 50-kDa fragment, of botulinum neurotoxin serotype A was constructed from oligonucleotides. Mice given three subcutaneous vaccinations were protected against an intraperitoneal administration of 10^6 50% lethal doses (ID50) of serotype A toxin [PubMed: 7790092]. BotA Protegen ID: 447; NCBI Protein GI: 733429; NCBITaxon: 32630 YH, ZX Mice and rabbits were immunized with recombinant HCR/A1 (rHCR/A1) from the classical type A-Hall strain (ATCC 3502) (BoNT/A1) and rHCR/E from BoNT serotype E Beluga (BoNT/E(B)). The protection elicited by rHCR/A1 to BoNT/A1 and BoNT/A2 and by rHCR/E(B) to BoNT/E(A) indicate that immunization with receptor binding domains elicit protection within sub-serotypes of BoNT [PubMed: 16177380]. BoNT/A1 from C. botulinum A str. Hall Protegen ID: 448; NCBI Gene GI: 5398487; NCBI Protein GI: 153936924; NCBI Protein Accession: YP_001386738; NCBITaxon: 441771 YH, ZX The DNA replicon vaccine (pSCARSBHc) encoding the Hc domain of BoNT/B (BHc) induced better responses and protection against BoNT/B mouse challenge than conventional DNA vaccine. Recombinant SFV particle VRP-BHc protected mice from high-dose BoNT/B challenge [PubMed: 19712769]. BoNT/B Protegen ID: 449; NCBI Gene GI: 6030102; NCBI Protein GI: 169834607; NCBI Protein Accession: YP_001693307; NCBITaxon: 498213 YH, ZX Researchers constructed a replication-incompetent adenovirus encoding a synthesized codon-optimized gene for expression of the heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C). After a single dose of 2 x 10^7pfu adenoviral vectors in a mouse model, the animals were completely protected against intraperitoneal challenge with 100 x MLD(50) of active BoNT/C [PubMed: 17897756]. BoNT/C(Hc50) Protegen ID: 450; NCBI Protein GI: 217781; NCBI Protein Accession: BAA14235.1; NCBITaxon: 12336 YH, ZX A recombinant vaccinia virus containing most of the P1 region of hepatitis A virus (HAV) was constructed bearing epitopes from structural polypeptides VP4, -3 and -2, and the N terminus of VP. Inoculation of tamarin monkeys with the recombinant virus resulted in the development of a specific anti-HAV immune response which was protective against challenge with a virulent strain of HAV [PubMed: 1654376]. HAVgp2 Protegen ID: 680; NCBI Gene GI: 1493919; NCBI Protein GI: 9626734; NCBI Protein Accession: NP_041008; NCBITaxon: 12092 YH, ZX Following two intragastric immunizations in BALB/c mice, the Yersinia vectors harboring a DNA vaccine encoding BFR (P39) induced antigen-specific serum immunoglobulin and Th1-type responses among splenocytes. The best protection was conferred by a serotype O:9 strain carrying pCIP39, confirming the importance of the P39 T-cell antigen in this mechanism [PubMed: 11895955]. Bfr from B. abortus S19 Protegen ID: 681; NCBI Gene GI: 6326162; NCBI Protein GI: 189022832; NCBI Protein Accession: YP_001932573; NCBITaxon: 430066 YH, ZX Study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein, rplL) and Omp16 protein (outer membrane lipoprotein). This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice [PubMed: 16622210]. RplL Protegen ID: 682; NCBI Gene GI: 3788918; NCBI Protein GI: 82700077; NCBI Protein Accession: YP_414651; NCBITaxon: 359391 YH, ZX The fragment C of tetanus toxin was amplified from Clostridium tetani DNA by PCR. Immunization of mice with rTTC resulted in the production of antibodies that were able to protect mice against a challenge with tetanus toxin furthermore, rTTC in vivo appeared to be able to undergo retrograde axonal transport [PubMed: 12075415]. TTC Protegen ID: 451; NCBI Protein GI: 157829735; NCBITaxon: 1513 YH, ZX Cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV (GP) and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV [PubMed: 20502688]. GP from Zaire ebolavirus Protegen ID: 452; NCBI Gene GI: 911829; NCBI Protein GI: 10313995; NCBI Protein Accession: NP_066246; NCBITaxon: 186538 YH, ZX Cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV (GP) and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV [PubMed: 20502688]. GP from Sudan ebolavirus Protegen ID: 453; NCBI Gene GI: 3160774; NCBI Protein GI: 55770812; NCBI Protein Accession: YP_138523; NCBITaxon: 186540 YH, ZX Guinea pigs infected with a single intranasal inoculation of HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 10(3) PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge [PubMed: 16474134]. NP Protegen ID: 454; NCBI Gene GI: 911830; NCBI Protein GI: 10314000; NCBI Protein Accession: NP_066243; NCBITaxon: 186538 YH, ZX Ten mice were inoculated subcutaneously, administered booster injections after one month, and challenged with 130 LD(50) of wild type Y. pestis CO92. The vaccinated animals produced high levels of specific antibodies against YscF as determined by Western blot. The data were statistically significant (P = 0.053 by two-tailed Fisher's test), suggesting that the YscF protein can provide a protective immune response against lethal plague challenge during subcutaneous plague infection [PubMed: 15939303]. YscF from Y. pestis CO92 Protegen ID: 54; NCBI Gene GI: 1172700; NCBI Protein GI: 16082743; NCBI Protein Accession: NP_395189; NCBITaxon: 214092 YH, ZX The P4 protein is an integral outer membrane protein that has a role in acquiring hemin and nucleosides [PubMed: 1715322 ]. P4 Protegen ID: 100; NCBITaxon: 727 YH, ZX Recombinant P6 (pal) was capable of eliciting a protective antibody response against live H. influenzae type b challenge in a modified infant rat model of bacteremia [PubMed: 9261944]. Pal Protegen ID: 101; NCBI Gene GI: 3429820; NCBI Protein GI: 68248984; NCBI Protein Accession: YP_248096; NCBITaxon: 281310 YH, ZX When mice immunized intranasally with recombinant protein corresponding to the C-terminal region of Hap(S) from H. influenzae strains N187, P860295, and TN106 plus mutant cholera toxin CT-E29H were challenged with strain TN106, they were protected against nasopharyngeal colonization [PubMed: 15557618]. Hap from H. influenzae Protegen ID: 102; NCBI Protein GI: 21686508; NCBITaxon: 727 YH, ZX Hap from H. influenzae Protegen ID: 103; NCBITaxon: 727 YH, ZX OMP26 was used to immunize rats via intestinal Peyer's patches, followed by an intratracheal boost. Immunization was found to significantly enhance bacterial clearance following pulmonary challenge with both the homologous NTHI strain and a different NTHI strain [PubMed: 9573117]. Omp26 Protegen ID: 276; NCBI Nucleotide GI: 4574245; NCBI Protein GI: 4574246; NCBI Protein Accession: AAD23967.1; NCBITaxon: 727 YH, ZX The heterologous prime-boost strategy of live Salmonella vaccine expressing Mycobacterium tuberculosis fusion antigen Age5B-ESAT6 (esxA) from the chromosome followed by a systemic boost of antigen and adjuvant reduced the levels of M. tuberculosis bacteria in the lungs and spleen to the same extent as BCG. Additionally, this vaccination regimen was observed to be statistically equivalent in terms of protection to immunisation with BCG [PubMed: 19755145]. EsxA Protegen ID: 104; NCBI Gene GI: 886209; NCBI Protein GI: 57117165; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX TRAP from P. falciparum Protegen ID: 138; NCBI Gene GI: 814170; NCBI Protein GI: 124513464; NCBI Protein Accession: XP_001350088; NCBITaxon: 36329 YH, ZX LolC was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the LolC protein domain afforded significant protection against a subsequent challenge with B. pseudomallei. LolC provided a greater level of protection when it was administered with immune-stimulating complexes complexed with CpG oligodeoxynucleotide 10103. Immunization with LolC also protected against a subsequent challenge with a heterologous strain of B. pseudomallei, demonstrating the potential utility of this protein as a vaccine antigen for melioidosis [PubMed: 17517877]. LolC/E Protegen ID: 768; NCBI Gene GI: 3093214; NCBI Protein GI: 53719887; NCBI Protein Accession: YP_108873; NCBITaxon: 272560 YH, ZX PotF was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the PotF protein domain afforded significant protection against a subsequent challenge with B. pseudomallei [PubMed: 17517877]. PotF Protegen ID: 769; NCBI Gene GI: 3095748; NCBI Protein GI: 53721504; NCBI Protein Accession: YP_110489; NCBITaxon: 272560 YH, ZX AMA1 from P. falciparum 3D7 Protegen ID: 139; NCBI Gene GI: 810891; NCBI Protein GI: 124804478; NCBI Protein Accession: XP_001348015; NCBITaxon: 36329 YH, ZX The ompA codon was adapted to the codon usage in birds, resulting in pcDNA1/MOMP(opt). Researchers examined the capacity of nebulised or intramuscularly (IM) administered brPEI-pcDNA1/MOMP(opt) to induce a significant protective immune response in SPF turkeys experimentally infected with 10^8 TCID(50) of a virulent Cp. psittaci strain. Vaccinated groups were significantly protected against Cp. psittaci challenge [PubMed: 20199760]. OmpA from C. psittaci Protegen ID: 766; NCBI Protein GI: 94467392; NCBITaxon: 83554 YH, ZX Plasmid DNA (pcDNA1::MOMP A) expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci genotype A strain 89/1051 has been tested for its ability to induce protective immunity against Cp. psittaci challenge in budgerigars. DNA immunisation significantly reduced clinical signs, macroscopic lesions, pharyngeal and cloacal excretion as well as chlamydial replication, even in the presence of pre-existing serum antibodies, as compared to the placebo-vaccinated controls [PubMed: 19640395]. MOMP from C. psittaci Protegen ID: 767; NCBI Nucleotide GI: 144544; NCBI Protein GI: 144545; NCBI Protein Accession: AAA17396.1; NCBITaxon: 83554 YH, ZX Protective antigen [PubMed: 11489167] ABRA Protegen ID: 137; NCBITaxon: 5835 YH, ZX This gene was originally isolated from a lambda gt11 expression library probed with sera from Brucella-infected sheep. Sequence analysis of the cloned gene revealed the presence of an open reading frame of 158 amino acids encoding a protein of 17.3 kDa [PubMed: 7664168 ]. It was later identified as a cytoplasmic protein lumazine synthase [PubMed: 10482294 ]. This gene can be used for diagnosis [PubMed: 7664168 ] [PubMed: 10482294 ] and vaccine development [PubMed: 11953389 ]. ORF Protegen ID: 113; NCBI Nucleotide GI: 599653; NCBI Protein GI: 599654; NCBI Protein Accession: CAA86936.1; NCBITaxon: 235 YH, ZX B. abortus strain 19 L7/L12 Protegen ID: 114; NCBI Protein GI: 304271 YH, ZX Guinea pigs were vaccinated with recombinant VEE replicons (packaged into VEE-like particles), inoculated with MBGV, and evaluated for viremia and survival after challenge with typical MGBV disease. Results indicated that VP35 afforded incomplete protection [PubMed: 9813200 ]. VP35 Protegen ID: 167; NCBI Gene GI: 920948; NCBI Protein GI: 13489277; NCBI Protein Accession: NP_042026.1; NCBITaxon: 11269 YH, ZX The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [PubMed: 16481504 ]. P1 Protegen ID: 171; NCBI Protein GI: 30025845; NCBITaxon: 777 YH, ZX NP from Zaire ebolavirus Protegen ID: 172; NCBI Gene GI: 911830; NCBI Protein GI: 10314000; NCBI Protein Accession: NP_066243; NCBITaxon: 186538 YH, ZX GP from Zaire ebolavirus Protegen ID: 173; NCBI Protein GI: 21702651; NCBITaxon: 186538 YH, ZX NP Marburgvirus - Ravn Protegen ID: 174; NCBI Protein GI: 91177744; NCBITaxon: 378809 YH, ZX The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [PubMed: 16481504 ]. HspB Protegen ID: 175; NCBI Protein GI: 197253489; NCBITaxon: 777 YH, ZX Mice were immunized with recombinant H3L protein to examine H3L-specific antibody responses in greater detail. H3L-immunized mice developed high-titer vaccinia virus-neutralizing antibodies (mean PRNT50 = 1:3,760). Importantly, H3L-immunized mice were subsequently protected against lethal intranasal challenges with 1 or 5 50% lethal doses (LD50) of pathogenic vaccinia virus strain WR, demonstrating the in vivo value of an anti-H3L response. To formally demonstrate that neutralizing anti-H3L antibodies are protective in vivo, we performed anti-H3L serum passive-transfer experiments. Mice receiving H3L-neutralizing antiserum were protected from a lethal challenge with 3 LD50 of vaccinia virus strain WR (5/10 versus 0/10; P < 0.02) [PubMed: 16140750]. H3L Protegen ID: 62; NCBI Gene GI: 3707557; NCBI Protein GI: 66275898; NCBI Protein Accession: YP_232983; NCBITaxon: 10245 YH, ZX Ag85A Protegen ID: 154; NCBITaxon: 1773 YH, ZX Env Gp160 Protegen ID: 153; NCBITaxon: 11676 YH, ZX StxB2 Protegen ID: 225; NCBI Gene GI: 1262010; NCBI Protein GI: 9632507; NCBI Protein Accession: NP_049501; NCBITaxon: 10730 YH, ZX Omp31 Protegen ID: 231; NCBI Gene GI: 3788834; NCBI Protein GI: 82700421; NCBI Protein Accession: YP_414995; NCBITaxon: 359391 YH, ZX Tir Protegen ID: 199; NCBI Gene GI: 960860; NCBI Protein GI: 15804222; NCBI Protein Accession: NP_290261.1; NCBITaxon: 562 YH, ZX ETEC also expresses a range of colonisation factor antigens (CFAs), which allow adherence to the mucosal surface and therefore colonisation of the intestine. Some CFAs are sub-divided into coli surface (CS) antigens [PubMed: 17566016]. CS1 Protegen ID: 79; NCBI Gene GI: 4188469; NCBI Protein GI: 110643341; NCBI Protein Accession: YP_671071; NCBITaxon: 362663 YH, ZX FlaA from C. jejuni NCTC 11168 Protegen ID: 87; NCBI Gene GI: 905631; NCBI Protein GI: 15792662; NCBI Protein Accession: NP_282485.1; NCBITaxon: 197 YH, ZX LT is a hetero-oligomeric AB5 type enterotoxin composed of a 27 kDa A subunit with toxic ADP ribosyl transferase activity and a stable noncovalent-linked pentamer of 11.6 kDa B subunits. ETEC infection and colonization of the small intestine, and the production of LT, causes acute diarrhea that can be fatal without intervention [PubMed: 17188785]. EltB Protegen ID: 92; NCBI Protein GI: 157021162; NCBITaxon: 562 YH, ZX EHEC strains produce intimin, an outer membrane adhesin encoded by the eae gene located in a chromosomal pathogenicity island termed the locus of enterocyte effacement [PubMed: 17258324]. Eae Protegen ID: 93; NCBI Gene GI: 960862; NCBI Protein GI: 15804220; NCBI Protein Accession: NP_290259; NCBITaxon: 155864 YH, ZX FimH is a protective antigen [PubMed: 9110982] FimH from E. coli UTI89 Protegen ID: 263; NCBI Gene GI: 3992235; NCBI Protein GI: 91213965; NCBI Protein Accession: YP_543951; NCBITaxon: 364106 YH, ZX Protective antigen [PubMed: 10710308]. GNA2132 Protegen ID: 264; NCBI Gene GI: 903357; NCBI Protein GI: 15677945; NCBI Protein Accession: NP_275117; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 10710308] GNA2001 Protegen ID: 265; NCBI Gene GI: 904124; NCBI Protein GI: 15677829; NCBI Protein Accession: NP_274993; NCBITaxon: 122586 YH, ZX The 39-kDa protein is immunogenic. B. melitensis M5 P39 Protegen ID: 110; NCBI Protein GI: 122892474; NCBI Protein Accession: ABM67295 YH, ZX A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV [PubMed: 11522184]. Gag protein from SIV-mnd 2 Protegen ID: 98; NCBI Gene GI: 956108; NCBITaxon: 159122 YH, ZX Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Gurin vaccination [PubMed: 17671656]. SecA2 Protegen ID: 117; NCBI Gene GI: 885594; NCBI Protein GI: 15608958; NCBI Protein Accession: NP_216337; NCBITaxon: 83332 YH, ZX The 10-kDa culture filtrate protein (CFP-10, esxB) and 6-kDa early secretory antigen of T cells (ESAT-6) are secreted in abundance by Mycobacterium tuberculosis. Study demonstrated that protective immunity is induced by CFP-10 DNA vaccination in C3H mice as measured by a CFU reduction in the lung and spleen 4 and 8 weeks after challenge with M. tuberculosis [PubMed: 18332205]. EsxB Protegen ID: 121; NCBI Gene GI: 886194; NCBI Protein GI: 15611010; NCBI Protein Accession: NP_218391; NCBITaxon: 83332 YH, ZX Researchers have developed DNA vaccines expressing M. tuberculosis antigen 85A (Ag85A, fbpA) and cytokine granulocyte macrophage colony stimulating factor (GM-CSF). The immune strategy of BCG-prime and DNA vaccine boost induced mice to generate efficient immune protection against M. tuberculosis challenge [PubMed: 19450898]. FbpA Protegen ID: 122; NCBI Gene GI: 886132; NCBI Protein GI: 15610940; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX PepA Protegen ID: 123; NCBI Gene GI: 886924; NCBI Protein GI: 15607267; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX PPE18 Protegen ID: 124; NCBI Gene GI: 886073; NCBI Protein GI: 57116841; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX CjaA from C. jejuni RM 1221 Protegen ID: 133; NCBI Gene GI: 3231573; NCBI Protein GI: 57237809; NCBI Protein Accession: YP_179057.1; NCBITaxon: 197 YH, ZX A total of 840 Light Sussex chickens were used to evaluate a Salmonella enterica serovar Typhimurium DeltaaroA vaccine expressing the C. jejuni amino acid binding protein CjaA. Chickens were given the vaccine at 1-day-old and two weeks later by oral gavage, then challenged after a further two weeks with C. jejuni. Across six biological replicates, statistically significant reductions in caecal C. jejuni of c. 1.4log(10) colony-forming units/g were observed at three and four weeks post-challenge relative to age-matched unvaccinated birds. Protection was associated with the induction of CjaA-specific serum IgY and biliary IgA [PubMed: 19853682]. CjaA from C. jejuni Protegen ID: 134; NCBI Protein GI: 1813949; NCBITaxon: 197 YH, ZX Pvs25 Protegen ID: 141; NCBITaxon: 5855 YH, ZX Aotus monkeys were challenged with the virulent Vietnam Oak Knoll (FVO) strain of P. falciparum. Vaccination of A. nancymai with yMSP1(19) induced protective immune responses. Both of the A. nancymai vaccinated with yMSP1(19) self-resolved an otherwise lethal infection [PubMed: 8529111]. MSP1 from P. falciparum Protegen ID: 143; NCBI Protein GI: 94420988; NCBITaxon: 5833 YH, ZX RESA Protegen ID: 144 YH, ZX Study compared the immunogenicity and protective efficacy of recombinant DOBV nucleocapsid protein (rDOBV N, S) given with Alum or Freund's as adjuvant, or PBS, in C57/BL6 mice. Mice receiving rDOBV N with Freund's adjuvant were protected from challenge (75% protected) [PubMed: 15364453]. S nucleocapsid protein from Dobrava-Belgrade virus Protegen ID: 146; NCBI Gene GI: 2656266; NCBI Protein GI: 38505524; NCBI Protein Accession: NP_942553; NCBITaxon: 12506 YH, ZX Study developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein from Lake Victoria marburgvirus - Musoke. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges [PubMed: 15937495]. GP from Lake Victoria marburgvirus Protegen ID: 150; NCBI Protein GI: 77543430; NCBITaxon: 33727 YH, ZX This is a protective antigen [PubMed: 17239499]. Bp26 Protegen ID: 232; NCBI Gene GI: 1196247; NCBI Protein GI: 17986819; NCBI Protein Accession: NP_539453; NCBITaxon: 224914 YH, ZX RpsL Protegen ID: 236; NCBI Gene GI: 1196463; NCBI Protein GI: 161511151; NCBI Protein Accession: NP_539669; NCBITaxon: 224914 YH, ZX Iss Protegen ID: 240; NCBI Gene GI: 5616654; NCBI Protein GI: 157418230; NCBI Protein Accession: YP_001481302; NCBITaxon: 405955 YH, ZX FyuA Protegen ID: 247; NCBI Gene GI: 4492541; NCBI Protein GI: 117624167; NCBI Protein Accession: YP_853080; NCBITaxon: 405955 YH, ZX Brucella Omp25 is a protective antigen [PubMed: 17049676]. Omp25 Protegen ID: 253; NCBI Gene GI: 1196960; NCBI Protein GI: 17987532; NCBI Protein Accession: NP_540166; NCBITaxon: 224914 YH, ZX Brucella IalB is a protective antigen [PubMed: 17049676]. IalB Protegen ID: 254; NCBI Gene GI: 1197295; NCBI Protein GI: 17987867; NCBI Protein Accession: NP_540501; NCBITaxon: 224914 YH, ZX Brucella bacterioferritin is a protective antigen [PubMed: 11447155 ] Bfr from B. melitensis biovar Abortus 2308 Protegen ID: 255; NCBI Gene GI: 3828133; NCBI Protein GI: 83269559; NCBI Protein Accession: YP_418850; NCBITaxon: 359391 YH, ZX protective antigen [PubMed: 17239499] Tig Protegen ID: 256; NCBI Gene GI: 1196780; NCBI Protein GI: 17987352; NCBI Protein Accession: NP_539986; NCBITaxon: 224914 YH, ZX Brucella DnaK is a protective antigen [PubMed: 17686554]. DnaK Protegen ID: 257; NCBI Gene GI: 3341115; NCBI Protein GI: 62290965; NCBI Protein Accession: YP_222758; NCBITaxon: 262698 YH, ZX Brucella SurA is a protective antigen [PubMed: 17686554]. SurA Protegen ID: 258; NCBI Gene GI: 3787419; NCBI Protein GI: 82699574; NCBI Protein Accession: YP_414148; NCBITaxon: 359391 YH, ZX Brucella Omp19 is a protective antigen [PubMed: 18981242]. Omp19 Protegen ID: 259; NCBI Gene GI: 3788831; NCBI Protein GI: 82700695; NCBI Protein Accession: YP_415269; NCBITaxon: 359391 YH, ZX Brucella Omp16 is a protective antigen [PubMed: 18981242]. Omp16 Protegen ID: 260; NCBI Gene GI: 3788229; NCBI Protein GI: 82700483; NCBI Protein Accession: YP_415057; NCBITaxon: 359391 YH, ZX Protective antigen [PubMed: 10710308] GNA1946 Protegen ID: 266; NCBI Gene GI: 904205; NCBI Protein GI: 15677776; NCBI Protein Accession: NP_274940; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 10710308] GNA1220 Protegen ID: 267; NCBI Gene GI: 903642; NCBI Protein GI: 15677093; NCBI Protein Accession: NP_274245; NCBITaxon: 122586 YH, ZX Protective antigen[PubMed: 10710308] GNA1162 Protegen ID: 268; NCBI Gene GI: 903582; NCBI Protein GI: 15677037; NCBI Protein Accession: NP_274189; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 10710308] GNA992 (hsf) Protegen ID: 269; NCBI Gene GI: 903112; NCBI Protein GI: 15676883; NCBI Protein Accession: NP_274028; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 10710308] GNA33 Protegen ID: 270; NCBI Gene GI: 902136; NCBI Protein GI: 15675973; NCBI Protein Accession: NP_273099; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 9104804] NspA from N. meningitidis MC58 Protegen ID: 271; NCBI Gene GI: 902774; NCBI Protein GI: 15676561; NCBI Protein Accession: NP_273705; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 16825336][PubMed: 12045242] with GeneID: 902509. However, according to sequence analysis, this nadA is not the same NadA that was found to be protective antigen [PubMed: 16825336][PubMed: 12045242]. NadA Protegen ID: 272; NCBI Gene GI: 904134; NCBI Protein GI: 15677822; NCBI Protein Accession: NP_274986; NCBITaxon: 122586 YH, ZX Protective antigen [PubMed: 16825336] GNA1870 Protegen ID: 273; NCBI Gene GI: 904318; NCBI Protein GI: 15677705; NCBI Protein Accession: NP_274866; NCBITaxon: 122586 YH, ZX Protective antigen as shown in some assays [PubMed: 16825336] GNA2091 Protegen ID: 274; NCBI Gene GI: 903958; NCBI Protein GI: 15677911; NCBI Protein Accession: NP_275079; NCBITaxon: 122586 YH, ZX Protective antigen as shown in some assays [PubMed: 16825336] GNA1030 Protegen ID: 275; NCBI Gene GI: 903167; NCBI Protein GI: 15676917; NCBI Protein Accession: NP_274064; NCBITaxon: 122586 YH, ZX A vaccine made by Hma from E. coli strain CFT073 and 536 induced protection to the infection of virulent strain CFT073 and 536, respectively, in the bladder in the CBA/J mice. [PubMed: 19806177]. Hma Protegen ID: 278; NCBI Gene GI: 1037732; NCBI Protein GI: 26248334; NCBI Protein Accession: NP_754374; NCBITaxon: 199310 YH, ZX Immunization with IreA protects against urinary tract colinization by E.coli CFT073 and reduces colinization by E.coli 536 in the bladder of CBA/J mice [PubMed: 19806177]. IreA Protegen ID: 279; NCBI Gene GI: 1037614; NCBI Protein GI: 26250982; NCBI Protein Accession: NP_757022; NCBITaxon: 199310 YH, ZX Immunization with IutA protects against urinary tract colinization by E.coli CFT073 in the bladders of CBA/J mice [PubMed: 19806177]. IutA Protegen ID: 280; NCBI Gene GI: 1039578; NCBI Protein GI: 26249458; NCBI Protein Accession: NP_755498; NCBITaxon: 199310 YH, ZX Antibodies directed at the putative binding region of FimH (anti- s-FimH1-25) significantly reduced E. coli bladder infections in the experimental mouse model of urinary tract infections [PubMed: 9276729]. FimH Protegen ID: 281; NCBI Gene GI: 948847; NCBI Protein GI: 16132141; NCBI Protein Accession: NP_418740; NCBITaxon: 511145 YH, ZX Active immunization of BALB/c mice with IroN antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948 ]. IroN Protegen ID: 282; NCBI Gene GI: 7379404; NCBI Protein GI: 222104801; NCBI Protein Accession: YP_002539290; NCBITaxon: 562 YH, ZX Active immunization of BALB/c mice with C0393 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948]. C0393 Protegen ID: 283; NCBI Gene GI: 1034958; NCBI Protein GI: 26246291; NCBI Protein Accession: NP_752330; NCBITaxon: 199310 YH, ZX Active immunization of BALB/c mice with C4424 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948]. C4424 Protegen ID: 284; NCBI Gene GI: 1038067; NCBI Protein GI: 26250246; NCBI Protein Accession: NP_756286; NCBITaxon: 199310 YH, ZX Active immunization of BALB/c mice with recombinant E. coli protein C3389 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948]. C3389 Protegen ID: 285; NCBI Gene GI: 1039252; NCBI Protein GI: 26249224; NCBI Protein Accession: NP_755264; NCBITaxon: 199310 YH, ZX S. flexneri M90T is a colonisation-defective mutant with a transposon in fnr, which encodes a regulator of anaerobic metabolism. To establish whether FNR-mediated repression of spa32 and spa33 contributes to increased Shigella entry into cells in an anaerobic cabinet, recombinant M90T strains were constructed which contain spa32 and spa33 under the control of either their native promoters (M90Tp32/33) or promoters with disrupted FNR boxes (M90Tp#32/#33).The presence in M90T of spa32 and spa33 alleles that are not repressed by FNR led to IpaB secretion during anaerobic growth, and loss of the increased entry of Shigella into cells in an anaerobic cabinet [PubMed: 20436458]. Spa32 Protegen ID: 288; NCBI Gene GI: 876502; NCBI Protein GI: 13449098; NCBI Protein Accession: NP_085314; NCBITaxon: 424718 YH, ZX Oral immunization of FaeG-expressing L. lactis exhibits a protective response against ETEC infection in mice [PubMed: 19277476]. ECSE_P3-0034 Protegen ID: 289; NCBI Gene GI: 7003192; NCBI Protein GI: 209921909; NCBI Protein Accession: YP_002295988; NCBITaxon: 409438 YH, ZX The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774]. IpaB Protegen ID: 307; NCBI Protein GI: 22036246; NCBITaxon: 42897 YH, ZX The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774]. IpaC Protegen ID: 308; NCBI Protein GI: 47056; NCBITaxon: 42897 YH, ZX The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774]. IpaD Protegen ID: 309; NCBI Protein GI: 22036352; NCBITaxon: 42897 YH, ZX Thirty-day-old chickens were immunized intramuscularly with purified IroN from Salmonella Typhimurium mixed with Freund's incomplete adjuvant; the chickens were then challenged intravenously with Salmonella Enteritidis. The mortality rate of immunized chickens was 10%. On the other hand, that of control chickens was 80% [PubMed: 20095157]. IroN Protegen ID: 318; NCBI Protein GI: 259475459; NCBITaxon: 90371 YH, ZX Researchers evaluated the immunogenicity and protective efficacy of GroEL of Salmonella enterica serovar Typhi against lethal infection by S. typhi Ty2 in mice with or without adjuvants. Immunization of mice with GroEL-alone, GroEL + alum, and GroEL + CFA provided 70, 50 and 80% protection, respectively, against lethal challenge by S. typhi in mice. The present study shows that GroEL forms an ideal candidate molecule to develop a recombinant protein based vaccine against human typhoid [PubMed: 19851830]. GroEL Protegen ID: 320; NCBI Gene GI: 1068458; NCBI Protein GI: 29144631; NCBI Protein Accession: NP_807973; NCBITaxon: 209261 YH, ZX The entire SopB and SifB genes were cloned into DNA vaccine vectors and were administered along with live attenuated Salmonella. It was found that SopB vaccination reduced the bacterial burden of organs by about 5-fold on day 4 and day 8 after challenge with virulent Salmonella and proved to be a more efficient vaccination strategy than live attenuated bacteria alone [PubMed: 19428891]. SopB Protegen ID: 321; NCBI Protein GI: 54036439; NCBITaxon: 90371 YH, ZX Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 10(7) and 10(8)CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate [PubMed: 18590785]. SAG1 Protegen ID: 326; NCBI Gene GI: 7900172; NCBI Protein GI: 237839159; NCBI Protein Accession: XP_002368877; NCBITaxon: 508771 YH, ZX Modified YscF antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562]. YscF from Y. pestis KIM 10 Protegen ID: 338; NCBI Gene GI: 1149286; NCBI Protein GI: 31795470; NCBI Protein Accession: NP_857922; NCBITaxon: 187410 YH, ZX Modified yopD antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562]. YopD from Y. pestis KIM 10 Protegen ID: 339; NCBI Gene GI: 1149313; NCBI Protein GI: 31795494; NCBI Protein Accession: NP_857949; NCBITaxon: 187410 YH, ZX Modified yopO antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562]. YopO Protegen ID: 340; NCBI Gene GI: 5798322; NCBI Protein GI: 162417777; NCBI Protein Accession: YP_001604502; NCBITaxon: 349746 YH, ZX Intranasal immunization with flagellin and the F1 antigen was protective against intranasal challenge with virulent Y. pestis CO92, with 93 to 100% survival of immunized mice. Lastly, vaccination of cynomolgus monkeys with flagellin and a fusion of the F1 and V antigens of Y. pestis induced a robust antigen-specific IgG antibody response [PubMed: 16428759]. YPMT1.84 (F1 capsule antigen) Protegen ID: 341; NCBI Gene GI: 1172839; NCBI Protein GI: 16082876; NCBI Protein Accession: NP_395430; NCBITaxon: 214092 YH, ZX Using a mouse model, YPO0606 (yapF) partially protected mice from infection with Y. pestis at a high challenge dosage (200x LD(50)) [PubMed: 19651863]. YapF Protegen ID: 342; NCBI Gene GI: 1173449; NCBI Protein GI: 218927800; NCBI Protein Accession: YP_002345675; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO1914 (irp7) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. Irp7 Protegen ID: 343; NCBI Gene GI: 1174753; NCBI Protein GI: 218929030; NCBI Protein Accession: YP_002346905; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO0612 may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YPO0612 Protegen ID: 344; NCBI Gene GI: 1173455; NCBI Protein GI: 218927806; NCBI Protein Accession: YP_002345681; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO3119 (htpG) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. HtpG Protegen ID: 345; NCBI Gene GI: 1175934; NCBI Protein GI: 218930152; NCBI Protein Accession: YP_002348027; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO3047 (ydeN) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YdeN Protegen ID: 346; NCBI Gene GI: 1175868; NCBI Protein GI: 218930092; NCBI Protein Accession: YP_002347967; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO1377 (lolA) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. LolA Protegen ID: 347; NCBI Gene GI: 1174218; NCBI Protein GI: 218928525; NCBI Protein Accession: YP_002346400; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPCD1.05c (yerA) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YerA Protegen ID: 348; NCBI Gene GI: 1172650; NCBI Protein GI: 16082696; NCBI Protein Accession: NP_395142; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO0420 may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. YPO0420 Protegen ID: 349; NCBI Gene GI: 1173265; NCBI Protein GI: 218927621; NCBI Protein Accession: YP_002345496; NCBITaxon: 214092 YH, ZX Using a mouse plague model, YPO3720 (hpmB) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863]. HpmB Protegen ID: 350; NCBI Gene GI: 1176539; NCBI Protein GI: 218930726; NCBI Protein Accession: YP_002348601; NCBITaxon: 214092 YH, ZX Study tested the efficacy of 2 proteins, Psn and a portion of LcrV in protecting mice against virulent Yersinia pestis challenge. Results show that the truncated LcrV protein delivered by RASV is sufficient to afford a full protective immune response in a mouse model of bubonic plague and the Psn protein afforded partial protection in a non-optimized system [PubMed: 17966435]. Psn Protegen ID: 351; NCBI Gene GI: 1147351; NCBI Protein GI: 22126288; NCBI Protein Accession: NP_669711; NCBITaxon: 187410 YH, ZX Study evaluated the humoral immune response of mice that survived lethal Y. pestis aerosol challenge after antibiotic treatment. Results indicated that one of the predominant antibody response of mice surviving pneumonic plague after treatment with antibiotics was to yopH [PubMed: 10085037]. YopH from Y. pestis CO92 Protegen ID: 352; NCBI Gene GI: 1172712; NCBI Protein GI: 16082755; NCBI Protein Accession: NP_395201; NCBITaxon: 214092 YH, ZX Complexes of YopB (pYV0055), YopD, and YopE (BDE) secreted by Yersinia pseudotuberculosis were purified by affinity chromatography and used as immunogens to determine if antibodies to the translocon could provide protection against Y. pestis in mice. The YopB protein or a complex of YopB and YopD (BD) was purified and determined by vaccination to be immunogenic in mice. Mice actively vaccinated with BD or passively vaccinated with anti-BD serum were protected against lethal challenge with F1(-) Y. pestis [PubMed: 18765742]. pYV0055 Protegen ID: 354; NCBI Gene GI: 2952948; NCBI Protein GI: 51593897; NCBI Protein Accession: YP_068464; NCBITaxon: 273123 YH, ZX Vaccination of mice with deF1 DNA conferred protection against subcutaneous infection with the virulent Y. pestis Kimberley53 strain, even at challenge amounts as high as 4,000 50% lethal doses [PubMed: 12496187 ]. Caf1 from Y. pestis Protegen ID: 355; NCBI Protein GI: 48621; NCBITaxon: 632 YH, ZX Following passive immunization, antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. As assessed by immunoblotting, pooled adult human sera contained antibodies reactive with P145. Following passive immunization, these antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. Antibody to P145 may contribute to protection against Brazilian purpuric fever [PubMed: 1937817]. P145 Protegen ID: 356 YH, ZX The ApxI antigen is an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p < 0.01) [PubMed: 17993753]. ApxIA Protegen ID: 358; NCBI Protein GI: 312899; NCBITaxon: 715 YH, ZX The levels of local and systemic antibodies specific to the Apx antigens were investigated in mice orally immunized with Apx antigen-expressing yeast. Specific IgA responses to ApxIA or ApxIIA in the intestines and lungs from mice immunized with yeast expressing Apx antigens were significantly higher than those in the control groups after the second and third immunizations, respectively (p < 0.05). All mice were monitored for up to 72 h after challenge with the MLD of an A. pleuropneumoniae field isolate. Overall, the final survival rates of the vaccinated groups were higher than those of the control groups at each time point [PubMed: 17993753]. ApxIIA Protegen ID: 360; NCBI Protein GI: 52630374; NCBITaxon: 715 YH, ZX Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP (cps5C), LPS, and HP was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686]. CP Protegen ID: 361 YH, ZX Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP, LPS, and HP (APP7_1016) was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686]. APP7_1016 Protegen ID: 362; NCBI Gene GI: 6398034; NCBI Protein GI: 190150285; NCBI Protein Accession: YP_001968810; NCBITaxon: 537457 YH, ZX The aroA gene of A. salmonicida was cloned in Escherichia coli, and the nucleotide sequence was determined. Vaccination of brown trout with 10(7) CFU of A. salmonicida 644Rb aroA by intraperitoneal injection resulted in a 253-fold increase in the 50% lethal dose (LD50) compared with unvaccinated controls challenged with a virulent clinical isolate 9 weeks later [PubMed: 8478107]. AroA Protegen ID: 366; NCBI Protein GI: 512545; NCBITaxon: 645 YH, ZX Passive immunisation of Atlantic salmon with rainbow trout or rabbit anti-AsaP1 antisera conferred significant protection against challenge with a virulent A. salmonicida [Ref1011:Gudmundsdottir et al., 1997] AsaP1 Protegen ID: 367; NCBI Gene GI: 4998702; NCBITaxon: 382245 YH, ZX RAP-1 (21B4) is a candidate for inclusion in a B. bovis vaccine based on its ability to induce partial protection in vaccinates, defined as a significant reduction in parasitemia upon challenge [PubMed: 1441189]. RAP-1 Protegen ID: 368; NCBI Gene GI: 5479143; NCBI Protein GI: 156087004; NCBI Protein Accession: XP_001610909; NCBITaxon: 484906 YH, ZX Crude extracts of Babesia bovis parasites were systematically fractionated and tested in numerous sequential vaccination/challenge experiments in adult cattle. Two of these, GST-12D3 and GST-11C5, when used in combination were almost as protective as has been previously shown for the commercially available live attenuated vaccine [PubMed: 1441189]. 12D3 Protegen ID: 371; NCBI Gene GI: 5478971; NCBI Protein GI: 156086656; NCBI Protein Accession: XP_001610737; NCBITaxon: 484906 YH, ZX Crude extracts of Babesia bovis parasites were systematically fractionated and tested in numerous sequential vaccination/challenge experiments in adult cattle. A short fragment of the third antigen (21B4) has been shown to be protective [PubMed: 1441189]. 21B4 Protegen ID: 373; NCBI Protein GI: 1246924; NCBITaxon: 5865 YH, ZX Study described the construction and evaluation of an adenovirus vaccine expressing domain 4 of Bacillus anthracis protective antigen, Ad.D4. Ad.D4 elicited antibodies to protective antigen 14 days after a single intramuscular injection, which were further increased upon boosting. Furthermore, two doses of Ad.D4 4 weeks apart were sufficient to protect 67% of mice from toxin challenge [PubMed: 16428747]. PagA from B. anthracis Protegen ID: 374; NCBI Protein GI: 9280533; NCBITaxon: 1392 YH, ZX A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test [PubMed: 2056199]. FhaB Protegen ID: 375; NCBI Protein GI: 3980256; NCBITaxon: 520 YH, ZX A study demonstrated that passive immunization with specific anti-B. pertussis adenylate cyclase antibodies or active immunization with purified B. pertussis secreted adenylate cyclase (cyaA) protect mice against a lethal respiratory challenge with B. pertussis or B. parapertussis. Results suggest that adenylate cyclase might be the primary cytotoxin responsible for mouse pulmonary lesions during respiratory tract infection with B. pertussis or with the related species B. parapertussis and is a protective antigen of B. pertussis [PubMed: 2622329]. CyaA Protegen ID: 376; NCBI Protein GI: 580668; NCBITaxon: 520 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. PtxD Protegen ID: 377; NCBI Protein GI: 225311181; NCBITaxon: 520 YH, ZX Researchers constructed isogenic mutants of B. pertussis Tohama expressing the alleles ptxA1 or ptxA2 and prn1 or prn2 and compared the efficacies of an acellular pertussis vaccine against the mutants in a mouse model. While the vaccine was effective against all of the B. pertussis strains regardless of the allele expression pattern, the strain expressing ptxA1 and prn2 displayed a survival advantage over the other strains [PubMed: 20357056]. Prn Protegen ID: 378; NCBI Gene GI: 2664290; NCBI Protein GI: 33592195; NCBI Protein Accession: NP_879839; NCBITaxon: 257313 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. PtxA Protegen ID: 379; NCBI Gene GI: 2665068; NCBI Protein GI: 33594638; NCBI Protein Accession: NP_882282; NCBITaxon: 257313 YH, ZX A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [PubMed: 17011680]. Cpn60 Protegen ID: 382; NCBI Protein GI: 968920; NCBITaxon: 520 YH, ZX A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [PubMed: 17011680]. BrkA Protegen ID: 383; NCBI Protein GI: 562026; NCBITaxon: 520 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. PtxB Protegen ID: 384; NCBI Protein GI: 225311180; NCBITaxon: 520 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. PtxC Protegen ID: 385; NCBI Protein GI: 225311183; NCBITaxon: 520 YH, ZX BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973]. PtxE Protegen ID: 386; NCBI Protein GI: 225311182; NCBITaxon: 520 YH, ZX Protection against a BHV-1 challenge was obtained in calves immunized with the plasmid encoding tgD-VP22 (UL49), as shown by significant reductions in viral excretion [PubMed: 15650221]. UL49 Protegen ID: 389; NCBI Gene GI: 1487397; NCBI Protein GI: 9629826; NCBI Protein Accession: NP_045310; NCBITaxon: 10320 YH, ZX Calves were injected intranasally with either AdCMVgC or AdCMVgD (US6) or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD (US6) followed by the live vaccine and to a lower extent with the combination of the two recombinants. Calves were protected against intranasal BHV-1 challenge performed 3 weeks after the second immunization [PubMed: 11818166]. US6 Protegen ID: 390; NCBI Gene GI: 1487406; NCBI Protein GI: 9629886; NCBI Protein Accession: NP_045370; NCBITaxon: 10320 YH, ZX Immunization of calves with truncated gpI (US7) protein induced gpI-specific nasal IgA, IgG1, serum neutralizing antibodies and gpI-specific peripheral lymphocyte proliferation. All immunized calves were protected from clinical disease after BHV-1 challenge. Further, nine of ten immunized calves had no intranasal viral shedding [PubMed: 8147097]. US7 Protegen ID: 392; NCBI Gene GI: 4783432; NCBI Protein GI: 9629887; NCBI Protein Accession: NP_045371; NCBITaxon: 10320 YH, ZX A DNA vaccine expressing glycoprotein C (gC, UL44) of bovine herpesvirus-1 (BHV-1) was evaluated for inducing immunity in bovines. Results indicate that DNA immunization with gC could induce neutralizing antibody and lymphoproliferative responses with BHV-1 responsive memory B cells in bovines. However, the immunity developed sufficient for only partial protection against BHV-1 challenge [PubMed: 11182496]. UL44 Protegen ID: 393; NCBI Gene GI: 4783424; NCBI Protein GI: 9629830; NCBI Protein Accession: NP_045314; NCBITaxon: 10320 YH, ZX Chitosan-DNA vaccines were prepared by embedding pcDNA3.1(+)-cadF and pcDNA3.1(+)-peblA with chitosan respectively. The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87 respectively. The chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70 [PubMed: 18206008]. CadF Protegen ID: 396; NCBI Protein GI: 4704601; NCBITaxon: 197 YH, ZX Chitosan-DNA vaccines were prepared by embedding pcDNA3.1(+)-cadF and pcDNA3.1(+)-peblA with chitosan respectively. The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87 respectively. The chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70 [PubMed: 18206008]. Peb1A Protegen ID: 397; NCBI Protein GI: 112360246; NCBITaxon: 192222 YH, ZX Mice were immunized intranasally with two doses of 3 to 50 microgram of MBP-FlaA. The protective efficacies of a 50 microgram of MBP-FlaA plus LT(R192G) dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized with 50 microgram of MBP-FlaA plus LT(R192G) intranasally were challenged orally with 8 x 10(10), 8 x 10(9), or 8 x 10(8) cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively [PubMed: 10531231]. FlaA from C. jejuni 81-176 Protegen ID: 398; NCBI Gene GI: 4682159; NCBI Protein GI: 121612545; NCBI Protein Accession: YP_001000997; NCBITaxon: 354242 YH, ZX Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176 [PubMed: 18426878]. FspA1 Protegen ID: 399; NCBI Protein GI: 116292649; NCBITaxon: 197 YH, ZX Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. All three proteins were immunogenic, FlaC provided an 18% protection against disease from C. jejuni 81-176 [PubMed: 18426878]. FlaC Protegen ID: 400; NCBI Gene GI: 4682885; NCBI Protein GI: 121612344; NCBI Protein Accession: YP_001000416; NCBITaxon: 354242 YH, ZX Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486 [PubMed: 18426878]. FspA2 Protegen ID: 409; NCBI Protein GI: 116292677; NCBITaxon: 197 YH, ZX A DNA vaccination trial was performed on sheep to determine whether vaccination with bovine leukemia virus (BLV) transactivator Tax DNA is effective against BLV infection. Results showed higher levels of virus titers in control sheep than those in Tax-vaccinated sheep. Higher levels of IFN-gamma mRNA expression have been demonstrated in vaccinated sheep after the challenge. These results suggested that Th1 type immune response induced by Tax DNA vaccine inhibited BLV propagation in vaccinated sheep at the early phase of infection [PubMed: 14665749]. Tax Protegen ID: 410; NCBI Gene GI: 2760848; NCBI Protein GI: 9626228; NCBI Protein Accession: NP_056895; NCBITaxon: 11901 YH, ZX The bovine leukemia virus (BLV) envelope gene encoding extracellular glycoprotein gp51 (encoded by env gene) and transmembrane glycoprotein gp30 was cloned into a vehicle expression vector under the human cytomegalovirus (CMV) intermediate early promoter. The intramuscular injection of this plasmid vector generated a cellular immune response. Seven out of ten cows vaccinated with the DNA construct resisted a drastic challenge [PubMed: 10824867]. Env/Rex/Tax Protegen ID: 411; NCBI Gene GI: 2760849; NCBI Protein GI: 9626230; NCBI Protein Accession: NP_056898; NCBITaxon: 11901 YH, ZX Young mink kits (n=8) were vaccinated with DNA plasmids encoding the viral haemagglutinin protein (H) of a vaccine strain of Canine distemper virus (CDV). The mink were protected against viraemia, lymphopenia, clinical disease and changes in the percentage of IFN-gamma producing peripheral blood leucocytes after challenge inoculation with a recent wild type strain of CDV. Essentially, these results demonstrate that early life DNA vaccination with the H gene of a CDV vaccine strain induced robust protective immunity against a recent wild type CDV [PubMed: 19596418]. CDVgp6 haemagglutinin protein H Protegen ID: 412; NCBI Gene GI: 1489792; NCBI Protein GI: 9630651; NCBI Protein Accession: NP_047206; NCBITaxon: 11232 YH, ZX Study reports the engineering and the characterization of two replication-competent canine adenovirus type 2 (CAV2)-based vaccines expressing, respectively, the CDV hemagglutinin (HA) and fusion (F) antigens (CDVgp5). We first demonstrated that the intranasal vaccination with a mixture of both recombinant CAV2s provides an excellent level of protection in seronegative puppies, confirming the value of replication-competent adenovirus-based vectors for mucosal vaccination [PubMed: 12297394]. CDVgp5 Protegen ID: 413; NCBI Gene GI: 1489793; NCBI Protein GI: 9630650; NCBI Protein Accession: NP_047205; NCBITaxon: 11232 YH, ZX A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). Results show that the inactivated CVP is able to protect dogs from a lethal challenge with CPV following parenteral immunization with the vaccine. Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge. [PubMed: 11395200]. VP2 Protegen ID: 414; NCBI Gene GI: 1489588; NCBITaxon: 10788 YH, ZX This study shows that a plasmid DNA (pGT36VP1) encoding the full length VP1 region of canine parvovirus (CPV) induces immunity that protects dogs against challenge with virulent virus [PubMed: 9569471]. VP1 Protegen ID: 415; NCBI Gene GI: 1489587; NCBITaxon: 10788 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. DNA pol III Gamma and Tau (CP #1, dnaX) was found to be protective. CP #1 (dnaX) was more protective than the live-vaccine, positive control. [PubMed: 15811648]. DnaX Protegen ID: 416; NCBI Protein GI: 62148024; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #2, gatC) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. GatC Protegen ID: 417; NCBI Protein GI: 62184917; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Protective clone CP #4 (OMP90A, pomp90A) was diluted 1/2000 in a non-protective sublibrary pool of clones. This CP #4-spiked sublibrary conferred protection. Five clones were significantly more protective than the genes encoding fewer than 50 amino acids (CP #1 and 7, p-value of less than 0.05 when comparing lung weights). [PubMed: 15811648]. Pomp90A Protegen ID: 418; NCBI Protein GI: 187438939; NCBITaxon: 83555 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. CP #5 (Transglycolase/transpeptidase, CAB049 putative penicillin-binding protein) was significantly more protective than the genes encoding fewer than 50 amino acids (p-value of less than 0.05 when comparing lung weights). The chlamydial loads generally tracked with protection and the most protective genes were significantly lower than in unvaccinated controls (p < 0.05 in the Mannhitney U-test for genes CP #1, 2, 4, 9, 10) [PubMed: 15811648]. CAB049 putative penicillin-binding protein Protegen ID: 419; NCBI Protein GI: 62184696; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. CP #7 (omlA) was significantly more protective than the genes encoding fewer than 50 amino acids (p-value of less than 0.05 when comparing lung weights). The chlamydial loads generally tracked with protection and the most protective genes were significantly lower than in unvaccinated controls (p < 0.05 in the Mannhitney U-test for genes CP #1, 2, 4, 9, 10) [PubMed: 15811648]. OmlA Protegen ID: 420; NCBI Protein GI: 62184824; NCBITaxon: 218497 YH, ZX Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Of the 14 individually tested clones, CP #1 through CP #9 had positive relative protection scores. CP #8 (CAB613, Oligopeptidase) was found to confer protection [PubMed: 15811648]. CAB613 putative peptidase Protegen ID: 421; NCBI Protein GI: 62185225; NCBITaxon: 218497 YH, ZX Animals vaccinated with Gam82 and challenged with E. maxima showed lower oocyst shedding and reduced intestinal pathology compared with non-vaccinated and parasite-challenged animals. Gam82 vaccination also stimulated the production of antigen-specific serum antibodies and induced greater levels of IL-2 and IL-15 mRNAs compared with non-vaccinated controls. These results demonstrate that the Gam82 recombinant protein protects against E. maxima and augments humoral and cell-mediated immunity [PubMed: 20178868]. Gam82 Protegen ID: 457; NCBI Protein GI: 38565038; NCBITaxon: 5804 YH, ZX Birds vaccinated with Eimeria tenella microneme recombinant gene (EtMIC2) and encoded protein developed protective immunity against infection by E. tenella as assessed by significantly increased body weight gain and decreased fecal oocyst shedding compared with non-vaccinated controls. Vaccination with the EtMIC2 gene also led to protective immunity against infection by E. acervulina, but not E. maxima [PubMed: 15882535]. MIC2 Protegen ID: 459; NCBI Protein GI: 225579627; NCBITaxon: 5802 YH, ZX Two recombinant Mycobacterium bovis BCG (rBCG) strains carrying the Eimeria tenella rhomboid gene (Rho) delivered by extrachromosomal vector pMV261 and integrative vector pMV361 were evaluated for their ability to protect chickens against E. tenella challenge. Chickens were immunized intranasal with BCG, rBCG pMV261-Rho, or rBCG pMV361-Rho twice at a 2-week interval. All the recombinant BCG immunized chickens developed specific immune responses, and there was a significant increases of the percentages of CD4(+) and CD8(+) cells compared to the control (P<0.05). Challenge experiments demonstrated that the two rBCG strains could provide significant protection against E. tenella challenge [PubMed: 19117681]. Rho Protegen ID: 460; NCBI Protein GI: 84043169; NCBITaxon: 5802 YH, ZX The immunization procedure of DNA vaccine pcDNA-TA4-IL-2 of Eimeria tenella, including route, dose, time of immunization and age of primary immunization of chicken, was optimized. results illustrated that 25 microg was the optimal dose and intramuscular injection was the most effective route to induce protective immunity in Chinese Yellow chickens [PubMed: 19019543]. TA4 Protegen ID: 461; NCBI Protein GI: 84783094; NCBITaxon: 5802 YH, ZX The Eimeria tenella antigen gene (3-1E) and chicken interferon gamma gene (ChIFN-gamma) were subcloned into the mammalian expression vector proVAX forming the plasmids proE and prol. After challenge the proIE-vaccinated chickens showed protective immunity as demonstrated by significantly reduced oocyst shedding [PubMed: 17274297]. 3-1E Protegen ID: 463; NCBI Protein GI: 126362934; NCBITaxon: 5802 YH, ZX A cDNA clone derived from sporulated oocysts of Eimeria tenella and encoding the expression product GX3262 was identified using a monoclonal antibody raised against Eimeria acervulina sporozoites. After challenge with an experimental E. tenella infection, the greatest degree of protection in immunized broiler chickens was seen after only a single immunization of 2-day-old birds with a live recombinant E. coli preparation [PubMed: 2659532]. GX3262 Protegen ID: 464; NCBI Protein GI: 102304; NCBITaxon: 5802 YH, ZX Study describes experiments which demonstrate that the vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge [PubMed: 12934796]. Env Protegen ID: 465; NCBI Gene GI: 1491868; NCBI Protein GI: 9630709; NCBI Protein Accession: NP_047256; NCBITaxon: 11768 YH, ZX The vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge [PubMed: 12934796]. Gag Protegen ID: 466; NCBI Protein GI: 323916; NCBITaxon: 11768 YH, ZX Intranasal immunization of HLA-DR4 tg mice with the single antigen FopB from F. tularensis subsp. novicida conferred significant protection against lethal pulmonary challenge with an F. tularensis subsp. holarctica live vaccine strain. FopB Protegen ID: 468; NCBI Gene GI: 4547777; NCBI Protein GI: 118496734; NCBI Protein Accession: YP_897784; NCBITaxon: 401614 YH, ZX Intranasal vaccination with KKF235 (F. tularensis subsp. novicida mutant (DeltaiglB) ) protected mice from subsequent homotypic challenge with U112 as well as heterotypic challenge with F. tularensis subsp. holarctica (LVS). Most significantly, oral immunization with KKF235 protected mice from a highly lethal subsp. tularensis (SCHU S4) pulmonary challenge [PubMed: 20016043]. IglB Protegen ID: 469; NCBI Gene GI: 4548125; NCBI Protein GI: 118497903; NCBI Protein Accession: YP_898953; NCBITaxon: 401614 YH, ZX Mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain [PubMed: 19126421]. IglC1 Protegen ID: 470; NCBI Gene GI: 3191591; NCBI Protein GI: 56708413; NCBI Protein Accession: YP_170309; NCBITaxon: 177416 YH, ZX Mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain [PubMed: 19126421]. IglC2 Protegen ID: 471; NCBI Gene GI: 3191814; NCBI Protein GI: 56708721; NCBI Protein Accession: YP_170617; NCBITaxon: 177416 YH, ZX Immunization with WbtI(G191V) protected mice against a relatively low-dose intraperitoneal challenge with LVS (F. tularensis subspecies holarctica live vaccine strain), but was less protective against a high-dose challenge [PubMed: 17768257]. WbtI Protegen ID: 472; NCBI Gene GI: 5522688; NCBI Protein GI: 156502002; NCBI Protein Accession: YP_001428067; NCBITaxon: 458234 YH, ZX Researchers have shown that mice that had been immunized with purified heat shock protein 60 (Hsp60, groEL) isolated from Francisella tularensis were protected against a subsequent challenge with some strains of the bacterium [PubMed: 15213156]. GroEL Protegen ID: 473; NCBI Protein GI: 282159959; NCBITaxon: 510831 YH, ZX A 17-kDa lipoprotein, TUL4, of the facultative intracellular bacterium Francisella tularensis is one of several membrane proteins that induce an in vitro response in T cells from F. tularensis-primed humans. When mice were immunized with S. typhimurium chi 4072(pTUL4-15), some animals showed an antibody response and a T-cell response to TUL4. The present study demonstrated that the 17-kDa lipoprotein TUL4 of F. tularensis is involved in a protective immunity to tularemia [PubMed: 1612751]. TUL4 Protegen ID: 474; NCBI Protein GI: 148688; NCBITaxon: 263 YH, ZX C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. SodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice [PubMed: 18692537]. SodB from F. tularensis SCHU S4 Protegen ID: 475; NCBI Gene GI: 3190713; NCBI Protein GI: 56707247; NCBI Protein Accession: YP_169143; NCBITaxon: 177416 YH, ZX Anti-FopA MAbs protected 90% of nave C3H/HeN mice from lethal challenge with F. tularensis LVS when administered prophylactically as well as therapeutically [PubMed: 19176692]. FopA Protegen ID: 476; NCBI Gene GI: 4306351; NCBI Protein GI: 115315051; NCBI Protein Accession: YP_763774; NCBITaxon: 393011 YH, ZX Anti-lpnA MAbs conferred significant, although not complete, protection of nave C3H/HeN mice from lethal challenge with F. tularensis LVS when administered therapeutically [PubMed: 19176692]. LpnA Protegen ID: 477; NCBI Gene GI: 3191792; NCBI Protein GI: 56708002; NCBI Protein Accession: YP_169898; NCBITaxon: 177416 YH, ZX The gene encoding the full length cyst wall protein-2 (CWP2) from Giardia lamblia was subcloned into the pCDNA3 mammalian expression vector and stably introduced into S. typhimurium STM1. Challenge infection with live Giardia muris cysts revealed that mice receiving the CWP2-encoding DNA vaccine were able to reduce cyst shedding by approximately 60% compared to control mice [PubMed: 17996337]. CWP2 Protegen ID: 479; NCBI Gene GI: 5703171; NCBI Protein GI: 159120052; NCBI Protein Accession: XP_001710242; NCBITaxon: 50803 YH, ZX Rats vaccinated with PD (hpd) cleared NT H. influenzae better after middle ear and pulmonary bacterial challenge, and chinchillas vaccinated with PD showed significant protection against NT H. influenzae-dependent acute otitis media. In a clinical trial involving children, PD was used as an antigenically active carrier protein in an 11-valent pneumococcal conjugate investigational vaccine; significant protection was achieved against acute otitis media not only caused by pneumococci but also caused by NT H. influenzae [PubMed: 18230042]. Hpd Protegen ID: 480; NCBI Protein GI: 148971; NCBITaxon: 727 YH, ZX In a chinchilla model of otitis media, initial screening of P5-fimbrin, delivered singly or in combination with either Freund's adjuvant or alum, indicated that augmented bacterial clearance from the nasopharynx, the middle ears, or both anatomical sites could be induced by parenteral immunization with P5-fimbrin combined with lipoprotein D, lipoprotein D alone, or the synthetic chimeric peptide LB1 (derived from P5-fimbrin), respectively [PubMed: 10338477]. OmpP5 Protegen ID: 482; NCBI Gene GI: 3430592; NCBI Protein GI: 68249712; NCBI Protein Accession: YP_248824; NCBITaxon: 281310 YH, ZX Purified rD15 was found to be highly immunogenic in mice, guinea pigs, and rabbits, and passive transfer of anti-rD15 antibodies protected infant rats from challenge with H. influenzae type b or type a in infant rat models of bacteremia [PubMed: 9284140]. D15 Protegen ID: 483; NCBI Gene GI: 3430379; NCBI Protein GI: 68249503; NCBI Protein Accession: YP_248615; NCBITaxon: 281310 YH, ZX Rabbit antibody prepared against P2 from one strain was cross-reactive with P2 isolated from the other two heterologous strains by Western blot. This antibody passively protected infant rats against type b Haemophilus infection caused by the homologous organism, but not against challenge by a strain with the heterologous 36,500 mol wt P2 protein [PubMed: 6603479]. OmpP2 Protegen ID: 485; NCBI Gene GI: 3429565; NCBI Protein GI: 68248747; NCBI Protein Accession: YP_247859; NCBITaxon: 281310 YH, ZX Seoul virus (SEOV) is one of the four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). A replication-competent recombinant canine adenovirus type 2 expressing the Gc protein of SEOV (rCAV-2-Gc) in BALB/c mice induced complete protection against a intensive infectious challenge with ~1,000 50% infective doses (ID50) for SEOV strain CC-2 [PubMed: 20181748]. Gc Protegen ID: 486; NCBI Protein GI: 284157806; NCBITaxon: 11608 YH, ZX Study used a deer mouse infection model to test the protective efficacy of genetic vaccine candidates for Sin Nombre (SN) virus that were known to provoke immunological responses in BALB/c mice. Protective epitopes were localized in each of four overlapping cDNA fragments that encoded portions of the SN virus G1 glycoprotein antigen; the nucleocapsid gene also was protective [PubMed: 12075094]. G1 Protegen ID: 487; NCBI Protein GI: 1113859; NCBITaxon: 37705 YH, ZX Study used a deer mouse infection model to test the protective efficacy of genetic vaccine candidates for Sin Nombre (SN) virus that were known to provoke immunological responses in BALB/c mice. Protective epitopes were localized in each of four overlapping cDNA fragments that encoded portions of the SN virus G1 glycoprotein antigen; the nucleocapsid gene (SNVsSgp1) also was protective [PubMed: 12075094]. SNVsSgp1 Protegen ID: 489; NCBI Gene GI: 2943142; NCBI Protein GI: 38371726; NCBI Protein Accession: NP_941975; NCBITaxon: 37705 YH, ZX To investigate the ability of recombinant N (rN, nucleocapsid proteins) from different hantaviruses to elicit cross-protection, we immunized bank voles with rN from Puumala (PUUV), Topografov (TOPV), Andes (ANDV), and Dobrava (DOBV) viruses and subsequently challenged them with PUUV. All animals immunized with PUUV (PUUVsSgp1) and TOPV rN were completely protected [PubMed: 12050380]. PUUVsSgp1 Protegen ID: 490; NCBI Gene GI: 2943083; NCBI Protein GI: 38371721; NCBI Protein Accession: NP_941984; NCBITaxon: 11604 YH, ZX To investigate the ability of recombinant N (rN, nucleocapsid proteins) from different hantaviruses to elicit cross-protection, we immunized bank voles with rN from Puumala (PUUV), Topografov (TOPV), Andes (ANDV), and Dobrava (DOBV) viruses and subsequently challenged them with PUUV. All animals immunized with PUUV and TOPV rN were completely protected [PubMed: 12050380]. N protein [Topografov virus] Protegen ID: 491; NCBI Protein GI: 4757106; NCBITaxon: 83192 YH, ZX Researchers vaccinated hamsters with a vaccinia virus-vectored vaccine expressing the M and the S segments of Hantaan (HTN) virus and challenged them with HTN, Seoul (SEO), or Puumala (PUU) virus. Study found that vaccinated hamsters, challenged with HTN or SEO virus, were neither viremic nor had evidence of virus in their lungs or kidneys [PubMed: 7666542]. M Segment Protegen ID: 492; NCBI Protein GI: 1389703; NCBITaxon: 11599 YH, ZX Passive transfer of spleen cells from mice immunized with rNP (HTNVsSgp1) conferred partial protection or prolongation of time to death from fatal Hantaan virus infection in suckling mice which were challenged with Hantaan virus at 40 LD50 (survival rate: 43%) or 4 LD50 (survival rate: 43%) [PubMed: 8517793]. HTNVsSgp1 Protegen ID: 493; NCBI Gene GI: 2943078; NCBI Protein GI: 38371711; NCBI Protein Accession: NP_941977; NCBITaxon: 11599 YH, ZX Nonreplicating adenovirus (Ad) vectors that express Andes hantavirus (ANDV) nucleocapsid protein (AdN, ANDVsSgp1) or glycoproteins (AdG(N) and AdG(C)) were constructed . When administered once, all three Ad vectors, individually or in combination, elicited a robust immune response that protected Syrian hamsters from a lethal ANDV infection that mimics the pulmonary disease seen in humans. No vaccinated animal died, and there were no obvious clinical signs of disease [PubMed: 19403663]. ANDVsSgp1 Protegen ID: 494; NCBI Gene GI: 991232; NCBI Protein GI: 19744950; NCBI Protein Accession: NP_604471; NCBITaxon: 46607 YH, ZX Study compared a current HBV vaccine that contains recombinant hepatitis B surface antigen HBsAg) adsorbed to alum in chimpanzees, with two novel vaccine strategies that have proven superior to the current vaccine in mice. All animals receiving either control or CpG-containing subunit vaccines at 0 and 4 weeks attained titers of HBsAg-specific antibody (anti-HBs) considered protective (> or =10 mIU/ml) and were indeed protected from challenge at 8 weeks with 10(3.5) 50% chimp infectious doses (CID(50)) of intravenous HBV [PubMed: 16428890]. Hepatitis B surface antigen Protegen ID: 495; NCBI Protein GI: 128168861; NCBITaxon: 10407 YH, ZX The immunological protection of pVAX-PS, a DNA vaccine, was assessed in the tree shrews model. pVAX-PS was constructed by inserting the gene encoding the middle (pre-S2 plus S) envelope protein of HBV into a plasmid vector pVAX1. Results indicated that pVAX-PS immunization could induce remarkable humoral immune response and prevent the experimental tree shrews from infection of HBV [PubMed: 12932306]. PreS2 middle surface protein Protegen ID: 496; NCBI Protein GI: 113207330; NCBITaxon: 10407 YH, ZX Immunisation with a plasmid encoding the DHBV large (L) envelope protein (HBVgp2 pre-S1/pre-S2/S) induced a strong, specific, highly neutralising and long-lasting anti-preS humoral response in uninfected ducks. Importantly, maternal antibodies elicited by such DNA immunisation were vertically transmitted and protected progeny against viral challenge [PubMed: 12531335]. HBVgp2 pre-S1/pre-S2/S Protegen ID: 497; NCBI Gene GI: 944569; NCBI Protein GI: 77680739; NCBI Protein Accession: YP_355333; NCBITaxon: 10407 YH, ZX The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome. Expression of gD2 in cells infected with the recombinant Oka strain VZV (ROka-gD2) was confirmed by antibody staining of fixed cells and by immunoblot analysis. Forty days after the third inoculation, guinea pigs were challenged intravaginally with HSV-2. Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001) [PubMed: 7494331]. US6 Protegen ID: 499; NCBI Gene GI: 1487358; NCBI Protein GI: 9629336; NCBI Protein Accession: NP_044536; NCBITaxon: 10310 YH, ZX The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection [PubMed: 19641376]. UL27 from Herpes simplex virus type 2 Protegen ID: 500; NCBI Protein GI: 1869850; NCBITaxon: 10310 YH, ZX BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 [PubMed: 19174474]. US5 Protegen ID: 501; NCBI Gene GI: 2703406; NCBI Protein GI: 9629447; NCBI Protein Accession: NP_044668; NCBITaxon: 10298 YH, ZX Study demonstrated that recombinant Listeria monocytogenes (Lm) expressing the H-2K(b) glycoprotein B (gB, UL27)(498-505) peptide from HSV-1 triggers a robust CD8 T cell response to this Ag resulting in protective immunity to HSV infection in mice [PubMed: 17404252]. UL27 from Herpes simplex virus type 1 Protegen ID: 502; NCBI Gene GI: 2703455; NCBI Protein GI: 9629408; NCBI Protein Accession: NP_044629; NCBITaxon: 10298 YH, ZX Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality [PubMed: 16621198]. ICP27 from Herpes simplex virus type 2 Protegen ID: 503; NCBI Protein GI: 124181; NCBITaxon: 10315 YH, ZX Epitopes from the ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins of HSV-1 were attached to either the J TCBL/ICBL or the G TCBL/ICBL. The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge with HSV [PubMed: 15569635]. ICP27 from Herpes simplex virus type 1 Protegen ID: 504; NCBI Protein GI: 75812153; NCBITaxon: 10298 YH, ZX In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 [PubMed: 10725197]. US4 Protegen ID: 505; NCBI Gene GI: 1487356; NCBI Protein GI: 9629334; NCBI Protein Accession: NP_044534; NCBITaxon: 10310 YH, ZX Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge [PubMed: 9728527]. UL44 Protegen ID: 506; NCBI Gene GI: 2703410; NCBI Protein GI: 9629425; NCBI Protein Accession: NP_044646; NCBITaxon: 10298 YH, ZX Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge [PubMed: 9728527]. US8 Protegen ID: 507; NCBI Gene GI: 2703448; NCBI Protein GI: 9629449; NCBI Protein Accession: NP_044670; NCBITaxon: 10298 YH, ZX E7 Researchers combined the HPV16 E7 peptide(38-61) with a murine IgG heavy chain constant region to construct a chimeric protein compound. The chimeric vaccine candidate was able to effectively protect mice against the challenge of HPV16-positive tumor cells, and to eradicate HPV16-expressing tumors in mice [PubMed: 15661238]. HPV E7 Protegen ID: 509; NCBI Gene GI: 1489079; NCBI Protein GI: 9627105; NCBI Protein Accession: NP_041326; NCBITaxon: 333760 YH, ZX L2 Antibody responses of mice (n = 120) and rabbits (n = 23) to vaccination with HPV-16 amino-terminal L2 polypeptides or multitype L2 fusion proteins were compared. 11-200 x 3 formulated in GPI-0100 adjuvant or alum with 1018 ISS protected mice against HPV-16 challenge (reduction in HPV-16 infection vs phosphate-buffered saline control, P < .001) 4 months after vaccination as well as HPV-16 L1 VLPs [PubMed: 19470949]. HPV L2 Protegen ID: 510; NCBI Gene GI: 1489081; NCBI Protein GI: 9627107; NCBI Protein Accession: NP_041331; NCBITaxon: 333760 YH, ZX E6 C57BL/6 mice vaccinated with pNGVL4a-E6/opt are able to generate potent protective and therapeutic antitumor effects against challenge with E6-expressing tumor cell line, TC-1 of HPV [PubMed: 16649071]. HPV E6 Protegen ID: 511; NCBI Gene GI: 1489078; NCBI Protein GI: 9627104; NCBI Protein Accession: NP_041325; NCBITaxon: 333760 YH, ZX L1 rAAV5, -8 and -9 vectors expressing an HPV16 L1/E7 fusion gene were generated and applied intranasally for combined prophylactic and therapeutic vaccination of mice. Vaccination with the rAAV vectors led to a significant protection of animals against a challenge with different HPV tumour cell lines [PubMed: 20032542]. HPV L1 Protegen ID: 512; NCBI Gene GI: 1489082; NCBI Protein GI: 9627108; NCBI Protein Accession: NP_041332; NCBITaxon: 333760 YH, ZX The DNA vaccine pIHNw-G encodes the glycoprotein of the fish rhabdovirus infectious hematopoietic necrosis virus (IHNV). Vaccine performance in rainbow trout was measured 3, 6, 13, 24, and 25 months after vaccination. At three months all fish vaccinated with 0.1 microg pIHNw-G had detectable neutralizing antibody (NAb) and they were completely protected from lethal IHNV challenge with a relative percent survival (RPS) of 100% compared to control fish [PubMed: 16154239]. G glycoprotein Protegen ID: 513; NCBI Gene GI: 1489848; NCBI Protein GI: 9628086; NCBI Protein Accession: NP_042679; NCBITaxon: 11290 YH, ZX BALB/c mice were immunized intranasally with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin)-combined with A or B virus recombinant NP. The NP-immune mice, when challenged intranasally with a sublethal dose of the virus 3 wk after immunization, had accelerated virus clearance from the nasal site in both an influenza type-specific and a nonspecific manner, as shown by the protection from high morbidity from the second day after challenge [PubMed: 8621928]. NP from Influenza B virus Protegen ID: 514; NCBI Gene GI: 956539; NCBI Protein GI: 8486155; NCBI Protein Accession: NP_056661; NCBITaxon: 11520 YH, ZX BALB/c mice were immunized intranasally with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin)-combined with A or B virus recombinant NP. The NP-immune mice, when challenged intranasally with a sublethal dose of the virus 3 wk after immunization, had accelerated virus clearance from the nasal site in both an influenza type-specific and a nonspecific manner, as shown by the protection from high morbidity from the second day after challenge [PubMed: 8621928]. NP from Influenza A virus H3N2 Protegen ID: 515; NCBI Protein GI: 3722159; NCBITaxon: 41857 YH, ZX Skin and mucosal vaccination provided complete protection from clinical signs of infection with ponies subjected to a challenge infection of Equine influenza virus, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding [PubMed: 10403592]. HA from Equine influenza virus H3N8 Protegen ID: 516; NCBI Protein GI: 404517; NCBITaxon: 31660 YH, ZX A nonpathogenic vector of the cytoplasmic domain of the VSV G protein and expressing influenza virus HA (derived from Influenza A virus (A/WSN/1933(H1N1))) provides complete protection from lethal influenza virus challenge after intranasal administration. A second vector with VSV G deleted and expressing HA (DeltaG-HA) is also protective and nonpathogenic and has the advantage of not inducing neutralizing antibodies to the vector itself [PubMed: 10196265]. HA from Influenza A virus (A/WSN/1933(H1N1)) Protegen ID: 518; NCBI Protein GI: 324200; NCBITaxon: 382835 YH, ZX A recombinant baculovirus expressing the hemagglutinin gene of the influenza virus, A/PR/8/34 (H1N1), under the control of the chicken beta-actin promoter, was constructed. Protection from a lethal challenge of the influenza virus was achieved by intranasal immunization of the recombinant baculovirus [PubMed: 12874198]. HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1)) Protegen ID: 519; NCBI Protein GI: 126599271; NCBITaxon: 211044 YH, ZX Two cyclic peptide analogues corresponding to residues 139-146 (site A) of influenza A virus haemagglutinin (strain X31) were synthesized. When OF1 mice were immunized with cyclic peptides, approximately 80% of the animals were protected against an intranasal challenge with influenza virus [PubMed: 2396470]. HA from Influenza A virus (A/Aichi/2/1968(H3N2)), (X31) Protegen ID: 520; NCBI Protein GI: 324132; NCBITaxon: 387139 YH, ZX Mice and ferrets were immunised with two doses of the split virus vaccine (12-24 microg haemagglutinin derived from Influenza A virus (A/chicken/Italy/13474/99(H7N1))) with or without aluminium hydroxide adjuvant and challenged 3 weeks after second dose with the highly pathogenic A/chicken/Italy/13474/99 (H7N1) virus. The vaccine induced significant protection from disease after challenge with the wild-type virus. In the murine lethal challenge model, vaccination effectively prevented death and, furthermore, formulation with adjuvant reduced excessive weight loss and viral shedding [PubMed: 19453487]. HA from Influenza A virus (A/chicken/Italy/13474/99(H7N1)) Protegen ID: 521; NCBI Protein GI: 32261025; NCBITaxon: 199442 YH, ZX Immunization and challenge experiments in mice indicated that even though vaccination with the recombinant HA vaccinia viruses derived from Influenza B virus (Strain B/England/222/82) induced different levels of cross-reactive neutralizing antibodies, mice vaccinated with either recombinant vaccinia virus were protected from infection with either subpopulation of influenza virus [PubMed: 3318092]. HA from Influenza B virus (Strain B/England/222/82) Protegen ID: 522; NCBI Protein GI: 122955; NCBITaxon: 11527 YH, ZX Mice vaccinated with a recombinant VLP vaccine from both influenza A H5N1 clade 1 and clade 2 isolates (Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1))) with pandemic potential were protected against challenge with lethal reassortant viruses expressing the H5N1 HA and NA, regardless if the H5N1 clade was homologous or heterologous to the vaccine [PubMed: 18231588]. HA from Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1)) Protegen ID: 523; NCBI Protein GI: 190344179; NCBITaxon: 389226 YH, ZX A targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope derived from Influenza A virus (A/Puerto Rico/8/34(H1N1)), CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity [PubMed: 18243429]. M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1)) Protegen ID: 524; NCBI Gene GI: 956528; NCBI Protein GI: 56583270; NCBI Protein Accession: NP_040979; NCBITaxon: 211044 YH, ZX Vaccination with HA-VRP derived from Influenza A virus (A/Hong Kong/1/68(H3N2)) did not strongly stimulate either neutralizing or IgG1 antibodies but did induce IgG2a antibodies. Expression of IgG2a antibodies in this context correlated with clearance of virus and increased protection against lethal influenza challenge [PubMed: 16960108]. HA from Influenza A virus (A/Hong Kong/1/68(H3N2)) Protegen ID: 525; NCBI Protein GI: 16960108; NCBITaxon: 10090 YH, ZX Researchers report that a DNA vaccine encoding hemagglutinin from the index human influenza isolate A/HK/156/97 provides immunity against H5N1 infection of mice [PubMed: 9971791]. HA from Influenza A virus (A/environment/Hong Kong/156/1997(H5N1)) Protegen ID: 527; NCBI Protein GI: 269826115; NCBITaxon: 680785 YH, ZX A simian adenovirus 24 (AdC7) vector expressing the influenza A/Puerto Rico/8/34 NP was tested for its efficacy in protecting BALB/c mice against two H5N1 strains. When tested in a mouse challenge model, there was a significantly improved survival rate following challenge with the Vietnam/1203/04 strain of H5N1 that has caused human outbreaks [PubMed: 17728024]. NP from Influenza A virus (A/Puerto Rico/8/34(H1N1)) Protegen ID: 528; NCBI Gene GI: 956531; NCBI Protein GI: 8486130; NCBI Protein Accession: NP_040982; NCBITaxon: 211044 YH, ZX The protective effect of neuraminidase (NA) was studied in a mouse protection test using isolated neuraminidase of A2/Aichi/68(H3N2) virus and the complete recombinant virus A/eq(Heq-1)-HK(N2) as antigens. Immunized mice were protected against A2/Aichi(H3N2) challenge virus; however, the protection rate was low in comparison to animals immunized with comparable amounts of the complete A2/68(H3N2) virus9 [PubMed: 1126575]. NA from Influenza A virus (A/Aichi/2/1968(H3N2)) Protegen ID: 530; NCBI Protein GI: 46401580; NCBITaxon: 387139 YH, ZX In mouse models of influenza infection, the vaccines derived from Influenza A virus (A/Solomon Islands/3/2006(H1N1)) hemagglutinin elicit robust antibody responses that mitigate disease and protect mice from lethal challenge [PubMed: 18493310]. HA from Influenza A virus (A/Solomon Islands/3/2006(H1N1)) Protegen ID: 531; NCBI Protein GI: 156123416; NCBITaxon: 464623 YH, ZX Results indicated that two doses of 10 microg of pCAGGoptiHA derived from Influenza A virus (A/Goose/Guangdong/1/96(H5N1)) could induce complete protection in chickens against H5 lethal virus challenge [PubMed: 17451817]. HA from Influenza A virus (A/Goose/Guangdong/1/96(H5N1)) Protegen ID: 532; NCBI Gene GI: 3654620; NCBI Protein GI: 73852955; NCBI Protein Accession: YP_308669; NCBITaxon: 93838 YH, ZX The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice [PubMed: 2781859]. HA from Influenza A virus (A/Yamagata/120/1986(H1N1)) Protegen ID: 533; NCBI Protein GI: 221344; NCBITaxon: 379740 YH, ZX The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice [PubMed: 2781859]. HA from Influenza A virus (A/Fukuoka/C29/85(H3N2)) Protegen ID: 534; NCBI Protein GI: 221306; NCBITaxon: 62549 YH, ZX Protection against a lethal influenza B virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding hemagglutinin (HA), neuraminidase (NA and NB) and nucleoprotein (NP) from the B/Ibaraki/2/85 virus. Both HA and NA DNAs conferred complete protection against the lethal challenge in all the tested mouse strains [PubMed: 11163667]. HA from Influenza B virus (B/Ibaraki/2/85) Protegen ID: 535; NCBI Protein GI: 122959; NCBITaxon: 107411 YH, ZX Protection against a lethal influenza B virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding hemagglutinin (HA), neuraminidase (NA and NB) and nucleoprotein (NP) from the B/Ibaraki/2/85 virus. Both HA and NA DNAs conferred complete protection against the lethal challenge in all the tested mouse strains [PubMed: 11163667]. NA from Influenza B virus (B/Ibaraki/2/85) Protegen ID: 536; NCBI Protein GI: 53829726; NCBITaxon: 107411 YH, ZX Viral challenge studies showed that live BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1 [PubMed: 20071572]. HA from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) Protegen ID: 537; NCBI Protein GI: 113497156; NCBITaxon: 400828 YH, ZX Viral challenge studies showed that live BacHA derived from Influenza A virus (A/Indonesia/CDC594/2006(H5N1)) was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1 [PubMed: 20071572]. HA from Influenza A virus (A/Indonesia/CDC594/2006(H5N1)) Protegen ID: 538; NCBI Protein GI: 113495780; NCBITaxon: 400810 YH, ZX A DNA vaccine encoding HA (from Influenza A virus (A/Hawaii/01/1991(H3N2))), NP and M1 (from a 1989 strain) protected ferrets better against challenge with the antigenic drift variant A/Georgia/03/93 than did the inactivated vaccine from the 1992-93 influenza season. Researchers report that the same DNA vaccine protected ferrets against a second, further divergent, drift variant (A/Johannesburg/33/94) [PubMed: 9234535]. HA from Influenza A virus (A/Hawaii/01/1991(H3N2)) Protegen ID: 539; NCBI Protein GI: 110313990; NCBITaxon: 387158 YH, ZX Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with HA plasmid once and the NA plasmid twice survived 100% [PubMed: 19067149]. HA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Protegen ID: 540; NCBI Protein GI: 61698018; NCBITaxon: 319102 YH, ZX Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with NP plasmid showed 60-80% survival rate with at least three immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus [PubMed: 19067149]. NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Protegen ID: 541; NCBI Protein GI: 61698066; NCBITaxon: 319102 YH, ZX Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with HA plasmid once and the NA plasmid twice survived 100% [PubMed: 19067149]. NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Protegen ID: 542; NCBI Protein GI: 61698053; NCBITaxon: 319102 YH, ZX Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with M1 plasmid survived 25% with five immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus [PubMed: 19067149]. M1 from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) Protegen ID: 543; NCBI Protein GI: 61698034; NCBITaxon: 319102 YH, ZX Vaccination with ptPAs/NP derived from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) efficiently cleared the homologous H5N1 influenza virus in the infected lungs and induced partial cross-protection against heterologous, highly pathogenic H5N1 strains in mice [PubMed: 18789973]. NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) Protegen ID: 544; NCBI Protein GI: 55233233; NCBITaxon: 298603 YH, ZX Researchers evaluated the immunogenicity and efficacy of a panel of flagellin-based hemagglutinin (HA) globular head fusion vaccines in inbred mice. The HA globular head of these vaccines was derived from the A/Vietnam/1203/04 (VN04; H5N1) HA molecule. Results show that replacement of domain D3 of flagellin with the VN04 HA globular head creates a highly effective vaccine that elicits protective HAI titers which protect mice against disease and death in a lethal challenge model with H5 VN virus [PubMed: 19654064]. HA from Influenza A virus (A/Viet Nam/1203/2004(H5N1)) Protegen ID: 545; NCBI Protein GI: 159144921; NCBITaxon: 284218 YH, ZX Using reverse genetics, we constructed a recombinant NDV expressing an H9 AIV hemagglutinin (HA) from an H9N2 field isolate, A/Chicken/ Shandong/2/2007. When tested, 90% of chickens were protected from clinical disease, mortality, and virus shedding against challenge with homologous H9N2 AIV [PubMed: 20521648]. HA from Influenza A virus (A/chicken/Guangdong/02/2007(H9N2)) Protegen ID: 546; NCBI Protein GI: 206812650; NCBITaxon: 563925 YH, ZX Immunization with DNA/rAd5 vaccines encoding HA derived from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) conferred protection in ferrets against a stringent virus challenge [PubMed: 20352112]. HA from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) Protegen ID: 547; NCBI Nucleotide GI: 46578137; NCBI Protein GI: 46578138; NCBI Protein Accession: AAS65615.2; NCBITaxon: 266827 YH, ZX All specific-pathogen-free chickens immunized with (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 were clinically protected from HPAI challenge [PubMed: 20521642]. HA from Influenza A virus (A/turkey/Ireland/1378/1983(H5N8)) Protegen ID: 549; NCBI Protein GI: 115279333; NCBITaxon: 380285 YH, ZX All specific-pathogen-free chickens immunized with (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003 were clinically protected from HPAI challenge [PubMed: 20521642]. HA from Influenza A virus (A/chicken/Indonesia/7/2003(H5N1)) Protegen ID: 550; NCBI Protein GI: 129282887; NCBITaxon: 430432 YH, ZX A neutralizing monoclonal antibody (mAb) 9F4 against the hemagglutinin (HA) of the influenza A/chicken/hatay/2004 H5N1 virus was generated. MAb 9F4 was found to be protective, both prophylactically and therapeutically, against lethal viral challenge of mice [PubMed: 20519402]. HA from Influenza A virus (A/Hatay/2004/(H5N1)) Protegen ID: 551; NCBI Protein GI: 56311402; NCBITaxon: 303316 YH, ZX Chickens immunized with attenuated Salmonella strains expressing the hemagglutinin (HA1) gene from a highly pathogenic avian influenza (HPAI) H5N1 (A/whooper swan/Mongolia/3/2005) demonstrated a statistically significant increase in survival compared to control groups [PubMed: 20406663]. HA from Influenza A virus (A/whooper swan/Mongolia/3/05(H5N1)) Protegen ID: 553; NCBI Protein GI: 81687119; NCBITaxon: 344596 YH, ZX Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice. Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine [PubMed: 19006097]. Envelope protein Protegen ID: 554; NCBI Protein GI: 16445023; NCBITaxon: 11072 YH, ZX Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold. After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA [PubMed: 12634382]. PrM Protegen ID: 555; NCBI Protein GI: 90019439; NCBITaxon: 11072 YH, ZX Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV [PubMed: 15121294]. NS1 Protegen ID: 556; NCBI Protein GI: 18418672; NCBITaxon: 11072 YH, ZX Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model. Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus [PubMed: 12922097]. NS3 Protegen ID: 557; NCBI Protein GI: 27696332; NCBITaxon: 11072 YH, ZX Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus [PubMed: 12922097]. NS5 Protegen ID: 558; NCBI Protein GI: 158702649; NCBITaxon: 11072 YH, ZX A cDNA clone representing the genome of structural proteins of Japanese encephalitis virus (JEV) was inserted into the thymidine kinase gene of vaccinia virus strains LC16mO and WR. Inoculation of rabbits with the infectious recombinant vaccinia virus resulted in rapid production of antiserum specific for the PreM and E glycoproteins of JEV. Mice vaccinated with the recombinant produced JEV-neutralizing antibodies and were resistant to challenge with JEV [PubMed: 2159544]. PreM Protegen ID: 559; NCBI Protein GI: 14600066; NCBITaxon: 11072 YH, ZX Vaccine efficacy trials in guinea pigs indicated that the nucleoprotein is capable of eliciting a protective immune response against a lethal dose of Lassa virus. Ninety-four percent of the animals vaccinated with V-LSN survived a Lassa virus challenge in which only 14% of unvaccinated animals and 39% of animals vaccinated with the New York Board of Health (NYBH) strain of vaccinia virus survived [PubMed: 2741340]. LASVsSgp1 nucleoprotein Protegen ID: 560; NCBI Gene GI: 956584; NCBI Protein GI: 23343510; NCBI Protein Accession: NP_694869; NCBITaxon: 11620 YH, ZX BALB/c mice were immunized with a vaccine expressing the 78kDa (GRP-78) antigen of Leishmania donovani. Challenge infection was given intracardially after 2 weeks of second booster. A significant decrease in parasite burden was seen in vaccinees over the infected controls on all post challenge days and was found that maximum protection was provided by 78kDa+rIL-12 vaccine. It was highly immunogenic as depicted by the reduction in parasite load (71-94.8%) [PubMed: 20093205]. GRP-78 Protegen ID: 561; NCBI Protein GI: 16797868; NCBITaxon: 5661 YH, ZX Study results show that a single intraperitoneal administration of the A2-recombinant L. tarentolae strain expressing the Leishmania donovani A2 antigen protects BALB/c mice against L. infantum challenge and that protective immunity is associated with high levels of IFN-gamma production prior and after challenge [PubMed: 19818721]. A2 Protegen ID: 563; NCBI Protein GI: 30385439; NCBITaxon: 5671 YH, ZX Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD31 (ATP synthase alpha chain) reduced parasite burden by 74%-77% [PubMed: 19503834]. F1-ATPase Protegen ID: 564; NCBI Protein GI: 722242; NCBITaxon: 5661 YH, ZX Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD51 (beta-tubulin) reduced parasite burden by 72%-75% [PubMed: 19503834]. Beta-tubulin Protegen ID: 565; NCBI Protein GI: 262233287; NCBITaxon: 5661 YH, ZX Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD72 (Hsp70) reduced parasite burden by 65%-67% [PubMed: 19503834]. Hsp70 Protegen ID: 566; NCBI Protein GI: 281426606; NCBITaxon: 5661 YH, ZX KMP-11 DNA vaccination alone in an experimental BALB/c mice model showed significant potential in terms of resolution of splenic and hepatic parasite burden against virulent LD challenge. KMP-11 DNA immunization significantly protects against L. donovani infection [PubMed: 19162111]. KMP-11 Protegen ID: 567; NCBI Protein GI: 7579896; NCBITaxon: 5661 YH, ZX Study showed that cationic distearoyl phosphatidylcholine (DSPC) liposomes, when used as vaccine adjuvant with the immunodominant 63-kDa glycoprotein (gp63, mspC) of Leishmania donovani promastigotes, induced significant protection against progressive visceral leishmaniasis in susceptible BALB/c mice. gp63 used without adjuvant elicited partial protection but in association with liposomes exhibited marked resistance in both the livers and spleens of the mice challenged 10 days after the last vaccination [PubMed: 18195029]. MspC Protegen ID: 568; NCBI Protein GI: 21954466; NCBITaxon: 5661 YH, ZX An expression plasmid encoding both p35 and p40 subunits of IL-12 when co-administered with a recombinant open-reading frame (rORFF) gene from the LD1 locus of Leishmania donovani induces significant protection with around 82% protection in both liver and spleen of BALB/c mice when challenged with L. donovani [PubMed: 16413950]. ORFF Protegen ID: 569; NCBI Protein GI: 703122; NCBITaxon: 5661 YH, ZX Immunization of mice with recombinant BT1 proteins (a biopterin transporter) from multigenic LD1 locus on chromosome 35 of L. donovani conferred partial protection against challenge with Leishmania donovani in a BALB/c mice [PubMed: 15357215]. BT1 Protegen ID: 570; NCBI Protein GI: 703123; NCBITaxon: 5661 YH, ZX Experimental infection of immunized BALB/c mice demonstrated that the VR1012-NH36 DNA vaccine derived from the nucleoside hydrolase gene (NH) of L. donovani induced an 88% reduction in L. chagasi parasite load and a 65% reduction in L. mexicana lesion size [PubMed: 15664920]. NH Protegen ID: 571; NCBI Protein GI: 19697561; NCBITaxon: 5661 YH, ZX Study demonstrated for the first time that a recombinant stage-specific hydrophilic surface protein of Leishmania donovani, recombinant hydrophilic acylated surface protein B1 (HASPB1), is able to confer protection against experimental challenge with L. donovani in BALB/c mice [PubMed: 11120835]. L. donovani HASPB1 Protegen ID: 572; NCBI Protein GI: 51847753; NCBITaxon: 5661 YH, ZX Nonhuman primates (cynomolgus macaques) were inoculated with VEE replicons expressing MBGV GP and/or NP and challenged with MGBV. MBGV NP afforded incomplete (partial) protection, sufficient to prevent death but not disease in two of three macaques [PubMed: 9813200 ]. NP from Lake Victoria marburgvirus Protegen ID: 573; NCBI Protein GI: 332181; NCBITaxon: 11269 YH, ZX Recombinant fowl poxviruses (rFPVs) were constructed to express genes from serotype 1 Marek's disease virus (MDV, Gallid herpesvirus 2). rFPV/gB1 expressing MDV040 conferred 42% protection in maternal antibody-positive chickens when challenged with highly virulent MDV isolates [PubMed: 14562881]. MDV040 Protegen ID: 574; NCBI Gene GI: 4811501; NCBI Protein GI: 125745079; NCBI Protein Accession: YP_001033956; NCBITaxon: 10390 YH, ZX Recombinant fowl poxviruses (rFPVs) were constructed to express genes from serotype 1 Marek's disease virus (MDV, Gallid herpesvirus 2). rFPV/gI expressing MDV095 conferred 43% protection in maternal antibody-positive chickens when challenged with highly virulent MDV isolates [PubMed: 14562881]. MDV095 Protegen ID: 575; NCBI Gene GI: 4811454; NCBI Protein GI: 125745128; NCBI Protein Accession: YP_001034012; NCBITaxon: 10390 YH, ZX Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles were used to express the hemagglutinin (H) and fusion (F) proteins of measles virus (MV). When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia [PubMed: 20130066]. H hemagglutinin protein Protegen ID: 577; NCBI Gene GI: 1489801; NCBI Protein GI: 9626951; NCBI Protein Accession: NP_056923; NCBITaxon: 11234 YH, ZX Mice vaccinated with a vaccinia virus recombinant encoding the fusion protein of Measles virus developed measles neutralizing antibodies. The mice also resisted a normally lethal intracerebral inoculation of a cell-associated measles virus subacute sclerosing panencephalitis strain [PubMed: 3422488]. F fusion protein Protegen ID: 578; NCBI Gene GI: 1489800; NCBI Protein GI: 9626950; NCBI Protein Accession: NP_056922; NCBITaxon: 11234 YH, ZX Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVN (Nucleocapsid Protein) -immunized rats survived a MV challenge infection [PubMed: 1833505]. N nucleocapsid protein Protegen ID: 579; NCBI Gene GI: 1489804; NCBI Protein GI: 9626946; NCBI Protein Accession: NP_056918; NCBITaxon: 11234 YH, ZX Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge [PubMed: 1833505]. P phosphoprotein Protegen ID: 580; NCBI Gene GI: 1489805; NCBI Protein GI: 9626947; NCBI Protein Accession: NP_056919; NCBITaxon: 11234 YH, ZX Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge [PubMed: 1833505]. M matrix protein Protegen ID: 581; NCBI Gene GI: 1489803; NCBI Protein GI: 9626949; NCBI Protein Accession: NP_056921; NCBITaxon: 11234 YH, ZX A novel mumps vaccine with good immunity and safety was developed by selecting an antigen (HN) component of the mumps virus. The clinical and pathological observations after challenge of vaccinated rhesus monkeys indicated further that the immune response induced by this vaccine provided complete protection from wild-type virus infection [PubMed: 18597904]. HN Protegen ID: 582; NCBI Gene GI: 1489765; NCBI Protein GI: 9695422; NCBI Protein Accession: NP_054713; NCBITaxon: 11161 YH, ZX Immunization with DNA encoding Ag85B (fbpB), a candidate vaccine antigen of Mycobacterium tuberculosis, elicited in mice a low but protective CD4(+) T cell-mediated IFN-gamma response [PubMed: 20544034]. FbpB from M. tuberculosis Protegen ID: 583; NCBI Gene GI: 885785; NCBI Protein GI: 15609023; NCBI Protein Accession: NP_216402; NCBITaxon: 83332 YH, ZX Our lead construct, Mtb72F, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32(C)-Mtb39-Mtb32(N). All forms of Mtb72F immunization tested resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis [PubMed: 15187142]. Mtb72F Protegen ID: 584; NCBI Protein GI: 283801990; NCBITaxon: 32630 YH, ZX Protective experiments of DNA vaccine pcDNA3-MIC3 (pMIC3i) in Kumming mice showed that the vaccine could significantly prolong the survival time of the mice challenged by virulent RH strains of T. gondii [PubMed: 19800170]. MIC3 Protegen ID: 587; NCBI Gene GI: 7901253; NCBI Protein GI: 237841071; NCBI Protein Accession: XP_002369833; NCBITaxon: 508771 YH, ZX We show that the 50- to 55-kDa Apa protein, specified by the Rv1860 gene of M. tuberculosis, can elicit both lymphoproliferative response and gamma interferon (IFN-gamma) production. A poxvirus recombinant expressing the Apa protein conferred a significant level of protective immunity in guinea pigs against a challenge dose of virulent M. tuberculosis [PubMed: 12654810]. Apa Protegen ID: 588; NCBI Gene GI: 885896; NCBI Protein GI: 57116926; NCBI Protein Accession: YP_177849; NCBITaxon: 83332 YH, ZX MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis, is immunoreactive in antibody assays in humans and animals and provides protection as a combined DNA vaccine in mice [PubMed: 19281533]. Mpt63 Protegen ID: 589; NCBI Gene GI: 885334; NCBI Protein GI: 15609063; NCBI Protein Accession: NP_216442; NCBITaxon: 83332 YH, ZX The immunogenicity and protective efficacy of a recombinant subunit West Nile virus (WNV) vaccine was evaluated in rhesus macaques (Macaca mulatta). The vaccine consisted of a recombinant envelope (E) protein truncated at the C-terminal end, resulting in a polypeptide containing 80% of the N-terminal amino acids of the native WNV protein (WN-80E), mixed with an adjuvant (GPI-0100). Groups of monkeys were immunized with the WN-80E/GPI-0100 vaccine or an adjuvant-only control formulation. Animals were then challenged by inoculation of wild-type WNV, and the level of viremia in each animal was monitored daily for 10 days. The results showed that whereas all animals in the control group had detectable viremia for at least 3 days after challenge, all of the vaccinated animals were negative on all days after challenge. Thus, the WN-80E vaccine was 100% efficacious in protecting monkeys against infection with WNV [PubMed: 19641099]. E protein Protegen ID: 590; NCBI Protein GI: 111145461; NCBITaxon: 11082 YH, ZX An antiserum raised in chicken against the TM-1 polypeptide, which was produced by recombinant Escherichia coli cells and purified by column chromatography, inhibited growth of M.g. cells in vitro. Moreover, chickens immunized with this 29 kDa polypeptide (TM-1) were partially protected from a challenge with virulent M.g [PubMed: 8212828]. TM-1 Protegen ID: 591; NCBI Protein GI: 7249262; NCBITaxon: 2096 YH, ZX Starting with a previously designed eukaryotic expression vector, a recombinant plasmid (pCBWN) that expressed the WN virus prM and E proteins was constructed. A single intramuscular injection of pCBWN DNA induced protective immunity, preventing WN virus infection in mice and horses when subjected to challenge with the NY99-6480 strain of WNV [PubMed: 11287553]. PrM Protegen ID: 592; NCBI Gene GI: 5714902; NCBI Protein GI: 158516888; NCBI Protein Accession: YP_001527877; NCBITaxon: 11082 YH, ZX Seventeen monoclonal antibodies to one of three main cell surface antigens of Neisseria meningitidis group B were tested for protective efficacy in the infant rat using as challenge seven strains of different class 2/3 protein serotypes. Survival of the animals was regularly obtained with antibodies to the P1 protein and to LPS [PubMed: 2510417]. P1 Protegen ID: 594; NCBI Gene GI: 902192; NCBI Protein GI: 15676020; NCBI Protein Accession: NP_273150; NCBITaxon: 122586 YH, ZX Sera of the challenge group immunized with CCPS-P64kR showed a three-fold higher bactericidal response than the sera of the group immunized with the plain CCPS and they were able to protect against challenge with Neisseria meningococci in the infant rat protection model [PubMed: 15039094]. LpdA Protegen ID: 596; NCBI Protein GI: 1017430; NCBITaxon: 487 YH, ZX Mice immunized with purified Tbp2 survived a lethal challenge to a similar degree as animals immunized with the Tbp1-Tbp2 complex, demonstrating that Tbp2 played an important role in the protective activity observed with the complex, eliciting antibodies that are not only bactericidal but also inhibitory for meningococcal growth [PubMed: 7868259]. TBP2 Protegen ID: 597; NCBI Protein GI: 1017433; NCBITaxon: 487 YH, ZX Immunization with recombinant forms of a sporozoite surface antigen (r-p67), derived from either bacterial or insect cells, induces high levels of sporozoite neutralizing antibodies in cattle.In vivo immunization studies have shown that approximately 30% of immunized cattle are nonreactors to a needle LD70 sporozoite challenge, 40% experience a mild disease reaction from which they recover, and the remaining 30% suffer severe disease and are clinically indistinguishable from controls. Transient parasitosis and mild clinical reactions are also observed in challenge of cattle immunized by infection and treatment and such responses constitute immunity to ECF. Hence, p67 is able to routinely induce immunity at a level of about 70% [PubMed: 11193661]. P67 Protegen ID: 598; NCBI Protein GI: 4106806; NCBITaxon: 5875 YH, ZX NspA-containing outer membrane vesicles conferred protection against otherwise lethal intraperitoneal challenge of mice with N. meningitidis serogroup B, and sera raised against them mediated opsonophagocytosis of meningococcal strains expressing this antigen [PubMed: 15501782]. NspA from N. meningitidis Protegen ID: 599; NCBI Protein GI: 5825543; NCBITaxon: 487 YH, ZX A total of 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect mice against live bacterial challenge against N. meningitidis; the lactate permease (LctP) elicited protective immunity [PubMed: 15964482]. LctP Protegen ID: 600; NCBI Protein GI: 254667969; NCBITaxon: 662598 YH, ZX A total of 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect mice against live bacterial challenge against N. meningitidis; ExbB, which is required for iron acquisition, elicited protective immunity [PubMed: 15964482]. ExbB Protegen ID: 601; NCBI Gene GI: 903370; NCBI Protein GI: 15677575; NCBI Protein Accession: NP_274732; NCBITaxon: 122586 YH, ZX The trial vaccination of cattle against T. annulata using recombinant sporozoite antigens (SPAG-1 and p67) and/or merozoite antigens (TAMS 1-1 and 1-2). The aim of these trials was to try and enhance the levels of protection induced compared with previous trials. Different approaches were tried. SPAG-1 was expressed as a fusion protein with a His6 tag and then either incorporated into ISCOMs, with or without TAMS 1-1 and 1-2, or administered with RWL, a proprietary saponin-based adjuvant. Cross-protection studies were also performed by immunizing cattle with the T. parva sporozoite antigen, p67, and then challenging with a T. annulata sporozoite stabilate.All the data collected from these two trials indicate that SPAG-1 administered with RWL is better at inducing an effective immune response than SPAG-1 incorporated into ISCOMs, with or without the presence of merozoite antigens [PubMed: 9668470]. Spag-1 Protegen ID: 602; NCBI Protein GI: 161885; NCBITaxon: 5874 YH, ZX To test the potential of subunit vaccines against T. annulata infection, we immunized four groups of three calves with either recombinant (re-) (Tams1-1 and Tams1-2) proteins or naked DNA encoding these antigens. All calves vaccinated with ISCOMs proved to be protected from T. annulata infection and had generated antibodies against both re-(Tams1-1 and Tams1-2) at the time of challenge [PubMed: 9364686]. TA17050 merozoite-piroplasm surface antigen Tams1 Protegen ID: 603; NCBI Gene GI: 3864438; NCBI Protein GI: 84997996; NCBI Protein Accession: XP_953719; NCBITaxon: 353154 YH, ZX Intraperitoneal application of NcMAG1 suspended in saponin adjuvants lead to protection against disease in 50% of animals vaccinated in a C57Bl/6 mouse cerebral infection model [PubMed: 19835644]. NcMAG1 Protegen ID: 604; NCBI Protein GI: 147886433; NCBITaxon: 29176 YH, ZX Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2(d)) or C57BL/6 (haplotype H2(b)) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3) [PubMed: 20479086]. PsaA Protegen ID: 605; NCBI Protein GI: 209867628; NCBITaxon: 1313 YH, ZX A 90% protection rate was achieved following intra-nasal vaccination with recNcPDI emulsified in cholera toxin employing the C57Bl/6 mouse cerebral infection model when challenged with Neospora caninum tachyzoites [PubMed: 19835644]. NcPDI Protegen ID: 606; NCBI Protein GI: 82568727; NCBITaxon: 29176 YH, ZX The protective effects a pneumolysin mutant (DeltaA146 Ply) against pneumococcal infections in mice was evaluated. Vaccinated mice were challenged with pneumococcal strain D39 at 1,500 times the LD50 (1.5 x 105 CFU) and the vaccinated mice survived significantly longer than control mice after challenge [PubMed: 20038538]. Ply Protegen ID: 607; NCBI Gene GI: 4441611; NCBI Protein GI: 116515376; NCBI Protein Accession: YP_817150; NCBITaxon: 373153 YH, ZX The protective effects of ATP-dependent caseinolytic protease (ClpP) was evaluated. Vaccinated mice were intraperitoneally and/or intranasally challenged with different pneumococcal strains. In intraperitoneal challenge models with pneumococcal strain D39 (serotype 2), clpP elicited some protection in mice [PubMed: 20038538]. ClpP Protegen ID: 608; NCBI Gene GI: 4441476; NCBI Protein GI: 116516216; NCBI Protein Accession: YP_816144; NCBITaxon: 373153 YH, ZX The production of a recombinant vaccine was achieved following PCR amplification of putative lipoate protein ligase (Lpl), with subsequent cloning and expression of the genes in E. coli. The putative lipoate protein ligase (Lpl) , resulted in a reduced CFU titre and a trend towards reduced mortality in an animal sepsis model [PubMed: 18034862]. LplA Protegen ID: 609; NCBI Gene GI: 934072; NCBI Protein GI: 15903091; NCBI Protein Accession: NP_358641; NCBITaxon: 171101 YH, ZX NcSAG1 and NcSRS2, the two major immunodominant tachyzoite surface antigens of the apicomplexan parasite Neospora caninum, were investigated for their potential as vaccine candidates in mice. Results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice [PubMed: 12741509]. NcSRS2 Protegen ID: 610; NCBI Protein GI: 5579384; NCBITaxon: 29176 YH, ZX NcSAG1 and NcSRS2, the two major immunodominant tachyzoite surface antigens of the apicomplexan parasite Neospora caninum, were investigated for their potential as vaccine candidates in mice. Results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice [PubMed: 12741509]. NcSAG1 Protegen ID: 611; NCBI Protein GI: 4583447; NCBITaxon: 29176 YH, ZX Mice immunized with recombinant (r)PsrP(BR) had significantly less bacteria in their blood and improved survival versus controls following intranasal challenge [PubMed: 19627498]. PsrP Protegen ID: 613; NCBI Gene GI: 7329552; NCBI Protein GI: 221232510; NCBI Protein Accession: YP_002511663; NCBITaxon: 561276 YH, ZX This study used an immunisation/challenge model of transplacental transmission, based on the Qs mouse with an Nc-Liverpool challenge to investigate the vaccine potential of a number of formulations based on four recombinant proteins of N. caninum. A mixture of MIC10 and p24B produced partial protection against transplacental transmission of N. caninum in this mouse model [PubMed: 18789996]. Note: MIC10 must be used in conjunction with p24B in order to confer protection against N. caninum. MIC10 Protegen ID: 614; NCBI Protein GI: 11141617; NCBITaxon: 29176 YH, ZX Intraperitoneal immunization with recombinant SrtA was found to have conferred to mice protection against S. pneumoniae intraperitoneal challenge and the passive transfer of immune serum before intraperitoneal challenge was also protective. Moreover, by using the intranasal challenge model, significant reduction of bacteremia when mice were intraperitoneally immunized with SrtA was observed, while a moderate decrease of lung infection was achieved by intranasal immunization, even though no influence on nasopharynx colonization was seen [PubMed: 19433540]. SrtA Protegen ID: 615; NCBI Gene GI: 4442999; NCBI Protein GI: 116515518; NCBI Protein Accession: YP_816547; NCBITaxon: 373153 YH, ZX Study assessed the potential protectivity of NcMIC1-based vaccination against experimental N. caninum infection in mice. Quantitative real-time PCR revealed that the infection intensity was significantly reduced in the group vaccinated with recNcMIC1 antigen. Serological analysis showed that only recNcMIC1-immunized animals generated detectable antibody levels recognizing native NcMIC1. Thus, of all protocols applied, only recNcMIC1 vaccination appears to be suited to reduce cerebral infection in mice challenged with N. caninum tachyzoites [PubMed: 16108562]. NcMIC1 Protegen ID: 616; NCBI Protein GI: 17226315; NCBITaxon: 29176 YH, ZX Glutamyl tRNA synthetase (GtS) has been found to be among the Streptococcus pneumoniae cell wall-derived proteins that have age-dependent immunogenicity in children. Here, GtS was cloned, expressed, and purified and then was used to immunize 7-week-old BALB/c OlaHsd mice. Thirty-nine percent of rGtS-immunized mice survived a lethal bacterial challenge, whereas no control mice survived [PubMed: 17703427]. GltX Protegen ID: 617; NCBI Gene GI: 931970; NCBI Protein GI: 15901888; NCBI Protein Accession: NP_346492; NCBITaxon: 170187 YH, ZX Separate groups of gerbils were immunized with purified recombinant proteins singly or in combinations and animals were then challenged with N. caninum. The protective efficacy of each vaccination was determined by assessing animal survival rate. The highest protection efficacy was observed for combined vaccination with NcSRS2 and NcDG1 (67.5% survival) compared to control (17.4% survival). Vaccination with NcDG1 alone elicited 62.5% survival in the challenge model [PubMed: 15793355]. NcDG1 Protegen ID: 618; NCBI Protein GI: 2149142; NCBITaxon: 29176 YH, ZX Mice were actively immunized with a fragment of choline binding protein A (CbpA; also known as PspC, Hic, and SpsA). CbpA was able to protect mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39 [PubMed: 11553536]. CbpA Protegen ID: 619; NCBI Gene GI: 4441159; NCBI Protein GI: 116515359; NCBI Protein Accession: YP_817402; NCBITaxon: 373153 YH, ZX Groups of BALB/c mice immunized with choline binding protein PspA were challenged with either D39 or WCH16. PspA elicited protection by using moderate challenge doses of S. pneumoniae [PubMed: 17088353]. PspA Protegen ID: 620; NCBI Gene GI: 4441373; NCBI Protein GI: 116515876; NCBI Protein Accession: YP_815641; NCBITaxon: 373153 YH, ZX Separate groups of gerbils were immunized with purified recombinant proteins singly or in combinations and animals were then challenged with N. caninum. The protective efficacy of each vaccination was determined by assessing animal survival rate. All experimental groups showed protective effects. Vaccination with NcDG2 alone elicited 50% survival rate compared to a control survival rate of 17.4% [PubMed: 15793355]. NcDG2 Protegen ID: 621; NCBI Protein GI: 3237325; NCBITaxon: 29176 YH, ZX BALB/c mice were immunized with recombinant 6-Phosphogluconate dehydrogenase (r6PGD) and boosted after 3 weeks. Immunized mice were challenged intranasally with a lethal dose of S. pneumoniae. Immunization of mice with r6PGD protected 60% (P < 0.001) of mice for 5 days and 40% (P < 0.05) of the mice for 21 days following intranasal lethal challenge [PubMed: 16634799]. Gnd Protegen ID: 622; NCBI Gene GI: 4441177; NCBI Protein GI: 116515453; NCBI Protein Accession: YP_815856; NCBITaxon: 373153 YH, ZX Mice immunized with recombinant PiaA were protected against systemic challenge to a degree similar to those immunized with an existing protein vaccine candidate, PdB (a genetically modified pneumolysin toxoid). Immunization with a combination of both PiuA and PiaA resulted in additive protection and was highly protective against systemic infection with S. pneumoniae [PubMed: 11598041]. PiaA Protegen ID: 623; NCBI Gene GI: 4442863; NCBI Protein GI: 116515816; NCBI Protein Accession: YP_815744; NCBITaxon: 373153 YH, ZX A recombinant fowlpox virus expressing the fusion protein of Newcastle disease virus strain F48E8 protected chickens against virulent NDV challenge. The protective rate was 96.7% [PubMed: 11191764]. F fusion protein Protegen ID: 624; NCBI Gene GI: 912271; NCBI Protein GI: 11545723; NCBI Protein Accession: NP_071469; NCBITaxon: 11176 YH, ZX Recombinant baculoviruses containing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein gene of the viscerotropic velogenic (vv) Newcastle disease virus (NDV) isolate, Kr-005/00, and a lentogenic La Sota strain of the NDV were constructed. A single dose of rNDHN(V) had a protective effect against mortality (p <0.01) in chickens [PubMed: 18716451]. HN hemagglutinin-neuraminidase Protegen ID: 625; NCBI Gene GI: 912270; NCBI Protein GI: 11545724; NCBI Protein Accession: NP_071470; NCBITaxon: 11176 YH, ZX Researchers constructed a new recombinant molecule of SERA5, namely SE36. Vaccination of Squirrel monkeys with SE36 protein and aluminium hydroxyl gel (SE36/AHG) conferred protection against high parasitemia and boosted serum anti-SE36 IgG after P. falciparum parasite challenge [PubMed: 20493274]. SERA-5 Protegen ID: 626; NCBI Protein GI: 238629807; NCBITaxon: 5833 YH, ZX Vaccination of mice with EAG (2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein) as a single antigen with EtxB (as an adjuvant) induced protection in mice against bacterial challenge, but was less protective than at affording protection than immunization with FNZ, SFS, EAG, and EtxB [PubMed: 15155624]. binding protein Eag Protegen ID: 627; NCBI Gene GI: 7696154; NCBI Protein GI: 225870123; NCBI Protein Accession: YP_002746070; NCBITaxon: 553482 YH, ZX Researchers found that the cysteine-rich, carboxyl-terminal region of the MSP-1 protein from the rodent malarial parasite Plasmodium yoelii yoelii can be expressed in a native configuration as a fusion protein in Escherichia coli. This recombinant polypeptide elicits antibodies in mice which recognize the native parasite MSP-1. Most significantly, both inbred and outbred mice immunized with the fusion protein in Ribi adjuvant are partially and in some cases completely protected against challenge infection with an otherwise lethal parasite strain [PubMed: 8363656]. MSP1 from P. yoelii str. 17XNL Protegen ID: 628; NCBI Gene GI: 3791597; NCBI Protein GI: 82596427; NCBI Protein Accession: XP_726257; NCBITaxon: 352914 YH, ZX Mice were immunised i.n. with collagen-binding protein (CNE) and were subsequently subjected to infection with S. equi subsp. equi. A control group of mice was given only adjuvant. The CNE vaccinated group had a delayed onset of infection compared to the control group. Immunization with CNE led to significant protection from infection [PubMed: 16580099]. collagen binding, ancillary pilus subunit Cne Protegen ID: 629; NCBI Gene GI: 7695900; NCBI Protein GI: 225870316; NCBI Protein Accession: YP_002746263; NCBITaxon: 553482 YH, ZX Parts of the three recombinant proteins (FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein)) were used to immunize mice, either subcutaneously or intranasally, prior to nasal challenge with S. equi subsp. equi. The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin. It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) [PubMed: 15155624]. Fnz Protegen ID: 630; NCBI Gene GI: 7695217; NCBI Protein GI: 225869227; NCBI Protein Accession: YP_002745175; NCBITaxon: 40041 YH, ZX Parts of the three recombinant proteins (FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein)) were used to immunize mice, either subcutaneously or intranasally, prior to nasal challenge with S. equi subsp. equi. The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin. It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) [PubMed: 15155624]. Sfs Protegen ID: 631; NCBI Gene GI: 7696331; NCBI Protein GI: 225869898; NCBI Protein Accession: YP_002745845; NCBITaxon: 553482 YH, ZX The fibrinogen-binding protein (FgBP) reacted with serum taken from horses recovering from strangles and protected mice against lethal challenge from S. equi subsp. equi [PubMed: 9579073]. Fbp Protegen ID: 632; NCBI Gene GI: 7697172; NCBI Protein GI: 225871286; NCBI Protein Accession: YP_002747233; NCBITaxon: 553482 YH, ZX Researchers produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. Researchers used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite (CS) protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared. [PubMed: 19915055]. CS from P. berghei str. ANKA Protegen ID: 633; NCBI Gene GI: 3428738; NCBI Protein GI: 68076353; NCBI Protein Accession: XP_680096; NCBITaxon: 5823 YH, ZX CS from P. falciparum P. falciparum circumsporozoite protein https://www.ncbi.nlm.nih.gov/pubmed/18159254 A P. berghei parasite line was used to expresses a heterologous circumsporozoite protein (CSP) from P. falciparum. A sterile immunity was obtained by vaccination with the radiation-attenuated P. berghei parasite [PubMed: 18159254]. P. falciparum CSP Protegen ID: 634; NCBI Protein GI: 552191; NCBITaxon: 5833 YH, ZX Study showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. yoelii conferred sterile protection against challenge with wild type P. berghei sporozoites [PubMed: 19890387]. CS from P. yoelii str. 17XNL Protegen ID: 635; NCBI Gene GI: 3830374; NCBI Protein GI: 83317409; NCBI Protein Accession: XP_731149; NCBITaxon: 352914 YH, ZX Immunization with a recombinant yeast-expressed Plasmodium falciparum merozoite surface protein 3 (MSP3) protected Aotus nancymai monkeys against a virulent challenge infection [PubMed: 19073223]. MSP3 Protegen ID: 636; NCBI Protein GI: 113207288; NCBITaxon: 5833 YH, ZX Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice from lethal malaria but does not prevent infection [PubMed: 18097046]. MSP8 Protegen ID: 637; NCBI Protein GI: 58197887; NCBITaxon: 5861 YH, ZX Intranasal or oral delivery of the chimeric rotavirus VP6 protein MBP::VP6 to mice elicited >90% reductions in fecal rotavirus shedding after murine rotavirus challenge [PubMed: 17629371]. VP6 Protegen ID: 638; NCBI Protein GI: 268080815; NCBITaxon: 28327 YH, ZX Mice immunized with r-Pfen (recombinant P. falciparum enolase protein) showed protection against a challenge with the 17XL lethal strain of the mouse malarial parasite Plasmodium yoelii [PubMed: 17785475]. PF10_0155 enolase Protegen ID: 639; NCBI Gene GI: 810313; NCBI Protein GI: 124802328; NCBI Protein Accession: XP_001347440; NCBITaxon: 36329 YH, ZX Mice immunized with recombinant PbAMA-1 were partially protected from the challenge of P. berghei [PubMed: 17639690]. AMA-1 from P. berghei Protegen ID: 640; NCBI Protein GI: 1438889; NCBITaxon: 5821 YH, ZX Mice vaccinated with recombinant rMSP1 (rPbMSP1), which was generated from Plasmodium berghei, in alum mounted significant protective immunity against challenge infection (P < 0.01). On day 121 after the booster, three out of ten mice immunized with rPbMSP1 in PBS survived parasite infection (P < 0.05) and eight out of ten mice vaccinated with r MSP1 in alum did (P < 0.01). Hence, immunization with MSP1 in alum obviously has conferred protective effects, which prevented death from P. berghei lethal infection in mice (P < 0.01) [PubMed: 17568385]. MSP1 from P. berghei Protegen ID: 641; NCBI Protein GI: 1762646; NCBITaxon: 5821 YH, ZX Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Neonates of animals immunized with virus-like particles composed of VP7 assembled on VP6 spherical particles were protected against challenge with the homotypic virus and significantly protected from a heterotypic challenge. Unassembled VP7 protein provided partial protection against challenge [PubMed: 8382422]. VP7 Protegen ID: 642; NCBI Protein GI: 195661008; NCBITaxon: 10927 YH, ZX Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Challenge of neonates born to animals immunized with VP4 protein on assembled particles or in cell lysates showed protection against challenge with both homologous (bovine C486) and heterologous (SA-11) strains of rotavirus [PubMed: 8382422]. VP4 Protegen ID: 643; NCBI Protein GI: 172054621; NCBITaxon: 10927 YH, ZX Immunization of mice with subunit vaccines based on the Plasmodium yoelii 17kDa hepatocyte erythrocyte protein (PyHEP17), orthologue of Plasmodium falciparum exported protein 1 (PfExp1), induces antigen-specific immune responses and protects against sporozoite challenge [PubMed: 17303242]. HEP17 Protegen ID: 644; NCBI Protein GI: 1399353; NCBITaxon: 5861 YH, ZX Immunized animals were challenged in vivo with various parasite strains or clones of malaria. Immunization with the PfEMP1-DBL1 alpha domain abolished the PfEMP1-dependent sequestration of the homologous strain in immunized rats and substantially inhibited parasite adhesion in immunized monkeys. Protection against sequestration of heterologous parasite strains was also confirmed by direct or indirect challenge in the rat model [PubMed: 17074852]. EMP1 Protegen ID: 645; NCBI Protein GI: 2961468; NCBITaxon: 5833 YH, ZX Immunization of BALB/c mice and Aotus monkeys with PvMSP-1 induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages [PubMed: 16291762]. MSP1 from P. vivax Protegen ID: 646; NCBI Protein GI: 26985160; NCBITaxon: 5855 YH, ZX A DNA vaccine based on lysosome-targeted glycoprotein of the rabies virus was evaluated in BALB/c mice. It imparted partial protection (60%) against challenge with 20 LD(50) of the challenge virus standard (CVS) strain of rabies virus [PubMed: 19741168]. Glycoprotein Protegen ID: 647; NCBI Protein GI: 56384945; NCBITaxon: 11292 YH, ZX Mice vaccinated intraperitoneally (i.p.) with 10^7 p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection [PubMed: 8207400]. RABVgp1 nucleoprotein N Protegen ID: 648; NCBI Gene GI: 1489853; NCBI Protein GI: 9627198; NCBI Protein Accession: NP_056793; NCBITaxon: 11292 YH, ZX Two large fragments of PfKbeta representing the N- and C-terminal halves were expressed in E. coli. The recombinant proteins were highly immunogenic in mice, and also found to be the target for immune response in natural infections of Plasmodium spp. Immunization with recombinant PfKbeta fragments was partially protective against a heterologous challenge infection in mice [PubMed: 15987343]. Kbeta Protegen ID: 649; NCBI Gene GI: 813054; NCBI Protein GI: 124506397; NCBI Protein Accession: XP_001351796; NCBITaxon: 36329 YH, ZX Immunization with one of the constructs of M. vaccae expressing OmpA in combination with booster immunization with the homologous recombinant protein protected a significant portion of mice from lethal challenge [PubMed: 11738766]. OmpA Protegen ID: 650; NCBI Protein GI: 112710; NCBITaxon: 783 YH, ZX R. rickettsii OmpB contain B and T lymphocyte epitopes. Immunizations with each of two fragments from OmpB (rompB1550-2738 and rompB2459-4123) conferred protection against challenge with a lethal dose of R. conorii. Protection appeared to be better achieved among the groups that received both DNA and recombinant protein immunizations, although recombinant protein immunizations alone provided some protection [PubMed: 11693887]. OmpB Protegen ID: 651; NCBI Protein GI: 6685726; NCBITaxon: 783 YH, ZX Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection [PubMed: 15385527]. MSP4/5 Protegen ID: 652; NCBI Protein GI: 49798469; NCBITaxon: 73239 YH, ZX Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami [PubMed: 10861076]. AMA-1 from P. chabaudi Protegen ID: 653; NCBI Protein GI: 1469500; NCBITaxon: 5825 YH, ZX Recombinant adenovirus expressing gB (rAd-gB) was found to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route [PubMed: 19116444]. GB Protegen ID: 654; NCBI Protein GI: 4138504; NCBITaxon: 10345 YH, ZX A trial vaccine containing pseudorabies virus (PRV) glycoprotein gC as the main component showed excellent protection against virulent virus infection in pigs [PubMed: 9300361]. UL44 Protegen ID: 655; NCBI Gene GI: 2952505; NCBI Protein GI: 51557513; NCBI Protein Accession: YP_068347; NCBITaxon: 10345 YH, ZX The pseudorabies virus (PrV) DNA vaccine carrying the glycoprotein D (gD) gene delivered by E. coli was able to induce protective immune responses in mice against a lethal PrV challenge [PubMed: 11312026]. Immunization of mice with affinity-purified gD of Aujeszky's disease virus (ADV, Suid herpesvirus 1) induced a strong humoral immune response and protected mice against lethal ADV challenge [PubMed: 17601050]. US6 Protegen ID: 656; NCBI Gene GI: 2952521; NCBI Protein GI: 51557553; NCBI Protein Accession: YP_068387; NCBITaxon: 10345 YH, ZX A monkey vaccination trial using a Plasmodium falciparum protein fraction containing antigens of 90-110 kDa is reported. Three monkeys out of five resisted a heavy challenge dose of highly virulent parasites. Hsp90 was found in the immunoprecipitates obtained with SERP antisera. Interestingly, the response to hsp90 correlated with protection, high antibody titres being found only in the protected monkeys [PubMed: 8303938]. Hsp90 Protegen ID: 657; NCBI Protein GI: 1093612; NCBITaxon: 5833 YH, ZX To examine the response by IE180 more closely, a vaccine trial in mice with a vector DNA construct that contains the gene encoding for IE180, designated pcDNAIE180 was conducted. Seven months after immunization with pcDNAIE180, an overall 25% of BALB/c, C3H/HeJ, and C57BL/6 mice receiving a lethal PrV challenge were protected [PubMed: 9586695]. IE180 Protegen ID: 658; NCBI Gene GI: 2952540; NCBI Protein GI: 51557548; NCBI Protein Accession: YP_068382; NCBITaxon: 10345 YH, ZX An open reading frame 2 plasmid (pORF2) and the capsid protein (Cap) of PCV2 were used as DNA and subunit vaccines, respectively. In FCM analysis, although pORF2 and Cap alone showed comparable efficacy in eliciting lymphoproliferative responses and Cap-specific CD4(+) T cells, pORF2 was superior to the Cap protein in triggering CD8(+) T cells. Following virus challenge, real-time PCR and histopathological analysis confirmed that only low viral DNA loads and mild microscopic lesions appeared in pORF2-immunized mice [PubMed: 18632956]. ORF2 Protegen ID: 659; NCBI Protein GI: 78217439; NCBITaxon: 85708 YH, ZX To examine the mechanism of immunity in vivo, researchers used poliovirus receptor-transgenic mice on a BALB/c (H-2d) background. Mice immunized with the vaccine strain were protected against a subsequent challenge with wild-type virus. Protection was observed when mice received primed B cells in the presence of a VP4-specific Th1 clone. Findings demonstrate that CD4+ T cells, specific for the internal poliovirus capsid protein, VP4, can provide effective help for a protective antibody response directed against surface capsid proteins [PubMed: 7699320]. VP4 Protegen ID: 660; NCBI Protein GI: 68532656; NCBITaxon: 12080 YH, ZX Series of plasmid constructs encoding different forms of the envelope glycoprotein E of the flavivirus tick-borne encephalitis virus were constructed. These included a secreted recombinant subviral particle, a secreted carboxyl-terminally truncated soluble homodimer, a nonsecreted full-length form, and an inefficiently secreted truncated form. Mice were immunized using both i.m. injection and Gene Gun-mediated application of plasmids. The functional immune response was evaluated by determining specific neutralizing and hemagglutination-inhibiting Ab activities and by challenging the mice with a lethal dose of the virus.The plasmid construct encoding a secreted subviral particle, which carries multiple copies of the protective Ag on its surface, was superior to the other constructs in terms of extent and functionality of the Ab response as well as protection against virus challenge [PubMed: 10586074]. TBEVgp1 polyprotein Protegen ID: 661; NCBI Gene GI: 1489719; NCBI Protein GI: 9628432; NCBI Protein Accession: NP_043135; NCBITaxon: 11084 YH, ZX Monoclonal antibodies to gE neutralize VZV in vitro in a complement- dependent manner [PubMed: 9125048]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [PubMed: 9697709]. ORF68 Protegen ID: 662; NCBI Gene GI: 1487709; NCBI Protein GI: 9625942; NCBI Protein Accession: NP_040190; NCBITaxon: 10335 YH, ZX Monoclonal antibodies to gI neutralize VZV in vitro in a complement- dependent manner [PubMed: 3021804]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [PubMed: 9697709]. ORF67 Protegen ID: 663; NCBI Gene GI: 1487689; NCBI Protein GI: 9625941; NCBI Protein Accession: NP_040189; NCBITaxon: 10335 YH, ZX A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [PubMed: 8904669]. Gp50 Protegen ID: 664; NCBI Protein GI: 2440155; NCBITaxon: 10345 YH, ZX A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [PubMed: 8904669]. GII Protegen ID: 665; NCBI Protein GI: 1335775; NCBITaxon: 10345 YH, ZX Mice immunized with either gII, gIII, gVI antigen or a mixture of them were challenged intraperitoneally with 8.5 x 10(3) plaque forming units of PRV. All the mice immunized with 1.5 and 4.5 micrograms of the mixture and 4.5 micrograms of the gIII antigen survived [PubMed: 1322712]. GIII Protegen ID: 667; NCBI Protein GI: 334050; NCBITaxon: 10345 YH, ZX Vaccination of mice with fusion proteins containing the N terminus of gI from Suid herpesvirus 1 are able to confer protection to mice against a lethal challenge of PRV [PubMed: 1693164]. GI Protegen ID: 668; NCBI Protein GI: 255957222; NCBITaxon: 10345 YH, ZX A recombinant, vP869, expressing prM and E induced high titers of neutralizing and hemagglutination inhibiting antibodies in mice and was protective against intracranial challenge with the French neurotropic strain of YFV [PubMed: 1736531]. E (envelope glycoprotein) Protegen ID: 669; NCBI Protein GI: 262283879; NCBITaxon: 11089 YH, ZX Horses were vaccinated with adjuvanted recombinant SnSAG1 (rSnSAG1)and 5 control (sham vaccinated) horses were vaccinated with adjuvant only. The effect of vaccination with rSnSAG1 on in vivo infection by S. neurona was evaluated by challenging all the horses with S. neurona merozoites. The study showed that vaccination with rSnSAG-1 produced antibodies in horses that neutralized merozoites when tested by in vitro culture and significantly reduced clinical signs demonstrated by in vivo challenge [PubMed: 19794889]. SAG1 Protegen ID: 672; NCBI Protein GI: 295682690; NCBITaxon: 42890 YH, ZX Both inbred BALB/c and outbred CD-1 mice were immunized with rotavirus VP2/6-rVLPs (2/6-VLPs) combined with CT-E29H, orally or intranasally (i.n.), and the comparative efficacy of different formulations was then determined. Two immunizations with 2-6VLPs and CT-E29H were sufficient to protect BALB/c mice, regardless of the route of administration [PubMed: 11270595]. VP2 Protegen ID: 673; NCBI Protein GI: 431460; NCBITaxon: 10970 YH, ZX Plasmid DNA vaccines encoding for murine rotaviral proteins VP4, VP6, and VP7 were tested in adult BALB/c mice for their ability to induce immune responses and provide protection against rotavirus challenge. Vaccines encoding VP4 were effective in protecting mice against infection after rotavirus (100 ID50) challenge [PubMed: 9015117]. VP4 Protegen ID: 675; NCBI Protein GI: 475695; NCBITaxon: 28327 YH, ZX Plasmid DNA vaccines encoding for murine rotaviral proteins VP4, VP6, and VP7 were tested in adult BALB/c mice for their ability to induce immune responses and provide protection against rotavirus challenge. Vaccines encoding VP7 were effective in protecting mice against infection after rotavirus (100 ID50) challenge [PubMed: 9015117]. VP7 Protegen ID: 676; NCBI Protein GI: 475697; NCBITaxon: 28327 YH, ZX VP6 derived from Group A rotavirus conferred in vivo partial protection against rotavirus challenge in a neonatal mouse model [PubMed: 18632867]. VP6 Protegen ID: 677; NCBI Gene GI: 7011372; NCBI Protein GI: 210136699; NCBI Protein Accession: YP_002302229; NCBITaxon: 28875 YH, ZX Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Challenge of neonates born to animals immunized with VP6 protein showed partial protection [PubMed: 8382422]. VP6 Protegen ID: 678; NCBI Protein GI: 195661002; NCBITaxon: 10927 YH, ZX Protection from lethal viral infection has been achieved with passively administered monoclonal antibody specific for flavivirus glycoprotein NS1 [PubMed: 1736531]. Immunization of monkeys with yellow fever virus-specified nonstructural protein NS1 resulted in protection against fatal hepatitis as well as marked reduction in the magnitude of viremia after subcutaneous challenge with yellow fever virus [PubMed: 3783816]. NS1 (non-structural protein 1) Protegen ID: 684; NCBITaxon: 11089 YH, ZX Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge. A truncated portion of the LACK antigen (LACKp24) was able to induce the highest protective effect compared to other constructs. The DNA vaccine encoding LACK was able to induce partial protection in mice [PubMed: 18951941]. LACK Protegen ID: 734; NCBI Nucleotide GI: 1276476; NCBI Protein GI: 1276477; NCBI Protein Accession: AAA97577.1; NCBITaxon: 5664 YH, ZX Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 108 plaque forming units of vv-nef, whereas the intact protein was less protective [PubMed: 19193636]. Nef Protegen ID: 707; NCBI Gene GI: 156110; NCBI Protein GI: 28872818; NCBI Protein Accession: NP_057857; NCBITaxon: 11676 YH, ZX HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [PubMed: 17707956]. Tat Protegen ID: 711; NCBI Gene GI: 155871; NCBI Protein GI: 9629358; NCBI Protein Accession: NP_057853; NCBITaxon: 11676 YH, ZX HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [PubMed: 17707956]. Gag from HIV 1 Protegen ID: 713; NCBI Gene GI: 155030; NCBI Protein GI: 9629360; NCBI Protein Accession: NP_057850; NCBITaxon: 11676 YH, ZX Mice immunized with Recombinant-derived nucleoprotein (rNP) from S. typhimurium expressing the cloned NP gene from A/NT/60/68 (Jones & Brownlee, 1985) were protected against a lethal challenge with Influenza A/Puerto Rico/8/34 (A/PR8) virus but showed considerable morbidity before recovery [PubMed: 2172156]. NP from Influenza A virus (A/nt/60/1968(H3N2)) Protegen ID: 718; NCBI Protein GI: 324704; NCBITaxon: 384505 YH, ZX Since the E2 amino-terminal sequence for all VEE subtype viruses is conserved, we tested the protective capacity in mice of passively transferred mAb 1A2B-10 and found it to protect from both epizootic and enzootic VEE virus challenge. Since horses are an important natural host for VEE virus, pep1-19 was used to immunize horses and was found to be immunogenic and to elicit virus-reactive antibody [PubMed: 7543231]. E2 envelope protein Protegen ID: 725; NCBI Protein GI: 25140296; NCBITaxon: 11036 YH, ZX Study demonstrated that a recombinant construction of heat-shock protein (hslU) with lypopolysaccharide (rcHSP-LPS) administered 24 hours before inoculation induced resistance to S. typhimurium infection. Protection formed after 3 injections of rcHSP-LPS with 10 mcg in each or single injection with 100 mcg/mouse. Forty to eighty percent of immunized mice survived after challenge while 90% of control animals died. Destruction of the HSP by boiling of the construction led to loss of protective effect [PubMed: 19621817]. HslU Protegen ID: 726; NCBI Protein GI: 9650897; NCBITaxon: 90371 YH, ZX The monoclonal antibody against E1 glycoprotein protect outbred albino mice from lethal infection caused by the virulent strain Trd of the VEE virus [PubMed: 7529989]. E1 glycoprotein Protegen ID: 727; NCBI Protein GI: 798795; NCBITaxon: 11036 YH, ZX Immunisation of mice with DnaJ derived from Salmonella enterica subsp. enterica serovar Typhi str. CT18 was found to provide 70% protection against lethal challenge by S. Typhimurium indicating the possible use of DnaJ as vaccine candidate against typhoid [PubMed: 16887241]. DnaJ Protegen ID: 728; NCBI Gene GI: 1246524; NCBI Protein GI: 16759006; NCBI Protein Accession: NP_454623; NCBITaxon: 220341 YH, ZX The viaB (tviB) gene coding for the Vi antigen of Salmonella typhi Ty2 was subcloned into expression vector pYA248. The recombinant plasmid was termed SMM202 and transformed into Salmonella typhimurium 4072, an attenuated crp mutant. Immunization of mice with Vi4072 afforded complete protection against fatal infection with virulent S. typhi Ty2 [PubMed: 1612747]. TviB Protegen ID: 729; NCBI Gene GI: 1067316; NCBI Protein GI: 29144603; NCBI Protein Accession: NP_807945; NCBITaxon: 209261 YH, ZX The immune sera elicited by CTB DNA vaccine were functional and protective against V. cholerae O1 infection in mice [PubMed: 19443090]. CtxB Protegen ID: 731; NCBI Protein GI: 110264635; NCBITaxon: 127906 YH, ZX Antibodies against TCP were able to protect baby mice against challenge with V. cholerae O1 of the classical but not of the El Tor biotype [PubMed: 7911787]. TcpA Protegen ID: 732; NCBI Protein GI: 21616882; NCBITaxon: 127906 YH, ZX Antibodies generated against TcpF are protective against experimental V. cholerae infection in the infant mouse cholera model [PubMed: 16040956]. TcpF Protegen ID: 733; NCBI Gene GI: 2614504; NCBI Protein GI: 15640854; NCBI Protein Accession: NP_230485; NCBITaxon: 243277 YH, ZX Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-TSA developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941]. TSA Protegen ID: 735; NCBI Nucleotide GI: 3411093; NCBI Protein GI: 3411094; NCBI Protein Accession: AAC31146.1; NCBITaxon: 5664 YH, ZX Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-LmSTI1 developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941]. LmSTI1 Protegen ID: 736; NCBI Nucleotide GI: 1698879; NCBI Protein GI: 1698880; NCBI Protein Accession: AAB37318.1; NCBITaxon: 5664 YH, ZX Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-CPa developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941]. Cpa Protegen ID: 737; NCBI Nucleotide GI: 71084305; NCBI Protein GI: 71084306; NCBI Protein Accession: AAZ23598.1; NCBITaxon: 5664 YH, ZX The potential protection of Lmjsp (Leishmania major signal peptidase) was evaluated in three different vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein), against L. major infection. We demonstrated that vaccination with SPase through all three mentioned strategies induced a parasite specific Th1 response and conferred partial protection against parasite challenge. However, our results indicated that DNA/DNA strategy developed more effective protective responses than the other two approaches and induced 81% reduction in L. major parasite load [PubMed: 16481076]. SP Protegen ID: 738; NCBI Protein GI: 23168331; NCBITaxon: 5664 YH, ZX Researchers tested the ability of the entire H2B protein of L. major, its divergent or conserved regions to provide protection against virulent L. major challenge. The divergent amino-terminal region of H2B is able to confer potent protection against a virulent challenge in BALB/c mice [PubMed: 16417957]. H2B Protegen ID: 739; NCBI Protein GI: 13384083; NCBITaxon: 5664 YH, ZX Cell-mediated immunity to Leishmania major (L. major) was induced by injecting BALB/c mice intradermally with plasmid DNA expressing the conserved L. major cell surface glycoprotein gp63 (gp63-pcDNA-3). Challenge studies revealed that gp63-pcDNA-3 vaccination protected 30% of susceptible mice (21 of 70) from Leishmania infection [PubMed: 9741428]. Gp63 Protegen ID: 741; NCBI Protein GI: 259011719; NCBITaxon: 5664 YH, ZX Intraperitoneal vaccination of C3H/He mice with PSA-2 with Corynebacterium parvum as an adjuvant resulted in complete protection from lesion development after challenge infection with virulent L. major. Significant protection was also obtained in the genetically susceptible BALB/cH-2k and BALB/c mice [PubMed: 7591056]. PSA-2 Protegen ID: 742; NCBI Protein GI: 1129058; NCBITaxon: 5664 YH, ZX In a murine model of experimental cutaneous leishmaniasis, researchers investigated the protection elicited by injection of histone H1 (SW3.1) isolated from parasites by perchloric extraction, of a H1 recombinant protein produced in E. coli, and of H1 long and short synthetic peptides, against infection by L. major. Partial protection was achieved in most of the animals as shown by reduction in lesion size, upon immunization with histone H1 or its peptides, provided that the region 1-60 was present in the molecule [PubMed: 10580198]. SW3.1 Protegen ID: 743; NCBI Protein GI: 4008565; NCBITaxon: 5664 YH, ZX Together with poloxamer 407 as adjuvant the recombinant type I (rCPB) cysteine proteinase of Leishmania major was screened as a potential vaccines against L. major in a mouse model. Using the footpad thickness increase to monitor the clinical outcome/cutaneous lesion at site of L. major delivery, it was possible to document that rCPB allowed BALB/c mice to mount a partial protective response [PubMed: 12057598]. Cpb Protegen ID: 744; NCBI Protein GI: 54287314; NCBITaxon: 5664 YH, ZX Upon challenge with L. infantum, C57BL/6 mice immunized with SMT formulated in MPL-SE adjuvant showed significantly lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone [PubMed: 17804125]. SMT Protegen ID: 745; NCBI Protein GI: 146104463; NCBITaxon: 435258 YH, ZX Study examined the immunogenic properties of the Leishmania infantum acidic ribosomal protein P0 (LiP0) in the BALB/c mouse model. When mice were immunized with pcDNA3-LiP0, noticeable protection against L. major infection was achieved [PubMed: 14573678]. LIPO-A Protegen ID: 746; NCBI Protein GI: 730579; NCBITaxon: 5671 YH, ZX BALB/c mice immunized with a DNA vector expressing p36/LACK of Leishmania infantum followed by a booster with VVp36/LACK induced significant protection against Leishmania major infection [PubMed: 11489418]. P36/LACK Protegen ID: 747; NCBI Protein GI: 134085114; NCBITaxon: 5671 YH, ZX Following infection with L. infantum promastigotes, five out of eight beagle dogs immunized with H1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that H1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions [PubMed: 17576026]. H1 Protegen ID: 748; NCBI Nucleotide GI: 78146499; NCBI Protein GI: 78146500; NCBI Protein Accession: ABB22792.1; NCBITaxon: 5671 YH, ZX Following infection with L. infantum promastigotes, four out of eight beagle dogs immunized with HASPB1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that HASPB1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions [PubMed: 17576026]. HASPB1 Protegen ID: 749; NCBI Nucleotide GI: 3724133; NCBI Protein GI: 3724134; NCBI Protein Accession: CAA09789.1; NCBITaxon: 5661 YH, ZX In 1923, it was discovered that treatment with formalin eliminated the toxicity of diphtheria toxin (DT) without destroying its immunogenicity. Formalinreated DT, now called diphtheria toxoid, rapidly became the preferred vaccine against diphtheria, and diphtheria toxoid (usually in combined vaccines, such as diphtheriaetanus toxoidsertussis vaccine [DTP] or diphtheriaetanus toxoidscellular pertussis vaccine [DTaP] for children and tetanusiphtheria toxoids vaccine for adults [Td]) is still used throughout the world for active immunization against diphtheria [PubMed: 10657208]. Tox Protegen ID: 750; NCBI Protein GI: 38199106; NCBITaxon: 1717 YH, ZX Susceptible BALB/c mice were immunized with the DNA encoding P4 alone, P4/IL-12, or P4/HSP70 prior to challenge with L. amazonensis promastigotes. Mice immunized with P4 alone had a delayed onset of lesion development and significantly smaller lesions than the infection control group at 11 weeks postinfection (P < 0.05). P4/IL-12 immunized animals showed no sign of lesion development in three independent experiments (P < 0.01). Our results indicate that different vaccine combinations, including DNA encoding P4, HSP70, or IL-12, can provide significant protection against both Old World and New World cutaneous leishmaniasis [PubMed: 14573646]. P4 Protegen ID: 751; NCBI Nucleotide GI: 29165286; NCBI Protein GI: 29165287; NCBI Protein Accession: AAO65599.1; NCBITaxon: 5659 YH, ZX To examine the efficacy of a new mode of recombinant viral vaccine, a vaccine was constructed of two non-transmissible Sendai viruses (rSeV/dF) encoding the full-length parasite antigen amastigote surface protein-2 (ASP2) or ASP2 fused with a mono-ubiquitin on its N-terminus (UASP2). C57BL/6 mice immunized intranasally with rSeV/dF expressing either ASP2 or UASP2 showed significantly suppressed parasitemia and could be protected from lethal T. cruzi challenge [PubMed: 19712768]. T. cruzi amastigote surface protein-2 Protegen ID: 752; NCBI Protein GI: 284180153; NCBITaxon: 5693 YH, ZX DNA vaccination in BALB/c mice with the LAWD (for Leishmania antigenic WD protein) and IL-12 genes significantly delayed lesion development from challenge with Leishmania amazonensis, which correlated with a dramatic reduction in parasite burdens [PubMed: 15039343]. WD Protegen ID: 753; NCBI Nucleotide GI: 38455440; NCBI Protein GI: 38455441; NCBI Protein Accession: AAR20840.1; NCBITaxon: 5659 YH, ZX Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 10^4 and 10^6 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) [PubMed: 3182080]. M2 Protegen ID: 754; NCBI Nucleotide GI: 2828562; NCBI Protein GI: 2828563; NCBI Protein Accession: AAC08302.1; NCBITaxon: 5659 YH, ZX cDNAs encoding L. m. amazonensis gp46 antigen were subcloned into the VR1012 plasmid, and susceptible BALB/c mice were immunised with two i.m. injections of 100 microg of plasmid DNA. Mice were challenged by the injection of 4 x 10^6 L. m. mexicana parasites in the foot pad to evaluate protection. Measurement of lesion size indicated that mice immunised with VR012-GP46 were partially protected against infection [PubMed: 11713811]. Gp46 Protegen ID: 755; NCBI Nucleotide GI: 159320; NCBI Protein GI: 159321; NCBI Protein Accession: AAA29234.1; NCBITaxon: 5659 YH, ZX To study the protective effects in vivo of cruzipain-specific Th1 responses against systemic T. cruzi challenges, mice were immunized with recombinant cruzipain plus interleukin 12 (IL-12) and a neutralizing anti-IL-4 MAb. These immunized mice developed potent cruzipain-specific memory Th1 cell responses and were significantly protected against normally lethal systemic T. cruzi challenges. To study whether cruzipain could induce mucosal immune responses relevant for vaccine development, recombinant attenuated Salmonella enterica serovar Typhimurium vaccines expressing cruzipain were prepared. BALB/c mice immunized with salmonella expressing cruzipain were significantly protected against T. cruzi mucosal infection [PubMed: 12183554]. T. cruzi Cruzipain Protegen ID: 756; NCBI Protein GI: 1136308; NCBITaxon: 5693 YH, ZX To develop a vaccine strategy taking advantage of activated CD8(+)T cells,a DNA vaccine, designated pGFP-TSA1, encoding a fusion protein linking GFP to a single CTL epitope of TSA1(TS), a leading candidate for vaccine against T. cruzi was constructed. C57BL/6 mice vaccinated with this plasmid showed suppressed parasitemia and prolonged survival. Vaccination with pGFP-TSA1 enhanced epitope-specific cytotoxicity and IFN-gamma secretion by CD8(+)T cells [PubMed: 18321749]. T. cruzi TS Protegen ID: 757; NCBI Protein GI: 258547365; NCBITaxon: 5693 YH, ZX A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24. Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice [PubMed: 19735658]. CP cysteine proteinase Protegen ID: 758; NCBI Nucleotide GI: 30142041; NCBI Protein GI: 30142042; NCBI Protein Accession: AAN34826.1; NCBITaxon: 5659 YH, ZX Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H-2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2Kb-restricted TSA-1515-522 epitope. In H-2(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi-infected cells in an antigen-specific, MHC class I-restricted, and CD8(+)-T-cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64%) H-2(b) and 16 of 18 (89%) H-2(d) mice survived the infection [PubMed: 9784506]. T. cruzi TSA-1 Protegen ID: 759; NCBI Protein GI: 162315; NCBITaxon: 5693 YH, ZX A complement regulatory protein (CRP) of Trypanosoma cruzi was evaluated as a vaccine candidate in a murine model of experimental T. cruzi infection. Recombinant CRP derived from an Escherichia coli expression system and a plasmid encoding the full-length crp structural gene under the control of a eukaryotic promoter were used to immunize BALB/c mice. Immunization with both protein and DNA vaccines resulted in a Th1-type T-cell response, comparable antibody titers, and similar immunoglobulin G isotype profiles. Only mice immunized with the crp DNA plasmid produced antibodies capable of lysing the parasites in the presence of complement and were protected against a lethal challenge with T. cruzi trypomastigotes [PubMed: 10948115]. T. cruzi CRP-10 Protegen ID: 760; NCBI Protein GI: 1389837; NCBITaxon: 5693 YH, ZX The vaccine efficacy of a putative candidate antigen against T. cruzi infection and disease in a mouse model. C57BL/6 mice vaccinated with a T. cruzi G4-encoding plasmid and cytokine (interleukin-12 and granulocyte-macrophage colony-stimulating factor) expression plasmids elicited a strong Th1-type antibody response dominated by immunoglobulin G2b (IgG2b)/IgG1 isotypes. The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 90% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase, as determined by a sensitive T. cruzi 18S rRNA gene-specific real-time PCR approach [PubMed: 18550728]. T. cruzi G4 Protegen ID: 761; NCBI Protein GI: 52424038; NCBITaxon: 5693 YH, ZX The vaccine efficacy of a putative candidate antigen against T. cruzi infection and disease in a mouse model. C57BL/6 mice vaccinated with a T. cruzi G2-encoding plasmid and cytokine (interleukin-12 and granulocyte-macrophage colony-stimulating factor) expression plasmids elicited a strong Th1-type antibody response dominated by immunoglobulin G2b (IgG2b)/IgG1 isotypes. The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 50% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase, as determined by a sensitive T. cruzi 18S rRNA gene-specific real-time PCR approach [PubMed: 18550728]. T. cruzi G2 Protegen ID: 762; NCBI Protein GI: 205278890; NCBITaxon: 5693 YH, ZX Tc00.1047053434931.10 C57BL/6 mice were immunized s.c. with recombinant PFR-2 (PAR2) protein co-adsorbed to alum with rIL-12. rPFR-2 immunized animals were able to successfully resolve parasitemia by day 30 p.i., with the peak parasitemia occurring between days 17 and 21 p.i. [PubMed: 12798650]. T. cruzi PAR2 Protegen ID: 763; NCBI Gene GI: 3532027; NCBI Protein GI: 71398801; NCBI Protein Accession: XP_802646; NCBITaxon: 353153 YH, ZX C57BL/6 mice were immunized s.c. with recombinant PFR-1 (PAR1) protein co-adsorbed to alum with rIL-12. rPFR-1 immunized animals were able to successfully resolve parasitemia by day 30 p.i., with the peak parasitemia occurring between days 17 and 21 p.i. [PubMed: 12798650]. T. cruzi PAR1 Protegen ID: 764; NCBI Protein GI: 2209137; NCBITaxon: 5693 YH, ZX Skin and mucosal vaccination of ponies with HA from influenza virus A/equine/Ky/1/81 provided complete protection from clinical signs of infection after challenge, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding [PubMed: 10403592]. HA from Influenza A virus (A/equine/Kentucky/1/1981(H3N8)) Protegen ID: 765; NCBI Nucleotide GI: 166079523; NCBI Protein GI: 166079524; NCBI Protein Accession: ABY81481.1; NCBITaxon: 475467 YH, ZX Flagellin encoding plasmid DNA was injected into Balb/c mice intramuscularly and this elicited both a humoral and a cellular immune response. Subsequent intravenous challenge of the vaccinated Balb/c mice with 10^5CFU of B. pseudomallei resulted in the number of bacterial cells detected in liver and/or spleen being significantly reduced in the flagellin plasmid DNA vaccinated mice. At 7 days subsequent to infection of B. pseudomallei, 5/6 (83%) of flagellin plasmid DNA vaccinated mice had survived [PubMed: 16169637]. FliC Protegen ID: 770; NCBI Protein GI: 1929918; NCBITaxon: 28450 YH, ZX Transgenic rice immunization expressing the Chlamydophila psittaci (Cp. psittaci) antigen (MOMP) fused to the B subunit of Escherichia coli heat-labile enterotoxin (LTB) induced partial protection (53.3%) against a lethal challenge with the highly virulent Cp. psittaci 6BC strain in a BALB/c mouse model [PubMed: 19146896]. MOMP from C. psittaci 6BC Protegen ID: 771; NCBI Nucleotide GI: 40568; NCBI Protein GI: 40569; NCBI Protein Accession: CAA40300.1; NCBITaxon: 331636 YH, ZX This report describes the successful cloning of the E2 gene of WEEV and expression in Escherichia coli as inclusion bodies. The immunogenicity of the refolded rE2 protein was demonstrated by strong humoral and cell mediated immune (CMI) responses in rE2-immunized BALB/c mice. The current study also demonstrated that rE2-immunized mice could be partially protected from lethal challenge of WEEV [PubMed: 17499379]. E2 Protegen ID: 773; NCBI Protein GI: 29611992; NCBITaxon: 11039 YH, ZX DNA vaccines encoding different portions of the structural proteins of western equine encephalitis virus were tested for the efficacy of their protection in a 100% lethal mouse model of the virus. The 6K-E1 structural protein encoded by the DNA vaccine conferred complete protection against challenge with the homologous strain and limited protection against challenge with a heterologous strain [PubMed: 19923571]. Note: The E1 glycoprotein is part of the 6K-E1 structural protein E1 Protegen ID: 774; NCBI Nucleotide GI: 17148716; NCBI Protein GI: 17148717; NCBI Protein Accession: AAL35792.1; NCBITaxon: 11039 YH, ZX DNA vaccines encoding different portions of the structural proteins of western equine encephalitis virus were tested for the efficacy of their protection in a 100% lethal mouse model of the virus. The 6K-E1 structural protein encoded by the DNA vaccine conferred complete protection against challenge with the homologous strain and limited protection against challenge with a heterologous strain [PubMed: 19923571]. Note: The 6K protein is part of the 6K-E1 structural protein 6K Protegen ID: 775; NCBI Protein GI: 29611993; NCBITaxon: 11039 YH, ZX In this study, Cp23 antigen was investigated as a vaccine candidate using the DNA vaccine model in adult interleukin-12 (IL-12) knockout (KO) mice, which are susceptible to C. parvum infection. Cp23-DNA vaccination induced a 50-60% reduction in oocysts shedding, indicating a partial protection against C. parvum infection in IL-12 KO mice [PubMed: 17487508]. CP23 Protegen ID: 776; NCBI Protein GI: 88659549; NCBITaxon: 5807 YH, ZX Preparturient cows were immunized three times over a six-week period with recombinant plasmid DNA encoding the Cryptosporidium parvum CP15/60 antigen by injecting the DNA in the mammary gland. Colostrum from these cows contained Ab specific for C. parvum sporozoites and oocysts as indicated by immunofluorescence Ab (IFA) staining. Mice receiving immune colostrum showed partial protection (about 50% reduction) against intestinal C. parvum development compared to mice receiving control colostrum. This protection was evident at a challenge dose of 10^3 C. parvum oocysts per mouse [PubMed: 10392628]. CP15/60 Protegen ID: 777; NCBI Nucleotide GI: 170676501; NCBI Protein GI: 170676502; NCBI Protein Accession: ACB30404.1; NCBITaxon: 5807 YH, ZX A subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein G from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Upon oronasal challenge with NiV (50,000TCID50), all vaccinated cats were protected from disease although virus was detected on day 21 post-challenge in one animal [PubMed: 18556094]. G glycoprotein Protegen ID: 779; NCBI Gene GI: 1446471; NCBI Protein GI: 29468607; NCBI Protein Accession: NP_047112; NCBITaxon: 63330 YH, ZX A recombinant baculovirus encoding a dengue (DEN)-2 virus envelope glycoprotein truncated of 102 amino acids (aa) at its C-terminus (D2EA102) was constructed. Both intracellular and extracellular D2EA102 induced neutralizing antibodies in mice and were thus immunogenic. Sixty eight percent (P < 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge [PubMed: 7826210]. E protein Protegen ID: 780; NCBI Protein GI: 202078796; NCBITaxon: 11060 YH, ZX The protective efficacy and immune responses of mice intramuscularly injected with plasmid encoding DEN-2 non-structural protein 1 (NS1) was evaluated. Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival [PubMed: 12922127]. NS1 Protegen ID: 781; NCBI Protein GI: 288848; NCBITaxon: 11060 YH, ZX Hamsters were immunized subcutaneously with either 107 PFU of VV-NiV.G or VV-NiV.F expressing the G and F glycoproteins, respectively, or with the two combined. When the VV-NiV.G-vaccinated animals were challenged with Nipah virus 3 months after the last immunization (1,000 PFU/animal intraperitoneally), there was complete protection against mortality [PubMed: 14694115]. G glycoprotein Protegen ID: 782; NCBI Gene GI: 920955; NCBI Protein GI: 13559814; NCBI Protein Accession: NP_112027; NCBITaxon: 121791 YH, ZX Hamsters were immunized subcutaneously with either 10^7 PFU of VV-NiV.G or VV-NiV.F expressing the G and F glycoproteins, respectively, or with the two combined. When the VV-NiV.F-vaccinated animals were challenged with Nipah virus 3 months after the last immunization (1,000 PFU/animal intraperitoneally), there was complete protection against mortality [PubMed: 14694115]. F fusion protein Protegen ID: 783; NCBI Nucleotide GI: 8164021; NCBI Protein GI: 8164022; NCBI Protein Accession: AAF73956.1; NCBITaxon: 121791 YH, ZX A recombinant vaccinia virus that expressed the pre-M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [PubMed: 1926792]. PrM Protegen ID: 784; NCBI Protein GI: 18308086; NCBITaxon: 11070 YH, ZX A recombinant vaccinia virus that expressed the M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [PubMed: 1926792]. M protein Protegen ID: 785; NCBI Protein GI: 73671170; NCBITaxon: 11070 YH, ZX Guinea pigs immunized with different doses of the SPA appear to be protected against challenge with live organisms as compared with nonimmunized controls [PubMed: 2122457]. SpaP Protegen ID: 786; NCBI Protein GI: 152498; NCBITaxon: 782 YH, ZX The glycoprotein (GP) and nucleocapsid (NC) genes of Rift Valley fever virus (RVFV) were expressed in different expression systems and were evaluated for their ability to protect mice from virulent challenge using a prime-boost regime. Mice vaccinated with a lumpy skin disease virus-vectored recombinant vaccine (rLSDV-RVFV) expressing the two RVFV glycoproteins (G1 and G2, expressed by the RVFV M Segment) developed neutralising antibodies and were fully protected when challenged, as were those vaccinated with a crude extract of truncated G2 glycoprotein (tG2) [PubMed: 16870311]. RVFVsMgp1 M protein Protegen ID: 787; NCBI Gene GI: 956559; NCBI Protein GI: 27881464; NCBI Protein Accession: NP_777376; NCBITaxon: 11588 YH, ZX Immunisation of mice with cDNA encoding the nucleocapsid protein induced strong humoral and lymphocyte proliferative immune responses. Even though complete protection was not achieved by genetic immunisation, four out of eight mice vaccinated with cDNA encoding the nucleocapsid protein displayed no clinical signs of infection after challenge. In contrast, all fourteen control animals displayed clinical manifestations of Rift Valley Fever after challenge [PubMed: 19149901]. RVFVsSgp2 N protein Protegen ID: 788; NCBI Gene GI: 956562; NCBI Protein GI: 9632367; NCBI Protein Accession: NP_049344; NCBITaxon: 11588 YH, ZX The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines. A previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV) induces high titer of neutralizing antibodies. The immune responses and protective effect of the immunization with RBD-rAAV prime/RBD-specific T cell peptide boost were assessed. Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone [PubMed: 18289745]. S protein of SARS-CoV Protegen ID: 789; NCBI Gene GI: 1489668; NCBI Protein GI: 29836496; NCBI Protein Accession: NP_828851; NCBITaxon: 694009 YH, ZX Mice actively immunized using a recombinant V antigen (rVagHis, encoded by lcrV gene) of Y. enterocolitica were completely protected against challenge with both, Y. enterocolitica 0:8 and Y. pseudotuberculosis serotype III [PubMed: 10089162]. LcrV Protegen ID: 790; NCBI Gene GI: 1449458; NCBI Protein GI: 32470278; NCBI Protein Accession: NP_863514; NCBITaxon: 630 YH, ZX 80% of C3H/HeJ mice immunized with Eh29 administered in combination with a subclinical dose of whole cholera toxin, but not as an Eh29-CTxB fusion, showed no evidence of infection in tissue sections harvested following intracecal challenge with virulent E. histolytica trophozoites. These results suggest that Eh29 is capable of inducing protective anti-amoebic immune responses in mice following oral immunization and could be used in the development of oral vaccines against amoebiasis [PubMed: 20303954]. GEh29 Protegen ID: 791; NCBI Nucleotide GI: 399673; NCBI Protein GI: 399674; NCBI Protein Accession: CAA50324.1; NCBITaxon: 5759 YH, ZX Study tested if vaccination with the E. histolytica Gal/GalNAc lectin could prevent cecal infection in a C3H mouse model of amebic colitis. Vaccination prevented intestinal infection with efficacies of 84 and 100% in the two native lectin trials and 91 and 34% in the two LecA trials. Results show for the first time that immunization with the Gal/GalNAc lectin can prevent intestinal amebiasis in mice [PubMed: 14741152]. Gal/GalNAc lectin Protegen ID: 792; NCBI Gene GI: 3404842; NCBI Protein GI: 67469085; NCBI Protein Accession: XP_650534; NCBITaxon: 294381 YH, ZX Report describes a recombinant fusion protein containing the serine-rich Entamoeba histolytica protein (SREHP), a protective antigen derived from virulent amebae, and a bacterially derived maltose-binding protein (MBP) from an attenuated strain of Salmonella typhimurium. Gerbils vaccinated with S typhimurium SREHP-MBP were protected against amebic liver abscess after challenge with E. histolytica, the most common extraintestinal complication of amebiasis [PubMed: 8613356]. SREHP Protegen ID: 793; NCBI Gene GI: 3402462; NCBI Protein GI: 67463194; NCBI Protein Accession: XP_648254; NCBITaxon: 294381 YH, ZX Groups of C57BL/6 mice (20 per group) vaccinated with rPep1 (1 mug per dose) plus adjuvant and challenged with an intranasal inoculum began to die at about 14 to 16 days but then showed significantly greater survival than the control mice [PubMed: 16369008]. PEP1 Protegen ID: 794; NCBI Protein GI: 73915320; NCBITaxon: 199306 YH, ZX Researcherse tested the ability of the galactose-specific adherence lectin of E. histolytica to elicit a protective immune response in conjunction with Freund's incomplete and complete adjuvants. Four independent trials demonstrated complete protection from amebic liver abscess formation in 67% of lectin-immunized gerbils. The gerbil antilectin antibodies were shown by Western immunoblotting to be directed to the heavy subunit (CEL-170/4) but not the light subunit of the lectin [PubMed: 1987067]. CEL-170/4 Protegen ID: 795; NCBI Protein GI: 401088; NCBITaxon: 5759 YH, ZX C57BL/6 mice immunized with rPlb showed a significant reduction of the fungal burden in their lungs at 90 days postchallenge compared to the control mice at 15 days [PubMed: 16369008]. PLB Protegen ID: 796; NCBI Protein GI: 74486661; NCBITaxon: 199306 YH, ZX C57BL/6 mice immunized with rAMN1 showed a significant reduction of the fungal burden in their lungs at 90 days postchallenge compared to the control mice at 15 days [PubMed: 16369008]. AMN1 Protegen ID: 797; NCBI Protein GI: 76786276; NCBITaxon: 199306 YH, ZX ELI-Antigen 1 (ELI-Ag1) was tested for its protective capacity in BALB/c mice against intraperitoneal challenge with 2500 arthroconidia of this dimorphic fungus and was found to be highly protective [PubMed: 14505918]. ELI-Ag1 Protegen ID: 798; NCBI Protein GI: 37779128; NCBITaxon: 5501 YH, ZX The GEL1 mRNA of C. posadasii was detected at the highest level during the endosporulation stage of the parasitic cycle, and the mature protein was immunolocalized to the surface of endospores. BALB/c or C57BL/6 mice were immunized subcutaneously with the bacterium-expressed recombinant protein (rGel1p) to evaluate its protective efficacy against a lethal challenge of C. posadasii by either the intraperitoneal or intranasal route. In both cases, rGel1p-immune mice infected with the pathogen showed a significant reduction in fungal burden and increased survival compared to nonimmune mice [PubMed: 12761077]. GEL1 Protegen ID: 799; NCBI Protein GI: 14582416; NCBITaxon: 199306 YH, ZX Recombinant urease (rURE) of C. immitis was expressed in Escherichia coli and tested asa vaccine candidate in BALB/c mice. BALB/c mice immunized subcutaneously with rURE and subsequently challenged by the intraperitoneal (i.p.) route with a lethal inoculum of C. immitis arthroconidia demonstrated a significant reduction in the level of C. immitis infection compared to control animals [PubMed: 11292702]. URE Protegen ID: 800; NCBI Protein GI: 73808050; NCBITaxon: 5501 YH, ZX Recombinant Pmp1 was reactive with serum from individuals with both acute and protracted disease, and evoked protection in two murine models of infection with C. posadasii [PubMed: 16495561]. Pmp1 Protegen ID: 801; NCBI Protein GI: 78364922; NCBITaxon: 199306 YH, ZX C57BL6 mice were immunized with syngeneic, bone marrow-derived DCs (JAWS II cells) transfected with a cDNA encoding the protective Coccidioides-Ag2/proline-rich Ag (pra). The immunized mice were lethally challenged with C. posadasii through either an i.p. or intranasal route. Upon necropsy after 10 days of infection, fungal burden in lung and spleen of immunized mice was significantly reduced as compared with the control animals. The lung tissue homogenates of immunized animals showed higher levels of IFN-gamma. Histologically, lung tissues of immunized mice were in better condition than the control mice [PubMed: 16148136]. Pra Protegen ID: 802; NCBI Protein GI: 42742528; NCBITaxon: 5501 YH, ZX The microtubule-associate protein (MAP p15) was tested as a vaccine in mice, and tests showed that p15 (native or recombinant) generated up to 100% protection from an otherwise lethal challenge of a heterologous strain of Trypanosoma brucei [PubMed: 15161078]. MAPP15 Protegen ID: 803; NCBI Protein GI: 777767; NCBITaxon: 5691 YH, ZX Vaccination with poliovirus vector containing the gene for the B subunit of H. pylori urease provides significant prophylactic and strong therapeutic protection against H. pylori in mice [PubMed: 15603891]. UreB Protegen ID: 804; NCBI Protein GI: 40737733; NCBITaxon: 210 YH, ZX Researchers prepared an oral liposome-encapsulated recombinant Helicobacter pylori (Hp) heat shock protein 60 (Hsp60) vaccine and investigate its effect against Hp infection in mice. rHsp60 plus CT (choleratoxin), liposome-encapsulated rHsp60 and liposome-encapsulated rHsp60 plus CT had protective rates against Hp infection of 73.3%, 66.7% and 86.7%, respectively [PubMed: 15897126]. Hsp60 Protegen ID: 805; NCBI Protein GI: 397869; NCBITaxon: 210 YH, ZX A study shows that vaccination of mice with HP-NAP (H. pylori NAP) induces protection against H. pylori challenge, and that the majority of infected patients produce antibodies specific for HP-NAP, suggesting an important role of this factor in immunity [PubMed: 10790422]. NAP Protegen ID: 806; NCBI Protein GI: 8777456; NCBITaxon: 210 YH, ZX BALB-c mice immunized intramuscularly with a single dose (100 microg) of a plasmid DNA encoding the 5'-terminal region of the trans-sialidase (nTSA) gene of T. brucei brucei are able to produce IgG antibodies that bind to the bloodstream form of T. brucei-protein extract and recognize the recombinant nTSA protein, expressed in Escherichia coli. Furthermore, this DNA vaccination process was able to protect 60% of mice submitted to a challenge assay with the infective form of T. brucei brucei parasites [PubMed: 19582478]. TSA Protegen ID: 807; NCBI Protein GI: 62175539; NCBITaxon: 5691 YH, ZX Recombinant H. pylori catalase plus CT was used for immunization, and groups of mice were challenged with the Sydney strain of H. pylori. Immunization with recombinant catalase protected a significant proportion (9 of 10) of the mice from H. pylori challenge, indicating that this enzyme should be considered as a candidate for a future vaccine [PubMed: 9353048]. Catalase Protegen ID: 808; NCBI Protein GI: 3128145; NCBITaxon: 210 YH, ZX A study to examine the immunostimulatory properties of Leishmania infantum Hsp83 (83) to elicit humoral and cellular response against the Toxoplasma gondii Rop2 protein in an adjuvant-free vaccination system was conducted. Mice immunized with fusion Rop2-83 elicited a stronger humoral and cellular response in comparison to mice immunized with Rop2 alone, or a mix of LiHsp83 and Rop2. The fusion protein induced a Th1 type response, with predominance of specific IgG2a/IgG2c isotype and IFN-gamma secretions, whereas Rop2 alone or mixed with LiHsp83 produced a Th1/Th2 mixed response. Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups [PubMed: 16545504]. Rop2 Protegen ID: 809; NCBI Protein GI: 115299638; NCBITaxon: 5811 YH, ZX Treatment of the Helicobacter pylori vacuolating cytotoxin with very low concentrations of formaldehyde resulted in abrogation of toxic activity in both a HeLa cell vacuolation assay and an in vivo assay of gastric epithelial damage. Detoxification had only a minimal effect on the integrity of the oligomeric or monomeric structure. The toxoid retained the ability to bind to target cells and to induce high-titer neutralizing antibodies after immunization of rabbits. Furthermore, oral immunization of mice with the toxoid resulted in protection against infective challenge with mouse-adapted strains of H. pylori [PubMed: 9353041]. VacA Protegen ID: 810; NCBI Protein GI: 50313203; NCBITaxon: 210 YH, ZX The immunogenicity of a 48-kDa T-cell-reactive protein (TCRP) was investigated. Immunization of BALB/c and C3H/HeN mice with the rTCRP affords a modest but significant level of protection against an intraperitoneal challenge with C. immitis. It is suggested that the rTCRP may be able to contribute to a multicomponent vaccine designed to stimulate CMI response against the parasitic cycle of C. immitis. TcrP Protegen ID: 811; NCBI Protein GI: 13508695; NCBITaxon: 5501 YH, ZX Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens [PubMed: 15049780]. GLURP Protegen ID: 812; NCBI Gene GI: 810501; NCBI Protein GI: 124802897; NCBI Protein Accession: XP_001347628; NCBITaxon: 36329 YH, ZX Asian seabass vaccinated with the OMP38 (OmpU) DNA vaccine was challenged with pathogenic V. anguillarum by intramuscular injection. A relative percent survival (RPS) rate of 55.6% was recorded [PubMed: 17337208]. OmpU Protegen ID: 813; NCBI Protein GI: 26513901; NCBITaxon: 55601 YH, ZX Japanese encephalitis virus DNA vaccine encoding PrM VIOLIN Vaccine ID: 1067 YH, ZX DeltaFTT0918 VIOLIN Vaccine ID: 439 YH, ZX rLm/iglC VIOLIN Vaccine ID: 440 YH, ZX 5CVMB VIOLIN Vaccine ID: 438 YH, ZX L. amazonensis DNA vaccine encoding WD protein VIOLIN Vaccine ID: 1041 YH, ZX L. infantum H1 protein vaccine VIOLIN Vaccine ID: 1042 YH, ZX L. infantum HASPB1 protein vaccine VIOLIN Vaccine ID: 1043 YH, ZX Japanese encephalitis virus DNA vaccine pUJENS5 VIOLIN Vaccine ID: 1036 YH, ZX Japanese encephalitis virus DNA vaccine encoding E protein VIOLIN Vaccine ID: 1037 YH, ZX L. amazonensis DNA vaccine encoding GP46 VIOLIN Vaccine ID: 1038 YH, ZX L. amazonensis M2 protein vaccine VIOLIN Vaccine ID: 1039 YH, ZX A. pleuropneumoniae ApxIA protein vaccine VIOLIN Vaccine ID: 782 YH, ZX B. pertussis Cpn60 protein vaccine VIOLIN Vaccine ID: 797 YH, ZX B. pertussis CyaA protein vaccine VIOLIN Vaccine ID: 799 YH, ZX V. cholerae CTB DNA Vaccine VIOLIN Vaccine ID: 800 YH, ZX B. pertussis PTx protein vaccine VIOLIN Vaccine ID: 801 YH, ZX C. parvum DNA vaccine encoding CP23 VIOLIN Vaccine ID: 1050 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:C7828795 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1051 https://github.com/vaccineontology/VO/issues/343 2064 1051 Research Gene name: ERBB2 Cancer Her-2/neu Protein Subunit Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:17266027 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1052 https://github.com/vaccineontology/VO/issues/315 6528 1052 Research Gene name: SLC5A5 Cancer DNA Vaccine MIDGE/hNIS encoding hNIS protein Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:19526360 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1053 https://github.com/vaccineontology/VO/issues/318 2315863 1053 Research Gene name: Survivin Cancer DNA Vaccine pSURV encoding Survivin Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:21448901 PubMed:31980914 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1047 https://github.com/vaccineontology/VO/issues/368 1485 1047 Research Gene name: CTAG1B Cancer Subunit NY-ESO-1 Protein Vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1048 https://github.com/vaccineontology/VO/issues/314 13805 1048 Research Gene name: Eng Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:10678354 PubMed:8363286 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1049 https://github.com/vaccineontology/VO/issues/345 14972 1049 Research Gene name: H2-K1 Cancer recombinant vector vaccine encoding H-2Kb Allen Xiang Oliver He 1046 cancer DNA vaccine encoding TEM8 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:10881691 PubMed:19188665 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1064 https://github.com/vaccineontology/VO/issues/319 4072 1064 Research Gene name: EPCAM Cancer EPCAM protein vaccine Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:19034678 PubMed:32164575 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1066 https://github.com/vaccineontology/VO/issues/371 7422 1066 Clinical trial Gene name: VEGFA Cancer VEGFA protein vaccine Allen Xiang Oliver He VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1058 1058 cancer Retroviral vector vaccine encoding Cd40lg Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:/7533183 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=1059 https://github.com/vaccineontology/VO/issues/317 12524 1059 Research Gene name: Cd86 Cancer DNA Vaccine pLXSHDmB7-2 encoding Cd86 YH, ZX Phleum pratense Allergy Phl p 12 Subunit Vaccine VIOLIN Vaccine ID: 1054 YH, ZX B. bovis GST-12D3 VIOLIN Vaccine ID: 791 YH, ZX B. pertussis BrkA protein vaccine VIOLIN Vaccine ID: 796 YH, ZX Bovine leukemia virus DNA vaccine encoding Env VIOLIN Vaccine ID: 825 YH, ZX Bovine leukemia virus DNA vaccine encoding Tax VIOLIN Vaccine ID: 828 YH, ZX B. abortus DNA vaccine encoding RplL and Omp16 VIOLIN Vaccine ID: 831 YH, ZX Bovine herpesvirus 1 DNA vaccine AdCMVgD VIOLIN Vaccine ID: 821 YH, ZX Bovine herpesvirus 1 DNA vaccine AdCMVgC VIOLIN Vaccine ID: 823 YH, ZX Bovine herpesvirus 1 GPI protein vaccine VIOLIN Vaccine ID: 824 YH, ZX A. pleuropneumoniae ApxIa and ApxIIa protein vaccine VIOLIN Vaccine ID: 784 YH, ZX A. pleuropneumoniae HS93C-Ampr VIOLIN Vaccine ID: 786 YH, ZX A. salmonicida live-attenuated vaccine encoding AroA VIOLIN Vaccine ID: 788 YH, ZX NP-VRP VIOLIN Vaccine ID: 443 YH, ZX Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein VIOLIN Vaccine ID: 1044 YH, ZX Rickettsia DNA Vaccine encoding OmpB Protein boosted with Recombinant OmpB VIOLIN Vaccine ID: 1045 YH, ZX B. pertussis DNA vaccine encoding Prn VIOLIN Vaccine ID: 808 YH, ZX Marek's Disease Virus Vaccine rFPV/gI VIOLIN Vaccine ID: 993 YH, ZX Marek's Disease Virus Vaccine rFPV/gB1 VIOLIN Vaccine ID: 994 YH, ZX Marburg Virus Nucleoprotein Vaccine VIOLIN Vaccine ID: 997 YH, ZX Human papillomavirus E7 protein vaccine VIOLIN Vaccine ID: 986 YH, ZX P. falciparum Hsp90 Protein Subunit Vaccine VIOLIN Vaccine ID: 987 YH, ZX Human papillomavirus L2 protein vaccine VIOLIN Vaccine ID: 988 YH, ZX IHNV DNA vaccine pIHNw-G VIOLIN Vaccine ID: 989 YH, ZX Rift Valley Fever Virus DNA Vaccine encoding N Protein VIOLIN Vaccine ID: 990 YH, ZX Puumala virus PUUVsSgp1 (NP) protein vaccine VIOLIN Vaccine ID: 949 YH, ZX Sin Nombre virus DNA vaccine encoding G1 VIOLIN Vaccine ID: 950 YH, ZX Seoul virus vaccine rCAV-2-Gc VIOLIN Vaccine ID: 951 YH, ZX Topografov virus N protein vaccine VIOLIN Vaccine ID: 952 YH, ZX Hepatitis B virus DNA vaccine pVAX-PS VIOLIN Vaccine ID: 968 YH, ZX Herpes simplex virus type 2 DNA vaccine encoding ICP27 VIOLIN Vaccine ID: 969 YH, ZX Herpes simplex virus type 2 DNA vaccine encoding GB VIOLIN Vaccine ID: 970 YH, ZX NIpah Virus G and F Proteins Subunit Vaccine VIOLIN Vaccine ID: 971 YH, ZX Herpes simplex virus type 1 DNA vaccine encoding GC VIOLIN Vaccine ID: 972 YH, ZX Hendra virus G protein vaccine VIOLIN Vaccine ID: 963 YH, ZX M. tuberculosis DNA Vaccine encoding Ag85B Protein VIOLIN Vaccine ID: 964 YH, ZX Hepatitis B virus DNA vaccine encoding HBVgp2 pre-S1/pre-S2/S VIOLIN Vaccine ID: 965 YH, ZX M. tuberculosis Mtb72F protein subunit vaccine VIOLIN Vaccine ID: 967 YH, ZX B. pertussis DNA vaccine encoding TcfA VIOLIN Vaccine ID: 813 YH, ZX E. histolytica CEL-170/4 protein vaccine VIOLIN Vaccine ID: 918 YH, ZX P. falciparum Subunit SE36 Protein Vaccine VIOLIN Vaccine ID: 919 YH, ZX E. histolytica SREHP protein vaccine VIOLIN Vaccine ID: 920 YH, ZX E. coli C3389 protein vaccine VIOLIN Vaccine ID: 921 YH, ZX P. falciparum Pfen Protein Subunit Vaccine VIOLIN Vaccine ID: 922 YH, ZX Mumps HN Protein Subunit Vaccine VIOLIN Vaccine ID: 973 YH, ZX Herpes simplex virus type 2 vaccine using phage displaying GG protein VIOLIN Vaccine ID: 974 YH, ZX Herpes simplex virus type 1 DNA vaccine encoding GD VIOLIN Vaccine ID: 975 YH, ZX Measles Virus vaccine VEE/SIN-H+F VIOLIN Vaccine ID: 976 YH, ZX Herpes simplex virus type 1 DNA vaccine encoding GE VIOLIN Vaccine ID: 977 YH, ZX C. pneumoniae DNA vaccine encoding PknD VIOLIN Vaccine ID: 887 YH, ZX C. pneumoniae DNA vaccine encoding Ssb VIOLIN Vaccine ID: 888 YH, ZX C. psittaci DNA vaccine pcDNA1/MOMP VIOLIN Vaccine ID: 889 YH, ZX Classical swine fever virus vaccine VAC-E0 VIOLIN Vaccine ID: 890 YH, ZX C. abortus DNA vaccine encoding GatC VIOLIN Vaccine ID: 878 YH, ZX C. abortus DNA vaccine encoding OmlA VIOLIN Vaccine ID: 879 YH, ZX C. abortus DNA vaccine encoding MOMP VIOLIN Vaccine ID: 880 YH, ZX C. abortus DNA vaccine Pomp90A VIOLIN Vaccine ID: 881 YH, ZX C. pneumoniae CopN protein vaccine VIOLIN Vaccine ID: 882 Allen Xiang Oliver He 883 prostate cancer DNA vaccine encoding prostatic acid phosphatase (PAP) YH, ZX C. pneumoniae DNA vaccine encoding FabD VIOLIN Vaccine ID: 884 YH, ZX C. pneumoniae LcrE protein vaccine VIOLIN Vaccine ID: 885 YH, ZX B. pseudomallei Subunit LolC Protein Vaccine VIOLIN Vaccine ID: 860 YH, ZX C. muridarum RplF protein vaccine VIOLIN Vaccine ID: 861 YH, ZX B. pseudomallei Subunit PotF Protein Vaccine VIOLIN Vaccine ID: 862 YH, ZX P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine VIOLIN Vaccine ID: 984 YH, ZX P. falciparum MSP3 Protein Subunit Vaccine VIOLIN Vaccine ID: 985 YH, ZX Lassa Virus Nucleoprotein Subunit Vaccine VIOLIN Vaccine ID: 1035 YH, ZX E. coli C4424 protein vaccine VIOLIN Vaccine ID: 923 YH, ZX E. coli Hma protein vaccine VIOLIN Vaccine ID: 924 YH, ZX E. coli IreA protein vaccine VIOLIN Vaccine ID: 925 YH, ZX E. coli IutA protein vaccine VIOLIN Vaccine ID: 926 YH, ZX F. tularensis GroEL protein vaccine VIOLIN Vaccine ID: 928 YH, ZX F. tularensis DNA vaccine rLm/iglC VIOLIN Vaccine ID: 929 YH, ZX E. tenella vaccine rBCG pMV361-Rho VIOLIN Vaccine ID: 912 YH, ZX E. tenella DNA vaccine pcDNA-TA4-IL-2 VIOLIN Vaccine ID: 913 YH, ZX E. histolytica Eh29 protein vaccine VIOLIN Vaccine ID: 915 YH, ZX E. histolytica Gal/GalNAc lectin protein vaccine VIOLIN Vaccine ID: 916 YH, ZX Dengue Vaccine using Vaccinia Virus expressing prM Protein VIOLIN Vaccine ID: 853 YH, ZX C. muridarum MOMP protein vaccine VIOLIN Vaccine ID: 854 YH, ZX Dengue DNA Vaccine encoding NS1 Protein VIOLIN Vaccine ID: 855 YH, ZX Dengue Vaccine using Vaccinia Virus expressing M Protein VIOLIN Vaccine ID: 856 YH, ZX C. muridarum PmpE/F-2 protein vaccine VIOLIN Vaccine ID: 857 YH, ZX Dengue Subunit E Protein Vaccine VIOLIN Vaccine ID: 858 YH, ZX C. muridarum PmpG-1 protein vaccine VIOLIN Vaccine ID: 859 YH, ZX Canine distemper virus DNA vaccine encoding HA VIOLIN Vaccine ID: 847 a Coccidioides vaccine that contains C. posadasii PMP1 protein YH, ZX C. posadasii subunit PMP1 protein vaccine VIOLIN Vaccine ID: 848 a Coccidioides vaccine that contains C. posadasii DNA vaccine encoding PRA protein YH, ZX C. posadasii DNA Vaccine encoding PRA protein VIOLIN Vaccine ID: 849 YH, ZX Canine parvovirus DNA vaccine pGT36VP1 VIOLIN Vaccine ID: 850 a Coccidioides vaccine that contains C. immitis subunit URE protein YH, ZX C. immitis subunit URE protein vaccine VIOLIN Vaccine ID: 851 YH, ZX Canine parvovirus CPMV-PARVO1 protein vaccine VIOLIN Vaccine ID: 852 YH, ZX Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP VIOLIN Vaccine ID: 901 YH, ZX S. flexneri Invaplex 24 Subunit Vaccine VIOLIN Vaccine ID: 902 YH, ZX E. maxima Gam82 protein vaccine VIOLIN Vaccine ID: 903 YH, ZX S. flexneri Invaplex 50 Subunit Vaccine VIOLIN Vaccine ID: 904 YH, ZX E. tenella DNA vaccine proIE VIOLIN Vaccine ID: 905 YH, ZX E. tenella GX3262 protein vaccine VIOLIN Vaccine ID: 907 YH, ZX E. tenella DNA vaccine EtMIC2 VIOLIN Vaccine ID: 909 YH, ZX E. tenella DNA vaccine rBCG pMV261-Rho VIOLIN Vaccine ID: 910 YH, ZX Vaxxitek HVT+IBD VIOLIN Vaccine ID: 397 YH, ZX Newcastle disease virus vaccine by Dow AgroSciences VIOLIN Vaccine ID: 398 YH, ZX Theileria parva vaccine by Centre for Ticks and Tickborne Disease, Malawi VIOLIN Vaccine ID: 427 YH, ZX Theileria annulata vaccine by Local veterinary institutes VIOLIN Vaccine ID: 428 YH, ZX H. pylori DNA vaccine encoding UreB VIOLIN Vaccine ID: 960 YH, ZX M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting VIOLIN Vaccine ID: 961 YH, ZX H. pylori VacA protein vaccine VIOLIN Vaccine ID: 962 YH, ZX Human papillomavirus DNA vaccine pNGVL4a-E6/opt VIOLIN Vaccine ID: 981 YH, ZX PCV2 DNA Vaccine encoding ORF2 Protein VIOLIN Vaccine ID: 982 A multivalent vaccine against tetanus, diphtheria, and poliomyelitis. YH, ZX, NF Tetanus and Diphtheria Toxoids Adsorbed and Inactivated Poliomyelitis Vaccine WEB: https://www.vaccineshoppecanada.com/document.cfm?file=td_polio_adsorbed_e.pdf Td Polio Adsorbed ATC Code: J07CA01 VIOLIN Vaccine ID: 630; VIOLIN Vaccine ID: 629; VIOLIN Vaccine ID: 628 YH, ZX This term is obsolete since there is another term with the same name. obsolete Td Polio Adsorbed VIOLIN Vaccine ID: 629 true YH, ZX This term is obsolete since there is another term with the same name. obsolete Td Polio Adsorbed VIOLIN Vaccine ID: 628 true YH, ZX C. jejuni FspA1 protein vaccine VIOLIN Vaccine ID: 841 YH, ZX SARS Subunit Spike Protein Vaccine VIOLIN Vaccine ID: 842 YH, ZX C. jejuni FspA2 protein vaccine VIOLIN Vaccine ID: 843 YH, ZX C. jejuni DNA vaccine pcDNA3.1(+)-peblA VIOLIN Vaccine ID: 844 YH, ZX Canine distemper virus DNA vaccine encoding F and HA VIOLIN Vaccine ID: 845 a Coccidioides vaccine that contains C. posadasii subunit GEL1 protein YH, ZX C. posadasii subunit GEL1 protein vaccine VIOLIN Vaccine ID: 846 YH, ZX T. brucei DNA Vaccine encoding TSA protein VIOLIN Vaccine ID: 836 YH, ZX T. brucei Subunit p15 Protein Vaccine VIOLIN Vaccine ID: 837 YH, ZX C. jejuni MBP-FlaA protein vaccine VIOLIN Vaccine ID: 838 YH, ZX T. parva Subunit p67 Protein Vaccine VIOLIN Vaccine ID: 839 YH, ZX C. jejuni FlaC protein vaccine VIOLIN Vaccine ID: 840 YH, ZX B. pertussis FhaB and 69 kDa OMP protein vaccine VIOLIN Vaccine ID: 805 YH, ZX H. influenzae Hap protein vaccine VIOLIN Vaccine ID: 936 YH, ZX Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1) VIOLIN Vaccine ID: 1033 YH, ZX Japanese encephalitis virus DNA vaccine pUJENS3 VIOLIN Vaccine ID: 1034 YH, ZX C. parvum DNA vaccine encoding CP15/60 VIOLIN Vaccine ID: 900 YH, ZX Y. enterocolititica Subunit V Antigen Protein Vaccine VIOLIN Vaccine ID: 896 YH, ZX C. botulinum FHc protein vaccine VIOLIN Vaccine ID: 897 YH, ZX WEEV DNA Vaccine encoding 6K-E1 Protein VIOLIN Vaccine ID: 898 YH, ZX WEEV Subunit E2 Protein Vaccine VIOLIN Vaccine ID: 899 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:C5187854 VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=891 https://github.com/vaccineontology/VO/issues/367 7015 891 Clinical trial Gene name: TERT Cancer Subunit GV1001 Protein Vaccine YH, ZX Classical swine fever virus vaccine VAC-E2 VIOLIN Vaccine ID: 892 YH, ZX Classical swine fever virus E1 protein vaccine VIOLIN Vaccine ID: 893 Eliyas Asfaw Ibrahim Seleznev Jie Zheng Oliver He PubMed:wler=tru VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=894 https://github.com/vaccineontology/VO/issues/366 1084 894 Research Gene name: CEACAM3 Cancer Subunit DC (Tat-CEA) vaccine YH, ZX C. botulinum DNA vaccine pSCARSBHc VIOLIN Vaccine ID: 895 YH, ZX Dobrava-Belgrade virus S nucleocapsid protein vaccine VIOLIN Vaccine ID: 954 YH, ZX H. pylori catalase protein vaccine VIOLIN Vaccine ID: 955 YH, ZX H. pylori NAP protein vaccine VIOLIN Vaccine ID: 958 YH, ZX M. gallisepticum TM-1 Protein Subunit Vaccine VIOLIN Vaccine ID: 959 YH, ZX Japanese encephalitis virus vaccine BV-G-E VIOLIN Vaccine ID: 1027 YH, ZX T. annulata Subunit SPAG-1 Protein Vaccine VIOLIN Vaccine ID: 873 YH, ZX C. abortus DNA vaccine encoding DnaK VIOLIN Vaccine ID: 874 YH, ZX C. abortus DNA vaccine encoding DnaX VIOLIN Vaccine ID: 875 YH, ZX C. abortus DNA vaccine encoding GatA/GatB VIOLIN Vaccine ID: 876 YH, ZX T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine VIOLIN Vaccine ID: 866 YH, ZX C. muridarum DNA vaccine encoding TC0757 VIOLIN Vaccine ID: 867 YH, ZX T. gondii DNA vaccine pcDNA3-MIC3 VIOLIN Vaccine ID: 868 YH, ZX C. muridarum DNA vaccine encoding TC0767/768 VIOLIN Vaccine ID: 869 YH, ZX T. gondii DNA Vaccine encoding SAG1 Protein VIOLIN Vaccine ID: 870 YH, ZX C. abortus DNA vaccine encoding CAB049 VIOLIN Vaccine ID: 871 YH, ZX C. abortus DNA vaccine encoding CAB613 VIOLIN Vaccine ID: 872 YH, ZX Infleunza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) VIOLIN Vaccine ID: 1023 YH, ZX Influenza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) VIOLIN Vaccine ID: 1024 YH, ZX http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1025 L. donovani DNA vaccine encoding KMP-11 VIOLIN Vaccine ID: 1025 YH, ZX Influenza virus NP protein vaccine (Influenza A virus (A/nt/60/1968(H3N2))) VIOLIN Vaccine ID: 1026 YH, ZX L. donovani gp63 Protein Subunit Vaccine VIOLIN Vaccine ID: 1022 YH, ZX C. muridarum DNA vaccine encoding TC0439 VIOLIN Vaccine ID: 864 YH, ZX C. muridarum DNA vaccine encoding TC0512 VIOLIN Vaccine ID: 865 YH, ZX Measles Virus Vaccine VVN VIOLIN Vaccine ID: 978 YH, ZX Measles Virus Vaccine VVP VIOLIN Vaccine ID: 979 YH, ZX Measles Virus Vaccine VVM VIOLIN Vaccine ID: 980 YH, ZX B. pseudomallei DNA vaccine encoding Flagellin Protein VIOLIN Vaccine ID: 863 YH, ZX L. donovani ORFF Protein Subunit Vaccine VIOLIN Vaccine ID: 1017 YH, ZX Influenza virus DNA vaccine encoding NA from Influenza B virus (B/Ibaraki/2/85) VIOLIN Vaccine ID: 1018 YH, ZX Influenza virus DNA vaccine encoding NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1)) VIOLIN Vaccine ID: 1019 YH, ZX L. donovani DNA Vaccine encoding NH36 Protein VIOLIN Vaccine ID: 1020 YH, ZX Sin Nombre virus DNA vaccine encoding SNVsSgp1 (NP) VIOLIN Vaccine ID: 945 YH, ZX S. equi Subunit EAG, FNZ and SFS Protein Vaccine VIOLIN Vaccine ID: 832 YH, ZX C. jejuni DNA vaccine pcDNA3.1(+)-cadF VIOLIN Vaccine ID: 833 YH, ZX S. equi Subunit CNE Protein Vaccine VIOLIN Vaccine ID: 834 YH, ZX F. tularensis DNA vaccine pTUL4-15 VIOLIN Vaccine ID: 930 YH, ZX P. berghei CS protein subunit vaccine VIOLIN Vaccine ID: 931 YH, ZX G. duodenalis DNA vaccine encoding CWP2 VIOLIN Vaccine ID: 932 YH, ZX H. influenzae D15 protein vaccine VIOLIN Vaccine ID: 933 YH, ZX Newcastle Disease Virus HN Glycoprotein Subunit Vaccine VIOLIN Vaccine ID: 934 YH, ZX Rabies DNA Vaccine encoding Rabies virus Glycoprotein VIOLIN Vaccine ID: 816 YH, ZX Bovine herpesvirus 1 DNA vaccine tgD-VP22 VIOLIN Vaccine ID: 817 YH, ZX Rabies vaccine rVac-N VIOLIN Vaccine ID: 818 YH, ZX Vivotif L VIOLIN Vaccine ID: 645 YH, ZX Bovine herpesvirus 1 DNA vaccine pRSV-gC VIOLIN Vaccine ID: 815 Kallan Roan, Oliver He, OT, ZX http://purl.bioontology.org/ontology/RXNORM/845529 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179132.htm IXIARO Japanese Encephalitis Vaccine, Inactivated, Adsorbed Valneva Austria GmbH For the prevention of disease caused by Japanese encephalitis virus in persons 2 months of age and older. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142569.pdf BL 125280 845529 Ixiaro CVX: 134 VIOLIN Vaccine ID: 741 Kallan Roan, Oliver He, ZX http://purl.bioontology.org/ontology/RXNORM/661026 https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm Cervarix Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Biologicals Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human papillomavirus (HPV) types 16 and 18, in females9 through 25 years of age. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf BL 125259 661026 Cervarix CVX: 118 VIOLIN Vaccine ID: 740 YH, ZX Andes virus vaccine using adenovirus viral vector expressing ANDV NP VIOLIN Vaccine ID: 943 YH, ZX H. influenzae Omp26 protein vaccine VIOLIN Vaccine ID: 938 YH, ZX N. caninum NcMIC1 Protein Subunit Vaccine VIOLIN Vaccine ID: 939 YH, ZX N. caninum NcMAG1 Protein Subunit Vaccine VIOLIN Vaccine ID: 941 YH, ZX N. caninum NcDG2 Protein Subunit Vaccine VIOLIN Vaccine ID: 942 A vaccine that protects against Leishmania amazonensis. YH, ZX Leishmania amazonensis Leishmania amazonensis vaccine A vaccine that protects against Leishmania infantum. YH, ZX Leishmania infantum Leishmania infantum vaccine A vaccine that protects against Cryptosporidium parvum. YH, ZX Cryptosporidium parvum Cryptosporidium parvum vaccine A vaccine that protects against Bovine Leukemia virus. YH, ZX bovine leukemia virus bovine leukemia virus vaccine A vaccine that protects against Marek's; disease virus. YH, ZX Marek's; disease virus Marek's disease virus vaccine A vaccine that protects against Marburg Virus. YH, ZX Marburg Virus Marburg Virus vaccine A vaccine that protects against Infectious Hematopoietic Necrosis Virus. YH, ZX Infectious Hematopoietic Necrosis Virus Infectious Hematopoietic Necrosis Virus vaccine A vaccine that protects against Rift Valley Fever virus. YH, ZX Rift Valley Fever virus Rift Valley Fever virus vaccine A vaccine that protects against Hantavirus. YH, ZX Hantavirus Hantavirus vaccine A vaccine that protects against Herpes simplex virus type 1 and 2. YH, ZX Herpes simplex virus type 1 and 2 Herpes simplex virus type 1 and 2 vaccine A vaccine that protects against Nipah virus. YH, ZX Nipah virus Nipah virus vaccine A vaccine that protects against Hendra virus. YH, ZX Hendra virus Hendra virus vaccine A vaccine that protects against Entamoeba histolytica. YH, ZX Entamoeba histolytica Entamoeba histolytica vaccine A Chlamydia vaccine that protects against Chlamydophila pneumoniae. YH, ZX Chlamydophila pneumoniae vaccine A Chlamydia bacterial vaccine against Chlamydophila psittaci infection YH, ZX Chlamydophila psittaci vaccine A vaccine that protects against Burkholderia pseudomallei. YH, ZX Burkholderia pseudomallei Burkholderia pseudomallei vaccine A Chlamydia vaccine that protects against Chlamydia muridarum. YH, ZX Chlamydia muridarum Chlamydia muridarum vaccine A vaccine that protects against Lassa Fever Virus. YH, ZX Lassa Fever Virus Lassa Fever Virus vaccine A vaccine that protects against Canine distemper virus. YH, ZX canine distemper virus vaccine A vaccine that protects against Coccidioides spp. YH, ZX Coccidioides spp. vaccine Coccidioides vaccine A vaccine that protects against Canine parvovirus. YH, ZX Canine parvovirus canine parvovirus vaccine A vaccine that protects against Helicobacter pylori. YH, ZX Helicobacter pylori Helicobacter pylori vaccine A Campylobacter vaccine that protects against Campylobacter jejuni. YH, ZX Campylobacter jejuni vaccine A vaccine that protects against SARS-CoV. YH, ZX SARS-CoV vaccine SARS vaccine A vaccine that protects against Trypanosoma brucei. YH, ZX Trypanosoma brucei Trypanosoma brucei vaccine A vaccine that protects against Haemophilus influenzae. YH, ZX Haemophilus influenzae Haemophilus influenzae vaccine A vaccine that protects against Yersinia enterocolitica. YH, ZX Yersinia enterocolitica Yersinia enterocolitica vaccine A vaccine that protects against Clostridium botulinum . YH, ZX Clostridium botulinum Clostridium botulinum vaccine A vaccine that protects against Western equine encephalomyelitis virus. YH, ZX Western equine encephalomyelitis virus Western equine encephalomyelitis virus vaccine A vaccine that protects against Tick-borne Encephalitis Virus (TBEV). YH, ZX Tick-borne Encephalitis Virus (TBEV) Tick-borne Encephalitis Virus (TBEV) vaccine A vaccine preparation that results in the generation of a Cancer vaccine YH, ZX Cancer vaccine preparation VIOLIN Pathogen ID: 99 A vaccine preparation that results in the generation of a Allergy vaccine YH, ZX Allergy vaccine preparation VIOLIN Pathogen ID: 114 YH, ZX Staphylococcus aureus protein YH, ZX Streptococcus agalactiae protein YH, ZX Streptococcus pyogenes protein YH, ZX Treponema pallidum protein YH, ZX YopH from Y. pestis strain: CO92, biovar: Orientalis Protegen ID: 51; NCBI Gene GI: 1172712; NCBI Protein GI: 16082755; NCBI Protein Accession: NP_395201; NCBITaxon: 214092 YH, ZX The oprF gene was cloned into plasmid vector pVR1020, and the plasmid vaccines were delivered to mice by biolistic (gene gun) intradermal inoculation. Following the initial immunization and two consecutive boosts, each at 2-week intervals, protection was demonstrated in a mouse model of chronic pulmonary infection by P. aeruginosa. Eight days postchallenge, both lungs were removed and examined. A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen [PubMed: 11292786]. OprF Protegen ID: 843; NCBI Gene GI: 878442; NCBI Protein GI: 15596974; NCBI Protein Accession: NP_250468; NCBITaxon: 208964 YH, ZX Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls [PubMed: 11500471]. PcrV Protegen ID: 844; NCBI Gene GI: 882997; NCBI Protein GI: 15596903; NCBI Protein Accession: NP_250397; NCBITaxon: 208964 YH, ZX Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa [PubMed: 2114360]. OprI Protegen ID: 845; NCBI Gene GI: 879851; NCBI Protein GI: 15598049; NCBI Protein Accession: NP_251543; NCBITaxon: 208964 YH, ZX AY243312 Protegen ID: 68; NCBI Nucleotide GI: 29692106 YH, ZX In mice, a primary vaccination with Ag85B-encoding plasmid DNA (DNA-85B) was protective against Mycobacterium tuberculosis (MTB) infection and associated with Ag85B-specific CD4+ T cells producing IFN-gamma and controlling intramacrophagic MTB growth [PubMed: 17250590]. Ag85B from M. tuberculosis H37Rv Protegen ID: 118; NCBI Gene GI: 885785; NCBI Protein GI: 15609023; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773 YH, ZX znuA Protegen ID: 228; NCBI Gene GI: 3341411; NCBI Protein GI: 62317941; NCBI Protein Accession: YP_223794; NCBITaxon: 262698 YH, ZX Intravenous vaccination with recombinant bacteria carrying expression plasmid for MPB/MPT51 in BALB/c mice elicited significant protective responses, comparable to those evoked by a live Mycobacterium bovis BCG vaccine [PubMed: 15039321]. FbpD Protegen ID: 814; NCBI Gene GI: 7562680; NCBI Protein GI: 224992215; NCBI Protein Accession: YP_002646905; NCBITaxon: 561275 YH, ZX DNA vaccines encoding secreted proteins Ag85B and MPT64 protect mice from the tuberculosis H37Rv strain [PubMed: 15498274]. *Note* MPT64 in combination with Ag85B was protective, DNA vaccine of just MPT64 was mildly protective in mice. MPT64 Protegen ID: 815; NCBI Gene GI: 885925; NCBI Protein GI: 15609117; NCBI Protein Accession: NP_216496; NCBITaxon: 83332 YH, ZX In a prophylactic vaccine model, immunization with the Mycobacterium tuberculosis protein ESAT-6 with LANAC adjuvant elicited significant protective immunity against aerosol challenge with virulent M. tuberculosis [PubMed: 16751377]. ESAT-6 Protegen ID: 816; NCBI Gene GI: 886209; NCBI Protein GI: 57117165; NCBI Protein Accession: YP_178023; NCBITaxon: 83332 YH, ZX DNA vaccines encoding KatG antigen fused to TPA signal sequences evoked a significant protective response in mice aerogenically challenged with low doses of Mycobacterium tuberculosis Erdman 17 to 21 days after the final immunization [PubMed: 10456931]. KatG Protegen ID: 817; NCBI Gene GI: 885638; NCBI Protein GI: 15609045; NCBI Protein Accession: NP_216424; NCBITaxon: 83332 YH, ZX Mice vaccinated with PstS-3 DNA demonstrated significant and sustained reduction in bacterial CFU numbers in spleen and lungs for 3 mo after M. tuberculosis challenge, as compared with CFU counts in mice vaccinated with control DNA [PubMed: 9916741]. PstS3 Protegen ID: 818; NCBI Gene GI: 885366; NCBI Protein GI: 57116798; NCBI Protein Accession: YP_177768; NCBITaxon: 83332 YH, ZX A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs [PubMed: 16520093]. PE20 Protegen ID: 819; NCBI Gene GI: 885537; NCBI Protein GI: 57116919; NCBI Protein Accession: YP_177843; NCBITaxon: 83332 YH, ZX A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs [PubMed: 16520093]. PPE31 Protegen ID: 820; NCBI Gene GI: 885072; NCBI Protein GI: 57116920; NCBI Protein Accession: YP_177653; NCBITaxon: 83332 YH, ZX Purified preparations of HBHA were emulsified in a dimethyldioctadecylammonium bromide-monophosphoryl lipid A adjuvant and tested for the ability to reduce M. tuberculosis infection in the mouse aerosol challenge model for tuberculosis. The HBHA-containing vaccine gave a approximately 0.7-log reduction in CFU in both mouse lungs and spleens compared to adjuvant controls 28 days following challenge [PubMed: 15557600]. HBHA Protegen ID: 821; NCBI Gene GI: 5211814; NCBI Protein GI: 148660242; NCBI Protein Accession: YP_001281765; NCBITaxon: 25177 YH, ZX immunization with the soluble recombinant rMTB41 protein plus adjuvant, a regimen known to generate primarily CD4+ T cells, resulted in induction of protection comparable to BCG in two well-established animal models of tuberculosis (mice and guinea pigs) [PubMed: 15917115]. PPE14 Protegen ID: 822; NCBI Gene GI: 885069; NCBI Protein GI: 57116795; NCBI Protein Accession: YP_177765; NCBITaxon: 83332 YH, ZX GAPDH (Gap) associated with murine IL-12 gene in a DNA vaccine formulation partially protected mice against experimental infection [PubMed: 12171297]. Gap Protegen ID: 823; NCBI Gene GI: 3340207; NCBI Protein GI: 62290600; NCBI Protein Accession: YP_222393; NCBITaxon: 262698 YH, ZX rHtrA was found to be very immunogenic and partially protective in both the passive infant rat model of bacteremia and the active chinchilla model of otitis media [PubMed: 9488373]. HtrA Protegen ID: 824; NCBI Protein GI: 2935168; NCBITaxon: 727 YH, ZX Orogastric immunization of mice with recombinant H. pylori HspA proteins protected 80% of animals from a challenge dose of 10^4 Helicobacter felis bacteria [PubMed: 7604021]. HspA Protegen ID: 825; NCBI Protein GI: 712830; NCBITaxon: 210 YH, ZX Orogastric immunization of mice with recombinant H. pylori HspB proteins protected 70% of animals from a challenge dose of 10^4 Helicobacter felis bacteria [PubMed: 7604021]. HspB Protegen ID: 826; NCBI Protein GI: 712831; NCBITaxon: 210 YH, ZX Mice were immunised with the citrate synthase protein by intra-Peyer's patch immunisation. Pre-immunisation with the citrate synthase protein led to a 84-91% reduction in H. pylori infection compared to unimmunised controls [PubMed: 10378424]. GltA Protegen ID: 827; NCBI Protein GI: 2493711; NCBITaxon: 210 YH, ZX Recombinant TbpA protein was used in a mouse intraperitoneal-infection model to determine their ability to protect against meningococcal infection and to induce cross-reactive and bactericidal antibodies. TbpA was found to afford protection against meningococcal challenge when administered as the sole immunogen [PubMed: 11179327]. TbpA Protegen ID: 833; NCBI Protein GI: 8926211; NCBITaxon: 487 YH, ZX In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites [PubMed: 11062538]. LSA-3 Protegen ID: 834; NCBI Gene GI: 812783; NCBI Protein GI: 124801463; NCBI Protein Accession: XP_001349701; NCBITaxon: 36329 YH, ZX 1 of 3 Monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes [PubMed: 11471569]. eba-175 Protegen ID: 835; NCBI Gene GI: 2654998; NCBI Protein GI: 296004911; NCBI Protein Accession: XP_001349207; NCBITaxon: 36329 YH, ZX Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain [PubMed: 11349048]. phpA-79 Protegen ID: 836; NCBI Protein GI: 13447096; NCBITaxon: 32630 YH, ZX Mice immunized with recombinant OspA protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958]. OspA Protegen ID: 838; NCBI Gene GI: 1194357; NCBI Protein GI: 11496927; NCBI Protein Accession: NP_045688; NCBITaxon: 224326 YH, ZX Mice immunized with recombinant OspB protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958]. OspB Protegen ID: 839; NCBI Gene GI: 1194340; NCBI Protein GI: 11496910; NCBI Protein Accession: NP_045689; NCBITaxon: 224326 YH, ZX Mice immunized with recombinant OspC protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958]. OspC Protegen ID: 840; NCBI Gene GI: 1194415; NCBI Protein GI: 11497024; NCBI Protein Accession: NP_047005; NCBITaxon: 224326 YH, ZX Mice immunized with recombinant DbpA protein are protected against challenge with Borrelia burgdorferi [PubMed: 11035759]. DbpA Protegen ID: 841; NCBI Gene GI: 8319341; NCBI Protein GI: 256041910; NCBI Protein Accession: YP_003110629; NCBITaxon: 521009 YH, ZX In an attempt to generate a subunit vaccine in this experimental disease model, eukaryotic plasmid DNA expression vectors containing genes encoding either the wild-type or modified forms of recombinant listeriolysin O (hly) were generated and used for genetic vaccination of naive mice. Results of these studies indicate that the intramuscular immunization of mice with specifically designed plasmid DNA constructs encoding recombinant forms of listeriolysin O (hly) stimulates peptide-specific CD8+ immune T cells that exhibit in vitro cytotoxic activity. More importantly, such immunization can provide protective immunity against a subsequent challenge with viable L. monocytogenes [PubMed: 10384131]. Hly Protegen ID: 842; NCBI Gene GI: 987033; NCBI Protein GI: 16802248; NCBI Protein Accession: NP_463733; NCBITaxon: 169963 YH, ZX Mice were immunized with a recombinant fragment of CNA protein, and were then challenged with the S. aureus clinical isolate strain Phillips. At 14 d after inoculation, mortality in the collagen adhesin-vaccinated group was only 13%, compared with 87% in the control antigen immunized group [PubMed: 9637697]. CNA Protegen ID: 846; NCBI Nucleotide GI: 387879; NCBI Protein GI: 387880; NCBI Protein Accession: AAA20874.1; NCBITaxon: 1280 YH, ZX Mice immunized with recombinant ClfA and challenged with S. aureus developed less-severe arthritis than did mice immunized with a control antigen [PubMed: 11740733]. ClfA Protegen ID: 847; NCBI Gene GI: 5330438; NCBI Protein GI: 151220968; NCBI Protein Accession: YP_001331790; NCBITaxon: 426430 YH, ZX An internal region from the transpeptidase domain from the PBP2a (encoded by mecA) was cloned into a mammalian expression vector, to be used as DNA vaccine in a Murine model. After three sets of DNA vaccination, the immune response represented by antibodies against a fragment of PBP2a was evaluated by enzyme linked immunosorbent assay (ELISA), showing a significant antibody response. The antibacterial effect of the DNA vaccine was evaluated by intraperitoneal immunization and challenge with a sublethal dose of MRSA for 7 days in mice. After the challenge, the number of bacteria from kidneys from immunized and non-immunized mice were determined. Kidneys from immunized mice had 1000 times less on bacteria than the positive controls (non-immunized mice) [PubMed: 12744903]. MecA Protegen ID: 848; NCBI Gene GI: 2861157; NCBI Protein GI: 49482291; NCBI Protein Accession: YP_039515; NCBITaxon: 282458 YH, ZX Mice were immunized with fusion proteins encompassing the fibronectin-binding domain of a staphylococcal fibronectin-binding protein (FnBP-A). Vaccination of mice with recombinant FnBP resulted in significant protection against challenge with S. aureus [PubMed: 7975852]. FnbA Protegen ID: 849; NCBI Protein GI: 120457; NCBITaxon: 93061 YH, ZX Immunization of mice with recombinant BPS protein by the subcutaneous route produced an efficient antigen-specific response, and immunized animals survived challenge with a lethal dose of a virulent strain [PubMed: 11796614]. BPS Protegen ID: 850; NCBI Protein GI: 5327234; NCBITaxon: 1311 YH, ZX Intranasal immunization of mice with either SfbI alone or coupled to cholera toxin B subunit (CTB) triggered efficient SfbI-specific humoral (mainly IgG) and lung mucosal (14% of total IgA) responses. SfbI-vaccinated animals showed 80% and 90% protection against homologous and heterologous challenge, respectively [PubMed: 10068585]. SfbI Protegen ID: 851; NCBI Nucleotide GI: 511149; NCBI Protein GI: 511150; NCBI Protein Accession: CAA48133.1; NCBITaxon: 1314 YH, ZX Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice [PubMed: 11159987]. FBP54 Protegen ID: 852; NCBI Nucleotide GI: 496254; NCBITaxon: 1314 YH, ZX Mice immunized with FbpA were protected from challenge with group A streptococcus [PubMed: 19254483]. FbaA Protegen ID: 853; NCBI Protein GI: 14915682; NCBITaxon: 1314 YH, ZX Mice were intranasally immunized with diphtheria toxoid (DT) conjugated polypeptides encompassing a conformational-constrained B cell epitope of the M1 protein (J8). Vaccinated mice were challenged 10 days after the last boost by the intranasal route. Animals had 60% protection against challenge [PubMed: 16828529]. Emm1 Protegen ID: 854; NCBI Nucleotide GI: 311757; NCBI Protein GI: 311758; NCBI Protein Accession: CAA44062.1; NCBITaxon: 1314 YH, ZX Immunization with Sib 35 enhanced survival rates in mice challenged with a GAS strain, while exhibiting no toxicity in hosts [PubMed: 15990202]. Sib35 Protegen ID: 855; NCBI Protein GI: 90567992; NCBITaxon: 342023 YH, ZX Immunization with the recombinant GlpQ significantly protected rabbits from subsequent T. pallidum challenge, altering lesion development at the sites of challenge [PubMed: 9826352]. GlpQ Protegen ID: 856; NCBI Gene GI: 2611763; NCBI Protein GI: 15639249; NCBI Protein Accession: NP_218698; NCBITaxon: 243276 YH, ZX Treponema pallidum-susceptible guinea pigs of strain C4D were immunized with recombinant T. pallidum antigen TmpB. Guinea pigs receiving TmpB antigen demonstrated protection expressed by the development of significantly (P less than 0.01) smaller, atypical lesions of significantly (P less than 0.01) shorter duration and devoid of or containing fewer T. pallidum organisms than lesions in the remaining immunized and control animals [PubMed: 1937794]. TmpB Protegen ID: 857; NCBI Gene GI: 2611387; NCBI Protein GI: 15639756; NCBI Protein Accession: NP_219206; NCBITaxon: 243276 YH, ZX Immunization with recombinant Tp92 partially protected rabbits from subsequent T. pallidum challenge [PubMed: 10762571]. Tp92 Protegen ID: 858; NCBI Protein GI: 159158965; NCBITaxon: 243276 YH, ZX Immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI [PubMed: 10992461]. Sip Protegen ID: 859; NCBI Gene GI: 3685788; NCBI Protein GI: 76788047; NCBI Protein Accession: YP_328758; NCBITaxon: 205921 YH, ZX Vaccination of mice with the Rib protein protected against two strains of capsular type III and two strains of type II, and vaccination with the alpha protein protected against one strain of type II and one strain of type Ib [PubMed: 8751893]. Rib Protegen ID: 860; NCBI Protein GI: 1620648; NCBITaxon: 1311 YH, ZX Mice immunized with p60 encapsulated in liposomes launched a strong CTL response and were protected against a subsequent challenge with L. monocytogenes [PubMed: 18433404]. p60 Protegen ID: 862; NCBI Protein GI: 215422507; NCBITaxon: 1639 YH, ZX Mouse antiserum directed against the recombinant NucA protein was reactive on Western immunoblots and whole-cell ELISA with all H. influenzae strains tested including Eagan and was bactericidal for two heterologous strains tested. The antiserum also resulted in a log reduction in bacteremia, in an infant-rat protection study with H. influenzae type b as the challenge strain [PubMed: 10768940]. NucA Protegen ID: 863; NCBI Protein GI: 4929317; NCBITaxon: 727 YH, ZX When chinchillas were immunized with recombinant P1 (rP1) obtained from one of these isolates (BCH-3), all animals developed antibodies specific for rP1. Immunized animals were protected against disease when challenged with BCH-3, but not with an ompP1 mutant of BCH-3 or a strain (BCH-2) possessing a heterologous P1 (91% identity). We conclude that (i) while P1 induces protection against NTHI-mediated otitis media, development of a polyvalent vaccine reflecting the variability of P1 would be necessary to construct an efficacious vaccine [PubMed: 10899849]. OmpP1 Protegen ID: 864; NCBI Protein GI: 9716645; NCBITaxon: 727 YH, ZX Vaccination with the recombinant PstS-1 antigen and cholera toxin significantly protected against the challenge given 10 days later, but only marginally after 12 weeks [PubMed: 10869767]. PstS1 Protegen ID: 865; NCBI Gene GI: 885724; NCBI Protein GI: 57116801; NCBI Protein Accession: YP_177770; NCBITaxon: 83332 YH, ZX In an ex vivo transfection approach with a retroviral vector a single antigen (hsp70) could evoke strong protection in mice [PubMed: 9234527]. DnaK Protegen ID: 866; NCBI Gene GI: 885946; NCBI Protein GI: 15607491; NCBI Protein Accession: NP_214864; NCBITaxon: 83332 YH, ZX A single DNA vaccine encoding the MPT-83 tuberculosis antigens evoked partial protection against an aerogenic challenge with M. tuberculosis Erdman in the mouse model of pulmonary tuberculosis [PubMed: 10715531]. MPT83 Protegen ID: 867; NCBI Gene GI: 887155; NCBI Protein GI: 15610010; NCBI Protein Accession: NP_217389; NCBITaxon: 83332 Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/803365 803365 Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Twinrix] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/803371 803371 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/803367 803367 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657671 1657671 Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injection [Twinrix] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/803370 803370 Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300468 1300468 0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection [ActHIB] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300467 1300467 Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML [ActHIB] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658093 1658093 Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection [ActHIB] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1169156 1169156 ActHIB Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300465 1300465 Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300464 1300464 Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798279 798279 Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1300466 1300466 0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658069 1658069 Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1160291 1160291 Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1166419 1166419 Engerix-B Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658143 1658143 Hepatitis B Surface Antigen Vaccine Injection [Engerix-B] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1190916 1190916 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Tenivac] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1190919 1190919 0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Tenivac] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1190918 1190918 diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Tenivac] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657592 1657592 diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tenivac] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1190914 1190914 Tenivac Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1190912 1190912 diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Tenivac] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1292427 1292427 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML [Varivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1292459 1292459 0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1187569 1187569 Varivax Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658008 1658008 Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Varivax] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798267 798267 L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597084 1597084 L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597099 1597099 0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Injection [Gardasil 9] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597096 1597096 L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML [Gardasil 9] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597103 1597103 0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Prefilled Syringe [Gardasil 9] Khadeejah Khan, Oliver He L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 31 Vaccine / L1 protein, Human papillomavirus type 33 Vaccine / L1 protein, Human papillomavirus type 45 Vaccine / L1 protein, Human papillomavirus type 52 Vaccine / L1 protein, Human papillomavirus type 58 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injection [Gardasil 9] http://purl.bioontology.org/ontology/RXNORM/1656976 1656976 Gardasil 9 injection Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597098 1597098 Gardasil 9 Injectable Product Khadeejah Khan, Oliver He L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 31 Vaccine / L1 protein, Human papillomavirus type 33 Vaccine / L1 protein, Human papillomavirus type 45 Vaccine / L1 protein, Human papillomavirus type 52 Vaccine / L1 protein, Human papillomavirus type 58 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Prefilled Syringe [Gardasil 9] http://purl.bioontology.org/ontology/RXNORM/1597102 1597102 Gardasil 9 prefilled syringe Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798263 798263 L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597083 1597083 L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597085 1597085 L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597086 1597086 L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597087 1597087 L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597088 1597088 L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597089 1597089 L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1597090 1597090 L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804184 804184 Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML [M-M-R II] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804186 804186 0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injection [M-M-R II] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658025 1658025 Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection [M-M-R II] Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1184336 1184336 M-M-R II Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804179 804179 Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804180 804180 Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762817 762817 Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/762818 762818 Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798372 798372 Mumps Virus Vaccine Live, Jeryl Lynn Strain Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798373 798373 Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1156380 1156380 Mumps Virus Vaccine Live, Jeryl Lynn Strain Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/798375 798375 Mumps Virus Vaccine Live, Jeryl Lynn Strain 40000 UNT/ML Injectable Solution Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/804181 804181 Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797629 797629 Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797630 797630 Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797632 797632 Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797631 797631 Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797634 797634 Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797633 797633 Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797635 797635 Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/797634 797634 Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658702 1658702 Fluzone 2015-2016 Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1658705 1658705 Fluzone 2015-2016 Injectable Product Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657128 1657128 Influenza A virus (H1N1) antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657131 1657131 influenza A virus (H3N2) antigen Khadeejah Khan, Oliver He http://purl.bioontology.org/ontology/RXNORM/1657134 1657134 influenza B virus antigen Plasmodium falciparum protein Plasmodium knowlesi protein Plasmodium vivax protein Plasmodium yoelii protein Plasmodium berghei protein Plasmodium chabaudi protein Leishmania protein AH Giardia lamblia protein a role that inheres in a cell line repository organization. SS, YH cell line repository role Obsolete Class A transmision blocking is a vaccine that prevents or reduce the transmission of a disorder within a target host or among a population by inducing or modifying specific adaptive immune responses against the antigens present in the vaccine transmission blocking vaccine example to be eventually removed example to be eventually removed failed exploratory term The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job Person:Alan Ruttenberg failed exploratory term metadata complete Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. metadata complete organizational term Term created to ease viewing/sort terms for development purpose, and will not be included in a release organizational term ready for release Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." ready for release metadata incomplete Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. metadata incomplete uncurated Nothing done yet beyond assigning a unique class ID and proposing a preferred term. uncurated pending final vetting All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. pending final vetting Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. PERSON: Alan Ruttenberg PERSON: Melanie Courtot obsolete_core true placeholder removed placeholder removed terms merged An editor note should explain what were the merged terms and the reason for the merge. terms merged term imported This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. term imported term split This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. term split universal Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. Alan Ruttenberg A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf universal defined class A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. Alan Ruttenberg defined class named class expression A named class expression is a logical expression that is given a name. The name can be used in place of the expression. named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions Alan Ruttenberg named class expression to be replaced with external ontology term Terms with this status should eventually replaced with a term from another ontology. Alan Ruttenberg group:OBI to be replaced with external ontology term requires discussion A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. Alan Ruttenberg group:OBI requires discussion The term was added to the ontology on the assumption it was in scope, but it turned out later that it was not. This obsolesence reason should be used conservatively. Typical valid examples are: un-necessary grouping classes in disease ontologies, a phenotype term added on the assumption it was a disease. https://github.com/information-artifact-ontology/ontology-metadata/issues/77 https://orcid.org/0000-0001-5208-3432 out of scope The term was added to the ontology on the assumption it was a valid domain entity, but it turns out the entity does not exist in reality. This obsolesence reason should be used conservatively. For example: Obsoleting class that describes a breed of cow based on a record in an existing database, that was later retracted as faulty (breed does not exist). Do not use this term to obsolete a historic concept (that was once valid, but not anymore). https://github.com/information-artifact-ontology/ontology-metadata/issues/136 https://orcid.org/0000-0002-4142-7153 domain entity does not exist YH, ZX http://www.invitrogen.com Invitrogen http://www.unitedvaccines.com/ United Vaccines, Inc Heska Corporation Texas Vet lab, Inc SolidTech Animal Health, Inc http://www.mvplabs.com/ MVP Laboratories, Inc www.addisonlabs.com/ Addison Biological Laboratory, Inc Neotech, LLC neotechvaccines.com/ Aceto Pharma Corp Intervet has merged with Schering-Plough Animal Health and become Intervet/Schering-Plough Animal Health™ (YL.) YH http://www.intervet.com/ Intervet YH http://www.wyeth.com/divisions/fort_dodge.asp Fort Dodge ProtaTek International, Inc www.protatek.com/ Arko Laboratories Ltd www.arkolabs.com/ Newport Laboratories, Inc www.newportlabs.com Texas Agricultural Experiment Station Brinton Laboratories Inc YL http://www.petwellness.com/ Novartis Animal Health US, Inc. Intercell Biomedical YH http://www.acambis.com/ Acambis, Inc YH http://www.crucell.com/ Berna Biotech, Ltd YH http://www.bioport.com/ BioPort Corp YH http://www.csl.com.au/ CSL Limited A British multinational pharmaceutical company headquartered in Brentford, England Oliver He, Philip Huang https://en.wikipedia.org/wiki/GlaxoSmithKline https://www.gsk.com/en-gb/home/ GlaxoSmithKline plc YH http://www.greerlabs.com/ Greer Laboratories Inc YH http://www.ctidirectory.com/search/company.cfm?company=129584 ID Biomedical Corp of Quebec YH Massachusetts Public Health Biologic Lab YH http://www.medimmune.com/ MedImmune Vaccines, Inc YH Merck Sharp & Dohme Corp. http://www.merck.com/ Merck & Co., Inc. YH http://www.novartis.com/about-novartis/our-businesses/vaccines-diagnostic.shtml Novartis Vaccines and Diagnostics 100 Rodolphe Street Building 1300 Durham, NC 27712 YH Organon Teknika Corp LLC YH http://read.jst.go.jp/public/cs_kkn_004EventAction.do?action5=event&lang_act5=E&kcd1_act5=9535000000&judge_act5=2 Research Foundation for Microbial Diseases of Osaka University YH http://www.sanofipasteur.com Sanofi Pasteur Limited YH Aventis Pasteur Inc. http://www.sanofipasteur.us Sanofi Pasteur, Inc YH http://www.wyeth.com/ Wyeth Pharmaceuticals Inc YH http://www.sanofipasteur.co.za/ Sanofi Pasteur, SA YH http://www.vetechinc.com/ Vetech Labs YH http://www.pfizerah.com/ Pfizer Animal Health YH BIOPHARM YH Cutter Biological YH http://www.bioproperties.com.au/ Bioproperties YH Solvay Pharmaceuticals YH https://www.webstervet.com/app.aspx Websters Animal Health YH http://www.colorado-serum.com/ Colorado Serum Company CZ Veterinaria YH, ZX Biken YH http://www.schering-plough.com/ Schering-Plough YH, ZX http://www.baxter.com/ Baxter Healthcare Corporation YH, ZX http://www.merckfrosst.ca/ Merck Frosst YH http://www.bi-vetmedica.com/ Boehringer-Ingelheim Vetmedica, Inc YH, ZX SBL Vaccine YH, ZX http://www.wyeth.ca/ Wyeth Canada YH http://www.virbac.com/ Virbac YH http://www.embrex.com/ Embrex YH http://www.ah.novartis.com/ Novartis Animal Health YH Aqua Health http://www.novartis.com/ Novartis YH http://www.novusint.com/ Novus International YH http://www.biomunecompany.com/ Biomune Vical, Inc. http://www.vical.com/ http://www.promega.com/ Promega YH http://www.lahinternational.com/ Lohman Animal Health International YH Centre for Ticks and Tickborne Disease, Malawi YH http://www.immunovaccine.com ImmunoVaccine Technologies, Canada YH Local veterinary institutes YH http://www.merial.com/ Merial, Inc Intervet has merged with Schering-Plough Animal Health and become Intervet/Schering-Plough Animal Health™ (YL.) YH http://www.intervet.com/ Schering-Plough Animal Health YH http://www.bayer.com/ Bayer Leverkusen YH http://www.coopersanimalhealth.com.au/ Coopers Animal Health YH http://www.dowagro.com/homepage/index.htm?DCSext.das=dowagro.com Dow AgroSciences YL International Duck Research Cooperative, Inc. http://www.duckhealth.com/idrc.html YL Vaccicel, Inc. has a location in Belton, TX. Active officers include Andre Menchu, Andres Menchu, Kathryn M Baker, Katheryn Becker and Andres Menches. Vaccicel, Inc. filed as a Domestic For-Profit Corporation on Tuesday, August 22, 1995 in the state of Texas and is currently active. Andres Menchu serves as the registered agent for this organization.The company's line of business includes Mfg Research & Development Veterinary Bacterial Vaccines. (http://www.corporationwiki.com/Texas/Belton/vaccicel-inc/34296230.aspx) VacciCel, Inc. YL GSK Acquires Influenza Vaccine Manufacturer ID Biomedical Corporation http://www.medicalnewstoday.com/releases/34803.php GlaxoSmithKline plc (NYSE:GSK) announced the completion of the acquisition of ID Biomedical. This follows regulatory clearances of the transaction and adoption of the acquisition agreement by ID Biomedical's shareholders (which occurred on the 16th of November). ID Biomedical becomes a wholly-owned subsidiary of GSK. ... ID Biomedical Corporation of Quebec http://www.proteinsciences.com/ Protein Sciences Corporation Valneva SE An Israeli research and development laboratory Philip Huang https://en.wikipedia.org/wiki/Israel_Institute_for_Biological_Research https://iibr.gov.il/Pages/home.aspx Israel Institute for Biological Research PaxVax, Inc. https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=7884644 Out of buisness Lederle Laboratories Division Abbot Laboratories Parke, Davis, Company Max Planck Institute for Infection Biology Bio-Manguinhos Mylan Products Limited French National Agency for Research on AIDS and Viral Hepatitis (ANRS) A company trhat is located at Berkeley, CA, USA. Its website is: http://www.dynavax.com. Oliver He, Randi Rita, Kallan Roan http://www.dynavax.com/ Dynavax Technologies Corporation Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. http://novavax.com/ Novavax, Inc. Kallan Roan, Oliver He https://www.tevausa.com/ Teva Pharmaceuticals USA, Inc. Kallan Roan, Oliver He https://www.seqirus.com/ Seqirus, Inc. Located in Swiftwater, Pennsylvania, this company is now known as Sanofi Pasteur Limited. Kallan Roan, Oliver He Connaught Laboratories, Inc. Chiron Behring Vaccines Private Ltd https://www.advent-gmp.com/about-us/ ADVENT SRL VIA CRESCENZIO 9 ROMA, ROMA, 00193 Italy +39-0691093692 Company Type: Corporation Subsidiary http://www.hoovers.com/company-information/cs/company-profile.advent_srl.aebb99e74ae57b09.html?aka_re=1 Advent Srl., Italy A pharmaceutical company that was founded in 1953 by Paul Janssen, is headquartered in Beerse, Belgium, and owned by Johnson & Johnson. Oliver He, Philip Huang https://en.wikipedia.org/wiki/Janssen_Pharmaceutica https://www.janssen.com/us/ Janssen Pharmaceutica Philip Huang, Oliver He 康希诺生物 http://www.cansinotech.com/ https://en.wikipedia.org/wiki/CanSino_Biologics CanSino Biologics A German biotechnology company that is dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. Philip Huang, Oliver He https://en.wikipedia.org/wiki/BioNTech https://biontech.de/ BioNTech An American multinational pharmaceutical corporation headquartered in New York City. Philip, Oliver https://en.wikipedia.org/wiki/Pfizer https://www.pfizer.com/ Pfizer Inc. A British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. AstraZeneca makes products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. Philip Huang, Oliver He https://en.wikipedia.org/wiki/AstraZeneca https://www.astrazeneca.com/ AstraZeneca Philip, Oliver https://www.cnbg.com.cn/ https://www.trialsitenews.com/chinas-beijing-institute-of-biological-products-covid-19-vaccine-reportedly-ready-for-phase-iii/ Beijing Institute of Biological Products Philip Huang, Oliver He Sinopharm Sinopharm Group 国药控股股份有限公司 http://www.sinopharm.com/1156.html https://en.wikipedia.org/wiki/Sinopharm_Group Sinopharm Group Co., Ltd. Philip Huang, Oliver He http://www.wibp.com.cn Wuhan Institute of Biological Products Philip Huang, Oliver He https://en.wikipedia.org/wiki/Gamaleya_Research_Institute_of_Epidemiology_and_Microbiology https://gamaleya.org/en/ Gamaleya Research Institute Philip, Oliver https://en.wikipedia.org/wiki/Moderna https://www.modernatx.com/ Moderna A biopharmaceutical company headquartered in Beijing, China Sinovac http://www.sinovac.com/ Sinovac Biotech Ltd Philip Huang https://www.anges.co.jp/en/ AnGes, Inc. An American biotech company focused on the discovery, development and commercialization of therapeutics for rare diseases with focus on RNA Philip Huang https://en.wikipedia.org/wiki/Arcturus_Therapeutics arcturusrx.com Arcturus Therapeutics Philip Huang http://en.biominhai.com/ Beijing Minhai Biotechnology Co., Ltd. Philip Huang, Oliver He https://vaxxinity.com/ Vaxxinity Philip Huang http://www.ystwt.cn/ Beijing Wantai Biological Pharmacy Philip Huang FBRI SRC VB VECTOR Federal Budgetary Research Institution State Research Center of Virology and Biotechnology Vector Institute http://www.vector.nsc.ru/ State Research Center of Virology and Biotechnology VECTOR Philip Huang http://www.genexine.com/ Genexine, Inc. An American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases Philip Huang https://en.wikipedia.org/wiki/Inovio_Pharmaceuticals https://www.inovio.com/ Inovio Pharmaceuticals, Inc. Philip Huang https://kentuckybioprocessing.com/ Kentucky Bioprocessing, Inc. Philip Huang Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. A manufacturer of immunobiological drugs including vaccines in India Philip Huang https://en.wikipedia.org/wiki/Serum_Institute_of_India https://www.seruminstitute.com/ Serum Institute of India Philip Huang https://zyduscadila.com/ Zydus Cadila Philip Huang http://www.adimmune.com.tw/en/ Adimmune Corporation A China-based company principally engaged in the research, development, production and distribution of vaccines, monoclonal antibodies and blood products Philip Huang https://www.reuters.com/companies/300142.SZ http://www.walvax.com/wosen/27.aspx Walvax Biotechnology Co., Ltd. Philip Huang https://www.symvivo.com/ Symvivo Philip Huang https://www.chula.ac.th/en/ Chulalongkorn University A public research university in London Philip Huang https://en.wikipedia.org/wiki/Imperial_College_London https://www.imperial.ac.uk/ Imperial College London A Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications Philip Huang https://en.wikipedia.org/wiki/Medicago_Inc. https://www.medicago.com/en/ Medicago Inc. Philip Huang https://www.entospharma.com/ Entos Pharmaceuticals Philip Huang https://www.reithera.com/ ReiThera Srl Philip Huang https://immunitybio.com/ ImmunityBio, Inc. Philip Huang https://nantkwest.com/ NantKwest, Inc. The teaching hospital of the University of Hamburg and one of the largest hospitals in Hamburg, Germany Philip Huang https://en.wikipedia.org/wiki/University_Medical_Center_Hamburg-Eppendorf https://www.uke.de/ University Medical Center Hamburg-Eppendorf Philip Huang https://medigen-usa.com/ Medigen, Inc. A public research university in Chengdu, Sichuan, China Philip Huang 四川大学 https://en.wikipedia.org/wiki/Sichuan_University http://en.scu.edu.cn/ Sichuan University Philip Huang https://vaxine.net/ Vaxine Pty Ltd. Philip Huang https://www.finlay.edu.cu/ Instituto Finlay de Vacunas Philip Huang www.cloverbiopharma.com Clover Biopharmaceuticals, Inc. A French non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines Philip Huang Pasteur Institute https://en.wikipedia.org/wiki/Pasteur_Institute https://www.pasteur.fr/en Institut Pasteur Philip Huang https://www.covaxx.com/ COVAXX A public research university located primarily in Brisbane, Queensland, Australia Philip Huang https://en.wikipedia.org/wiki/University_of_Queensland https://www.uq.edu.au/ University of Queensland An American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines Philip Huang https://en.wikipedia.org/wiki/Vaxart https://vaxart.com/ Vaxart, Inc. Philip Huang http://www.cellid.co.kr/eng/ Cellid Co., Ltd. Philip Huang https://www.umcg.nl/EN/corporate/The_University_Medical_Center/Paginas/default.aspx University Medical Center Groningen Philip Huang https://aivitabiomedical.com/ AIVITA Biomedical, Inc. Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France. Philip Huang https://en.wikipedia.org/wiki/Sanofi https://www.sanofi.com/ Sanofi S.A. Philip Huang https://www.curevac.com/en/ CureVac AG Philip Huang Research Institute for Biological Safety Problems Philip Huang Bharat Biotech International Limited Philip Huang University of Munich (Ludwig-Maximilians) Philip Huang West China Hospital Philip Huang University Hospital Tuebingen Philip Huang Shenzhen Geno-Immune Medical Institute Philip Huang Providence Health & Services Philip Huang City of Hope Medical Center Philip Huang https://codagenix.com/ Codagenix, Inc. Philip Huang Center for Genetic Engineering and Biotechnology Philip Huang Biological E. Ltd Philip Huang GeneOne Life Science, Inc. Philip Huang Nanogen Pharmaceutical Biotechnology Philip Huang Shionogi Philip Huang Altimmune, Inc. Philip Huang Erciyes University Philip Huang Vaccine and Infectious Disease Organization VAC An NIAID compendium repository that stores vaccine adjuvants derived from their research studies. Oliver He, Amogh Madireddi, Wolfgang Leitner VAC https://vac.niaid.nih.gov/ Vaccine Adjuvant Compendium